PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Periana, RA; Taube, DJ; Gamble, S; Taube, H; Satoh, T; Fujii, H				Periana, RA; Taube, DJ; Gamble, S; Taube, H; Satoh, T; Fujii, H			Platinum catalysts for the high-yield oxidation of methane to a methanol derivative	SCIENCE			English	Article							ACTIVATION; ALKANES	Platinum catalysts are reported for the direct, low-temperature, oxidative conversion of methane to a methanol derivative at greater than 70 percent one-pass yield based on methane. The catalysts are platinum complexes derived from the bidiazine ligand family that are stable, active, and selective for the oxidation of a carbon-hydrogen bond of methane to produce methyl esters. Mechanistic studies show that platinum(ll) is the most active oxidation state of platinum for reaction with methane, and are consistent with reaction proceeding through carbon-hydrogen bond activation of methane to generate a platinum-methyl intermediate that is oxidized to generate the methyl ester product.	Catalyt Adv Technol Inc, Mt View, CA 94043 USA		Periana, RA (corresponding author), Catalyt Adv Technol Inc, 430 Ferguson Dr, Mt View, CA 94043 USA.	rap@mv.catalytica-inc.com						ARNDTSEN BA, 1995, ACCOUNTS CHEM RES, V28, P154, DOI 10.1021/ar00051a009; Bromberg SE, 1997, SCIENCE, V278, P260, DOI 10.1126/science.278.5336.260; DAIES JA, 1990, SELECTIVE HYDROCARBO; EPHRITIKHINE M, 1988, IND APPL HOMOGENEOUS, P257; Hall C, 1996, CHEM REV, V96, P3125, DOI 10.1021/cr9502615; Henry P. M., 1980, PALLADIUM CATALYZED; Hill C. L., 1989, ACTIVATION FUNCTIONA; HOLCAMP MW, 1997, J AM CHEMSOC, V119, P848; Knott D, 1997, OIL GAS J, V95, P16; PERIANA RA, 1993, SCIENCE, V259, P340, DOI 10.1126/science.259.5093.340; PERIANA RA, Patent No. 5233113; PERIANA RA, Patent No. 5306855; SCHNEIDER JJ, 1996, ANGEW CHEM INT EDIT, V35, P1068; SEN A, 1988, ACCOUNTS CHEM RES, V21, P421, DOI 10.1021/ar00155a006; Shilov A. E., 1984, ACTIVATION SATURATED; SHILOV AE, 1994, CATAL MET C, V17, P87; SOMMER J, 1993, ACCOUNTS CHEM RES, V26, P370, DOI 10.1021/ar00031a003; Waltz KM, 1997, SCIENCE, V277, P211, DOI 10.1126/science.277.5323.211; Wick DD, 1997, J AM CHEM SOC, V119, P10235, DOI 10.1021/ja971952g; 4833170; 5658497; 5506272; 5639401; 4686238; 5543437; 5500449; 5621155; 5620670; 5504118; 5653916; 5628931; 4973453; 5324335; 5645613	34	1031	1076	10	628	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					560	564		10.1126/science.280.5363.560	http://dx.doi.org/10.1126/science.280.5363.560			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554841				2022-12-28	WOS:000073242100038
J	Zou, L; Stillman, B				Zou, L; Stillman, B			Formation of a preinitiation complex by S-phase cyclin CDK-dependent loading of Cdc45p onto chromatin	SCIENCE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; CDC6 PROTEIN; YEAST; ORIGINS; TRANSITION; KINASES	Cdc45p, a protein essential for initiation of DNA replication, associates with chromatin after "start" in late G(1) and during the S phase of the cell cycle. Binding of Cdc45p to chromatin depends on Clb-Cdc28 kinase activity as well as functional Cdc6p and Mcm2p, which suggests that Cdc45p associates with the prereplication complex after activation of S-phase cyclin-dependent kinases (CDKs). As indicated by the timing and the CDK dependence, binding of Cdc45p to chromatin is crucial for commitment to initiation of DNA replication, During S phase, Cdc45p physically interacts with minichromosome maintenance (MCM) proteins on chromatin; however, dissociation of Cdc45p from chromatin is slower than that of MCMs, which indicates that the proteins are released by different mechanisms.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	stillman@cshl.org		Stillman, Bruce/0000-0002-9453-4091	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45436] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LIANG C, GENES DEV, V11, P3375; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; LUCCHINI G, 1990, GENE, V90, P99, DOI 10.1016/0378-1119(90)90444-V; NASMYTH K, 1996, DNA REPLICATION EUKA, P311; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WEINREICH M, UNPUB; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZOU L, UNPUB	32	272	272	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					593	596		10.1126/science.280.5363.593	http://dx.doi.org/10.1126/science.280.5363.593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554851				2022-12-28	WOS:000073242100048
J	Dell'Angelica, EC; Klumperman, J; Stoorvogel, W; Bonifacino, JS				Dell'Angelica, EC; Klumperman, J; Stoorvogel, W; Bonifacino, JS			Association of the AP-3 adaptor complex with clathrin	SCIENCE			English	Article							PROTEIN; VESICLES; MEMBRANE; SUBUNITS; BINDING; GOLGI	A heterotetrameric complex termed AP-3 is involved in signal-mediated protein sorting to endosomal-lysosomal organelles. AP-3 has been proposed to be a component of a nonclathrin coat. In vitro binding assays showed that mammalian AP-3 did associate with clathrin by interaction of the appendage domain of its beta 3 subunit with the amino-terminal domain of the clathrin heavy chain. The beta 3 appendage domain contained a conserved consensus motif for clathrin binding. AP-3 colocalized with clathrin in cells as observed by immunofluorescence and immunoelectron microscopy. Thus, AP-3 function in protein sorting may depend on clathrin.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Utrecht, Sch Med, Dept Cell Biol, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utrecht University	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370				BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DELLANGELICA EC, UNPUB; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ooi CE, 1997, EMBO J, V16, P4508; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; Ramjaun A. R., 1997, Molecular Biology of the Cell, V8, p93A; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Seymour A. B., 1997, Molecular Biology of the Cell, V8, p227A; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x	27	298	303	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					431	434		10.1126/science.280.5362.431	http://dx.doi.org/10.1126/science.280.5362.431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545220				2022-12-28	WOS:000073159600046
J	O'Brien, KL; Selanikio, JD; Hecdivert, C; Placide, MF; Louis, M; Barr, DB; Barr, JR; Hospedales, CJ; Lewis, MJ; Schwartz, B; Philen, RM; St Victor, S; Espindola, J; Needham, LL; Denerville, K				O'Brien, KL; Selanikio, JD; Hecdivert, C; Placide, MF; Louis, M; Barr, DB; Barr, JR; Hospedales, CJ; Lewis, MJ; Schwartz, B; Philen, RM; St Victor, S; Espindola, J; Needham, LL; Denerville, K		Acute Renal Failure Invest Team	Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG	Context.-Contaminated pharmaceutical products can result in substantial morbidity and mortality and should be included in the differential diagnosis of deaths of unknown origin. Objective.-To investigate an outbreak of deaths among children from acute renal failure in Haiti to determine the etiology and institute control measures. Design.-Case-control study, cohort study, and laboratory toxicologic evaluation. Setting.-Pediatric population of Haiti. Participants.-Cases were defined as Haitian residents younger than 18 years with idiopathic anuria or severe oliguria for 24 hours or longer, Febrile hospitalized children without renal failure were enrolled as control subjects. Main Outcome Measure.-The odds of exposure to suspected etiologic agents among cases and controls. Results.-We identified 109 cases of acute renal failure among children. The clinical syndrome included renal failure, hepatitis, pancreatitis, central nervous system impairment, coma, and death, Of 87 patients with follow-up information who remained in Haiti for treatment, 85 (98%) died; 3 (27%) of 11 patients transported to the United States for intensive care unit management died before hospital discharge. A locally manufactured acetaminophen syrup was highly associated with disease (odds ratio, 52.7; 95% confidence interval, 15.2-197.2), Diethylene glycol (DEG) was found in patients' bottles in a median concentration of 14.4%, The median estimated toxic dose of DEG was 1.34 mL/kg (range, 0.22-4.42 mL/kg). Glycerin, a raw material imported to Haiti and used in the acetaminophen formulation, was contaminated with 24% DEG. Conclusions.-An epidemic of severe systemic toxicity and deaths from DEG-contaminated acetaminophen syrup occurred in Haiti. Good manufacturing practice regulations should be used by all pharmaceutical manufacturers to prevent such tragedies.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; Minist Publ & Populat, Port au Prince, Haiti; Univ Etat Haiti, Inst Haiten Enfance, Port au Prince, Haiti; Pan Amer Hlth Org, Port au Prince, Haiti; Pan Amer Hlth Org, Caribbean Epidemiol Ctr, Port of Spain, Trinidad Tobago	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Pan American Health Organization; Pan American Health Organization	O'Brien, KL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, 1600 Clifton Rd,Mailstop C-23, Atlanta, GA 30333 USA.		Barr, Dana B/E-2276-2013; Barr, Dana B/E-6369-2011; Needham, Larry/E-4930-2011	O'Brien, Katherine/0000-0002-0164-4030				CALVERY H. 0., 1939, SOUTHERN MED JOUR, V32, P1105; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P649; CLAESON M, 1990, PEDIATR INFECT DIS J, V9, P345, DOI 10.1097/00006454-199005000-00008; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Douglas R M, 1991, Semin Respir Infect, V6, P217; DRUT R, 1994, MEDICINA-BUENOS AIRE, V54, P1; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GRANT JP, 1988, STATE WORLDS CHILDRE; HANIF M, 1995, BRIT MED J, V311, P88, DOI 10.1136/bmj.311.6997.88; KENYON TA, 1994, B WORLD HEALTH ORGAN, V72, P615; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; *POISINDEX ED STAF, 1998, POISINDEX SYST, V95; WAX PM, 1995, ANN INTERN MED, V122, P456, DOI 10.7326/0003-4819-122-6-199503150-00009	15	123	129	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1175	1180		10.1001/jama.279.15.1175	http://dx.doi.org/10.1001/jama.279.15.1175			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555756	Bronze			2022-12-28	WOS:000072969400030
J	Howarth, PH				Howarth, PH			ABC of allergies - Pathogenic mechanisms: a rational basis for treatment	BRITISH MEDICAL JOURNAL			English	Review									Southampton Gen Hosp, Sch Med, Southampton, Hants, England	University of Southampton	Howarth, PH (corresponding author), Southampton Gen Hosp, Sch Med, Southampton, Hants, England.			Howarth, Peter/0000-0003-0619-7927				Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; JARVIS D, 1997, ALLERGY ALLERGIC DIS, P1208; 1997, THORAX S1, V52, pS1	5	27	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					758	761		10.1136/bmj.316.7133.758	http://dx.doi.org/10.1136/bmj.316.7133.758			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529415	Green Published			2022-12-28	WOS:000072463700040
J	Lindberg, G; Bingefors, K; Ranstam, J; Rastam, L; Melander, A				Lindberg, G; Bingefors, K; Ranstam, J; Rastam, L; Melander, A			Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; BLOCKADE	Objective: To investigate possible associations between use of cardiovascular drugs and suicide. Design: Cross sectional ecological study based on rates of use of eight cardiovascular drug groups by outpatients. A population based cohort study including users of drugs to control hypertension. Subjects: The ecological study included 152 of Sweden's 284 municipalities, The cohort study included all inhabitants of one Swedish municipality who during 1988 or 1989 had purchased cardiovascular agents from pharmacies within the municipality. Six hundred and seventeen subjects (18.2%) were classified as users of calcium channel blockers and 2780 (81.8%) as non-users. Main outcome measures: Partial correlations (least squares method) between rates of use of cardiovascular drugs and age standardised mortality from suicide in Swedish municipalities. Hazard ratios for risk of suicide with adjustments for difference in age and sex in users of calcium channel blockers compared with users of other hypertensive drugs. Results: Among the Swedish municipalities the use of each cardiovascular drug group except angiotensin converting enzyme inhibitors correlated significantly and positively with suicide rates, After adjustment for the use of other cardiovascular drug groups, as a substitute for the prevalence of cardiovascular morbidity, only the correlation with calcium channel blockers remained significant (r = 0.29, P < 0.001). In the cohort study, five users and four non-users of calcium channel blockers committed suicide during the follow up until the end of 1994. The absolute risk associated with use of calcium channel blockers was 1.1 suicides per 1000 person years. The relative risk, adjusted for differences in age and sex, among users versus non-users was 5.4 (95% confidence interval 1.4 to 20.5). Conclusions: Use of calcium channel blockers may increase the risk of suicide.	Malmo Univ Hosp Fdn, Swedish Network Pharmacoepidemiol, SE-20502 Malmo, Sweden; Uppsala Univ, Dept Pharmaceut Serv Res, SE-75123 Uppsala, Sweden; Lund Univ, Malmo Univ Hosp, Dept Community Med, SE-20502 Malmo, Sweden	Uppsala University; Lund University; Skane University Hospital	Lindberg, G (corresponding author), Malmo Univ Hosp Fdn, Swedish Network Pharmacoepidemiol, SE-20502 Malmo, Sweden.	gunnar.lindberg@nepi.a.se	Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; BIRIELI C, 1989, BRIT MED J, V299, P796, DOI 10.1136/bmj.299.6702.796; BOLANDER AM, 1981, MED ASPECTS MORTALIT, P236; Capella D, 1993, WHO Reg Publ Eur Ser, V45, P55; DASSYLVA B, 1993, CAN J PSYCHIAT, V38, P299, DOI 10.1177/070674379303800420; Hallas J, 1996, EPIDEMIOLOGY, V7, P478, DOI 10.1097/00001648-199609000-00005; HULLETT FJ, 1988, AM J PSYCHIAT, V145, P1277; KAHN JK, 1986, AM J MED, V81, P705, DOI 10.1016/0002-9343(86)90561-9; MCALLISTERWILLIAMS RH, 1990, BRIT J PSYCHIAT, V157, P618, DOI 10.1192/bjp.157.4.618; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999	10	48	49	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					741	745		10.1136/bmj.316.7133.741	http://dx.doi.org/10.1136/bmj.316.7133.741			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB358	9529409	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072463700031
J	Fournier, AM				Fournier, AM			The Gram stain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Miami, Sch Med, Miami Beach, FL 33139 USA	University of Miami	Fournier, AM (corresponding author), Univ Miami, Sch Med, POB 016700,R700, Miami, FL 33101 USA.								0	5	5	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					776	776		10.7326/0003-4819-128-9-199805010-00015	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556475				2022-12-28	WOS:000073363800014
J	Kemp, M				Kemp, M			Hesse-Honegger's hand-work	NATURE			English	Editorial Material								Cornelia Hesse-Honegger is fascinated by the beauty of bugs. After the Chernobyl disaster she set out with her paintbox on the trail of mutated insects, convinced that they were the result of radiation poisoning.	Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	1	1	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					555	555		10.1038/33298	http://dx.doi.org/10.1038/33298			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560149	Bronze			2022-12-28	WOS:000072987200035
J	Kitada, T; Asakawa, S; Hattori, N; Matsumine, H; Yamamura, Y; Minoshima, S; Yokochi, M; Mizuno, Y; Shimizu, N				Kitada, T; Asakawa, S; Hattori, N; Matsumine, H; Yamamura, Y; Minoshima, S; Yokochi, M; Mizuno, Y; Shimizu, N			Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism	NATURE			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN-DEGRADATION; LEWY BODIES; UBIQUITIN; DISEASE; ETIOLOGY; TAU	Parkinson's disease is a common neurodegenerative disease with complex clinical features(1). Autosomal recessive juvenile parkinsonism (AR-JP)(2,3) maps to the long arm of chromosome 6 (6q25.2-q27) and is linked strongly to the markers D6S305 and D6S253 (ref. 4); the former is deleted in one Japanese AR-JP patient(5). By positional cloning within this microdeletion, we have now isolated a complementary DNA clone of 2,960 base pairs with a 1,395-base-pair open reading frame, encoding a protein of 465 amino acids with moderate similarity to ubiquitin at the amino terminus and a RING-finger motif at the carboxy terminus, The gene spans more than 500 kilobases and has 12 exons, five of which (exons 3-7) are deleted in the patient, Four other AR-JP patients from three unrelated families have a deletion affecting exon 4 alone. A 4.5-kilobase transcript that is expressed in many human tissues but is abundant in the brain, including the substantia nigra, is shorter in brain tissue from one of the groups of exon-4-deleted patients. Mutations in the newly identified gene appear to be responsible for the pathogenesis of AR-JP, and we have therefore named the protein product 'Parkin'.	Keio Univ, Sch Med, Dept Biol Mol, Shinjuku Ku, Tokyo 1608582, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1130033, Japan; Hiroshima Univ, Sch Med, Dept Hlth Sci, Minami Ku, Hiroshima 7340037, Japan; Tokyo Metropolitan Ebara Hosp, Dept Neurol, Ota Ku, Tokyo 1450065, Japan	Keio University; Juntendo University; Hiroshima University	Shimizu, N (corresponding author), Keio Univ, Sch Med, Dept Biol Mol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	shimizu@dmb.med.keio.ac.jp	Hattori, Nobutaka/ACR-0069-2022					AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Asakawa S, 1997, GENE, V191, P69, DOI 10.1016/S0378-1119(97)00044-9; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GALLOWAY PG, 1992, AM J PATHOL, V140, P809; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Ishikawa A, 1996, NEUROLOGY, V47, P160, DOI 10.1212/WNL.47.1.160; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; LOVE S, 1988, J NEUROPATH EXP NEUR, V47, P393, DOI 10.1097/00005072-198807000-00001; Matsumine H, 1997, AM J HUM GENET, V60, P588; MATSUMINE H, IN PRESS GENOMICS; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Parkinson J, 1817, ESSAY SHAKING PALSY; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sambrook J., 2002, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; YAMAMURA Y, 1993, CLIN NEUROL, V33, P491	27	3853	4013	9	273	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					605	608		10.1038/33416	http://dx.doi.org/10.1038/33416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560156				2022-12-28	WOS:000072987200060
J	Vento, S; Renzini, C; Casali, F; Ghironzi, G; Concia, E				Vento, S; Renzini, C; Casali, F; Ghironzi, G; Concia, E			Highly active antiretroviral therapy	LANCET			English	Letter									Univ Verona, Dept Infect Dis, I-37124 Verona, Italy; San Marino State Hosp, Internal Med & Cent Lab, San Marino, CA USA	University of Verona	Vento, S (corresponding author), Univ Verona, Dept Infect Dis, I-37124 Verona, Italy.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062				CARR A, 1997, LANCET, V349, P996; Sepkowitz KA, 1998, LANCET, V351, P228, DOI 10.1016/S0140-6736(05)78279-9; Vento S, 1998, AIDS, V12, P116	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1058	1058		10.1016/S0140-6736(05)79024-3	http://dx.doi.org/10.1016/S0140-6736(05)79024-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546533				2022-12-28	WOS:000072927200050
J	Williams, G				Williams, G			Misleading, unscientific, and unjust: the United Kingdom's research assessment exercise	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England	University of Liverpool	Williams, G (corresponding author), Univ Liverpool, Dept Med, Duncan Bldg, Liverpool L69 3GA, Merseyside, England.							BIRD J, 1995, TIMES HIGHER ED 0609, P15; Dickson D, 1997, NAT MED, V3, P133, DOI 10.1038/nm0297-133; *HIGH ED FUND COUN, 1996, 1996 RES ASS EX; Seglen PO, 1997, BRIT MED J, V314, P498	4	65	65	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1079	1082						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552915				2022-12-28	WOS:000072987400036
J	Grazzini, E; Guillon, G; Mouillac, B; Zingg, HH				Grazzini, E; Guillon, G; Mouillac, B; Zingg, HH			Inhibition of oxytocin receptor function by direct binding of progesterone	NATURE			English	Article							RAT GLOMERULOSA CELLS; RECIPROCAL MODULATION; VASOPRESSIN RECEPTOR; ANTAGONIST BINDING; PREGNANCY; AGONIST; SPECIFICITY; EXPRESSION; UTERUS; LIGAND	The steroid hormone progesterone (P-4) is essential for establishing and maintaining pregnancy in mammals(1-3). One of its functions includes maintenance of uterine quiescence by decreasing uterine sensitivity to the uterotonic peptide hormone oxytocin(3-5). Although it is generally held that steroid hormones such as P-4 act at a genomic level by binding to nuclear receptors and modulating the expression of specific target genes(6), we show here that the effect of P-4 on uterine sensitivity to oxytocin involves direct, nongenomic action of P-4 on the uterine oxytocin receptor (OTR), a member of the G-protein-coupled receptor family. P-4 inhibits oxytocin binding to OTR-containing membranes in virro, binds with high affinity to recombinant rat OTR expressed in CHO cells, and suppresses oxytocin-induced inositol phosphate production and calcium mobilization. These effects are highly steroid-and receptor-specific, because binding and signalling functions of the closely related human OTR are not affected by P-4 itself but by the P-4 metabolite 5 beta-dihydroprogesterone. Our findings provide the first evidence for a direct Interaction between a steroid hormone and a G-protein-coupled receptor and define a new level of crosstalk between the peptide-and steroid-hormone signalling pathways.	McGill Univ, Royal Victoria Hosp, Mol Endocrinol Lab, Res Inst, Montreal, PQ H3A 1A1, Canada; CNRS, INSERM, Ctr Pharmacol Endocrinol, U469, F-34094 Montpellier, France	McGill University; Royal Victoria Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Zingg, HH (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Endocrinol Lab, Res Inst, Montreal, PQ H3A 1A1, Canada.	zingg@rvhri.lan.mcgill.ca	Zingg, Hans/GPS-9984-2022; MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				Blackmore PF, 1996, MOL PHARMACOL, V49, P727; BURGISSER E, 1982, P NATL ACAD SCI-BIOL, V79, P1732, DOI 10.1073/pnas.79.6.1732; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CSAPO AI, 1981, PROSTAGLANDINS, V22, P131, DOI 10.1016/0090-6980(81)90060-5; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; GARFIELD RE, 1982, AM J OBSTET GYNECOL, V142, P21; Grazzini E, 1996, MOL PHARMACOL, V50, P1273; Grazzini E, 1996, CELL CALCIUM, V19, P29, DOI 10.1016/S0143-4160(96)90011-1; GREEN RD, 1984, J NEUROSCI, V4, P2472; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; Jeng YJ, 1996, NEUROPEPTIDES, V30, P557, DOI 10.1016/S0143-4179(96)90039-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LARCHER A, 1995, ENDOCRINOLOGY, V136, P5350, DOI 10.1210/en.136.12.5350; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; PEPE GJ, 1995, ENDOCR REV, V16, P608, DOI 10.1210/er.16.5.608; PEPE GJ, 1974, ENDOCRINOLOGY, V95, P275, DOI 10.1210/endo-95-1-275; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SCHUMACHER M, 1989, P NATL ACAD SCI USA, V86, P6798, DOI 10.1073/pnas.86.17.6798; SOLOFF MS, 1983, CAN J BIOCHEM CELL B, V61, P625, DOI 10.1139/o83-078; SUNDARAM H, 1993, BIOCHEM PHARMACOL, V45, P1003, DOI 10.1016/0006-2952(93)90243-P; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949; WASSERMAN WJ, 1980, P NATL ACAD SCI-BIOL, V77, P1534, DOI 10.1073/pnas.77.3.1534; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WONG M, 1994, J NEUROENDOCRINOL, V6, P347, DOI 10.1111/j.1365-2826.1994.tb00592.x; Zingg HH, 1996, BAILLIERE CLIN ENDOC, V10, P75, DOI 10.1016/S0950-351X(96)80314-4	27	371	384	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					509	512		10.1038/33176	http://dx.doi.org/10.1038/33176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548257				2022-12-28	WOS:000072875200062
J	Johnson, DS; Goel, RP; Birtwistle, P; Hirst, P				Johnson, DS; Goel, RP; Birtwistle, P; Hirst, P			Transferring medical images on the World Wide Web for emergency clinical management: A case report	BRITISH MEDICAL JOURNAL			English	Article							TELERADIOLOGY		Manchester Royal Infirm, Dept Orthoped, Manchester M13 9WL, Lancs, England	University of Manchester	Johnson, DS (corresponding author), Manchester Royal Infirm, Dept Orthoped, Oxford Rd, Manchester M13 9WL, Lancs, England.			Johnson, David/0000-0002-6683-8645				[Anonymous], 1929, DENT RADIOGR PHOTOGR, V2, P16; KAGETSU NJ, 1987, RADIOLOGY, V165, P551, DOI 10.1148/radiology.165.2.3659383; Yamamoto LG, 1996, AM J EMERG MED, V14, P416, DOI 10.1016/S0735-6757(96)90064-9; YAMAMOTO LG, 1993, AM J EMERG MED, V11, P384, DOI 10.1016/0735-6757(93)90173-9; YAMAMOTO LG, 1992, AM J EMERG MED, V10, P226, DOI 10.1016/0735-6757(92)90215-J	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					988	989		10.1136/bmj.316.7136.988	http://dx.doi.org/10.1136/bmj.316.7136.988			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550960	Green Published			2022-12-28	WOS:000072856100024
J	Deckert, G; Warren, PV; Gaasterland, T; Young, WG; Lenox, AL; Graham, DE; Overbeek, R; Snead, MA; Keller, M; Aujay, M; Huber, R; Feldman, RA; Short, JM; Olsen, GJ; Swanson, RV				Deckert, G; Warren, PV; Gaasterland, T; Young, WG; Lenox, AL; Graham, DE; Overbeek, R; Snead, MA; Keller, M; Aujay, M; Huber, R; Feldman, RA; Short, JM; Olsen, GJ; Swanson, RV			The complete genome of the hyperthermophilic bacterium Aquifex aeolicus	NATURE			English	Article							HYDROGEN-OXIDIZING BACTERIA; FACTOR-BASED VECTOR; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; HUMAN DNA; SP-NOV; GENE; PYROPHILUS; EXPRESSION; PROTEINS	Aquifex aeolicus was one of the earliest diverging, and is one of the most thermophilic, bacteria known. It can grow on hydrogen, oxygen, carbon dioxide, and mineral salts. The complex metabolic machinery needed for A. aeolicus to function as a chemolithoautotroph (an organism which uses an inorganic carbon source for biosynthesis and an inorganic chemical energy source) is encoded within a genome that is only one-third the size of the E, coli genome, Metabolic flexibility seems Po be reduced as a result of the limited genome size, The use of oxygen (albeit at very low concentrations) as an electron acceptor is allowed by the presence of a complex respiratory apparatus. Although this organism grows at 95 degrees C, the extreme thermal limit of the Bacteria, only a few specific indications of thermophily are apparent from the genome. Here we describe the complete genome sequence of 1,551,335 base pairs of this evolutionarily and physiologically interesting organism.	Diversa Corp, San Diego, CA 92121 USA; Argonne Natl Lab, Div Math & Comp Sci, Argonne, IL 60439 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Regensburg, Lehrstuhl Mikrobiol, D-8400 Regensburg, Germany	United States Department of Energy (DOE); Argonne National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign; University of Regensburg	Swanson, RV (corresponding author), Diversa Corp, 10665 Sorrento Valley Rd, San Diego, CA 92121 USA.	Robert.huber@biologie.uni-regensburg.de; rswanson@diversa.com	Graham, David E/F-8578-2010; Keller, Martin/C-4416-2012	Graham, David E/0000-0001-8968-7344; Swanson, Ronald/0000-0002-6486-2676				ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; BEH M, 1993, ARCH MICROBIOL, V160, P306, DOI 10.1007/BF00292082; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bocchetta M, 1995, J MOL EVOL, V41, P803; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BROCK TD, 1995, ANNU REV MICROBIOL, V49, P1; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; Choi IG, 1997, EXTREMOPHILES, V1, P125, DOI 10.1007/s007920050025; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUCHS G, 1987, AUTOTROPHIC BACTERIA, P365; Gaasterland T, 1996, BIOCHIMIE, V78, P302, DOI 10.1016/0300-9084(96)84761-4; Gaasterland T, 1996, TRENDS GENET, V12, P76, DOI 10.1016/0168-9525(96)81406-5; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Jarrell KF, 1996, J BACTERIOL, V178, P5057, DOI 10.1128/jb.178.17.5057-5064.1996; Kaneko T, 1996, DNA Res, V3, P109; KAWASUMI T, 1984, INT J SYST BACTERIOL, V34, P5, DOI 10.1099/00207713-34-1-5; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; KLENK HP, 1994, MOL BIOL ARCHAEA, P139; KRISTJANSSON JK, 1985, ARCH MICROBIOL, V140, P321, DOI 10.1007/BF00446971; KRYUKOV VR, 1983, MICROBIOLOGY+, V52, P611; LANDER E S, 1988, Genomics, V2, P231; Lim JH, 1997, FEBS LETT, V406, P142, DOI 10.1016/S0014-5793(97)00262-7; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mai XH, 1996, J BACTERIOL, V178, P5890, DOI 10.1128/jb.178.20.5890-5896.1996; MOTOSHIMA H, 1990, AGR BIOL CHEM TOKYO, V54, P2385, DOI 10.1080/00021369.1990.10870335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PITULLE C, 1994, INT J SYST BACTERIOL, V44, P620, DOI 10.1099/00207713-44-4-620; REYSENBACH AL, 1994, APPL ENVIRON MICROB, V60, P2113, DOI 10.1128/AEM.60.6.2113-2119.1994; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; RUDOLPH J, 1995, EMBO J, V14, P4249, DOI 10.1002/j.1460-2075.1995.tb00099.x; Setchell W A, 1903, Science, V17, P934, DOI 10.1126/science.17.441.934; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WETMUR JG, 1994, J BIOL CHEM, V269, P25928	49	941	1793	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					353	358		10.1038/32831	http://dx.doi.org/10.1038/32831			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537320	Bronze			2022-12-28	WOS:000072713600041
J	Mitchell, R; McCulloch, D; Lutz, E; Johnson, M; MacKenzie, C; Fennell, M; Fink, G; Zhou, W; Sealfon, SC				Mitchell, R; McCulloch, D; Lutz, E; Johnson, M; MacKenzie, C; Fennell, M; Fink, G; Zhou, W; Sealfon, SC			Rhodopsin-family receptors associate with small G proteins to activate phospholipase D	NATURE			English	Article							ADP-RIBOSYLATION-FACTOR; GUANINE-NUCLEOTIDE; HL-60 CELLS; GTP; ARF; RHO; EXCHANGE; FRACTIONS; FLUORIDE; CONTAINS	G-protein-coupled receptors of the rhodopsin family transduce many important neural and endocrine signals, These receptors activate heterotrimeric G proteins and in many cases also cause activation of phospholipase D, an enzyme that can be controlled by the small G proteins ARF and RhoA(1-3). Here we show that the activation of phospholipase D that is induced by many, but not all, Ca2+-mobilizing G-protein-coupled receptors is sensitive to inhibitors of ARF and of RhoA. Receptors of this type were coimmunoprecipitated with ARF or RhoA on exposure to agonists, and the effects of GTP analogues on ligand binding to the receptor changed to a profile that is characteristic of small G proteins, These receptors contain the amino-acid sequence Asn-ProXXTyr in their seventh transmembrane domain, whereas receptors capable of activating phospholipase D without involving ARF contain the sequence AspProXXTyr. Mutation of this latter sequence to AsnProXXTyr in the gonadotropin-releasing hormone receptor conferred sensitivity to an inhibitor of ARF, and the reciprocal mutation in the 5-HT2A receptor for 5-hydroxy-tryptamine reduced its sensitivity to the inhibitor, Receptors carrying the AsnProXXTyr motif thus seem to form functional complexes with ARF and RhoA.	MRC, Brain Metab Unit, Edinburgh EH8 9JZ, Midlothian, Scotland; Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Mitchell, R (corresponding author), MRC, Brain Metab Unit, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.			SEALFON, Stuart/0000-0001-5791-1217; Fink, George/0000-0002-0713-527X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVANAGH MM, 1996, J BIOL CHEM, V271, P21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FENG DM, 1995, J MED CHEM, V38, P4125, DOI 10.1021/jm00020a029; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; Hoffenberg S, 1996, MOL PHARMACOL, V49, P156; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; MITCHELL R, 1995, BIOCHEM SOC T, V23, pS208, DOI 10.1042/bst023208s; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; NIETO M, 1994, MOL PHARMACOL, V46, P406; OGIER SA, 1987, J ENDOCRINOL, V115, P151, DOI 10.1677/joe.0.1150151; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; WALL SJ, 1991, MOL PHARMACOL, V40, P783; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG LX, 1994, ENDOCRINOLOGY, V134, P1446, DOI 10.1210/en.134.3.1446; ZHOU W, 1994, MOL PHARMACOL, V45, P165	30	183	185	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					411	414		10.1038/32937	http://dx.doi.org/10.1038/32937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537328				2022-12-28	WOS:000072713600058
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			A 27-year-old woman with migraine headaches, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Welch KMA, 1997, JAMA-J AM MED ASSOC, V278, P322	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					954	954		10.1001/jama.279.12.954	http://dx.doi.org/10.1001/jama.279.12.954			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544771				2022-12-28	WOS:000072563600037
J	Fahey, T; Stocks, N; Thomas, T				Fahey, T; Stocks, N; Thomas, T			Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; ACUTE BRONCHITIS; GENERAL-PRACTICE; COMMON-COLD; COMMUNITY; ERYTHROMYCIN; ETIOLOGY; SYMPTOMS; DOXYCYCLINE; SPUTUM	Objectives: To assess whether antibiotic treatment for acute cough is effective and to measure the side effects of such treatment Design: Quantitative systematic review of randomised placebo controlled trials. Data sources: Nine trials (8 published, 1 unpublished) retrieved from a systematic search (electronic databases, contact with authors, contact with drug manufacturers, reference lists); no restriction on language. Main outcome measures: Proportion of subjects with productive cough at follow up (7-11 days after consultation with general practitioner); proportion of subjects who had not improved clinically at follow up; proportion of subjects who reported side effects from taking antibiotic or placebo. Results: Eight trials contributed to the meta-analysis. Resolution of cough was not affected by antibiotic treatment (relative risk 0.85 (95% confidence interval 0.73 to 1.00)), neither was clinical improvement at re-examination (relative risk 0.62 (0.36 to 1.09)). The side effects of antibiotic were more common in the antibiotic group when compared to placebo (relative risk 1.51 (0.86 to 2.64)). Conclusions: Treatment with antibiotic does not affect the resolution of cough or alter the course of illness. The benefits of antibiotic treatment are marginal for most patients with acute cough and may be outweighed by the side effects of treatment.	Univ Bristol, Div Primary Care, Bristol BS8 2PR, Avon, England; United Med & Dent Sch Guys & St Thomas Hosp, London SE11 6SP, England	University of Bristol; University of London; King's College London	Fahey, T (corresponding author), Univ Bristol, Div Primary Care, Canynge Hall, Bristol BS8 2PR, Avon, England.		Stocks, Nigel P/I-1083-2012; Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Stocks, Nigel/0000-0002-9018-0361				BOLDY DAR, 1990, RESP MED, V84, P377, DOI 10.1016/S0954-6111(08)80072-8; BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; *COCHR COLL COCHR, 1997, UPD SOFTW; DAVEY P, 1994, BRIT J GEN PRACT, V44, P509; Dickersin K, 1995, SYSTEMATIC REV, P17; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; FRANKS P, 1984, J FAM PRACTICE, V19, P185; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; GWALTNEY JM, 1995, PRINCIPLES PRACTICE, P606; Hamm RM, 1996, J FAM PRACTICE, V43, P56; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Howie J G, 1971, J R Coll Gen Pract, V21, P657; HOWIE JGR, 1970, LANCET, V2, P1099; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; Hueston WJ, 1997, J FAM PRACTICE, V44, P261; Johnson PH, 1996, RESP MED, V90, P87, DOI 10.1016/S0954-6111(96)90203-6; JONES PH, 1953, JAMA-J AM MED ASSOC, V99, P262; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; King DE, 1996, J FAM PRACTICE, V42, P601; KING DE, 1991, J FAM PRACTICE, V32, P529; KUYVENHOVEN M, 1993, FAM PRACT, V10, P366, DOI 10.1093/fampra/10.4.366; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Little P, 1997, BRIT MED J, V315, P350; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; MacKay DN, 1996, J GEN INTERN MED, V11, P557, DOI 10.1007/BF02599608; Mainous AG, 1996, J FAM PRACTICE, V42, P357; *MRC WORK PART AC, 1965, BRIT MED J, V2, P319; MULROW CD, 1996, COCHRANE LIB; ORR PH, 1993, J FAM PRACTICE, V36, P507; ORTQVIST A, 1993, LANCET, V341, P529; Petitti D, 1994, METAANALYSIS DECISIO; Royal College of General Practitioners Office of Population Consensus & Survey. Department of Health, 1995, MORB STAT GEN PRACT; Sackett D., 1996, EVIDENCE BASED MED P; Scherl E R, 1987, J Ky Med Assoc, V85, P539; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; THOMAS S, 1978, BMJ-BRIT MED J, V1, P1374; VERHEIJ T, 1995, SCAND J PRIM HEALTH, V13, P8, DOI 10.3109/02813439508996728; VERHEIJ T, 1995, LANCET, V345, P1244, DOI 10.1016/S0140-6736(95)92030-7; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; VERKATESUM P, 1995, THORAX, V50, P481; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P481; Wise R, 1996, LANCET, V347, P1499, DOI 10.1016/S0140-6736(96)90664-9; *WORLD ORG NAT COL, 1983, INT CLASS HLTH PROM; WYATT TD, 1990, BRIT MED J, V300, P441, DOI 10.1136/bmj.300.6722.441; 1974, BMJ, V2, P1	48	139	141	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					906	910		10.1136/bmj.316.7135.906	http://dx.doi.org/10.1136/bmj.316.7135.906			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552842	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072713300031
J	Walker, BR; McConnachie, A; Noon, JP; Webb, DJ; Watt, GCM				Walker, BR; McConnachie, A; Noon, JP; Webb, DJ; Watt, GCM			Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK; FETAL GROWTH; HYPERTENSION; CHILDREN; PREGNANCY; WOMEN	Objective: To examine the possibility that low birth weight is a feature of the inherited predisposition to high blood pressure. Design: Cross sectional study. Setting: Primary care medical centre in Edinburgh. Subjects: One offspring of 12 families (231 men and 221 women aged 16-26 years) in whom blood pressure, weight, and height were measured in 1986 and whose parents had blood pressure measured in 1979. Birth weights were obtained from case records (270 offspring) or by questionnaires sent to the mothers (182 offspring). Main outcome measures: Birth weight and adult systolic blood pressure in offspring in relation to parental blood pressure. Results: If parental blood pressures were not considered, a 1 kg decrease in birth weight was associated with a 2.24 mm Hg increase in systolic blood pressure of offspring (P = 0.06) after correction for current weight and sex. However, parental blood pressures correlated positively with blood pressure of offspring, and higher maternal blood pressure was associated with lower birth weight (-3.03 g/mm Hg, P < 0.01). After correction for parental blood pressures, a 1 kg decrease in birth weight was associated with only a 1.71 mm Hg increase in the systolic blood pressure of the offspring (P = 0.15). Conclusions: Low birth weight is a feature of the inherited predisposition to hypertension, perhaps because it is associated with higher maternal blood pressure during pregnancy. Parental blood pressure may be an important confounding factor in the relation between low birth weight and subsequent hypertension.	Univ Edinburgh, Western Gen Hosp, Dept Med, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland	University of Edinburgh; University of Glasgow	Walker, BR (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Med, Edinburgh EH4 2XU, Midlothian, Scotland.							BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHESLEY LC, 1980, CLIN EXP HYPERTENS, V2, P777, DOI 10.3109/10641968009037142; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DGANI J, 1992, J PERINAT MED, V20, P365, DOI 10.1515/jpme.1992.20.5.365; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; Harrap SB, 1997, CIRCULATION, V96, P556; HIMMELMANN A, 1994, J INTERN MED, V235, P347, DOI 10.1111/j.1365-2796.1994.tb01085.x; Lalande M, 1996, ANNU REV GENET, V30, P173, DOI 10.1146/annurev.genet.30.1.173; LangleyEvans SC, 1996, CLIN SCI, V91, P607, DOI 10.1042/cs0910607; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; LUMEY LH, 1994, INT J EPIDEMIOL, V23, P1006, DOI 10.1093/ije/23.5.1006; McCowan LME, 1996, BRIT J OBSTET GYNAEC, V103, P123, DOI 10.1111/j.1471-0528.1996.tb09662.x; MORTON NE, 1955, ANN HUM GENET, V20, P125; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; SEIDMAN DS, 1991, BRIT J OBSTET GYNAEC, V98, P1009, DOI 10.1111/j.1471-0528.1991.tb15339.x; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; WATT GCM, 1991, J HYPERTENS, V9, P55; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337	26	77	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					834	837		10.1136/bmj.316.7134.834	http://dx.doi.org/10.1136/bmj.316.7134.834			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549456	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072584300034
J	Bown, SG				Bown, SG			Science, medicine, and the future - New techniques in laser therapy	BRITISH MEDICAL JOURNAL			English	Review							PHOTODYNAMIC THERAPY; ACID; CANCER		UCL, Sch Med, Dept Surg, Natl Med Laser Ctr, London W1P 7LD, England	University of London; University College London; UCL Medical School	Bown, SG (corresponding author), UCL, Sch Med, Dept Surg, Natl Med Laser Ctr, Mortimer St, London W1P 7LD, England.		Bown, Stephen/AAX-6573-2020; Bown, Stephen G/C-5713-2009					AMIN Z, 1993, RADIOLOGY, V187, P339, DOI 10.1148/radiology.187.2.8475270; Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; BOWN SG, 1990, J PHOTOCH PHOTOBIO B, V6, P1, DOI 10.1016/1011-1344(90)85069-9; delaRosette JJMCH, 1997, BRIT J UROL, V80, P433, DOI 10.1046/j.1464-410X.1997.00369.x; FAN KFM, 1997, INT J CANCER, V72, P1; Fehr MK, 1996, AM J OBSTET GYNECOL, V175, P1253, DOI 10.1016/S0002-9378(96)70037-6; LIN SC, 1994, CURR EYE RES, V13, P513, DOI 10.3109/02713689408999883; MULLER PJ, 1995, SEMIN SURG ONCOL, V11, P346, DOI 10.1002/ssu.2980110504; Mumtaz H, 1996, RADIOLOGY, V200, P651, DOI 10.1148/radiology.200.3.8756910; NYAMEKYE I, 1995, CIRCULATION, V91, P417, DOI 10.1161/01.CIR.91.2.417; Raab O, 1900, Z BIOL-MUNICH, V39, P524; SIBILLE A, 1995, GASTROENTEROLOGY, V108, P337, DOI 10.1016/0016-5085(95)90058-6; Spencer GM, 1996, GUT, V39, P726, DOI 10.1136/gut.39.5.726; SVANBERG K, 1994, BRIT J DERMATOL, V130, P743, DOI 10.1111/j.1365-2133.1994.tb03412.x; Wilson BC, 1997, LASER MED SCI, V12, P182, DOI 10.1007/BF02765099	15	16	16	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					754	757		10.1136/bmj.316.7133.754	http://dx.doi.org/10.1136/bmj.316.7133.754			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529414	Green Published			2022-12-28	WOS:000072463700039
J	Casarett, DJ; Lantos, JD				Casarett, DJ; Lantos, JD			Have we treated AIDS too well? Rationing and the future of AIDS exceptionalism	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH; HIV; PHYSICIANS; TRIALS; CARE	During the past decade, medical therapy for AIDS has become more effective but also prohibitively expensive. A medical tragedy has been transformed into a financial crisis, and society has responded by establishing special programs and sources of funding for AIDS. These maneuvers parallel earlier approaches to HIV resting and reporting that have collectively come to be known as "exceptionalism." This paper suggests that exceptionalism in resource allocation is a fragile, short-term solution. In the long run, AIDS exceptionalism will create growing injustice and should be avoided. However, we should not eliminate the advances that this exceptionalism has already achieved. Instead, we need a working dialogue between these advances and public policy.	Univ Chicago, Dept Med, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA; Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA	University of Chicago; University of Iowa	Lantos, JD (corresponding author), Univ Chicago, Dept Med, MacLean Ctr Clin Med Eth, 5841 S Maryland Ave, Chicago, IL 60637 USA.							[Anonymous], 1987, FED REG, V52, P19466; [Anonymous], 1989, PRIVATE ACTS SOCIAL; ARISTOTLE, 1962, NICHOMACHEAN ETHICS, P118; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; CALABRESI G, 1978, TRAGIC CHOICES, P189; Callahan D., 1987, MED GOALS AGEING SOC; Carter D, 1996, ACAD MED, V71, P1250, DOI 10.1097/00001888-199611000-00024; Cohen J, 1996, SCIENCE, V272, P1882, DOI 10.1126/science.272.5270.1882; CRAWFORD R, 1994, SOC SCI MED, V38, P1347, DOI 10.1016/0277-9536(94)90273-9; DIAZ T, 1994, AM J PUBLIC HEALTH, V84, P1015, DOI 10.2105/AJPH.84.6.1015; DOUGHERTY CJ, 1991, HASTINGS CENT REP, V21, pS1; Emanuel Ezekial, 1991, ENDS HUMAN LIFE MED; ENGLEHARDT HT, 1986, FDN BIOETHICS, P339; FLECK LM, 1992, U PENN LAW REV, V140, P1597, DOI 10.2307/3312427; FLEISHMAN JA, 1993, INQUIRY-J HEALTH CAR, V30, P180; Food and Drug Administration (FDA), 1988, FED REGISTER, V53, P41516; Frank RG, 1996, ARCH GEN PSYCHIAT, V53, P933; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; HAYWARD RA, 1993, J GEN INTERN MED, V8, P10, DOI 10.1007/BF02600286; Hull AR, 1997, SEMIN NEPHROL, V17, P160; LEIGH JP, 1995, J ACQ IMMUN DEF SYND, V8, P392; MERIGAN TC, 1990, NEW ENGL J MED, V323, P1341, DOI 10.1056/NEJM199011083231911; *NAT ALL STAT TERR, 1996, FISC STWAT UPD STAT; NEFF JM, 1995, JAMA-J AM MED ASSOC, V274, P1866, DOI 10.1001/jama.274.23.1866; *US I MED, 1973, DIS DIS NAT INS REP	26	33	32	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					756	759		10.7326/0003-4819-128-9-199805010-00009	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZK790	9556470				2022-12-28	WOS:000073363800008
J	Parkes, CM				Parkes, CM			Coping with loss - The dying adult	BRITISH MEDICAL JOURNAL			English	Article									St Christophers Hospice, London SE26 6DZ, England		Parkes, CM (corresponding author), St Christophers Hospice, London SE26 6DZ, England.	cmparkes@aol.com						BENNER G, IN PRESS BMJ; Kubler Ross E., 1970, DEATH DYING; Maguire P, 1998, BRIT MED J, V316, P1086; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; PARKES CM, 1973, SUPPORT INNOVATION A, P151; SCHULZ R, 1974, OMEGA-J DEATH DYING, V5, P137, DOI 10.2190/HYRB-7VQK-VU9Y-7L5D	7	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1313	1315		10.1136/bmj.316.7140.1313	http://dx.doi.org/10.1136/bmj.316.7140.1313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554907	Green Published			2022-12-28	WOS:000073335900032
J	Chan, WP; Prete, F; Dickinson, MH				Chan, WP; Prete, F; Dickinson, MH			Visual input to the efferent control system of a fly's "gyroscope"	SCIENCE			English	Article							BLOWFLY CALLIPHORA; LOBULA PLATE; FLIGHT; HALTERE; DIPTERA; NEURONS; VICINA; LOCUST; CELLS	Dipterous insects (the true flies) have a sophisticated pair of equilibrium organs called halteres that evolved from hind wings, The halteres are sensitive to Coriolis forces that result from angular rotations of the body and mediate corrective reflexes during flight, Like the aerodynamically functional fore wings, the halteres beat during flight and are equipped with their own set of control muscles. It is shown that motoneurons innervating muscles of the haltere receive strong excitatory input from directionally sensitive visual interneurons. Visually guided flight maneuvers of flies may be mediated in part by efferent modulation of hard-wired equilibrium reflexes.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; De Paul Univ, Dept Psychol, Chicago, IL 60614 USA	University of California System; University of California Berkeley; DePaul University	Dickinson, MH (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.			Prete, Frederick R./0000-0001-9642-9298				AUTRUM H., 1958, EXPTL CELL RES SUPPL, V5, P426; BONHAG PF, 1948, MEM CORNELL U AGR EX, V285, P3; Chan WP, 1996, J COMP NEUROL, V369, P405, DOI 10.1002/(SICI)1096-9861(19960603)369:3&lt;405::AID-CNE6&gt;3.0.CO;2-9; COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; DERHAM W, 1714, PHYSICOTHEOLOGY, pCH4; Dickinson M. H., 1997, Society for Neuroscience Abstracts, V23, P769; Dickinson MH, 1997, COMP BIOCHEM PHYS A, V116, P223, DOI 10.1016/S0300-9629(96)00162-4; ECCLES J. C., 1930, PROC ROY SOC [LONDON] B, V106, P326, DOI 10.1098/rspb.1930.0032; FAUST R., 1952, ZOOL JAHRB ABT ALLG ZOOL U PHYSIOL TIERE, V63, P325; Fayyazuddin A, 1996, J NEUROSCI, V16, P5225; Fraenkel G, 1938, NATURE, V141, P919, DOI 10.1038/141919a0; GALAMBOS R, 1956, J NEUROPHYSIOL, V19, P424, DOI 10.1152/jn.1956.19.5.424; GNATZY W, 1987, ZOOMORPHOLOGY, V106, P312, DOI 10.1007/BF00312005; HAUSEN K, 1982, BIOL CYBERN, V46, P67, DOI 10.1007/BF00335352; HAUSEN K, 1976, Z NATURFORSCH C, V31, P629; Heide G, 1971, ZOOL JB PHYSL, V76, P87; HELDE G, 1968, Z VERGL PHYSIOL, V59, P456; HELDE G, 1983, BIONA REPORT, V2, P35; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P179, DOI 10.1007/BF00619212; HENGSTENBERG R, 1986, PROC R SOC SER B-BIO, V227, P455, DOI 10.1098/rspb.1986.0034; HENGSTENBERG R, 1988, J COMP PHYSIOL A, V163, P151, DOI 10.1007/BF00612425; KUFFLER SW, 1955, J GEN PHYSIOL, V39, P155, DOI 10.1085/jgp.39.1.155; Lehmann FO, 1998, J EXP BIOL, V201, P385; MCCREA RA, 1996, BEHAV CONTINGENT PRO, P292; Mickoleit G., 1962, Zoologische Jahrbuecher Jena Anatomie, V80, P213; MIYAN JA, 1985, PHILOS T ROY SOC B, V311, P271, DOI 10.1098/rstb.1985.0154; NALBACH G, 1994, NEUROSCIENCE, V61, P149, DOI 10.1016/0306-4522(94)90068-X; NALBACH G, 1994, J COMP PHYSIOL A, V175, P695; NALBACH G, 1993, J COMP PHYSIOL A, V173, P293, DOI 10.1007/BF00212693; Pflugstaedt H, 1912, Z WISS ZOOL ABT A, V100, P1; PRINGLE JWS, 1949, J PHYSIOL-LONDON, V108, P226, DOI 10.1113/jphysiol.1949.sp004326; REICHERT H, 1985, NATURE, V315, P142, DOI 10.1038/315142a0; REICHERT H, 1985, J NEUROPHYSIOL, V53, P1201, DOI 10.1152/jn.1985.53.5.1201; SANDEMAN DC, 1980, J EXP BIOL, V85, P43; SANDEMAN DC, 1980, J COMP PHYSIOL, V136, P361, DOI 10.1007/BF00657358; SCHNEIDER G, 1953, Z VERGL PHYSIOL, V35, P416, DOI 10.1007/BF00297884; Trimarchi JR, 1997, J NEUROSCI, V17, P4700; WAGNER H, 1986, PHILOS T ROY SOC B, V312, P553, DOI 10.1098/rstb.1986.0018; WOLF H, 1993, J EXP BIOL, V182, P229	39	97	98	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					289	292		10.1126/science.280.5361.289	http://dx.doi.org/10.1126/science.280.5361.289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535659				2022-12-28	WOS:000073082400052
J	Sakowicz, R; Berdelis, MS; Ray, K; Blackburn, CL; Hopmann, C; Faulkner, DJ; Goldstein, LSB				Sakowicz, R; Berdelis, MS; Ray, K; Blackburn, CL; Hopmann, C; Faulkner, DJ; Goldstein, LSB			A marine natural product inhibitor of kinesin motors	SCIENCE			English	Article							CRYSTAL-STRUCTURE; DOMAIN; PROTEIN; MYOSIN; NCD	Members of the kinesin superfamily of motor proteins are essential for mitotic and meiotic spindle organization, chromosome segregation, organelle and vesicle transport, and many other processes that require microtubule-based transport. A compound, adociasulfate-2, was isolated from a marine sponge, Haliclona (also known as Adocia) species, that inhibited kinesin activity by targeting its motor domain and mimicking the activity of the microtubule. Thus, the kinesin-microtubule interaction site could be a useful target for small molecule modulators, and adociasulfate-2 should serve as an archetype for specific inhibitors of kinesin functions.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Ray, Krishanu/0000-0001-6406-3199				Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Faulkner DJ, 1997, NAT PROD REP, V14, P259, DOI 10.1039/np9971400259; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirokawa N, 1996, CELL STRUCT FUNCT, V21, P357, DOI 10.1247/csf.21.357; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Minden JS, 1996, BIOTECHNIQUES, V20, P122; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sheetz MP, 1996, CELL STRUCT FUNCT, V21, P369, DOI 10.1247/csf.21.369; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	19	87	95	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					292	295		10.1126/science.280.5361.292	http://dx.doi.org/10.1126/science.280.5361.292			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535660				2022-12-28	WOS:000073082400053
J	York, RD; Yao, H; Dillon, T; Ellig, CL; Eckert, SP; McCleskey, EW; Stork, PJS				York, RD; Yao, H; Dillon, T; Ellig, CL; Eckert, SP; McCleskey, EW; Stork, PJS			Rap1 mediates sustained MAP kinase activation induced by nerve growth factor	NATURE			English	Article							PC12 CELLS; NEURONAL DIFFERENTIATION; SIGNALING PATHWAYS; CRK PROTEIN; SH3 DOMAIN; FACTOR C3G; RECEPTOR; RAS; SPECIFICITY; SUFFICIENT	Activation of mitogen-activated protein (MAP) kinase (also known as extracellular-signal-regulated kinase, or ERK)(1) by growth factors can trigger either cell growth or differentiation. The intracellular signals that couple growth factors to MAP kinase may determine the different effects of growth factors: for example, transient activation of MAP kinase by epidermal growth factor stimulates proliferation of PC12 cells(1), whereas they differentiate in response to nerve growth factor, which acts partly by inducing a sustained activation of MAP kinase(1). Here we show that activation of MAP kinase by nerve growth factor involves two distinct pathways: the initial activation of MAP kinase requires the small G protein Ras, but its activation is sustained by the small G protein Rap1. Rap1 is activated by CRK adaptor proteins and the guanine-nucleotide-exchange factor C3G, and forms a stable complex with B-Raf, an activator of MAP kinase. Rap1 is required for at least two indices of neuronal differentiation by nerve growth factor: electrical excitability and the induction of neuron-specific genes. We propose that the activation of Rap1 by C3G represents a common mechanism to induce sustained activation of the MAP kinase cascade in cells that express B-Raf.	Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA.	stork@ohsu.edu						Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; PAN MG, 1995, ONCOGENE, V11, P2005; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA M, 1995, MOL CELL BIOL, V15, P689; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748	30	757	771	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					622	626		10.1038/33451	http://dx.doi.org/10.1038/33451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560161				2022-12-28	WOS:000072987200065
J	Parry, SM; Salmon, RL; Willshaw, GA; Cheasty, T				Parry, SM; Salmon, RL; Willshaw, GA; Cheasty, T			Risk factors for and prevention of sporadic infections with vero cytotoxin (shiga toxin) producing Escherichia coli O157	LANCET			English	Article							HEMORRHAGIC COLITIS	Background Recent outbreaks of vero cytotoxin (shiga toxin) producing Escherichia coli O157 (VTEC O157) infection have stimulated debate on food safety. However, 90% of cases in England and Wales are sporadic. We report a case-control study of sporadic VTEC O157 infection. Methods We compared 85 sporadic cases of VTEC O157 infection, identified through population surveillance, with 142 controls, randomly selected from general practitioners' lists. We matched cases and controls for age, sex, and family doctor's practice. Exposures to foods, water, animals, farms, and environmental factors were recorded. We visited the premises concerned when cases had eaten beefburgers or cooked sliced meats from caterers or had had contact with a farm. Findings Consumption of a beefburger from a catering premises other than from a fast-food chain A (a national chain) and consumption of cold cooked sliced meat leg, in a salad or sandwich) from caterers, but not butchers, was associated with VTEC O157 infection (odds ratios 4.63 [95% CI 1.33-30.14] and 3.36 [1.04-12.74), respectively). Policies for ensuring thorough cooking of burgers by one national fast-food chain differed from the other catering premises we visited. There was evidence of person-to-person spread and transmission of VTEC O157 infection from animals. Interpretation Local inspection of catering establishments that serve cooked meats together with public education to prevent spread on farms and in houses would reduce the burden of VTEC O157 infection by about 10% for each risk factor.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Cardiff CF4 3QX, S Glam, Wales; Welsh Combined Ctr Publ Hlth, Cardiff, S Glam, Wales; Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England	Public Health England	Salmon, RL (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Abton House, Cardiff CF4 3QX, S Glam, Wales.							*ADV COMM MICR SAF, 1995, REP VER PROD ESCH CO; Allaby M A, 1995, Commun Dis Rep CDR Rev, V5, pR4; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BRYANT HE, 1989, J INFECT DIS, V160, P858, DOI 10.1093/infdis/160.5.858; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P85; CHAPMAN PA, 1993, VET REC, V133, P171, DOI 10.1136/vr.133.7.171; COIA JE, 1994, RECENT ADV VEROCYTOT; Cowden J M, 1995, Commun Dis Rep CDR Rev, V5, pR109; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; *INF AG SURV CTR, 1996, INFECT AGENTS SURVEI, V17, P180; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; LESAUX N, 1993, J INFECT DIS, V167, P500, DOI 10.1093/infdis/167.2.500; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; Mead PS, 1997, ARCH INTERN MED, V157, P204, DOI 10.1001/archinte.157.2.204; PARRY SM, 1995, LANCET, V346, P572, DOI 10.1016/S0140-6736(95)91407-2; Pennington Group, 1997, REP CIRC LEAD 1996 O; SALMON RL, 1994, RECENT ADV VEROCYTOX; *SCOTT CTR INF ENV, 1997, SCIEH WKLY REP, V31, P41; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; Stevenson J, 1996, Commun Dis Rep CDR Rev, V6, pR116; Thomas A, 1996, EPIDEMIOL INFECT, V117, P1, DOI 10.1017/S0950268800001060; *WHO DIV FOOD NUTR, 1993, TRAIN CONS APPL HAZ	23	68	70	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1019	1022		10.1016/S0140-6736(97)08376-1	http://dx.doi.org/10.1016/S0140-6736(97)08376-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546508				2022-12-28	WOS:000072927200012
J	Kitazawa, S; Kimura, T; Yin, PB				Kitazawa, S; Kimura, T; Yin, PB			Cerebellar complex spikes encode both destinations and errors in arm movements	NATURE			English	Article							PURKINJE-CELL COMPLEX; MONKEY; DISCHARGE; NEURONS	Purkinje cells of the cerebellum discharge complex spikes, named after the complexity of their waveforms(1), with a frequency of similar to 1 Hz during arm movements(1-13). Despite the low frequency of firing, complex spikes have been proposed to contribute to the initiation of arm movements(2,7-10) or to the gradual improvement of motor skills(2,4-6,14-6). Here we recorded the activity of Purkinje cells from the hemisphere of cerebellar lobules IV-VI while trained monkeys made short-lasting reaching movements (of similar to 200 milliseconds in duration) to touch a visual target that appeared at a random location on a tangent screen, We examined the relationship between complex-spike discharges and the absolute touch position, and between complex-spike discharges and relative errors in touching the screen. We used information theory to show that the complex spikes occurring at the beginning of the reach movement encode the absolute destination of the reach, and the complex spikes occurring at the end of the short-lasting movements encode the relative errors, Thus, complex spikes convey multiple types of information, consistent with the idea that they contribute both to the generation of movements and to the gradual, long-term improvement of these movements.	Electrotech Lab, Informat Sci Div, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, PRESTO, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki 3058568, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Kitazawa, S (corresponding author), Electrotech Lab, Informat Sci Div, 1-1-4 Umezono, Tsukuba, Ibaraki 3058568, Japan.							ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; ARBIB A, 1996, BEHAV BRAIN SCI, V19, P434; BAUSWEIN E, 1983, J PHYSIOL-LONDON, V339, P379, DOI 10.1113/jphysiol.1983.sp014722; FU QG, 1997, NEUROREPORT, V8, P253; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Houk JC, 1996, BEHAV BRAIN SCI, V19, P368, DOI 10.1017/S0140525X00081474; Ito M, 1984, CEREBELLUM NEURAL CO; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KEATING JG, 1995, J NEUROPHYSIOL, V73, P1329, DOI 10.1152/jn.1995.73.4.1329; KITAZAWA S, 1995, J NEUROSCI, V15, P7644; MANO N, 1989, EXP BRAIN RES, V17, P265; MANO NI, 1986, J NEUROPHYSIOL, V56, P137, DOI 10.1152/jn.1986.56.1.137; OJAKANGAS CL, 1992, J NEUROPHYSIOL, V68, P2222, DOI 10.1152/jn.1992.68.6.2222; OJAKANGAS CL, 1994, J NEUROPHYSIOL, V72, P2617, DOI 10.1152/jn.1994.72.6.2617; Simpson JI, 1996, BEHAV BRAIN SCI, V19, P384, DOI 10.1017/S0140525X00081486; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; THACH WT, 1968, J NEUROPHYSIOL, V31, P785, DOI 10.1152/jn.1968.31.5.785; THACH WT, 1970, J NEUROPHYSIOL, V33, P537, DOI 10.1152/jn.1970.33.4.537; WANG JJ, 1987, BRAIN RES, V410, P323, DOI 10.1016/0006-8993(87)90331-3	19	274	276	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					494	497		10.1038/33141	http://dx.doi.org/10.1038/33141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548253				2022-12-28	WOS:000072875200058
J	Wu, YC; Horvitz, HR				Wu, YC; Horvitz, HR			C-elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; DEATH; RECOGNITION; APOPTOSIS; MUTATIONS; ENCODES; MUSCLE	During programmed cell death, cell corpses are rapidly engulfed(1). This engulfment process involves the recognition and subsequent phagocytosis of cell corpses by engulfing cells(1-4). How cell corpses are engulfed is largely unknown, Here we report that ced-5, a gene that is required for cell-corpse engulfment in the nematode Caenorhabditis elegan(5), encodes a protein that is similar to the human protein DOCK180 and the Drosophila melanogaster protein Myoblast City (MBC), both of which have been implicated in the extension of cell surfaces(6). ced-5 mutants are defective not only in the engulfment of cell corpses but also in the migrations of two specific gonadal cells, the distal tip cells. The expression of human DOCK180 in C. elegans rescued the cell-migration defect of a ced-5 mutant. We present evidence that ced-5 functions in engulfing cells during the engulfment of cell corpses. We suggest that ced-5 acts in the extension of the surface of an engulfing cell around a dying cell during programmed cell death, We name this new family of proteins that function in the extension of cell surfaces the CDM (for CED-5, DOCK180 and MBC) family.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	horvitz@mit.edu	Wu, Yi-Chun/F-7934-2012	Wu, Yi-Chun/0000-0002-8621-4098				BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HESEGAWA H, 1996, MOL CELL BIOL, V16, P1770; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	317	327	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					501	504		10.1038/33163	http://dx.doi.org/10.1038/33163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548255				2022-12-28	WOS:000072875200060
J	Newman, B; Mu, H; Butler, LM; Millikan, RC; Moorman, PG; King, MC				Newman, B; Mu, H; Butler, LM; Millikan, RC; Moorman, PG; King, MC			Frequency of breast cancer attributable to BRCA1 in a population-based series of American women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; FAMILIAL BREAST; GENETIC-HETEROGENEITY; SCREENING MAMMOGRAPHY; MUTATIONS; LINKAGE; JEWISH	Context.-Previous studies of BRCA1 mutation prevalence have been based on high-risk groups, yielding estimates that do not reflect the experience of the general population of US patients with breast cancer. Objective.-To determine prevalence of known disease-related mutations and other variants in BRCA1 and how it differs by race, age at diagnosis, and family history status in a population-based sample of white and black patients with breast cancer unselected for family history, Design.-Case-control study. Setting.-A 24-county area of central and eastern North Carolina. Participants.-Cases were women aged 20 to 74 years diagnosed as having a first invasive breast cancer between May 1993 and June 1996. Controls were frequency matched to cases by 5-year age range and race. The first 211 cases and 188 controls regardless of race and the subsequent 99 cases and 108 controls of African American ancestry are included in this report. Main Outcome Measure.-Germline variants at any site in the coding sequence, splice junctions, 5' untranslated region, or 3' untranslated region of the BRCA1 gene were analyzed in cases, and selected variants were analyzed in controls. Screening was performed using multiplex single-strand conformation analysis, with all potential variants confirmed using genomic sequencing. Results.-Three of 211 patients with breast cancer had disease-related variants at BRCA1, all of which were protein-truncating mutations. After adjustment for sampling probabilities, the proportion of patients with breast cancer with disease-related variants was 3.3% (95% confidence interval, 0%-7.2%) in white women and 0% in black women. Young age at diagnosis alone did not predict BRCA1 carrier status in this population, In white women, prevalence of inherited mutation was 23% for cases with family history of ovarian cancer, 13% for cases from families with at least 4 cases of breast cancer with or without ovarian cancer, and 33% for cases from families with both breast and ovarian cancer and at least 4 affected relatives. Because these results are based on few families at the highest levels of risk, confidence intervals around these estimates are wide. An additional 5 patients had rare missense mutations or a single amino acid deletion, the biological significance of which is unknown, In black women, a variant in the 3' untranslated region was statistically significantly more common in cases than in controls. Conclusions.-These data suggest that in the general US population, widespread screening of BRCA1 is not warranted. In contrast, BRCA1 mutations are sufficiently frequent in families with both breast and ovarian cancer, or at least 4 cases of breast cancer (at any age), that genotyping might be considered. The emerging picture of BRCA1 population genetics involves complex interactions of family history, age, and genetic ancestry, all of which should be taken into account when considering testing or interpreting results.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University	Newman, B (corresponding author), Univ N Carolina, Dept Epidemiol, CB 7400 McGavran-Greenberg Hall, Chapel Hill, NC 27599 USA.	beth_newman@unc.edu		King, Mary-Claire/0000-0001-9426-1743	NATIONAL CANCER INSTITUTE [P50CA058223, R01CA027632] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA27632, P50-CA58223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDRICH TE, 1995, BREAST CANCER RES TR, V35, P61, DOI 10.1007/BF00694746; *AM SOC HUM GEN AD, 1994, AM J HUM GENET, V55, P2; ARENA J, 1996, AM J HUM GENET, V59, P34; Bradley Martin B., 1992, CHURCHES CHURCH MEMB; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FORD D, 1995, AM J HUM GENET, V57, P1457; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Ford LG, 1997, PROG CLIN BIOL RES, V396, P271; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gao Q, 1997, AM J HUM GENET, V60, P1233; HALL J, 1900, SCIENCE, V250, P1684; Hartmann L., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P168; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; Hubbard R., 1993, EXPLODING GENE MYTH; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Langston AA, 1996, AM J HUM GENET, V58, P881; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD S, 1995, AM J HUM GENET, V57, P957; NAROD SA, 1991, LANCET, V338, P82; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1997, CANCER RES, V57, P828; Rebbeck TR, 1996, AM J HUM GENET, V59, P547; *RES TRIANGL I, 1996, SUDAAN SOFTW STAT AN; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAS, 1996, SAS STAT SOFTW CHANG; *SAS I INC, 1993, SAS STAT SOFTW GENMO; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Serova OM, 1997, AM J HUM GENET, V60, P486; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; WEINBERG CR, 1991, AM J EPIDEMIOL, V134, P421, DOI 10.1093/oxfordjournals.aje.a116104; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441; Whittemore AS, 1997, AM J HUM GENET, V60, P496	53	288	293	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					915	921		10.1001/jama.279.12.915	http://dx.doi.org/10.1001/jama.279.12.915			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544765	Bronze			2022-12-28	WOS:000072563600031
J	Nielsen, H; Pappot, H; Christensen, IJ; Brunner, N; Thorlacius-Ussing, O; Moesgaard, F; Dano, K; Grondahl-Hansen, J				Nielsen, H; Pappot, H; Christensen, IJ; Brunner, N; Thorlacius-Ussing, O; Moesgaard, F; Dano, K; Grondahl-Hansen, J			Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer	BRITISH MEDICAL JOURNAL			English	Article							PAI-1		Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark; Aalborg Hosp, Dept Surg Gastroenterol, DK-9000 Aalborg, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen; Aalborg University; Aalborg University Hospital	Nielsen, H (corresponding author), Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark.		Pappot, Helle/ADY-3530-2022	Nielsen, Hans Jorgen/0000-0003-2619-4379; Thorlacius-Ussing, Ole/0000-0003-4963-1551				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; CASSLEN B, 1994, EUR J CANCER, V30A, P1302, DOI 10.1016/0959-8049(94)90178-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; MEIJER P, 1994, CLIN CHEM, V40, P110	5	75	77	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					829	830		10.1136/bmj.316.7134.829	http://dx.doi.org/10.1136/bmj.316.7134.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549453	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000072584300029
J	Greenhalgh, T				Greenhalgh, T			Effective prescribing at practice level should be identified and rewarded	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; EXPLAINING VARIATIONS; COSTS; AGE; SEX; ENGLAND; WEIGHTINGS; UNIT; PUS		Whittington Hosp, UCLMS RFHSM, Joint Dept Primary Care & Populat Sci, Unit Evidence Based Practice & Policy, London N19 5NF, England	University of London; University College London	Greenhalgh, T (corresponding author), Whittington Hosp, UCLMS RFHSM, Joint Dept Primary Care & Populat Sci, Unit Evidence Based Practice & Policy, London N19 5NF, England.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				*AUD COMM, 1994, PRESCR IMPR MOR RAT; Baines DL, 1996, J CLIN PHARM THER, V21, P343, DOI 10.1111/j.1365-2710.1996.tb00029.x; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; *DEP HLTH, 1990, IMPR PRESCR; *DEP HLTH, 1989, 4 DEP HLTH; Department of Health, 1996, PRIM CAR DEL FUT; Greenhalgh T, 1997, BRIT MED J, V315, P1482, DOI 10.1136/bmj.315.7121.1482; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; LLOYD DCE, 1997, BRIT J MED EC, V11, P81; LLOYD DCEF, 1995, BRIT MED J, V311, P991; MAJEED A, 1997, PRESCRIBER       MAY, P19; MAJEED A, 1998, BRIT MED J, V316, P48; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MAJEED FA, 1996, HLTH TRENDS, V28, P52; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; Roberts SJ, 1997, BRIT J GEN PRACT, V47, P13; *SECR STAT HLTH, 1997, NEW NHS; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; Wilson RPH, 1996, BRIT MED J, V313, P595; Worrall A, 1997, BRIT MED J, V314, P38, DOI 10.1136/bmj.314.7073.38	24	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					750	753		10.1136/bmj.316.7133.750	http://dx.doi.org/10.1136/bmj.316.7133.750			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529413	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072463700037
J	Vongpatanasin, W; Brickner, ME; Hillis, LD; Lange, RA				Vongpatanasin, W; Brickner, ME; Hillis, LD; Lange, RA			The Eisenmenger syndrome in adults	ANNALS OF INTERNAL MEDICINE			English	Review							CONGENITAL HEART-DISEASE; SINGLE-LUNG TRANSPLANTATION; PULMONARY VASCULAR-DISEASE; VENTRICULAR SEPTAL-DEFECT; PATENT DUCTUS-ARTERIOSUS; RIGHT-TO-LEFT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; EPIDURAL-ANESTHESIA; SELECTION CRITERIA; CESAREAN-SECTION	For this article, the literature on the pathophysiology, clinical features, natural history, prognosis, and management of the Eisenmenger syndrome in adults was reviewed. English-language articles from 1966 to the present were identified through a search of the MEDLINE database by using the terms Eisenmenger, congenital heart disease, and pulmonary hypertension. Selected cross-referenced articles were also included. Articles on the pathophysiology, clinical presentation, evaluation, natural history, complications, and treatment of the Eisenmenger syndrome in adults were selected, and descriptive and analytical data relevant to the practicing physician were manually extracted. The Eisenmenger syndrome is characterized by elevated pulmonary vascular resistance and right-to-left shunting of blood through a systemic-to-pulmonary circulation connection. Most patients with the syndrome survive for 20 to 30 years. The hemostatic changes associated with the syndrome may lead to thromboembolic events, cerebrovascular complications, or the hyperviscosity syndrome. Erythrocytosis is present in most patients, but excessive phlebotomy may cause microcytosis and exacerbate the symptoms of hyperviscosity. Other complications associated with the Eisenmenger syndrome include hemoptysis, gout, cholelithiasis, hypertrophic osteoarthropathy, and decreased renal function. Pregnancy or noncardiac surgery is associated with a high mortality rate in patients with the Eisenmenger syndrome. Because most pediatric patients with the Eisenmenger syndrome survive to adulthood, primary care physicians should have a thorough understanding of the syndrome; its associated complications; and medical and surgical management, especially with regard to the appropriate timing of phlebotomy and lung or heart-lung transplantation. In addition, patients with the syndrome should undergo routine follow-up at a tertiary care center that has physicians and nurses with special expertise in congenital heart disease. In patients with the Eisenmenger syndrome who are pregnant or require noncardiac surgery, a multidisciplinary approach should be used to reduce the excessive mortality associated with these conditions.	Univ Texas, SW Med Ctr, Room CS 7-102,5323 Harry Hines Blvd, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lange, RA (corresponding author), Univ Texas, SW Med Ctr, Room CS 7-102,5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Lange, Richard/AAM-9594-2021	Vongpatanasin, Wanpen/0000-0002-7531-9388				AEBA R, 1993, CIRCULATION, V88, P452; Altman R, 1996, CLIN CARDIOL, V19, P549, DOI 10.1002/clc.4960190706; Ammash N, 1996, J AM COLL CARDIOL, V28, P768, DOI 10.1016/0735-1097(96)00196-9; ASLING JH, 1974, ANESTH ANALG, V53, P965, DOI 10.1213/00000539-197453060-00028; Athens John W., 1993, P1245; AVILA WS, 1995, EUR HEART J, V16, P460, DOI 10.1093/oxfordjournals.eurheartj.a060936; BANDO K, 1994, J THORAC CARDIOV SUR, V108, P1056, DOI 10.1016/S0022-5223(94)70148-2; Berner M, 1996, AM J CARDIOL, V77, P532, DOI 10.1016/S0002-9149(97)89353-8; BITSCH M, 1988, EUR J OBSTET GYN R B, V28, P69, DOI 10.1016/0028-2243(88)90061-5; BOEHRER JD, 1993, AM HEART J, V125, P215, DOI 10.1016/0002-8703(93)90077-M; BOLMAN RM, 1991, ANN SURG, V214, P456, DOI 10.1097/00000658-199110000-00010; BOLMAN RM, 1995, CURR T GEB THOR SURG, V3, P17; BOWYER JJ, 1986, BRIT HEART J, V55, P385; BRIDGES ND, 1995, ANN THORAC SURG, V59, P813, DOI 10.1016/0003-4975(95)00065-S; BROOK MM, 1994, CIRCULATION, V90, P1287, DOI 10.1161/01.CIR.90.3.1287; CACOUB P, 1993, AM J CARDIOL, V71, P448, DOI 10.1016/0002-9149(93)90452-I; CELERMAJER DS, 1993, CIRCULATION, V87, P440, DOI 10.1161/01.CIR.87.2.440; CHEN WJ, 1995, CHEST, V107, P8, DOI 10.1378/chest.107.1.8; CHIEN CT, 1991, AM HEART J, V122, P1065, DOI 10.1016/0002-8703(91)90473-U; CHUNG KJ, 1990, CONGENITAL HEART DIS, P375; CLARKSON MB, 1968, CIRCULATION, V38, P129, DOI 10.1161/01.CIR.38.1.129; COLONOTERO G, 1987, MAYO CLIN PROC, V62, P379, DOI 10.1016/S0025-6196(12)65442-1; COTTRILL CM, 1973, AM J DIS CHILD, V125, P484, DOI 10.1001/archpedi.1973.04160040010003; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DILLARD TA, 1993, CHEST, V103, P422, DOI 10.1378/chest.103.2.422; Dinh Xuan AT, 1990, BRIT J PHARMACOL, V99, P9, DOI 10.1111/j.1476-5381.1990.tb14643.x; Eisenmenger V., 1897, Z KLIN MED, V32, P1; FLANAGAN MF, 1991, AM J CARDIOL, V68, P403, DOI 10.1016/0002-9149(91)90842-9; FREMES SE, 1990, J THORAC CARDIOV SUR, V100, P1; FRIST WH, 1995, ANN THORAC SURG, V60, P268, DOI 10.1016/0003-4975(95)00365-R; FUSE S, 1994, CIRCULATION, V90, P2952, DOI 10.1161/01.CIR.90.6.2952; GAULT JH, 1968, CIRCULATION, V37, P261, DOI 10.1161/01.CIR.37.2.261; GILL JC, 1986, BLOOD, V67, P758; GILMAN DH, 1991, ANAESTHESIA, V46, P371, DOI 10.1111/j.1365-2044.1991.tb09547.x; Gleicher N, 1979, Obstet Gynecol Surv, V34, P721, DOI 10.1097/00006254-197910000-00001; GORCSAN J, 1995, ANN THORAC SURG, V59, P717, DOI 10.1016/0003-4975(94)01054-4; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HENRIKSSON P, 1979, BRIT HEART J, V41, P23; HIGGINS CB, 1984, CIRCULATION, V70, P851, DOI 10.1161/01.CIR.70.5.851; Hopkins WE, 1996, J HEART LUNG TRANSPL, V15, P100; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; JACKSON GM, 1993, OBSTET GYNECOL, V82, P680; JEYAMALAR R, 1992, AUST NZ J OBSTET GYN, V32, P275; JONES P, 1995, BRIT J HOSP MED, V54, P214; KAHN ML, 1993, NEW ENGL J MED, V329, P887, DOI 10.1056/NEJM199309163291217; Katz WE, 1996, J AM COLL CARDIOL, V27, P384, DOI 10.1016/0735-1097(95)00502-1; KIDD L, 1993, CIRCULATION, V87, P38; KRAMER MR, 1994, AM J CARDIOL, V73, P494, DOI 10.1016/0002-9149(94)90681-5; KRAMER MR, 1995, CHEST, V108, P1292, DOI 10.1378/chest.108.5.1292; KURLAN R, 1983, ARCH NEUROL-CHICAGO, V40, P209, DOI 10.1001/archneur.1983.04050040039005; LIEBER S, 1985, ACTA CARDIOL, V40, P421; LINDERKAMP O, 1979, J PEDIATR-US, V95, P567, DOI 10.1016/S0022-3476(79)80770-2; LOPES AAB, 1995, EUR RESPIR J, V8, P530; LUMLEY J, 1977, ANESTH ANALG, V56, P543; LUPINETTI FM, 1994, ANN THORAC SURG, V57, P1545, DOI 10.1016/0003-4975(94)90119-8; MAURER HM, 1975, AM J CARDIOL, V35, P831, DOI 10.1016/0002-9149(75)90119-8; MCCARTHY PM, 1991, ANN THORAC SURG, V52, P300, DOI 10.1016/0003-4975(91)91359-4; MERCHO N, 1994, CHEST, V105, P931, DOI 10.1378/chest.105.3.931; MIDWALL J, 1978, AM J CARDIOL, V42, P299, DOI 10.1016/0002-9149(78)90915-3; NEWMAN JH, 1984, SOUTHERN MED J, V77, P1057, DOI 10.1097/00007611-198408000-00037; OKELLY SW, 1994, BRIT J HOSP MED, V51, P150; OLDERSHAW PJ, 1980, BRIT HEART J, V44, P584; PASQUE MK, 1995, CIRCULATION, V92, P2252, DOI 10.1161/01.CIR.92.8.2252; PASQUE MK, 1995, CURR T GEB THOR SURG, V3, P61; PATTERSON GA, 1995, CURR T GEB THOR SURG, V3, P385; PERKETT EA, 1992, AM J RESP CELL MOL, V6, P82, DOI 10.1165/ajrcmb/6.1.82; PERKETT EA, 1990, J CLIN INVEST, V86, P1459, DOI 10.1172/JCI114862; PERLOFF JK, 1993, CIRCULATION, V87, P1954, DOI 10.1161/01.CIR.87.6.1954; Perloff Joseph K., 1993, Cardiology Clinics, V11, P689; PHORNPHUTKUL C, 1973, AM J CARDIOL, V32, P329, DOI 10.1016/S0002-9149(73)80142-0; PITTS JA, 1977, AM HEART J, V93, P321, DOI 10.1016/S0002-8703(77)80251-2; POLLACK KL, 1990, ANESTH ANALG, V70, P212; RABINOVITCH M, 1987, CIRCULATION, V76, P1043, DOI 10.1161/01.CIR.76.5.1043; Rees R S, 1967, Clin Radiol, V18, P366, DOI 10.1016/S0009-9260(67)80038-2; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; ROSENTHAL A, 1970, CIRCULATION, V42, P297, DOI 10.1161/01.CIR.42.2.297; ROSOVE MH, 1986, LANCET, V2, P313; SAHA A, 1994, INT J CARDIOL, V45, P199, DOI 10.1016/0167-5273(94)90166-X; SEWARD JB, 1977, AM J CARDIOL, V39, P202, DOI 10.1016/S0002-9149(77)80192-6; SHYU KG, 1995, CHEST, V108, P1201, DOI 10.1378/chest.108.5.1201; SMEDSTAD KG, 1994, CAN J ANAESTH, V41, P502, DOI 10.1007/BF03011545; SPINNATO JA, 1981, NEW ENGL J MED, V304, P1215, DOI 10.1056/NEJM198105143042007; TODOROVICHHUNTER L, 1992, AM REV RESPIR DIS, V146, P213, DOI 10.1164/ajrccm/146.1.213; TRULOCK EP, 1991, JAMA-J AM MED ASSOC, V266, P1943, DOI 10.1001/jama.266.14.1943; WEDEMEYER AL, 1973, J PEDIATR-US, V83, P46, DOI 10.1016/S0022-3476(73)80311-7; WIMMER M, 1992, CARDIOVASC DRUG THER, V6, P183, DOI 10.1007/BF00054569; WOLFE RR, 1993, CIRCULATION, V87, P89; WONG CK, 1991, CLIN CARDIOL, V14, P957, DOI 10.1002/clc.4960141205; WOOD P, 1958, BRIT MED J, V2, P700; YOSHIBAYASHI M, 1991, CIRCULATION, V84, P2280, DOI 10.1161/01.CIR.84.6.2280; YOUNG D, 1971, AM J CARDIOL, V28, P658, DOI 10.1016/0002-9149(71)90054-3	91	183	201	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					745	755		10.7326/0003-4819-128-9-199805010-00008	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556469				2022-12-28	WOS:000073363800007
J	Niimura, H; Bachinski, LL; Sangwatanaroj, S; Watkins, H; Chudley, AE; McKenma, W; Kristinsson, A; Roberts, R; Sole, M; Maron, BJ; Seidman, JG; Seidman, CE				Niimura, H; Bachinski, LL; Sangwatanaroj, S; Watkins, H; Chudley, AE; McKenma, W; Kristinsson, A; Roberts, R; Sole, M; Maron, BJ; Seidman, JG; Seidman, CE			Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEAVY-CHAIN GENE; PROGNOSTIC IMPLICATIONS; SKELETAL-MUSCLE; TROPONIN-T; MYBP-C; PHOSPHORYLATION; CHROMOSOME-11; EXPRESSION; DISEASE; ARMS	Background Mutations in the gene for cardiac myosin-binding protein C account for approximately 15 percent of cases of familiar hypertrophic cardiomyopathy. The spectrum of disease-causing mutations and the associated clinical features of these gene defects are unknown. Methods DNA sequences encoding cardiac myosin-binding protein C were determined in unrelated patients with familial hypertrophic cardiomyopathy. Mutations were found in 16 probands, who had 574 family members at risk of inheriting these defects. The genotypes of these family members were determined, and the clinical status of 212 family members with mutations in the gene for cardiac myosin-binding protein C was assessed. Results Twelve novel mutations were identified in probands from 16 families. Four were missense mutations; eight defects (insertions, deletions, and splice mutations) were predicted to truncate cardiac myosin-binding protein C. The clinical expression of either missense or truncation mutations was similar to that observed for other genetic causes of hypertrophic cardiomyopathy, but the age at onset of the disease differed markedly. Only 58 percent of adults under the age of 50 years who had a mutation in the cardiac myosin-binding protein C gene (68 of 117 patients) had cardiac hypertrophy; disease penetrance remained incomplete through the age of 60 years. Survival was generally better than that observed among patients with hypertrophic cardiomyopathy caused by other mutations in the genes for sarcomere proteins. Most deaths due to cardiac causes in these families occurred suddenly. Conclusions The clinical expression of mutations in the gene for cardiac myosin-binding protein C is often delayed until middle age or old age. Delayed expression of cardiac hypertrophy and a favorable clinical course may hinder recognition of the heritable nature of mutations in the cardiac myosin-binding protein C gene. Clinical screening in adult life may be warranted for members of families characterized by hypertrophic cardiomyopathy. (C)1998, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Kagoshima Univ, Dept Internal Med 1, Kagoshima 890, Japan; Baylor Coll Med, Dept Med, Mol Cardiol Unit, Houston, TX 77030 USA; Univ Oxford, Oxford, England; Univ Manitoba, Dept Pediat, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Human Genet, Winnipeg, MB, Canada; Childrens Hosp, Sect Genet & Metab, Winnipeg, MB R3A 1S1, Canada; St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Univ Hosp, Dept Med, Reykjavik, Iceland; Univ Toronto, Toronto Hosp, Cardiovasc Res Ctr, Toronto, ON, Canada; Minneapolis Heart Inst Fdn, Div Cardiol Res, Minneapolis, MN USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Kagoshima University; Baylor College of Medicine; University of Oxford; University of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; St Georges University London; Landspitali National University Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Minneapolis Heart Institute Foundation; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Alpert Rm 533,200 Longwood Ave, Boston, MA 02114 USA.		Niimura, Hideshi/H-1814-2012	Watkins, Hugh/0000-0002-5287-9016	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054313] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50: HL54313-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMAHDAWI S, 1993, BRIT HEART J, V69, P136; ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Becker KD, 1997, J CELL BIOL, V137, P131, DOI 10.1083/jcb.137.1.131; Benson DW, 1996, CIRCULATION, V93, P1791, DOI 10.1161/01.CIR.93.10.1791; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Coviello DA, 1997, J AM COLL CARDIOL, V29, P635, DOI 10.1016/S0735-1097(96)00538-4; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; FAY WP, 1990, J AM COLL CARDIOL, V16, P821, DOI 10.1016/S0735-1097(10)80328-6; FERRIE RM, 1992, AM J HUM GENET, V51, P251; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Gilbert R, 1996, J CELL SCI, V109, P101; HARTZELL HC, 1985, J MOL BIOL, V186, P185, DOI 10.1016/0022-2836(85)90268-2; HOFMANN PA, 1991, J GEN PHYSIOL, V97, P1141, DOI 10.1085/jgp.97.6.1141; LEVER HM, 1989, CIRCULATION, V79, P580, DOI 10.1161/01.CIR.79.3.580; LEWIS JF, 1989, J AM COLL CARDIOL, V13, P36, DOI 10.1016/0735-1097(89)90545-7; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; RHEE D, 1994, CELL MOTIL CYTOSKEL, V28, P1, DOI 10.1002/cm.970280102; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; Rottbauer W, 1997, J CLIN INVEST, V100, P475, DOI 10.1172/JCI119555; SEIDMAN CE, 1996, MOL GENETICS GENE TH, P153; SHENOY MM, 1986, ARCH INTERN MED, V146, P658, DOI 10.1001/archinte.146.4.658; Solomon SD, 1993, J AM COLL CARDIOL, V22, P498, DOI 10.1016/0735-1097(93)90055-6; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; Weisberg A, 1996, P NATL ACAD SCI USA, V93, P8999, DOI 10.1073/pnas.93.17.8999; WIGLE ED, 1995, CURR OPIN CARDIOL, V10, P299, DOI 10.1097/00001573-199505000-00011; WYNNE J, 1997, HEART DIS TXB CARDIO, P1404; YAMAMOTO K, 1983, J BIOL CHEM, V258, P8395	39	527	545	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1248	1257		10.1056/NEJM199804303381802	http://dx.doi.org/10.1056/NEJM199804303381802			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562578				2022-12-28	WOS:000073335800002
J	Fischer, MB; Goerg, S; Shen, LM; Prodeus, AP; Goodnow, CC; Kelsoe, G; Carroll, MC				Fischer, MB; Goerg, S; Shen, LM; Prodeus, AP; Goodnow, CC; Kelsoe, G; Carroll, MC			Dependence of germinal center B cells on expression of CD21/CD35 for survival	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELL; LYMPHOCYTES-B; COMPLEMENT RECEPTOR-1; IMMUNE-RESPONSE; ANTIGEN; MICE; CR-2; MEMORY; CD19; C3D	Affinity-driven selection of B lymphocytes within germinal centers is critical for the development of high-affinity memory cells and host protection. To investigate the role of the CD21/CD35 coreceptor in B cell competition for follicular retention and survival within the germinal center, either Cr2(+) or Cr2(null) lysozyme-specific transgenic B cells were adoptively transferred into normal mice immunized with duck (DEL) or turkey (TEL) lysozyme, which bind with different affinities. In mice injected with high-affinity turkey lysozyme, Cr2(null) B cells responded by follicular retention; however, they could not survive within germinal centers. This suggests that CD21 provides a signal independent of antigen that is required for survival of B cells in the germinal center.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Med Genome Ctr, Canberra, ACT 2601, Australia; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Harvard University; Harvard Medical School; Australian National University; John Curtin School of Medical Research; University System of Maryland; University of Maryland Baltimore	Carroll, MC (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Goodnow, Christopher C/V-8108-2018; Fischer, Michael/AAU-5579-2020	Goodnow, Christopher C/0000-0001-5296-6155; Fischer, Michael/0000-0002-5876-0243				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Cook MC, 1997, J EXP MED, V186, P631, DOI 10.1084/jem.186.5.631; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; Fischer M., UNPUB; Fischer MB, 1996, J IMMUNOL, V157, P549; FISCHER MB, IN PRESS J IMMUNOL; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; MOLINA H, 1990, J IMMUNOL, V145, P2974; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; PRAGER EM, 1971, J BIOL CHEM, V246, P5978; QIN DL, UNPUB; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; VANNOESEL CJM, 1993, IMMUNOL TODAY, V9, P8; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; Wu JH, 1996, J IMMUNOL, V157, P3404; ZHENG B, 1996, J EXP MED, V184, P1	27	211	216	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					582	585		10.1126/science.280.5363.582	http://dx.doi.org/10.1126/science.280.5363.582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554848				2022-12-28	WOS:000073242100045
J	Mazel, D; Dychinco, B; Webb, VA; Davies, J				Mazel, D; Dychinco, B; Webb, VA; Davies, J			A distinctive class of integron in the Vibrio cholerae genome	SCIENCE			English	Article							SITE-SPECIFIC INTEGRATION; GENES; EVOLUTION; ELEMENTS; BACTERIA; FAMILY	The ability of bacteria to acquire and disseminate heterologous genes has been a major factor in the development of multiple drug resistance. A gene, intl4, was identified that encodes a previously unknown integrase that is associated with a "gene-VCR" organization (VCRs are Vibrio cholerae repeated sequences), similar to that of the well-characterized antibiotic resistance integrons, The similarity was confirmed by Intl1-mediated recombination of a gene-VCR cassette into a class 1 integron. VCR cassettes are found in a number of Vibrio species including a strain of V. metschnikovii isolated in 1888, suggesting that this mechanism of heterologous gene acquisition predated the antibiotic era.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Davies, J (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Mazel, Didier/F-9200-2013	Mazel, Didier/0000-0001-6482-6002				Barker A, 1997, MICROBIOL-SGM, V143, P1805, DOI 10.1099/00221287-143-6-1805; BARKER A, 1994, J BACTERIOL, V176, P5450, DOI 10.1128/JB.176.17.5450-5458.1994; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BUNNY KL, 1995, ANTIMICROB AGENTS CH, V39, P686, DOI 10.1128/AAC.39.3.686; *GENB, U14749 GENB; HALL RM, 1993, GENETICA, V90, P115, DOI 10.1007/BF01435034; KITATSUKAMOTO K, 1993, INT J SYST BACTERIOL, V43, P8, DOI 10.1099/00207713-43-1-8; Kovach ME, 1996, MICROBIOL-SGM, V142, P2165, DOI 10.1099/13500872-142-8-2165; Lee CA, 1996, INFECT AGENT DIS, V5, P1; MARTINEZ E, 1988, MOL GEN GENET, V211, P320, DOI 10.1007/BF00330610; MARTINEZ E, 1990, EMBO J, V9, P1275, DOI 10.1002/j.1460-2075.1990.tb08236.x; MAZEL D, UNPUB; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OGAWA A, 1993, MICROBIOL IMMUNOL, V37, P607, DOI 10.1111/j.1348-0421.1993.tb01683.x; Recchia GD, 1997, TRENDS MICROBIOL, V5, P389, DOI 10.1016/S0966-842X(97)01123-2; Recchia GD, 1995, MICROBIOL-UK, V141, P3015, DOI 10.1099/13500872-141-12-3015; van Dongen WMAM, 1987, MOL GEN LIFE SCI ADV, V6, P85; Vicente ACP, 1997, J MED MICROBIOL, V46, P398, DOI 10.1099/00222615-46-5-398; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	19	285	321	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					605	608		10.1126/science.280.5363.605	http://dx.doi.org/10.1126/science.280.5363.605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554855				2022-12-28	WOS:000073242100052
J	Kolk, MH; van der Graaf, M; Wijmenga, SS; Pleij, CWA; Heus, HA; Hilbers, CW				Kolk, MH; van der Graaf, M; Wijmenga, SS; Pleij, CWA; Heus, HA; Hilbers, CW			NMR structure of a classical pseudoknot: Interplay of single- and double-stranded RNA	SCIENCE			English	Article							MOSAIC-VIRUS RNA; IMPROVED SENSITIVITY; VIRAL RNAS; TYMV-RNA; C-13; SPECTROSCOPY; PROTEINS; RIBOZYME; PROTONS; VALINE	Pseudoknot formation folds the 3' ends of many plant viral genomic RNAs into structures that resemble transfer RNA in global folding and in their reactivity to transfer RNA-specific proteins. The solution structure of the pseudoknotted T arm and acceptor arm of the transfer RNA-like structure of turnip yellow mosaic virus (TYMV) was determined by nuclear magnetic resonance (NMR) spectroscopy. The molecule is stabilized by the hairpin formed by the 5' end of the RNA, and by the intricate interactions related to the loops of the pseudoknot. Loop 1 spans the major groove of the helix with only two of its four nucleotides. Loop 2, which crosses the minor groove, interacts closely with its opposing helix, in particular through hydrogen bonds with a highly conserved adenine. The structure resulting from this interaction between the minor groove and single-stranded RNA at helical junctions displays internal mobility, which may be a general feature of RNA pseudoknots that regulates their interaction with proteins or other RNA molecules.	Univ Nijmegen, Biophys Chem Lab, Nijmegen SON Res Ctr Mol Struct Design & Synth, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Hilbers, CW (corresponding author), Univ Nijmegen, Biophys Chem Lab, Nijmegen SON Res Ctr Mol Struct Design & Synth, Toernooiveld, NL-6525 ED Nijmegen, Netherlands.		van der Graaf, Marinette/D-4086-2009; Heus, Hans/F-9696-2015	Heus, Hans/0000-0001-7256-4241				BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHASTAIN M, 1993, BIOCHEMISTRY-US, V32, P14220, DOI 10.1021/bi00214a022; DEIMAN BAL, IN PRESS J VIROL; Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FLORENTZ C, 1982, EMBO J, V1, P269, DOI 10.1002/j.1460-2075.1982.tb01158.x; FOLMER RHA, 1995, J BIOMOL NMR, V5, P427, DOI 10.1007/BF00182287; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hall T C, 1979, Int Rev Cytol, V60, P1, DOI 10.1016/S0074-7696(08)61257-7; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEGAULT P, 1995, FEBS LETT, V362, P156, DOI 10.1016/0014-5793(95)00232-X; LEGAULT P, 1994, J AM CHEM SOC, V116, P2203, DOI 10.1021/ja00084a094; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; PINCK M, 1970, NATURE, V226, P954, DOI 10.1038/226954a0; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PLEIJ CWA, 1994, CURR OPIN STRUC BIOL, V4, P337, DOI 10.1016/S0959-440X(94)90101-5; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; RIETVELD K, 1982, NUCLEIC ACIDS RES, V10, P1929, DOI 10.1093/nar/10.6.1929; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUDINGER J, 1992, NUCLEIC ACIDS RES, V20, P1865, DOI 10.1093/nar/20.8.1865; SCHIMMEL P, 1989, CELL, V58, P9, DOI 10.1016/0092-8674(89)90395-4; Schweisguth DC, 1997, J MOL BIOL, V267, P505, DOI 10.1006/jmbi.1996.0903; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Simorre JP, 1995, J BIOMOL NMR, V6, P427; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; TENDAM E, 1992, BIOCHEMISTRY-US, V31, P11665, DOI 10.1021/bi00162a001; VANBELKUM A, 1989, EUR J BIOCHEM, V183, P591; VANBELKUM A, 1988, NUCLEIC ACIDS RES, V16, P1931, DOI 10.1093/nar/16.5.1931; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; Wijmenga SS, 1997, J BIOMOL NMR, V10, P337, DOI 10.1023/A:1018348123074; Yao LJ, 1997, J BIOMOL NMR, V9, P229, DOI 10.1023/A:1018618606857; YOT P, 1970, P NATL ACAD SCI USA, V67, P1345, DOI 10.1073/pnas.67.3.1345	43	128	130	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					434	438		10.1126/science.280.5362.434	http://dx.doi.org/10.1126/science.280.5362.434			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545221				2022-12-28	WOS:000073159600047
J	Knorr, B; Matz, J; Bernstein, JA; Nguyen, H; Seidenberg, BC; Reiss, TF; Becker, A				Knorr, B; Matz, J; Bernstein, JA; Nguyen, H; Seidenberg, BC; Reiss, TF; Becker, A		Pediat Montelukast Study Grp	Montelukast for chronic asthma in 6- to 14-year-old children - A randomized, double-blind trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIRWAY RESPONSIVENESS; LEUKOTRIENE-D4; CROMOLYN	Context.-Leukotrienes are important mediators of asthma by causing bronchoconstriction, mucous secretion, and increased vascular permeability. Studies using compounds that block leukotrienes have demonstrated improvement in asthma control in adults and adolescents, but children younger than 12 years, for whom asthma is the most common chronic disease, have not been studied. Objective.-To determine the clinical effect of montelukast, a leukotriene receptor antagonist, in 6- to 14-year-old children with asthma. Design.-Eight-week, multicenter, randomized, double-blind study. Setting.-Forty-seven outpatient centers at private practices and academic medical centers in the United States and Canada. Patients.-A total of 336 children with forced expiratory volume in 1 second (FEV1) between 50% to 85% of the predicted value, at least 15% reversibility after inhaled beta-agonist administration, a minimal predefined level of daytime asthma symptoms, and daily beta-agonist use, Concomitant inhaled corticosteroids at a constant daily dose were used by 39% of patients receiving montelukast and 33% receiving placebo. Intervention.-After a 2-week placebo run-in period, patients received either montelukast (5-mg chewable tablet) or matching-image placebo once daily at bedtime for 8 weeks. Main Outcome Measure.-Morning FEV1 percent change from baseline. Results.-Mean morning FEV1 increased from 1.85 L to 2.01 L in the montelukast group and from 1.85 L to 1.93 L in the placebo group, This represents an 8.23% (95% confidence interval [CI], 6.33% to 10.13%) increase from baseline in the montelukast group and a 3.58% (95% CI, 1.29% to 5.87%) increase from baseline in the placebo group (P<.001 for montelukast vs placebo). Conclusion.-Montelukast improves morning FEV1 in 6- to 14-year-old children with chronic asthma.	Merck Res Labs, Dept Pulm Immunol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Biostat, Rahway, NJ 07065 USA; Atlantic Asthma & Allergy Ctr Inc, Baltimore, MD USA; Bernstein Allergy Grp Inc, Cincinnati, OH USA; Univ Manitoba, Dept Pediat, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada	Merck & Company; Merck & Company; University of Manitoba	Knorr, B (corresponding author), Merck Res Labs, Dept Pulm Immunol, POB 2000,RY33-656, Rahway, NJ 07065 USA.			Bernstein, Jonathan/0000-0002-3476-1196				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; CLARK TJH, 1977, BRIT J DIS CHEST, V71, P87, DOI 10.1016/0007-0971(77)90087-0; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kraemer R, 1993, Agents Actions Suppl, V40, P211; LEFF JA, 1997, AM J RESP CRIT CARE, V155, pA976; MACKENZIE CA, 1993, EUR J PEDIATR, V152, P856, DOI 10.1007/BF02073387; *NAT ASTHM ED PREV, 1995, EXP PAN REP, V2; Reiss T. F., 1996, European Respiratory Journal Supplement, V9, p273S; REISS TF, 1995, AM J RESP CRIT CARE, V151, pA378; REISS TF, 1995, EUR RESPIR J, V19, pS289; Santanello N. C., 1996, Journal of Allergy and Clinical Immunology, V97, P257, DOI 10.1016/S0091-6749(96)80516-1; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SHAPIRO GG, 1991, J ALLERGY CLIN IMMUN, V88, P742, DOI 10.1016/0091-6749(91)90181-M; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TANNER JM, 1956, GROWTH ADOLESCENCE; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P757, DOI 10.1016/0091-6749(92)90099-N	26	366	386	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1181	1186		10.1001/jama.279.15.1181	http://dx.doi.org/10.1001/jama.279.15.1181			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555757	Bronze			2022-12-28	WOS:000072969400031
J	Saito, H; Kanamori, Y; Takemori, T; Nariuchi, H; Kubota, E; Takahashi-Iwanaga, H; Iwanaga, T; Ishikawa, H				Saito, H; Kanamori, Y; Takemori, T; Nariuchi, H; Kubota, E; Takahashi-Iwanaga, H; Iwanaga, T; Ishikawa, H			Generation of intestinal T cells from progenitors residing in gut cryptopatches	SCIENCE			English	Article							RECEPTOR-ALPHA-BETA; INTRAEPITHELIAL LYMPHOCYTES; GAMMA-DELTA; NEGATIVE SELECTION; DEFICIENT MICE; IMMUNE-SYSTEM; MUTANT MICE; EPITHELIUM; DIFFERENTIATION; IDENTIFICATION	Cryptopatches (CPs) are part of the murine intestinal immune compartment, Cells isolated from CPs of the small intestine that were c-kit positive (c-kit(+)) but lineage markers negative (Lin(-)) gave rise to T cell receptor (TCR) alpha beta and TCR gamma delta intestinal intraepithelial T cells after in vivo transfer or tissue engraftment into severe combined immunodeficient mice. In contrast, cells from Peyer's patches and mesenteric lymph nodes, which belong in the same intestinal immune compartment but lack c-kit(+)Lin(-) cells, failed lo do so, These findings and results of electron microscopic analysis provide evidence of a local intestinal T cell precursor that develops in the CPs.	Keio Univ, Sch Med, Dept Microbiol, Tokyo 160, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Allergol, Tokyo 108, Japan; Kanagawa Dent Coll, Dept Oral & Maxillofacial Surg, Yokosuka, Kanagawa 238, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 060, Japan	Keio University; National Institute of Infectious Diseases (NIID); University of Tokyo; Kanagawa Dental College; Hokkaido University; Hokkaido University	Ishikawa, H (corresponding author), Keio Univ, Sch Med, Dept Microbiol, Tokyo 160, Japan.		Takemori, Toshitada/A-5909-2016; Takahashi-Iwanaga, Hiromi/A-4294-2012					Aranda R, 1997, J IMMUNOL, V158, P3464; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BARRETT TA, 1992, J IMMUNOL, V149, P1124; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; Fujihashi K, 1996, J EXP MED, V183, P1929, DOI 10.1084/jem.183.4.1929; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; Guehler SR, 1996, J EXP MED, V184, P493, DOI 10.1084/jem.184.2.493; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; Huleatt JW, 1996, IMMUNITY, V5, P263, DOI 10.1016/S1074-7613(00)80321-0; Kagnoff MF, 1996, IMMUNOL TODAY, V17, P57, DOI 10.1016/0167-5699(96)80579-2; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Klein JR, 1996, J EXP MED, V184, P1203, DOI 10.1084/jem.184.4.1203; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; LEFRANCOIS L, 1995, IMMUNOL TODAY, V16, P16, DOI 10.1016/0167-5699(95)80065-4; LEFRANCOIS L, 1991, J IMMUNOL, V147, P1746; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LIN T, 1994, EUR J IMMUNOL, V24, P1080, DOI 10.1002/eji.1830240511; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Mizoguchi A, 1996, J EXP MED, V184, P707, DOI 10.1084/jem.184.2.707; MOSLEY RL, 1992, J EXP MED, V176, P1365, DOI 10.1084/jem.176.5.1365; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; PASQUIER LD, 1993, EVOLUTION IMMUNE SYS, P199; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; POUSSIER P, 1993, J EXP MED, V178, P1947, DOI 10.1084/jem.178.6.1947; Regnault A, 1996, EUR J IMMUNOL, V26, P914, DOI 10.1002/eji.1830260429; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; Shanahan F, 1997, SCIENCE, V275, P1897, DOI 10.1126/science.275.5308.1897; SIM GK, 1995, ADV IMMUNOL, V58, P297, DOI 10.1016/S0065-2776(08)60622-7; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TOMONAGA S, 1973, Zoological Magazine (Tokyo), V82, P215; VANKERCKHOVE C, 1992, J EXP MED, V175, P57, DOI 10.1084/jem.175.1.57; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Weiner HL, 1997, ANNU REV MED, V48, P341; ZAPATA A, 1983, B I PASTEUR, V81, P165	47	246	254	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					275	278		10.1126/science.280.5361.275	http://dx.doi.org/10.1126/science.280.5361.275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535655				2022-12-28	WOS:000073082400048
J	Middleton, MD				Middleton, MD			Words - The accurate use of language	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1078	1078						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552914				2022-12-28	WOS:000072987400035
J	Jin, DY; Spencer, F; Jeang, KT				Jin, DY; Spencer, F; Jeang, KT			Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1	CELL			English	Article							SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; I TAX; ACTIVATION; EXPRESSION; HTLV; GENE; P53; MITOSIS; LINE	In searching for cellular targets of the HTLV-I oncoprotein Tax, we identified TXBP181,which we characterized as the human homolog of yeast mitotic checkpoint MAD1 protein. Evidence supporting TXBP181 as HsMAD1 includes sequence conservation with yeast MAD1, hyperphosphorylation during S/G(2)/M phases and upon treatment of cells with nocodazole, and binding to HsMAD2. HsMAD1 functions as a homodimer. It localizes to the centrosome during metaphase and to the spindle midzone and the midbody during anaphase and telophase. Expression of either Tax or a transdominant-negative TXBP181 results in multinucleated cells, a phenotype consistent with a loss of HsMAD1 function. We propose a model of viral transformation in which Tax targets TXBP181, thereby abrogating a mitotic checkpoint.	NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA; Johns Hopkins Univ, Ctr Genet Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008					Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Glotzer M, 1997, CURR OPIN CELL BIOL, V9, P815, DOI 10.1016/S0955-0674(97)80082-8; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; Knecht H, 1996, ONCOGENE, V13, P947; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Oegema K, 1997, P NATL ACAD SCI USA, V94, P4817, DOI 10.1073/pnas.94.10.4817; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P6815, DOI 10.1073/pnas.77.11.6815; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; TAGUCHI H, 1993, CANCER, V71, P133, DOI 10.1002/1097-0142(19930101)71:1<133::AID-CNCR2820710121>3.0.CO;2-G; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	55	447	468	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					81	91		10.1016/S0092-8674(00)81148-4	http://dx.doi.org/10.1016/S0092-8674(00)81148-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546394	hybrid			2022-12-28	WOS:000072910800012
J	Nightingale, SL				Nightingale, SL			New rules require financial disclosure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Lane, Rockville, MD 20857 USA.							1998, FED REG 5233, V63, P5233	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-28	WOS:000072669700004
J	Andersen, RE; Crespo, CJ; Bartlett, SJ; Cheskin, LJ; Pratt, M				Andersen, RE; Crespo, CJ; Bartlett, SJ; Cheskin, LJ; Pratt, M			Relationship of physical activity and television watching with body weight and level of fatness among children - Results from the Third National Health and Nutrition Examination Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD WEIGHT; US ADULTS; ADOLESCENTS; OVERWEIGHT; OBESITY; EXERCISE; PREVALENCE; MORTALITY; STATEMENT; MORBIDITY	Context.-Physical inactivity contributes to weight gain in adults, but whether this relationship is true for children of different ethnic groups is not well established, Objective.-To assess participation in vigorous activity and television watching habits and their relationship to body weight and fatness in US children, Design.-Nationally representative cross-sectional survey with an in-person interview and medical examination, Setting and Participants.-Between 1988 and 1994, 4063 children aged 8 through 16 years were examined as part of the National Health and Nutrition Examination Survey III, Mexican Americans and non-Hispanic blacks were oversampled to produce reliable estimates for these groups, Main Outcome Measures.-Episodes of weekly vigorous activity and daily hours of television watched, and their relationship to body mass index and body fatness. Results.-Eighty percent of US children reported performing 3 or more bouts of vigorous activity each week, This rate was lower in non-Hispanic black and Mexican American girls (69% and 73%, respectively). Twenty percent of US children participated in 2 or fewer bouts of vigorous activity per week, and the rate was higher in girls (26%) than in boys (17%), Overall, 26% of US children watched 4 or more hours of television per day and 67% watched at least 2 hours per day, Non-Hispanic black children had the highest rates of watching 4 or more hours of television per day (42%), Boys and girls who watch 4 or more hours of television each day had greater body fat (P<.001) and had a greater body mass index (P<.001) than those who watched less than 2 hours per day, Conclusions.-Many US children watch a great deal of television and are inadequately vigorously active. Vigorous activity levels are lowest among girls, non-Hispanic blacks, and Mexican Americans, Intervention strategies to promote lifelong physical activity among US children are needed to stem the adverse health consequences of inactivity.	Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21224 USA; NHLBI, Dept Hlth & Fitness, NIH, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA	Andersen, RE (corresponding author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, 333 Cassell Dr,Suite 1640, Baltimore, MD 21224 USA.		Bartlett, Susan Joan/AAD-4103-2020; Bartlett, Susan J./J-9864-2012; Cheskin, Lawrence/AAM-1094-2021	Bartlett, Susan Joan/0000-0001-9755-2490; Cheskin, Lawrence/0000-0003-0262-1030				ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; ANDERSEN RE, 1992, HLTH FITNESS CLUB LE; ANDERSEN RE, 1995, MED EXERC NUTR HLTH, V4, P57; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], VITAL HLTH STAT; BRICK JM, 1997, USERS GUIDE WESVAR P; BROWN JR, 1974, USES MASS COMMUNICAT, P93; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; *CDCP, 1994, 1994 BRFSS SUMM PREV; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; COOPER DM, 1994, MED SCI SPORT EXER, V26, P733, DOI 10.1249/00005768-199406000-00013; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; DIETZ WH, 1985, PEDIATRICS, V75, P807; DIETZ WH, 1991, CURR PROBL PEDIATR, V1, P8; DIPIETRO L, 1994, INT J OBESITY, V18, P585; DURANT RH, 1994, PEDIATRICS, V94, P449; Epstein LH, 1996, MED SCI SPORT EXER, V28, P428, DOI 10.1097/00005768-199604000-00006; Epstein LH, 1997, HEALTH PSYCHOL, V16, P107, DOI 10.1037/0278-6133.16.2.107; Ezzati T M, 1992, Vital Health Stat 2, P1; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; JEFFREY DB, 1982, HLTH ED Q, V9, P78; KANN L, 1993, PUBLIC HEALTH REP, V108, P47; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MALINA RM, 1990, EXERCISE, FITNESS, AND HEALTH, P637; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; PATRICK K, 1994, PHYSICIAN SPORTSMED, V22, P245; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; SALLIS JF, 1991, RES Q EXERCISE SPORT, V62, P124, DOI 10.1080/02701367.1991.10608701; SALLIS JF, 1994, PEDIATR EXERC SCI, V6, P302; SALLIS JF, 1994, HLTH FITNESS PHYS ED, P31; SAS Institute Inc, 1989, SAS STAT US GUID VER; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Strasburger V C, 1992, Pediatr Rev, V13, P144, DOI 10.1542/pir.13-4-144; Tanner JM, 1975, ASSESSMENT SKELETAL; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Williams TM, 1986, IMPACT TELEVISION NA, P143; 1994, PREVENTION, V46, P65	43	872	894	1	108	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					938	942		10.1001/jama.279.12.938	http://dx.doi.org/10.1001/jama.279.12.938			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC304	9544768				2022-12-28	WOS:000072563600034
J	Jacobson, J				Jacobson, J			After the miracle	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					906	906		10.1001/jama.279.12.906	http://dx.doi.org/10.1001/jama.279.12.906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544753				2022-12-28	WOS:000072563600011
J	Gleave, ME; Elhilali, M; Fradet, Y; Davis, I; Venner, P; Saad, F; Klotz, LH; Moore, MJ; Paton, V; Bajamonde, A				Gleave, ME; Elhilali, M; Fradet, Y; Davis, I; Venner, P; Saad, F; Klotz, LH; Moore, MJ; Paton, V; Bajamonde, A		Canadian Urologic Oncology Grp	Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; ACTIVATED KILLER-CELLS; SPONTANEOUS REGRESSION; PULMONARY METASTASES; ANTITUMOR-ACTIVITY; ALPHA-INTERFERON; INTERLEUKIN-2; THERAPY; IMMUNOTHERAPY; MELANOMA	Background Most trials of immunomodulators in metastatic renal-cell carcinoma have been uncontrolled and subject to selection bias. The objective of this blinded, placebo-controlled study was to compare overall response rates, time to disease progression, and survival of patients with metastatic renal-cell carcinoma treated with recombinant human interferon gamma-1b or placebo. Methods Patients with biopsy-proved metastatic renal-cell carcinoma were randomly assigned to receive interferon gamma-1b (60 mu g per square meter of body-surface area subcutaneously once weekly) or placebo. The primary tumor had been treated by nephrectomy or angioinfarction at least three weeks previously. Patients were evaluated for radiologic evidence of progression, and all responses were independently reviewed by a committee that was unaware of the treatment. Results A total of 197 patients with metastatic renal-cell carcinoma were enrolled at 17 centers in Canada. One hundred eighty-one patients could be evaluated; of these, 91 were assigned to receive interferon gamma-1b and 90 were given placebo. The groups were well balanced in terms of prognostic factors. Two thirds of all patients had Karnofsky scores of 90 or 100, and more than half had two or more metastatic sites. Grade I and II toxicity, mostly chills, fever, asthenia, or headaches, was reported in 91 percent and 61 percent, respectively, of the patients in the interferon group, as compared with 76 percent and 63 percent in the placebo group. Life-threatening drug-related events were rare, occurring in 1 percent of patients in the interferon group. No significant differences between groups were observed in overall response rates, time to disease progression, or survival. The overall response rate was 4.4 percent (3.3 percent complete response and 1.1 percent partial response) in the interferon group and 6.6 percent (3.3 percent complete response and 3.3 percent partial response) in the placebo group (P = 0.54), with a rate of durable complete response of 1 percent in both groups. The median time to disease progression was 1.9 months in both groups (P = 0.49), and there was no significant difference in median survival (12.2 months with interferon vs. 15.7 months with placebo, P = 0.52). Conclusions No difference in outcome was observed in patients with metastatic renal-cell carcinoma who were treated with interferon gamma-1b as compared with placebo. These results emphasize the necessity of testing the efficacy of immunomodulators in randomized studies. (C)1998, Massachusetts Medical Society.	Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Div Urol, Vancouver, BC V5Z 3J5, Canada; McGill Univ, Montreal, PQ, Canada; Univ Laval, Quebec City, PQ, Canada; McMaster Univ, Hamilton, ON, Canada; Cross Canc Ctr, Edmonton, AB, Canada; Univ Montreal, Montreal, PQ, Canada; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Genentech Inc, San Francisco, CA 94080 USA	University of British Columbia; McGill University; Laval University; McMaster University; University of Alberta; Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Roche Holding; Genentech	Gleave, ME (corresponding author), Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Div Urol, D-9 Heather Pavill, Vancouver, BC V5Z 3J5, Canada.			Bell, David/0000-0002-9357-9298; Fradet, Yves/0000-0002-7581-2500				*AM CANC SOC, 1996, CANC FACTS FIG 1996; ANTONELLI G, 1988, CELL IMMUNOL, V115, P156, DOI 10.1016/0008-8749(88)90170-0; AULITZKY W, 1989, J CLIN ONCOL, V7, P1875, DOI 10.1200/JCO.1989.7.12.1875; BUKOWSKI RM, 1990, J NATL CANCER I, V82, P143, DOI 10.1093/jnci/82.2.143; DAVIS SD, 1989, UROLOGY, V33, P141, DOI 10.1016/0090-4295(89)90014-9; ELLERHORST JA, 1994, J UROLOGY, V152, P841, DOI 10.1016/S0022-5347(17)32587-9; ELSON PJ, 1988, CANCER RES, V48, P7310; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FIGLIN RA, 1988, J CLIN ONCOL, V6, P1604, DOI 10.1200/JCO.1988.6.10.1604; Fleiss J. L, 1981, STATISTICAL METHODS, P24; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; HARRIS DT, 1983, SEMIN ONCOL, V10, P422; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KERBL K, 1993, AUST NZ J SURG, V63, P901, DOI 10.1111/j.1445-2197.1993.tb00368.x; KOISO K, 1987, CANCER-AM CANCER SOC, V60, P929; MALUISH AE, 1988, J CLIN ONCOL, V6, P434, DOI 10.1200/JCO.1988.6.3.434; MCLEOD DG, 1984, CANCER KIDNEY, P149; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; NANUS DM, 1990, CANCER RES, V50, P4190; OLIVER R T D, 1988, Molecular Biotherapy, V1, P14; OLIVER RTD, 1989, BRIT J UROL, V63, P128, DOI 10.1111/j.1464-410X.1989.tb05147.x; OMLAND H, 1989, SCAND J UROL NEPHROL, V23, P159, DOI 10.3109/00365598909180834; OTTO U, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1658; PAULNOCK DM, 1989, J INTERFERON RES, V9, P457, DOI 10.1089/jir.1989.9.457; *PROL, 1992, CET ONC; PYRHONEN S, 1996, P AN M AM SOC CLIN, V15, pA244; QUESADA JR, 1985, J CLIN ONCOL, V3, P1522, DOI 10.1200/JCO.1985.3.11.1522; QUESADA JR, 1987, J BIOL RESP MODIF, V6, P20; RABINOVITCH RA, 1994, J CLIN ONCOL, V12, P206, DOI 10.1200/JCO.1994.12.1.206; RINEHART JJ, 1986, J BIOL RESP MODIF, V5, P300; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; TANEJA SS, 1995, UROLOGY, V45, P911, DOI 10.1016/S0090-4295(99)80108-3; VOGELZANG NJ, 1992, J UROLOGY, V148, P1247, DOI 10.1016/S0022-5347(17)36874-X; WACHTER H, 1989, ADV CLIN CHEM, V27, P81, DOI 10.1016/S0065-2423(08)60182-1; WAGSTAFF J, 1987, CANCER IMMUNOL IMMUN, V25, P54; WEISS GR, 1992, J CLIN ONCOL, V10, P275, DOI 10.1200/JCO.1992.10.2.275; WIRTH MP, 1993, UROL CLIN N AM, V20, P283; Yagoda A, 1989, Semin Urol, V7, P199	39	224	229	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1265	1271		10.1056/NEJM199804303381804	http://dx.doi.org/10.1056/NEJM199804303381804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562580				2022-12-28	WOS:000073335800004
J	Orth, SR; Ritz, E				Orth, SR; Ritz, E			Medical progress - The nephrotic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ATRIAL-NATRIURETIC-PEPTIDE; RENAL-VEIN THROMBOSIS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IDIOPATHIC MEMBRANOUS NEPHROPATHY; ANGIOTENSIN-CONVERTING ENZYME; ACE-INHIBITION; BLOOD-PRESSURE; MINIMAL CHANGE; ANTIPROTEINURIC TREATMENT; GLOMERULAR-PERMEABILITY		Heidelberg Univ, Dept Internal Med, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Orth, SR (corresponding author), Heidelberg Univ, Dept Internal Med, Bergheimer Str 56A, D-69115 Heidelberg, Germany.							Adu D, 1996, NEPHROL DIAL TRANSPL, V11, P12; ALBANDER H, 1991, PEDIATR NEPHROL, V5, P482, DOI 10.1007/BF01453686; Ambalavanan S, 1996, J AM SOC NEPHROL, V7, P290; ANDRASSY K, 1980, KLIN WOCHENSCHR, V58, P1029, DOI 10.1007/BF01476873; ARISZ L, 1976, ACTA MED SCAND, V199, P121; BEAUFILS F, 1985, CRIT CARE MED, V13, P132, DOI 10.1097/00003246-198502000-00018; BELLOMO R, 1993, NEPHRON, V63, P249, DOI 10.1159/000187205; BERGREM H, 1983, KIDNEY INT, V23, P876, DOI 10.1038/ki.1983.110; BERNARD DB, 1988, KIDNEY INT, V33, P1184, DOI 10.1038/ki.1988.129; BLACK DAK, 1970, BRIT MED J, V3, P421, DOI 10.1136/bmj.3.5720.421; BRIDGES CR, 1982, KIDNEY INT, V22, P677, DOI 10.1038/ki.1982.229; CAMERON JS, 1987, AM J KIDNEY DIS, V10, P157, DOI 10.1016/S0272-6386(87)80170-1; CHAN MK, 1981, CLIN CHIM ACTA, V117, P317, DOI 10.1016/0009-8981(81)90119-4; COMPER WD, 1995, KIDNEY INT, V47, P1242, DOI 10.1038/ki.1995.178; Cortes L, 1996, KIDNEY INT, V49, pS57; Covic A, 1996, NEPHROL DIAL TRANSPL, V11, P2074, DOI 10.1093/oxfordjournals.ndt.a027101; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; DAMICO G, 1992, LANCET, V339, P1131, DOI 10.1016/0140-6736(92)90731-H; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; Dantal Jacques, 1996, Journal of the American Society of Nephrology, V7, P1696; DAVIES RW, 1990, J CLIN INVEST, V86, P600, DOI 10.1172/JCI114750; Dimitrov Y, 1997, NEPHROL DIAL TRANSPL, V12, P200, DOI 10.1093/ndt/12.1.200; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; DON BR, 1991, AM J KIDNEY DIS, V17, P10, DOI 10.1016/S0272-6386(12)80243-5; DONKER AJM, 1978, NEPHRON, V22, P374, DOI 10.1159/000181478; Dullaart RPF, 1996, METABOLISM, V45, P723, DOI 10.1016/S0026-0495(96)90138-9; DUSING R, 1980, NEPHRON, V25, P187, DOI 10.1159/000181779; FLISER D, 1994, KIDNEY INT, V46, P482, DOI 10.1038/ki.1994.298; Fuchshuber A, 1996, NEPHROL DIAL TRANSPL, V11, P468; GANSEVOORT RT, 1995, NEPHROL DIAL TRANSPL, V10, P497, DOI 10.1093/ndt/10.4.497; GANSEVOORT RT, 1994, NEPHROL DIAL TRANSPL, V9, P244; GANSEVOORT RT, 1995, NEPHROL DIAL TRANSPL, V10, P1963; GANSEVOORT RT, 1994, KIDNEY INT, V45, P861, DOI 10.1038/ki.1994.113; GANSEVOORT RT, 1993, KIDNEY INT, V44, P579, DOI 10.1038/ki.1993.284; GEERS AB, 1984, KIDNEY INT, V26, P324, DOI 10.1038/ki.1984.176; GOLBETZ H, 1989, AM J PHYSIOL, V256, pF44, DOI 10.1152/ajprenal.1989.256.1.F44; Goode NP, 1996, NEPHROL DIAL TRANSPL, V11, P1714; GRAUSZ H, 1972, KIDNEY INT, V1, P47, DOI 10.1038/ki.1972.7; Gregory MJ, 1996, J AM SOC NEPHROL, V7, P543; GRYMONPREZ A, 1995, PEDIATR NEPHROL, V9, P278, DOI 10.1007/BF02254183; HALL AV, 1992, J AM SOC NEPHROL, V3, P1321; HAWS RM, 1993, PEDIATRICS, V91, P1142; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; Hemmelder MH, 1996, KIDNEY INT, V49, P174, DOI 10.1038/ki.1996.24; Hergesell O, 1998, NEPHROL DIAL TRANSPL, V13, P975, DOI 10.1093/ndt/13.4.975; HUMPHREYS MH, 1995, KIDNEY INT, V48, P311, DOI 10.1038/ki.1995.299; HUTCHISON FN, 1995, J AM SOC NEPHROL, V6, P1216; ICHIKAWA I, 1983, J CLIN INVEST, V71, P91, DOI 10.1172/JCI110756; INGULLI E, 1992, J AM SOC NEPHROL, V3, P254; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JONES CL, 1991, PEDIATR NEPHROL, V5, P56, DOI 10.1007/BF00852846; JOVEN J, 1990, NEW ENGL J MED, V323, P579, DOI 10.1056/NEJM199008303230905; KASSIRER JP, 1983, KIDNEY INT, V24, P561, DOI 10.1038/ki.1983.194; KATZ AI, 1995, TXB NEPHROLOGY, P1148; KAYSEN GA, 1986, LAB INVEST, V54, P479; KAYSEN GA, 1993, AM J NEPHROL, V13, P347, DOI 10.1159/000168649; KAYSEN GA, 1986, KIDNEY INT, V29, P572, DOI 10.1038/ki.1986.36; KIRCHNER KA, 1991, KIDNEY INT, V40, P418, DOI 10.1038/ki.1991.228; KOOMANS HA, 1987, NEPHRON, V47, P173, DOI 10.1159/000184486; KOYAMA A, 1991, KIDNEY INT, V40, P453, DOI 10.1038/ki.1991.232; KUSTER S, 1990, AM J NEPHROL, V10, P76, DOI 10.1159/000168198; LEWIS EJ, 1988, NEPHROTIC SYNDROME, P461; Lieberman KV, 1996, J AM SOC NEPHROL, V7, P56; LIN CY, 1995, KIDNEY INT, V47, P225, DOI 10.1038/ki.1995.27; LLACH F, 1980, AM J MED, V69, P819, DOI 10.1016/S0002-9343(80)80006-4; MARKOWITZ GS, 1995, AM J KIDNEY DIS, V25, P801, DOI 10.1016/0272-6386(95)90558-8; MASSY ZA, 1995, KIDNEY INT, V48, P188, DOI 10.1038/ki.1995.284; MEYRIER A, 1994, KIDNEY INT, V45, P1446, DOI 10.1038/ki.1994.189; MILLER PFW, 1990, ARCH DIS CHILD, V65, P196, DOI 10.1136/adc.65.2.196; Moriyama T, 1995, J AM SOC NEPHROL, V6, P1674; NOLASCO F, 1986, KIDNEY INT, V29, P1215, DOI 10.1038/ki.1986.130; OGI M, 1994, AM J KIDNEY DIS, V24, P427, DOI 10.1016/S0272-6386(12)80899-7; OLIVERO JJ, 1993, AM J KIDNEY DIS, V21, P260, DOI 10.1016/S0272-6386(12)80743-8; ORDONEZ JD, 1993, KIDNEY INT, V44, P638, DOI 10.1038/ki.1993.292; PERICO N, 1989, KIDNEY INT, V36, P57, DOI 10.1038/ki.1989.161; PETERSON C, 1988, KIDNEY INT, V34, P825, DOI 10.1038/ki.1988.256; PICCOLI A, 1994, KIDNEY INT, V45, P1193, DOI 10.1038/ki.1994.158; Plum J, 1996, NEPHROL DIAL TRANSPL, V11, P1034; Ponticelli C, 1995, NEPHROL DIAL TRANSPL, V10, P2351, DOI 10.1093/ndt/10.12.2351; PONTICELLI C, 1995, KIDNEY INT, V48, P1600, DOI 10.1038/ki.1995.453; POOL MO, 1990, NEW ENGL J MED, V323, P552; PRIMACK WA, 1994, AM J KIDNEY DIS, V23, P524, DOI 10.1016/S0272-6386(12)80373-8; RABELINK TJ, 1994, KIDNEY INT, V46, P287, DOI 10.1038/ki.1994.274; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; ROBERT A, 1987, KIDNEY INT, V31, P830, DOI 10.1038/ki.1987.73; SARASIN FP, 1994, KIDNEY INT, V45, P578, DOI 10.1038/ki.1994.75; Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402; SHAFRIR E, 1979, LIPIDS, V14, P695, DOI 10.1007/BF02533892; SHEMESH O, 1986, J CLIN INVEST, V77, P868, DOI 10.1172/JCI112384; SPITALEWITZ S, 1993, AM J KIDNEY DIS, V22, P143, DOI 10.1016/S0272-6386(12)70180-4; STAPRANS I, 1980, BIOCHIM BIOPHYS ACTA, V617, P514, DOI 10.1016/0005-2760(80)90017-X; THOMAS ME, 1993, KIDNEY INT, V44, P1124, DOI 10.1038/ki.1993.358; TREW PA, 1978, MEDICINE, V57, P69, DOI 10.1097/00005792-197801000-00005; Tune BM, 1997, J AM SOC NEPHROL, V8, P824; VALENTIN JP, 1992, J CLIN INVEST, V90, P1302, DOI 10.1172/JCI115995; Vande Walle J. G., 1995, Lancet (North American Edition), V346, P148, DOI 10.1016/S0140-6736(95)91210-X; VandeWalle JC, 1996, NEPHROL DIAL TRANSPL, V11, P2202, DOI 10.1093/oxfordjournals.ndt.a027137; VAZIRI ND, 1995, KIDNEY INT, V48, P1979, DOI 10.1038/ki.1995.500; VAZIRI ND, 1983, AM J NEPHROL, V3, P1, DOI 10.1159/000166678; VEGA GL, 1995, KIDNEY INT, V47, P579, DOI 10.1038/ki.1995.73; WANNER C, 1993, ANN INTERN MED, V119, P263, DOI 10.7326/0003-4819-119-4-199308150-00002; WASS V, 1981, NEPHRON, V27, P58, DOI 10.1159/000182025; WEIDMANN P, 1993, NEPHROL DIAL TRANSPL, V8, P582; WEISS RA, 1984, NEW YORK STATE J MED, V84, P384; WHEELER DC, 1995, NEPHROL DIAL TRANSPL, V10, P14; WILCOX CS, 1983, J LAB CLIN MED, V102, P450; WONG KR, 1988, AM J PHYSIOL, V255, pF1220, DOI 10.1152/ajprenal.1988.255.6.F1220	108	288	305	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1202	1211		10.1056/NEJM199804233381707	http://dx.doi.org/10.1056/NEJM199804233381707			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554862				2022-12-28	WOS:000073208400007
J	Friedmann, PD; Saitz, R; Samet, JH				Friedmann, PD; Saitz, R; Samet, JH			Management of adults recovering from alcohol or other drug problems - Relapse prevention in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; SUBSTANCE-ABUSE; PREVALENCE; DEPENDENCE; DEPRESSION; ADDICTION; PHYSICIAN; DRINKING	Patients recovering from substance use disorders are commonly seen in the primary care setting, and relapse is a serious long-term problem for these patients. Extrapolating from therapeutic strategies effective in specialty addiction treatment settings, this article outlines a practical approach to relapse prevention in the primary care setting. Working within a supportive patient-physician relationship, the primary care physician can help recovering patients decrease their susceptibility to relapse, recognize and manage high-risk situations, and use available self-help, pharmacological, and specialty resources, Drawing on the therapeutic relationship and skills they already possess, primary care physicians can have an important, productive, and satisfying role in the long-term management of patients in recovery from alcohol or other drug problems.	Univ Chicago, Pritzker Sch Med, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA; Boston Univ, Sch Med, Boston Med Ctr, Dept Med,Sect Gen Internal Med,Clin Addict Res & E, Boston, MA 02118 USA	University of Chicago; Boston Medical Center; Boston University	Friedmann, PD (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, Gen Internal Med Sect, 5841 S Maryland Ave,MC2007, Chicago, IL 60637 USA.	pfriedman@medicine.bsd.uchicago.edu		/0000-0002-2535-1427; Samet, Jeffrey/0000-0002-0897-3400	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010019, K08DA000320] Funding Source: NIH RePORTER; NIAAA NIH HHS [5R01-AA10870] Funding Source: Medline; NIDA NIH HHS [1K08-DA00320, 5R01-DA10019] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		*ALC AN WORLD SERV, 1952, 12 STEPS 12 TRAD; *ALC AN WORLD SERV, 1975, ALC AN; *ALC AN WORLD SERV, 1975, LIV SOB; Allen J, 1997, ADDICTION, V92, P1671; Allen JP, 1997, J STUD ALCOHOL, V58, P7; *AM SOC ADD MED, 1997, ASAM NEWS, V17, P17; Babor TF, 1996, AM J PUBLIC HEALTH, V86, P948; Barnes HN, 1997, MED CLIN N AM, V81, P867, DOI 10.1016/S0025-7125(05)70553-8; BARNES HN, 1995, SUBST ABUSE, V16, P31; BIGBY JA, 1987, ALCOHOLISM GUIDE PRI, P66; BUCHSBAUM DG, 1995, ARCH INTERN MED, V155, P104, DOI 10.1001/archinte.155.1.104; Carroll KM, 1996, EXP CLIN PSYCHOPHARM, V4, P46, DOI 10.1037/1064-1297.4.1.46; COLLETTI G, 1980, J CONSULT CLIN PSYCH, V48, P665, DOI 10.1037/0022-006X.48.5.665; Connors GJ, 1996, ADDICTION, V91, pS173, DOI 10.1111/j.1360-0443.1996.tb02337.x; Connors GJ, 1996, ADDICTION, V91, pS5, DOI 10.1111/j.1360-0443.1996.tb02323.x; Connors GJ, 1996, ADDICTION, V91, pS191, DOI 10.1111/j.1360-0443.1996.tb02338.x; DALEY DC, 1989, RELAPSE CONCEPTUAL R, P3; DEJONG W, 1994, DHHS PUBLICATION; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FLITCRAFT AH, 1994, AM MED ASS DIAGNOSTI; GORSKI T.T, 1988, STAYING SOBER WORKBO; GORSKI TT, 1989, RELAPSE CONCEPTUAL R, P153; GORSKI TT, 1991, ADDICT RECOVERY, V3, P17; HASIN DS, 1990, ARCH INTERN MED, V150, P397, DOI 10.1001/archinte.150.2.397; HAWKINS JD, 1985, INT J ADDICT, V20, P917, DOI 10.3109/10826088509047759; Hirschfeld RMA, 1997, NEW ENGL J MED, V337, P910, DOI 10.1056/NEJM199709253371307; HOFFMANN NG, 1996, COMMITTEE BENEFITS P; HUNT WA, 1971, J CLIN PSYCHOL, V27, P455, DOI 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R; Institute of Medicine, 1997, DISP MYTHS ADD; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; KURTZ E, 1982, J STUD ALCOHOL, V43, P38, DOI 10.15288/jsa.1982.43.38; Larson MJ, 1997, MED CLIN N AM, V81, P1053, DOI 10.1016/S0025-7125(05)70563-0; Liebschutz JM, 1997, ARCH INTERN MED, V157, P1093, DOI 10.1001/archinte.157.10.1093; Marlatt GA., 2005, RELAPSE PREVENTION M; Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761; MCAULIFFE WE, 1990, J PSYCHOACTIVE DRUGS, V22, P197, DOI 10.1080/02791072.1990.10472544; MCCRADY BS, 1996, TREATING SUBSTANCE A, P117; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Miller WR, 1996, ADDICTION, V91, pS15, DOI 10.1111/j.1360-0443.1996.tb02324.x; *NARC AN WORLD SER, 1983, NARC AN; *NAT I ALC AB ALC, 1995, NIH PUBL; NOWINSKI J, 1995, DHHS PUBLICATION, V1; O'Connor P. G., 1996, JGIM, V11, P53; O'Connor PG, 1997, AM J MED, V103, P477, DOI 10.1016/S0002-9343(97)00271-4; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OFARELL TJ, 1993, TREATING ALCOHOL PRO; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; ROUNSAVILLE BJ, 1987, ARCH GEN PSYCHIAT, V44, P505; Saitz R, 1997, AM J DRUG ALCOHOL AB, V23, P343, DOI 10.3109/00952999709016881; Saitz R, 1997, MED CLIN N AM, V81, P881, DOI 10.1016/S0025-7125(05)70554-X; Samet J. H., 1995, JGIM, V10, P48; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; Warner EA, 1997, MED CLIN N AM, V81, P909, DOI 10.1016/S0025-7125(05)70555-1; Wilk AI, 1997, J GEN INTERN MED, V12, P274; Ziedonis D, 1997, MED CLIN N AM, V81, P1017, DOI 10.1016/S0025-7125(05)70561-7; ZIEDONIS DM, 1991, PSYCHOPHARMACOL BULL, V27, P337	63	89	90	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1227	1231		10.1001/jama.279.15.1227	http://dx.doi.org/10.1001/jama.279.15.1227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG133	9555766				2022-12-28	WOS:000072969400039
J	Duley, L; Mahomed, K				Duley, L; Mahomed, K			Magnesium sulphate in eclampsia	LANCET			English	Letter									Magpie Trial Coordinating Ctr, Inst Hlth Sci, Oxford OX3 7LF, England	University of Oxford	Duley, L (corresponding author), Magpie Trial Coordinating Ctr, Inst Hlth Sci, Oxford OX3 7LF, England.		Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178				Bennett P, 1997, LANCET, V350, P1491, DOI 10.1016/S0140-6736(05)63935-9; DULEY L, 1995, LANCET, V345, P1455; FOX R, 1995, BRIT MED J, V311, P1433, DOI 10.1136/bmj.311.7017.1433	3	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1061	1062		10.1016/S0140-6736(05)79031-0	http://dx.doi.org/10.1016/S0140-6736(05)79031-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546538				2022-12-28	WOS:000072927200057
J	Berger, A; Smith, R				Berger, A; Smith, R			Developing the BMJ's coverage of basic science - We are introducing science commentaries	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1260	1260		10.1136/bmj.316.7140.1260	http://dx.doi.org/10.1136/bmj.316.7140.1260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554894	Green Published			2022-12-28	WOS:000073335900005
J	Hourihane, JO; Roberts, SA; Warner, JO				Hourihane, JO; Roberts, SA; Warner, JO			Resolution of peanut allergy: case-control study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL COURSE; HYPERSENSITIVITY; CHILDREN; MILK	Objectives: To determine whether there are any differences between children who remain mildly or moderately allergic to peanut and children with similar histories but a negative reaction on challenge with peanut Design: Case-controls matched for age and sex. Setting: Children's day wards in two teaching hospitals. Intervention: Open food challenge with peanut. Subjects: 15 children with resolved peanut allergy (resolvers) and 15 with persistent allergy (persisters). Main outcome measure: Reaction on challenge with peanut, serum total and peanut specific IgE concentrations. Results: The groups had a similar median age at first reaction to peanut (11 months, range 5-38) and similar symptoms. Allergy to other foods was less common in resolvers (2/15) than persisters (9/15) (P = 0.02). On skin prick testing with peanut all 13 resolvers tested but only 3/14 persisters had a weal of < 6 mm CP < 0.0001). Total and peanut specific IgE concentrations did not differ much between the groups. Conclusion: Appropriately trained clinicians must be prepared to challenge preschool children with peanut as some will be tolerant despite a history of reactions to peanut and a positive skin prick test with peanut Preschool children whose apparent peanut allergy is refuted by food challenge show allergy to other foods less often than those in whom peanut allergy persists. The size of weal on skin prick testing to peanut predicts reactivity but not severity on peanut challenge.	Univ Southampton, Southampton SO16 6YD, Hants, England; Univ S Manchester Hosp, Withington Hosp, Manchester M20 2LR, Lancs, England	University of Southampton; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Hourihane, JO (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.		Warner, John/AAF-9587-2020					BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Cooke SK, 1997, J IMMUNOL, V159, P2026; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Ewan PW, 1996, BRIT MED J, V312, P1074; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P1101; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; HOST A, 1997, J ALLERGY CLIN IMM 2, V99, pS491; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sporik R, 1996, BRIT MED J, V313, P1477, DOI 10.1136/bmj.313.7070.1477c; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	15	203	206	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1271	1275		10.1136/bmj.316.7140.1271	http://dx.doi.org/10.1136/bmj.316.7140.1271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554896	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000073335900020
J	Wurman, J; Winslow, J				Wurman, J; Winslow, J			Intense sub-kilometer-scale boundary layer rolls observed in Hurricane Fran	SCIENCE			English	Article							DOPPLER RADAR OBSERVATIONS; MATURE HURRICANES; MESOSCALE; ANDREW	High-resolution observations obtained with the Doppler On Wheels (DOW) mobile weather radar near the point of landfall of hurricane Fran (1996) revealed the existence of intense, sub-kilometer-scale, boundary layer rolls that strongly modulated the nearsurface wind speed. It is proposed that these structures are one cause of geographically varying surface damage patterns that have been observed after some landfalling hurricanes and that they cause much of the observed gustiness, bringing high-velocity air from aloft to the lowest observable levels. High-resolution DOW radar observations are contrasted with lower-resolution observations obtained with an operational weather radar, which underestimated peak low-level wind speeds.	Univ Oklahoma, Sch Meteorol, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Wurman, J (corresponding author), Univ Oklahoma, Sch Meteorol, 100 E Boyd St, Norman, OK 73019 USA.							Asai T., 1972, J METEOR SOC JAPAN, V50, P525, DOI [10.2151/jmsj1965.50.6_525, DOI 10.2151/JMSJ1965.50.6_525]; Asai T., 1970, J METEOR SOC JAPAN, V48, P18, DOI DOI 10.2151/JMSJ1965.48.1_18; Dodge P, 1997, 22ND CONFERENCE ON HURRICANES AND TROPICAL METEOROLOGY, P115; FALLER AJ, 1965, J ATMOS SCI, V23, P466; Fujita T.T., 1992, STORM DATA, V34, P25; Houston SH, 1997, 22ND CONFERENCE ON HURRICANES AND TROPICAL METEOROLOGY, P92; JORGENSEN DP, 1984, J ATMOS SCI, V41, P1268, DOI 10.1175/1520-0469(1984)041<1268:MACSCO>2.0.CO;2; JORGENSEN DP, 1984, J ATMOS SCI, V41, P1287, DOI 10.1175/1520-0469(1984)041<1287:MACSCO>2.0.CO;2; KIM J, 1987, J FLUID MECH, V177, P133, DOI 10.1017/S0022112087000892; KLINE SJ, 1967, J FLUID MECH, V30, P741, DOI 10.1017/S0022112067001740; KRAYER WR, 1992, B AM METEOROL SOC, V73, P613, DOI 10.1175/1520-0477(1992)073<0613:GFATHW>2.0.CO;2; KROPFLI RA, 1978, J APPL METEOROL, V17, P669, DOI 10.1175/1520-0450(1978)017<0669:PHRITU>2.0.CO;2; KUETTNER JP, 1971, TELLUS, V23, P404, DOI 10.1111/j.2153-3490.1971.tb00585.x; LEMONE MA, 1973, J ATMOS SCI, V30, P1077, DOI 10.1175/1520-0469(1973)030<1077:TSADOH>2.0.CO;2; MARKS FD, 1984, B AM METEOROL SOC, V65, P569, DOI 10.1175/1520-0477(1984)065<0569:ADROIH>2.0.CO;2; OYE R, 1981, 20TH C RAD MET BOST, P683; Powell MD, 1996, WEATHER FORECAST, V11, P329, DOI 10.1175/1520-0434(1996)011<0329:HALISF>2.0.CO;2; Stewart SR, 1997, 22ND CONFERENCE ON HURRICANES AND TROPICAL METEOROLOGY, P106; SUN WY, 1978, J ATMOS SCI, V35, P466, DOI 10.1175/1520-0469(1978)035<0466:SAODCS>2.0.CO;2; SYKES RI, 1989, J ATMOS SCI, V46, P1106, DOI 10.1175/1520-0469(1989)046<1106:LESOTS>2.0.CO;2; WAKIMOTO RM, 1994, B AM METEOROL SOC, V75, P189, DOI 10.1175/1520-0477(1994)075<0189:DSOHAA>2.0.CO;2; Weckwerth TM, 1996, MON WEATHER REV, V124, P769, DOI 10.1175/1520-0493(1996)124<0769:TVWTCB>2.0.CO;2; Weckwerth TM, 1997, MON WEATHER REV, V125, P505, DOI 10.1175/1520-0493(1997)125<0505:HCRDTE>2.0.CO;2; Wurman J, 1997, J ATMOS OCEAN TECH, V14, P1502, DOI 10.1175/1520-0426(1997)014<1502:DADOAP>2.0.CO;2; Wurman J, 1996, SCIENCE, V272, P1774, DOI 10.1126/science.272.5269.1774	26	123	131	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					555	557		10.1126/science.280.5363.555	http://dx.doi.org/10.1126/science.280.5363.555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554839				2022-12-28	WOS:000073242100036
J	Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK				Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK			A national survey of physician-assisted suicide and euthanasia in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONCOLOGISTS; ATTITUDES; DEATH; ILL	Background Although there have been many studies of physician-assisted suicide and euthanasia in the United States, national data are lacking. Methods In 1996, we mailed questionnaires to a stratified probability sample of 3102 physicians in the 10 specialties in which doctors are most likely to receive requests from patients for assistance with suicide or euthanasia. We weighted the results to obtain nationally representative data. Results We received 1902 completed questionnaires (response rate, 61 percent). Eleven percent of the physicians said that under current legal constraints; there were circumstances in which they would be willing to hasten a patient's death by prescribing medication, and 7 percent said that they would provide a lethal injection; 36 percent and 24 percent, respectively, said that they would do so if it were legal. Since entering practice, 18.3 percent of the physicians (unweighted number, 320) reported having received a request from a patient for assistance with suicide and 11.1 percent (unweighted number, 196) had received a request for a lethal injection. Sixteen percent of the physicians receiving such requests (unweighted number, 42), or 3.3 percent of the entire sample, reported that they had written at least one prescription to be used to hasten death, and 4.7 percent (unweighted number, 59), said that they had administered at least one lethal injection. Conclusions A substantial proportion of physicians in the United States in the specialties surveyed report that they receive requests for physician-assisted suicide and euthanasia, and about 6 percent have complied with such requests at least once. (C)1998, Massachusetts Medical Society.	Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Chicago	Meier, DE (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Box 1070, New York, NY 10029 USA.				NATIONAL INSTITUTE OF NURSING RESEARCH [R03NR003109] Funding Source: NIH RePORTER; NINR NIH HHS [1RO3NR03109] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; CRANE D, 1977, SANCTITY SOCIAL LIFE; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; HOSMER DW, 1989, APPL LOGISTIC REGRES; JOBE JB, 1989, AM J PUBLIC HEALTH, V79, P1053, DOI 10.2105/AJPH.79.8.1053; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; McKeogh M, 1997, NEW ENGL J MED, V337, P56, DOI 10.1056/NEJM199707033370118; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; MEIER DE, 1993, PHYSICIAN ASSISTED D; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; TAYLOR H, 1995, DOCTOR ASSISTED SUCI	22	366	367	2	69	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1193	1201		10.1056/NEJM199804233381706	http://dx.doi.org/10.1056/NEJM199804233381706			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554861	Bronze			2022-12-28	WOS:000073208400006
J	Basson, JV				Basson, JV			Fate of special hospitals in England has not yet been decided	BRITISH MEDICAL JOURNAL			English	Letter									Broadmoor Hosp, Broadmoor Hosp Author, Crowthorne RG45 7EG, Berks, England		Basson, JV (corresponding author), Broadmoor Hosp, Broadmoor Hosp Author, Crowthorne RG45 7EG, Berks, England.							Warden J, 1998, BRIT MED J, V316, P956	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1243	1244		10.1136/bmj.316.7139.1243	http://dx.doi.org/10.1136/bmj.316.7139.1243			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553013				2022-12-28	WOS:000073224100045
J	McKeegan, KD; Leshin, LA; Russell, SS; MacPherson, GJ				McKeegan, KD; Leshin, LA; Russell, SS; MacPherson, GJ			Oxygen isotopic abundances in calcium-aluminum-rich inclusions from ordinary chondrites: Implications for nebular heterogeneity	SCIENCE			English	Article							SOLAR NEBULA; CARBONACEOUS CHONDRITES; ALLENDE INCLUSIONS; METEORITES; ORIGIN; COMPONENT; ANOMALIES; AL-26	The oxygen isotopic compositions of two calcium-aluminum-rich inclusions (CAIs) from the unequilibrated ordinary chondrite meteorites Quinyambie and Semarkona are enriched in O-16 by an amount similar to that in CAIs from carbonaceous chondrites. This may indicate that most CAIs formed in a restricted region of the solar nebula and were then unevenly distributed throughout the various chondrite accretion regions. The Semarkona CAI is isotopically homogeneous and contains highly O-16-enriched melilite, supporting the hypothesis that all CAI minerals were originally O-16-rich, but that in most carbonaceous chondrite inclusions some minerals exchanged oxygen isotopes with an external reservoir following crystallization.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Smithsonian Inst, Museum Natl Hist Nat, Dept Mineral Sci, Washington, DC 20560 USA	University of California System; University of California Los Angeles; Smithsonian Institution; Smithsonian National Museum of Natural History	McKeegan, KD (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	kdm@ess.ucla.edu	McKeegan, Kevin D/A-4107-2008	McKeegan, Kevin D/0000-0002-1827-729X; Russell, Sara/0000-0001-5531-7847				BISCHOFF A, 1984, GEOCHIM COSMOCHIM AC, V48, P693, DOI 10.1016/0016-7037(84)90096-6; BLANDER M, 1975, GEOCHIM COSMOCHIM AC, V39, P1605, DOI 10.1016/0016-7037(75)90083-6; BOYNTON WV, 1975, GEOCHIM COSMOCHIM AC, V39, P569, DOI 10.1016/0016-7037(75)90003-4; CHEN JH, 1981, EARTH PLANET SC LETT, V52, P1, DOI 10.1016/0012-821X(81)90202-8; Choi BG, 1997, METEORIT PLANET SCI, V32, pA28; Clayton R. N., 1983, CHONDRULES THEIR ORI, P37; CLAYTON RN, 1977, GEOPHYS RES LETT, V4, P295, DOI 10.1029/GL004i007p00295; CLAYTON RN, 1977, EARTH PLANET SC LETT, V34, P209, DOI 10.1016/0012-821X(77)90005-X; CLAYTON RN, 1991, GEOCHIM COSMOCHIM AC, V55, P2317, DOI 10.1016/0016-7037(91)90107-G; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; CLAYTON RN, 1978, EARTH PLANET SC LETT, V40, P168, DOI 10.1016/0012-821X(78)90087-0; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; CLAYTON RN, 1976, EARTH PLANET SC LETT, V30, P10, DOI 10.1016/0012-821X(76)90003-0; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P1, DOI 10.1016/0012-821X(83)90066-3; CLAYTON RN, 1986, TERRA COGNITA, V6, P130; Engrand C, 1997, METEORIT PLANET SCI, V32, pA39; FAHEY AJ, 1988, THESIS WASHINGTON U; GOSWAMI JN, 1997, LUNAR PLANET SCI, V28, P349; GRAHAM A. L., 1985, CATALOGUE METEORITES; KIMURA M, 1993, GEOCHIM COSMOCHIM AC, V57, P2329, DOI 10.1016/0016-7037(93)90573-F; Leshin LA, 1997, GEOCHIM COSMOCHIM AC, V61, P835, DOI 10.1016/S0016-7037(96)00374-2; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MAYEDA TK, 1986, LUNAR PLANET SCI, V17, P526; McKeegan K.D., 1996, METEORIT PLANET SCI, V31, pA86; MCKEEGAN KD, 1987, SCIENCE, V237, P1468, DOI 10.1126/science.237.4821.1468; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; ROWE MW, 1994, GEOCHIM COSMOCHIM AC, V58, P5341, DOI 10.1016/0016-7037(94)90317-4; Russell SS, 1997, METEORIT PLANET SCI, V32, pA111; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; RYERSON FJ, 1994, GEOCHIM COSMOCHIM AC, V58, P3713, DOI 10.1016/0016-7037(94)90161-9; SAXTON JM, 1995, METEORITICS, V30, P571; Sears D.W.G., 1988, METEORITES EARLY SOL, P3; SHENG YJ, 1991, GEOCHIM COSMOCHIM AC, V55, P581, DOI 10.1016/0016-7037(91)90014-V; SLODZIAN G, 1987, CAMECA NEWS      MAY, P1; Tilton G. G., 1988, METEORITES EARLY SOL, P259; VALLEY JW, IN PRESS SOC EC GEOL, V7	39	111	112	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					414	418		10.1126/science.280.5362.414	http://dx.doi.org/10.1126/science.280.5362.414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545215				2022-12-28	WOS:000073159600041
J	Halasz, CLG; Strauss, EB				Halasz, CLG; Strauss, EB			Unilateral livedo reticularis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Norwalk Hosp, Norwalk, CT 06856 USA	Columbia University	Halasz, CLG (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.			Halasz, Charles/0000-0001-8179-1841					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1127	1127		10.1056/NEJM199804163381606	http://dx.doi.org/10.1056/NEJM199804163381606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545361				2022-12-28	WOS:000073070100006
J	Fischer, A; Malissen, B				Fischer, A; Malissen, B			Natural and engineered disorders of lymphocyte development	SCIENCE			English	Review							B-CELL DEVELOPMENT; SEVERE COMBINED IMMUNODEFICIENCY; RECEPTOR-GAMMA CHAIN; HYPEREOSINOPHILIA OMENNS SYNDROME; X-LINKED AGAMMAGLOBULINEMIA; PROTEIN-TYROSINE KINASES; CLASS-II MOLECULES; HUMAN T-CELLS; MICE LACKING; THYMOCYTE DEVELOPMENT	Mammals have evolved complex developmental pathways to generate a large repertoire of B and T lymphocytes capable of mounting effective immune responses. Analysis of natural and engineered immunodeficiencies constitutes a powerful approach to delineating these pathways and identifying the molecular sensors that couple the survival of developing lymphocytes to the achievement of successful gene rearrangements at the loci coding for B and T cell antigen receptors. Besides identifying cytokines, growth factors, and transcription factors involved in lymphocyte development, genetic analysis also makes it possible to organize most of these protagonists into gene networks that control critical events in the life of developing lymphocytes.	CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille 9, France; Hop Necker Enfants Malad, INSERM, U429, F-75743 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Malissen, B (corresponding author), CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille 9, France.		Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342				Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ardouin L, 1998, J EXP MED, V187, P105, DOI 10.1084/jem.187.1.105; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Buer J, 1997, J EXP MED, V185, P1541, DOI 10.1084/jem.185.9.1541; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; BYTH KF, 1996, J EXP MED, V183, P1708; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHENGMING Z, 1996, CELL, V86, P379; Contractor NV, 1998, J IMMUNOL, V160, P385; Danska JS, 1996, MOL CELL BIOL, V16, P5507; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DELAMORENA M, 1995, EUR J IMMUNOL, V25, P809, DOI 10.1002/eji.1830250327; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DISANTO JP, IN PRESS CURR OPIN I; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; FISCHER AM, UNPUB; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GELFAND EW, 1995, J EXP MED, V182, P1057, DOI 10.1084/jem.182.4.1057; Gong Q, 1997, IMMUNITY, V7, P369, DOI 10.1016/S1074-7613(00)80358-1; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GREENBERG F, 1993, J MED GENET, V30, P803, DOI 10.1136/jmg.30.10.803; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; HACEINBAY S, UNPUB; Haffter P, 1996, DEVELOPMENT, V123, P1; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; Hendriks RW, 1996, EMBO J, V15, P4862, DOI 10.1002/j.1460-2075.1996.tb00867.x; Jacobs H, 1996, J EXP MED, V184, P1833, DOI 10.1084/jem.184.5.1833; Kanazawa S, 1996, BLOOD, V87, P865, DOI 10.1182/blood.V87.3.865.bloodjournal873865; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klug CA, 1998, P NATL ACAD SCI USA, V95, P657, DOI 10.1073/pnas.95.2.657; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lin SY, 1997, J EXP MED, V185, P707, DOI 10.1084/jem.185.4.707; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; LOWELL CA, 1996, GENE DEV, V10, P1345; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; Meffre E, 1996, J CLIN INVEST, V98, P1519, DOI 10.1172/JCI118943; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Miyazaki T, 1997, J EXP MED, V186, P877, DOI 10.1084/jem.186.6.877; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NEGISHI I, 1995, NATURE, V378, P198; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; OShea CC, 1997, IMMUNITY, V7, P591, DOI 10.1016/S1074-7613(00)80380-5; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Puck JM, 1997, BLOOD, V89, P1968; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Ramiro AR, 1996, J EXP MED, V184, P519, DOI 10.1084/jem.184.2.519; Rodewald HR, 1997, IMMUNITY, V6, P265, DOI 10.1016/S1074-7613(00)80329-5; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SCHILHAM MW, 1993, EUR J IMMUNOL, V23, P1299, DOI 10.1002/eji.1830230617; SCHWARZ K, 1991, J EXP MED, V174, P1039, DOI 10.1084/jem.174.5.1039; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; SPITS H, 1995, BLOOD, V85, P2654, DOI 10.1182/blood.V85.10.2654.bloodjournal85102654; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; SUGAMURA K, 1995, ADV IMMUNOL, V59, P275; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Van Parijs L, 1998, SCIENCE, V280, P243; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, IMMUNOL TODAY, V17, P502, DOI 10.1016/0167-5699(96)30058-3; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; WIRT DP, 1989, NEW ENGL J MED, V321, P370, DOI 10.1056/NEJM198908103210606; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2; Xu Y, 1996, P NATL ACAD SCI USA, V93, P2169, DOI 10.1073/pnas.93.5.2169; Yasunaga M, 1995, Semin Immunol, V7, P185, DOI 10.1016/1044-5323(95)90046-2; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	136	78	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					237	243		10.1126/science.280.5361.237	http://dx.doi.org/10.1126/science.280.5361.237			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535646				2022-12-28	WOS:000073082400039
J	Stahmer, SA				Stahmer, SA			Accident and emergency medicine	BRITISH MEDICAL JOURNAL			English	Review							CREATINE-KINASE-MB; ACUTE MYOCARDIAL-INFARCTION; CHEST PAIN; DOMESTIC VIOLENCE; PREVALENCE; TRAUMA; ASSAY; WOMEN; RISK; RULE		Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Stahmer, SA (corresponding author), Hosp Univ Penn, Dept Emergency Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	stahmer@mail.med.upenn.edu						ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; ADAMS JE, 1994, CLIN CHEM, V40, P1291; BIRBAUM A, 1996, ACAD EMERG MED, V3, P246; Brogan GX, 1996, ANN EMERG MED, V27, P22, DOI 10.1016/S0196-0644(96)70291-3; Corbett SW, 1997, ANN EMERG MED, V29, P317, DOI 10.1016/S0196-0644(97)70342-1; Davis CP, 1996, ACAD EMERG MED, V3, P590, DOI 10.1111/j.1553-2712.1996.tb03469.x; Durham B, 1997, ANN EMERG MED, V29, P338, DOI 10.1016/S0196-0644(97)70345-7; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; Hedges JR, 1996, ACAD EMERG MED, V3, P7, DOI 10.1111/j.1553-2712.1996.tb03295.x; Hedges JR, 1996, ACAD EMERG MED, V3, P27, DOI 10.1111/j.1553-2712.1996.tb03299.x; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; Hilty WM, 1997, ANN EMERG MED, V29, P331, DOI 10.1016/S0196-0644(97)70344-5; Ingeman JE, 1996, ACAD EMERG MED, V3, P931, DOI 10.1111/j.1553-2712.1996.tb03322.x; KERNS JR, 1993, ANN EMERG MED, V22, P794, DOI 10.1016/S0196-0644(05)80793-0; Ma OJ, 1997, ANN EMERG MED, V29, P312, DOI 10.1016/S0196-0644(97)70341-X; MA OJ, 1995, J TRAUMA, V38, P879; Mateer JR, 1996, ANN EMERG MED, V27, P283, DOI 10.1016/S0196-0644(96)70260-3; McGrath ME, 1997, ACAD EMERG MED, V4, P297, DOI 10.1111/j.1553-2712.1997.tb03552.x; Mikhail MG, 1997, ANN EMERG MED, V29, P88, DOI 10.1016/S0196-0644(97)70314-7; Muelleman RL, 1996, ANN EMERG MED, V28, P486, DOI 10.1016/S0196-0644(96)70110-5; Olson L, 1996, ANN EMERG MED, V27, P741, DOI 10.1016/S0196-0644(96)70193-2; Porter RS, 1997, ANN EMERG MED, V29, P323, DOI 10.1016/S0196-0644(97)70343-3; PORTER RS, 1997, ANN EMERG MED, V29, P357; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RICHARDSON DM, 1996, ANN EMERG MED, V27, P138; Roberts GL, 1996, ANN EMERG MED, V27, P747, DOI 10.1016/S0196-0644(96)70194-4; ROSEN CL, 1996, ACAD EMERG MED, V3, P482; Shih CHY, 1997, ANN EMERG MED, V29, P348, DOI 10.1016/S0196-0644(97)70346-9; Sixsmith DM, 1997, ACAD EMERG MED, V4, P301, DOI 10.1111/j.1553-2712.1997.tb03553.x; Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2; TILMAN B, 1997, ACAD EMERG MED, V4, P129; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; Waller AE, 1996, ANN EMERG MED, V27, P754, DOI 10.1016/S0196-0644(96)70195-6; WU AHB, 1995, CLIN CHEM, V41, P1228; Zalenski RJ, 1997, ANN EMERG MED, V29, P99, DOI 10.1016/S0196-0644(97)70315-9	35	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1071	1074						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552912				2022-12-28	WOS:000072987400031
J	Ditzel, L; Lowe, J; Stock, D; Stetter, KO; Huber, H; Huber, R; Steinbacher, S				Ditzel, L; Lowe, J; Stock, D; Stetter, KO; Huber, H; Huber, R; Steinbacher, S			Crystal structure of the thermosome, the archaeal chaperonin and homolog of CCT	CELL			English	Article							T-COMPLEX POLYPEPTIDE-1; GROEL-GROES COMPLEXES; MOLECULAR CHAPERONE; CYTOPLASMIC CHAPERONIN; HEAT-SHOCK; THERMOPHILIC ARCHAEBACTERIUM; SULFOLOBUS-SOLFATARICUS; PROTEIN SUBSTRATE; BINDING DOMAINS; ATP HYDROLYSIS	We have determined to 2.6 Angstrom resolution the crystal structure of the thermosome, the archaeal group II chaperonin from T. acidophilum. The hexadecameric homolog of the eukaryotic chaperonin CCT/TRiC shows an (alpha beta)(4)(alpha beta)(4) subunit assembly. Domain folds are homologous to GroEL but form a novel type of inter-ring contact. The domain arrangement resembles the GroEL-GroES cis-ring. Parts of the apical domains form a lid creating a closed conformation. The lid substitutes for a GroES-like cochaperonin that is absent in the CCT/TRiC system. The central cavity has a polar surface implicated in protein folding. Binding of the transition state analog MS-ADP-AIF(3) suggests that the closed conformation corresponds to the ATP form.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Regensburg, Inst Mikrobiol, D-93053 Regensburg, Germany	Max Planck Society; University of Regensburg	Steinbacher, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019	Lowe, Jan/0000-0002-5218-6615				Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; DARLAND G, 1971, J GEN MICROBIOL, V67, P9, DOI 10.1099/00221287-67-1-9; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KNAPP S, 1994, J MOL BIOL, V242, P397; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TURK D, 1992, THESIS TU MUNCHEN; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Willison KR, 1994, BIOL HEAT SHOCK PROT, P299; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667	80	362	371	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					125	138		10.1016/S0092-8674(00)81152-6	http://dx.doi.org/10.1016/S0092-8674(00)81152-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546398	Bronze			2022-12-28	WOS:000072910800016
J	Hertz, R; Magenheim, J; Berman, I; Bar-Tana, J				Hertz, R; Magenheim, J; Berman, I; Bar-Tana, J			Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4 alpha	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; ACID; PROLIFERATORS; PROTEINS; PROMOTER; BINDING; LIPIDS; GENE	Dietary fatty acids specifically modulate the onset and progression of various diseases, including cancer(1,2), atherogenesis(3), hyperlipidaemia(4), insulin resistance(5) and hypertension(6), as well as blood coagulability and fibrinolytic defects(7); their effects depend on their chain length and degree of saturation. Hepatocyte nuclear factor-4 alpha (ref. 8) (HNF-4 alpha) is an orphan transcription factor of the superfamily of nuclear receptors and controls the expression of genes (reviewed in ref. 9) that govern the pathogenesis and course of some of these diseases. Here we show that long-chain fatty acids directly modulate the transcriptional activity of HNF-4 alpha by binding as their acyl-CoA thioesters to the ligand-binding domain of HNF-4 alpha, This binding may shift the oligomeric-dimeric equilibrium of HNF-4 alpha or may modulate the affinity of HNF-4 alpha for its cognate promoter element, resulting in either activation or inhibition of HNF-4 alpha transcriptional activity as a function of chain length and the degree of saturation of the fatty acyl-CoA ligands, In addition to their roles as substrates to yield energy, as an energy store, or as constituents of membrane phospholipids, dietary fatty acids may affect the course of a disease by modulating the expression of HNF-4 alpha-controlled genes.	Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, POB 12272, IL-91010 Jerusalem, Israel.							CAVE WT, 1991, FASEB J, V5, P2160, DOI 10.1096/fasebj.5.8.1673664; CHIN JPF, 1994, PROSTAG LEUKOTR ESS, V50, P211, DOI 10.1016/0952-3278(94)90156-2; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DAHLBERG E, 1980, ANAL BIOCHEM, V106, P380, DOI 10.1016/0003-2697(80)90537-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hultin M B, 1991, Prog Hemost Thromb, V10, P215; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LEFF T, 1989, J BIOL CHEM, V264, P16132; Malik S, 1996, MOL CELL BIOL, V16, P1824; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; THOLSTRUP T, 1994, AM J CLIN NUTR, V59, P371, DOI 10.1093/ajcn/59.2.371; WELSCH CW, 1992, CANCER RES, V52, pS2040; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	29	430	446	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					512	516		10.1038/33185	http://dx.doi.org/10.1038/33185			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548258				2022-12-28	WOS:000072875200063
J	Nightingale, SL				Nightingale, SL			New warning for isotretinoin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-28	WOS:000072669700006
J	Ong, S				Ong, S			Good engineering is not good medicine	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1014	1014		10.1136/bmj.316.7136.1014	http://dx.doi.org/10.1136/bmj.316.7136.1014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9552878	Green Published			2022-12-28	WOS:000072856100039
J	Clement, K; Vaisse, C; Lahlou, N; Cabrol, S; Pelloux, V; Cassuto, D; Gourmelen, M; Dina, C; Chambaz, J; Lacorte, JM; Basdevant, A; Bougneres, P; Lebouc, Y; Froguel, P; Guy-Grand, B				Clement, K; Vaisse, C; Lahlou, N; Cabrol, S; Pelloux, V; Cassuto, D; Gourmelen, M; Dina, C; Chambaz, J; Lacorte, JM; Basdevant, A; Bougneres, P; Lebouc, Y; Froguel, P; Guy-Grand, B			A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction	NATURE			English	Article							GROWTH-HORMONE; OB/OB MICE; MOUSE; EXPRESSION; PROTEINS; CLONING; SERUM	The adipocyte-specific hormone leptin, the product of the obese (ob) gene, regulates adipose-tissue mass through hypothalamic effects on satiety and energy expenditure(1-4), Leptin acts through the leptin receptor, a single-transmembrane-domain receptor of the cytokine-receptor family(5-7). In rodents, homozygous mutations in genes encoding leptin(1) or the leptin receptor(6) cause early-onset morbid obesity, hyperphagia and reduced energy expenditure, These rodents also show hypercortisolaemia, alterations in glucose homeostasis, dyslipidaemia, and infertility due to hypogonadotropic hypogonadism(8). In humans. leptin deficiency due to a mutation in the leptin gene is associated with early-onset obesity(9), Here we describe a homozygous mutation in the human leptin receptor gene that results in a truncated leptin receptor lacking both the transmembrane and the intracellular domains, In addition to their early-onset morbid obesity, patients homozygous for this mutation have no pubertal development and their secretion of growth hormone and thyrotropin is reduced. These results indicate that leptin is an important physiological regulator of several endocrine functions in humans.	Hotel Dieu, Lab Nutr, F-75004 Paris, France; Hotel Dieu, Serv Med & Nutr, F-75004 Paris, France; Inst Pasteur, Inst Biol, CNRS, EP10, F-59000 Lille, France; Hop St Vincent de Paul, INSERM, U342, F-75674 Paris, France; Serv Endocrinol Diabete Enfant, F-75014 Paris, France; Hop Enfant Armand Trousseu, F-75012 Paris, France; INSERM, CJF 9508, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Froguel, P (corresponding author), Hotel Dieu, Lab Nutr, Pl Parvis Notre Dame, F-75004 Paris, France.		Vaisse, Christian/F-1067-2011; Clément, karine/R-1120-2017; Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017	Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BERNINI GP, 1990, CLIN ENDOCRINOL, V32, P453, DOI 10.1111/j.1365-2265.1990.tb00885.x; Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/S0899-9007(97)00191-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carro E, 1997, ENDOCRINOLOGY, V138, P2203, DOI 10.1210/en.138.5.2203; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Clayton PE, 1997, CLIN ENDOCRINOL, V46, P727, DOI 10.1046/j.1365-2265.1997.2081026.x; Clement K, 1997, INT J OBESITY, V21, P556, DOI 10.1038/sj.ijo.0800440; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Diamond FB, 1997, BIOCHEM BIOPH RES CO, V233, P818, DOI 10.1006/bbrc.1997.6538; Echwald SM, 1997, BIOCHEM BIOPH RES CO, V233, P248, DOI 10.1006/bbrc.1997.6430; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARDOUIN S, 1989, J CLIN ENDOCR METAB, V69, P1291, DOI 10.1210/jcem-69-6-1291; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; TANNENBAUM GS, 1990, ENDOCRINOLOGY, V127, P3080; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VIGNOLO M, 1988, EUR J PEDIATR, V147, P242, DOI 10.1007/BF00442687; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1650	1712	1	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					398	401		10.1038/32911	http://dx.doi.org/10.1038/32911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537324				2022-12-28	WOS:000072713600054
J	Mitchell, A				Mitchell, A			Visionaries seek UK national strategy	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					419	420		10.1038/32952	http://dx.doi.org/10.1038/32952			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537331				2022-12-28	WOS:000072713600061
J	Beecham, L				Beecham, L			BUPA sets up "doctors' scheme"	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					943	943						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552865				2022-12-28	WOS:000072713300080
J	Hammond, R				Hammond, R			Commentary: Pregnancy should not have affected treatment for melanoma	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Nottingham Hosp, Queens Med Ctr, Nottingham NG7 2UH, England	University of Nottingham	Hammond, R (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Nottingham NG7 2UH, England.							MACKIE RM, 1991, LANCET, V337, P653, DOI 10.1016/0140-6736(91)92462-B; SUTHERLAND CM, 1983, J SURG ONCOL, V22, P191, DOI 10.1002/jso.2930220312	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					849	850						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549461				2022-12-28	WOS:000072584300041
J	Spitz, IM; Bardin, CW; Benton, L; Robbins, A				Spitz, IM; Bardin, CW; Benton, L; Robbins, A			Early pregnancy termination with mifepristone and misoprostol in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UTERINE CONTRACTILITY; PROSTAGLANDIN ANALOG; EARLY ABORTION; RU-486; INDUCTION; COMBINATION; ANTAGONIST; EXPERIENCE; WOMEN; TRIAL	Background Mifepristone and a prostaglandin have been used successfully to terminate pregnancy in Europe and China. We report the results of a large U.S. study of mifepristone and misoprostol in women with pregnancies of up to nine weeks' duration. Methods We administered 600 mg of mifepristone and then 400 mu g of misoprostol two days later to 2121 women seeking termination of their pregnancies at 17 centers. The women were observed for four hours after the administration of misoprostol and returned on day 15 for final assessment. Results Two thousand fifteen women completed the final assessment. Among them, pregnancy was terminated in 762 of the 827 women pregnant for less than or equal to 49 days (92 percent), 563 of the 678 women pregnant for 50 to 56 days (83 percent), and 395 of the 510 women pregnant for 57 to 63 days (77 percent) (P<0.001). Termination occurred within 4 hours after the administration of misoprostol in 49 percent of the women and within 24 hours in 75 percent. Failures, defined as cases requiring surgical intervention for medical reasons or because the patient requested it, the abortion was incomplete, or the pregnancy was ongoing, increased with increasing duration of pregnancy. The largest increase was in failures representing ongoing pregnancy, which increased from 1 percent in the less than or equal to 49-days group to 9 percent in the 57-to-63-days group (P<0.001). Abdominal pain, nausea, vomiting, diarrhea, and vaginal bleeding also increased with advancing gestational age. Two percent of the women in the less than or equal to 49-days group, as compared with 4 percent in each of the other two groups, were hospitalized, underwent surgical intervention, and received intravenous fluids (P=0.008). Conclusions This mifepristone-misoprostol regimen is effective in terminating pregnancies, especially in women with pregnancies of 49 days' duration or less. (C)1998, Massachusetts Medical Society.	Populat Council, Ctr Biomed Res, New York, NY 10021 USA	Population Council	Robbins, A (corresponding author), Populat Council, Ctr Biomed Res, 1230 York Ave, New York, NY 10021 USA.							[Anonymous], 1993, BMJ, V307, P532; Aubeny E, 1995, Int J Fertil Menopausal Stud, V40 Suppl 2, P85; BAIRD DT, 1995, HUM REPROD, V10, P1521, DOI 10.1093/HUMREP/10.6.1521; BAULIEU EE, 1985, ANTIPROGESTIN STEROI, P123; BROOME M, 1994, BR J FAM PLANN, V20, P11; BYGDEMAN M, 1985, CONTRACEPTION, V32, P45, DOI 10.1016/0010-7824(85)90115-5; COELHO HL, 1994, CONTRACEPTION, V49, P101, DOI 10.1016/0010-7824(94)90084-1; COUZINET B, 1986, NEW ENGL J MED, V315, P1565, DOI 10.1056/NEJM198612183152501; Creinin MD, 1996, CONTRACEPTION, V53, P321, DOI 10.1016/0010-7824(96)00080-7; CREININ MD, 1995, AM J OBSTET GYNECOL, V175, P1578; ELREFAEY H, 1994, BRIT J OBSTET GYNAEC, V101, P792, DOI 10.1111/j.1471-0528.1994.tb11948.x; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; Grimes DA, 1997, OBSTET GYNECOL, V89, P790, DOI 10.1016/S0029-7844(97)81439-1; HENSHAW SK, 1994, FAM PLANN PERSPECT, V26, P100, DOI 10.2307/2136033; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; JOST A, 1986, CR ACAD SCI III-VIE, V303, P281; MCKINLEY C, 1993, HUM REPROD, V8, P1502, DOI 10.1093/oxfordjournals.humrep.a138287; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; Prasad RNV, 1996, AUST NZ J OBSTET GYN, V36, P20, DOI 10.1111/j.1479-828X.1996.tb02915.x; Schaff EA, 1997, J FAM PRACTICE, V44, P353; SILVESTRE L, 1990, NEW ENGL J MED, V322, P645, DOI 10.1056/NEJM199003083221001; SPITZ IM, 1993, CONTRACEPTION, V48, P403, DOI 10.1016/0010-7824(93)90133-R; SPITZ IM, 1993, NEW ENGL J MED, V329, P404; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; Urquhart DR, 1997, CONTRACEPTION, V55, P1, DOI 10.1016/S0010-7824(96)00252-1; WOLF JP, 1990, CONTRACEPTION, V41, P85, DOI 10.1016/0010-7824(90)90129-J; Zieman M, 1997, OBSTET GYNECOL, V90, P88, DOI 10.1016/S0029-7844(97)00111-7; [No title captured]	31	301	308	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1241	1247		10.1056/NEJM199804303381801	http://dx.doi.org/10.1056/NEJM199804303381801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562577				2022-12-28	WOS:000073335800001
J	Lambiase, A; Rama, P; Bonini, S; Caprioglio, G; Aloe, L				Lambiase, A; Rama, P; Bonini, S; Caprioglio, G; Aloe, L			Topical treatment with nerve growth factor for corneal neurotrophic ulcers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MESSENGER-RNA; NGF; DISEASES; INFUSION; LIMBAL; SYSTEM; RAT	Background Corneal neurotrophic ulcers associated with impairment of sensory innervation of the cornea may lead to loss of vision, and there is no effective treatment for these ulcers. We evaluated the effects of nerve growth factor in patients with this disorder. Methods Twelve patients (14 eyes) with severe corneal neurotrophic ulcers associated with corneal anesthesia were treated with topical nerve growth factor 10 times daily for two days and then 6 times daily until the ulcers healed. Treatment continued for 2 weeks after the ulcers healed, and the patients were then followed for up to 15 months. The evolution of the corneal disease during treatment and follow-up was evaluated by slit-lamp examination, photography, fluorescein-dye testing, and tests of corneal sensitivity and best corrected visual acuity. Results Corneal healing began 2 to 14 days after the initiation of treatment with nerve growth factor, and all patients had complete healing of their corneal ulcers after 10 days to 6 weeks of treatment. Corneal sensitivity improved in 13 eyes, and returned to normal in 2 of the 13 eyes. Corneal integrity and sensitivity were maintained during the follow-up period (range, 3 to 15 months). Best corrected visual acuity increased progressively during treatment and follow-up in all patients. There were no systemic or local side effects of treatment. Conclusions In this preliminary, uncontrolled study, topically applied exogenous nerve growth factor restored corneal integrity in patients with corneal neurotrophic ulcers. (C)1998, Massachusetts Medical Society.	CNR, Inst Neurobiol, I-00132 Rome, Italy; Univ Roma Tor Vergata, Dept Ophthalmol, Rome, Italy; Hosp Venice SS Giovanni & Paolo, Div Ophthalmol, Venice, Italy; GB Bietti Eye Fdn, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; ULSS 3 Serenissima; Ospedale SS Giovanni Paolo Venezia; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia	Aloe, L (corresponding author), CNR, Inst Neurobiol, Viale Marx 15, I-00132 Rome, Italy.		Bonini, Sergio/T-6594-2019; Rama, Paolo/S-5150-2019; Bonini, Stefano/A-2250-2012; Lambiase, Alessandro/K-3902-2016	Bonini, Sergio/0000-0003-0079-3031; Rama, Paolo/0000-0002-2429-159X; Bonini, Stefano/0000-0002-7787-2144; Lambiase, Alessandro/0000-0002-8974-991X				Anand P, 1996, PHILOS T ROY SOC B, V351, P449, DOI 10.1098/rstb.1996.0041; ANAND P, 1994, LANCET, V344, P129, DOI 10.1016/S0140-6736(94)91316-1; BEUERMAN RW, 1980, EXP NEUROL, V69, P196, DOI 10.1016/0014-4886(80)90154-5; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; Brown SM, 1997, ARCH OPHTHALMOL-CHIC, V115, P926, DOI 10.1001/archopht.1997.01100160096021; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EPSTEIN DL, 1968, NEW ENGL J MED, V279, P396, DOI 10.1056/NEJM196808222790802; FAULKNER WJ, 1997, CORNEA FUNDAMENTALS, P275; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; KRUSE FE, 1993, INVEST OPHTH VIS SCI, V34, P1963; LAMBIASE A, 1995, INVEST OPHTH VIS SCI, V36, P2127; LAMBIASE A, 1997, INVEST OPHTH VIS SCI, V38, pS1078; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; Liberini P, 1994, Rev Neurosci, V5, P89; MACKIE IA, 1995, CURRENT OCULAR THERA, V4, P506; MEAROW KM, 1993, NEUROREPORT, V4, P351, DOI 10.1097/00001756-199304000-00002; MITTAG TW, 1974, ANN NY ACAD SCI, V228, P301; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; OLSON L, 1991, ARCH NEUROL-CHICAGO, V48, P373, DOI 10.1001/archneur.1991.00530160037011; Paton L, 1926, Br J Ophthalmol, V10, P305, DOI 10.1136/bjo.10.6.305; PETTY BG, 1994, ANN NEUROL, V36, P244, DOI 10.1002/ana.410360221; PRICE FW, 1991, OPHTHALMOLOGY, V98, P322; PUANGSRICHARERN V, 1995, OPHTHALMOLOGY, V102, P1476; Riaz SS, 1996, PROG NEUROBIOL, V49, P125; SIGELMAN S, 1954, AMA ARCH OPHTHALMOL, V52, P46, DOI 10.1001/archopht.1954.00920050048005; Simone S, 1958, ARCH OTTALMOL, V62, P151; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; TERVO K, 1994, ARCH OPHTHALMOL-CHIC, V112, P1466, DOI 10.1001/archopht.1994.01090230080025; TRIPATHI BJ, 1990, CORNEA, V9, P2; VERGE VMK, 1992, J NEUROSCI, V12, P4011; VERHOEFF FH, 1925, AM J OPHTHALMOL, V8, P273	35	338	350	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1174	1180		10.1056/NEJM199804233381702	http://dx.doi.org/10.1056/NEJM199804233381702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554857				2022-12-28	WOS:000073208400002
J	Gottschalk, A; Smith, DS; Jobes, DR; Kennedy, SK; Lally, SE; Noble, VE; Grugan, KF; Seifert, HA; Cheung, A; Malkowicz, SB; Gutsche, BB; Wein, AJ				Gottschalk, A; Smith, DS; Jobes, DR; Kennedy, SK; Lally, SE; Noble, VE; Grugan, KF; Seifert, HA; Cheung, A; Malkowicz, SB; Gutsche, BB; Wein, AJ			Preemptive epidural analgesia and recovery from radical prostatectomy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAJOR ABDOMINAL-SURGERY; POSTOPERATIVE PAIN; GENERAL-ANESTHESIA; LIMB AMPUTATION; NERVE BLOCK; BUPIVACAINE; MORPHINE; FORMALIN; RATS; NEUROPLASTICITY	Context.-Preemptive analgesia can decrease the sensitization of the central nervous system that would ordinarily amplify subsequent nociceptive input, but a clear demonstration of its clinical efficacy is necessary for it to become a routine component of acute pain therapy. Objective.-To determine the impact of preemptive epidural analgesia on postoperative pain and other clinically important outcome variables after radical retropubic prostatectomy. Design and Setting.-A block randomized double-blind clinical trial lasting 20 months at a single academic medical center. Patients.-A total of 100 generally healthy and neurologically intact patients scheduled for radical retropubic prostatectomy for the treatment of prostate cancer in whom an epidural catheter for treating postoperative pain was to be placed prior to the induction of general anesthesia. Interventions.-Epidural bupivacaine, epidural fentanyl, or no epidural drug was administered prior to induction of anesthesia and throughout the entire operation, followed by aggressive postoperative epidural analgesia for all patients. Main Outcome Measures.-Daily pain scores during hospitalization and pain scores obtained 3.5, 5.5, and 9.5 weeks after hospital discharge. Results.-The patients who received epidural fentanyl or bupivacaine prior to surgical incision (preemptive analgesia) experienced 33% less pain while hospitalized (P=.007). Pain scores in those receiving preemptive analgesia were significantly lower at 9.5 weeks (P=.02), but were not significantly different at 3.5 or 5.5 weeks. At 9.5 weeks, 32 (86%) of 37 patients receiving preemptive analgesia were pain-free compared with 9 (47%) of 19 control patients (P=.004), Patients receiving preemptive analgesia were more active 3.5 weeks after surgery (P=.01), but not at 5.5 or 9.5 weeks. Conclusions.-Even in the presence of aggressive postoperative pain management, preemptive epidural analgesia significantly decreases postoperative pain during hospitalization and long after discharge, and is associated with increased activity levels after discharge.	Univ Penn, Sch Med, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Div Urol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Gottschalk, A (corresponding author), Hosp Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.	ag@network3.entropy.upenn.edu	lei, cao/ABA-7520-2021	Seifert, Harry/0000-0001-8048-5885				ABRAM SE, 1993, ANESTHESIOLOGY, V78, P713, DOI 10.1097/00000542-199304000-00015; BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; BRIDENBAUGH PO, 1994, ANESTH ANALG, V78, P203, DOI 10.1213/00000539-199402000-00001; BUGEDO GJ, 1990, REGION ANESTH, V15, P130; CARR DB, 1992, 950034 US DEP HLTH H; CHAPMAN CR, 1990, MANAGEMENT PAIN, P580; CODERRE TJ, 1990, BRAIN RES, V535, P155, DOI 10.1016/0006-8993(90)91835-5; Cousins MJ, 1980, NEURAL BLOCKADE CLIN; CRAIG DB, 1981, ANESTH ANALG, V60, P46; DAHL JB, 1992, BRIT J ANAESTH, V69, P4, DOI 10.1093/bja/69.1.4; DAHL JB, 1993, ANESTHESIOLOGY, V78, P801, DOI 10.1097/00000542-199304000-00044; DAJCZMAN E, 1991, CHEST, V99, P270, DOI 10.1378/chest.99.2.270; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; FERRANTE FM, 1990, PATIENT CONTROLLED A; Fletcher D, 1996, ANESTHESIOLOGY, V84, P1129, DOI 10.1097/00000542-199605000-00015; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GONZALEZDARDER JM, 1986, PAIN, V24, P87, DOI 10.1016/0304-3959(86)90029-1; Hannibal K, 1996, ANESTH ANALG, V83, P376, DOI 10.1097/00000539-199608000-00030; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; KALSO E, 1992, ACTA ANAESTH SCAND, V36, P96, DOI 10.1111/j.1399-6576.1992.tb03430.x; KASTUB EK, 1997, DRUG FACTS COMP, pA242; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; MANTHA S, 1993, ANESTH ANALG, V77, P1041; MCEVOY GK, 1997, AM HOSP FORMULARY SE, P1559; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; NEGRE I, 1994, ANESTH ANALG, V79, P298; Pedersen JL, 1996, ANESTHESIOLOGY, V84, P1020, DOI 10.1097/00000542-199605000-00002; Rockemann MG, 1996, ANESTHESIOLOGY, V84, P1027, DOI 10.1097/00000542-199605000-00003; ROYTBLAT L, 1993, ANESTH ANALG, V77, P1161; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; STEIN C, 1993, ANESTH ANALG, V76, P182; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1989, BRIT J ANAESTH, V63, P139, DOI 10.1093/bja/63.2.139; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; YAMAMOTO T, 1992, ANESTHESIOLOGY, V77, P757, DOI 10.1097/00000542-199210000-00021; Yashpal K, 1996, ANESTHESIOLOGY, V84, P1119, DOI 10.1097/00000542-199605000-00014; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004	43	140	146	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1076	1082		10.1001/jama.279.14.1076	http://dx.doi.org/10.1001/jama.279.14.1076			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546566	Bronze			2022-12-28	WOS:000072875300031
J	Mullan, F				Mullan, F			Eugene McGregor, MD - A legacy of general practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Biographical-Item									Hlth Affairs, Bethesda, MD 20814 USA; George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA	George Washington University	Mullan, F (corresponding author), Hlth Affairs, 7500 Old Georgetown Rd,Suite 600, Bethesda, MD 20814 USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1117	1120		10.1001/jama.279.14.1117	http://dx.doi.org/10.1001/jama.279.14.1117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546574				2022-12-28	WOS:000072875300039
J	Cox, CJC				Cox, CJC			Seeds Naunton Briggs - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1096	1096						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552928				2022-12-28	WOS:000072987400061
J	Preiss, T; Hentze, MW				Preiss, T; Hentze, MW			Dual function of the messenger RNA cap structure in poly(A)-tail-promoted translation in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; INTERNAL INITIATION; POLY(A) TAIL	The messenger RNA 3' poly(A) tail critically affects the initiation and control of translation in eukaryotes(1-3). By analogy to elements involved in transcription initiation, the poly(A) tail has been described as a 'translational enhancer' that enhances the 'translational promoter' activity of the mRNA 5'-cap structure(3,4). Elongation or shortening of the poly(A) tail regulates translation during development(2). Here we show, using cell-free and in vivo translation analyses in SRccharomyces cerevisiae, that the poly(A) tail can act as an independent 'translational promoter: delivering ribosomes to uncapped mRNAs even if their 5' end is blocked. When mRNAs compete for ribosome binding, neither the cap structure nor the poly(A) tail alone is enough to drive efficient translation, but together they synergize and direct ribosome entry to the 5' end. The cap structure both promotes ribosome recruitment, together with the poly(A) tail, and tethers recruited ribosomes to the 5' end, Correct choice of translation initiation codons and the function of translational regulators acting on the 5' untranslated region are thus ensured by the functional interaction of the poly(A) tail with the cap structure.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Hentze, MW (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Preiss, Thomas/F-7355-2010; Hentze, Matthias W/V-3980-2017	Preiss, Thomas/0000-0001-6273-784X; Hentze, Matthias W/0000-0002-4023-7876				EVERETT JG, 1992, YEAST, V8, P1007, DOI 10.1002/yea.320081203; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; MASSON DC, 1995, MOL CELL BIOL, V15, P2763; Muckenthaler M, 1997, RNA, V3, P983; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wickens M., 1996, TRANSLATIONAL CONTRO, P411	19	215	248	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					516	520		10.1038/33192	http://dx.doi.org/10.1038/33192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548259				2022-12-28	WOS:000072875200064
J	Cowl, CT; Jones, MP; Lynch, CF; Sprince, NL; Zwerling, C; Fuortes, LJ				Cowl, CT; Jones, MP; Lynch, CF; Sprince, NL; Zwerling, C; Fuortes, LJ			Factors associated with fatalities and injuries from hot-air balloon crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Despite the increased popularity of hot-air balloon flight, data on injuries and fatalities associated with hot-air balloon crashes are limited. Objective.-To determine factors associated with injury and death in hot-air balloon crashes, Design.-Retrospective review of data collected from reports and investigations by the Civil Aeronautics Board and the National Transportation Safety Board. Study Subjects.-Individuals involved in US hot-air balloon crashes from 1964 to 1995. Main Outcome Measures.-Total number of crashes and factors associated with fatality or serious injury. Results.-Form 1964 to 1995, a total of 495 hot-air balloon crashes involving 1533 persons were reported and included 92 fatalities and 384 serious injuries. Pilot error or incapacitation was determined subjectively by crash investigators to contribute to 85.1% of the crashes. In univariate analysis, collision with the ground was the most significant predictor of a fatality or serious injury (P<.001), and power-line contact was the most significant predictor of fatality (P<.001). In multiple logistic regression, only the type of object struck by a balloon predicted a fatal crash or a fatality or serious injury. Conclusions.-Although a number of factors likely contribute to increased seventy of hot-air balloon crashes, the object struck during a crash is most predictive of fatality or serious injury. Preventive efforts are needed to decrease future injuries.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Prevent & Occupat Med, Rochester, MN 55905 USA; Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA USA	Mayo Clinic; University of Iowa	Cowl, CT (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Prevent & Occupat Med, Rochester, MN 55905 USA.				CIT NIH HHS [T01/CCT710440] Funding Source: Medline	CIT NIH HHS		*FED AV ADM, 1994, FED AV REG REG 145; *FED AV ADM, 1994, FED AV REG REG 61; *FED AV ADM, 1994, FED AV REG REG 31; *FED AV ADM, 1994, FED AV REG REG 91; *FED AV ADM, 1994, FED AV REG REG 43; *FED AV ADM, 1995, US CIV AIRM STAT ANN; *FED AV ADM, 1994, FED AV REG REG 1; *FED AV ADM, 1994, FED AV REG REG 141; FRANKENFIELD DL, 1994, AVIAT SPACE ENVIR MD, V65, P3; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; MARCUS NA, 1981, AM J SPORT MED, V9, P318, DOI 10.1177/036354658100900506; MCCONNELL TS, 1985, J FORENSIC SCI, V30, P350	12	14	14	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1011	1014		10.1001/jama.279.13.1011	http://dx.doi.org/10.1001/jama.279.13.1011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533500	Bronze			2022-12-28	WOS:000072669700029
J	Romo, R; Hernandez, A; Zainos, A; Salinas, E				Romo, R; Hernandez, A; Zainos, A; Salinas, E			Somatosensory discrimination based on cortical microstimulation	NATURE			English	Article							PSYCHOPHYSICAL MEASUREMENTS; AREA MT; MONKEYS; PERFORMANCE; FREQUENCY; DIRECTION; NEURONS; EVENTS	The sensation of flutter is produced when mechanical vibrations in the range of 5-50 Hz are applied to the skin(1-3). A flutter stimulus activates neurons in the primary somatosensory cortex (S1) that somatotopically map to the site of stimulation(4,5). A subset of these neurons-those with quickly adapting properties, associated with Meissner's corpuscles-are strongly entrained by periodic flutter vibrations, firing with a probability that oscillates at the input frequency(1,6) Hence, quickly adapting neurons provide a dynamic representation of such flutter stimuli. However, are these neurons directly involved in the perception of flutter? Here we investigate this in monkeys trained to discriminate the difference in frequency between two flutter stimuli delivered sequentially on the fingertips(1,7). Microelectrodes were inserted into area 3b of S1 and the second stimulus was substituted with a train of injected current pulses. Animals reliably indicated whether the frequency of the second (electrical) signal was higher or lower than that of the first (mechanical) signal, even though both frequencies changed from trial to trial. Almost identical results were obtained with periodic and aperiodic stimuli of equal average frequencies. Thus, the quickly adapting neurons in area 3b activate the circuit leading to the perception of flutter. Furthermore, as far as can be psychophysically quantified during discrimination, the neural code underlying the sensation of flutter can be finely manipulated, to the extent that the behavioural responses produced by natural and artificial stimuli are indistinguishable.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Romo, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.			Salinas, Emilio/0000-0001-7411-5693; romo, ranulfo/0000-0003-3529-3635; zainos, antonio/0000-0001-6137-1794				BAIR W, 1994, J NEUROSCI, V14, P2870; Hernandez A, 1997, J NEUROSCI, V17, P6391; LAMOTTE RH, 1979, J NEUROPHYSIOL, V42, P400, DOI 10.1152/jn.1979.42.2.400; LAMOTTE RH, 1975, J NEUROPHYSIOL, V38, P539, DOI 10.1152/jn.1975.38.3.539; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1990, J NEUROSCI, V10, P3032; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P133; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SUR M, 1984, J NEUROPHYSIOL, V51, P724, DOI 10.1152/jn.1984.51.4.724; TALBOT WH, 1968, J NEUROPHYSIOL, V31, P301, DOI 10.1152/jn.1968.31.2.301; Vallbo Ake B., 1995, P237; Zainos A, 1997, EXP BRAIN RES, V115, P357, DOI 10.1007/PL00005704; [No title captured]; [No title captured]	17	336	348	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					387	390		10.1038/32891	http://dx.doi.org/10.1038/32891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537321				2022-12-28	WOS:000072713600051
J	Tunstall-Pedoe, H				Tunstall-Pedoe, H			An initiation - Unequal encounter	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					920	920		10.1136/bmj.316.7135.920	http://dx.doi.org/10.1136/bmj.316.7135.920			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552847	Green Published			2022-12-28	WOS:000072713300036
J	Croft, LB; Goldman, ME				Croft, LB; Goldman, ME			Echocardiographic detection of a renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Mt Sinai Med Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Croft, LB (corresponding author), Mt Sinai Med Ctr, New York, NY 10029 USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1279	1279		10.1056/NEJM199804303381806	http://dx.doi.org/10.1056/NEJM199804303381806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562582				2022-12-28	WOS:000073335800006
J	Forrow, L; Blair, BG; Helfand, I; Lewis, G; Postol, T; Sidel, V; Levy, BS; Abrams, H; Cassel, C				Forrow, L; Blair, BG; Helfand, I; Lewis, G; Postol, T; Sidel, V; Levy, BS; Abrams, H; Cassel, C			Accidental nuclear war - A post-Cold War assessment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background In the 1980s, many medical organizations identified the prevention of nuclear war as one of the medical profession's most important goals, An assessment of the current danger is warranted given the radically changed context of the post-Cold War era. Methods We reviewed the recent literature on the status of nuclear arsenals and the risk of nuclear war, We then estimated the likely medical effects of a scenario identified by leading experts as posing a serious danger: an accidental launch of nuclear weapons. We assessed possible measures to reduce the risk of such an event. Results U.S. and Russian nuclear-weapons systems remain on high alert. This fact, combined with the aging of Russian technical systems, has recently increased the risk of an accidental nuclear attack. As a conservative estimate, an accidental intermediate-sized launch of weapons from a single Russian submarine would result in the deaths of 6,838,000 persons from firestorms in eight U.S. cities, Millions of other people would probably be exposed to potentially lethal radiation from fallout. An agreement to remove all nuclear missiles from high-level alert status and eliminate the capability of a rapid launch would put an end to this threat. Conclusions The risk of an accidental nuclear attack has increased in recent years, threatening a public health disaster of unprecedented scale. Physicians and medical organizations should work actively to help build support for the policy changes that would prevent such a disaster. (C)1998, Massachusetts Medical Society.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Brookings Inst, Washington, DC 20036 USA; Phys Social Responsibil, Washington, DC USA; MIT, Cambridge, MA 02139 USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, New York, NY USA; Albert Einstein Coll Med, New York, NY USA; Barry S Levy Associates, Boston, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Stanford Univ, Ctr Int Secur & Arms Control, Stanford, CA 94305 USA; Mt Sinai Sch Med, New York, NY USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Brookings Institution; Massachusetts Institute of Technology (MIT); Montefiore Medical Center; Yeshiva University; Tufts University; Stanford University; Stanford University; Icahn School of Medicine at Mount Sinai	Forrow, L (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, East Campus,330 Brookline Ave, Boston, MA 02215 USA.							Abrams Herbert L., 1993, INADVERTENT NUCL WAR, P39; ABRAMS HL, 1981, NEW ENGL J MED, V305, P1226, DOI 10.1056/NEJM198111123052027; ABRAMS HL, 1984, JAMA-J AM MED ASSOC, V252, P653, DOI 10.1001/jama.252.5.653; ABRAMS HL, 1987, PREV MED, V16, P319, DOI 10.1016/0091-7435(87)90031-4; ABRAMS HL, 1986, MED IMPLICATIONS NUC, P490; ABRAMS HL, 1991, SCI GLOBAL SECURITY, V2, P325; *AM BURN ASS, 1997, BURN CAR RES N AM 19; *AM COLL PHYS, 1996, RES BOARD GOV; *AM MED ASS, 1981, POL 520 999 520 997; *BALL MISS DEF ORG, 1995, NAT MISS DEF OPT; BLAIR B, 1995, GLOBAL ZERO ALERT NU; Blair BG, 1997, SCI AM, V277, P74, DOI 10.1038/scientificamerican1197-74; BLAIR BG, IN PRESS DEALERTING; BLAIR BG, 1993, LOGIC ACCIDENTAL NUC, P97; BLAIR BG, 1997, FOR DEF MIN OFF FINL; BLAIR BG, 1996, WASHINGTON POST 1015, pA15; BLAIR BG, 1993, LOGIC ACCIDENTAL NUC, P154; BLAIR BG, 1996, WASHINGTON POST 0929, pC1; BUTLER GL, 1996, STAT WORLD FOR SAN F; *C SEN COMM ARM SE, 1980, REC FALS AL NAT MISS; *CAN COMM, 1996, FIN M CANB COMM EL N; CANSTON A, 1998, COMMUNICATION   0202; CASSEL C, 1982, ANN INTERN MED, V97, P426, DOI 10.7326/0003-4819-97-3-426; CENSUS CD, 1996, GEOLYTICS; ERVIN FR, 1962, NEW ENGL J MED, V266, P1127, DOI 10.1056/NEJM196205312662204; FORROW L, 1997, WAR PUBLIC HLTH, P336; GERTZ B, 1997, WASHINGTON TIME 0512, pA1; GERTZ B, 1996, WASHINGTON TIME 1022, pA1; *GOV COUNC AM PUBL, 1997, AM J PUBLIC HEALTH, V87, P500; HOFFMAN D., 1998, WASHINGTON POST 0315, pA01; *INT I STRAT STUD, 1993, MIL BAL 1993 1994, P342; LEITENBERG M, 1977, SIPRI YB WORLD ARMAM, P53; LEVY BS, 1997, WAR PUBLIC HLTH, P338; Lewis G, 1997, B ATOM SCI, V53, P18, DOI 10.1080/00963402.1997.11456749; LOWN B, 1981, NEW ENGL J MED, V304, P726, DOI 10.1056/NEJM198103193041210; LOWN B, 1995, JAMA-J AM MED ASSOC, V274, P416, DOI 10.1001/jama.274.5.416; MARTINO R, 1997, COMMUNICATION   1015; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; *NAT AC SCI, 1997, FUT US NUCL WEAP POL, P62; *NAT AC SCI, 1997, FUT US NUCL WEAP POL, P17; NAT'L INST. OF CORR. U.S. DEP'T OF JUSTICE, 1997, FUT US NUCL WEAP POL; *NOB PEAC PRIZ COM, 1986, CIT INT PHYS PREV NU; Nunn Sam, 1997, WASHINGTON POST 0622, pC1; ONEILL JE, 1996, COMMUNICATION   0603; POSTOL TA, 1986, MED IMPLICATIONS NUC, P15; RELMAN AS, 1986, NEW ENGL J MED, V315, P889, DOI 10.1056/NEJM198610023151410; Sagan SD., 1993, LIMITS SAFETY ORG AC; SCHELL J, 1998, NATION          0202; SIDEL VW, 1962, NEW ENGL J MED, V266, P1137, DOI 10.1056/NEJM196205312662205; SIDEL VW, 1996, GENOCIDE WAR HUMAN S, P193; Solomon F, 1986, MED IMPLICATIONS NUC; Tanaka K, 1996, Eur J Emerg Med, V3, P263, DOI 10.1097/00063110-199612000-00009; TURNER S, 1997, CAGING NUCL GENIE AM; WHO, 1987, EFF NUCL WAR HLTH HL; WOODWELL GM, 1983, AFTERMATH HUMAN ECOL, P131	55	22	22	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1326	1331		10.1056/NEJM199804303381824	http://dx.doi.org/10.1056/NEJM199804303381824			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZK547	9562589				2022-12-28	WOS:000073335800033
J	Edmonds, HN; Moran, SB; Hoff, JA; Smith, JN; Edwards, RL				Edmonds, HN; Moran, SB; Hoff, JA; Smith, JN; Edwards, RL			Protactinium-231 and thorium-230 abundances and high scavenging rates in the western Arctic Ocean	SCIENCE			English	Article							WATER COLUMN; DEEP-SEA; TH-230; PA-231; CIRCULATION; DISTRIBUTIONS; VENTILATION; SEDIMENTS; PROFILES; ISOTOPES	The Canadian Basin of the Arctic Ocean, largely ice covered and isolated from deep contact with the more dynamic Eurasian Basin by the Lomonosov Ridge, has historically been considered an area of low productivity and particle flux and sluggish circulation. High-sensitivity mass-spectrometric measurements of the naturally occurring radionuclides protactinium-231 and thorium-230 in the deep Canada Basin and on the adjacent shelf indicate high particle fluxes and scavenging rates in this region. The thorium-232 data suggest that offshore advection of particulate material from the shelves contributes to scavenging of reactive materials in areas of permanent ice cover.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; Univ Minnesota, Dept Geol & Geophys, Minnesota Isotope Lab, Minneapolis, MN 55455 USA; Bedford Inst Oceanog, Dartmouth, NS B2Y 4A2, Canada	University of Rhode Island; University of Minnesota System; University of Minnesota Twin Cities; Bedford Institute of Oceanography	Edmonds, HN (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.		Edwards, R. Lawrence/I-3124-2014	Edwards, R. Lawrence/0000-0002-7027-5881; Moran, Bradley/0000-0001-9263-2889				AAGAARD K, 1994, POLAR OCEANS THEIR R, V85, P1; ANDERSON RF, 1983, EARTH PLANET SC LETT, V62, P7, DOI 10.1016/0012-821X(83)90067-5; ANDERSON RF, 1983, EARTH PLANET SC LETT, V66, P73, DOI 10.1016/0012-821X(83)90127-9; ANDERSON RF, 1982, ANAL CHEM, V54, P1142, DOI 10.1021/ac00244a030; BACON MP, 1989, EARTH PLANET SC LETT, V95, P15, DOI 10.1016/0012-821X(89)90164-7; BACON MP, 1982, J GEOPHYS RES-OCEANS, V87, P2045, DOI 10.1029/JC087iC03p02045; BACON MP, 1988, PHILOS T R SOC A, V325, P147, DOI 10.1098/rsta.1988.0048; Carmack E. C., 1990, POLAR OCEANOGRAPHY A, P171, DOI DOI 10.1016/B978-0-12-653031-5.50009-6; Cochran JK, 1995, DEEP-SEA RES PT II, V42, P1495; Edwards RL, 1997, SCIENCE, V276, P782, DOI 10.1126/science.276.5313.782; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; GUO LD, 1995, EARTH PLANET SC LETT, V133, P117, DOI 10.1016/0012-821X(95)00063-I; HUH CA, 1985, NATURE, V316, P718, DOI 10.1038/316718a0; KUMAR N, 1993, NATURE, V362, P45, DOI 10.1038/362045a0; MACDONALD RW, 1993, SCIENCE, V259, P103, DOI 10.1126/science.259.5091.103; MORAN SB, 1995, GEOPHYS RES LETT, V22, P2589, DOI 10.1029/95GL02652; Moran SB, 1997, EARTH PLANET SC LETT, V150, P151, DOI 10.1016/S0012-821X(97)00081-2; NOZAKI Y, 1985, DEEP-SEA RES, V32, P1209, DOI 10.1016/0198-0149(85)90004-4; NOZAKI Y, 1987, J GEOPHYS RES-OCEANS, V92, P772, DOI 10.1029/JC092iC01p00772; NOZAKI Y, 1981, EARTH PLANET SC LETT, V54, P203, DOI 10.1016/0012-821X(81)90004-2; OSTLUND HG, 1987, J GEOPHYS RES-OCEANS, V92, P3769, DOI 10.1029/JC092iC04p03769; PICKETT DA, 1994, ANAL CHEM, V66, P1044, DOI 10.1021/ac00079a020; Schlosser P, 1995, DEEP-SEA RES PT II, V42, P1341, DOI 10.1016/0967-0645(95)00045-3; Scholten JC, 1995, DEEP-SEA RES PT II, V42, P1519, DOI 10.1016/0967-0645(95)00052-6; SCOTT MR, 1968, EARTH PLANET SC LETT, V4, P245; VANDERLOEFF MMR, 1993, DEEP-SEA RES PT I, V40, P339; Walter HJ, 1997, EARTH PLANET SC LETT, V149, P85, DOI 10.1016/S0012-821X(97)00068-X; YANG HS, 1986, GEOCHIM COSMOCHIM AC, V50, P81, DOI 10.1016/0016-7037(86)90050-5; Yu EF, 1996, NATURE, V379, P689, DOI 10.1038/379689a0	29	50	51	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					405	407		10.1126/science.280.5362.405	http://dx.doi.org/10.1126/science.280.5362.405			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545211				2022-12-28	WOS:000073159600037
J	Sulmasy, DP; Terry, PB; Weisman, CS; Miller, DJ; Stallings, RY; Vettese, MA; Haller, KB				Sulmasy, DP; Terry, PB; Weisman, CS; Miller, DJ; Stallings, RY; Vettese, MA; Haller, KB			The accuracy of substituted judgments in patients with terminal diagnoses	ANNALS OF INTERNAL MEDICINE			English	Article						terminal care; advance directives; ethics, medical; resuscitation orders; decision making	AMYOTROPHIC-LATERAL-SCLEROSIS; ELDERLY PERSONS; SURVIVAL; DECISIONS; CARE; PREDICTIONS; AGREEMENT; ATTITUDES; PROXIES; HEART	Background: Patients' loved ones often make end-of-life treatment decisions, but the accuracy of their substituted judgments and the factors associated with accuracy are poorly understood. Objective: To assess the accuracy of judgments made by surrogate decision makers; ascertain the beliefs, practices, and clinical and sociodemographic factors associated with accuracy of surrogates' decisions; assess the preferences of patients for life-sustaining treatments; and compare differences in accuracy across diagnoses. Design: Cross-sectional paired interviews. Setting: Outpatient practices of three university hospitals. Patients: 250 patients with terminal diagnoses of congestive heart failure, AIDS, amyotrophic lateral sclerosis, lung cancer, and chronic obstructive pulmonary disease (50 patient-surrogate pairs in each group) and 50 general medical patients and their surrogates. Measurements: The accuracy of surrogate predictions was measured by using scales based on 10 potential treatments in each of three hypothetical clinical scenarios. Results: Preferences varied according to mode of treatment and scenario. On average, surrogates made correct predictions in 66% of instances. Accuracy was better for the permanent coma scenario than for the scenarios of severe dementia or coma with a small chance of recovery (P < 0.001). In a binary legit model, the accuracy of substituted judgments was positively associated with the patient having spoken with the surrogate about end-of-life issues (odds ratio [OR], 1.9 [95% CI, 1.6 to 2.3]), the patient having private insurance (OR, 1.4 [CI, 1.1 to 1.7]), the surrogate's level of education (OR, 1.5 [CI, 1.2 to 1.9]), and the patient's level of education (OR, 1.7 [CI, 1.4 to 2.2]). Accuracy was negatively associated with the patient's belief that he or she would live longer than 10 years (OR, 0.6 [CI, 0.5 to 0.7]), surrogate experience with life-sustaining treatment (OR, 0.4 [CI, 0.3 to 0.5]), surrogate participation in religious services (OR, 0.67 [CI, 0.50 to 0.91]), and a diagnosis of heart failure (OR, 0.6 [CI, 0.5 to 0.8]). Age, ethnicity, marital status, religion, and advance directives were not associated with accuracy. Conclusions: The accuracy of substituted judgments is associated with multiple clinically apparent patient and surrogate factors. This information can help clinicians identify conditions under which substituted judgments are likely to be accurate or inaccurate and can help target populations for education designed to improve the accuracy of surrogate decision making.	Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA	Georgetown University	Sulmasy, DP (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Room 236,Bldg D, Washington, DC 20007 USA.	sulmasyd@gunet.georgetown.edu			NINR NIH HHS [NIH-RO1NR03045-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR003045] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BAERGEN R, 1995, J CLIN ETHIC, V6, P30; Breslow N E, 1987, STATISTICAL METHODS, V2, P120; Buchanan AE, 1990, DECIDING OTHERS ETHI; BURROWS B, 1969, AM REV RESPIR DIS, V99, P865; COUGHLIN SS, 1992, J CLIN EPIDEMIOL, V45, P1, DOI 10.1016/0895-4356(92)90180-U; DUBOIS P, 1994, CHEST, V105, P469, DOI 10.1378/chest.105.2.469; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GAY PC, 1991, MAYO CLIN PROC, V66, P686, DOI 10.1016/S0025-6196(12)62080-1; HARE J, 1992, ARCH INTERN MED, V152, P1049, DOI 10.1001/archinte.152.5.1049; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; Layde P M, 1995, Arch Fam Med, V4, P518, DOI 10.1001/archfami.4.6.518; Libbus M K, 1995, Image J Nurs Sch, V27, P135; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; LYNN J, NEW HORIZ, V5, P56; MADSEN BK, 1994, EUR HEART J, V15, P303, DOI 10.1093/oxfordjournals.eurheartj.a060495; MCDONALD ER, 1994, ARCH NEUROL-CHICAGO, V51, P17, DOI 10.1001/archneur.1994.00540130027010; MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; PREGIBON D, 1981, ANN STAT, V9, P705, DOI 10.1214/aos/1176345513; ROSSING TH, 1982, AM REV RESPIR DIS, V126, P771; RYBASH JM, 1989, APPL COGNITIVE PSYCH, V3, P171, DOI 10.1002/acp.2350030207; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SUHL J, 1994, ARCH INTERN MED, V154, P90, DOI 10.1001/archinte.154.1.90; Sulmasy D. P., 1997, JGIM, V12, P105; SULMASY DP, 1994, AM J MED, V96, P432, DOI 10.1016/0002-9343(94)90170-8; TOMLINSON T, 1990, GERONTOLOGIST, V30, P54, DOI 10.1093/geront/30.1.54; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; *US GOV PR OFF, 1982, SUBST PROC PRINC DEC, P177; Voorhees CC, 1996, PREV MED, V25, P277, DOI 10.1006/pmed.1996.0057; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	33	224	226	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					621	+		10.7326/0003-4819-128-8-199804150-00002	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537935				2022-12-28	WOS:000073052500002
J	Danesh, J; Peto, R				Danesh, J; Peto, R			Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies	BRITISH MEDICAL JOURNAL			English	Article							SEROPOSITIVITY; ASSOCIATION	Objective: To find out if chronic infection with Helicobacter pylori is correlated with risk factors for coronary heart disease. Design: Meta-analysis of 18 epidemiological studies, involving a total of 10 000 patients, that measured serum antibody titres to H pylori and risk factors for coronary heart disease. Any study published in any language before 1998 was eligible for inclusion. Results: Only small absolute differences in body mass index, blood pressure, ol haematological risk factors were found between subjects who were seropositive and those who were seronegative. In those who were seropositive body mass index was slightly higher (0.37, SE 0.09) and concentrations of high density lipoprotein cholesterol were slightly lower (0.032 mmol/l, 0.008), None of the other differences were highly significant. Conclusion: Previous claims of substantial correlations between H pylori seropositivity and certain vascular risk factors were larger or wholly due to chance or the preferential publication of positive results, or both.	Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Epidemiol Studies Unit, Nuffield Dept Clin Med, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England.							BARNES RJ, 1991, BRIT J GEN PRACT, V41, P286; Brenner H, 1997, BRIT MED J, V315, P1489, DOI 10.1136/bmj.315.7121.1489; BRUNNER E, 1995, J EPIDEMIOL COMMUNIT, V49, P545; Carter A M, 1996, Helicobacter, V1, P65, DOI 10.1111/j.1523-5378.1996.tb00011.x; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; deArgila CM, 1997, GUT, V41, pA173; KARTTUNEN T, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_1; Karttunen TJ, 1996, DIGEST DIS SCI, V41, P1332, DOI 10.1007/BF02088556; Lip GYH, 1996, BRIT MED J, V312, P250; McDonagh TA, 1997, EUR HEART J, V18, P1257; Mendall MA, 1996, BRIT MED J, V312, P1061; MENDALL MA, 1994, BRIT HEART J, V71, P437; MURRAY LJ, 1995, BRIT HEART J, V74, P497; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; OsseiGerning N, 1997, CARDIOVASC RES, V35, P120, DOI 10.1016/S0008-6363(97)00090-4; Parente F, 1997, BRIT MED J, V314, P1318, DOI 10.1136/bmj.314.7090.1318; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PATEL P, 1994, LANCET, V343, P1634, DOI 10.1016/S0140-6736(94)93084-8; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; ROSENSTOCK SJ, 1996, GUT, V39, pA62; Scragg RKR, 1996, J EPIDEMIOL COMMUN H, V50, P578, DOI 10.1136/jech.50.5.578; Wald NJ, 1997, BMJ-BRIT MED J, V315, P1199, DOI 10.1136/bmj.315.7117.1199; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	23	213	217	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1130	1132		10.1136/bmj.316.7138.1130	http://dx.doi.org/10.1136/bmj.316.7138.1130			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552950	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000073067500023
J	MacAuley, D; McCrum, E; Brown, C				MacAuley, D; McCrum, E; Brown, C			Randomised controlled trial of the READER method of critical appraisal in general practice	BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONERS; INFORMATION; ACRONYM		Queens Univ Belfast, Royal Victoria Hosp, Div Epidemiol, Belfast BT12 6BJ, Antrim, North Ireland	Queens University Belfast	MacAuley, D (corresponding author), Queens Univ Belfast, Royal Victoria Hosp, Div Epidemiol, Belfast BT12 6BJ, Antrim, North Ireland.							BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; Greenhalgh T, 1996, BRIT MED J, V313, P957; KITCHENS JM, 1989, J GEN INTERN MED, V4, P384, DOI 10.1007/BF02599686; MacAuley D, 1996, FAM PRACT, V13, P104, DOI 10.1093/fampra/13.1.104; MACAULEY D, 1994, BRIT J GEN PRACT, V44, P83; MACAULEY D, 1994, FORUM J IRISH COLL G, V10, P52; McAvoy BR, 1996, BRIT MED J, V313, P732; MIDDLETON JF, 1995, BRIT MED J, V311, P34, DOI 10.1136/bmj.311.6996.34; OBRIEN J, 1995, BRIT MED J, V311, P1208, DOI 10.1136/bmj.311.7014.1208; SIDEROV J, 1995, ARCH INTERN MED, V155, P1193; Smith R, 1996, BRIT MED J, V313, P1062; Watura R, 1995, BRIT MED J, V311, P1614, DOI 10.1136/bmj.311.7020.1614; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	14	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1134	1137		10.1136/bmj.316.7138.1134	http://dx.doi.org/10.1136/bmj.316.7138.1134			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552953	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000073067500025
J	Miettinen, TA; Gylling, H; Strandberg, T; Sarna, S				Miettinen, TA; Gylling, H; Strandberg, T; Sarna, S		Finnish 4S Investigators	Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	11th International Symposium on Atherosclerosis	OCT 05-09, 1997	PARIS, FRANCE	Int Atherosclerosis Soc, Bristol Myers Squibb, Merck & Co Inc, Novartis, Parke Davis, Sanofi Recherche			CHOLESTEROL ABSORPTION; PLANT STEROLS; METABOLISM; POPULATION; PRECURSORS; DISEASE; MEN	Objectives: To investigate whether baseline serum cholestanol:cholesterol ratio, which is negatively related to cholesterol synthesis, could predict reduction of coronary events in the Scandinavian simvastatin survival study. Design: Follow up of patients with coronary heart disease in whom baseline ratios were related to major coronary events. Setting: Four universities in Finland. Subjects: A subgroup of 868 patients with coronary heart disease selected from the Scandinavian simvastatin survival study. Intervention: Treatment with simvastatin or placebo. Main outcome measures: Serum concentrations of low density lipoprotein and high density lipoprotein cholesterol, total triglyceride concentration, and cholesterol:cholestanol ratio. Major coronary events. Results: With increasing baseline quarter of cholestanol distribution the reduction in relative risk increased gradually from 0.623 (95% confidence interval 0.395 to 0.982) to 1.166 (0.791 to 1.72). The risk of recurrence of major coronary events increased 2.2-fold (P < 0.01) by multiple logistic regression analysis between the lowest and highest quarter of cholestanol. The ratio of cholestanol was related inversely to the body mass index and directly to high density lipoprotein cholesterol and triglyceride concentrations but their quarters of distribution were not related to risk reduction. Conclusions: Measurement of serum cholestanol concentration revealed a subgroup of patients with coronary heart disease in whom coronary events were not reduced by simvastatin treatment Thus, patients with high baseline synthesis of cholesterol seem to be responders whereas those with low synthesis of cholesterol are non-responders.	Univ Helsinki, Dept Med, Div Internal Med, FI-00290 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Miettinen, TA (corresponding author), Univ Helsinki, Dept Med, Div Internal Med, FI-00290 Helsinki, Finland.	tatu.a.miettinen@helsinki.fi		Sarna, Seppo/0000-0003-3458-1627; strandberg, timo/0000-0001-6299-925X				BJORKHEM I, 1987, J LIPID RES, V28, P1137; BJORKHEM I, 1980, METABOLIC BASIS INHE, P1283; DIXON W, 1992, BMDP STAT SOFTWARE M, V1; FARKKILA MA, 1988, GUT, V29, P188, DOI 10.1136/gut.29.2.188; GARDNER MJ, 1989, CONFIDENCE INTERVAL; GLUECK CJ, 1991, METABOLISM, V40, P842, DOI 10.1016/0026-0495(91)90013-M; Gylling H, 1997, ATHEROSCLEROSIS, V134, P157, DOI 10.1016/S0021-9150(97)88834-X; GYLLING H, 1988, CLIN CHIM ACTA, V178, P41, DOI 10.1016/0009-8981(88)90267-7; Gylling H, 1996, J LIPID RES, V37, P1776; KEMPEN HJM, 1988, J LIPID RES, V29, P1149; KJEKSHUS J, 1993, AM J CARDIOL, V71, P393; MIETTINEN T A, 1970, Annals of Clinical Research, V2, P300; MIETTINEN TA, 1989, AM J CLIN NUTR, V49, P629, DOI 10.1093/ajcn/49.4.629; MIETTINEN TA, 1989, METABOLISM, V38, P136, DOI 10.1016/0026-0495(89)90252-7; MIETTINEN TA, 1988, J LIPID RES, V29, P43; MIETTINEN TA, 1990, AM J EPIDEMIOL, V131, P20, DOI 10.1093/oxfordjournals.aje.a115479; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Miettinen TA, 1996, MED SCI SYMP SER, V10, P473; MIETTINEN TA, 1971, ANN CLIN RES, V3, P264; Miettinen TA, 1983, BILE ACIDS CHOLESTER, P183; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; TILVIS RS, 1986, AM J CLIN NUTR, V43, P92, DOI 10.1093/ajcn/43.1.92; VUORISTO M, 1986, GUT, V27, P1312, DOI 10.1136/gut.27.11.1312	24	193	204	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	1998	316	7138					1127	1130		10.1136/bmj.316.7138.1127	http://dx.doi.org/10.1136/bmj.316.7138.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZH054	9552949	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000073067500022
J	Uitterlinden, AG; Burger, H; Huang, WJ; Yue, F; McGuigan, FEA; Grant, SFA; Hofman, A; van Leeuwen, JPTM; Pols, HAP; Ralston, SH				Uitterlinden, AG; Burger, H; Huang, WJ; Yue, F; McGuigan, FEA; Grant, SFA; Hofman, A; van Leeuwen, JPTM; Pols, HAP; Ralston, SH			Relation of alleles of the collagen type I alpha 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN-RECEPTOR GENE; MINERAL DENSITY; OSTEOGENESIS IMPERFECTA; MASS; MUTATION; DETERMINANTS; ASSOCIATION; PREDICTION; ROTTERDAM; RICKETS	Background Osteoporosis is a common disorder with a strong genetic component. One way in which the genetic component could be expressed is through polymorphism of COLIA1, the gene for collagen type l alpha 1, a bone-matrix protein, Methods We determined the COLIA1 genotypes SS, Ss,and ss in a population-based sample of 1778 postmenopausal women using a polymerase-chain-reaction-based assay. We then related the genotypes to bone mineral density and the occurrence of osteoporotic fractures in these women. Results As compared with the 1194 women with the SS genotype, the 526 women with the Ss genotype had 2 percent lower bone mineral density at the femoral neck (P = 0.003) and the lumbar spine (P = 0.02); the 58 women with the ss genotype had reductions of 4 percent at the femoral neck (P = 0.05) and 6 percent at the lumbar spine (P = 0.005). These differences increased with age (P = 0.01 for modification by age of the effect of COLIA1 on femoral-neck bone density, and P = 0.004 for modification of the effect on lumbar-spine bone density). Women with the Ss and ss genotypes were overrepresented among the 111 women who had incident nonvertebral fractures (relative risk per copy of the s allele, 1.5; 95 percent confidence interval, 1.1 to 2.1). Conclusions The COLIA1 polymorphism is associated with reduced bone density and predisposes women to osteoporotic fractures. (C) 1998, Massachusetts Medical Society.	Erasmus Univ, Sch Med, Dept Internal Med 3, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland	Erasmus University Rotterdam; Erasmus University Rotterdam; University of Aberdeen	Uitterlinden, AG (corresponding author), Erasmus Univ, Sch Med, Dept Internal Med 3, FGG-EUR,POB 1738, NL-3000 DR Rotterdam, Netherlands.		van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006; Grant, Struan/0000-0003-2025-5302	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURGER H, 1994, BONE MINER, V25, P1, DOI 10.1016/S0169-6009(08)80203-6; Burger H, 1997, J BONE MINER RES, V12, P152, DOI 10.1359/jbmr.1997.12.1.152; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; Cooper GS, 1996, J BONE MINER RES, V11, P1841; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Gong YQ, 1996, AM J HUM GENET, V59, P146; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; GRANT SFA, 1996, THESIS U ABERDEEN AB; GUEGUEN R, 1995, J BONE MINER RES, V10, P2017; Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; JOUANNY P, 1995, ARTHRITIS RHEUM, V38, P61, DOI 10.1002/art.1780380110; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KELLY PJ, 1993, J BONE MINER RES, V8, P11; Kobayashi S, 1996, J BONE MINER RES, V11, P306; KRALL EA, 1993, J BONE MINER RES, V8, P1; Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756-3282(96)00363-8; MALLOY PJ, 1994, J CLIN ENDOCR METAB, V78, P313, DOI 10.1210/jc.78.2.313; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Murray RE, 1997, BONE, V21, P89, DOI 10.1016/S8756-3282(97)00081-1; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Seeman E, 1996, AM J PHYSIOL-ENDOC M, V270, pE320, DOI 10.1152/ajpendo.1996.270.2.E320; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SOROKO SB, 1994, J BONE MINER RES, V9, P761; SPOTILA LD, 1994, J BONE MINER RES, V9, P923; WILLING MC, 1994, AM J HUM GENET, V55, P638	33	352	387	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1016	1021		10.1056/NEJM199804093381502	http://dx.doi.org/10.1056/NEJM199804093381502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535665	Green Published			2022-12-28	WOS:000072969500002
J	Goodwin, JS				Goodwin, JS			Switching sides	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1070	1070		10.1016/S0140-6736(05)79049-8	http://dx.doi.org/10.1016/S0140-6736(05)79049-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546548				2022-12-28	WOS:000072927200071
J	Greco, RS				Greco, RS			The oasis	LANCET			English	Editorial Material									Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Surg, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Greco, RS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Surg, 1 Robert Wood Johnson Pl,CN 19, New Brunswick, NJ 08903 USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1052	1053		10.1016/S0140-6736(97)12034-7	http://dx.doi.org/10.1016/S0140-6736(97)12034-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546527				2022-12-28	WOS:000072927200044
J	Wang, F; Nemes, A; Mendelsohn, M; Axel, R				Wang, F; Nemes, A; Mendelsohn, M; Axel, R			Odorant receptors govern the formation of a precise topographic map	CELL			English	Article							OCULAR DOMINANCE COLUMNS; RABBIT OLFACTORY-BULB; MITRAL TUFTED CELLS; IMPULSE ACTIVITY; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; ORGANIZATION; EPITHELIUM; RAT	Olfactory neurons expressing a given odorant receptor project with precision to 2 of the 1800 glomeruli within the olfactory bulb to create a topographic map of odor quality. We demonstrate that deletions or nonsense mutations in the P2 odorant receptor gene cause the axons of these cells to wander rather than converge on a specific glomerulus. Receptor substitution experiments that replace the P2 gene with the coding region of the P3 gene result in the projection of P3-->P2 axons to a glomerulus touching the wildtype P3 glomerulus. These data, along with additional receptor substitutions, indicate that the odorant receptor plays an instructive role in the establishment of the topographic map.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Axel, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076	NIMH NIH HHS [5 P50 MH50733] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KING AJ, 1991, TRENDS NEUROSCI, V14, P31, DOI 10.1016/0166-2236(91)90181-S; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SAUER B, 1990, New Biologist, V2, P441; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; STRYKER MP, 1986, J NEUROSCI, V6, P2117; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Woolsey T.A., 1990, P461; Yoshihara Y, 1997, J NEUROSCI, V17, P5830	51	484	494	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					47	60		10.1016/S0092-8674(00)81145-9	http://dx.doi.org/10.1016/S0092-8674(00)81145-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546391	hybrid			2022-12-28	WOS:000072910800009
J	Weiner, JH; Bilous, PT; Shaw, GM; Lubitz, SP; Frost, L; Thomas, GH; Cole, JA; Turner, RJ				Weiner, JH; Bilous, PT; Shaw, GM; Lubitz, SP; Frost, L; Thomas, GH; Cole, JA; Turner, RJ			A novel and ubiquitous system for membrane targeting and secretion of cofactor-containing proteins	CELL			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; ENGINEERED 3FE-4S CLUSTER; COLI FUMARATE REDUCTASE; GROWN ESCHERICHIA-COLI; DIMETHYLSULFOXIDE REDUCTASE; NITRITE REDUCTION; DMSO REDUCTASE; IDENTIFICATION; MOLYBDOENZYME; PURIFICATION	We report the identification of the proteins encoded by the mttABC operon (formerly yigTUW), which mediate a novel Sec-independent membrane targeting and translocation system in Escherichia coli that interacts with cofactor-containing redox proteins having a S/TRRXFLK "twin arginine" leader motif. A pleiotropic-negative mutant in mttA prevents the periplasmic localization of twin arginine redox enzymes, including nitrate reductase (NapA) and trimethylamine N-oxide reductase (TorA). The mutation also prevents the correct localization of the integral membrane molybdoenzyme dimethylsulfoxide reductase (DmsABC). The DmsA subunit has a twin arginine leader. Proteins with a Sec-dependent leader or which assemble spontaneously in the membrane are not affected by this mutation. MttA, B, and C are members of a large family of related sequences extending from archaebacteria to higher eukaryotes.	Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E1, Canada; Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Alberta; University of Alberta; University of Birmingham	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada.		Turner, Raymond J./M-3961-2015; Thomas, Gavin H/E-5753-2011; Frost, Laura/A-2639-2014	Turner, Raymond J./0000-0002-9263-0776; Thomas, Gavin H/0000-0002-9763-1313; Frost, Laura/0000-0002-8433-8230				Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DARWIN A, 1993, J GEN MICROBIOL, V139, P1829, DOI 10.1099/00221287-139-8-1829; DICKIE P, 1979, CAN J BIOCHEM CELL B, V57, P813, DOI 10.1139/o79-101; DOUNG F, 1997, CELL, V91, P567; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FROST L, 1989, MOL GEN GENET, V218, P152, DOI 10.1007/BF00330578; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; LATOUR DJ, 1987, J GEN MICROBIOL, V133, P597; LEMIRE BD, 1986, METHOD ENZYMOL, V126, P377; LEMIRE BD, 1983, J BACTERIOL, V155, P391, DOI 10.1128/JB.155.1.391-397.1983; LEMIRE BD, 1982, J BACTERIOL, V152, P1126; MCEWAN AG, 1994, ANTON LEEUW INT J G, V66, P151, DOI 10.1007/BF00871637; MCEWAN AG, 1984, ARCH MICROBIOL, V137, P344, DOI 10.1007/BF00410732; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEWMAN BM, 1978, J GEN MICROBIOL, V106, P1; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Turner RJ, 1997, PROTEIN ENG, V10, P285, DOI 10.1093/protein/10.3.285; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1971, J BIOL CHEM, V246, P6933; WEINER JH, 1993, J BIOL CHEM, V268, P3238	41	399	422	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					93	101		10.1016/S0092-8674(00)81149-6	http://dx.doi.org/10.1016/S0092-8674(00)81149-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546395	Bronze			2022-12-28	WOS:000072910800013
J	Craig, AWB; Haghighat, A; Yu, ATK; Sonenberg, N				Craig, AWB; Haghighat, A; Yu, ATK; Sonenberg, N			Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation	NATURE			English	Article							POLY(A)-BINDING PROTEIN; INITIATION; RNA; MOTIF	In the initiation of translation in eukaryotes, binding of the small ribosomal subunit to the messenger RNA results from recognition of the 5' cap structure (m(7)GpppX) of the mRNA by the cap-binding complex eIF4F(1). eIF4F is itself a three-subunit complex comprising the cap-binding protein eIF4E(2), eIF4A, an ATP-dependent RNA helicase(3), and eIF4G, which interacts with both eIF4A and eIF4E and enhances cap binding by eIF4E(4). The mRNA 3' polyadenylate tail and the associated poly(A)-binding protein (PABP) also regulate translational initiation(5), probably by interacting with the 5' end of the mRNA(6,7). In yeast(8,9) and plants(10), PABP interacts with eIF4G(8,9) but no such interaction has been reported in mammalian cells. Here, we describe a new human PABP-interacting protein, PAIP-1, whose sequence is similar to the central portion of eIF4G and which interacts with eIE4A. Overexpression of PAIP-1 in COS-7 cells stimulates translation, perhaps by providing a physical link between the mRNA termini.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				ASSELBERGS FAM, 1978, EUR J BIOCHEM, V88, P483, DOI 10.1111/j.1432-1033.1978.tb12473.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; MADER S, 1995, MOL CELL BIOL, V15, P4990; Merrick WC., 1996, TRANSLATION CONTROL, P31; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YANG HD, 1995, MOL CELL BIOL, V15, P6770	29	309	323	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					520	523		10.1038/33198	http://dx.doi.org/10.1038/33198			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548260				2022-12-28	WOS:000072875200065
J	Steinberg-Yfrach, G; Rigaud, JL; Durantini, EN; Moore, AL; Gust, D; Moore, TA				Steinberg-Yfrach, G; Rigaud, JL; Durantini, EN; Moore, AL; Gust, D; Moore, TA			Light-driven production of ATP catalysed by F0F1-ATP synthase in an artificial photosynthetic membrane	NATURE			English	Article							RECONSTITUTION PROCEDURE; LIPOSOMES; BACTERIORHODOPSIN; CHLOROPLASTS; CF0F1; SITE; ENERGY	Energy-transducing membranes of living organisms couple spontaneous to non-spontaneous processes through the intermediacy of protonmotive force (p.m.f.)-an imbalance in electrochemical potential of protons across the membrane, In most organisms, p.m.f. is generated by redox reactions that are either photochemically driven, such as those in photosynthetic reaction centres, or intrinsically spontaneous, such as those of oxidative phosphorylation in mitochondria. Transmembrane proteins (such as the cytochromes and complexes I, III and IV in the electron-transport chain in the inner mitochondrial membrane) couple the redox reactions to proton translocation, thereby conserving a fraction of the redox chemical potential as p.m.f. Many transducer proteins couple p.m.f. to the performance of biochemical work, such as biochemical synthesis and mechanical and transport processes, Recently, an artificial photosynthetic membrane was reported in which a photocyclic process was used to transport protons across a liposomal membrane, resulting in acidification of the Liposome's internal volume(1), If significant p.m.f. is generated in this system, then incorporating an appropriate transducer into the liposomal bilayer should make it possible to drive a non-spontaneous chemical process, Here we report the incorporation of F0F1-ATP synthase into liposomes containing the components of the proton-pumping photocycle, Irradiation of this artificial membrane,vith visible Light results in the uncoupler-and inhibitor-sensitive synthesis of adenosine triphosphate (ATP) against an ATP chemical potential of similar to 12 kcal mol(-1), with a quantum yield of more than 7%, This system mimics the process by which photosynthetic bacteria convert light energy into ATP chemical potential.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA; Inst Curie, CNRS, UMR 168, Sect Rech, F-75231 Paris, France; CEA, LCR, F-75231 Paris 05, France	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; CEA	Moore, TA (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.			Durantini, Edgardo N./0000-0001-8901-7543				Cladera J, 1996, J BIOENERG BIOMEMBR, V28, P503, DOI 10.1007/BF02110440; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GUST D, 1993, ACCOUNTS CHEM RES, V26, P198, DOI 10.1021/ar00028a010; HANGARTER RP, 1982, BIOCHIM BIOPHYS ACTA, V681, P397, DOI 10.1016/0005-2728(82)90181-5; PETITOU M, 1978, ANAL BIOCHEM, V91, P350, DOI 10.1016/0003-2697(78)90849-7; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RICHARD P, 1992, EUR J BIOCHEM, V210, P287, DOI 10.1111/j.1432-1033.1992.tb17419.x; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; SCHMIDT G, 1985, BIOCHIM BIOPHYS ACTA, V808, P46, DOI 10.1016/0005-2728(85)90026-X; SIGALAT C, 1995, FEBS LETT, V368, P253, DOI 10.1016/0014-5793(95)00664-U; SteinbergYfrach G, 1997, NATURE, V385, P239, DOI 10.1038/385239a0	13	392	395	5	169	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					479	482		10.1038/33116	http://dx.doi.org/10.1038/33116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548252				2022-12-28	WOS:000072875200053
J	Davies, HTO; Crombie, IK; Tavakoli, M				Davies, HTO; Crombie, IK; Tavakoli, M			When can odds ratios mislead?	BRITISH MEDICAL JOURNAL			English	Article									Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland	University of St Andrews; University of Dundee	Davies, HTO (corresponding author), Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland.		Deeks, Jonathan/AAV-5745-2020	Deeks, Jonathan/0000-0002-8850-1971				Altman D.G., 1991, PRACTICAL STAT MED R; DEEKS J, 1996, BANDOLIER, V3, P6; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0	3	620	627	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					989	991		10.1136/bmj.316.7136.989	http://dx.doi.org/10.1136/bmj.316.7136.989			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550961	Green Published			2022-12-28	WOS:000072856100025
J	Reynolds, DF				Reynolds, DF			Flora Bridge - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1023	1023		10.1136/bmj.316.7136.1023	http://dx.doi.org/10.1136/bmj.316.7136.1023			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9552882				2022-12-28	WOS:000072856100062
J	Tudor-Smith, C; Nutbeam, D; Moore, L; Catford, J				Tudor-Smith, C; Nutbeam, D; Moore, L; Catford, J			Effects of the Heartbeat Wales programme over five years on behavioural risks for cardiovascular disease: quasi-experimental comparison of result from Wales and a matched reference area	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-PROGRAM; INTERVENTION; EDUCATION; SMOKING	Objective: To assess the net 5 year effects of intervention of a community based demonstration project, the Heartbeat Wales programme, on modifiable behavioural risks for prevention of cardiovascular disease. Design and setting: Quasi-experimental design comparing results from two independent cross sectional population surveys conducted in 1985 and 1990 in Wales and a matched reference area in north east England. Subjects: Random, stratified samples of people aged 18-64 years (18 538 in 1985 and 13 045 in 1990) in Wales and in north east England (1483 and 4534, respectively). Intervention: A coordinated range of activities for heart health promotion in Wales entailing public education campaigns along with supportive policy and infrastructure change. In the reference area no additional community heart health promotion was planned, though considerable activity did take place, "contaminating" the reference area. Main outcome measures: Fifteen self reported behavioural indicators relating to dietary choice, smoking, frequency of exercise, and weight. Results: Positive changes (for health) in behavioural outcomes were observed among the population in Wales, including a reduction in reported smoking prevalence and improvements in dietary choice. There was no net intervention effect for the programme over and above observed change in the reference area. Conclusions: No definite conclusions can be drawn concerning the efficacy of the programme in terms of behavioural outcomes. With hindsight, the difficulties of evaluating such a complex multifaceted intervention were underestimated. Further debate on the most appropriate methods for assessing the effectiveness of community based health promotion programmes is called for.	Hlth Promot Wales, Cardiff CF4 5DZ, S Glam, Wales; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Deakin Univ, Burwood, Vic 3125, Australia	University of Sydney; University of Bristol; Deakin University	Tudor-Smith, C (corresponding author), Hlth Promot Wales, Cardiff CF4 5DZ, S Glam, Wales.		Nutbeam, Don/AAU-1571-2021	Moore, Laurence/0000-0003-2182-823X; Nutbeam, Don/0000-0001-6497-2827				BENNETT N, 1996, LIVING BRITAIN RESUL; Black N, 1996, BRIT MED J, V312, P1215; BOAZ A, 1995, CORONARY HEART DIS S; CARLETON RA, 1995, AM J PUBLIC HEALTH, V85, P777, DOI 10.2105/AJPH.85.6.777; CATFORD J, 1992, COMMUNITY PREVENTION, P164; CHAPMAN S, 1993, BRIT MED J, V307, P429, DOI 10.1136/bmj.307.6901.429; CLARKSON J, 1991, J NUTR HLTH, V7, P101; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; GREEN LW, 1993, PROMOTION ED, P11; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; *MIN AGR FISH FOOD, 1970, HOUS FOOD CONS EXP; MURPHY S, 1994, J NUTR HLTH, V9, P317; NUTBEAM D, 1990, PUBLIC HEALTH, V104, P353, DOI 10.1016/S0033-3506(05)80528-1; NUTBEAM D, 1993, J EPIDEMIOL COMMUN H, V47, P127, DOI 10.1136/jech.47.2.127; Nutbeam D., 1996, HEALTH PROMOT J AUST, V6, P58; PHILLIPS CJ, 1993, J EPIDEMIOL COMMUN H, V47, P215, DOI 10.1136/jech.47.3.215; PULLEN E, 1992, J EPIDEMIOL COMMUN H, V46, P455, DOI 10.1136/jech.46.4.455; PUSKA P, 1995, N KARELIA PROJECT 20; ROBERTS RJ, 1995, PUBLIC HEALTH, V109, P275, DOI 10.1016/S0033-3506(95)80205-3; ROSE G, 1984, CORONARY HEART DIS P; Shah BV, 1997, SOFTWARE STAT ANAL C; SMITH C, 1990, Health Education Research, V5, P381, DOI 10.1093/her/5.3.381; Smith C, 1994, Health Trends, V26, P18; Speller V, 1997, BRIT MED J, V315, P361; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; *WHO EXP COMM, 1982, WHO TECH REP SER, V678; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; [No title captured]; [No title captured]	29	78	79	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					818	822		10.1136/bmj.316.7134.818	http://dx.doi.org/10.1136/bmj.316.7134.818			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC488	9549451	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000072584300026
J	Majeed, A; Head, S				Majeed, A; Head, S			Capitation based prescribing budgets will not work	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PERFORMANCE INDICATORS; CENSUS-DATA; COSTS		St George Hosp, Sch Med, Div Gen Practice & Primary Care, London SW17 0RE, England; N Derbyshire Hlth Author, Chesterfield S41 7PF, England	St Georges University London	Majeed, A (corresponding author), St George Hosp, Sch Med, Div Gen Practice & Primary Care, Cranmer Terrace, London SW17 0RE, England.	a.majeed@sghms.ac.uk	Head, Stewart/O-7016-2019; Greenhalgh, Trisha/B-1825-2015	Head, Stewart/0000-0002-6891-7590; Majeed, Azeem/0000-0002-2357-9858; Greenhalgh, Trisha/0000-0003-2369-8088				Armstrong D, 1996, BRIT MED J, V312, P949; *AUD COMM, 1994, PRESCR IMPR MOR RAT; Baker SJ, 1996, BRIT MED J, V312, P58, DOI 10.1136/bmj.312.7022.58b; Bateman DN, 1996, BRIT J GEN PRACT, V46, P20; Bloor K, 1996, BRIT MED J, V312, P1525, DOI 10.1136/bmj.312.7045.1525; Greenhalgh T, 1998, BRIT MED J, V316, P750, DOI 10.1136/bmj.316.7133.750; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MAJEED FA, 1995, BRIT MED J, V310, P1373, DOI 10.1136/bmj.310.6991.1373; MAJEED FA, 1996, HLTH TRENDS, V28, P52; MAJEED FA, 1997, BRIT MED J, V315, P1515; MCGUIGAN S, 1997, PHARM FACTS FIGURES; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; *NHS EX, 1996, EL9681 NHS EX; SCHEFFLER R, 1989, LANCET, V1, P950; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488	16	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					748	750		10.1136/bmj.316.7133.748	http://dx.doi.org/10.1136/bmj.316.7133.748			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529412	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072463700036
J	Friedmann, PS				Friedmann, PS			ABC of allergies - Allergy and the skin. II - Contact and atopic eczema	BRITISH MEDICAL JOURNAL			English	Review							DERMATITIS; PATHOGENESIS		Southampton Gen Hosp, Southampton, Hants, England	University of Southampton	Friedmann, PS (corresponding author), Southampton Gen Hosp, Southampton, Hants, England.							COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; FRIEDMANN PS, 1995, CLIN EXP ALLERGY, V25, P799, DOI 10.1111/j.1365-2222.1995.tb00021.x; FRIEDMANN PS, 1996, TOXICOLOGY CONTACT H, P26; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x	5	14	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1226	1229		10.1136/bmj.316.7139.1226	http://dx.doi.org/10.1136/bmj.316.7139.1226			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553003	Green Published			2022-12-28	WOS:000073224100030
J	Alward, WLM; Fingert, JH; Coote, MA; Johnson, AT; Lerner, SF; Junqua, D; Durcan, FJ; McCartney, PJ; Mackey, DA; Sheffield, VC; Stone, EM				Alward, WLM; Fingert, JH; Coote, MA; Johnson, AT; Lerner, SF; Junqua, D; Durcan, FJ; McCartney, PJ; Mackey, DA; Sheffield, VC; Stone, EM			Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLCIA)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKAGE; REGION	Background A substantial proportion of cases of glaucoma have a genetic basis, Mutations causing glaucoma have been identified in the chromosome 1 open-angle glaucoma gene (GLC1A), which encodes a 57-kd protein known as myocilin. The normal role of this protein and the mechanism by which mutations cause glaucoma are not known, Methods We screened 716 patients with primary open-angle glaucoma and 596 control subjects For sequence changes in the GLC1A gene. Results We identified 16 sequence variations that met the criteria for a probable disease-causing mutation because they altered the predicted amino acid sequence and they were found in one or more patients with glaucoma and in less than 1 percent of the control subjects. These 16 mutations were found in 33 patients (4.6 percent). Six of the mutations were found in more than 1 subject: (total, 99). Clinical features associated with these six mutations included an age at diagnosis ranging from 8 to 77 years and maximal recorded intraocular pressures ranging from 12 to 77 mm Hg, Conclusions A variety of mutations in the GLC1A gene are associated with glaucoma, The spectrum of disease can range from juvenile glaucoma to typical late-onset primary open-angle glaucoma. (C) 1998, Massachusetts Medical Society.	Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Melbourne, Dept Ophthalmol, Melbourne, Vic, Australia; Univ Buenos Aires, Santa Lucia Ophthalmol Hosp, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Buenos Aires, DF, Argentina; Univ Utah, Coll Med, Dept Ophthalmol, Salt Lake City, UT USA; Menzies Ctr Populat Res, Hobart, Tas, Australia; Univ Tasmania, Dept Ophthalmol, Hobart, Tas, Australia	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Melbourne; University of Buenos Aires; University of Buenos Aires; Utah System of Higher Education; University of Utah; University of Tasmania	Stone, EM (corresponding author), Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.		Alward, Wallace/AAY-4149-2020; Fingert, John/AAX-4750-2021; Fingert, John/F-8787-2012; Mackey, David A/H-5340-2014	Fingert, John/0000-0002-0377-0479; Fingert, John/0000-0002-0377-0479; Mackey, David A/0000-0001-7914-4709; Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835; Alward, Wallace/0000-0001-6368-9018; Johnson, Arlan/0000-0002-9519-2943; Lerner, Simon Fabian/0000-0002-4657-286X	NATIONAL EYE INSTITUTE [R01EY010564] Funding Source: NIH RePORTER; NEI NIH HHS [EY10564] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARMALY MF, 1967, ARCH OPHTHALMOL-CHIC, V78, P5; BECKER B, 1960, AM J OPHTHALMOL, V50, P557, DOI 10.1016/0002-9394(60)90233-6; BENEDICT TWG, 1842, ABHANDLUNGEN GEBIETE; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DAVIES TG, 1968, BRIT J OPHTHALMOL, V52, P32, DOI 10.1136/bjo.52.1.32; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; FRANCOIS J, 1966, AM J OPHTHALMOL, V62, P1067, DOI 10.1016/0002-9394(66)92555-4; Jay B, 1970, Trans Ophthalmol Soc U K, V90, P161; KELLERMAN L, 1955, AM J OPHTHALMOL, V40, P681, DOI 10.1016/0002-9394(55)91495-1; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; MILLER SJH, 1978, T OPHTHAL SOC UK, V98, P290; Paterson G, 1970, Trans Ophthalmol Soc U K, V90, P515; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; RICHARDS JE, 1994, AM J HUM GENET, V54, P62; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; Stoilova D, 1996, GENOMICS, V36, P142, DOI 10.1006/geno.1996.0434; Stokes WH, 1940, ARCH OPHTHALMOL-CHIC, V24, P885, DOI 10.1001/archopht.1940.00870050035002; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Sunden SLF, 1996, GENOME RES, V6, P862, DOI 10.1101/gr.6.9.862; WIGGS JL, 1994, GENOMICS, V21, P299, DOI 10.1006/geno.1994.1269; Wirtz MK, 1997, AM J HUM GENET, V60, P296	26	365	380	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1022	1027		10.1056/NEJM199804093381503	http://dx.doi.org/10.1056/NEJM199804093381503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535666				2022-12-28	WOS:000072969500003
J	Baggiolini, M				Baggiolini, M			Chemokines and leukocyte traffic	NATURE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; T-LYMPHOCYTES; MOLECULAR-CLONING; CC-CHEMOKINES; HIV-1 ENTRY; RECEPTOR; INTERLEUKIN-8; INFLAMMATION; EXPRESSION; SDF-1	Over the past ten years, numerous chemokines have been identified as attractants of different types of blood leukocytes to sites of infection and inflammation. They are produced locally in the tissues and act on leukocytes through selective receptors. Chemokines are now known to also function as regulatory molecules in leukocyte maturation, traffic and homing of lymphocytes, and the development of lymphoid tissues.	Univ Bern, Theodor Kocher Inst, CH-3000 Bern 9, Switzerland	University of Bern	Baggiolini, M (corresponding author), Univ Bern, Theodor Kocher Inst, CH-3000 Bern 9, Switzerland.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, J EXP MED, V186, P1189, DOI 10.1084/jem.186.8.1189; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cook DN, 1996, J LEUKOCYTE BIOL, V59, P61, DOI 10.1002/jlb.59.1.61; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FURIE MB, 1995, AM J PATHOL, V146, P1287; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Horuk R, 1997, J IMMUNOL, V158, P2882; KENNEDY J, 1995, J IMMUNOL, V155, P203; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lukacs NW, 1997, J IMMUNOL, V158, P4398; MASURE S, 1995, J INTERF CYTOK RES, V15, P955, DOI 10.1089/jir.1995.15.955; METCHNIKOFF E, 1901, IMMUNITE MALADIES IN; Moore JP, 1996, J EXP MED, V184, P311, DOI 10.1084/jem.184.2.311; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nishimura A, 1997, J LEUKOCYTE BIOL, V62, P444, DOI 10.1002/jlb.62.4.444; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; Rand ML, 1996, AM J PATHOL, V148, P855; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SALLUSTO F, IN PRESS J EXP MED; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Strieter RM, 1996, J IMMUNOL, V156, P3583; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Verfaillie CM, 1996, J LAB CLIN MED, V127, P148; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	69	2310	2460	6	102	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					565	568		10.1038/33340	http://dx.doi.org/10.1038/33340			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560152				2022-12-28	WOS:000072987200048
J	Epstein, R; Kanwisher, N				Epstein, R; Kanwisher, N			A cortical representation of the local visual environment	NATURE			English	Article							SPATIAL REORIENTATION; LANDMARK STABILITY	Medial temporal brain regions such as the hippocampal formation and parahippocampal cortex have been generally implicated in navigation(1-6) and visual memory(7-9). However, the specific function of each of these regions is not yet clear, Here we present evidence that a particular area within human parahippocampal cortex is involved in a critical component of navigation: perceiving the local visual environment, This region, which we name the 'parahippocampal place area' (PPA), responds selectively and automatically in functional magnetic resonance imaging (fMRI) to passively viewed scenes, but only weakly to single objects and not at all to faces, The critical factor for this activation appears to be the presence in the stimulus of information about the layout of local space. The response in the PPA to scenes with spatial layout but no discrete objects (empty rooms) is as strong as the response to complex meaningful scenes containing multiple objects (the same rooms furnished) and over twice as strong as the response to arrays of multiple objects without three-dimensional spatial context (the furniture from these rooms on a blank background). This response is reduced if the surfaces in the scene are rearranged so that they no longer define a coherent space, We propose that the PPA represents places by encoding the geometry of the local environment.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Epstein, R (corresponding author), MIT, Dept Brain & Cognit Sci, E10-238,79 Amherst St, Cambridge, MA 02139 USA.	epstein@psyche.mit.edu	Kennedy, Kristen M/B-4699-2008; Epstein, Russell/G-4517-2013	Kennedy, Kristen M/0000-0001-5373-9026; 				Aguirre GK, 1998, P NATL ACAD SCI USA, V95, P839, DOI 10.1073/pnas.95.3.839; Aguirre GK, 1997, J NEUROSCI, V17, P2512; Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; BIEGLER R, 1993, NATURE, V361, P631, DOI 10.1038/361631a0; BOHBOT V, IN PRESS NEUROPSYCHO; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; Fodor J. A, 1983, MODULARITY MIND; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; GAFFAN D, 1994, J COGNITIVE NEUROSCI, V6, P305, DOI 10.1162/jocn.1994.6.4.305; Gallistel C. R., 1990, ORG LEARNING; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hermer L, 1996, COGNITION, V61, P195, DOI 10.1016/S0010-0277(96)00714-7; HERMER L, 1994, NATURE, V370, P57, DOI 10.1038/370057a0; ISHAI A, 1997, NEUROIMAGE, V5, pS149; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; LANDIS T, 1986, ARCH NEUROL-CHICAGO, V43, P132, DOI 10.1001/archneur.1986.00520020026011; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1997, J NEUROSCI, V17, P7103; MAGUIRE EA, 1996, NEUROPSYCHOLOGIA, V34, P994; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Rolls ET, 1997, EUR J NEUROSCI, V9, P1789, DOI 10.1111/j.1460-9568.1997.tb01538.x; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660	24	1992	2018	6	176	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					598	601		10.1038/33402	http://dx.doi.org/10.1038/33402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZG300	9560155				2022-12-28	WOS:000072987200058
J	Beecham, L				Beecham, L			Juniors criticise study leave proposals	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1098	1098						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552929				2022-12-28	WOS:000072987400075
J	Woodcock, A; Custovic, A				Woodcock, A; Custovic, A			Avoiding exposure to indoor allergens	BRITISH MEDICAL JOURNAL			English	Review									Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Woodcock, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				Burge H, 1993, INDOOR ALLERGENS ASS; COLLOF MJ, 1992, CLIN EXP ALLERGY S2, V22, P28; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; MILLS TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS1	4	36	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1075	1078						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552913	Green Published			2022-12-28	WOS:000072987400032
J	Fisher, K; Hanspal, RS				Fisher, K; Hanspal, RS			Phantom pain, anxiety depression, and their relation in consecutive patients with amputated limbs: case reports	BRITISH MEDICAL JOURNAL			English	Article									Royal Natl Orthopaed Hosp Trust, Disablement Serv Ctr, Stanmore HA7 4LP, Middx, England	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust	Fisher, K (corresponding author), Royal Natl Orthopaed Hosp Trust, Disablement Serv Ctr, Brockley Hill, Stanmore HA7 4LP, Middx, England.							KATZ J, 1990, PAIN, V43, P319, DOI 10.1016/0304-3959(90)90029-D; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; PARKES CM, 1973, J PSYCHOSOM RES, V17, P97, DOI 10.1016/0022-3999(73)90010-X; Sherman R, 1995, J MILIT PSYCHOL, V7, P28; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	5	34	37	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					903	904		10.1136/bmj.316.7135.903	http://dx.doi.org/10.1136/bmj.316.7135.903			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD691	9552839	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072713300029
J	MacKnight, C				MacKnight, C			Stevie Smith: The caregiver-poet	ANNALS OF INTERNAL MEDICINE			English	Biographical-Item							SERVICE; CARE		Dalhousie Univ, Halifax, NS B3H 2E1, Canada	Dalhousie University	MacKnight, C (corresponding author), Div Geriatr Med, 1st Floor,Camp Hill Vet Mem Bldg,5955 Jubilee Rd, Halifax, NS B3H 2E1, Canada.							CARADOCDAVIES TH, 1995, DISABIL REHABIL, V17, P247, DOI 10.3109/09638289509166642; COHEN CA, 1994, CAN J AGING, V13, P378, DOI 10.1017/S071498080000619X; CROWELL SJ, 1996, CANADIAN J AGING, V15, P413; DEBER RB, 1995, CAN J AGING, V14, P294, DOI 10.1017/S0714980800011855; DICK K, 1983, IVY STEVIE; HEANEY S, 1991, SEARCH S SMITH, P212; ISAACS B, 1972, SURVIVAL UNFITTEST S; LARKIN P, 1991, SEARCH S SMITH, P76; LAWTON MP, 1989, GERONTOLOGIST, V29, P8, DOI 10.1093/geront/29.1.8; Perneger TV, 1997, ARCH INTERN MED, V157, P1495, DOI 10.1001/archinte.157.13.1495; PHILP I, 1995, BRIT MED J, V310, P1503, DOI 10.1136/bmj.310.6993.1503; SMITH SE, PUBLICATION LIST; Sternlicht Sanford, 1991, SEARCH S SMITH, P1; Williams Jonathan., 1991, SEARCH S SMITH SEARCH S SMITH, P38; 1994, CANADIAN J AGING, V13, P470	15	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					788	790		10.7326/0003-4819-128-9-199805010-00045	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00045			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZK790	9556492				2022-12-28	WOS:000073363800043
J	Hutchison, B; Birch, S; Evans, CE; Goldsmith, LJ; Markham, BA; Frank, J; Paterson, M				Hutchison, B; Birch, S; Evans, CE; Goldsmith, LJ; Markham, BA; Frank, J; Paterson, M			Screening for hypercholesterolaemia in primary care: randomised controlled trial of postal questionnaire appraising risk of coronary heart disease	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN COMPLIANCE; PREVENTIVE CARE; REMINDERS; MEDICINE; GUIDELINES; PERFORMANCE; ADULT	Objectives: To validate a self administered postal questionnaire appraising risk of coronary heart disease. To determine whether use of this questionnaire increased the percentage of people at high risk of coronary heart disease and decreased the percentage of people at low risk who had their cholesterol concentration measured. Design: Validation was by review of medical records and clinical assessment. The questionnaire appraising risk of coronary heart disease encouraged those meeting criteria for cholesterol measurement to have a cholesterol test and was tested in a randomised controlled trial. The intervention group was sent the risk appraisal questionnaire with a health questionnaire that determined risk of coronary heart disease without identifying the risk factors as related to coronary heart disease; the control group was sent the health questionnaire alone. Setting: One capitation funded primary care practice in Canada with an enrolled patient population of about 12 000. Subjects: Random sample of 100 participants in the intervention and control groups were included in the validation exercise. 5686 contactable patients aged 20 to 69 years who on the basis of practice records had not had a cholesterol test performed during the preceding 5 years were included in the randomised controlled trial. 2837 were in the intervention group and 2849 were in the control group. Main outcome measures: Sensitivity and specificity of assessment of risk of coronary heart disease with risk appraisal questionnaire. Rate of cholesterol testing during three months of follow up. Results: Sensitivity of questionnaire appraising coronary risk was 87.5% (95% confidence interval 73.2% to 95.8%) and specificity 91.7% (81.6% to 97.2%). Of the patients without pre-existing coronary heart disease who met predefined screening criteria based on risk, 45 out of 421 in the intervention group (10.7%) and 9 out of 504 in the control group (1.8%) had a cholesterol test performed during follow up (P < 0.0001). Of the patients without a history of coronary heart disease who did not meet criteria for cholesterol testing, 30 out of 1128 in the intervention group (2.7%) and 18 out of 1099 in the control group (1.6%) had a cholesterol test (P = 0.175). Of the patients with pre-existing coronary heart disease, 1 out of 15 in the intervention group (6.7%) and 1 out of 23 in the control group (4.3%) were tested during follow up (P = 0.851, one tailed Fisher's exact test). Conclusions: Although the questionnaire appraising coronary risk increased the percentage of people at high risk who obtained cholesterol testing, the effect was small. Most patients at risk who received the questionnaire did not respond by having a test.	McMaster Univ, Hlth Sci Ctr, Ctr Hlth Econ & Policy Anal, Dept Family Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Hutchison, B (corresponding author), McMaster Univ, Hlth Sci Ctr, Ctr Hlth Econ & Policy Anal, Dept Family Med, Room 3H1E,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	hutchb@fhs.mcmaster.ca	Frank, John/AAZ-1169-2020	Frank, John/0000-0003-3912-4214; Birch, Stephen/0000-0002-1372-0440				[Anonymous], 1988, CAN MED ASSOC J S, V139, P1; CHENEY C, 1987, AM J MED, V83, P129, DOI 10.1016/0002-9343(87)90507-9; COHEN DI, 1982, MED CARE, V20, P1040, DOI 10.1097/00005650-198210000-00006; DIETRICH AJ, 1984, AM J PUBLIC HEALTH, V74, P223, DOI 10.2105/AJPH.74.3.223; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; HUTCHISON B, 1995, WORKING PAPER SERIES, V9514; International Taskforce for Prevention of Coronary Heart Disease, 1992, NUTR METAB CARDIOVAS, V2, P113; JONES A, 1988, BRIT MED J, V296, P1711, DOI 10.1136/bmj.296.6638.1711; KORN JE, 1988, J GEN INTERN MED, V3, P156, DOI 10.1007/BF02596123; LEWIS B, 1987, EUR HEART J, V8, P77; LOGAN AG, 1993, CAN MED ASSOC J, V148, P521; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MANT D, 1991, BRIT MED J, V302, P1057, DOI 10.1136/bmj.302.6784.1057; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; OVHED I, 1991, FAM PRACT, V8, P360, DOI 10.1093/fampra/8.4.360; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; *ROYAL COLL GEN PR, 1992, 55 RCGP; SCHREINER DT, 1988, SOUTHERN MED J, V81, P1553, DOI 10.1097/00007611-198812000-00021; Shank J C, 1989, Fam Med, V21, P273; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; *TOR WORK GROUP CH, 1989, DET MAN ASYMPT HYP P; *TOR WORK GROUP CH, 1990, J CLIN EPIDEMIOL, V43, P1029; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480	27	16	16	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	1998	316	7139					1208	1213		10.1136/bmj.316.7139.1208	http://dx.doi.org/10.1136/bmj.316.7139.1208			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552998	Bronze, Green Published			2022-12-28	WOS:000073224100024
J	Rogal, AP				Rogal, AP			Brignole	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Rogal, AP (corresponding author), 200 South St, Brookline, MA 02167 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					691	692		10.7326/0003-4819-128-8-199804150-00016	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537945				2022-12-28	WOS:000073052500012
J	Schacker, TW; Hughes, JP; Shea, T; Coombs, RW; Corey, L				Schacker, TW; Hughes, JP; Shea, T; Coombs, RW; Corey, L			Biological and virologic characteristics of primary HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; disease progression; RNA, viral; CD4 lymphocyte count; viral load	HUMAN-IMMUNODEFICIENCY-VIRUS; MULTICENTER AIDS COHORT; CLINICAL MANIFESTATIONS; IMMUNE-DEFICIENCY; TYPE-1 INFECTION; PLASMA; ZIDOVUDINE; RNA; QUANTITATION; PROGRESSION	Background: The clinical events surrounding acute HIV-1 infection have been well described, but little is known about whether the virologic course of acute HIV-1 infection influences the subsequent progression of disease. Objective: To define the virologic natural history of acute and very early HIV infection. Design: Prospective, longitudinal cohort study. Setting: University of Washington Research Clinic. Participants: 74 adults enrolled soon after acquisition of HIV (mean, 69 days). Measurements: Plasma HIV-1 RNA levels; quantitative cell cultures; CD4 cell counts; and detailed clinical assessments done at study entry, biweekly for 1 month, monthly for 2 months, and quarterly thereafter. Results: In the first 30 days after acquisition of HIV, HIV-1 RNA levels varied greatly among participants (range, 27 200 to 1.6 x 10(6) copies per mt of plasma). Levels of HIV-1 RNA decreased by a mean of 6.5% per week for the first 120 days and then increased by a mean of 0.15% per week. CD4 cell counts decreased by a mean of 5.2 cells/mm(3) per week for the first 160 days and by a mean of 1.9 cells/mm(3) per week thereafter (P < 0.01). Disease progressed faster in participants who sought medical care for their acute seroconversion syndrome (P = 0.01) and those who had high plasma HIV-1 RNA levels 120 to 365 days after acquisition (P < 0.01). Peak levels in the first 120 days were not predictive of disease progression. Conclusions: The variability in viral RNA levels associated with acute HIV-1 infection is greater than previously appreciated. Within 120 days of acquisition, plasma HIV RNA levels rapidly decrease to an inflection point, after which they gradually increase. Virus-host interactions soon after acquisition seem to have a major influence on the long-term outcome of HIV-1 disease.	Univ Washington, Dept Lab Med 357110, Seattle, WA 98195 USA; Univ Washington, Seattle, WA 98122 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St,M-115, Seattle, WA 98104 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-01228, AI-45206, AI-26657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTELSMAN JFWM, 1990, ENDOSCOPY, V22, P184, DOI 10.1055/s-2007-1012836; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cleveland W. S., 1992, STAT MODELS S PACIFI; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Diggle P, 1994, ANAL LONGITUDINAL DA, VXI, P253; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FOX R, 1987, AIDS, V1, P35; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HENRARD DR, 1995, J ACQ IMMUN DEF SYND, V9, P305; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LEAVITT R, 1996, 36 INT C ANT AG CHEM; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MILLER RG, 1981, SURVIVAL ANAL, P7; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Perrin L, 1996, AIDS, V10, P1233, DOI 10.1097/00002030-199609000-00009; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; Revets H, 1996, J CLIN MICROBIOL, V34, P1058, DOI 10.1128/JCM.34.5.1058-1064.1996; SAIMOT AG, 1996, INT C AIDS, V11, P112; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TAMELET C, 1996, INT C AIDS, V11, P113; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TURNBULL BW, 1976, J R STAT SOC B, V38, P290	40	225	230	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					613	+		10.7326/0003-4819-128-8-199804150-00001	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537934				2022-12-28	WOS:000073052500001
J	Birse, CE; Minvielle-Sebastia, L; Lee, BA; Keller, W; Proudfoot, NJ				Birse, CE; Minvielle-Sebastia, L; Lee, BA; Keller, W; Proudfoot, NJ			Coupling termination of transcription to messenger RNA maturation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; POLYADENYLATION SIGNAL; POLY(A) POLYMERASE; GLOBIN GENE; END; SITE; PURIFICATION; SEPARATION; COMPONENTS	The direct association between messenger RNA (mRNA) 3'-end processing and the termination of transcription was established for the CYC1 gene of Saccharomyces cerevisiae. The mutation of factors involved in the initial cleavage of the primary transcript at the poly(A) site (RNA 14, RNA 15, and PCF11) disrupted transcription termination at the 3' end of the CYC1 gene. In contrast, the mutation of factors involved in the subsequent polyadenylation step (PAP1, FIP1, and YTH1) had little effect. Thus, cleavage factors link transcription termination of RNA polymerase II with pre-mRNA 3'-end processing.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Oxford; University of Basel	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		Minvielle-Sebastia, Lionel/M-7154-2014	Proudfoot, Nicholas/0000-0001-8646-3222	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amrani N, 1997, MOL CELL BIOL, V17, P1102, DOI 10.1128/MCB.17.3.1102; AMRANI N, 1997, MOL CELL BIOL, V17, P3674; BARABINO ML, 1997, GENE DEV, V11, P1703; BARRY K, 1987, MOL CELL BIOL, V7, P632, DOI 10.1128/MCB.7.2.632; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; BIRSE CE, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; Fink G., 1991, METHOD ENZYMOL, V194, P14; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GODING CR, UNPUB; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; HEIDMANN S, 1992, MOL CELL BIOL, V12, P4215, DOI 10.1128/MCB.12.9.4215; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; LANOIX J, 1988, EMBO J, V7, P2515, DOI 10.1002/j.1460-2075.1988.tb03099.x; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; RUSSO P, 1995, YEAST, V11, P447, DOI 10.1002/yea.320110507; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; Zhao J, 1997, J BIOL CHEM, V272, P10831	36	207	208	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					298	301		10.1126/science.280.5361.298	http://dx.doi.org/10.1126/science.280.5361.298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535662				2022-12-28	WOS:000073082400055
J	Beecham, L				Beecham, L			Doctors should have more input into merit award system	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1098	1098						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552929				2022-12-28	WOS:000072987400073
J	Davis, DL; Gottlieb, MB; Stampnitzky, JR				Davis, DL; Gottlieb, MB; Stampnitzky, JR			Reduced ratio of male to female births in several industrial countries - A sentinel health indicator?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEX-RATIO; AIR-POLLUTION; ABNORMALITIES; CHILDREN; EXPOSURE	Context.-The sex ratio of 1.06:1, the ratio of male to female births, has declined over the past decades. Recent reports from a number of industrialized countries indicate that the proportion of males born has significantly decreased, while some male reproductive tract disorders have increased. Objectives.-To examine the evidence for declines in the male proportion at birth and suspected causes for this decline, and to determine whether altered sex ratio can be considered a sentinel health event. Data Sources.-Birth records were analyzed from national statistical agencies. Study Selection.-Published analyses of trends in ratio of males to females at birth and studies of sex determinants evaluating epidemiological and endocrinological factors. Data Extraction.-Proportion of males born, 1950-1994 in Denmark; 1950-1994 in the Netherlands; 1970-1990 in Canada; and 1970-1990 in the United States, Data Synthesis.-Since 1950, significant declines in the proportion of males born have been reported in Denmark and the Netherlands. Similar declines have been reported for Canada and the United States since 1970 and parallel declines also have occurred in Sweden, Germany, Norway, and Finland. In Denmark, the proportion of males declined from 0.515 in 1950 to 0.513 in 1994. In the Netherlands, the proportion of males declined from 0.516 in 1950 to 0.513 in 1994, Similar declines in the proportion of males born in Canada and the United States are equivalent to a shift from male to female births of 8600 and 38 000 births, respectively. Known and hypothesized risk factors for reduced sex ratio at birth cannot fully account for recent trends. Conclusion.-Patterns of reduced sex ratio need to be carefully assessed to determine whether they are occurring more generally, whether temporal or spatial variations are evident, and whether they constitute a sentinel health event.	World Resources Inst, Washington, DC 20006 USA; Yeshiva Univ, Stern Coll Women, New York, NY 10016 USA	Yeshiva University	Davis, DL (corresponding author), World Resources Inst, 1709 New York Ave NW, Washington, DC 20006 USA.	davra@wri.org						Allan BB, 1997, CAN MED ASSOC J, V156, P37; BERKOVITZ GD, 1992, SEMIN PERINATOL, V16, P289; BRUIN KMV, 1997, LANCET, V349, P62; DAVIS DL, 1992, REPROD TOXICOL, V6, P289, DOI 10.1016/0890-6238(92)90190-5; DECOCK J, 1995, OCCUP ENVIRON MED, V52, P429; Dodds L, 1997, CAN MED ASSOC J, V156, P46; FEITOSA MF, 1992, HUM BIOL, V64, P523; Foster P. M. D., 1997, CIIT ACTIVITIES, V17, P1; GarciaRodriguez J, 1996, ENVIRON HEALTH PERSP, V104, P1090, DOI 10.2307/3433122; Garry VF, 1996, ENVIRON HEALTH PERSP, V104, P394, DOI 10.2307/3432683; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; GOLDSMITH JR, 1984, ARCH ENVIRON HEALTH, V39, P85, DOI 10.1080/00039896.1984.10545840; Gustafson ML, 1995, REPROD MED SURG, P39; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; Hardell L, 1997, INT J CANCER, V73, P828; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; JAMES WH, 1986, J THEOR BIOL, V118, P427, DOI 10.1016/S0022-5193(86)80163-1; JAMES WH, 1995, ANN HUM GENET, V59, P243, DOI 10.1111/j.1469-1809.1995.tb00744.x; JAMES WH, 1987, HUM BIOL, V59, P721; Manning JT, 1997, NATURE, V389, P344, DOI 10.1038/38647; MILHAM S, 1993, AM J IND MED, V23, P829, DOI 10.1002/ajim.4700230516; Mocarelli P, 1996, LANCET, V348, P409, DOI 10.1016/S0140-6736(05)65030-1; Moller H, 1998, APMIS, V106, P232, DOI 10.1111/j.1699-0463.1998.tb01341.x; Moller H, 1996, LANCET, V348, P828, DOI 10.1016/S0140-6736(05)65253-1; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.2307/3433065; *NAT AC SCI, 1989, BIOL MARK REPR TOX; *NAT CTR HLTH STAT, 1996, VIT STAT US 1992 M 2, V2; *NAT CTR HLTH STAT, 1997, US 1996 1997 INJ CHA; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; PELLINIEMI LJ, 1994, MATERNAL FETAL ENDOC; POTASHNIK G, 1984, ANDROLOGIA, V16, P213; Pyeritz RE, 1998, JAMA-J AM MED ASSOC, V279, P269, DOI 10.1001/jama.279.4.269; RUDER A, 1985, AM J HUM GENET, V37, P362; Sas M, 1980, Orv Hetil, V121, P2807; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHY C, 1994, ENVIRON HEALTH PERSP, V102, P316, DOI 10.1289/ehp.94102316; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; TOPPARI J, 1995, INT WORKSH ENV PROT; WHORTON MD, 1994, OCCUP ENVIRON MED, V51, P761, DOI 10.1136/oem.51.11.761; WILLIAMS FLR, 1992, INT J EPIDEMIOL, V21, P311, DOI 10.1093/ije/21.2.311; WILLIAMS FLR, 1995, OCCUP ENVIRON MED, V52, P164, DOI 10.1136/oem.52.3.164; WYATT R, 1973, BRIT MED J, V1, P675, DOI 10.1136/bmj.1.5854.675-a; Zonta LA, 1996, HUM BIOL, V68, P415	45	233	246	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1018	1023		10.1001/jama.279.13.1018	http://dx.doi.org/10.1001/jama.279.13.1018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533502				2022-12-28	WOS:000072669700031
J	De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP				De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP			Altered nociception, analgesia and aggression in mice lacking the receptor for substance P	NATURE			English	Article							STRESS-INDUCED ANALGESIA; PRIMARY SENSORY NEURONS; DORSAL HORN; SPINAL-CORD; RAT; ANTAGONIST; ACTIVATION; INHIBITION; INDUCTION; LOCALIZATION	The peptide neurotransmitter substance P modulates sensitivity to pain by activating the neurokinin-1 (NK-1) receptor, which is expressed by discrete populations of neurons throughout the central nervous system(1-4). Substance P is synthesized by small-diameter sensory 'pain' fibres(5), and release of the peptide into the dorsal horn of the spinal cord following intense peripheral stimulation(6) promotes central hyperexcitability and increased sensitivity to pain(7-10). However, despite the availability of specific NK-1 antagonists(4), the function of substance P in the perception of pain remains unclear Here we investigate the effect of disrupting the gene encoding the NK-1 receptor in mice, We found that the mutant mice were healthy and fertile, but the characteristic amplification ('wind up') and intensity coding of nociceptive reflexes was absent, Although substance P did not mediate the signalling of acute pain or hyperalgesia, it was essential for the full development of stress-induced analgesia and for an aggressive response to territorial challenge, demonstrating that the peptide plays an unexpected role in the adaptive response to stress.	MRC, Mol Neurobiol Lab, Div Neurobiol, Cambridge CB2 2QH, England; Univ Miguel Hernandez, Inst Neurociencias, Alicante 03080, Spain; Univ Alcala de Henares, Fac Med, Dept Fisiol, Madrid 28871, Spain; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad de Alcala; University of Edinburgh	Hunt, SP (corresponding author), MRC, Mol Neurobiol Lab, Div Neurobiol, Hills Rd, Cambridge CB2 2QH, England.	hunt@mrc-lmb.cam.ac.uk	de Felipe, Carmen/D-3813-2012; HUNT, STEPHEN P/C-1646-2008	Laird, Jennifer/0000-0001-6570-3995; Herrero, Juan F./0000-0003-1986-3482				Abbadie C, 1997, PAIN, V69, P101, DOI 10.1016/S0304-3959(96)03285-X; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; CERVERO F, 1985, J PHYSIOL-LONDON, V365, P223, DOI 10.1113/jphysiol.1985.sp015768; Chapman V, 1996, J NEUROPHYSIOL, V76, P1817, DOI 10.1152/jn.1996.76.3.1817; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; DUGGAN AW, 1988, BRAIN RES, V451, P261, DOI 10.1016/0006-8993(88)90771-8; HERRERO JF, 1993, BRIT J PHARMACOL, V110, P303, DOI 10.1111/j.1476-5381.1993.tb13809.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; LAIRD JMA, 1993, BRIT J PHARMACOL, V109, P713, DOI 10.1111/j.1476-5381.1993.tb13632.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MAENO H, 1993, MOL BRAIN RES, V18, P43, DOI 10.1016/0169-328X(93)90172-L; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; MANTYH PW, 1989, J NEUROSCI, V9, P258; MAREK P, 1992, BRAIN RES, V578, P197, DOI 10.1016/0006-8993(92)90248-8; MCCARTHY PW, 1989, NEUROSCIENCE, V28, P745, DOI 10.1016/0306-4522(89)90019-5; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; NOGUCHI K, 1992, J NEUROSCI, V12, P2563; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; SIEGEL A, 1995, AGGRESSIVE BEHAV, V21, P49, DOI 10.1002/1098-2337(1995)21:1<49::AID-AB2480210108>3.0.CO;2-2; VANDERAH TW, 1992, J PHARMACOL EXP THER, V262, P190; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7; YAKSH TL, 1994, TXB PAIN, P165; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	29	612	619	1	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					394	397		10.1038/32904	http://dx.doi.org/10.1038/32904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537323				2022-12-28	WOS:000072713600053
J	Wickware, P				Wickware, P			Action at the edges in cancer research	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					417	417		10.1038/32945	http://dx.doi.org/10.1038/32945			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537329				2022-12-28	WOS:000072713600059
J	Gramm, P; Rettenmaier, AJ; Saving, TR				Gramm, P; Rettenmaier, AJ; Saving, TR			Medicare policy for future generations - A search for a permanent solution	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US Senate, Washington, DC 20510 USA; Texas A&M Univ, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Gramm, P (corresponding author), US Senate, Washington, DC 20510 USA.							*BOARD TRUST FED H, 1997, 1997 ANN REP BOARD T; *C BUDG OFF, 1997, IMP COST SHAR PREM E; FELDSTEIN M, 1996, ECON REV, V82, P1; *KPMG PEAT MARW, 1997, HLTH BEN 1997	4	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1307	1310		10.1056/NEJM199804303381812	http://dx.doi.org/10.1056/NEJM199804303381812			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562588				2022-12-28	WOS:000073335800012
J	Sykes, JS; McCarter, TG				Sykes, JS; McCarter, TG			Renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Geisinger Med Ctr, Danville, PA 17822 USA	Geisinger Medical Center	Sykes, JS (corresponding author), Geisinger Med Ctr, Danville, PA 17822 USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1280	1280		10.1056/NEJM199804303381807	http://dx.doi.org/10.1056/NEJM199804303381807			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562583				2022-12-28	WOS:000073335800007
J	Barrat, JA; Gillet, P; Lecuyer, C; Sheppard, SMF; Lesourd, M				Barrat, JA; Gillet, P; Lecuyer, C; Sheppard, SMF; Lesourd, M			Formation of carbonates in the Tatahouine meteorite	SCIENCE			English	Article							ALH84001	The Tatahouine meteorite, in southern Tunisia, shows terrestrial contamination that developed during 63 years of exposure on Earth's surface. Samples collected on the day of the fall in 1931 contained fractures, with no secondary minerals, whereas samples collected in 1994 contain calcite aggregates (70 to 150 micrometers) and rod-shaped forms (100 to 600 nanometers in length and 70 to 80 nanometers in diameter) on the fractures. Carbon isotope analysis of the carbonates within the Tatahouine meteorite [delta(13)C = -2.0 per mil Pee Dee belemnite standard (PDB)] and the underlying ground (delta(13)C = -3.2 per mil PDB) confirm their terrestrial origin.	Univ Angers, Geol Lab, F-49045 Angers, France; Ecole Normale Super Lyon, Lab Ctr Terre, CNRS, UMR 5570, F-69364 Lyon 07, France; Ecole Normale Super Lyon, Inst Univ France, F-69364 Lyon 07, France; Fac Med, CNRS, F-49045 Angers, France; Fac Med, Serv Commun Microscopie Elect, F-49045 Angers, France	Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON); Institut Universitaire de France; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Universite d'Angers	Barrat, JA (corresponding author), Univ Angers, Geol Lab, 2 Blvd Lavoisier, F-49045 Angers, France.		Jean-Alix, BARRAT/F-8035-2012; Lecuyer, Christophe/C-8297-2012; Barrat, Jean-Alix/C-8416-2017; Lecuyer, Christophe/AAO-8154-2021	Barrat, Jean-Alix/0000-0003-3158-3109; Lecuyer, Christophe/0000-0001-9513-2492				BISCHOFF WD, 1985, AM MINERAL, V70, P581; Bradley JP, 1997, NATURE, V390, P454, DOI 10.1038/37257; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; Folk RL, 1997, J SEDIMENT RES, V67, P583; GILLET P, 1993, PHYS CHEM MINER, V20, P1; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kerr RA, 1997, SCIENCE, V278, P1706, DOI 10.1126/science.278.5344.1706; Lacroix A, 1931, CR HEBD ACAD SCI, V193, P305; Mason B., 1992, SMITHSON CONTRIB EAR, V30, P17; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; McKay DS, 1997, NATURE, V390, P455, DOI 10.1038/37257-c1; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; Nealson KH, 1997, ANNU REV EARTH PL SC, V25, P403, DOI 10.1146/annurev.earth.25.1.403; URMOS J, 1991, AM MINERAL, V76, P641; Zolensky M., 1988, METEORITES EARLY SOL, P114	16	45	47	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					412	414		10.1126/science.280.5362.412	http://dx.doi.org/10.1126/science.280.5362.412			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545214				2022-12-28	WOS:000073159600040
J	Jones, TH; Thompson, LJ; Lawton, JH; Bezemer, TM; Bardgett, RD; Blackburn, TM; Bruce, KD; Cannon, PF; Hall, GS; Hartley, SE; Howson, G; Jones, CG; Kampichler, C; Kandeler, E; Ritchie, DA				Jones, TH; Thompson, LJ; Lawton, JH; Bezemer, TM; Bardgett, RD; Blackburn, TM; Bruce, KD; Cannon, PF; Hall, GS; Hartley, SE; Howson, G; Jones, CG; Kampichler, C; Kandeler, E; Ritchie, DA			Impacts of rising atmospheric carbon dioxide on model terrestrial ecosystems	SCIENCE			English	Article							ELEVATED CO2; PLANT-RESPONSES; SOIL; COLLEMBOLA; FUNGI; DECOMPOSITION; COLONIZATION; RHIZOSPHERE; COMMUNITIES; PREFERENCES	In model terrestrial ecosystems maintained for three plant generations at elevated concentrations of atmospheric carbon dioxide, increases in photosynthetically fixed carbon were allocated below ground, raising concentrations of dissolved organic carbon in soil. These effects were then transmitted up the decomposer food chain. Soil microbial biomass was unaffected, but the composition of soil fungal species changed, with increases in rates of cellulose decomposition. There were also changes in the abundance and species composition of Collembola, fungal-feeding arthropods. These results have implications for long-term feedback processes in soil ecosystems that are subject to rising global atmospheric carbon dioxide concentrations.	Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Liverpool, Sch Biol Sci, Donnan Lab, Liverpool L69 7ZD, Merseyside, England; CABI Biosci, Surrey TW20 9TY, England; Inst Terr Ecol, Banchory Res Stn, Banchory AB31 4BY, Kincardine, Scotland; Inst Terr Ecol, Merlewood Res Stn, Grange Over Sands LA11 6JU, Cumbria, England; Inst Ecosyst Studies, Millbrook, NY 12545 USA; Univ Vienna, Inst Zool, A-1090 Vienna, Austria; Fed Agcy & Res Ctr Agr, Inst Soil Management, A-1226 Vienna, Austria	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Manchester; University of Liverpool; UK Centre for Ecology & Hydrology (UKCEH); UK Centre for Ecology & Hydrology (UKCEH); Cary Institute of Ecosystem Studies; University of Vienna	Jones, TH (corresponding author), Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.	t.h.jones@ic.ac.uk	Jones, Hefin/A-4331-2010; Blackburn, Tim M/A-7685-2011; Bezemer, Martijn/A-4068-2009; Jones, Clive G/I-4603-2014; Blackburn, Tim/AAC-3144-2019; Turan, Veysel/G-7722-2011; Kampichler, Christian/A-9603-2011	Bezemer, Martijn/0000-0002-2878-3479; Jones, Clive G/0000-0001-7630-7285; Blackburn, Tim/0000-0003-0152-2663; Kandeler, Ellen/0000-0002-2854-0012; Jones, T Hefin/0000-0002-7874-3627; Hartley, Sue/0000-0002-5117-687X				AGREN GI, 1991, ECOL APPL, V1, P118, DOI 10.2307/1941806; AGREN GI, 1987, ECOLOGY, V68, P1181, DOI 10.2307/1939202; AGREN GJ, 1996, EFFECTS CLIMATE CHAN, P207; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Ball AS, 1997, GLOB CHANGE BIOL, V3, P379, DOI 10.1046/j.1365-2486.1997.t01-1-00089.x; Barbosa P, 1991, MICROBIAL MEDIATION; BARDGETT RD, 1993, BIOL FERT SOILS, V16, P296, DOI 10.1007/BF00369308; BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123; Berntson GM, 1996, PLANT SOIL, V187, P119, DOI 10.1007/BF00017085; BEZEMER TM, UNPUB; BOWES G, 1993, ANNU REV PLANT PHYS, V44, P309, DOI 10.1146/annurev.pp.44.060193.001521; BRUCE KD, 1995, MOL ECOL, V4, P605, DOI 10.1111/j.1365-294X.1995.tb00260.x; Coleman D. C., 1986, Microfloral and faunal interactions in natural and agro-ecosystems, P317; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Godbold DL, 1997, TREE PHYSIOL, V17, P347; Griffiths B. S., 1997, Modern soil microbiology., P165; HANLON RDG, 1981, OIKOS, V36, P362, DOI 10.2307/3544634; HILL MO, 1985, CAN J SOIL SCI, V65, P609, DOI 10.4141/cjss85-067; Hopkins S., 1997, BIOL SPRINGTAILS INS; Hungate BA, 1997, NATURE, V388, P576, DOI 10.1038/41550; INEICHEN K, 1995, PLANT CELL ENVIRON, V18, P703, DOI 10.1111/j.1365-3040.1995.tb00572.x; INGHAM ER, 1991, MICROBIAL MEDIATION, pCH6; Kampichler C, 1998, GLOBAL CHANGE BIOL, V4, P335, DOI 10.1046/j.1365-2486.1998.00157.x; Klironomos JN, 1997, GLOBAL CHANGE BIOL, V3, P473, DOI 10.1046/j.1365-2486.1997.00085.x; Klironomos JN, 1996, FUNCT ECOL, V10, P527, DOI 10.2307/2389946; KLIRONOMOS JN, 1995, PLANT SOIL, V170, P183, DOI 10.1007/BF02183066; Koch G, 1996, CARBON DIOXIDE TERRE; KORNER C, 1995, PLANT CELL ENVIRON, V18, P1101, DOI 10.1111/j.1365-3040.1995.tb00622.x; KORNER C, 1992, SCIENCE, V257, P1672, DOI 10.1126/science.257.5077.1672; KORNER C, 1996, CARBON DIOXIDE POPUL; LAWTON JH, 1993, PHILOS T R SOC B, V341, P181, DOI 10.1098/rstb.1993.0102; Lawton JH, 1996, ECOLOGY, V77, P665, DOI 10.2307/2265488; Lee Q, 1996, SOIL BIOL BIOCHEM, V28, P689, DOI 10.1016/0038-0717(95)00158-1; LUSSENHOP J, 1992, ADV ECOL RES, V23, P1, DOI 10.1016/S0065-2504(08)60145-2; MOONEY HA, 1991, BIOSCIENCE, V41, P96, DOI 10.2307/1311562; MOORE JC, 1991, MICROBIAL MEDIATION, pCH4; MOORE JC, 1977, MULTITROPHIC INTERAC, P375; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; OECHEL WC, 1994, NATURE, V371, P500, DOI 10.1038/371500a0; ONEILL EG, 1987, CAN J FOREST RES, V17, P878, DOI 10.1139/x87-139; ONEILL EG, 1994, PLANT SOIL, V165, P55, DOI 10.1007/BF00009962; PARKINSON D, 1979, SOIL BIOL BIOCHEM, V11, P529, DOI 10.1016/0038-0717(79)90013-0; Paterson E, 1997, GLOBAL CHANGE BIOL, V3, P363, DOI 10.1046/j.1365-2486.1997.t01-1-00088.x; RABATIN SC, 1991, MICROBIAL MEDIATION, pCH5; RICE CW, 1994, PLANT SOIL, V165, P67, DOI 10.1007/BF00009963; ROGERS HH, 1994, ENVIRON POLLUT, V83, P155, DOI 10.1016/0269-7491(94)90034-5; ROGERS HH, 1992, CRIT REV PLANT SCI, V11, P251, DOI 10.1080/07352689209382346; Sadowsky MJ, 1997, GLOB CHANGE BIOL, V3, P217, DOI 10.1046/j.1365-2486.1997.00078.x; Schinner F., 1996, METHODS SOIL BIOL; Schlesinger WH., 1998, BIOGEOCHEMISTRY ANAL, V73, P353, DOI 10.1016/0016-7037(92)90106-s; THOMPSON LK, UNPUB; TORBERT HA, 1995, SOIL SCI SOC AM J, V59, P1321, DOI 10.2136/sssaj1995.03615995005900050018x; Visser S., 1985, Ecological interactions in soil: plants, microbes and animals, P297; VISSER S, 1977, OIKOS, V29, P320, DOI 10.2307/3543621; VITOUSEK PM, 1994, ECOLOGY, V75, P1861, DOI 10.2307/1941591; WEINER J, 1996, CARBON DIOXIDE POPUL, P431; WOODWARD FI, 1991, ANN BOT-LONDON, V67, P23, DOI 10.1093/oxfordjournals.aob.a088206	58	192	223	7	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					441	443		10.1126/science.280.5362.441	http://dx.doi.org/10.1126/science.280.5362.441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545223	Green Submitted			2022-12-28	WOS:000073159600049
J	Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Pekurinen, M; Peramaki, E; Saarelainen, S; Svahn, T; Liljas, B				Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Pekurinen, M; Peramaki, E; Saarelainen, S; Svahn, T; Liljas, B			Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland	BRITISH MEDICAL JOURNAL			English	Article									Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland; Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Helsinki 00250, Finland; Cent Hosp No Karelia, Dept Pulm Dis, Kontioniemi 80780, Finland; Hlth Serv Res, Helsinki 00150, Finland; Suomen Astra Oy, Masala 02430, Finland; Astro Draco AB, S-22100 Lund, Sweden	Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital	Lahdensuo, A (corresponding author), Tampere Univ Hosp, Dept Pulm Dis, Pikonlinna 36280, Finland.		Herrala, Jaakko/L-9797-2013	Herrala, Jaakko/0000-0002-6524-1759				*BRIT THOR SOC, 1993, THORAX, V48, pS1; Lahdensuo A, 1996, BRIT MED J, V312, P748; *NAT HEART LUNG BL, 1992, NAT I HLTH PUBL; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	4	61	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1138	1139		10.1136/bmj.316.7138.1138	http://dx.doi.org/10.1136/bmj.316.7138.1138			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552954	Green Published			2022-12-28	WOS:000073067500033
J	Melek, M; Gellert, M; van Gent, DC				Melek, M; Gellert, M; van Gent, DC			Rejoining of DNA by the RAG1 and RAG2 proteins	SCIENCE			English	Article							V(D)J RECOMBINATION; INTEGRATION; GENE	Assembly of immunoglobulin and T cell receptor genes from separate gene segments [V(D)J recombination] begins with DNA double-strand breakage by the RAG1 and RAG2 proteins, acting at a pair of recombination signal sequences (RSSs). Here, the RAG proteins are shown to reverse the cleavage reaction by joining an RSS to a broken coding sequence end. These "hybrid joints" have also been found in lymphoid cells, even when the normal pathway of DNA double-strand break repair is inactive, and can now be explained by this activity of the RAG proteins.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Erasmus University Rotterdam	Gellert, M (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			van Gent, Dik C./0000-0003-1473-8148				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Steen SB, 1997, EMBO J, V16, P2656, DOI 10.1093/emboj/16.10.2656; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VANGENT DC, 1997, EMBO J, V16, P2265; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7	19	88	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					301	303		10.1126/science.280.5361.301	http://dx.doi.org/10.1126/science.280.5361.301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535663				2022-12-28	WOS:000073082400056
J	Shen, ZX; White, PJ; Feng, DL; Kim, C; Gu, GD; Ikeda, H; Yoshizaki, R; Koshizuka, N				Shen, ZX; White, PJ; Feng, DL; Kim, C; Gu, GD; Ikeda, H; Yoshizaki, R; Koshizuka, N			Temperature-induced momentum-dependent spectral weight transfer in Bi2Sr2CaCu2O8+delta	SCIENCE			English	Article							ANGLE-RESOLVED PHOTOEMISSION; T-C SUPERCONDUCTORS; SINGLE-CRYSTALS; HUBBARD-MODEL; NORMAL-STATE; GAP; LA1.85SR0.15CUO4; SR2CUO2CL2; EVOLUTION; BEHAVIOR	Angle-resolved photoemission data from the cuprate superconductor Bi2Sr2CaCu2O8+delta above and below the superconducting transition temperature T-c reveal momentum-dependent changes that extend up to an energy of about 0.3 electron volt, or 40kT(c) (where k is the Boltzmann constant). The data suggest an anomalous transfer of spectral weight from one momentum to another, involving a sizable momentum transfer Q similar to (0.45 pi, 0). The observed Q is intriguingly near the charge-order periodicity required if fluctuating charge stripes are present.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; Univ New S Wales, Sch Phys, Kensington, NSW 2033, Australia; Univ Tsukuba, Inst Appl Phys, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Cryogen Ctr, Tsukuba, Ibaraki 305, Japan; ISTEC, Superconduct Res Lab, Koto Ku, Tokyo 135, Japan	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of New South Wales Sydney; University of Tsukuba; University of Tsukuba; International Superconductivity Technology Center (ISTEC)	Shen, ZX (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.		Feng, Donglai/R-1615-2018	Feng, Donglai/0000-0001-9370-5357				ANDERSON PW, 1991, PHYS REV LETT, V67, P2569; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; BARDEEN J, 1957, PHYS REV, V106, P162, DOI 10.1103/PhysRev.106.162; Bianconi A, 1996, PHYS REV LETT, V76, P3412, DOI 10.1103/PhysRevLett.76.3412; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; DESSAU DS, 1991, PHYS REV LETT, V66, P2160, DOI 10.1103/PhysRevLett.66.2160; DESSAU DS, 1993, PHYS REV LETT, V71, P2781, DOI 10.1103/PhysRevLett.71.2781; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; Emery VJ, 1997, PHYS REV B, V56, P6120, DOI 10.1103/PhysRevB.56.6120; Emery VJ, 1997, PHYSICA C, V282, P174, DOI 10.1016/S0921-4534(97)00255-4; GROEN WA, 1990, PHYSICA C, V165, P55, DOI 10.1016/0921-4534(90)90431-D; GU GD, 1993, J CRYST GROWTH, V130, P325, DOI 10.1016/0022-0248(93)90872-T; GU GD, 1994, J CRYST GROWTH, V137, P472, DOI 10.1016/0022-0248(94)90986-5; Harris JM, 1996, PHYS REV B, V54, P15665, DOI 10.1103/PhysRevB.54.R15665; HWU Y, 1991, PHYS REV LETT, V67, P2573, DOI 10.1103/PhysRevLett.67.2573; IBACH H, 1995, SOLID STATE PHYSICS; JEON DS, 1995, PHYSICA C, V253, P102, DOI 10.1016/0921-4534(95)00459-9; KIVELSON SA, 1994, PHYSICA C, V235, P189; Laughlin RB, 1995, J PHYS CHEM SOLIDS, V56, P1627, DOI 10.1016/0022-3697(95)00210-3; Laughlin RB, 1997, PHYS REV LETT, V79, P1726, DOI 10.1103/PhysRevLett.79.1726; Levi BG, 1996, PHYS TODAY, V49, P17, DOI 10.1063/1.881544; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; Marshall DS, 1996, PHYS REV LETT, V76, P4841, DOI 10.1103/PhysRevLett.76.4841; MASON TE, 1992, PHYS REV LETT, V68, P1414, DOI 10.1103/PhysRevLett.68.1414; MITZI DB, 1990, PHYS REV B, V41, P6564, DOI 10.1103/PhysRevB.41.6564; Moreo A, 1995, J PHYS CHEM SOLIDS, V56, P1645, DOI 10.1016/0022-3697(95)00106-9; Norman MR, 1997, PHYS REV LETT, V79, P3506, DOI 10.1103/PhysRevLett.79.3506; OTTA Y, 1995, J PHYS CHEM-US, V56, P1741; POILBLANC D, 1989, PHYS REV B, V39, P9749, DOI 10.1103/PhysRevB.39.9749; Preuss R, 1995, J PHYS CHEM SOLIDS, V56, P1659, DOI 10.1016/0022-3697(95)00101-8; RANDERIA M, 1995, PHYS REV LETT, V74, P4951, DOI 10.1103/PhysRevLett.74.4951; SAWATZKY GA, 1989, NATURE, V342, P480, DOI 10.1038/342480a0; Schrieffer J. R., 1988, THEORY SUPERCONDUCTI; SCHULZ HJ, 1989, J PHYS-PARIS, V50, P2833, DOI 10.1051/jphys:0198900500180283300; Shen ZX, 1997, PHYS REV LETT, V78, P1771, DOI 10.1103/PhysRevLett.78.1771; THURSTON TR, 1992, PHYS REV B, V46, P9128, DOI 10.1103/PhysRevB.46.9128; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; UEMURA YJ, 1995, P CCAST S HIGH TC SU, P113; WELLS BO, 1995, PHYS REV LETT, V74, P964, DOI 10.1103/PhysRevLett.74.964; WEN XG, 1997, CONDMAT9709108; White PJ, 1996, PHYS REV B, V54, P15669, DOI 10.1103/PhysRevB.54.R15669; Yamada K., UNPUB; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; ZIMMERMANN MV, IN PRESS EUROPHYS LE	44	67	67	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					259	262		10.1126/science.280.5361.259	http://dx.doi.org/10.1126/science.280.5361.259			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535649				2022-12-28	WOS:000073082400042
J	Chess, A				Chess, A			Immunology - Expansion of the allelic exclusion principle?	SCIENCE			English	Article							GENE; CELLS		MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Chess, A (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Held W, 1997, EUR J IMMUNOL, V27, P2876, DOI 10.1002/eji.1830271120; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042	10	48	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2067	2068		10.1126/science.279.5359.2067	http://dx.doi.org/10.1126/science.279.5359.2067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9537917				2022-12-28	WOS:000072775600034
J	Bolam, A; Manandhar, DS; Shrestha, P; Ellis, M; Costello, AMD				Bolam, A; Manandhar, DS; Shrestha, P; Ellis, M; Costello, AMD			The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: A randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES; SELF-EFFICACY; INTERVENTIONS	Objectives: To evaluate impact of postnatal health education for mothers on infant care and postnatal family planning practices in Nepal. Design: Randomised controlled trial with community follow up at 3 and 6 months post partum by interview Initial household survey of study areas to identify all pregnant women to facilitate follow up. Setting: Main maternity hospital in Kathmandu, Nepal. Follow up in urban Kathmandu and a periurban area southwest of the city. Subjects: 540 mothers randomly allocated to one of four groups: health education immediately after birth and three months later (group A), at birth only (group B), at three months only (group C), or none (group D). Interventions: Structured baseline household questionnaire; 20 minute, one to one health education at birth and three months later. Main outcome measures: Duration of exclusive breast feeding, appropriate immunisation of infant, knowledge of oral rehydration solution and need to continue breast feeding in diarrhoea, knowledge of infant signs suggesting pneumonia, uptake of postnatal family planning. Results: Mothers in groups A and B (received health education at birth) were slightly more likely to use contraception at six months after birth compared with mothers in groups C and D (no health education at birth) (odds ratio 1.62, 95% confidence interval 1.06 to 2.5). There were no other significant differences between groups with regards to infant feeding, infant care, or immunisation. Conclusions: Our findings suggest that the recommended practice of individual health education for postnatal mothers in poor communities has no impact on infant feeding, care, or immunisation, although uptake of family planning may be slightly enhanced.	Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England; Matern Hosp, Mother & Infant Res Act, Kathmandu, Nepal	University of London; University College London	Costello, AMD (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, 30 Guilford St, London WC1N 1EH, England.							Ad Hoc Group of the American Public Health Association, 1987, AM J PUBLIC HEALTH, V77, P89; ASHWORTH A, 1982, ARCH DIS CHILD, V57, P882, DOI 10.1136/adc.57.11.882; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BHARGAVA SK, 1990, NATL COLLABORATION S; BOLAM A, 1997, J NEPAL MED ASS, V35, P122; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS8; Hubley J. H., 1986, Health Education Research, V1, P233, DOI 10.1093/her/1.4.233; Kafatos A G, 1991, Hygie, V10, P32; KUNDI MZM, 1993, SOC SCI MED, V37, P649, DOI 10.1016/0277-9536(93)90104-C; LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V19, P788, DOI 10.1093/ije/19.4.788; MAIBACH E, 1995, HEALTH EDUC RES, V10, P37, DOI 10.1093/her/10.1.37; *NAT PLANN COMM, 1995, NEP MULT IND SURV PR; NEUPANE S, 1992, STUDY BREAST FEEDING; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; PARKIN JM, 1976, ARCH DIS CHILD, V51, P259, DOI 10.1136/adc.51.4.259; PRASAD B, 1995, BRIT MED J, V310, P621, DOI 10.1136/bmj.310.6980.621; TUPASI TE, 1989, ANN TROP PAEDIATR, V9, P82, DOI 10.1080/02724936.1989.11748603; *UN CHILDR FUND, 1993, STAT WORLDS CHILDR 1; UNITED NATIONS DEVELOPMENT PROGRAM, 1996, HUM DEV REP; *WHO, 1978, ABN AT DECL; World Bank, 1993, INV HLTH WORLD DEV R; World Bank, 1990, WORLD DEV REP 1990	22	103	105	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					805	811		10.1136/bmj.316.7134.805	http://dx.doi.org/10.1136/bmj.316.7134.805			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC488	9549449	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072584300024
J	Holtzman, NA; Shapiro, D				Holtzman, NA; Shapiro, D			The new genetics - Genetic testing and public policy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-INSURANCE; DISCRIMINATION; DISEASE; CANCER		Johns Hopkins Med Inst, Baltimore, MD 21205 USA; Woodstock Lodge, London W4 1DS, England	Johns Hopkins University; Johns Hopkins Medicine	Holtzman, NA (corresponding author), Johns Hopkins Med Inst, 550 N Broadway,Suite 511, Baltimore, MD 21205 USA.	holtzman@welchlink.welch.jhu.edu						Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Bernstein T, 1994, RADON RENTAL HOUSING; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Cao A, 1997, JAMA-J AM MED ASSOC, V278, P1273, DOI 10.1001/jama.278.15.1273; CHO MK, 1997, TASK FORCE GENETIC T, P125; CUTTING G, 1996, PRINCIPLES PRACTICE; *DEP HLTH, 1993, SICKL CELL THAL OTH; Dickson D, 1996, NATURE, V379, P195, DOI 10.1038/379195a0; Geller Lisa N, 1996, Sci Eng Ethics, V2, P71, DOI 10.1007/BF02639319; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Holtzman N. A., 1996, American Journal of Human Genetics, V59, pA56; Holtzman NA, 1996, ENVIRON HEALTH PERSP, V104, P987, DOI 10.2307/3433022; Holtzman NA, 1997, SCIENCE, V278, P602, DOI 10.1126/science.278.5338.602; HOLTZMAN NA, 1997, ADV ONCOL, V13, P9; HOLTZMAN NA, 1997, PROMOTING SAFE EFFEC, P99; HOLTZMAN NA, 1996, ACCOUNTABILITY RES, V5, P95; *HOUS COMM SEL COM, 1995, 3 HOUS COMM SEL COMM; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; *HUM GEN ADV COMM, 1997, IMPL GEN TEST INS; Juengst ET, 1996, SOC PHILOS POLICY, V13, P63, DOI 10.1017/S0265052500003460; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; Lerman C, 1997, JNCI-J NATL CANCER I, V89, P148, DOI 10.1093/jnci/89.2.148; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Marteau TM, 1998, BMJ-BRIT MED J, V316, P693, DOI 10.1136/bmj.316.7132.693; MorrisonBogorad M, 1997, JAMA-J AM MED ASSOC, V277, P837, DOI 10.1001/jama.277.10.837; MOUNTFORD R, 1996, MOL GENETICS QUALITY; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; PEAR R, 1997, NY TIMES        0216, pA1; PRESS NA, 1994, WOMEN PRENATAL TESTI, P201; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; *TASK FORC GEN INF, 1993, NIH PUBL; *TASK FORC GEN TES, IN PRESS PROM SAF EF; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; TREACY E, 1995, AM J HUM GENET, V56, P359; 1996, CM3061; 1997, FINANCIAL TIMES 0319, P22	41	59	59	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					852	856		10.1136/bmj.316.7134.852	http://dx.doi.org/10.1136/bmj.316.7134.852			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549463	Green Published			2022-12-28	WOS:000072584300045
J	Mehta, RH; Eagle, KA				Mehta, RH; Eagle, KA			Fortnightly review - Secondary prevention in acute myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MORTALITY; MORBIDITY; ENALAPRIL; BLOCKADE; SURVIVAL; THERAPY; TRIAL		Univ Michigan Hosp, Div Cardiol, Taubman Ctr 3910, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Eagle, KA (corresponding author), Univ Michigan Hosp, Div Cardiol, Taubman Ctr 3910, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; [Anonymous], 1986, Lancet, V2, P57; BALL SG, 1993, LANCET, V342, P821; BEHAR S, 1988, EUR HEART J, V9, P354; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HANSEN JF, 1984, EUR HEART J, V5, P516; HJALMARSON A, 1981, LANCET, V2, P823; HJALMARSON A, 1985, EUR HEART J, V6, P199; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; OCKENE JK, 1992, PREVENTION CORONARY, P201; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SPRINT STUD GROUP, 1989, HAREFUAH, V116, P1; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; WILCOX RG, 1986, BRIT HEART J, V55, P506; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	29	42	46	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					838	842		10.1136/bmj.316.7134.838	http://dx.doi.org/10.1136/bmj.316.7134.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549457	Green Published			2022-12-28	WOS:000072584300036
J	Turner, RC; Millns, H; Neil, HAW; Stratton, IM; Manley, SE; Matthews, DR; Holman, RR				Turner, RC; Millns, H; Neil, HAW; Stratton, IM; Manley, SE; Matthews, DR; Holman, RR		United Kingdom Prospective Diabet Study Grp	Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study (UKPDS : 23)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; SERUM-CHOLESTEROL CONCENTRATION; LOW-DENSITY-LIPOPROTEIN; 11-YEAR FOLLOW-UP; CARDIOVASCULAR MORTALITY; GLUCOSE-INTOLERANCE; BODY-WEIGHT; WOMEN; HYPERTRIGLYCERIDEMIA; HYPERGLYCEMIA	Objective: To evaluate baseline risk factors for coronary artery disease in patients with type 2 diabetes mellitus. Design: A stepwise selection procedure, adjusting for age and sex, was used in 2693 subjects with complete data to determine which risk factors for coronary artery disease should be included in a Cox proportional hazards model. Subjects: 3055 white patients (mean age 52) with recently diagnosed type 2 diabetes mellitus and without evidence of disease related to atheroma. Median duration of follow up was 7.9 years. 335 patients developed coronary artery disease within 10 years. Outcome measures: Angina with confirmatory abnormal electrocardiogram; non-fatal and fatal myocardial infarction. Results: Coronary artery disease was significantly associated with increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, and increased triglyceride concentration, haemoglobin A(1c), systolic blood pressure, fasting plasma glucose concentration, and a history of smoking. The estimated hazard ratios for the upper third relative to the lower third were 2.26 (95% confidence interval 1.70 to 3.00) for low density lipoprotein cholesterol, 0.55 (0.41 to 0.73) for high density lipoprotein cholesterol, 1.52 (1.15 to 2.01) for haemoglobin A(1c), and 1.82 (1.34 to 2.47) for systolic blood pressure. The estimated hazard ratio for smokers was 1.41(1.06 to 1.88). Conclusion: A quintet of potentially modifiable risk factors for coronary artery disease exists in patients with type 2 diabetes mellitus. These risk factors are increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, raised brood pressure, hyperglycaemia, and smoking.	Univ Oxford, Radcliffe Infirm, Diabet Res Labs, Dept Med, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Turner, RC (corresponding author), Univ Oxford, Radcliffe Infirm, Diabet Res Labs, Dept Med, Oxford OX2 6HE, England.	robert.turner@drl.ox.ac.uk	Adiels, Martin/C-9278-2011; stratton, irene/AAZ-3627-2020	stratton, irene/0000-0003-1172-7865; Manley, Susan/0000-0002-8298-4511				AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; BYERS T, 1995, NEW ENGL J MED, V333, P723, DOI 10.1056/NEJM199509143331109; COLEMAN MP, 1989, PERSON YEARS PYRS FO; COX DR, 1972, J R STAT SOC B, V34, P187; CULL C, 1993, DIABETOLOGIA, V36, P1021; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Folsom AR, 1997, DIABETES CARE, V20, P935, DOI 10.2337/diacare.20.6.935; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEYDEN S, 1980, J CHRON DIS, V33, P265, DOI 10.1016/0021-9681(80)90021-1; JARRETT RJ, 1976, LANCET, V2, P1009; KANNEL WB, 1995, MED CLIN N AM, V79, P951, DOI 10.1016/S0025-7125(16)30016-5; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANLEY SE, 1994, DIABETIC MED, V11, P534; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MODAN M, 1986, DIABETOLOGIA, V29, P82, DOI 10.1007/BF00456115; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PEDERSEN TR, 1994, LANCET, V344, P1383; *POP CENS SURV OFF, 1994, MORT STTAT REV REG G; PYORALA K, 1995, DIABETES, V44, pA35; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCHECTMAN G, 1993, CLIN CHEM, V39, P1495; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STENSVOLD I, 1993, BMJ-BRIT MED J, V307, P1318, DOI 10.1136/bmj.307.6915.1318; Stratton I, 1996, DIABETOLOGIA, V39, P1554, DOI 10.1007/s001250050614; STRATTON IM, 1995, DIABETES, V43, pS434; TURNER RC, 1991, DIABETOLOGIA, V34, P877; UK Prospective Diabetes Study Group, 1996, ANN INTERN MED, V124, P136; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; World Health Organization, 1978, INT CLASS PROC MED	47	1409	1483	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					823	828		10.1136/bmj.316.7134.823	http://dx.doi.org/10.1136/bmj.316.7134.823			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549452	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072584300028
J	Karkoschka, E				Karkoschka, E			Clouds of high contrast on Uranus	SCIENCE			English	Article							VOYAGER-2	Near-infrared images of Uranus taken with the Hubble Space Telescope in July and October 1997 revealed discrete clouds with contrasts exceeding 10 times the highest contrast observed before with other techniques. At visible wavelengths, these 10 clouds had lower contrasts than clouds seen by Voyager 2 in 1986. Uranus' rotational rates for southern latitudes were identical in 1986 and 1997. Clouds in northern latitudes rotate slightly more slowly than clouds in opposite southern latitudes.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Karkoschka, E (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							BAINES KH, 1995, ICARUS, V114, P328, DOI 10.1006/icar.1995.1065; Hammel H. B., 1997, B AM ASTRON SOC, V29, P994; KARKOSCHKA E, 1993, ICARUS, V106, P428, DOI 10.1006/icar.1993.1183; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; Lorenz RD, 1997, ICARUS, V127, P173, DOI 10.1006/icar.1997.5687; RAGES K, 1991, ICARUS, V89, P359, DOI 10.1016/0019-1035(91)90183-T; SMITH BA, 1986, SCIENCE, V233, P43, DOI 10.1126/science.233.4759.43	7	42	43	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					570	572		10.1126/science.280.5363.570	http://dx.doi.org/10.1126/science.280.5363.570			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554844				2022-12-28	WOS:000073242100041
J	MacKeith, J				MacKeith, J			William Louis Murray Bigby - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1249	1249		10.1136/bmj.316.7139.1249	http://dx.doi.org/10.1136/bmj.316.7139.1249			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553024	Green Published			2022-12-28	WOS:000073224100061
J	Pitkin, RM				Pitkin, RM			A lasting influence - Listen to the patient	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Calif, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Pitkin, RM (corresponding author), Univ Calif, Berkeley, CA 94720 USA.								0	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	1998	316	7139					1252	1252		10.1136/bmj.316.7139.1252	http://dx.doi.org/10.1136/bmj.316.7139.1252			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553028	Green Published			2022-12-28	WOS:000073224100073
J	Vetpillai, M				Vetpillai, M			A rare opportunity - I saved my father's life	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1235	1235		10.1136/bmj.316.7139.1235	http://dx.doi.org/10.1136/bmj.316.7139.1235			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553005	Green Published			2022-12-28	WOS:000073224100033
J	Nakagawa, T; Roth, W; Wong, P; Nelson, A; Farr, A; Deussing, J; Villadangos, JA; Ploegh, H; Peters, C; Rudensky, AY				Nakagawa, T; Roth, W; Wong, P; Nelson, A; Farr, A; Deussing, J; Villadangos, JA; Ploegh, H; Peters, C; Rudensky, AY			Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus	SCIENCE			English	Article							MHC CLASS-II; INVARIANT-CHAIN; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; MOLECULES; COMPLEXES; PEPTIDE; MICE; EXPRESSION	Degradation of invariant chain (li) is a critical step in major histocompatibility complex class II-restricted antigen presentation. Cathepsin L was found to be necessary for li degradation in cortical thymic epithelial cells (cTECs), but not in bone marrow (BM)derived antigen-presenting cells (APCs). Consequently, positive selection of CD4(+) T cells, was reduced. Because different cysteine proteinases are responsible for specific li degradation steps in cTECs and BM-derived APCs, the proteolytic environment in cells mediating positive and negative selection may be distinct. The identification of a protease involved in class II presentation in a tissue-specific manner suggests a potential means of manipulating CD4(+) T cell responsiveness in vivo.	Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Freiburg Klinikum, Abt Heamatol Onkol, D-79106 Freiburg, Germany; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Freiburg; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School	Rudensky, AY (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.	sasha@nucleus.immunol.washington.edu	Deussing, Jan M/ABB-5993-2021; Villadangos, Jose A/AAU-1404-2020	Villadangos, Jose A/0000-0001-6771-8891; Deussing, Jan/0000-0002-9329-5252				ADKINS B, 1988, IMMUNOGENETICS, V27, P180, DOI 10.1007/BF00346584; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Eastman S, 1996, EUR J IMMUNOL, V26, P385, DOI 10.1002/eji.1830260218; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; Farr A, 1996, EUR J IMMUNOL, V26, P3185, DOI 10.1002/eji.1830261252; FARR AG, 1986, ANAT REC, V216, P85, DOI 10.1002/ar.1092160115; Fineschi B, 1996, J IMMUNOL, V157, P3211; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; NAKAGAWA T, UNPUB; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RODRIGUEZ GM, 1995, EUR J IMMUNOL, V25, P1823, DOI 10.1002/eji.1830250705; ROTH WR, UNPUB; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SURH GD, 1997, IMMUNITY, V7, P209; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; VANNOORT JM, 1994, EUR J IMMUNOL, V24, P2175, DOI 10.1002/eji.1830240936; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; Wong P, 1996, J IMMUNOL, V156, P2133	32	560	571	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					450	453		10.1126/science.280.5362.450	http://dx.doi.org/10.1126/science.280.5362.450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545226				2022-12-28	WOS:000073159600052
J	Gilks, CF; Wilkinson, D				Gilks, CF; Wilkinson, D			Reducing the risk of nosocomial HIV infection in British health workers working-overseas: role of post-exposure prophylaxis	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England; Med Res Council, Ctr Epidemiol Res So Africa, Hlabisa, South Africa	Liverpool School of Tropical Medicine; University of Liverpool; South African Medical Research Council	Gilks, CF (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.		Gilks, Charles/B-4184-2012; Wilkinson, David/A-6207-2008	Gilks, Charles/0000-0002-8953-3123; Wilkinson, David/0000-0002-7265-9846				Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; CONSTEN ECJ, 1995, AIDS, V9, P585, DOI 10.1097/00002030-199506000-00009; *DEP HLTH, 1997, GUID POST EXP PROPH; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; Logie S, 1996, BRIT MED J, V312, P1679, DOI 10.1136/bmj.312.7047.1679; VEEKEN H, 1991, TROP DOCT, V21, P28, DOI 10.1177/004947559102100112; 1997, DRUG THERAPEUTICS B, V35, P25	7	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1158	1160		10.1136/bmj.316.7138.1158	http://dx.doi.org/10.1136/bmj.316.7138.1158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552961	Green Published			2022-12-28	WOS:000073067500040
J	Prvulovich, EM; Bomanji, JB				Prvulovich, EM; Bomanji, JB			Fortnightly review - The role of nuclear medicine in clinical investigation	BRITISH MEDICAL JOURNAL			English	Review							BONE-SCINTIGRAPHY; BREAST-CANCER; GA-67 SPECT; INFLAMMATION; LYMPHOMA; DISEASE; TUMORS		UCL, Sch Med, Inst Nucl Med, London W1N 8AA, England	University of London; University College London; UCL Medical School	Prvulovich, EM (corresponding author), UCL, Sch Med, Inst Nucl Med, Mortimer St, London W1N 8AA, England.	l.prvulovich@nucmed.ucl.ac.uk						ALAZRAKI NP, 1993, RADIOL CLIN N AM, V31, P783; Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; BOMANJI JB, 1995, BRIT J HOSP MED, V54, P70; BOMANJI JB, 1995, CLIN GUIDE NUCL MED; BOMANJI JB, 1996, ESSENTIAL GEN SURG O, P109; Brown KA, 1996, J NUCL CARDIOL, V3, P516, DOI 10.1016/S1071-3581(96)90061-6; BROWN ML, 1993, RADIOL CLIN N AM, V31, P731; COSTA DC, 1991, CLIN GUIDE NUCL MED; Fennerty T, 1997, BMJ-BRIT MED J, V314, P425, DOI 10.1136/bmj.314.7078.425; FOGELMAN I, 1986, EUR J NUCL MED, V11, P397; FRONT D, 1990, RADIOLOGY, V175, P515, DOI 10.1148/radiology.175.2.2183289; HARDING LK, 1990, CLIN GUIDE NUCL MED; HOEFNAGEL CA, 1994, EUR J NUCL MED, V21, P561; HOLDER LE, 1993, RADIOL CLIN N AM, V31, P739; KHALKHALI I, 1994, EUR J NUCL MED, V21, P357, DOI 10.1007/BF00947973; Lee VS, 1996, AM J ROENTGENOL, V167, P1555, DOI 10.2214/ajr.167.6.8956597; MCKILLOP JH, 1991, CLIN GUIDE NUCL MED; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; MESSA C, 1995, SEMIN NUCL MED, V25, P111, DOI 10.1016/S0001-2998(95)80022-0; NOTGHI A, 1995, BRIT J HOSP MED, V54, P80; OYEN WJG, 1995, BRIT J HOSP MED, V54, P75; PENNELL DJ, 1995, CLIN GUIDE NUCL MED; Peters AM, 1996, NUCL MED COMMUN, V17, P455; *RAD AUD SUBC, 1995, J R COLL PHYS, V29, P464; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; ROBINSON RG, 1992, SEMIN NUCL MED, V22, P28, DOI 10.1016/S0001-2998(05)80154-0; ROSS DS, 1991, J NUCL MED, V32, P2181; ROZANSKI A, 1987, SEMIN NUCL MED, V17, P104, DOI 10.1016/S0001-2998(87)80016-8; SAVERYMUTTU SH, 1982, BRIT MED J, V285, P255, DOI 10.1136/bmj.285.6337.255; Stein PD, 1996, CHEST, V109, P233; Taylor A, 1996, J NUCL MED, V37, P1876; Testa HJ, 1996, CLIN GUIDE NUCL MED; TUMEH SS, 1987, RADIOLOGY, V164, P111, DOI 10.1148/radiology.164.1.3495815; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Woolfson RG, 1997, EUR J NUCL MED, V24, P557; WORSLEY DF, 1995, J NUCL MED, V36, P2380; ZARET BL, 1993, NEW ENGL J MED, V329, P855, DOI 10.1056/NEJM199309163291208; ZARET BL, 1993, NEW ENGL J MED, V329, P775, DOI 10.1056/NEJM199309093291107	38	5	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1140	1146		10.1136/bmj.316.7138.1140	http://dx.doi.org/10.1136/bmj.316.7138.1140			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552956	Green Published			2022-12-28	WOS:000073067500035
J	Glas, R; Bogyo, M; McMaster, JS; Gaczynska, M; Ploegh, HL				Glas, R; Bogyo, M; McMaster, JS; Gaczynska, M; Ploegh, HL			A proteolytic system that compensates for loss of proteasome function	NATURE			English	Article							CLASS-I MOLECULES; SACCHAROMYCES-CEREVISIAE; DEGRADATION; LACTACYSTIN; INACTIVATION; ACIDOPHILUM; INHIBITORS; PROTEINS; PEPTIDES; PATHWAY	Proteolysis is essential for the execution of many cellular functions. These include removal of incorrectly folded or damaged proteins(1), the activation of transcription factors(2), the ordered degradation of proteins involved in cell cycle control(3), and the generation of peptides destined for presentation by class I molecules of the major histocompatibility complex(4). A multisubunit protease complex, the proteasome(5), accomplishes these tasks. Here we show that in mammalian cells inactivation of the proteasome by covalent inhibitors allows the outgrowth of inhibitor-resistant cells. The growth of such adapted cells is apparently maintained by the induction of other proteolytic systems that compensate for the loss of proteasomal activity.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Bogyo, Matthew/0000-0003-3753-4412				BAI A, J IMMUNOL, V159, P2139; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Sheaff RJ, 1996, CHEM BIOL, V3, P869, DOI 10.1016/S1074-5521(96)90174-X; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; Vinitsky A, 1997, J IMMUNOL, V159, P554	29	225	226	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					618	622		10.1038/33443	http://dx.doi.org/10.1038/33443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560160				2022-12-28	WOS:000072987200064
J	Niskar, AS; Kieszak, SM; Holmes, A; Esteban, E; Rubin, C; Brody, DJ				Niskar, AS; Kieszak, SM; Holmes, A; Esteban, E; Rubin, C; Brody, DJ			Prevalence of hearing loss among children 6 to 19 years of age - The Third National Health and Nutrition Examination Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOISE	Context.-Hearing loss in children influences the development of communication and behavioral skills, but few studies in the United States have used pure-tone audiometry to derive hearing loss prevalence estimates for children. Objective.-To describe the prevalence of hearing loss among US children by sociodemographic characteristics, reported hearing loss, and audiometric screening factors. Design.-National population-based cross-sectional survey with an in-person interview and audiometric testing at 0.5 to 8 kHz. Setting/Participants.-A total of 6166 children aged 6 to 19 years completed audiometry in the mobile examination center of the Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Main Outcome Measure.-Hearing loss, defined as audiometric threshold values of at least 16-dB hearing level based on a low or high pure-tone average. Results.-A total of 14.9% of children had low-frequency or high-frequency hearing loss of at least 16-dB hearing level, 7.1% had low-frequency hearing loss of at least 16-dB hearing level, and 12.7% had high-frequency hearing loss of at least 16-dB hearing level, Most hearing loss was unilateral and slight in severity (16- to 25-dB hearing level), Of those with measured hearing loss, 10.8% were reported to have current hearing loss during the interview. Conclusions.-This analysis indicates that 14.9% of US children have low-frequency or high-frequency hearing loss of at least 16-dB hearing level in 1 or both ears, Among children in elementary, middle, and high school, audiometric screening should include low-frequency and high-frequency testing to detect hearing loss.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Univ Florida, Gainesville, FL USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University System of Florida; University of Florida; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Niskar, AS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,MS F46, Atlanta, GA 30341 USA.	abn0@cdc.gov						ANDERSON K L, 1991, Seminars in Hearing, V12, P340, DOI 10.1055/s-0028-1085507; ANDERSON KL, 1992, P ASHA AUD SUP, V21, P38; [Anonymous], 1979, JAMA-J AM MED ASSOC, V241, P2055; BARONE JA, 1987, J OCCUP ENVIRON MED, V29, P741; Barrett K.A., 1994, HDB CLIN AUDIOLOGY, P476; BEHRMAN RE, 1992, NELSON TXB PEDIAT, P1602; BROOKHOUSER PE, 1992, LARYNGOSCOPE, V102, P645, DOI 10.1288/00005537-199206000-00010; BROOKHOUSER PE, 1994, PREV MED, V23, P665, DOI 10.1006/pmed.1994.1111; Clark J G, 1981, ASHA, V23, P493; COZAD RL, 1974, J SCHOOL HEALTH, V44, P92, DOI 10.1111/j.1746-1561.1974.tb05207.x; EZZATI T, 1992, VITAL HLTH STAT, V2; Goodman A.C., 1965, ASHA, V7, P262; GULYA AJ, 1995, PRIMARY CARE MED OFF, P985; HANNER P, 1988, SCAND AUDIOL, V17, P57, DOI 10.3109/01050398809042181; Holmes A E, 1996, J Am Acad Audiol, V7, P332; Holmes AE, 1997, LANG SPEECH HEAR SER, V28, P70, DOI 10.1044/0161-1461.2801.70; JOHNSON C, 1994, NHANES 3 ANAL REPORT; KLEIN JO, 1992, SCREENING CHILDREN A, P31; Lee DJ, 1996, AM J EPIDEMIOL, V144, P442; Leske M C, 1981, ASHA, V23, P229; Naeem Z, 1996, BRIT J AUDIOL, V30, P332, DOI 10.3109/03005369609076781; *NAT CTR HLTH STAT, 1967, VIT HLTH STAT, V1; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; *NAT CTR HLTH STAT, 1975, VIT HLTH STAT, V11; National Center for Health Statistics, 1988, NAT HLTH NUTR EX SUR, VIII; National Center for Health Statistics, 1996, NHANES 3 REF MAN REP; *NIH, 1990, NCI MON, P3; RIES PW, 1994, VITAL HLTH STAT, V10, P9; RYTZNER B, 1981, SCAND AUDIOL, V10, P213, DOI 10.3109/01050398109076183; *SAS I INC, 1990, SAS LANG VERS 6; SHAL BV, 1991, SUDAAN USERS MANUAL; 1987, FED REG, V52, P44117	32	266	284	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1071	1075		10.1001/jama.279.14.1071	http://dx.doi.org/10.1001/jama.279.14.1071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546565	Bronze			2022-12-28	WOS:000072875300030
J	Beecham, L				Beecham, L			Minister supports "doctor patient" campaign	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1098	1098						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552929				2022-12-28	WOS:000072987400074
J	Horton, B				Horton, B			Seeking the bigger picture in the puzzle	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					417	419		10.1038/32948	http://dx.doi.org/10.1038/32948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537330				2022-12-28	WOS:000072713600060
J	Black, D				Black, D			Coping with loss - Bereavement in childhood	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; PARENT; DEATH; DEPRESSION; ILLNESS		Traumat Stress Clin, London W1P 1LB, England	University of London; University College London	Black, D (corresponding author), Traumat Stress Clin, London W1P 1LB, England.							BIRTCHNELL J, 1970, BRIT J PSYCHIAT, V116, P281, DOI 10.1192/bjp.116.532.281; BIRTCHNELL J, 1970, BRIT J PSYCHIAT, V116, P307, DOI 10.1192/bjp.116.532.307; BLACK D, 1987, J CHILD PSYCHOL PSYC, V28, P467, DOI 10.1111/j.1469-7610.1987.tb01767.x; BLACK D, 1978, J CHILD PSYCHOL PSYC, V19, P287, DOI 10.1111/j.1469-7610.1978.tb00471.x; BLACK D, 1985, RECENT RES DEV PSYCH, P179; Bowlby J., 1988, SECURE BASE; Bowlby J, 1969, ATTACHMENT LOSS SEPA; BROWN GW, 1971, BRIT J PSYCHIAT, V130, P1; DYREGROV A, 1991, GRIEF CHILDHOOD HDB; FRISTAD MA, 1993, AM J PSYCHIAT, V150, P511; FURMAN E., 1974, CHILDS PARENT DIES; HEEGAARD M, 1991, SOMETHING TERRIBLE H; Heegaard M., 1991, SOMEONE VERY SPECIAL; LANSDOWN R, 1985, CHILD CARE HLTH DEV, V11, P13, DOI 10.1111/j.1365-2214.1985.tb00445.x; Parkes CM., 1986, BEREAVEMENT STUDIES; PARKES CM, 1998, BMJ, V316; ROSENHEIM E, 1985, J CHILD PSYCHOL PSYC, V26, P995, DOI 10.1111/j.1469-7610.1985.tb00613.x; Rutter, 1966, CHILDREN SICK PARENT; VANEERDEWEGH MM, 1982, BRIT J PSYCHIAT, V140, P23, DOI 10.1192/bjp.140.1.23; WELLER RA, 1991, AM J PSYCHIAT, V148, P1536	20	35	35	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	1998	316	7135					931	933		10.1136/bmj.316.7135.931	http://dx.doi.org/10.1136/bmj.316.7135.931			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD691	9552851	Green Published			2022-12-28	WOS:000072713300044
J	Jarvis, MJ				Jarvis, MJ			Ethical debate - Sex, drugs, and the invasion of privacy - Supermarket cigarettes: the brands that dare not speak their name	BRITISH MEDICAL JOURNAL			English	Article									UCL, Dept Epidemiol & Publ Hlth, Imperial Canc Res Fund, Hlth Behav Unit, London WC1E 6BT, England	Cancer Research UK; University of London; University College London	Jarvis, MJ (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Imperial Canc Res Fund, Hlth Behav Unit, Mortimer St, London WC1E 6BT, England.	martin.jarvis@ucl.ac.uk	Jarvis, Martin J/B-1034-2008	Jarvis, Martin J/0000-0001-9238-8038				BENNETT N, 1996, LIVING BRITAIN RESUL; BENTLEY S, 1997, MARKETING WEEK  0410, P7; Cavin SW, 1996, AM J PREV MED, V12, P17, DOI 10.1016/S0749-3797(18)30365-9; ITZCOVITZ J, 1992, TOBACCO MAGAZINE MAY, P13	4	4	4	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					929	931		10.1136/bmj.316.7135.929	http://dx.doi.org/10.1136/bmj.316.7135.929			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552850	Green Published			2022-12-28	WOS:000072713300043
J	Durham, S				Durham, S			ABC of allergies - Summer hay fever	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RHINITIS		Royal Brompton Hosp, London SW3 6LY, England	Royal Brompton Hospital	Durham, S (corresponding author), Royal Brompton Hosp, London SW3 6LY, England.							FREW AJ, 1993, BRIT MED J, V307, P919, DOI 10.1136/bmj.307.6909.919; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x	4	15	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					843	845		10.1136/bmj.316.7134.843	http://dx.doi.org/10.1136/bmj.316.7134.843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549458	Green Published			2022-12-28	WOS:000072584300037
J	Kapur, N; House, A; Creed, F; Feldman, E; Friedman, T; Guthrie, E				Kapur, N; House, A; Creed, F; Feldman, E; Friedman, T; Guthrie, E			Management of deliberate self poisoning in adults in four teaching hospitals: descriptive study	BRITISH MEDICAL JOURNAL			English	Article									Manchester Royal Infirm, Dept Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; John Radcliffe Hosp, Dept Psychol Med, Oxford OX3 9DU, England; Leicester Gen Hosp, Leicester LE5 4PW, Leics, England; Gen Infirm, Dept Liason Psychiat, Leeds LS1 3EX, W Yorkshire, England	University of Manchester; University of Oxford; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Leeds General Infirmary	Kapur, N (corresponding author), Manchester Royal Infirm, Dept Psychiat & Behav Sci, Oxford Rd, Manchester M13 9WL, Lancs, England.			House, Allan/0000-0001-8721-8026; Guthrie, Elspeth/0000-0002-5834-6616				*DEP HLTH SOC SEC, 1984, MAN DEL SELFHAR; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; Hawton K, 1995, Health Trends, V27, P18; HAWTON K, 1996, ATTEMPTED SUICIDE OX; HOUSE A, 1992, International Review of Psychiatry, V4, P15, DOI 10.3109/09540269209066298	5	106	107	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					831	832		10.1136/bmj.316.7134.831	http://dx.doi.org/10.1136/bmj.316.7134.831			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549454	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072584300031
J	Gahl, WA; Brantly, M; Kaiser-Kupfer, MI; Iwata, F; Hazelwood, S; Shotelersuk, V; Duffy, LF; Kuehl, EM; Troendle, J; Bernardini, I				Gahl, WA; Brantly, M; Kaiser-Kupfer, MI; Iwata, F; Hazelwood, S; Shotelersuk, V; Duffy, LF; Kuehl, EM; Troendle, J; Bernardini, I			Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY FIBROSIS; GRANULOMATOUS COLITIS; POPULATION; CHILDREN; GROWTH; CT	Background Hermansky-Pudlak syndrome is characterized by oculocutaneous albinism, a storage-pool deficiency, and lysosomal accumulation of ceroid lipofuscin, which causes pulmonary fibrosis and granulomatous colitis in some cases. All identified affected patients in northwest Puerto Rico are homozygous for a 16-bp duplication in exon 15 of a recently cloned gene, HPS. We compared the clinical and laboratory characteristics of these patients with those of patients without the 16-bp duplication. Methods Forty-nine patients - 27 Puerto Ricans and 22 patients from the mainland United States who were not of Puerto Rican descent - were given a diagnosis on the basis of albinism and the absence of platelet dense bodies. We used the polymerase chain reaction to determine which patients carried the 16-bp duplication. Results Twenty-five of the Puerto Rican patients were homozygous for the 16-bp duplication, whereas none of the non-Puerto Rican patients carried this mutation. Like the patients without the duplication, the patients with the 16-bp duplication had a broad variation in pigmentation. Nine of 16 adults with the duplication, but none of the 10 without it, had a diffusing capacity for carbon monoxide that was less than 80 percent of the predicted value. High-resolution computed tomography in 12 patients with the 16-bp duplication revealed minimal fibrosis in 8, moderate fibrosis in 1, severe fibrosis in 1, and no fibrosis in 2. Computed tomography in eight patients without the duplication revealed minimal fibrosis in three and no fibrosis in the rest. Inflammatory bowel disease developed in eight patients (four in each group) between 3 and 25 years of age. Conclusions The 16-bp duplication in exon 15 of HPS, which we found only in Puerto Rican patients, is associated with a broad range of pigmentation and an increased risk of restrictive lung disease in adults. (C)1998, Massachusetts Medical Society.	NICHHD, Heritable Disorders Branch, Bethesda, MD 20892 USA; NICHHD, Biometry & Math Stat Branch, Bethesda, MD 20892 USA; NHLBI, Pulm Crit Care Med Branch, Bethesda, MD 20892 USA; NEI, Ophthalm Genet & Clin Serv Branch, Bethesda, MD 20892 USA; NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA; Gastroenterol Associates No Virginia, Fairfax, VA USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	Gahl, WA (corresponding author), NICHD, Sect Human Biochem Genet, NIH, 10 Ctr Dr,MSC 1830,Bldg 10,Rm 9S-241, Bethesda, MD 20892 USA.		Brantly, Mark/AAH-2922-2020	Shotelersuk, Vorasuk/0000-0002-1856-0589				CHARNAS LR, 1991, NEW ENGL J MED, V324, P1318, DOI 10.1056/NEJM199105093241904; DAVIES BH, 1976, Q J MED, V45, P219; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; GARAY SM, 1979, AM J MED, V66, P737, DOI 10.1016/0002-9343(79)91111-2; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; HARMON KR, 1994, J LAB CLIN MED, V123, P617; Hazelwood S, 1997, AM J HUM GENET, V61, P1088, DOI 10.1086/301611; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; HOSTE P, 1979, SCAND J RESPIR DIS, V60, P128; HOTTA H, 1988, CANCER RES, V48, P2955; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; KING RA, 1995, METABOLIC MOL BASES, V3, P4353; KINNEAR PE, 1985, SURV OPHTHALMOL, V30, P75, DOI 10.1016/0039-6257(85)90077-3; LATTION F, 1983, HELV PAEDIATR ACTA, V38, P495; MAHADEO R, 1991, J PEDIATR-US, V118, P904, DOI 10.1016/S0022-3476(05)82204-8; *MAY MED LAB, 1990, GEN TEST CAT, P105; MULLER NL, 1987, RADIOLOGY, V165, P731; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; NOVAK EK, 1984, BLOOD, V63, P536; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALLREUTER KU, 1993, DERMATOLOGY, V187, P248, DOI 10.1159/000247258; SCHINELLA RA, 1980, ANN INTERN MED, V92, P20, DOI 10.7326/0003-4819-92-1-20; Schneider A., 1995, American Journal of Human Genetics, V57, pA125; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; Seymour A. B., 1997, Molecular Biology of the Cell, V8, p227A; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SUMMERS CG, 1988, OPHTHALMOLOGY, V95, P545; TAKAHASHI A, 1984, VIRCHOWS ARCH A, V402, P247, DOI 10.1007/BF00695079; TERRIFF BA, 1992, RADIOLOGY, V184, P445, DOI 10.1148/radiology.184.2.1620845; VANDORP DB, 1990, OPHTHALMIC PAED GEN, V11, P237, DOI 10.3109/13816819009020985; WILDENBERG SC, 1995, AM J HUM GENET, V57, P755; WITKOP CJ, 1987, AM J HEMATOL, V26, P305, DOI 10.1002/ajh.2830260403; WITKOP CJ, 1989, METABOLIC BASIS INHE, V2, P2905; WITKOP CPJ, 1990, B ASOC MED P R, V8, P333	36	206	209	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1258	1264		10.1056/NEJM199804303381803	http://dx.doi.org/10.1056/NEJM199804303381803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562579				2022-12-28	WOS:000073335800003
J	Bonnema, J; van Wersch, AMEA; van Geel, AN; Pruyn, JFA; Schmitz, PIM; Paul, MA; Wiggers, T				Bonnema, J; van Wersch, AMEA; van Geel, AN; Pruyn, JFA; Schmitz, PIM; Paul, MA; Wiggers, T			Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							MODIFIED RADICAL-MASTECTOMY; AXILLARY DRAINAGE; NODE DISSECTION; COMPLICATIONS; ADJUSTMENT; SUPPORT; STRESS; STAY; TERM	Objective: To assess the medical and psychosocial effects of early hospital discharge after surgery for breast cancer on complication rate, patient satisfaction, and psychosocial outcomes. Design: Randomised trial comparing discharge from hospital 4 days after surgery (with drain in situ) with discharge after drain removal (mean 9 days in hospital). Psychosocial measurements performed before surgery and 1 and 4 months after. Setting: General hospital and cancer clinic in Rotterdam with a socioeconomically diverse population. Subjects: 125 women with operable breast cancer. Main outcome measures: Incidence of complications after surgery for breast cancer, patient satisfaction with treatment, and psychosocial effects of short stay or long stay in hospital. Results: Patient satisfaction with the short stay in hospital was high; only 4% (2/56 at 1 month after surgery and 2/52 at 4 months after surgery) of patients indicated that they would have preferred a longer stay. There were no significant differences in duration of drainage from the axilla between the short stay and long stay groups (median 8 v 9 days respectively, P = 0.45) or the incidence of wound complications (10 patients v 9 patients). The median number of seroma aspirations per patient was higher for the long stay group (1 v 3.5, P = 0.04). Leakage along the drain occurred more frequently in short stay patients (21 v 10 patients, P = 0.04). The two groups did not differ in scores for psychosocial problems (uncertainty anxiety, loneliness, disturbed sleep, loss of control, threat to self esteem), physical or psychological complaints, or in the coping strategies used. Before surgery; short stay patients scored higher on scales of depression (P = 0.03) and after surgery they were more likely to discuss their disease with their families (at 1 month P = 0.004, at 4 months P = 0.04). Conclusions: Early discharge from hospital after surgery for breast cancer is safe and is well received by patients. Early discharge seems to enhance the opportunity for social support within the family.	Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Zuider Hosp, Dept Surg Oncol, NL-3008 AE Rotterdam, Netherlands; Inst Hlth & Environm Issues, NL-4797 ZH Willemstad, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Bonnema, J (corresponding author), Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Zuider Hosp, Dept Surg Oncol, POB 5201, NL-3008 AE Rotterdam, Netherlands.							BLOOM JR, 1982, SOC SCI MED, V16, P1329, DOI 10.1016/0277-9536(82)90028-4; BOMAN L, 1993, EUR J SURG, V159, P67; Bonnema J, 1997, AM J SURG, V173, P76, DOI 10.1016/S0002-9610(96)00416-3; CLARK JA, 1992, AM SURGEON, V58, P239; Coveney E C, 1993, Eur J Surg Oncol, V19, P143; Cronbach Lee J., 1990, ESSENTIALS PSYCHOL T, V5th; DEBOER MF, 1995, HEAD NECK-J SCI SPEC, V17, P503, DOI 10.1002/hed.2880170608; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOODMAN AA, 1993, ARCH SURG-CHICAGO, V128, P1149; Holcombe C, 1995, Eur J Surg Oncol, V21, P604, DOI 10.1016/S0748-7983(95)95133-4; INWANG R, 1991, ANN ROY COLL SURG, V73, P326; JEFFREY SS, 1995, ARCH SURG-CHICAGO, V130, P909; Kambouris A, 1996, AM SURGEON, V62, P123; Maddern GJ, 1996, BRIT J SURG, V83, P145, DOI 10.1046/j.1365-2168.1996.02185.x; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MCALEESE P, 1994, ANN SURG, V220, P740, DOI 10.1097/00000658-199412000-00006; McArdle JMC, 1996, BMJ-BRIT MED J, V312, P813; Mesters I, 1997, PSYCHOSOM MED, V59, P269, DOI 10.1097/00006842-199705000-00010; NELLES W B, 1991, Journal of Psychosocial Oncology, V9, P21, DOI 10.1300/J077v09n02_02; PEDERSEN SH, 1994, ANN SURG, V219, P374, DOI 10.1097/00000658-199404000-00008; PRUYN JFA, 1983, PATIENT EDUC COUNS, V5, P57, DOI 10.1016/0738-3991(83)90002-2; SOMERS RG, 1992, ANN SURG, V215, P146, DOI 10.1097/00000658-199202000-00009; SPIEGEL D, 1983, J PSYCHOSOC ONCOL, V1, P33, DOI DOI 10.1300/J077V01N01_04; Spielberger C., 1983, STAI MANUAL; TADYCH K, 1987, SURG GYNECOL OBSTET, V165, P483; VANDENBORNE HW, 1987, PATIENT EDUC COUNS, V9, P33, DOI 10.1016/0738-3991(87)90107-8; VANDENBORNE HW, 1985, LOTGENOTENCONTACT BI; vanWersch A, 1997, PATIENT EDUC COUNS, V30, P175, DOI 10.1016/S0738-3991(96)00950-0; VINTON AL, 1991, AM J SURG, V161, P584, DOI 10.1016/0002-9610(91)90905-S; WATSON M, 1990, PSYCHOL REP, V66, P39, DOI 10.2466/PR0.66.1.39-48; YLI M, 1995, ANN R COLL SURG ENGL, V77, P377	32	82	83	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1267	1271		10.1136/bmj.316.7140.1267	http://dx.doi.org/10.1136/bmj.316.7140.1267			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZK548	9554895	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000073335900019
J	Ingenito, EP; Evans, RB; Loring, SH; Kaczka, DW; Rodenhouse, JD; Body, SC; Sugarbaker, DJ; Mentzer, SJ; DeCamp, MM; Reilly, JJ				Ingenito, EP; Evans, RB; Loring, SH; Kaczka, DW; Rodenhouse, JD; Body, SC; Sugarbaker, DJ; Mentzer, SJ; DeCamp, MM; Reilly, JJ			Relation between preoperative inspiratory lung resistance and the outcome of lung-volume-reduction surgery for emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-FUNCTION	Background Surgery to reduce lung volume has recently been reintroduced to alleviate dyspnea and improve exercise tolerance in selected patients with emphysema. A reliable means of identifying patients who are likely to benefit from this surgery is needed. Methods We measured lung resistance during inspiration, static recoil pressure at total lung capacity, static lung compliance, expiratory flow rates, and lung volumes in 29 patients with chronic obstructive lung disease before lung-volume-reduction surgery. The changes in the forced expiratory volume in one second (FEV1) six months after surgery were related to the preoperatively determined physiologic measures. A response to surgery was defined as an increase in the FEV1 of at least 0.2 liter and of at least 12 percent above base-line values. Results Of the 29 patients, 23 had some improvement in FEV1 including 15 who met the criteria for a response to surgery. Among the variables considered, only preoperative lung resistance during inspiration predicted changes in expiratory flow rates after surgery. Inspiratory lung resistance correlated significantly and inversely with improvement in FEV1 after surgery (r=-0.63, P<0.001). A preoperative criterion of an inspiratory resistance of 10 cm of water per liter per second had a sensitivity of 88 percent (14 of 16 patients) and a specificity of 92 percent (12 of 13 patients) in identifying patients who were likely to have a response to surgery. Conclusions Preoperative lung resistance during inspiration appears to be a useful measure for selecting patients with emphysema for lung-volume-reduction surgery. (C)1998, Massachusetts Medical Society.	Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Anesthesia, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Ingenito, EP (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.		Kaczka, David Walter/A-2984-2008; Body, Simon/AAQ-7572-2020; Kaczka, David W./U-2580-2018; Body, Simon C/O-2605-2013	Kaczka, David Walter/0000-0003-4378-5242; Body, Simon/0000-0001-6721-7050; Kaczka, David W./0000-0003-4378-5242; Body, Simon C/0000-0001-6721-7050	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052586] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Bingisser R, 1996, J THORAC CARDIOV SUR, V112, P875, DOI 10.1016/S0022-5223(96)70086-7; BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; Brenner M, 1996, CHEST, V110, P205, DOI 10.1378/chest.110.1.205; BROWN R, 1980, J APPL PHYSIOL, V49, P398, DOI 10.1152/jappl.1980.49.3.398; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; CORBIN RP, 1979, AM REV RESPIR DIS, V120, P293; Daniel TM, 1996, ANN SURG, V223, P526, DOI 10.1097/00000658-199605000-00008; GRIMBY G, 1968, J CLIN INVEST, V47, P1455, DOI 10.1172/JCI105837; GURNEY JW, 1992, RADIOLOGY, V183, P457, DOI 10.1148/radiology.183.2.1561350; HOLOHAN TV, 1996, HEALTH TECHNOL ASSES, V10, P1; KACZKA DW, 1995, ANN BIOMED ENG, V23, P135, DOI 10.1007/BF02368321; Kotloff RM, 1996, CHEST, V110, P1399, DOI 10.1378/chest.110.6.1399; MEAD J, 1955, J CLIN INVEST, V34, P1005, DOI 10.1172/JCI103150; NAGELS J, 1950, J APPL PHYSIOL, V49, P408; Pride NB, 1986, HDB PHYSL RESP SYSTE, P659; SALAZAR E, 1964, J APPL PHYSIOL, V19, P97, DOI 10.1152/jappl.1964.19.1.97; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Slone RM, 1997, RADIOLOGY, V204, P685, DOI 10.1148/radiology.204.3.9280244; Snedecor G.W., 1989, AMES IOWA STATE U PR; Swanson SJ, 1997, J AM COLL SURGEONS, V185, P25, DOI 10.1016/S1072-7515(97)00021-5; Wang SC, 1997, RADIOLOGY, V205, P243, DOI 10.1148/radiology.205.1.9314992; Yusen R D, 1996, Semin Thorac Cardiovasc Surg, V8, P83	24	81	83	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1181	1185		10.1056/NEJM199804233381703	http://dx.doi.org/10.1056/NEJM199804233381703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554858				2022-12-28	WOS:000073208400003
J	Koren, G; Pastuszak, A; Ito, S				Koren, G; Pastuszak, A; Ito, S			Drug therapy - Drugs in pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FETAL ALCOHOL SYNDROME; NEURAL-TUBE DEFECTS; 1ST TRIMESTER; VALPROIC ACID; ORAL CLEFTS; CONGENITAL-MALFORMATIONS; INDUCED TERATOGENESIS; RETINOIC ACID; DIAZEPAM USE; MOUSE MODEL		Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherisk Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dep Populat Hlth Sci, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Koren, G (corresponding author), Hosp Sick Children, Div Clin Pharmacol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							ADAMS J, 1993, RETINOIDS CLIN PRACT, P111; [Anonymous], 1994, TERATOLOGY, V49, P446; BAXTER H, 1950, McGill Med J, V19, P245; BEALL JR, 1977, TOXICOL APPL PHARM, V39, P489, DOI 10.1016/0041-008X(77)90140-5; BRACKEN MB, 1990, OBSTET GYNECOL, V76, P552; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; BURESH JJ, 1964, J DENT RES, V43, P548, DOI 10.1177/00220345640430040901; Chasnoff I J, 1992, Curr Probl Pediatr, V22, P302, DOI 10.1016/0045-9380(92)90027-V; CLARREN SK, 1981, JAMA-J AM MED ASSOC, V245, P2436, DOI 10.1001/jama.245.23.2436; Czeizel A, 1987, Reprod Toxicol, V1, P183; DICKSON JH, 1977, CAN MED ASSOC J, V117, P721; DONNAI D, 1978, BRIT MED J, V1, P691, DOI 10.1136/bmj.1.6114.691; DOUGHERTY WJ, 1974, TOXICOL APPL PHARM, V29, P138; EINARSON TR, 1988, DRUG INTEL CLIN PHAR, V22, P813, DOI 10.1177/106002808802201021; EINARSON TR, 1990, AM J OBSTET GYNECOL, V162, P655, DOI 10.1016/0002-9378(90)90976-E; ELLIS FW, 1980, ALCOHOL CLIN EXP RES, V4, P123, DOI 10.1111/j.1530-0277.1980.tb05627.x; FAINSTAT T, 1954, ENDOCRINOLOGY, V55, P502, DOI 10.1210/endo-55-4-502; FANTEL AG, 1982, TERATOLOGY, V26, P17, DOI 10.1002/tera.1420260104; FANTEL AG, 1977, TERATOLOGY, V15, P65, DOI 10.1002/tera.1420150109; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; FINNELL RH, 1981, SCIENCE, V211, P483, DOI 10.1126/science.7455686; FINNELL RH, 1988, TERATOLOGY, V38, P313, DOI 10.1002/tera.1420380403; FRASER FC, 1995, TERATOLOGY, V51, P45, DOI 10.1002/tera.1420510107; FRATTA ID, 1965, TOXICOL APPL PHARM, V7, P268, DOI 10.1016/0041-008X(65)90095-5; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; Goldstein DJ, 1997, OBSTET GYNECOL, V89, P713, DOI 10.1016/S0029-7844(97)00070-7; GONEN R, 1994, MATERNAL FETAL TOXIC, P641; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HANSON JW, 1975, J PEDIATR-US, V87, P285, DOI 10.1016/S0022-3476(75)80604-4; HARBISON RD, 1969, THESIS STATE U IOWA; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4<745::AID-CNCR2820250402>3.0.CO;2-2; HOWE AM, 1992, TERATOLOGY, V46, P379, DOI 10.1002/tera.1420460408; JACOBSON SJ, 1992, LANCET, V339, P530, DOI 10.1016/0140-6736(92)90346-5; JAGERROMAN E, 1986, J PEDIATR-US, V108, P997, DOI 10.1016/S0022-3476(86)80949-0; JICK H, 1981, JAMA-J AM MED ASSOC, V245, P1329, DOI 10.1001/jama.245.13.1329; JONES GRN, 1994, LANCET, V343, P1041, DOI 10.1016/S0140-6736(94)90163-5; KLEIN KL, 1981, J EXP ZOOL, V216, P107, DOI 10.1002/jez.1402160111; KOREN G, 1990, TERATOLOGY, V41, P657, DOI 10.1002/tera.1420410602; KOREN G, 1989, AM J OBSTET GYNECOL, V160, P1190, DOI 10.1016/0002-9378(89)90186-5; KOREN G, 1994, MATERNAL FETAL TOXIC, P683; KOREN G, 1997, CHILDREN NEVERLAND S; LAMMER EJ, 1987, TERATOLOGY, V35, P465, DOI 10.1002/tera.1420350319; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232, DOI 10.1055/s-0028-1111892; Loebstein R, 1997, CLIN PHARMACOKINET, V33, P328, DOI 10.2165/00003088-199733050-00002; LUTIGER B, 1991, TERATOLOGY, V44, P405, DOI 10.1002/tera.1420440407; MASTROIACOVO P, 1995, J MED GENET, V32, P453, DOI 10.1136/jmg.32.6.453; MATSUMOTO H, 1965, J NEUROPATH EXP NEUR, V24, P563, DOI 10.1097/00005072-196510000-00002; Mazzota P, 1997, CAN FAM PHYSICIAN, V43, P1055; MCBRIDE WG, 1961, LANCET, V2, P1358; MCCALL RB, 1979, HDB INFANT DEV, P707; MCCLAIN RM, 1979, TOXICOL APPL PHARM, V48, pA32; MCKEIGUE PM, 1994, TERATOLOGY, V50, P27, DOI 10.1002/tera.1420500105; MILLER RP, 1975, TOXICOL APPL PHARM, V32, P53, DOI 10.1016/0041-008X(75)90194-5; MOORE KL, 1988, DEV HUMAN CLIN ORIEN, P131; NAU H, 1986, ENVIRON HEALTH PERSP, V70, P113, DOI 10.2307/3430348; NEUTEL CI, 1995, CAN J PUBLIC HEALTH, V86, P66; NEWTON ER, 1989, MED CLIN N AM, V73, P517, DOI 10.1016/S0025-7125(16)30655-1; NORA JJ, 1978, JAMA-J AM MED ASSOC, V240, P837, DOI 10.1001/jama.240.9.837; NORA JJ, 1974, LANCET, V2, P594; ORNSTEIN M, 1995, REPROD TOXICOL, V9, P1, DOI 10.1016/0890-6238(94)00050-7; PASTUSZAK A, 1994, REPROD TOXICOL, V8, P63, DOI 10.1016/0890-6238(94)90068-X; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; PINSKY L, 1965, SCIENCE, V147, P402, DOI 10.1126/science.147.3656.402; PIPKIN FB, 1980, LANCET, V1, P1256; POLANECZKY M, 1994, NEW ENGL J MED, V331, P1201, DOI 10.1056/NEJM199411033311806; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; ROSA FW, 1989, OBSTET GYNECOL, V74, P371; ROSA FW, 1991, NEW ENGL J MED, V324, P674, DOI 10.1056/NEJM199103073241006; ROSA FW, 1983, LANCET, V2, P513; ROSENBERG L, 1983, NEW ENGL J MED, V309, P1282, DOI 10.1056/NEJM198311243092103; SAXEN I, 1975, INT J EPIDEMIOL, V4, P37, DOI 10.1093/ije/4.1.37; Schardein J., 1993, CHEM INDUCED BIRTH D; SCHARDEIN JL, 1980, TERATOLOGY, V22, P251, DOI 10.1002/tera.1420220302; SCOLNIK D, 1994, JAMA-J AM MED ASSOC, V271, P767, DOI 10.1001/jama.271.10.767; SHEPARD TH, 1994, CATALOG TERATOGENIC; SHIONO PH, 1984, NEW ENGL J MED, V311, P919; SHOEMAKER WJ, 1980, NEUROTOXICOL TERATOL, V2, P239; SLONE D, 1976, LANCET, V1, P1373; SMITH J, 1994, MATERNAL FETAL TOXIC, P115; STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; SULLIVAN FM, 1977, TOXICOL APPL PHARM, V40, P365, DOI 10.1016/0041-008X(77)90108-9; Tatetsu M, 1968, PSYCHIAT NEUROL JPN, V70, P162; Theis JGW, 1996, CAN FAM PHYSICIAN, V42, P2347; WALKER BE, 1971, TERATOLOGY, V4, P39, DOI 10.1002/tera.1420040107; WEATHERS WT, 1993, PEDIATRICS, V91, P350; WERLER MM, 1989, NEW ENGL J MED, V321, P1639, DOI 10.1056/NEJM198912143212404; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WILBY OK, 1987, TERATOLOGY, V35, pA62; WILSON JG, 1977, TOXICOL APPL PHARM, V41, P67, DOI 10.1016/0041-008X(77)90054-0; WILSON JG, 1970, TERATOLOGY, V3, P210; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; 1992, LANCET, V339, P1600; 1982, US NEWS WORLD R 0517, P1	95	410	432	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1128	1137		10.1056/NEJM199804163381607	http://dx.doi.org/10.1056/NEJM199804163381607			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545362				2022-12-28	WOS:000073070100007
J	Norris, RM				Norris, RM		United Kingdom Heart Attack Study Collaborativ	Fatality outside hospital from acute coronary events in three British health districts, 1994-5	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; CHOLESTEROL LEVELS; UNITED-STATES; COMMUNITY; SURVIVAL; DEATHS; IMPACT; RATES	Objectives: To provide a contemporary account of the treatment and outcomes of acute coronary attacks in England and Wales and to identify strategies that might improve the outcome. Design: Two year community and hospital based study in three British health districts. Setting: Health districts of Brighton (population 282 000), South Glamorgan (408 000), and York (264 000). Subjects: 3523 men and women under 75 years of age who died outside hospital from acute coronary causes, who were admitted to hospital with acute myocardial infarction, or who developed acute infarction or died unexpectedly from acute coronary causes while they were already in hospital. Interventions: Attempted resuscitation in people having a cardiac arrest outside hospital. Main outcome measures: Total case fatality, case fatality outside and inside hospital, and the effect of resuscitation on case fatality outside hospital. Results: 1589 patients died within 30 days of the acute event. Case fatality was 45% (95% confidence interval 43% to 47%), rising from 27% (160/595) (23% to 31%) at age <55 years to 53% (1019/1916) (51% to 55%) at 65-74 years. Overall, 74% (1172/1589) (72% to 76%) of fatal events happened outside hospital, and there was a negative age gradient (P < 0.001) such that 91% (145/160) (87% to 95%) of fatalities occurred outside hospital at age <55 compared with 70% (710/1019) (67% to 73%) at 65-74 years. Without successful resuscitation of 55 patients outside hospital, total case fatality at 30 days would have risen from 45% to 46.7%. Conclusion: Opportunities for reducing fatality from acute coronary attacks lie mainly outside hospital. These results and others imply that survival from cardiac arrest outside hospital might be trebled by improved ambulance and patient response Proper application of secondary preventive measures for patients with coronary disease could have an even larger impact.	Royal Sussex Cty Hosp, Dept Cardiac, Coordinating Ctr, Brighton BN2 5BE, E Sussex, England	University of Brighton	Norris, RM (corresponding author), Royal Sussex Cty Hosp, Dept Cardiac, Coordinating Ctr, Brighton BN2 5BE, E Sussex, England.							ARMSTRONG A, 1972, BRIT HEART J, V34, P67; Blohm MB, 1996, HEART, V76, P430, DOI 10.1136/hrt.76.5.430; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; *BRIT HEART FDN, 1997, COR HEART DIS STAT; COBB LA, 1992, CIRCULATION, V85, P98; DIXON GF, 1996, HEART, V76, pP80; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; HERLITZ J, 1994, BRIT HEART J, V72, P408; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KINLEN LJ, 1973, BRIT HEART J, V35, P616; Kuisma M, 1996, HEART, V76, P18, DOI 10.1136/hrt.76.1.18; Leslie WS, 1996, HEART, V75, P195, DOI 10.1136/hrt.75.2.195; Lester C, 1996, RESUSCITATION, V31, P33, DOI 10.1016/0300-9572(95)00912-4; LEWIS SJ, 1993, BRIT HEART J, V70, P568; *NHS EX, 1996, REV AMB PERF STAND F; NORRIS RM, 1994, BRIT HEART J, V71, pP40; NORRIS RM, 1994, BR HEART J S, V71, pP33; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, 1975, LANCET, V2, P833; *UK HEART ATT STUD, IN PRESS HEART; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WESTON CFM, 1994, J ROY COLL PHYS LOND, V28, P402	27	135	137	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1065	1070						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552910				2022-12-28	WOS:000072987400029
J	Wardlaw, JM; Lammie, GA; Whittle, IR				Wardlaw, JM; Lammie, GA; Whittle, IR			A brain haemorrhage?	LANCET			English	Article									Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Wardlaw, JM (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.		Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022; whittle, ian/AAX-7309-2021	Wardlaw, Joanna M/0000-0002-9812-6642; 				BACAK G, 1997, NEURORADIOLOGY, V39, P566; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; Towbin A, 1973, STROKE, V4, P419, DOI 10.1161/01.STR.4.3.419	3	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1028	1028		10.1016/S0140-6736(97)12309-1	http://dx.doi.org/10.1016/S0140-6736(97)12309-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546510				2022-12-28	WOS:000072927200014
J	Vermeer-de Bondt, PE; Labadie, J; Rumke, HC				Vermeer-de Bondt, PE; Labadie, J; Rumke, HC			Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS		Natl Inst Publ Hlth & Environm, Lab Clin Vaccine Res, NL-3720 BA Bilthoven, Netherlands	Netherlands National Institute for Public Health & the Environment	Vermeer-de Bondt, PE (corresponding author), Natl Inst Publ Hlth & Environm, Lab Clin Vaccine Res, POB 1, NL-3720 BA Bilthoven, Netherlands.							BARAFF LJ, 1988, PEDIATRICS, V81, P789; CODY CL, 1981, PEDIATRICS, V68, P650; HANNIK CA, 1979, P 3 NT S PERT BETH 1, P279; Howson CP, 1991, ADVERSE EFFECTS PERT; OLIN P, 1997, EFFICACY TRIAL ACELL, V2	5	27	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					902	903		10.1136/bmj.316.7135.902	http://dx.doi.org/10.1136/bmj.316.7135.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552838	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072713300028
J	Gotzsche, PC; Johansen, HK				Gotzsche, PC; Johansen, HK			Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND TRIALS; ANTIRHEUMATIC DRUGS; GRIP STRENGTH; NSAID TRIALS; LONG-TERM; CORTICOSTEROIDS; THERAPY; BIAS; METAANALYSIS; EFFICACY	Objective: To determine whether short term, oral low dose prednisolone (less than or equal to 15 mg daily) is superior to placebo and non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Design: Meta-analysis of randomised trials of oral corticosteroids compared with placebo or a non-steroidal anti-inflammatory drug. Setting: Trials conducted anywhere in the world. Subjects: Patients with rheumatoid arthritis. Main outcome measures: Joint tenderness, pain, and grip strength. Outcomes measured on different scales were combined by using the standardised effect size (difference in effect divided bg SD of the measurements). Results: Ten studies were included in the meta-analysis. Prednisolone had a marked effect over placebo on joint tenderness (standardised effect size 1.31; 95% confidence interval 0.78 to 1.83), pain (1.75; 0.87 to 2.64), and grip strength (0.41; 0.13 to 0.69). Measured in the original units the differences were 12 (6 to 18) tender joints and 22 mm Hg (5 mm Hg to 40 mm Hg) for grip strength. Prednisolone also had a greater effect than non-steroidal anti-inflammatory drugs on joint tenderness (0.63; 0.11 to 1.16) and pain (1.25; 0.26 to 2.24), whereas the difference in grip strength was not significant (0.31; -0.02 to 0.64). Measured in the original units the differences were 9 (5 to 12) tender joints and 12 mm Hg (-6 mm Hg to 31 mm Hg). The risk of adverse effects during moderate and long term use seemed acceptable. Conclusion: Prednisolone in low doses (less than or equal to 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2200 Copenhagen N, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, Tagensvej 18 B, DK-2200 Copenhagen N, Denmark.	p.c.goetzsche@cochrane.dk						[Anonymous], 1957, BMJ-BRIT MED J, V1, P847; [Anonymous], 1959, ANN RHEUM DIS, V18, P173; [Anonymous], 1955, Ann Rheum Dis, V14, P353; BERRY H, 1974, ANN RHEUM DIS, V33, P523, DOI 10.1136/ard.33.6.523; BOARDMAN PL, 1967, BMJ-BRIT MED J, V4, P264, DOI 10.1136/bmj.4.5574.264; Bohm C, 1967, Med Welt, V35, P2047; CALDWELL JR, 1991, SEMIN ARTHRITIS RHEU, V21, P1, DOI 10.1016/0049-0172(91)90051-Z; Chamberlain M A, 1976, Rheumatol Rehabil, V15, P17, DOI 10.1093/rheumatology/15.1.17; *COCHR COLL, 1996, COCHR LIB DAT DISK C; DEODHAR SD, 1973, Q J MED, V42, P387; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICK WC, 1970, RHEUMATOL PHYS M S10, V10, P40; Dickersin K., 1993, ONLINE J CURR CLIN T, pDoc No 50; Empire Rheumatism Council, 1957, ANN RHEUM DIS, V16, P277; Fearnley M E, 1966, Ann Phys Med, V8, P204; FEARNLEY ME, 1966, ANN PHYS MED S, P109; FLORES JB, 1969, PRENSA MED MEX, V34, P382; GOTZSCHE PC, 1994, J INTERN MED, V236, P599, DOI 10.1111/j.1365-2796.1994.tb00853.x; GOTZSCHE PC, 1989, DAN MED BULL, V36, P493; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1990, J CLIN EPIDEMIOL, V43, P1313; GOTZSCHE PC, 1990, DAN MED BULL, V37, P329; GOTZSCHE PC, 1997, COCHRANE DATABASE SY; GUM OB, 1966, AM J MED SCI, V251, P328, DOI 10.1097/00000441-196603000-00012; HARRIS ED, 1983, J RHEUMATOL, V10, P713; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; JASANI MK, 1968, ANN RHEUM DIS, V27, P457, DOI 10.1136/ard.27.5.457; JICK H, 1965, LANCET, V2, P1203; JICK H, 1966, NEW ENGL J MED, V275, P1399, DOI 10.1056/NEJM196612222752502; *JOINT COMM MED RE, 1954, BMJ-BRIT MED J, V1, P1223; *JOINT COMM MED RE, 1960, ANN RHEUM DIS, V19, P331; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; KVIEN TK, 1982, J RHEUMATOL, V9, P696; LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003-4819-119-10-199311150-00001; Lee P, 1973, Scand J Rheumatol, V2, P71; LEE P, 1973, BMJ-BRIT MED J, V2, P685, DOI 10.1136/bmj.2.5868.685; LEE P, 1976, J RHEUMATOL, V3, P283; LEE P, 1974, SCAND J RHEUMATOL, V3, P17, DOI 10.3109/03009747409165124; MCDOUGALL R, 1994, J RHEUMATOL, V21, P1207; MILLION R, 1984, LANCET, V1, P812; MULROW CD, 1996, COCHRANE COLLABORATI; MURTHY MHV, 1978, RHEUMATOL REHABIL, V17, P8, DOI 10.1093/rheumatology/17.1.8; Saag KG, 1996, ARTHRITIS RHEUM-US, V39, P1818, DOI 10.1002/art.1780391107; SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002-9343(94)90131-7; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SCHOGER GA, 1968, ARZNEI-FORSCHUNG, V18, P758; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIEGMETH W, 1974, WIEN MED WOCHENSCHR, V124, P569; Slonim R R, 1969, J Fla Med Assoc, V56, P336; STENBERG VI, 1992, INT J CLIN PHARM RES, V12, P11; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; STUCK AE, 1989, REV INFECT DIS, V11, P954; VANGESTEL AM, 1995, BRIT J RHEUMATOL, V34, P347; WEBB J, 1973, Scandinavian Journal of Rheumatology, V2, P127; WEISS MM, 1989, SEMIN ARTHRITIS RHEU, V19, P9, DOI 10.1016/0049-0172(89)90083-8; West HF, 1967, ABSTR WORLD MED, V41, P401; Zuckner J, 1969, Mo Med, V66, P649	57	74	80	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					811	818		10.1136/bmj.316.7134.811	http://dx.doi.org/10.1136/bmj.316.7134.811			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549450	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072584300025
J	Cutts, FT; Steinglass, R				Cutts, FT; Steinglass, R			Should measles be eradicated?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES; IMMUNIZATION; VACCINE		Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Basic Support Institutionalising Child Survival, Arlington, VA 22209 USA	University of London; London School of Hygiene & Tropical Medicine	Cutts, FT (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	fcutts@lshtm.ac.uk						AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; AABY P, 1986, INT J EPIDEMIOL, V15, P101, DOI 10.1093/ije/15.1.101; AYLWARD B, 1995, B WORLD HEALTH ORGAN, V73, P531; CUTTS FT, 1994, J INFECT DIS, V170, pS32, DOI 10.1093/infdis/170.Supplement_1.S32; CUTTS FT, 1994, B WORLD HEALTH ORGAN, V72, P227; Cutts FT, 1997, BIOLOGICALS, V25, P323, DOI 10.1006/biol.1997.0103; CUTTS FT, 1991, B WORLD HEALTH ORGAN, V69, P1; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; *EXP PROGR IMM, 1996, WEEKLY EPIDEMIOL REC, V26, P201; *EXP PROGR IMM, 1996, WKLY EPIDEMIOL REC, V71, P305; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; GAY NJ, 1995, EPIDEMIOL INFECT, V115, P139, DOI 10.1017/S0950268800058209; *GLOB PROGR VACC I, 1996, PROGR VACC RES DEV P; HOPKINS DR, 1982, LANCET, V1, P1396; LOUTAN L, 1992, B WORLD HEALTH ORGAN, V70, P741; MCLEAN AR, 1995, LANCET, V345, P272, DOI 10.1016/S0140-6736(95)90272-4; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170; MULHOLLAND K, 1995, LANCET, V345, P305, DOI 10.1016/S0140-6736(95)90282-1; Nelson EAS, 1996, LANCET, V348, P1642, DOI 10.1016/S0140-6736(96)06389-1; STEINGLASS R, 1995, B WORLD HEALTH ORGAN, V73, P57; Taylor CE, 1997, AM J PUBLIC HEALTH, V87, P922, DOI 10.2105/AJPH.87.6.922; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; World Health Organization, 1996, STAT WORLDS VACC IMM, P1	23	13	13	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					765	767		10.1136/bmj.316.7133.765	http://dx.doi.org/10.1136/bmj.316.7133.765			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529417	Green Published			2022-12-28	WOS:000072463700042
J	White, RH; Zhou, H; Romano, PS				White, RH; Zhou, H; Romano, PS			Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California	ANNALS OF INTERNAL MEDICINE			English	Article							EPIDEMIOLOGY; COAGULATION	Background: Few studies have compared the incidence of deep venous thrombosis among ethnic groups. Objective: To determine the incidence of deep venous thrombosis among ethnic groups. Design: Analysis of the linked California Patient Discharge Data Set from 1991 to 1994. Setting: California. Patients: 17 991 patients with idiopathic deep venous thrombosis (thrombosis without cancer or hospitalization within preceding 6 months) and 5573 patients with secondary thromboembolism (thromboembolism occurring within 3 months of seven different events). Measurements: Ethnicity was determined by using race as documented in the data set. For idiopathic deep venous thrombosis, standardized age- and sex-adjusted incidences were calculated. For secondary thromboembolism, proportional hazards modeling was done. Results: The annual incidence of idiopathic deep venous thrombosis per 1 000 000 persons older than 18 years of age was 230 for white persons, 293 for African Americans (rate ratio, 1.27 [95% CI, 1.07 to 1.51]), 139 for Hispanic persons (rate ratio, 0.60 [CI, 0.54 to 0.67]), and 60 for Asians and Pacific Islanders (rate ratio, 0.26 [CI, 0.22 to 0.30]). Compared with white persons, Asians and Pacific Islanders who developed secondary thromboembolism had a significantly lower relative risk (range, 0.22 to 0.61) for all seven conditions analyzed. Conclusions: Compared with white persons, Asians and Pacific Islanders have a very low incidence of idiopathic deep venous thrombosis and a very low relative risk for secondary venous thromboembolism.	Univ Calif Davis, Sacramento, CA 95817 USA	University of California System; University of California Davis	White, RH (corresponding author), Primary Care Ctr, Room 3107,2221 Stockton Blvd, Sacramento, CA 95817 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979				ATICHARTAKARN V, 1988, ARCH INTERN MED, V148, P1349, DOI 10.1001/archinte.148.6.1349; *CENS BUR, 1992, 1990 CENS POP HOUS; CUNNINGHAM IG, 1974, BRIT J SURG, V61, P482, DOI 10.1002/bjs.1800610616; DUTHIE SJ, 1989, BRIT J OBSTET GYNAEC, V96, P4, DOI 10.1111/j.1471-0528.1989.tb01568.x; INADA K, 1983, AM J SURG, V145, P775, DOI 10.1016/0002-9610(83)90138-1; KATZ MH, 1993, J GEN INTERN MED, V8, P702, DOI 10.1007/BF02598295; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Lauderdale DS, 1996, AM J PUBLIC HEALTH, V86, P712, DOI 10.2105/AJPH.86.5.712; MEUX EF, 1990, EVALUATION RELIABILI; NANDI P, 1980, BRIT J SURG, V67, P251, DOI 10.1002/bjs.1800670407; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; ROTHMAN K, 1986, MODERN EPIDEMIOLOGY, P211; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; TSO SC, 1980, BRIT J HAEMATOL, V46, P603, DOI 10.1111/j.1365-2141.1980.tb06018.x	18	272	279	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					737	740		10.7326/0003-4819-128-9-199805010-00006	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556467				2022-12-28	WOS:000073363800005
J	Eccles, M; Freemantle, N; Mason, J				Eccles, M; Freemantle, N; Mason, J		N England Aspirin Gideline Dev Grp	North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; LOW-DOSE ASPIRIN; DOUBLE-BLIND TRIAL; CANADIAN AMERICAN TICLOPIDINE; ARTERIAL OCCLUSIVE DISEASE; STABLE ANGINA-PECTORIS; INTERMITTENT CLAUDICATION; ACETYLSALICYLIC-ACID; CEREBRAL-ISCHEMIA; UNSTABLE ANGINA		Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Martin.Eccles@ncl.ac.uk	Mason, James M/D-9904-2011; Eccles, Martin P/AAD-4029-2020; Jansen, Shirley/AAU-3889-2021	Mason, James M/0000-0001-9210-4082; Jansen, Shirley/0000-0001-7781-4748; Freemantle, Nick/0000-0001-5807-5740				ACHESON J, 1972, ATHEROSCLEROSIS, V15, P123, DOI 10.1016/0021-9150(72)90045-7; ACHESON J, 1969, BMJ-BRIT MED J, V1, P614, DOI 10.1136/bmj.1.5644.614; Adriaensen H, 1976, Curr Med Res Opin, V4, P395, DOI 10.1185/03007997609111994; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1987, Lancet, V2, P1351; [Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1987, Eur Heart J, V8, P634; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1976, J CHRON DIS, V29, P625; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1980, JAMA, V243, P661; ARCAN JC, 1988, ANGIOLOGY, V39, P802, DOI 10.1177/000331978803900904; *ASP MYOC INF STUD, 1980, CIRCULATION S5, V62, P79; AUKLAND A, 1982, J CLIN PATHOL, V35, P740, DOI 10.1136/jcp.35.7.740; BAIGENT C, 1993, CIRCULATION, V88, P291; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BALSANO F, 1993, CIRCULATION, V87, P1563, DOI 10.1161/01.CIR.87.5.1563; BALSANO F, 1989, J LAB CLIN MED, V114, P84; BAUDOIN C, 1989, DIABETES, V38, P491; BECKER MC, 1967, J NEWARK BETH ISRAEL, V18, P88; *BELG TICL RET STU, 1992, OPHTHALMOLOGICA, V204, P4; BERGLUND U, 1985, THROMB HAEMOSTASIS, V54, P808; BERGLUND U, 1987, EUR HEART J, V8, P25, DOI 10.1093/oxfordjournals.eurheartj.a062155; BLAKELY JA, 1979, P 7 INT C THROMB HAE, P161; BOURDE C, 1981, THROMB HAEMOSTASIS, V46, P91; BOURDE C, 1982, JMM, V4, P31; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOUSSER MG, 1983, PRESSE MED, V12, P3049; BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; BREDDIN K, 1980, CIRCULATION, V62, P63; *BRIT MED ASS ROYA, 1996, BRIT NAT FORM, V32; BRITTON M C H, 1987, Stroke, V18, P325; BROCHIER ML, 1993, EUR HEART J, V14, P951, DOI 10.1093/eurheartj/14.7.951; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; CHESEBRO JH, 1989, CIRCULATION S2, V80, P266; CLOAREC M, 1986, THROMB RES, P160; COLWELL JA, 1986, DIABETES CARE, V9, P140, DOI 10.2337/diacare.9.2.140; COLWELL JA, 1984, CONTROL CLIN TRIALS, V5, P165, DOI 10.1016/0197-2456(84)90122-3; *COR DRUG PROJ RES, 1980, CIRCULATION S5, V62, P59; *COR DRUG PROJ RES, 1973, CIRCULATION S1, V47, P149; DESTORS JM, 1985, THERAPIE, V40, P451; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; ELLIS DJ, 1986, P INT COMM THROMB HA, V63, P60; ELWOOD P, 1981, BRIT MED J, V282, P481, DOI 10.1136/bmj.282.6262.481; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; ELWOOD PC, 1980, CIRCULATION, V62, P53; *ESPS GROUP, 1990, STROKE, V21, P122; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; GAWEL M, 1982, ADV STROKE THERAPY, P158; GENT AE, 1968, BRIT MED J, V4, P366, DOI 10.1136/bmj.4.5627.366; GENT M, 1985, STROKE, V16, P416, DOI 10.1161/01.STR.16.3.416; GENT M, 1980, CIRCULATION, V62, P97; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GENT M, 1988, STROKE, V19, P1203, DOI 10.1161/01.STR.19.10.1203; GENTILE R, 1986, P 10 WORLD C CARD 19, P302; GUIRAUDCHAUMEIL B, 1982, REV NEUROL, V138, P367; HESS H, 1985, LANCET, V1, P415; HESS H, 1975, P COLFARIT S, V3, P80; HOLM J, 1984, VASA-J VASCULAR DIS, V13, P175; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; JONES EW, 1985, THESIS U NOTTINGHAM; JONES NAG, 1982, BRIT J SURG, V69, P38, DOI 10.1002/bjs.1800690113; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KATSUMURA T, 1982, ANGIOLOGY, V33, P357, DOI 10.1177/000331978203300601; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KNUDSEN JB, 1985, THROMB HAEMOSTASIS, V53, P332; KRAUSE D, 1983, 0016170 SAN WINTHR; KROL WF, 1980, CIRCULATION, V62, P449; KUPPER AJF, 1989, AM J CARDIOL, V63, P917, DOI 10.1016/0002-9149(89)90139-2; KUPPER AJF, 1986, P 10 WORLD C CARD WA, P419; LEMAK NA, 1986, NEUROLOGY, V36, P705; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LEWIS HD, 1985, CIRCULATION, V72, P155; MCCORMICK A, 1995, MORBIDITY STAT GEN P; Mirouze J, 1984, Agents Actions Suppl, V15, P230; Moher M, 1996, BRIT J GEN PRACT, V46, P367; *N ENGL EV BAS GUI, 1997, EV BAS GUID US ASP S; NYBERG G, 1984, CLIN NEPHROL, V21, P184; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; OAKLEY NW, 1983, 1050620019 SAN WINTH; PANNEBAKKER MAU, 1980, P 6 INT C MED LEAG T; *PERS ASP REINF ST, 1980, CIRCULATION S5, V62, P85; POLLI E, 1982, LANCET, V1, P237; POLLOCK A, 1979, 1050620019 SAN WINTH; Prandoni P, 1991, Minerva Cardioangiol, V39, P267; RASCOL A, 1982, ADV STROKE THERAPY, P147; RASMANIS G, 1988, LANCET, V2, P245; REUTHER R, 1980, MUNCHEN MED WOCHEN, V122, P795; REUTHER R, 1978, ACETYLSALICYLIC ACID, P97; ROBERTSON JT, 1975, THROMB DIATH HAEMOST, V34, P598; RODEN S, 1981, POSTGRAD MED J, V57, P275, DOI 10.1136/pgmj.57.667.275; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; RUSSELL RWR, 1985, 1050620051 SAN WINTH; SCHOOP W, 1984, INTERNIST, V25, P429; SCHOOP W, 1983, THROMB HAEMOSTASIS, V50, P137; SCHOOP W, 1983, THROMBOZYTENFUNKTION, P49; SCRUTINIO D, 1991, EUR HEART J, V12, P27; SHAR S, 1967, JAMA-J AM MED ASSOC, V201, P865; SHAW K, 1983, 0016241 SAN WINTHR; SHERRY S, 1982, NEW ENGL J MED, V306, P1005; SHERRY S, 1980, CIRCULATION, V62, P73; SHERRY S, 1980, NEW ENGL J MED, V302, P250; SIGNORINI GP, 1988, ANGIOLOGY, V39, P742, DOI 10.1177/000331978803900806; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; STIEGLER H, 1984, DEUT MED WOCHENSCHR, V109, P1240, DOI 10.1055/s-2008-1069356; STUART J, 1980, P 6 INT C MED LEAG T, P75; TEMPLE R, 1980, NEW ENGL J MED, V303, P1488, DOI 10.1056/NEJM198012183032534; UBERLA K, 1978, ACETYLSALICYLIC ACID, P159; *UN PHARM CLIN, 1987, ALDUSA PIL STUD REP; VERHAEGHE R, 1981, J CARDIOVASC PHARM, V3, P279, DOI 10.1097/00005344-198103000-00006; VERHEUGT FWA, 1988, AM J CARDIOL, V61, P904, DOI 10.1016/0002-9149(88)90368-2; VERHEUGT FWA, 1990, AM J CARDIOL, V66, P267, DOI 10.1016/0002-9149(90)90833-M; Vogel G, 1979, Folia Haematol Int Mag Klin Morphol Blutforsch, V106, P797; VOGEL G, 1981, PROPHYLAXIS VENOUS P, P123; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; WHISNANT JP, 1980, AM HEART J, V99, P129, DOI 10.1016/0002-8703(80)90323-3; WIRECKI M, 1967, J CHRON DIS, V20, P139, DOI 10.1016/0021-9681(67)90048-3	124	62	63	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1998	316	7140					1303	1309		10.1136/bmj.316.7140.1303	http://dx.doi.org/10.1136/bmj.316.7140.1303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554904	Green Published			2022-12-28	WOS:000073335900029
J	Akhter, SA; Luttrell, LM; Rockman, HA; Iaccarino, G; Lefkowitz, RJ; Koch, WJ				Akhter, SA; Luttrell, LM; Rockman, HA; Iaccarino, G; Lefkowitz, RJ; Koch, WJ			Targeting the receptor-G(q) interface to inhibit in vivo pressure overload myocardial hypertrophy	SCIENCE			English	Article							CARDIAC GENE-EXPRESSION; VENTRICULAR MYOCYTES; PATHWAYS MEDIATE; MICE; CARDIOMYOCYTES; INDUCTION; MECHANISM; KINASE	Hormones and neurotransmitters may mediate common responses through receptors that couple to the same class of heterotrimeric guanine nucleotide-binding (G) protein. For example, several receptors that couple to G(q) class proteins can induce cardiomyocyte hypertrophy. Class-specific inhibition of G(q)-mediated signaling was produced in the hearts of transgenic mice by targeted expression of a carboxyl-terminal peptide of the alpha subunit G alpha(q). When pressure overload was surgically induced, the transgenic mice developed significantly less ventricular hypertrophy than control animals. The data demonstrate the role of myocardial G(q) in the initiation of myocardial hypertrophy and indicate a possible strategy for preventing pathophysiological signaling by simultaneously blocking multiple receptors coupled to G(q).	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ N Carolina, Dept Med Cardiol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.	koch0002@mc.duke.edu	Lefkowitz, Robert/AAW-2649-2021; IACCARINO, Guido/A-7702-2010; Iaccarino, Guido/D-4540-2009	IACCARINO, Guido/0000-0002-8997-835X; Iaccarino, Guido/0000-0002-8997-835X; Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL-16037, HL-09436, HL-03041] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, K08HL003041, R37HL016037, F32HL009436] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHTER SA, UNPUB; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023	22	381	394	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					574	577		10.1126/science.280.5363.574	http://dx.doi.org/10.1126/science.280.5363.574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554846				2022-12-28	WOS:000073242100043
J	Stahle, DW; Cleaveland, MK; Blanton, DB; Therrell, MD; Gay, DA				Stahle, DW; Cleaveland, MK; Blanton, DB; Therrell, MD; Gay, DA			The Lost Colony and Jamestown droughts	SCIENCE			English	Article								Tree-ring data from Virginia indicate that the Lost Colony of Roanoke Island disappeared during the most extreme drought in 800 years (1587-1589) and that the alarming mortality and the near abandonment of Jamestown Colony occurred during the driest 7-year episode in 770 years (1606-1612), These extraordinary droughts can now be implicated in the fate of the Lost Colony and in the appalling death rate during the early occupations at Jamestown, the first permanent English settlement in America.	Univ Arkansas, Dept Geog, Tree Ring Lab, Fayetteville, AR 72701 USA; Coll William & Mary, Ctr Archaeol Res, Williamsburg, VA 23187 USA	University of Arkansas System; University of Arkansas Fayetteville; William & Mary	Stahle, DW (corresponding author), Univ Arkansas, Dept Geog, Tree Ring Lab, Fayetteville, AR 72701 USA.		Therrell, Matthew/N-8487-2016	Therrell, Matthew/0000-0002-9174-6005				*AM MET SOC, 1997, B AM METEOROL SOC, V78, P848; [Anonymous], 1976, TIME SERIES ANAL; *CLIM AN CTR, 1994, CLIM DAT 1993, P67; Cook E.R., 2013, METHODS DENDROCHRONO; Cook ER, 1997, J CLIMATE, V10, P1343, DOI 10.1175/1520-0442(1997)010<1343:ANAOPS>2.0.CO;2; Earle Carville V., 1979, CHESAPEAKE 17 CENTUR, P96; HUME IN, 1994, VIRGINIA ADVENTURE, P132; KARL TR, 1903, HIST CLIMATOLOGY SER; KUPPERMAN KO, 1979, J AM HIST, V66, P24, DOI 10.2307/1894672; LEWIS C, 1953, SPANISH JESUIT MISSI, P1570; Morgan Edmund S., 1975, AM SLAVERY AM FREEDO; Palmer W. C., 1965, 45 US DEP COMM WEATH; PRUGH BJ, 1992, VA911 US GEOL SURV; Quinn David, 1985, SET FAIR ROANOKE; *ROWM LITTL, 1990, SETTLING INDIANS; *ROWM LITTL, 1984, ROANOKE ABANDONED CO; STAHLE DW, 1992, B AM METEOROL SOC, V73, P1947, DOI 10.1175/1520-0477(1992)073<1947:RAAOSR>2.0.CO;2; STAHLE DW, 1988, SCIENCE, V240, P1517, DOI 10.1126/science.240.4858.1517; Stick David, 1983, ROANOKE ISLAND BEGIN; Stokes M.A., 1996, INTRO TREE RING DATI	20	149	161	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					564	567		10.1126/science.280.5363.564	http://dx.doi.org/10.1126/science.280.5363.564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554842				2022-12-28	WOS:000073242100039
J	Khaselev, O; Turner, JA				Khaselev, O; Turner, JA			A monolithic photovoltaic-photoelectrochemical device for hydrogen production via water splitting	SCIENCE			English	Article							TANDEM SOLAR-CELLS; SEMICONDUCTING PHOTOELECTRODES; EFFICIENCY; OXYGEN	Direct water electrolysis was achieved with a novel, integrated, monolithic photoelectrochemical-photovoltaic design. This photoelectrochemical cell, which is voltage biased with an integrated photovoltaic device, splits water directly upon illumination; light is the only energy input. The hydrogen production efficiency of this system, based on the short-circuit current and the lower heating value of hydrogen, is 12.4 percent.	Natl Renewable Energy Lab, Golden, CO 80401 USA	United States Department of Energy (DOE); National Renewable Energy Laboratory - USA	Turner, JA (corresponding author), Natl Renewable Energy Lab, 1617 Cole Blvd, Golden, CO 80401 USA.	jturner@nrel.gov						AHARONSHALOM E, 1982, J ELECTROCHEM SOC, V129, P2865, DOI 10.1149/1.2123695; Augustynski J., 1996, P 11 WORLD HYDR EN C, P2378; BARD AJ, 1995, ACCOUNTS CHEM RES, V28, P141, DOI 10.1021/ar00051a007; BERTNESS KA, 1994, APPL PHYS LETT, V65, P989, DOI 10.1063/1.112171; BERTNESS KA, 1994, AIP C P, V306, P100; Bogdanoff P, 1998, J ELECTROCHEM SOC, V145, P576, DOI 10.1149/1.1838306; Bolton JR, 1996, SOL ENERGY, V57, P37, DOI 10.1016/0038-092X(96)00032-1; BOLTON JR, 1985, NATURE, V316, P495, DOI 10.1038/316495a0; Gerischer H., 1979, Solar energy conversion. Solid-state physics aspects, P115; HELLER A, 1984, SCIENCE, V223, P1141, DOI 10.1126/science.223.4641.1141; KAINTHLA RC, 1987, J ELECTROCHEM SOC, V134, P841, DOI 10.1149/1.2100583; KHASELEV O, UNPUB; KOCHA S, IN PRESS SOL ENERGY; Kocha S., 1991, J ELECTROANAL CHEM, V367, P27; KOCHA SS, 1995, J ELECTROCHEM SOC, V142, P2625, DOI 10.1149/1.2050065; KURTZ SR, 1990, J APPL PHYS, V68, P1890, DOI 10.1063/1.347177; LIN GH, 1989, APPL PHYS LETT, V55, P386, DOI 10.1063/1.101879; NOZIK AJ, 1976, APPL PHYS LETT, V29, P150, DOI 10.1063/1.89004; SAKAI Y, 1988, CAN J CHEM, V66, P1853, DOI 10.1139/v88-299; SHAKHNAZARYAN GE, 1994, RUSS J ELECTROCHEM+, V30, P610; WEBER MF, 1986, INT J HYDROGEN ENERG, V11, P225, DOI 10.1016/0360-3199(86)90183-7; WEBER MF, 1984, J ELECTROCHEM SOC, V131, P1258, DOI 10.1149/1.2115797; YONEYAMA H, 1975, ELECTROCHIM ACTA, V20, P341, DOI 10.1016/0013-4686(75)90016-X	23	1803	1836	27	979	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					425	427		10.1126/science.280.5362.425	http://dx.doi.org/10.1126/science.280.5362.425			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545218				2022-12-28	WOS:000073159600044
J	Krivit, W; Shapiro, EG; Peters, C; Wagner, JE; Cornu, G; Kurtzberg, J; Wenger, DA; Kolodny, EH; Vanier, MT; Loes, DJ; Dusenbery, K; Lockman, LA				Krivit, W; Shapiro, EG; Peters, C; Wagner, JE; Cornu, G; Kurtzberg, J; Wenger, DA; Kolodny, EH; Vanier, MT; Loes, DJ; Dusenbery, K; Lockman, LA			Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; GENETIC DEMYELINATING DISEASE; STORAGE DISEASES; METACHROMATIC LEUKODYSTROPHY; NEUROLOGICAL DISORDERS; CEREBROSPINAL-FLUID; TWITCHER MOUSE; IGG ANALYSES; ADRENOLEUKODYSTROPHY; PRINCIPLES	Background Globoid-cell leukodystrophy is caused by a deficiency of galactocerebrosidase, which results in progressive central nervous system deterioration. We investigated whether allogeneic hematopoietic stem-cell transplantation can provide a source of leukocyte galactocerebrosidase and thereby prevent the decline of central nervous system function in patients with the disease. Methods Five children with globoid-cell leukodystrophy (one with the infantile type and four with late-onset disease) were treated with allogeneic hematopoietic stem-cell transplantation. Measurement of leukocyte galactocerebrosidase levels, neurologic examinations, neuropsychological tests, magnetic resonance imaging of the central nervous system, cerebrospinal fluid protein assays, and neurophysiologic measurements were performed before and after transplantation, with follow-up ranging from one to nine years. Results Engraftment of donor-derived hematopoietic cells occurred in all patients and was followed by restoration of normal leukocyte galactocerebrosidase levels. In the four patients with late-onset disease, the central nervous system deterioration was reversed, and in the patient with the infantile form of the disease, signs and symptoms have not appeared. Magnetic resonance imaging showed a decrease in signal intensity in the three patients with late-onset disease who were assessed both before and after transplantation. Abnormalities in cerebro spinal fluid total protein levels were corrected in three patients with late-onset disease and substantially reduced in the patient with the infantile form. Conclusions Central nervous system manifestations of globoid-cell leukodystrophy can be reversed by allogeneic hematopoietic stem-cell transplantation. (C) 1998, Massachusetts Medical Society.	Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Therapeut Radiol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Radiol, Minneapolis, MN 55455 USA; Univ Catholique Louvain, B-1200 Brussels, Belgium; Duke Univ, Sch Med, Durham, NC USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; NYU, Sch Med, New York, NY USA; Lyon Sud Sch Med, INSERM, U189, Lyons, France	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Universite Catholique Louvain; Duke University; Jefferson University; New York University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Krivit, W (corresponding author), Univ Minnesota Hosp & Clin, Box 477,Rm D-548,Mayo Bldg,420 Delaware St SE, Minneapolis, MN 55455 USA.				NIDDK NIH HHS [DK-38795] Funding Source: Medline; NINDS NIH HHS [NS-29099] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038795, R55DK038795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029099] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER RH, 1990, OPHTHALMOLOGY, V97, P1176; Bambach BJ, 1997, BONE MARROW TRANSPL, V19, P399, DOI 10.1038/sj.bmt.1700665; BENTZ JS, 1995, LAB MED, V26, P393, DOI 10.1093/labmed/26.6.393; CHEN YQ, 1993, HUM MOL GENET, V2, P1841, DOI 10.1093/hmg/2.11.1841; CHOI KG, 1991, J NEUROPATH EXP NEUR, V50, P336; CHRISTENSON RH, 1983, CLIN CHEM, V29, P1028; DeGasperi R, 1996, AM J HUM GENET, V59, P1233; DHUNA A, 1992, ARCH NEUROL-CHICAGO, V49, P1088, DOI 10.1001/archneur.1992.00530340114026; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; HAGBERG B, 1969, Neuropaediatrie, V1, P74, DOI 10.1055/s-0028-1091865; HOOGERBRUGGE PM, 1995, LANCET, V345, P1398, DOI 10.1016/S0140-6736(95)92597-X; KOLODNY EH, 1991, DEV NEUROSCI-BASEL, V13, P232, DOI 10.1159/000112166; KOLODNY EH, 1996, HDB CLIN NEUROLOGY, V66, P187; KRIVIT W, 1995, J INHERIT METAB DIS, V18, P398, DOI 10.1007/BF00710052; KRIVIT W, 1995, CELL TRANSPLANT, V4, P385, DOI 10.1016/0963-6897(95)00021-O; KRIVIT W, 1996, HDB CLIN NEUROLOGY, V66, P87; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; LOES DJ, 1994, AM J NEURORADIOL, V15, P1761; OHNO M, 1993, BRAIN RES, V602, P268, DOI 10.1016/0006-8993(93)90692-G; PETERS C, 1997, CORRECTION GENETIC D, V4, P12; PETERS C, 1997, 2 INT M UT STEM CELL; PHELPS M, 1991, J NEUROL NEUROSUR PS, V54, P293, DOI 10.1136/jnnp.54.4.293; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; SUZUKI K, 1995, MICROSC RES TECHNIQ, V32, P204, DOI 10.1002/jemt.1070320304; SUZUKI K, 1994, J NEUROPATH EXP NEUR, V53, P359, DOI 10.1097/00005072-199407000-00006; SUZUKI K, 1995, METABOLIC MOL BASES, V2, P2671; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; UNGER ER, 1993, J NEUROPATH EXP NEUR, V52, P460, DOI 10.1097/00005072-199309000-00004; VERDRU P, 1991, NEUROLOGY, V41, P1382, DOI 10.1212/WNL.41.9.1382; WAGNER J, 1996, BLOOD S1, V88, P267; Wagner JE, 1996, BLOOD, V88, P795; Wenger D.A., 1997, MOL GENETIC BASIS NE, P421	34	214	222	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1119	1126		10.1056/NEJM199804163381605	http://dx.doi.org/10.1056/NEJM199804163381605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545360				2022-12-28	WOS:000073070100005
J	Helms, C				Helms, C			Remembering Jinx	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1168	1168		10.1001/jama.279.15.1168-a	http://dx.doi.org/10.1001/jama.279.15.1168-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555743				2022-12-28	WOS:000072969400013
J	Herrada, J; Cabanillas, F; Rice, L; Manning, J; Pugh, W				Herrada, J; Cabanillas, F; Rice, L; Manning, J; Pugh, W			The clinical behavior of localized and multicentric Castleman disease	ANNALS OF INTERNAL MEDICINE			English	Review							LYMPH-NODE HYPERPLASIA; SYSTEMIC MANIFESTATIONS; KAPOSIS SARCOMA; POEMS SYNDROME; INTERLEUKIN-6; EXPRESSION; RADIOTHERAPY	Background: Castleman disease, an unusual condition of unknown cause consisting of a massive proliferation of lymphoid tissue, remains a clinicopathologic diagnosis. Three histologic variants (hyaline vascular, plasma-cell, and mixed) and two clinical types (localized and multicentric) of Castleman disease have been described. Objective: To analyze the clinical features, management, and outcome of patients with Castleman disease. Design: Case series. Setting: University referral hospitals. Patients: All patients with Castleman disease who were seen at Texas Medical Center, Houston, Texas, between 1977 and 1995. Interventions: Surgical excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric disease. Measurements: Patients were identified according to initial presentation as having localized or multicentric Castleman disease. Patients within each group were further subdivided according to whether they had hyaline vascular, plasma-cell, or mixed disease. Results: Data from 15 patients were analyzed. All 7 patients with localized disease underwent surgical excision and remain free of disease. The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma. Conclusions: Localized and multicentric Castleman disease are different clinical disorders with overlapping histologic features. Localized disease can be cured with surgery, but complete remissions in patients with multicentric disease have been achieved only with chemotherapy or prednisone given at the time of diagnosis.	Univ Texas, Md Anderson Canc Ctr, Dept Hematol, Lymphoma Sect,Baylor Coll Med, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Cabanillas, F (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Hematol, Lymphoma Sect,Baylor Coll Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Cabanillas, Fernando/0000-0001-9234-7893				AISENBERG AC, 1991, MALIGNANT LYMPHOMA B, P11; BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BARTOLI E, 1980, AM J CLIN PATHOL, V73, P423; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CASTLEMAN B, 1956, CANCER, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4; CHAN TM, 1993, NEPHRON, V65, P628, DOI 10.1159/000187576; CROS D, 1990, NEW ENGL J MED, V323, P895; FEIGERT JM, 1990, ANN INTERN MED, V113, P362, DOI 10.7326/0003-4819-113-5-362; Flendrig JA, 1969, FOLIA MED NEERD, V12, P119; FRIZZERA G, 1985, J CLIN ONCOL, V3, P1202, DOI 10.1200/JCO.1985.3.9.1202; FRIZZERA G, 1988, SEMIN DIAGN PATHOL, V5, P346; FRIZZERA G, 1992, NEOPLASTIC HEMATOPAT, P454; GABA AR, 1978, AM J CLIN PATHOL, V69, P86; GILI A, 1991, J AM ACAD DERMATOL, V25, P955, DOI 10.1016/0190-9622(91)70293-B; HANCHARD B, 1987, W INDIAN MED J, V36, P104; HSU SM, 1993, HUM PATHOL, V24, P833, DOI 10.1016/0046-8177(93)90132-Z; KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#; KESSLER E, 1985, CANCER-AM CANCER SOC, V56, P2446, DOI 10.1002/1097-0142(19851115)56:10<2446::AID-CNCR2820561020>3.0.CO;2-4; LACHANT NA, 1985, AM J CLIN PATHOL, V83, P27, DOI 10.1093/ajcp/83.1.27; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LOTZ M, 1993, CANCER INVEST, V11, P732, DOI 10.3109/07357909309046948; MARTI S, 1983, CANCER, V51, P808, DOI 10.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-5; MARTIN JME, 1985, AM J CLIN PATHOL, V84, P439, DOI 10.1093/ajcp/84.4.439; MUNOZ G, 1990, HISTOPATHOLOGY, V17, P172, DOI 10.1111/j.1365-2559.1990.tb00692.x; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; NORDSTROM DG, 1978, INT J RADIAT ONCOL, V4, P1045, DOI 10.1016/0360-3016(78)90019-6; ORDI J, 1993, AM J CLIN PATHOL, V100, P394, DOI 10.1093/ajcp/100.4.394; PAVLIDIS NA, 1990, MED PEDIATR ONCOL, V18, P333, DOI 10.1002/mpo.2950180416; PAVLIDIS NA, 1992, ANN ONCOL, V3, P85, DOI 10.1093/oxfordjournals.annonc.a058082; PETERSON BA, 1993, SEMIN ONCOL, V20, P636; REPETTO L, 1986, HEMATOL ONCOL, V4, P213, DOI 10.1002/hon.2900040305; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STEINBERG D, 1992, NEW ENGL J MED, V327, P1014; SUMMERFIELD GP, 1983, J CLIN PATHOL, V36, P1005, DOI 10.1136/jcp.36.9.1005; Ushio T, 1994, Nihon Kyobu Shikkan Gakkai Zasshi, V32, P1175; WEISENBURGER DD, 1985, HUM PATHOL, V16, P162, DOI 10.1016/S0046-8177(85)80065-4; WEISENBURGER DD, 1979, CANCER, V44, P457, DOI 10.1002/1097-0142(197908)44:2<457::AID-CNCR2820440212>3.0.CO;2-4; YOSHIZAKI K, 1989, BLOOD, V74, P1360	39	298	324	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					657	662		10.7326/0003-4819-128-8-199804150-00010	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537940				2022-12-28	WOS:000073052500007
J	Kearon, C; Julian, JA; Newman, TE; Ginsberg, JS				Kearon, C; Julian, JA; Newman, TE; Ginsberg, JS		McMaster Diagnostic Imaging Practice Guideline	Noninvasive diagnosis of deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Review							B-MODE ULTRASONOGRAPHY; TIME COMPRESSION ULTRASONOGRAPHY; SERIAL IMPEDANCE PLETHYSMOGRAPHY; CLINICAL-PRACTICE GUIDELINES; COLOR DOPPLER ULTRASOUND; PROXIMAL-VEIN THROMBOSIS; HIP-SURGERY; MEDICAL LITERATURE; USERS GUIDES; D-DIMER	Purpose: To review noninvasive methods for diagnosis of first and recurrent deep venous thrombosis and provide evidence-based recommendations for the diagnosis of deep venous thrombosis in symptomatic, asymptomatic, and pregnant patients. Data Sources: Accuracy (comparison with contrast venography) and management (safety of withholding anticoagulants when results were normal) studies that evaluated tests for diagnosis of deep venous thrombosis were identified from a MEDLINE search, personal files, and bibliographies of reviews and original studies. Study Selection: Prospective cohort studies (accuracy and management studies) and randomized comparisons (management studies) that satisfied predefined methodologic criteria were included. Data Extraction: Sensitivity, specificity, and positive and negative predictive values were determined for accuracy studies. Rates of venous thromboembolism during longterm follow-up of patients with normal results were determined for management studies. Data Synthesis: Data from individual studies were combined under a random-effects model. The accuracy of noninvasive tests was compared, with emphasis on within-study comparisons. Recommendations for diagnosis of deep venous thrombosis were developed by a multidisciplinary group and graded according to the strength of the supporting evidence. Venous ultrasonography is the most accurate noninvasive test for the diagnosis of a first symptomatic proximal deep venous thrombosis. However, neither ultrasonography nor impedance plethysmography is accurate in asymptomatic postoperative patients. Venous ultrasonography is less accurate for symptomatic isolated distal (calf) deep venous thrombosis than for proximal deep venous thrombosis, and the clinical utility of venous ultrasonography of the distal veins is uncertain. Withholding anticoagulant therapy in symptomatic patients with suspected deep venous thrombosis who have normal results on serial venous ultrasonography or impedance plethysmography is safe. Diagnosis of recurrent deep venous thrombosis requires evidence of new thrombus formation, such as a new noncompressible venous segment detected by venous ultrasonography, conversion of a normal result on impedance plethysmography to abnormal, or presence of an intraluminal filling defect on venography. Suspected deep venous thrombosis in pregnant patients can usually be managed with serial venous ultrasonography or impedance plethysmography. In symptomatic patients with a suspected first episode of deep venous thrombosis, clinical assessment and D-dimer testing are complementary to testing with venous ultrasonography and impedance plethysmography. Conclusions: Patients with suspected deep venous thrombosis can usually be managed with noninvasive testing. However, if the results of this testing are nondiagnostic or are discordant with the clinical assessment, venography should be considered.	Henderson Gen Hosp, McMaster Med Unit, Hamilton, ON L8V 1C3, Canada	McMaster University	Kearon, C (corresponding author), Henderson Gen Hosp, McMaster Med Unit, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		ginsberg, jeffrey s/ABC-1065-2020					AGNELLI G, 1995, THROMB HAEMOSTASIS, V74, P1042; AGNELLI G, 1990, ANGIOLOGY, V41, P559, DOI 10.1177/000331979004100709; AGNELLI G, 1993, THROMB HAEMOSTASIS, V70, P266; AGNELLI G, 1991, ARCH INTERN MED, V151, P2167, DOI 10.1001/archinte.151.11.2167; AGNELLI G, 1992, THROMB HAEMOSTASIS, V68, P257; ALPERT JS, 1994, PROG CARDIOVASC DIS, V36, P417, DOI 10.1016/S0033-0620(94)80050-2; ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; ARONEN HJ, 1994, ANN MED, V26, P377, DOI 10.3109/07853899409148354; Atri M, 1996, AM J ROENTGENOL, V166, P1361, DOI 10.2214/ajr.166.6.8633448; BARNES CL, 1991, CLIN ORTHOP RELAT R, V271, P180; BARNES RW, 1989, J VASC SURG, V9, P251, DOI 10.1067/mva.1989.vs0090251; BARRITT DW, 1960, LANCET, V1, P1309; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BELL WR, 1982, AM HEART J, V103, P239, DOI 10.1016/0002-8703(82)90498-7; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; Borris L C, 1990, Eur J Vasc Surg, V4, P473, DOI 10.1016/S0950-821X(05)80786-8; BORRIS LC, 1989, THROMB HAEMOSTASIS, V61, P363; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRADLEY MJ, 1993, CLIN RADIOL, V47, P399, DOI 10.1016/S0009-9260(05)81060-8; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; Burke P, 1994, J IRISH COLLEGE PHYS, V23, P105; Canadian Medical Association, 1994, GUID CAN CLIN PRACT; CARPENTER JP, 1993, J VASC SURG, V18, P734, DOI 10.1016/0741-5214(93)90325-G; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; CRIPPA L, 1995, THROMB HAEMOSTASIS, V74, P1235; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; CRUICKSHANK MK, 1989, THROMB HAEMOSTASIS, V62, P830; DALE S, 1994, THROMB HAEMOSTASIS, V71, P270; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DEBOER K, 1992, THROMB HAEMOSTASIS, V67, P4; DUPAS B, 1995, LANCET, V346, P17, DOI 10.1016/S0140-6736(95)92650-X; Egglin TKP, 1996, JAMA-J AM MED ASSOC, V276, P1752, DOI 10.1001/jama.276.21.1752; ELIAS A, 1987, INT ANGIOL, V6, P175; ELLIOTT CG, 1993, ANGIOLOGY, V44, P26, DOI 10.1177/000331979304400105; EVANS AJ, 1993, AM J ROENTGENOL, V161, P131, DOI 10.2214/ajr.161.1.8517292; FLINN WR, 1989, ARCH SURG-CHICAGO, V124, P901; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GINSBERG JS, 1989, THROMB HAEMOSTASIS, V61, P189; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; GINSBERG JS, 1994, ARCH INTERN MED, V154, P1930, DOI 10.1001/archinte.154.17.1930; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; GUYATT GH, 1986, CAN MED ASSOC J, V134, P587; HAYNES RB, 1981, CAN MED ASSOC J, V124, P703; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, ARCH INTERN MED, V152, P1901, DOI 10.1001/archinte.152.9.1901; HEIJBOER H, 1992, ACTA RADIOL, V33, P297; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HUISMAN MV, 1988, ARCH INTERN MED, V148, P681, DOI 10.1001/archinte.148.3.681; HULL R, 1979, THROMB RES, V15, P227, DOI 10.1016/0049-3848(79)90068-9; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JAY R, 1984, THROMB RES, V36, P259, DOI 10.1016/0049-3848(84)90225-1; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; JONKER JJC, 1986, THROMB RES, V42, P681, DOI 10.1016/0049-3848(86)90346-4; KAKKAR VV, 1969, LANCET, V2, P230; KOOPMAN MMW, 1993, THROMB HAEMOSTASIS, V69, P623; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LENSING AW, 1994, HEMOSTASIS THROMBOSI; Lensing AWA, 1997, ARCH INTERN MED, V157, P765, DOI 10.1001/archinte.157.7.765; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Magnusson M, 1996, THROMB HAEMOSTASIS, V75, P242; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; MITCHELL DC, 1991, BRIT J SURG, V78, P611, DOI 10.1002/bjs.1800780528; MONREAL M, 1989, ANGIOLOGY, V40, P527, DOI 10.1177/000331978904000603; NICOLAIDES AN, 1971, BRIT J RADIOL, V44, P653, DOI 10.1259/0007-1285-44-525-653; OLEARY DH, 1988, J CLIN ULTRASOUND, V16, P1, DOI 10.1002/jcu.1870160102; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; PEARSON SD, 1995, ARCH INTERN MED, V155, P1773, DOI 10.1001/archinte.155.16.1773; PETERS SHA, 1982, THROMB HAEMOSTASIS, V48, P297; PHILBRICK JT, 1988, ARCH INTERN MED, V148, P2131, DOI 10.1001/archinte.148.10.2131; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P229; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; QUINTAVALLA R, 1992, EUR J RADIOL, V15, P32, DOI 10.1016/0720-048X(92)90199-J; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Ricotta S, 1996, THROMB HAEMOSTASIS, V76, P887; Robinson KS, 1997, ANN INTERN MED, V127, P439, DOI 10.7326/0003-4819-127-6-199709150-00004; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SANDLER DA, 1984, LANCET, V2, P716; SCHINDLER JM, 1990, BRIT MED J, V301, P1369, DOI 10.1136/bmj.301.6765.1369; SIMONS GR, 1995, AM J MED, V99, P43, DOI 10.1016/S0002-9343(99)80103-X; SLUZEWSKI M, 1991, EUR J RADIOL, V13, P174, DOI 10.1016/0720-048X(91)90023-O; STEWART JH, 1992, MAYO CLIN PROC, V67, P1186, DOI 10.1016/S0025-6196(12)61150-1; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; Villalta S, 1997, THROMB HAEMOSTASIS, V78, P588; VOGEL P, 1987, RADIOLOGY, V163, P747, DOI 10.1148/radiology.163.3.3554344; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WELLS PS, IN PRESS J INT MED; WHEELER HB, 1974, PROG CARDIOVASC DIS, V17, P199; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; WHITE RH, 1990, J BONE JOINT SURG AM, V72A, P495, DOI 10.2106/00004623-199072040-00004; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLSON ST, 1990, J BONE JOINT SURG AM, V72A, P983, DOI 10.2106/00004623-199072070-00004; WOOLSON ST, 1991, CLIN ORTHOP RELAT R, V273, P131	117	513	542	1	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					663	677		10.7326/0003-4819-128-8-199804150-00011	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00011			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537941				2022-12-28	WOS:000073052500008
J	Van Parijs, L; Abbas, AK				Van Parijs, L; Abbas, AK			Homeostasis and self-tolerance in the immune system: Turning lymphocytes off	SCIENCE			English	Article							CD4(+) T-CELLS; TRANSGENIC MICE; IN-VIVO; LYMPHOPROLIFERATIVE SYNDROME; CD28 COSTIMULATION; CLONAL EXPANSION; LIFE-SPAN; FAS; MEMORY; CTLA-4	The immune system responds in a regulated fashion to microbes and eliminates them, but it does not respond to self-antigens. Several regulatory mechanisms function to terminate responses to foreign antigens, returning the immune system to a basal state after the antigen has been cleared, and to maintain unresponsiveness, or tolerance, to self-antigens. Here, recent advances in understanding of the molecular bases and physiologic roles of the mechanisms of immune homeostasis are examined.	Brigham & Womens Hosp, Dept Pathol, Div Immunol Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Van Parijs, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025022, P01AI035297, U01AI035231, R37AI025022] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35231, AI25022, AI35297] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Bachmann MF, 1998, J IMMUNOL, V160, P95; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BONOMO A, 1995, IMMUNOL TODAY, V16, P61, DOI 10.1016/0167-5699(95)80089-1; BOYD SD, UNPUB; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; CARROLL MC, IN PRESS ANN REV IMM; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Denny P, 1997, DIABETES, V46, P695, DOI 10.2337/diabetes.46.4.695; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FREITAS AA, 1993, IMMUNOL TODAY, V14, P25, DOI 10.1016/0167-5699(93)90320-K; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Khoruts A, 1998, J EXP MED, V187, P225, DOI 10.1084/jem.187.2.225; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925; Krummel MF, 1996, INT IMMUNOL, V8, P519, DOI 10.1093/intimm/8.4.519; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mondino A, 1996, P NATL ACAD SCI USA, V93, P2245, DOI 10.1073/pnas.93.6.2245; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; REFAELI Y, UNPUB; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; Sperling AI, 1996, J IMMUNOL, V157, P3909; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Van Parijs L, 1998, IMMUNITY, V8, P265, DOI 10.1016/S1074-7613(00)80478-1; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; VanParijs L, 1997, J IMMUNOL, V158, P3738; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; WELSH RM, 1995, J CELL BIOCHEM, V59, P135, DOI 10.1002/jcb.240590202; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	74	782	801	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					243	248						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535647				2022-12-28	WOS:000073082400040
J	Ferrari, MD				Ferrari, MD			Migraine	LANCET			English	Review							FAMILIAL HEMIPLEGIC MIGRAINE; CEREBRAL BLOOD-FLOW; CLUSTER HEADACHE; ERGOT ALKALOIDS; SUBCUTANEOUS SUMATRIPTAN; GENETIC-HETEROGENEITY; TRIGEMINAL NEURONS; DIHYDROERGOTAMINE; AURA; PREVALENCE		Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Ferrari, MD (corresponding author), Leiden Univ, Med Ctr, Dept Neurol, POB 9600, NL-2300 RC Leiden, Netherlands.	mferrari@neurology.azl.nl	Ferrari, Michel D./ABE-3758-2021	Ferrari, Michel D./0000-0001-9691-9449				ABUAREFEH I, 1994, BRIT MED J, V309, P765, DOI 10.1136/bmj.309.6957.765; Bille B, 1997, CEPHALALGIA, V17, P488, DOI 10.1046/j.1468-2982.1997.1704488.x; BRESLAU N, 1996, NEUROLOGY S7, V44, pS17; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; Connor HE, 1997, CEPHALALGIA, V17, P145, DOI 10.1046/j.1468-2982.1997.1703145.x; Cumberbatch MJ, 1997, EUR J PHARMACOL, V328, P37, DOI 10.1016/S0014-2999(97)83024-5; DAHLOF C, 1993, CEPHALALGIA, V13, P166, DOI 10.1046/j.1468-2982.1993.1303166.x; DELISSOVOY G, 1994, NEUROLOGY, V44, P56; Diener H. C., 1993, P721; DIENER HC, 1997, CEPHALALGIA, V17, P477; Ducros A, 1997, ANN NEUROL, V42, P885, DOI 10.1002/ana.410420610; EKBOM K, 1991, NEW ENGL J MED, V325, P322, DOI 10.1056/nejm199108013250505; FERRARI MD, 1993, TRENDS PHARMACOL SCI, V14, P129, DOI 10.1016/0165-6147(93)90084-W; FERRARI MD, 1995, ARCH NEUROL-CHICAGO, V52, P135, DOI 10.1001/archneur.1995.00540260037013; FERRARI MD, 1993, CEPHALALGIA, V13, P151, DOI 10.1046/j.1468-2982.1993.1303151.x; Ferrari MD, 1997, HEADACHE, P117; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FRIBERG L, 1991, LANCET, V338, P13, DOI 10.1016/0140-6736(91)90005-A; GALER BS, 1991, HEADACHE, V31, P446, DOI 10.1111/j.1526-4610.1991.hed3107446.x; Gardner K, 1997, NEUROLOGY, V49, P1231, DOI 10.1212/WNL.49.5.1231; Gijsman H, 1997, CEPHALALGIA, V17, P647, DOI 10.1046/j.1468-2982.1997.1706647.x; GIJSMAN HJ, 1995, NEUROLOGY, V45, P397, DOI 10.1212/WNL.45.2.397-b; Gilkey SJ, 1996, CNS DRUGS, V6, P83, DOI 10.2165/00023210-199606020-00001; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; Goadsby PJ, 1997, BRIT J PHARMACOL, V122, P918, DOI 10.1038/sj.bjp.0701456; Goadsby PJ, 1996, PAIN, V67, P355, DOI 10.1016/0304-3959(96)03118-1; Goadsby PJ, 1998, J NEUROL NEUROSUR PS, V64, P143, DOI 10.1136/jnnp.64.2.143; Goadsby PJ, 1997, CEPHALALGIA, V17, P85, DOI 10.1046/j.1468-2982.1997.1702085.x; GOADSBY PJ, 1997, HEADACHE, P5; GRONSETH GS, 1995, NEUROLOGY, V45, P1263, DOI 10.1212/WNL.45.7.1263; Gunasekara NS, 1997, CNS DRUGS, V8, P402, DOI 10.2165/00023210-199708050-00006; HAAN J, 1996, NEUROLOGIC CLIN ADV; Hartig PR, 1996, TRENDS PHARMACOL SCI, V17, P103, DOI 10.1016/0165-6147(96)30002-3; HERING R, 1991, LANCET, V337, P1442, DOI 10.1016/0140-6736(91)93129-W; Heywood J, 1997, PHARMACOECONOMICS, V11, P11, DOI 10.2165/00019053-199700111-00004; HILLIS WS, 1993, LANCET, V341, P1564, DOI 10.1016/0140-6736(93)90700-Q; HUMPHREY PPA, 1994, CEPHALALGIA, V14, P401, DOI 10.1046/j.1468-2982.1994.1406401.x; HUMPHREY PPA, 1991, TRENDS PHARMACOL SCI, V12, P444, DOI 10.1016/0165-6147(91)90630-B; JOUTEL A, 1994, AM J HUM GENET, V55, P1166; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; KAUBE H, 1993, BRIT J PHARMACOL, V109, P788, DOI 10.1111/j.1476-5381.1993.tb13643.x; Lassen LH, 1997, LANCET, V349, P401, DOI 10.1016/S0140-6736(97)80021-9; LAURITZEN M, 1983, ANN NEUROL, V13, P633, DOI 10.1002/ana.410130609; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LIPTON RB, 1992, ARCH INTERN MED, V152, P1273, DOI 10.1001/archinte.152.6.1273; LIPTON RB, 1997, HEADACHE, P75; Longmore J, 1997, CEPHALALGIA, V17, P833, DOI 10.1046/j.1468-2982.1997.1708833.x; MACINTYRE PD, 1993, CIRCULATION, V87, P401, DOI 10.1161/01.CIR.87.2.401; MARTIN GR, 1997, HEADACHE, P25; Mathew NT, 1997, NEUROLOGY, V49, P1485, DOI 10.1212/WNL.49.6.1485; MAY A, 1995, HUM GENET, V96, P604, DOI 10.1007/BF00197420; MEIJLER WJ, 1996, CEPHALALGIA, V16, P5; MOSKOWITZ MA, 1993, CEREBROVAS BRAIN MET, V5, P159; MOSKOWITZ MA, 1992, TRENDS PHARMACOL SCI, V13, P307, DOI 10.1016/0165-6147(92)90097-P; OLESEN J, 1995, CEPHALALGIA, V15, P94, DOI 10.1046/j.1468-2982.1995.015002094.x; OLESEN J, 1995, BRIT MED J, V310, P479, DOI 10.1136/bmj.310.6978.479; OPHOFF RA, 1994, GENOMICS, V22, P21, DOI 10.1006/geno.1994.1340; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; Palmer KJ, 1997, CNS DRUGS, V7, P468, DOI 10.2165/00023210-199707060-00005; PLOSKER GL, 1994, DRUGS, V47, P622, DOI 10.2165/00003495-199447040-00006; Ramadan NM, 1997, CEPHALALGIA, V17, P73, DOI 10.1046/j.1468-2982.1997.1702073.x; Rapoport AM, 1997, NEUROLOGY, V49, P1210, DOI 10.1212/WNL.49.5.1210; RASMUSSEN BK, 1995, CEPHALALGIA, V15, P45; *REP QUAL STAND SU, 1995, NEUROLOGY, V45, P585; ROON K, 1997, CEPHALALGIA, V17, P245; Russell MB, 1996, BRAIN, V119, P355, DOI 10.1093/brain/119.2.355; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1995, BRIT MED J, V311, P541, DOI 10.1136/bmj.311.7004.541; Schoenen J, 1997, CEPHALALGIA, V17, P28, DOI 10.1177/0333102497017S1805; Schoenen J, 1997, NEUROL CLIN, V15, P85, DOI 10.1016/S0733-8619(05)70296-6; SCOTT AK, 1992, CLIN NEUROPHARMACOL, V15, P289, DOI 10.1097/00002826-199208000-00003; Shepherd SL, 1997, NEUROPHARMACOLOGY, V36, P525, DOI 10.1016/S0028-3908(97)00057-9; SILBERSTEIN SD, 1995, NEUROLOGY, V45, P577, DOI 10.1212/WNL.45.3.577; Solomon GD, 1997, NEUROLOGY, V49, P1219, DOI 10.1212/WNL.49.5.1219; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEWART WF, 1994, NEUROLOGY, V44, P24; STEWART WF, 1994, NEUROLOGY, V44, P17; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; TERWINDT GM, 1997, CEPHALALGIA, V17, P332; TERWINDT GM, IN PRESS EUR J HUMAN; TFELTHANSEN P, 1995, LANCET, V346, P923, DOI 10.1016/S0140-6736(95)91554-0; TFELTHANSEN P, IN PRESS CEPHALALGIA; TFELTHANSEN P, 1997, NEUROLOGIC CLIN ADV, P153; TFELTHANSEN P, 1995, HAND CLINIC, V65, P61; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; VANDENBRINK AM, 1998, IN PRESS CIRCULATION; vanderKamp W, 1996, J NEUROL SCI, V139, P106, DOI 10.1016/S0022-510X(96)00044-5; Visser WH, 1996, CEPHALALGIA, V16, P554, DOI 10.1046/j.1468-2982.1996.1608554.x; Visser WH, 1996, CLIN PHARMACOL THER, V60, P452, DOI 10.1016/S0009-9236(96)90202-7; Visser WH, 1996, ARCH NEUROL-CHICAGO, V53, P1132, DOI 10.1001/archneur.1996.00550110072014; Visser WH, 1996, NEUROLOGY, V47, P46, DOI 10.1212/WNL.47.1.46; VONKORFF M, 1995, PAIN, V62, P179, DOI 10.1016/0304-3959(94)00263-E; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658; WELCH KMA, 1993, NEW ENGL J MED, V329, P1476; WELCH KMA, 1990, ARCH NEUROL-CHICAGO, V47, P458, DOI 10.1001/archneur.1990.00530040114027; WELCH KMA, 1995, J NEUROL SCI, V134, P9, DOI 10.1016/0022-510X(95)00196-1; WILKINSON M, 1995, CEPHALALGIA, V15, P337, DOI 10.1046/j.1468-2982.1995.1505337.x; Winner P, 1996, ARCH NEUROL-CHICAGO, V53, P180, DOI 10.1001/archneur.1996.00550020092020; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	101	391	402	1	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1043	1051		10.1016/S0140-6736(97)11370-8	http://dx.doi.org/10.1016/S0140-6736(97)11370-8			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546526				2022-12-28	WOS:000072927200043
J	Thorburn, KM				Thorburn, KM			Conditions in prisons	LANCET			English	Editorial Material											Thorburn, KM (corresponding author), W Rutter Pkwy, Spokane, WA 99208 USA.							ARAX M, 1996, LOS ANGELES TIM 1205; Campbell David, 1997, GUARDIAN        0301, P1; WAITE D, 1995, HONOLULU ADVERT 0823; WAITE D, 1995, HONOLULU ADVERT 1005; WESCHLER J, 1991, PRISON CONDITIONS US; 1997, TURTURE S, V1	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1003	1004		10.1016/S0140-6736(05)78993-5	http://dx.doi.org/10.1016/S0140-6736(05)78993-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546503				2022-12-28	WOS:000072927200007
J	Bell, CM; Crystal, M; Detsky, AS; Redelmeier, DA				Bell, CM; Crystal, M; Detsky, AS; Redelmeier, DA			Shopping around for hospital services - A comparison of the United States and Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE SYSTEMS; WAITING-TIMES; OUTCOMES; ONTARIO; WASHINGTON; COUNTRIES; COSTS	Context.-Historical comparisons indicate that US hospitals are more expensive than Canadian hospitals, but health care system reform might have changed the relative costs and timeliness of health care in the 2 countries. Objective.-To estimate the price and convenience of selected hospital services in the United States and Canada for patients in 1997 had they paid out-of-pocket. Design.-Cross-sectional telephone survey conducted May 1996 to April 1997. Participants.-The 2 largest acute care general hospitals from every city in the United States and Canada with a population greater than 500 000. Measures.-Each hospital was telephoned and asked their price and waiting time for 7 services: magnetic resonance imaging of the head without gadolinium; a screening mammogram; a 12-lead electrocardiogram; a prothrombin time measurement; a session of hemodialysis; a screening colonoscopy; and a total knee replacement. Waiting times were measured in days until earliest appointment and charges were converted to American currency. Results.-Overall, 48 US and 18 Canadian hospitals were surveyed. Median waiting times were significantly shorter in American hospitals for 4 services, particularly a magnetic resonance imaging of the head (3 days vs 150 days; P<.001). Median charges were significantly higher in American hospitals for 6 services, particularly for a total knee replacement ($26 805 vs $10 651; P<.001). Individual services showed no association between shorter waiting times and higher prices within each country, with the exception of a total knee replacement in the United States. Conclusion.-US hospitals still provide higher prices and faster care than Canadian hospitals for patients who pay out-of-pocket.	Univ Toronto, Dept Med & Hlth Adm, Toronto, ON, Canada; Univ Toronto, Program Clin Epidemion & Hlth Care Res, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Toronto Hosp, Dept Med, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Redelmeier, DA (corresponding author), Sunnybrook Hosp, G-151,2075 Bayview Ave, Toronto, ON M4W 3M5, Canada.		Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469				Altman SH, 1997, NEW ENGL J MED, V336, P798, DOI 10.1056/NEJM199703133361111; *AM HOSP ASS, 1996, GUID HLTH CAR FIELD, pA184; BEISER M, 1985, AM J PSYCHIAT, V142, P1047; BRODY BA, 1993, J MED PHILOS, V18, P437, DOI 10.1093/jmp/18.5.437; BUSKE L, 1997, CAN MED ASSOC J, V156, P960; *CAN HOSP ASS, 1996, GUID CAN HLTH CAR FA, P68; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Cox JL, 1997, CAN MED ASSOC J, V156, P497; COYTE PC, 1994, NEW ENGL J MED, V331, P1068, DOI 10.1056/NEJM199410203311607; DANZON PM, 1992, HEALTH AFFAIR, V11, P21, DOI 10.1377/hlthaff.11.1.21; DETSKY AS, 1983, NEW ENGL J MED, V309, P151, DOI 10.1056/NEJM198307213090306; EVANS RG, 1988, HEALTH AFFAIR, V7, P17, DOI 10.1377/hlthaff.7.5.17; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Gold R, 1996, COST EFFECTIVENESS H; Gorey KM, 1997, AM J PUBLIC HEALTH, V87, P1156, DOI 10.2105/AJPH.87.7.1156; Gray C, 1996, CAN MED ASSOC J, V155, P1599; Hahn B., 1992, ANN EXPENSES SOURCES; Harris RW, 1997, CAN MED ASSOC J, V156, P761; HELLING TS, 1995, J TRAUMA, V39, P980, DOI 10.1097/00005373-199511000-00027; HO E, 1994, J RHEUMATOL, V21, P2101; HSIAO WC, 1992, J HEALTH POLIT POLIC, V17, P613, DOI 10.1215/03616878-17-4-613; Kessler RC, 1997, NEW ENGL J MED, V336, P551, DOI 10.1056/NEJM199702203360806; KILPATRICK KE, 1991, HEALTH SERV RES, V26, P277; Levan NE, 1997, CAN MED ASSOC J, V156, P761; LINBECK G, 1995, AM J EMERG MED, V13, P405; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MATAS R, 1997, GLOBE MAIL      1104, pA10; NEWHOUSE JP, 1988, HEALTH AFFAIR, V7, P6, DOI 10.1377/hlthaff.7.5.6; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; RAMSAY C, 1997, WAITING YOUR TURN HO; REDELMEIER DA, 1993, NEW ENGL J MED, V328, P772, DOI 10.1056/NEJM199303183281107; Rettig RA, 1991, KIDNEY FAILURE FEDER; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS LL, 1992, HEALTH AFFAIR, V11, P56, DOI 10.1377/hlthaff.11.2.56; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Rovner J, 1996, LANCET, V347, P1685, DOI 10.1016/S0140-6736(96)91507-X; ROWLAND RS, 1994, CLIN INVEST MED, V17, P328; RUBLEE DA, 1994, HEALTH AFFAIR, V13, P113, DOI 10.1377/hlthaff.13.4.113; SAVER BG, 1993, AM J PUBLIC HEALTH, V83, P1583, DOI 10.2105/AJPH.83.11.1583; SAYWELL RM, 1992, AM J EMERG MED, V10, P8, DOI 10.1016/0735-6757(92)90116-F; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; SCHIEBER GJ, 1994, HEALTH AFFAIR, V13, P100, DOI 10.1377/hlthaff.13.4.100; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; SCHIEBER GJ, 1993, HEALTH AFFAIR, V12, P120, DOI 10.1377/hlthaff.12.2.120; THORPE KE, 1993, J HEALTH POLIT POLIC, V18, P477, DOI 10.1215/03616878-18-2-477; TU JV, 1997, NEW ENGL J MED, V336, P1501; *US BUR CENS, 1996, 1996 STAT ABSTR US, P44; Weil T P, 1995, Hosp Top, V73, P10; Weiner S J, 1993, Fam Pract Res J, V13, P331; WOOD J, 1995, CANADA YB 1994, P84; Woolhandler S, 1997, NEW ENGL J MED, V336, P769, DOI 10.1056/NEJM199703133361106; WOOLHANDLER S, 1993, INT J HEALTH SERV, V23, P193, DOI 10.2190/EGK0-F7H9-HY13-3YNA	52	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1015	1017		10.1001/jama.279.13.1015	http://dx.doi.org/10.1001/jama.279.13.1015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533501	Bronze			2022-12-28	WOS:000072669700030
J	Garvican, L; Grimsey, E; Littlejohns, P; Lowndes, S; Sacks, N				Garvican, L; Grimsey, E; Littlejohns, P; Lowndes, S; Sacks, N			Satisfaction with clinical nurse specialists in a breast care clinic: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Breast Unit, London SW17 0QT, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England	St Georges University London; St Georges University London	Garvican, L (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England.							*BRIT ASS SURG ONC, 1995, EUR J SURG ONCOL S, V21, pA13; BROWN LA, 1991, CYTOPATHOLOGY, V2, P1, DOI 10.1111/j.1365-2303.1991.tb00377.x; English T, 1997, BRIT MED J, V314, P661, DOI 10.1136/bmj.314.7081.661; HAMMOND C, 1994, THESIS U SURREY; WATSON M, 1988, COUNSEL PSYCHOL Q, V1, P25	5	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					976	+		10.1136/bmj.316.7136.976	http://dx.doi.org/10.1136/bmj.316.7136.976			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550957	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000072856100021
J	Montaner, JSG; Reiss, P; Cooper, D; Vella, S; Harris, M; Conway, B; Wainberg, MA; Smith, D; Robinson, P; Hall, D; Myers, M; Lange, JMA				Montaner, JSG; Reiss, P; Cooper, D; Vella, S; Harris, M; Conway, B; Wainberg, MA; Smith, D; Robinson, P; Hall, D; Myers, M; Lange, JMA		INCAS Study Grp	A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients - The INCAS trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CUBIC MILLIMETER; THERAPY; PHARMACOKINETICS; ASSAY; REPLICATION; INHIBITION; SAFETY; ADULTS	Context.-Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease, However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA. Objective.-To compare the virologic effects of various combinations of nevirapine, didanosine, and zidovudine. Design.-Double-blind, controlled, randomized trial. Setting.-University-affiliated ambulatory research clinics in Italy, the Netherlands, Canada, and Australia (INCAS). Patients.-Antiretroviral therapy-naive adults free of the acquired immunodeficiency syndrome with CD4 cell counts between 0.20 and 0.60 x 10(9)/L (200-600/mu L). Intervention.-Patients received zidovudine plus nevirapine (plus didanosine placebo), zidovudine plus didanosine (plus nevirapine placebo), or zidovudine plus didanosine plus nevirapine. Main Outcome Measure.-Plasma HIV-1 RNA. Results.-Of the 153 enrolled patients, 151 were evaluable, At week 8, plasma HIV-1 RNA levels had decreased by log 2.18, 1.55, and 0.90 in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.05). The proportions of patients with plasma HIV-1 RNA levels below 20 copies per milliliter at week 52 were 51%, 12%, and 0% in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.001). Viral amplification was attempted in 59 patients at 6 months. Viral isolation was unsuccessful in 19 (79%) of 24, 10 (53%) of 19, and 5 (31%) of 16 patients in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively. Among patients from whom virus could be amplified, resistance to nevirapine was found in all 11 patients receiving zidovudine plus nevirapine and in all 5 patients receiving triple drug therapy, Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=.08). Conclusions.-Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied, Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.	Univ British Columbia, St Pauls Hosp, Canadian HIV Trials Network, Vancouver, BC V6Z 1Y6, Canada; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ New S Wales, Community HIV Res Network, Sydney, NSW, Australia; Ist Super Sanita, I-00161 Rome, Italy; McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of Amsterdam; Academic Medical Center Amsterdam; University of New South Wales Sydney; Kirby Institute; University of New South Wales Sydney; Istituto Superiore di Sanita (ISS); McGill University; Boehringer Ingelheim	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, Canadian HIV Trials Network, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@hivnet.ubc.ca	Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/V-8440-2019; VELLA, STEFANO/ABI-3368-2020	VELLA, STEFANO/0000-0003-2347-5984; 				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; BABIKER A, 1997, 6 EUR C CLIN ASP TRE; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Carr A, 1996, AIDS, V10, P635, DOI 10.1097/00002030-199606000-00009; CHEESEMAN SH, 1993, ANTIMICROB AGENTS CH, V37, P178, DOI 10.1128/AAC.37.2.178; CHUMENCK N, 1998, 5 C RETR OPP INF FEB; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; deJong MD, 1997, J INFECT DIS, V175, P966, DOI 10.1086/514002; DEJONG MD, 1994, J INFECT DIS, V169, P1346, DOI 10.1093/infdis/169.6.1346; GOEBEL F, 1997, 6 EUR C CLIN ASP TRE; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HAMMER SM, 1997, INT WORKSH HIV DRUG; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; HAVLIR D, 1995, J INFECT DIS, V172, P1378; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; Luzuriaga K, 1996, J INFECT DIS, V174, P713, DOI 10.1093/infdis/174.4.713; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MONTANER J, 1997, 6 EUR C CLIN ASP TRE; Montaner JSG, 1997, LANCET, V349, P1042, DOI 10.1016/S0140-6736(05)62289-1; MONTANER JSG, IN PRESS AIDS; Mulder J, 1997, J CLIN MICROBIOL, V35, P1278, DOI 10.1128/JCM.35.5.1278-1280.1997; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994	30	636	643	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					930	937		10.1001/jama.279.12.930	http://dx.doi.org/10.1001/jama.279.12.930			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544767	Bronze			2022-12-28	WOS:000072563600033
J	Greenhalgh, T				Greenhalgh, T			Selling out	BRITISH MEDICAL JOURNAL			English	Editorial Material													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				CANC WAY CURE TRUTH	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					944	944		10.1136/bmj.316.7135.944	http://dx.doi.org/10.1136/bmj.316.7135.944			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552866	Green Published			2022-12-28	WOS:000072713300085
J	Parkes, CM				Parkes, CM			Coping with loss - Bereavement in adult life	BRITISH MEDICAL JOURNAL			English	Article							LYMPHOCYTE		St Christophers Hospice, London SE26 6DZ, England		Parkes, CM (corresponding author), St Christophers Hospice, London SE26 6DZ, England.							BARTROP RW, 1977, LANCET, V1, P834; Bowlby J, 1970, CHILD HIS FAMILY; CLARK S, 1986, LOSS GRIEF GEN PRACT; CLEGG F, 1988, GRIEF MOURNING CONT, V1, P191; Horowitz M.J., 2011, STRESS RESPONSE SYND; Jacobs SC, 1993, PATHOLOGIC GRIEF MAL; Kubler Ross E., 1970, DEATH DYING; Lindemann E, 1944, AM J PSYCHIAT, V101, P141, DOI 10.1176/ajp.101.2.141; SCHLEIFER SJ, 1983, JAMA-J AM MED ASSOC, V250, P374, DOI 10.1001/jama.250.3.374	9	118	121	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					856	859		10.1136/bmj.316.7134.856	http://dx.doi.org/10.1136/bmj.316.7134.856			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549464	Green Published			2022-12-28	WOS:000072584300046
J	Nakchbandi, IA; Longenecker, JC; Ricksecker, MA; Latta, RA; Healton, C; Smith, DG				Nakchbandi, IA; Longenecker, JC; Ricksecker, MA; Latta, RA; Healton, C; Smith, DG			A decision analysis of mandatory compared with voluntary HIV testing in pregnant women	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LOW-BIRTH-WEIGHT; PRENATAL-CARE; INFECTION	Background: The benefit of antiretroviral therapy in reducing maternal-fetal transmission of HIV during pregnancy has caused a public policy debate about the relative benefits of mandatory HIV screening and voluntary HIV screening in pregnant women. Objective: To evaluate the benefits and risks of mandatory compared with voluntary HIV testing of pregnant women to help guide research and policy. Design: A decision analysis that incorporated the following variables: acceptance and benefit of prenatal care, acceptance and benefit of zidovudine therapy in HIV-infected women, prevalence of HIV infection, and mandatory compared with voluntary HIV testing. Measurements: The threshold deterrence rate (defined as the percentage of women who, if deterred from seeking prenatal care because of a mandatory HIV testing policy, would offset the benefit of zidovudine in reducing vertical HIV transmission) and the difference between a policy of mandatory testing and a policy of voluntary testing in the absolute number of HIV-infected infants or dead infants. Results: Voluntary HIV testing was preferred over a broad range of values in the model. At baseline, the threshold deterrence rate was 0.4%. At a deterrence rate of 0.5%, the number of infants (n = 167) spared HIV infection annually in the United States under a mandatory HIV testing policy would be lower than the number of perinatal deaths (n = 189) caused by lack of prenatal care. Conclusions: The most important variables in the model were voluntary HIV testing, the deterrence rate associated with mandatory testing compared with voluntary testing, and the prevalence of HIV infection in women of child-bearing age. At high levels of acceptance of voluntary HIV testing, the benefits of a policy of mandatory testing are minimal and may create the potential harms of avoiding prenatal care to avoid mandatory testing.	Abington Mem Hosp, Dept Med, Abington, PA 19001 USA; Allegheny Univ Hlth Sci, Dept Community & Prevent Med, Philadelphia, PA 19102 USA; Columbia Univ, Sch Publ Hlth, New York, NY 10032 USA	Abington Memorial Hospital; Drexel University; Columbia University	Smith, DG (corresponding author), Abington Mem Hosp, Dept Med, 2B Elkins,1200 Old York Rd, Abington, PA 19001 USA.			Longenecker, Joseph/0000-0001-9471-5661				ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BRANDEAU ML, 1992, ARCH INTERN MED, V152, P2229, DOI 10.1001/archinte.152.11.2229; BROEKHUIZEN FF, 1992, AM J OBSTET GYNECOL, V166, P1747, DOI 10.1016/0002-9378(92)91565-R; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; FOSTER DC, 1992, OBSTET GYNECOL, V79, P40; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; LINDSAY MK, 1991, OBSTET GYNECOL, V78, P678; LINDSAY MK, 1991, OBSTET GYNECOL, V77, P599; *NAT CTR HLTH STAT, 1996, VIT STAT US A, V2; *NAT I HLTH NAT I, 1997, SUMM M PAN REV STUD; Paltiel AD, 1997, MED DECIS MAKING, V17, P490, DOI 10.1177/0272989X9701700415; PIPER JM, 1994, AM J PUBLIC HEALTH, V84, P1626, DOI 10.2105/AJPH.84.10.1626; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; *US OFF TECHN ASS, 1988, HLTH CHILDR INV FUT, P8; *US OFF TECHN ASS, 1988, HLTH CHILDR INV FUT, P75; VENTURA SA, 1995, MONTHLY VITAL STAT R, V44; VENTURA SJ, 1995, MONTHLY VITAL STAT R, V43; WILFERT CM, 1994, CLIN INFECT DIS, V19, P664, DOI 10.1093/clinids/19.4.664; 1995, MMWR MORB MORTAL WKL, V44, P81	21	28	28	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					760	767		10.7326/0003-4819-128-9-199805010-00010	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556471				2022-12-28	WOS:000073363800009
J	Rao, JH; Lahiri, J; Isaacs, L; Weis, RM; Whitesides, GM				Rao, JH; Lahiri, J; Isaacs, L; Weis, RM; Whitesides, GM			A trivalent system from vancomycin center dot D-Ala-D-Ala with higher affinity than avidin center dot biotin	SCIENCE			English	Article							STRONGLY INHIBIT AGGLUTINATION; INFLUENZA-VIRUS; BINDING; ANTIBIOTICS; ERYTHROCYTES; RECOGNITION; COMPLEXES; PEPTIDES; DIMERS	Tris(vancomycin carboxamide) binds a trivalent ligand derived from D-Ala-D-Ala with very high affinity: dissociation constant (K-d) approximate to 4 x 10(-17) +/- 1 x 10(-17) M. High-affinity trivalent binding and monovalent binding are fundamentally different. In trivalent (and more generally, polyvalent) binding, dissociation occurs in stages, and its rate can be accelerated by monovalent ligand at sufficiently high concentrations. In monovalent binding, dissociation is determined solely by the rate constant for dissociation and cannot be accelerated by added monomer. Calorimetric measurements for the trivalent system indicate an approximately additive gain in enthalpy relative to the corresponding monomers. This system is one of the most stable organic receptor-ligand pairs involving small molecules that is known. It illustrates the practicality of designing very high-affinity systems based on polyvalency.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	Harvard University; University of Massachusetts System; University of Massachusetts Amherst	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Isaacs, Lyle D/B-4472-2009	Isaacs, Lyle D/0000-0002-4079-332X	NIGMS NIH HHS [GM 53210, GM 30367, GM 51559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030367, R01GM051559, R37GM030367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breslow R, 1996, J AM CHEM SOC, V118, P8495, DOI 10.1021/ja961567b; COOPER A, 1993, PHILOS T R SOC A, V345, P23, DOI 10.1098/rsta.1993.0114; DEFREES SA, 1995, J AM CHEM SOC, V117, P66, DOI 10.1021/ja00106a008; GERHARD U, 1993, J AM CHEM SOC, V115, P232, DOI 10.1021/ja00054a033; GREEN NM, 1963, BIOCHEM J, V89, P585, DOI 10.1042/bj0890585; GROVES P, 1995, J AM CHEM SOC, V117, P7958, DOI 10.1021/ja00135a014; HARRIS CM, 1982, J AM CHEM SOC, V104, P4293, DOI 10.1021/ja00379a062; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; MATROSOVICH MN, 1989, FEBS LETT, V252, P1, DOI 10.1016/0014-5793(89)80879-8; NIETO M, 1971, BIOCHEM J, V123, P773, DOI 10.1042/bj1230773; POPIENIEK PH, 1991, J AM CHEM SOC, V113, P2264, DOI 10.1021/ja00006a053; Rao JH, 1997, J AM CHEM SOC, V119, P10286, DOI 10.1021/ja971225l; ROY R, 1988, J CHEM SOC CHEM COMM, P1058, DOI 10.1039/c39880001058; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SUNDRAM UN, 1995, J ORG CHEM, V60, P1102, DOI 10.1021/jo00110a004; Sundram UN, 1996, J AM CHEM SOC, V118, P13107, DOI 10.1021/ja9621298; WILLIAMS DH, 1984, ACCOUNTS CHEM RES, V17, P364, DOI 10.1021/ar00106a004; WILLIAMSON MP, 1984, TETRAHEDRON, V40, P569, DOI 10.1016/0040-4020(84)85062-0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	24	266	282	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					708	711		10.1126/science.280.5364.708	http://dx.doi.org/10.1126/science.280.5364.708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563940				2022-12-28	WOS:000073415600038
J	Femino, A; Fay, FS; Fogarty, K; Singer, RH				Femino, A; Fay, FS; Fogarty, K; Singer, RH			Visualization of single RNA transcripts in situ	SCIENCE			English	Article							ACTIN GENE-TRANSCRIPTION; HUMAN-COMPLEMENT GENES; INSITU HYBRIDIZATION; MESSENGER-RNA; GROWTH-FACTOR; C-MYC; CELLS; MICROFILAMENTS; LOCALIZATION; FLUORESCENCE	Fluorescence in situ hybridization (FISH) and digital imaging microscopy were modified to allow detection of single RNA molecules. Oligodeoxynucleotide probes were synthesized with five fluorochromes per molecule, and the light emitted by a single probe was calibrated. Points of light in exhaustively deconvolved images of hybridized cells gave fluorescent intensities and distances between probes consistent with single messenger RNA molecules. Analysis of beta-actin transcription sites after serum induction revealed synchronous and cyclical transcription from single genes. The rates of transcription initiation and termination and messenger RNA processing could be determined by positioning probes along the transcription unit. This approach extends the power of FISH to yield quantitative molecular information on a single cell.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Univ Massachusetts, Sch Med, Biomed Engn Facil, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	Yeshiva University; Albert Einstein College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Singer, RH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM 54887] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DIRKS RW, 1995, J CELL SCI, V108, P2565; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; Fay F S, 1986, Soc Gen Physiol Ser, V40, P51; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P412; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1990, J CELL BIOCHEM, V44, P241, DOI 10.1002/jcb.240440406; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; THUMMEL CS, 1992, SCIENCE, V255, P39, DOI 10.1126/science.1553530; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; ZHANG GH, 1994, NATURE, V372, P809	24	897	950	10	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					585	590		10.1126/science.280.5363.585	http://dx.doi.org/10.1126/science.280.5363.585			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554849				2022-12-28	WOS:000073242100046
J	Sorensen, HT; Mellemkjaer, L; Steffensen, FH; Olsen, JH; Nielsen, GL				Sorensen, HT; Mellemkjaer, L; Steffensen, FH; Olsen, JH; Nielsen, GL			The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Several small studies have indicated an association between deep venous thrombosis or pulmonary embolism and a subsequent diagnosis of cancer, but the subject is controversial. Methods We conducted a nationwide study of a cohort of patients with deep venous thrombosis or pulmonary embolism that was drawn from the Danish National Registry of Patients for the years 1977 th rough 1992. The occurrence of cancer in the cohort was determined by linkage to the Danish Cancer Registry. The expected number of cancer cases was estimated on the basis of national age-, sex-, and site-specific incidence rates. Results A total of 15,348 patients with deep venous thrombosis and 11,305 patients with pulmonary embolism were identified. We observed 1737 cases of cancer in the cohort with deep venous thrombosis, as compared with 1372 expected cases (standardized incidence ratio, 1.3; 95 percent confidence interval, 1.21 to 1.33). Among the patients with pulmonary embolism, the standardized incidence ratio was 1.3, with a 95 percent confidence interval of 1.22 to 1.41. The risk was substantially elevated only during the first six months of follow-up and declined rapidly thereafter to a constant level slightly above 1.0 one year after the thrombotic event. Forty percent of the patients given a diagnosis of cancer within one year after hospitalization for thromboembolism had distant metastases at the time of the diagnosis of cancer. There were strong associations with several cancers, most pronounced for those of the pancreas, ovary, liver (primary hepatic cancer), and brain. Conclusions An aggressive search for a hidden cancer in a patient with a primary deep venous thrombosis or pulmonary embolism is not warranted. (C)1998, Massachusetts Medical Society.	Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Internal Med, DK-8000 Aarhus, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Aalborg Hosp, Dept Internal Med M, Aalborg, Denmark	Aarhus University; Aarhus University; Danish Cancer Society; Aalborg University; Aalborg University Hospital	Sorensen, HT (corresponding author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Hoegh Guldbergs Gade 10, DK-8000 Aarhus, Denmark.		Sorensen, Henrik Toft/Z-6181-2019; Steffensen, Flemming Hald/AAH-8742-2020	Sorensen, Henrik Toft/0000-0003-4299-7040; Steffensen, Flemming Hald/0000-0003-0252-6631; Olsen, Jorgen Helge/0000-0001-9633-5662				Cornuz J, 1996, ANN INTERN MED, V125, P785, DOI 10.7326/0003-4819-125-10-199611150-00001; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; LEVINE M, 1990, SEMIN ONCOL, V17, P160; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; Naschitz JE, 1996, CANCER-AM CANCER SOC, V77, P1759; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; Piccioli A, 1996, AM HEART J, V132, P850, DOI 10.1016/S0002-8703(96)90321-X; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; ROTHMAN KJ, 1979, DHHS PUBLICATION; Sorensen H T, 1997, Int J Risk Saf Med, V10, P1, DOI 10.3233/JRS-1997-10101; Storm HH, 1997, DAN MED BULL, V44, P535; STORM HH, 1996, CANC INCIDENCE DENMA; *SUNDH, 1981, AKT SYG 1979; *SUNDH, 1976, KLASS SYGD; Trousseau A., 1872, LECT CLIN MED DELIVE, P281	18	471	491	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1169	1173		10.1056/NEJM199804233381701	http://dx.doi.org/10.1056/NEJM199804233381701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554856				2022-12-28	WOS:000073208400001
J	Eccles, M; Freemantle, N; Mason, J				Eccles, M; Freemantle, N; Mason, J			North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; METAANALYSIS		Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ York, Ctr Hlth Econ, York YP1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Martin.Eccles@nd.ac.uk	Mason, James M/D-9904-2011; Eccles, Martin P/AAD-4029-2020	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				Adams P, 1996, BMJ-BRIT MED J, V312, P827; Anderson J, 1996, BMJ-BRIT MED J, V312, P762; [Anonymous], 1994, EFF HLTH CAR B; Cook T.C., 1979, QUASIEXPERIMENTATION; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; ECCLES M, IN PRESS BMJ; Field MJ., 1992, GUIDELINES CLIN PRAC; Freemantle N, 1997, ANN INTERN MED, V126, P81, DOI 10.7326/0003-4819-126-1-199701010-00011; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GRIMSHAW JM, 1994, QUAL HEALTH CARE, V3, P552; HEDGES LV, 1992, J EDUC STAT, V17, P279, DOI 10.2307/1165125; Hedges LV, 2014, STAT METHODS META AN; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; *N ENGL ASTHM GUID, 1997, EV BAS CLIN PRACT GU; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; US Department of Health and Human Services Public Health Services Agency for Health Care Policy and Research, 1992, AC PAIN MAN OP MED P; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	21	88	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1232	1235		10.1136/bmj.316.7139.1232	http://dx.doi.org/10.1136/bmj.316.7139.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553004	Green Published			2022-12-28	WOS:000073224100032
J	Vincent, C; Taylor-Adams, S; Stanhope, N				Vincent, C; Taylor-Adams, S; Stanhope, N			Framework for analysing risk and safety in clinical medicine	BRITISH MEDICAL JOURNAL			English	Article							ERROR; CARE		UCL, Dept Psychol, Clin Risk Unit, London WC1E 6BT, England	University of London; University College London	Vincent, C (corresponding author), UCL, Dept Psychol, Clin Risk Unit, Mortimer St, London WC1E 6BT, England.	c.vincent@ucl.ac.uk	Vincent, Charles A/D-1134-2010	Vincent, Charles A/0000-0003-0270-0222				Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; Bogner MS, 1994, HUMAN ERROR MED; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCK N, 1987, CONFIDENTIAL ENQUIRY; Cook RI, 1994, HUMAN ERROR MED, P255; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; *DEP HLTH, 1994, REP CONF ENQ MAT DEA; DRISCOLL PA, 1992, INJURY, V23, P107, DOI 10.1016/0020-1383(92)90043-R; EAGLE CJ, 1992, CAN J ANAESTH, V39, P118, DOI 10.1007/BF03008640; GIRAUD T, 1993, CRIT CARE MED, V21, P40, DOI 10.1097/00003246-199301000-00011; GREEN R, 1990, PHILOS T ROY SOC B, V327, P503, DOI 10.1098/rstb.1990.0093; Guzzo RA, 1996, ANNU REV PSYCHOL, V47, P307, DOI 10.1146/annurev.psych.47.1.307; Helmreich RL., 1994, HUMAN ERROR MED, P225; Hurst N., 1994, DEV APPL STRUCTURED; Johnson W. G., 1980, MORT SAFETY ASSURANC; LAGASSE RS, 1995, ANESTHESIOLOGY, V82, P1181, DOI 10.1097/00000542-199505000-00013; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Mills DH, 1995, CLIN RISK MANAGEMENT, P3; MORAY N, 1994, HUMAN ERROR MED, P67; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; REASON JT, 1995, CLIN RISK MANAGEMENT, P31; Stanhope N, 1997, BRIT J OBSTET GYNAEC, V104, P1225, DOI 10.1111/j.1471-0528.1997.tb10967.x; Vincent C, 1997, BRIT MED J, V314, P1775, DOI 10.1136/bmj.314.7097.1775; Vincent C., 1995, CLIN RISK MANAGEMENT, P391; VINCENT C, 1993, MED ACCIDENTS; WAGENAAR WA, 1994, ERGONOMICS, V37, P1999, DOI 10.1080/00140139408964963	27	521	544	1	22	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1154	1157		10.1136/bmj.316.7138.1154	http://dx.doi.org/10.1136/bmj.316.7138.1154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552960	Green Published			2022-12-28	WOS:000073067500039
J	Landin, L; Miller, MS; Pistol, ME; Pryor, CE; Samuelson, L				Landin, L; Miller, MS; Pistol, ME; Pryor, CE; Samuelson, L			Optical studies of individual InAs quantum dots in GaAs: Few-particle effects	SCIENCE			English	Article							CHEMICAL BEAM EPITAXY; GROWTH; PHOTOLUMINESCENCE; ISLANDS; LUMINESCENCE; EXCITONS	Optical emission from individual strained indium arsenide (InAs) islands buried in gallium arsenide (GaAs) was studied. At low excitation power density, the spectra from these quantum dots consist of a single line. At higher excitation power density, additional emission lines appeared at both higher and lower energies, separated from the main line by about 1 millielectron volt. At even higher excitation power density, this set of lines was replaced by a broad emission peaking below the original line. The splittings were an order of magnitude smaller than the lowest single-electron or single-hole excited state energies, indicating that the fine structure results from few-particle interactions in the dot. Calculations of few-particle effects give splittings of the observed magnitude.	Univ Lund, Dept Solid State Phys, S-22100 Lund, Sweden; Nanometer Struct Consortium, Lund, Sweden	Lund University	Pistol, ME (corresponding author), Univ Lund, Dept Solid State Phys, Box 118, S-22100 Lund, Sweden.	mats-erik.pistol@ftf.lth.se	Pistol, Mats-Erik/A-5500-2010; Samuelson, Lars/A-2171-2010	Samuelson, Lars/0000-0003-1971-9894; Pryor, Craig/0000-0002-4351-3688				BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; CARLSSON N, 1994, APPL PHYS LETT, V65, P3093, DOI 10.1063/1.112447; CITRIN DS, 1995, OPT LETT, V20, P901, DOI 10.1364/OL.20.000901; DENBAARS SP, 1994, J CRYST GROWTH, V145, P721, DOI 10.1016/0022-0248(94)91133-9; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; GOLDSTEIN L, 1985, APPL PHYS LETT, V47, P1099, DOI 10.1063/1.96342; GRUNDMANN M, 1995, PHYS REV LETT, V74, P4043, DOI 10.1103/PhysRevLett.74.4043; GUHA S, 1990, APPL PHYS LETT, V57, P2110, DOI 10.1063/1.103914; Hessman D, 1996, APPL PHYS LETT, V69, P749, DOI 10.1063/1.117879; Ikezawa M, 1997, PHYS REV LETT, V79, P3522, DOI 10.1103/PhysRevLett.79.3522; Jeppesen S, 1996, APPL PHYS LETT, V68, P2228, DOI 10.1063/1.115867; JUNNO T, UNPUB; Kouwenhoven LP, 1997, SCIENCE, V278, P1788, DOI 10.1126/science.278.5344.1788; Lelong P, 1996, SOLID STATE COMMUN, V98, P819, DOI 10.1016/0038-1098(96)00024-5; LEON R, 1995, SCIENCE, V267, P1966, DOI 10.1126/science.267.5206.1966; LEONARD D, 1993, APPL PHYS LETT, V63, P3202; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; Miller MS, 1997, J CRYST GROWTH, V175, P747, DOI 10.1016/S0022-0248(96)01219-5; Miller MS, 1996, SOLID STATE ELECTRON, V40, P609, DOI 10.1016/0038-1101(95)00373-8; PISTOL ME, 1996, P 23 INT C PHYS SEM, P1317; Pryor C, 1997, PHYS REV B, V56, P10404, DOI 10.1103/PhysRevB.56.10404; Schedelbeck G, 1997, SCIENCE, V278, P1792, DOI 10.1126/science.278.5344.1792; Schmidt KH, 1996, PHYS REV B, V54, P11346, DOI 10.1103/PhysRevB.54.11346; Service RE, 1997, SCIENCE, V276, P1027, DOI 10.1126/science.276.5315.1027; Stewart DR, 1997, SCIENCE, V278, P1784, DOI 10.1126/science.278.5344.1784	26	289	293	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					262	264		10.1126/science.280.5361.262	http://dx.doi.org/10.1126/science.280.5361.262			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535650				2022-12-28	WOS:000073082400043
J	Feneley, MR				Feneley, MR			Electrovaporisation of the prostate	LANCET			English	Editorial Material							HYPERPLASIA		Royal Hosp NHS Trust, Dept Urol, London, England	University of London; Queen Mary University London	Feneley, MR (corresponding author), Royal Hosp NHS Trust, Dept Urol, London, England.							Cetinkaya M, 1996, BRIT J UROL, V78, P901, DOI 10.1046/j.1464-410X.1996.23616.x; Chen SS, 1997, UROLOGY, V50, P235, DOI 10.1016/S0090-4295(97)00214-8; Kaplan SA, 1996, UROLOGY, V48, P876, DOI 10.1016/S0090-4295(96)00487-6; Lim LM, 1997, UROLOGY, V49, P851, DOI 10.1016/S0090-4295(97)00092-7; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NARAYAN P, 1995, J UROLOGY, V154, P2083, DOI 10.1016/S0022-5347(01)66701-6; Schatzl G, 1997, J UROLOGY, V158, P105, DOI 10.1097/00005392-199707000-00029; Shokeir AA, 1997, BRIT J UROL, V80, P570, DOI 10.1046/j.1464-410X.1997.00428.x; TE AE, 1997, CURR OPIN UROL, V7, P25; Tewari A, 1996, BRIT J UROL, V78, P667, DOI 10.1046/j.1464-410X.1996.01771.x; Thomas KJ, 1997, BRIT J UROL, V79, P186, DOI 10.1046/j.1464-410X.1997.03098.x; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	12	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					999	1001		10.1016/S0140-6736(05)78989-3	http://dx.doi.org/10.1016/S0140-6736(05)78989-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546499				2022-12-28	WOS:000072927200003
J	Maguire, P; Parkes, CM				Maguire, P; Parkes, CM			Surgery and loss of body parts	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-SURGERY; CANCER-PATIENTS; ADJUSTMENT; MASTECTOMY; DISORDER		Christie Hosp & Holt Radium Inst, CRC, Psychol Med Grp, Manchester M20 9BX, Lancs, England; St Christophers Hospice, London SE26 6DZ, England	Christie NHS Foundation Trust; Christie Hospital	Maguire, P (corresponding author), Christie Hosp & Holt Radium Inst, CRC, Psychol Med Grp, Manchester M20 9BX, Lancs, England.							Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; Butler D J, 1992, J Am Board Fam Pract, V5, P69; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; GORTNER SR, 1990, J ADV NURS, V15, P1132, DOI 10.1111/j.1365-2648.1990.tb01704.x; HANNAH MT, 1992, PSYCHOSOC ONCOL, V1, P89; HARRISON J, 1994, PSYCHO-ONCOLOGY, V3, P173, DOI 10.1002/pon.2960030303; Horowitz M.J., 2011, STRESS RESPONSE SYND; MAGUIRE P, 1980, BMJ-BRIT MED J, V281, P1454, DOI 10.1136/bmj.281.6253.1454; MAGUIRE P, 1983, CLIN ONCOL, V9, P319; MAGUIRE P, 1989, SURG ONCOL, P272; MAGUIRE P, 1995, BRIT MED J, V24, P676; NISSEN SJ, 1992, ARCH PHYS MED REHAB, V73, P548; OXMAN TE, 1994, PSYCHOSOMATICS, V35, P557, DOI 10.1016/S0033-3182(94)71724-2; PARKES CM, 1975, BRIT J PSYCHIAT, V127, P204, DOI 10.1192/bjp.127.3.204; PARKES CM, 1973, J PSYCHOSOM RES, V17, P97, DOI 10.1016/0022-3999(73)90010-X; Parle M, 1996, PSYCHOL MED, V26, P735, DOI 10.1017/S0033291700037752; SCHAG CAC, 1994, QUAL LIFE RES, V3, P127, DOI 10.1007/BF00435256; TARRIER N, 1984, BEHAV RES THER, V22, P81, DOI 10.1016/0005-7967(84)90036-6; WADE BE, 1990, J ADV NURS, V15, P1297, DOI 10.1111/j.1365-2648.1990.tb01745.x; Walter P J, 1992, Qual Life Res, V1, P77, DOI 10.1007/BF00435439; WEISMAN AD, 1977, COPING VULNERABILITY; Wilkinson S, 1988, Nurs Times, V84, P34; Yeo B K, 1995, Ann Acad Med Singap, V24, P676	23	40	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1086	1088						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG302	9552917				2022-12-28	WOS:000072987400038
J	Rosendorff, C				Rosendorff, C			Statins for prevention of stroke	LANCET			English	Editorial Material							DISEASE		CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Rosendorff, C (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.							Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	7	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1002	1003		10.1016/S0140-6736(05)78991-1	http://dx.doi.org/10.1016/S0140-6736(05)78991-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546501				2022-12-28	WOS:000072927200005
J	Armstrong, C				Armstrong, C			The vision of the pore	SCIENCE			English	Article							K+ CHANNEL; POTASSIUM CHANNELS; SEQUENCE; MUTATIONS		Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Armstrong, C (corresponding author), Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.							Armstrong C. M., 1989, MEMBRANE TRANSPORT P, P261; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1996, NEUROPHARMACOLOGY, V35, P761, DOI 10.1016/0028-3908(96)00097-4; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; STAMPE P, 1992, BIOPHYS J, V62, P8, DOI 10.1016/S0006-3495(92)81761-7; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	16	27	27	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					56	57		10.1126/science.280.5360.56	http://dx.doi.org/10.1126/science.280.5360.56			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9556453				2022-12-28	WOS:000072885100031
J	Zheng, WJ; Johnston, SA; Joshua-Tor, L				Zheng, WJ; Johnston, SA; Joshua-Tor, L			The unusual active site of Gal6/bleomycin hydrolase can act as a carboxypeptidase, aminopeptidase, and peptide ligase	CELL			English	Article							BINDING CYSTEINE PROTEASE; HUMAN BLEOMYCIN HYDROLASE; 20S PROTEASOME; CRYSTAL-STRUCTURE; CLONING; PROTEINASE; DNA; EXPRESSION; RESOLUTION; PROGRAM	The Gal6 protease is in a class of cysteine peptidases identified by their ability to inactivate the anti-cancer drug bleomycin. The protein forms a barrel structure with the active sites embedded in a channel as in the proteasome. In Gal6 the C termini lie in the active site clefts. We show that Gal6 acts as a carboxypeptidase on its C terminus to convert itself to an aminopeptidase and peptide ligase. The substrate specificity of the peptidase activity is determined by the position of the C terminus of Gal6 rather than the sequence of the substrate. We propose a model to explain these diverse activities and Gal6's singular ability to inactivate bleomycin.	Cold Spring Harbor Lab, WM Keck Struct Biol Lab, Cold Spring Harbor, NY 11724 USA; Univ Texas, SW Med Ctr, Dept Med, Ctr Biomed Invent, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Cold Spring Harbor Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Joshua-Tor, L (corresponding author), Cold Spring Harbor Lab, WM Keck Struct Biol Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Joshua-Tor, Leemor/0000-0001-8185-8049	NATIONAL CANCER INSTITUTE [R01CA067982, R01CA071746] Funding Source: NIH RePORTER; NCI NIH HHS [CA67982, R01-CA71746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1997, EUR J BIOCHEM, V245, P283, DOI 10.1111/j.1432-1033.1997.t01-1-00283.x; AKIYAMA S, 1981, BIOCHEM BIOPH RES CO, V101, P55, DOI 10.1016/S0006-291X(81)80009-5; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; Ferrando AA, 1996, CANCER RES, V56, P1746; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; Klein JR, 1997, MICROBIOL-SGM, V143, P527, DOI 10.1099/00221287-143-2-527; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; Lazo JS, 1996, CANC CHEMOTHERAPY BI; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; Mata L, 1997, BIOCHEM J, V328, P343, DOI 10.1042/bj3280343; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OTWINSOWSKI Z, 1993, DATA COLLECTION PROC; SCHECTER I, 1968, BIOCHEM BIOPH RES CO, V32, P888; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Takeda A, 1996, J BIOCHEM-TOKYO, V120, P353; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; XU HE, 1994, J BIOL CHEM, V269, P21177; ZHENG W, 1997, IN PRESS MOL CELL BI; Zheng WJ, 1997, J BIOL CHEM, V272, P30350, DOI 10.1074/jbc.272.48.30350	32	45	46	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					103	109		10.1016/S0092-8674(00)81150-2	http://dx.doi.org/10.1016/S0092-8674(00)81150-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546396	Bronze			2022-12-28	WOS:000072910800014
J	Rice, DP				Rice, DP			The cost of instant access to health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94118 USA	University of California System; University of California San Francisco	Rice, DP (corresponding author), Univ Calif San Francisco, Inst Hlth & Aging, 3333 Calif St,Room 340, San Francisco, CA 94118 USA.							Anderson GF, 1997, HEALTH AFFAIR, V16, P163, DOI 10.1377/hlthaff.16.6.163; BEAUREGARD KM, 1997, MEPS SURVEY, V1, P1; Bell CM, 1998, JAMA-J AM MED ASSOC, V279, P1015, DOI 10.1001/jama.279.13.1015; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302	4	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1030	1030		10.1001/jama.279.13.1030	http://dx.doi.org/10.1001/jama.279.13.1030			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533504				2022-12-28	WOS:000072669700033
J	Bindslev-Jensen, C				Bindslev-Jensen, C			ABC of allergies - Food allergy	BRITISH MEDICAL JOURNAL			English	Review									Aarhus Marseilisborg Hosp, Dept Dermatol, Aarhus, Denmark	Aarhus University	Bindslev-Jensen, C (corresponding author), Aarhus Marseilisborg Hosp, Dept Dermatol, Aarhus, Denmark.		Bindslev-Jensen, Carsten/H-1877-2011	Bindslev-Jensen, Carsten/0000-0002-8940-038X				Bindslev-Jensen C., 1996, Food allergy: adverse reactions to food and food additives., P137; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; HOST A, 1994, PEDIATR ALLERGY IMMU, V5, P5; LAHTI A, 1980, Acta Dermato-Venereologica Supplementum, V60, P1	4	33	33	5	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1299	1302		10.1136/bmj.316.7140.1299	http://dx.doi.org/10.1136/bmj.316.7140.1299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554903	Green Published			2022-12-28	WOS:000073335900028
J	Naude, JH; Le Roux, PJ				Naude, JH; Le Roux, PJ			Topical treatment of erectile dysfunction did not show results	BRITISH MEDICAL JOURNAL			English	Letter									Univ Cape Town, Dept Urol, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Dept Urol, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Cape Town	Naude, JH (corresponding author), Univ Cape Town, Dept Urol, ZA-7925 Cape Town, South Africa.							Gomaa A, 1996, BRIT MED J, V312, P1512, DOI 10.1136/bmj.312.7045.1512	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1318	1318		10.1136/bmj.316.7140.1318	http://dx.doi.org/10.1136/bmj.316.7140.1318			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554911	Green Published			2022-12-28	WOS:000073335900039
J	Pirmohamed, M; Breckenridge, AM; Kitteringham, NR; Park, BK				Pirmohamed, M; Breckenridge, AM; Kitteringham, NR; Park, BK			Fortnightly review - Adverse drug reactions	BRITISH MEDICAL JOURNAL			English	Review							HIV-INFECTION; PARACETAMOL HEPATOTOXICITY; HYPERSENSITIVITY REACTIONS; INTRACELLULAR GLUTATHIONE; ACETAMINOPHEN; DEFICIENCY; HEPATITIS; FAILURE; FIALURIDINE; METABOLITES		Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Pirmohamed, M (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, POB 147, Liverpool L69 3BX, Merseyside, England.		Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266				ASSCHER AW, 1995, BRIT MED J, V311, P1003; ATKIN PA, 1995, ADVERSE DRUG REACT T, V14, P175; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BEAUNE PH, 1993, ANN NY ACAD SCI, V685, P641, DOI 10.1111/j.1749-6632.1993.tb35929.x; BELTON KJ, 1995, BRIT J CLIN PHARMACO, V39, P223, DOI 10.1111/j.1365-2125.1995.tb04440.x; BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; BUHL R, 1989, LANCET, V2, P1294; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; FRIEDMANN PS, 1994, ARCH DERMATOL, V130, P598, DOI 10.1001/archderm.130.5.598; HARB GE, 1993, DRUG SAFETY, V9, P1, DOI 10.2165/00002018-199309010-00001; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOOPMANS PP, 1995, AIDS, V9, P217, DOI 10.1097/00002030-199509030-00001; LAUTERBURG BH, 1988, GUT, V29, P1153, DOI 10.1136/gut.29.9.1153; Lee SST, 1996, J BIOL CHEM, V271, P12063, DOI 10.1074/jbc.271.20.12063; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; NELSON SD, 1990, SEMIN LIVER DIS, V10, P267, DOI 10.1055/s-2008-1040482; Park BK, 1995, PHARMACOL THERAPEUT, V68, P385, DOI 10.1016/0163-7258(95)02013-6; PARK BK, 1987, BIOCHEM PHARMACOL, V36, P581; PARK BK, 1992, BRIT J CLIN PHARMACO, V34, P377, DOI 10.1111/j.1365-2125.1992.tb05647.x; Pirmohamed M, 1996, AIDS, V10, P501, DOI 10.1097/00002030-199605000-00008; PIRMOHAMED M, 1994, DRUG SAFETY, V11, P114, DOI 10.2165/00002018-199411020-00006; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; POHL LR, 1988, ANNU REV PHARMACOL, V28, P367; POHL LR, 1990, SEMIN LIVER DIS, V10, P305, DOI 10.1055/s-2008-1040486; RAUCY JL, 1989, ARCH BIOCHEM BIOPHYS, V271, P270, DOI 10.1016/0003-9861(89)90278-6; RAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; ROEDERER M, 1991, INT IMMUNOL, V3, P933, DOI 10.1093/intimm/3.9.933; SHAH RR, 1982, BRIT MED J, V284, P295, DOI 10.1136/bmj.284.6312.295; Smith CC, 1996, BRIT J CLIN PHARMACO, V42, P423, DOI 10.1111/j.1365-2125.1996.tb00004.x; STRICKER BHC, 1992, DRUG INDUCED HEPATIC, V5; VANDERVEN AJAM, 1991, LANCET, V338, P431, DOI 10.1016/0140-6736(91)91046-W; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; WILLIAMS RT, 1959, DETOXICATION MECHANI, P717; ZIMMERMAN HJ, 1995, HEPATOLOGY, V22, P767, DOI 10.1002/hep.1840220312	39	290	304	2	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1295	1298		10.1136/bmj.316.7140.1295	http://dx.doi.org/10.1136/bmj.316.7140.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554902	Green Published			2022-12-28	WOS:000073335900027
J	Greenhalgh, T				Greenhalgh, T			Soundings - Patients not paper?	BRITISH MEDICAL JOURNAL			English	Editorial Material													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088					0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1251	1251		10.1136/bmj.316.7139.1251	http://dx.doi.org/10.1136/bmj.316.7139.1251			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553026	Green Published			2022-12-28	WOS:000073224100071
J	Honkoop, P; de Man, RA; Niesters, HGM				Honkoop, P; de Man, RA; Niesters, HGM			Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy	ANNALS OF INTERNAL MEDICINE			English	Letter									Erasme Univ Hosp, Rotterdam, Netherlands		Honkoop, P (corresponding author), Erasme Univ Hosp, Rotterdam, Netherlands.		Niesters, Hubert/AAH-6808-2019					Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Honkoop P, 1997, LIVER, V17, P103; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520	5	7	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					697	697		10.7326/0003-4819-128-8-199804150-00028	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00028			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537953				2022-12-28	WOS:000073052500024
J	Greaves, MW; Sabroe, RA				Greaves, MW; Sabroe, RA			ABC of allergies - Allergy and the skin. I - Urticaria	BRITISH MEDICAL JOURNAL			English	Review									St Thomas Hosp, St Johns Inst Dermatol, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Greaves, MW (corresponding author), St Thomas Hosp, St Johns Inst Dermatol, London, England.							CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; ODONNELL B, 1995, INT ANGIOL, V14, P166; SABROE RA, 1996, ARCH DERMATOL, V23, P735	5	34	38	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1147	1150		10.1136/bmj.316.7138.1147	http://dx.doi.org/10.1136/bmj.316.7138.1147			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552957	Green Published			2022-12-28	WOS:000073067500036
J	Davies, DG; Parsek, MR; Pearson, JP; Iglewski, BH; Costerton, JW; Greenberg, EP				Davies, DG; Parsek, MR; Pearson, JP; Iglewski, BH; Costerton, JW; Greenberg, EP			The involvement of cell-to-cell signals in the development of a bacterial biofilm	SCIENCE			English	Article							RHAMNOLIPID BIOSURFACTANT SYNTHESIS; AERUGINOSA VIRULENCE GENES; LUXR-LUXI FAMILY; PSEUDOMONAS-AERUGINOSA; SECONDARY METABOLITES; EXPRESSION; DETERMINANTS; REGULATORS; PAO1; LASR	Bacteria in nature often exist as sessile communities called biofilms. These communities develop structures that are morphologically and physiologically differentiated from free-living bacteria. A cell-to-cell signal is involved in the development of Pseudomonas aeruginosa biofilms. A specific signaling mutant, a lasl mutant, forms flat, undifferentiated biofilms that unlike wild-type biofilms are sensitive to the biocide sodium dodecyl sulfate, Mutant biofilms appeared normal when grown in the presence of a synthetic signal molecule. The involvement of an intercellular signal molecule in the development of P. aeruginosa biofilms suggests possible targets to control biofilm growth on catheters, in cystic fibrosis, and in other environments where P. aeruginosa biofilms are a persistent problem.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Iowa; Montana State University System; Montana State University Bozeman; University of Rochester	Greenberg, EP (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	epgreen@blue.weeg.uiowa.edu		Greenberg, Everett/0000-0001-9474-8041	NIAID NIH HHS [5T32AI07362, AI33713] Funding Source: Medline; NIGMS NIH HHS [GM 18740] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007362, R01AI033713, R37AI033713] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRINT JM, 1995, J BACTERIOL, V177, P7155, DOI 10.1128/jb.177.24.7155-7163.1995; BROWN ML, 1995, APPL ENVIRON MICROB, V61, P187, DOI 10.1128/AEM.61.1.187-193.1995; COHENBAZIRE G, 1957, J CELL COMP PHYSL, V49, P35; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DAVIES DG, 1993, APPL ENVIRON MICROB, V59, P1181, DOI 10.1128/AEM.59.4.1181-1186.1993; DEBEER D, 1994, BIOTECHNOL BIOENG, V44, P636, DOI 10.1002/bit.260440510; DOGGETT RG, 1966, J PEDIATR-US, V68, P215, DOI 10.1016/S0022-3476(66)80152-X; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Dworkin M., 1991, MICROBIAL CELL CELL, P179; EVANS LR, 1973, J BACTERIOL, V116, P915, DOI 10.1128/JB.116.2.915-924.1973; FASSEL TA, 1992, MICROSC RES TECHNIQ, V20, P87, DOI 10.1002/jemt.1070200109; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; KHOURY AE, 1992, AM SOC ARTIF INTERN, V38, P174; KINTNER PK, 1982, J FOOD SCI, V47, P756, DOI 10.1111/j.1365-2621.1982.tb12708.x; Latifi A, 1996, MOL MICROBIOL, V21, P1137, DOI 10.1046/j.1365-2958.1996.00063.x; LATIFI A, 1995, MOL MICROBIOL, V17, P333, DOI 10.1111/j.1365-2958.1995.mmi_17020333.x; LAWRENCE JR, 1991, J BACTERIOL, V173, P6558, DOI 10.1128/jb.173.20.6558-6567.1991; Losick R, 1997, SCI AM, V276, P68, DOI 10.1038/scientificamerican0297-68; McLean RJC, 1997, FEMS MICROBIOL LETT, V154, P259, DOI 10.1111/j.1574-6968.1997.tb12653.x; OCHSNER UA, 1995, P NATL ACAD SCI USA, V92, P6424, DOI 10.1073/pnas.92.14.6424; OCHSNER UA, 1994, J BACTERIOL, V176, P2044, DOI 10.1128/jb.176.7.2044-2054.1994; PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556; Pearson JP, 1997, J BACTERIOL, V179, P5756, DOI 10.1128/jb.179.18.5756-5767.1997; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pesci EC, 1997, TRENDS MICROBIOL, V5, P132, DOI 10.1016/S0966-842X(97)01008-1; SUTHERLAND IW, 1977, SURFACE CARBOHYDRATE, P27; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427	31	2356	2546	24	725	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					295	298		10.1126/science.280.5361.295	http://dx.doi.org/10.1126/science.280.5361.295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535661				2022-12-28	WOS:000073082400054
J	Taylor, SJ; Morken, JP				Taylor, SJ; Morken, JP			Thermographic selection of effective catalysts from an encoded polymer-bound library	SCIENCE			English	Article							COMBINATORIAL LIBRARIES; NUCLEOPHILIC CATALYSTS; SH3 DOMAIN; DISCOVERY; TEMPERATURE; REACTIVITY; CHEMISTRY; COMPLEXES; KINETICS; LIGANDS	A general method is introduced for the rapid and simultaneous evaluation of each member of large encoded catalyst libraries for the ability to catalyze a reaction in solution. The procedure was used to select active catalysts from a library of potential polymer-bound multifunctional catalysts, From similar to 7000 beads screened (3150 distinct catalysts), 23 beads were selected for catalysis of an acylation reaction. Kinetic experiments indicate that the most strongly selected beads are also the most efficient catalysts.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Morken, JP (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.							BORCHARDT A, 1994, J AM CHEM SOC, V116, P373, DOI 10.1021/ja00080a044; BURGER MT, 1995, J ORG CHEM, V60, P7382, DOI 10.1021/jo00128a002; Burgess K, 1996, ANGEW CHEM INT EDIT, V35, P220, DOI 10.1002/anie.199602201; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; Cole BM, 1996, ANGEW CHEM INT EDIT, V35, P1668, DOI 10.1002/anie.199616681; Combs AP, 1996, J AM CHEM SOC, V118, P287, DOI 10.1021/ja953750v; Cox J.D., 1970, THERMOCHEMISTRY ORGA; DELANEY EJ, 1982, J AM CHEM SOC, V104, P799, DOI 10.1021/ja00367a025; DERATANI A, 1987, MACROMOLECULES, V20, P767, DOI 10.1021/ma00170a011; ESKENDIROV I, 1995, J CHEM SOC FARADAY T, V91, P991, DOI 10.1039/ft9959100991; FERSHT AR, 1970, J AM CHEM SOC, V92, P5432, DOI 10.1021/ja00721a023; Francis MB, 1996, J AM CHEM SOC, V118, P8983, DOI 10.1021/ja961842u; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GUIBEJAMPEL E, 1979, TETRAHEDRON LETT, P1157; HOFLE G, 1978, ANGEW CHEM INT EDIT, V17, P596; Kawabata T, 1997, J AM CHEM SOC, V119, P3169, DOI 10.1021/ja963275g; KUSTIN K, 1993, J CHEM EDUC, V70, P454, DOI 10.1021/ed070p454; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LIU GC, 1995, J ORG CHEM, V60, P7712, DOI 10.1021/jo00129a002; MENGER FM, 1995, J ORG CHEM, V60, P6666, DOI 10.1021/jo00126a008; MENGER FM, 1985, J ORG CHEM, V50, P3928, DOI 10.1021/jo00220a052; Moates FC, 1996, IND ENG CHEM RES, V35, P4801, DOI 10.1021/ie960476k; NAGY IP, 1992, CHEM PHYS LETT, V200, P147, DOI 10.1016/0009-2614(92)87060-3; Nestler HP, 1996, BIOORG MED CHEM LETT, V6, P1327, DOI 10.1016/0960-894X(96)00228-4; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Ruble JC, 1997, J AM CHEM SOC, V119, P1492, DOI 10.1021/ja963835b; Ruble JC, 1996, J ORG CHEM, V61, P7230, DOI 10.1021/jo961433g; TOMOI M, 1982, MAKROMOL CHEM-RAPID, V3, P537; VEDEJS E, 1993, J AM CHEM SOC, V115, P3358, DOI 10.1021/ja00061a056; Vedejs E, 1996, J AM CHEM SOC, V118, P1809, DOI 10.1021/ja953631f	30	266	284	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					267	270		10.1126/science.280.5361.267	http://dx.doi.org/10.1126/science.280.5361.267			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535652				2022-12-28	WOS:000073082400045
J	Gelles, J; Landick, R				Gelles, J; Landick, R			RNA polymerase as a molecular motor	CELL			English	Review							SINGLE; CONFORMATIONS; TRANSCRIPTION; ELONGATION; FORCE		Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Brandeis University; Brandeis University; University of Wisconsin System; University of Wisconsin Madison	Gelles, J (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA.			Gelles, Jeff/0000-0001-7910-3421				CORDOVA NJ, 1992, P NATL ACAD SCI USA, V89, P339, DOI 10.1073/pnas.89.1.339; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FINZI L, 1995, SCIENCE, V267, P378, DOI 10.1126/science.7824935; FRITZSCHE W, 1995, SCANNING MICROSCOPY, V9, P729; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Kasas S, 1997, BIOCHEMISTRY-US, V36, P461, DOI 10.1021/bi9624402; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	16	137	141	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					13	16		10.1016/S0092-8674(00)81140-X	http://dx.doi.org/10.1016/S0092-8674(00)81140-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546386	Bronze			2022-12-28	WOS:000072910800004
J	Puigserver, P; Wu, ZD; Park, CW; Graves, R; Wright, M; Spiegelman, BM				Puigserver, P; Wu, ZD; Park, CW; Graves, R; Wright, M; Spiegelman, BM			A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis	CELL			English	Article							BROWN ADIPOSE-TISSUE; MITOCHONDRIAL UNCOUPLING PROTEIN; THYROID-HORMONE RECEPTOR; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; ENERGY-BALANCE; MESSENGER-RNA; IN-VITRO; EXPRESSION; GENE	Adaptive thermogenesis is an important component of energy homeostasis and a metabolic defense against obesity. We have cloned a novel transcriptional coactivator of nuclear receptors, termed PGC-1, from a brown fat cDNA library. PGC-I mRNA expression is dramatically elevated upon cola exposure of mice in both brown fat and skeletal muscle, key thermogenic tissues. PGC-1 greatly increases the transcriptional activity of PPAR gamma and the thyroid hormone receptor on the uncoupling protein (UCP-1) promoter. Ectopic expression of PGC-1 in white adipose cells activates expression of UCP-1 and key mitochondrial enzymes of the respiratory chain, and increases the cellular content of mitochondrial DNA. These results indicate that PGC-1 plays a key role in linking nuclear receptors to the transcriptional program of adaptive thermogenesis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Chicago, Dept Med, Div Gastroenterol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Wu, Zhidan/0000-0001-7289-9420	NIDDK NIH HHS [R37DK31405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLARUD F, 1986, J BIOL CHEM, V5, P1487; BOURHIM M, 1990, AM J PHYSIOL, V258, pR1291, DOI 10.1152/ajpregu.1990.258.5.R1291; Cannon B, 1996, BIOCHEM SOC T, V24, P407, DOI 10.1042/bst0240407; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Klingenspor M, 1996, BIOCHEM J, V316, P607, DOI 10.1042/bj3160607; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Maniatis T., 1989, MOL CLONING LAB MANU; MARTIN I, 1995, BIOCHEM J, V308, P749, DOI 10.1042/bj3080749; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLLS D, 1986, BIOCHEM SOC T, V14, P223, DOI 10.1042/bst0140223; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pillar TM, 1997, EUR J ENDOCRINOL, V136, P231, DOI 10.1530/eje.0.1360231; Puigserver P, 1996, BIOCHEM J, V317, P827, DOI 10.1042/bj3170827; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V43, P1271; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	57	2906	3059	6	222	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					829	839		10.1016/S0092-8674(00)81410-5	http://dx.doi.org/10.1016/S0092-8674(00)81410-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529258	Bronze			2022-12-28	WOS:000072661200015
J	Conacher, ID				Conacher, ID			A memorable patient - Truth drug	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1309	1309		10.1136/bmj.316.7140.1309	http://dx.doi.org/10.1136/bmj.316.7140.1309			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554905	Green Published			2022-12-28	WOS:000073335900030
J	D'Amico, R; Pifferi, S; Leonetti, C; Torri, V; Tinazzi, A; Liberati, A				D'Amico, R; Pifferi, S; Leonetti, C; Torri, V; Tinazzi, A; Liberati, A		Study Investigators	Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	4th Cochrane Colloquium	OCT, 1996	ADELAIDE, AUSTRALIA				INTENSIVE-CARE UNIT; SELECTIVE DIGESTIVE DECONTAMINATION; MECHANICALLY VENTILATED PATIENTS; RESPIRATORY-TRACT INFECTIONS; MULTIPLE TRAUMA PATIENTS; DOUBLE-BLIND; OROPHARYNGEAL DECONTAMINATION; NOSOCOMIAL PNEUMONIA; CLINICAL-TRIAL; PREVENTION	Objective: To determine whether antibiotic prophylaxis reduces respiratory tract infections and overall mortality in unselected critically ill adult patients. Design: Meta-analysis of randomised controlled trials from 1984 and 1996 that compared different forms of antibiotic prophylaxis used to reduce respiratory tract infections and mortality with aggregate data and, in a subset of trials, data from individual patients. Subjects: Unselected critically ill adult patients; 5727 patients for aggregate data meta-analysis, 4343 for confirmatory meta-analysis with data from individual patients. Main outcome measures: Respiratory tract infections and total mortality. Results: Two categories of eligible trials were defined: topical plus systemic antibiotics versus no treatment and topical preparation with or without a systemic antibiotic versus a systemic agent or placebo, Estimates from aggregate data meta-analysis of 16 trials (3361 patients) that tested combined treatment indicated a strong significant reduction in infection (odds ratio 0.35; 95% confidence interval 0.29 to 0.41) and total mortality (0.80; 0.69 to 0.93). With this treatment five and 23 patients would need to be treated to prevent one infection and one death, respectively Similar analysis of 17 trials (2366 patients) that tested only topical antibiotics indicated a clear reduction in infection (0.56; 0.46 to 0.68) without a significant effect on total mortality (1.01; 0.84 to 1.22). Analysis of data from individual patients yielded similar results. No significant differences in treatment effect by major subgroups of patients emerged from the analyses. Conclusions: This meta-analysis of 15 years of clinical research suggests that antibiotic prophylaxis with a combination of topical and systemic drugs can reduce respiratory tract infections and overall mortality in critically ill patients. This effect is significant and worth while, and it should be considered when practice guidelines are defined.	Mario Negri Inst Pharmacol Res, Lab Hlth Serv Res, Italian Cochrane Ctr, I-20157 Milan, Italy; Osped Maggiore, IRCCS, I-20122 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Ca Granda Ospedale Maggiore Policlinico	D'Amico, R (corresponding author), Mario Negri Inst Pharmacol Res, Lab Hlth Serv Res, Italian Cochrane Ctr, Via Eritrea 62, I-20157 Milan, Italy.		Torri, Valter/H-7550-2015; D'Amico, Roberto/I-8106-2014	Torri, Valter/0000-0001-9541-9354; D'Amico, Roberto/0000-0002-3211-6687				AbeleHorn M, 1997, INTENS CARE MED, V23, P187, DOI 10.1007/s001340050314; AERDTS SJA, 1993, BRIT MED J, V307, P525; AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; *AM THOR SOC, 1995, AM J RESP CRIT CARE, V153, P1711; BION JF, 1994, CRIT CARE MED, V22, P40, DOI 10.1097/00003246-199401000-00011; BLAIR P, 1991, SURGERY, V110, P303; Boland JP, 1991, 17 C CHEM BERL; BRAZZI L, 1992, REANIMATION URGENCES, V1, P501; BRUNBUISSON C, 1989, ANN INTERN MED, V110, P873, DOI 10.7326/0003-4819-110-11-873; CERRA FB, 1992, ARCH SURG-CHICAGO, V127, P163; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FERRER M, 1994, ANN INTERN MED, V120, P389, DOI 10.7326/0003-4819-120-5-199403010-00006; Finch RG, 1991, 17 INT C CHEM BERL; FLAHERTY J, 1990, J INFECT DIS, V162, P1393, DOI 10.1093/infdis/162.6.1393; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Gaussorgues P., 1991, REANIMATION SOINS IN, V7, P169; Georges B, 1994, REANIMATION SOINS IN, V3, P621; *GRUPP IT MULT RIC, 1983, MINERVA ANESTESIOL, V59, P451; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; Hunefeld G, 1989, Anaesthesiol Reanim, V14, P131; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; Jacobs S., 1992, CLIN INTENSIVE CARE, V3, P52; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; KORINEK AM, 1993, CRIT CARE MED, V21, P1466, DOI 10.1097/00003246-199310000-00013; LAGGNER AN, 1994, WIEN KLIN WOCHENSCHR, V106, P15; Lecky FE, 1996, J ACCID EMERG MED, V13, P373; LENHART FP, 1994, 17 INT C CHEM VIENN, pK101; LIBERATI A, 1997, COCHRANE LIB; Lingnau W, 1997, J TRAUMA, V42, P687, DOI 10.1097/00005373-199704000-00018; LIPMAN J, 1994, CRIT CARE MED, P141; LUITEN EJT, 1995, ANN SURG, V222, P57, DOI 10.1097/00000658-199507000-00010; MARTINEZPELLUS AE, 1993, CRIT CARE MED, V21, P1684, DOI 10.1097/00003246-199311000-00017; Mason CM, 1997, J INFECT DIS, V176, P1293, DOI 10.1086/514125; NATHENS AB, 1997, SHOCK S, V7, pA697; Palomar M., 1997, CLIN INTENSIVE CARE, V8, P228, DOI [10.3109/tcic.8.5.228.235, DOI 10.3109/TCIC.8.5.228.235]; Parmar MKB, 1996, BRIT J CANCER, V74, P496, DOI 10.1038/bjc.1996.392; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Quinio B, 1996, CHEST, V109, P765, DOI 10.1378/chest.109.3.765; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; SANCHEZGARCIA M, 1992, EUR C INT CAR MED BA; Schardey HM, 1997, ANN SURG, V225, P172, DOI 10.1097/00000658-199702000-00005; SMITH SD, 1993, TRANSPLANTATION, V55, P1306; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; STOUTENBEEK CP, 1996, MECHANISMS THERAPEUT; STOUTENBEEK CP, IN PRESS ANN SURG; Sun XL, 1996, CRIT CARE MED, V24, P753, DOI 10.1097/00003246-199605000-00005; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TETTEROO GWM, 1990, LANCET, V335, P704, DOI 10.1016/0140-6736(90)90813-K; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; vanSaene JJM, 1996, J ENDOTOXIN RES, V3, P337, DOI 10.1177/096805199600300408; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; WIENER J, 1995, CLIN INFECT DIS, V20, P861, DOI 10.1093/clinids/20.4.861; WINTER R, 1992, J ANTIMICROB CHEMOTH, V30, P73, DOI 10.1093/jac/30.1.73; YONG MY, 1997, J TRAUMA, V42, P1073; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	64	275	280	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1998	316	7140					1275	1285		10.1136/bmj.316.7140.1275	http://dx.doi.org/10.1136/bmj.316.7140.1275			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZK548	9554897	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000073335900022
J	Wilcock, PR				Wilcock, PR			Two-fraction model of initial sediment motion in gravel-bed rivers	SCIENCE			English	Article							BEDLOAD TRANSPORT RATES; SAND; STREAM; FLOW; ENTRAINMENT; THRESHOLD	The prediction of sediment transport in gravel-bed rivers is essential to the management of land, water, and ecological resources in mountain regions. Dividing the bed sediment into two populations-sand and gravel-permits realistic and useful predictions of the onset of sediment transport. The critical flow initiating grain motion decreases rapidly with sand content over the transition from a gravel-framework bed to a sand-matrix bed. The two-fraction model provides a simple means of forecasting the movement of excess fine sediment supply. The model also helps to explain the development of the abrupt gravel-sand transition commonly observed in natural rivers.	Johns Hopkins Univ, Dept Geog & Environm Engn, Baltimore, MD 21218 USA	Johns Hopkins University	Wilcock, PR (corresponding author), Johns Hopkins Univ, Dept Geog & Environm Engn, Baltimore, MD 21218 USA.		Wilcock, Peter/A-3299-2010					ANDREWS ED, 1983, GEOL SOC AM BULL, V94, P1225, DOI 10.1130/0016-7606(1983)94<1225:EOGFNS>2.0.CO;2; Ashida L., 1972, P JPN SOC CIV ENG, V206, P59, DOI [10.2208/jscej1969.1972.206_59, DOI 10.2208/JSCEJ1969.1972.206_59]; BAGNOLD RA, 1980, P ROY SOC LOND A MAT, V372, P453, DOI 10.1098/rspa.1980.0122; Buffington JM, 1997, WATER RESOUR RES, V33, P1993, DOI 10.1029/96WR03190; CARLING PA, 1982, EARTH SURF PROC LAND, V7, P349, DOI 10.1002/esp.3290070407; CARLING PA, 1983, EARTH SURF PROC LAND, V8, P1, DOI 10.1002/esp.3290080102; DIPLAS P, 1985, 190 U MINN ST ANTH F; EMMETT WW, 1980, 801189 US GEOL SURV; EMMETT WW, 1985, 85486 US GEOL SURV; Engelund F., 1972, MONOGRAPH SEDIMENT T; FENTON JD, 1977, P ROY SOC LOND A MAT, V352, P523, DOI 10.1098/rspa.1977.0014; FERGUSON RI, 1989, WATER RESOUR RES, V25, P635, DOI 10.1029/WR025i004p00635; HILL M T, 1991, Rivers, V2, P198; Ikeda H., 1988, 12 U TSUK ENV RES CT; ISEYA F, 1987, GEOGR ANN A, V69, P15, DOI 10.2307/521363; JACKSON WL, 1982, EARTH SURF PROC LAND, V7, P517, DOI 10.1002/esp.3290070602; Kondolf GM, 1996, WATER RESOUR RES, V32, P2589, DOI 10.1029/96WR00898; KUHNLE RA, 1992, DYNAMICS GRAVEL BED, pCH7; Lane E., 1955, AM SOC CIV ENG, V81, P1, DOI [10.1061/JYCEAJ.0000048, DOI 10.1061/JYCEAJ.0000048, DOI 10.1016/J.GEOMORPH.2006.06.031]; LEOPOLD LB, 1992, DYNAMICS GRAVEL BED, pCH14; LIGON FK, 1995, BIOSCIENCE, V45, P183, DOI 10.2307/1312557; LISLE TE, 1989, WATER RESOUR RES, V25, P1303, DOI 10.1029/WR025i006p01303; MACKIN JH, 1948, GEOL SOC AM BULL, V59, P463; Meyer-Peter E., 1948, P 2 M INT ASS HYDRAU, P39; Milhous R.T., 1973, THESIS OREG STATE, P231; MILLER MC, 1977, SEDIMENTOLOGY, V24, P507, DOI 10.1111/j.1365-3091.1977.tb00136.x; PAOLA C, 1995, WATER RESOUR RES, V31, P395; PARKER G, 1982, J HYDR ENG DIV-ASCE, V108, P544; Parker G, 1996, ISSUES AND DIRECTIONS IN HYDRAULICS, P115; SEAL R, 1995, WATER RESOUR RES, V31, P1409, DOI 10.1029/94WR02976; SMITH GHS, 1995, J SEDIMENT RES A, V65, P423; Wilcock P. R., 1992, DYNAMICS GRAVEL BED; WILCOCK PR, 1988, WATER RESOUR RES, V24, P1127, DOI 10.1029/WR024i007p01127; Wilcock PR, 1996, WATER RESOUR RES, V32, P2897, DOI 10.1029/96WR01628; WILCOCK PR, 1993, WATER RESOUR RES, V29, P1297, DOI 10.1029/92WR02748; Yatsu E., 1955, T AM GEOPHYSICAL UNI, V36, P655, DOI DOI 10.1029/TR036I004P00655; [No title captured]	37	152	152	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					410	412		10.1126/science.280.5362.410	http://dx.doi.org/10.1126/science.280.5362.410			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545213				2022-12-28	WOS:000073159600039
J	Daugherty, SR; Baldwin, DC; Rowley, BD				Daugherty, SR; Baldwin, DC; Rowley, BD			Learning, satisfaction, and mistreatment during medical internship - A national survey of working conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SLEEP-DEPRIVATION; SEXUAL HARASSMENT; STUDENT ABUSE; RESIDENTS; DISCRIMINATION; PERFORMANCE; PERCEPTIONS; EDUCATION; STRESS	Context.-Concerns about the working and learning environment of residency training continue to surface. Previous surveys of residents have focused on work hours and income, but have shed little light on how residents view their training experience. Objective.-To provide a description of the internship year as seen by a large cross section of second-year residents. Design.-Mail survey conducted in 1991. Setting.-Residency programs in the United States. Participants.-Random 10% sample (N=1773) of all second-year residents listed in the American Medical Association's medical research and information database. Main Outcome Measures.-What and who contributes most to residents' learning during internships, degree of satisfaction with the internship experience, on-call and sleep schedules, incidents of perceived mistreatment or abuse, observations of unethical behavior, and experiences of harassment or discrimination. Results.-A total of 1277 surveys (72%) of 1773 mailed were returned, Overall, respondents reported a moderate level of satisfaction with their first year of residency. On a scale of 0 to 3, residents rated other residents as contributing most (score of 2.3) to their learning, with special patients ranked second (2.1), During a typical work week, residents reported that they spent an average of 56.9 hours on call in the hospital. A total of 1185 (93%) residents reported experiencing at least 1 incident of perceived mistreatment, with 53% reporting being belittled or humiliated by more senior residents. Among women residents, 63% reported having experienced at least 1 episode of sexual harassment or discrimination, A total of 45% of residents reported having observed another individual falsifying medical records, and 70% saw a colleague working in an impaired condition, most often lack of sleep. Regression analyses suggest that satisfaction with the residency experience was associated with the presence of factors that enhanced learning, and fewer experiences of perceived mistreatment. Conclusions.-Residents report significant problems during their internship experience. Satisfaction with internship is enhanced by positive learning experiences and lack of mistreatment.	Rush Med Coll, Rush Primary Care Inst, Chicago, IL 60612 USA; Amer Med Assoc, Chicago, IL 60610 USA; Maricopa Med Ctr, Phoenix, AZ USA	Rush University; American Medical Association	Daugherty, SR (corresponding author), Rush Med Coll, Rush Primary Care Inst, 1653 W Congress Pkwy, Chicago, IL 60612 USA.							ALEXANDER D, 1985, J MED EDUC, V60, P830; ASKEN MJ, 1983, J MED EDUC, V58, P382; Badger L W, 1987, Fam Pract Res J, V7, P104; Baldwin DC, 1996, ACAD MED, V71, pS25, DOI 10.1097/00001888-199610000-00034; BALDWIN DWC, 1991, WESTERN J MED, V155, P140; Cook DJ, 1996, CAN MED ASSOC J, V154, P1657; Daugherty SR, 1996, ACAD MED, V71, pS93, DOI 10.1097/00001888-199601000-00054; FLYNN TC, 1986, PHAROS           SPR, P7; FOX RE, 1995, SOCIOLOGY MED PARTIC, P108; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; KENDRICK SB, 1993, MED EDUC, V27, P55, DOI 10.1111/j.1365-2923.1993.tb00229.x; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; Lubitz R M, 1996, JAMA, V275, P414, DOI 10.1001/jama.275.5.414; ROWLEY BD, 1991, JAMA-J AM MED ASSOC, V266, P933, DOI 10.1001/jama.266.7.933; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; SCHWARTZ AJ, 1987, J MED EDUC, V62, P744; SHEEHAN KH, 1990, JAMA-J AM MED ASSOC, V263, P533, DOI 10.1001/jama.263.4.533; SILBERGER AB, 1988, HEALTH AFFAIR, V7, P121, DOI 10.1377/hlthaff.7.2.121; SILVER HK, 1990, JAMA-J AM MED ASSOC, V263, P527, DOI 10.1001/jama.263.4.527; Thomas W, 1919, POLISH PEASANT EUROP; URBACH J R, 1989, Psychiatric Quarterly (New York), V60, P283, DOI 10.1007/BF01064352; vanIneveld CHM, 1996, J GEN INTERN MED, V11, P401, DOI 10.1007/BF02600186	22	225	230	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1194	1199		10.1001/jama.279.15.1194	http://dx.doi.org/10.1001/jama.279.15.1194			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555759	Bronze			2022-12-28	WOS:000072969400033
J	Inouye, SK; Peduzzi, PN; Robison, JT; Hughes, JS; Horwitz, RI; Concato, J				Inouye, SK; Peduzzi, PN; Robison, JT; Hughes, JS; Horwitz, RI; Concato, J			Importance of functional measures in predicting mortality among older hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY MEDICAL PATIENTS; MINI-MENTAL STATE; MYOCARDIAL-INFARCTION; SEVERITY; OUTCOMES; DELIRIUM; ILLNESS; DISEASE; SYSTEM; IMPAIRMENT	Context.-Measures of physical and cognitive function are strong prognostic predictors of hospital outcomes for older persons, but current risk adjustment and burden of illness assessment indices do not include these measures. Objective.-To evaluate and validate the contribution of functional measures to the ability of 5 standard burden of illness indices (Charlson, Acute Physiology and Chronic Health Evaluation [APACHE] II, Disease Staging, All Patient Refined Diagnosis Related Groups, and a clinician's subjective rating) in predicting 90-day and 2-year mortality among older hospitalized patients. Design.-Two prospective cohort studies. Setting.-General medicine service, university teaching hospital. Patients.-For the development cohort, 207 consecutive patients aged 70 years or older, and for the validation cohort, 318 comparable patients. Main Outcome Measure.-Death within 90 days and 2 years from the index admission. Results.-In the development cohort, 29 patients (14%) and 81 patients (39%) died within 90 days and 2 years, respectively, A functional axis was developed using 3 independent risk factors: impairment in instrumental activities of daily living, Mini-Mental State Examination score of less than 20, and shortened Geriatric Depression Scale score of 7 or higher, creating low-, intermediate-, and high-risk groups with associated mortality rates of 20%, 32%, and 60%, respectively (P<.001); the C statistic for the final model was 0.69, The corresponding mortality rates in the validation cohort, in which 59 (19%) and 138 (43%) died within 90 days and 2 years, respectively, were 24%, 45%, and 60% (P<.001); the C statistic for the final model was 0.66. For each burden of illness index, the functional axis contributed significantly to the predictive ability of the model for both 90 days and 2 years. When the functional axis and each burden of illness measure were analyzed in cross-stratified format, mortality rates increased progressively from low-risk to high-risk functional groups within strata of burden of illness indices (double-gradient phenomenon), The contributions of functional and burden of illness measures were substantive and interrelated. Conclusions.-Functional measures are strong predictors of 90-day and 2-year mortality after hospitalization. Furthermore, these measures contribute substantially to the prognostic ability of 5 burden of illness indices. Optimal risk adjustment for older hospitalized patients should incorporate functional status variables.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Vet Affairs Connecticut Healthcare Syst, Dept Vet Affairs Cooperat Studies Program Coordina, West Haven, CT USA; Vet Affairs Connecticut Healthcare Syst, Med Serv, West Haven, CT USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Inouye, SK (corresponding author), Yale Univ, Sch Med, Yale New Haven Hosp, 20 York St,Tompkins 15, New Haven, CT 06504 USA.		Inouye, Sharon/R-7216-2019		NIA NIH HHS [T32AG00153, R01AG12551] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000153, R01AG012551] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Auerswald KB, 1997, AM J MED, V103, P410, DOI 10.1016/S0002-9343(97)00152-6; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CORNONIHUNTLEY J, 1986, NIH PUBLICATION; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; EDWARDS N, 1994, HEALTH CARE FINANC R, V16, P45; FEINSTEIN AR, 1990, MEDICINE, V69, P1; FIELDS SD, 1986, J AM GERIATR SOC, V34, P579, DOI 10.1111/j.1532-5415.1986.tb05763.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1995, J GEN INTERN MED, V10, P406, DOI 10.1007/BF02599844; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MARKSON LE, 1991, EVAL HEALTH PROF, V14, P201, DOI 10.1177/016327879101400205; NARAIN P, 1988, J AM GERIATR SOC, V36, P775, DOI 10.1111/j.1532-5415.1988.tb04259.x; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; RUDBERG MA, 1993, J GERONTOL, V48, pM261, DOI 10.1093/geronj/48.6.M261; Sager MA, 1996, ARCH INTERN MED, V156, P645, DOI 10.1001/archinte.156.6.645; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P778, DOI 10.1111/j.1532-5415.1991.tb02700.x	39	567	575	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1187	1193		10.1001/jama.279.15.1187	http://dx.doi.org/10.1001/jama.279.15.1187			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG133	9555758	Bronze			2022-12-28	WOS:000072969400032
J	Fabbri, S; Fruscoloni, P; Bufardeci, E; Negri, EDN; Baldi, MI; Attardi, DG; Mattoccia, E; Tocchini-Valentini, GP				Fabbri, S; Fruscoloni, P; Bufardeci, E; Negri, EDN; Baldi, MI; Attardi, DG; Mattoccia, E; Tocchini-Valentini, GP			Conservation of substrate recognition mechanisms by tRNA splicing endonucleases	SCIENCE			English	Article							INTRON	Accuracy in transfer RNA (tRNA) splicing is essential for the formation of functional tRNAs, and hence for gene expression, in both Eukaryotes and Archaea. The specificity for recognition of the tRNA precursor (pre-tRNA) resides in the endonuclease, which removes the intron by making two independent endonucleolytic cleavages. Although the eukaryal and archaeal enzymes appear to use different features of pre-tRNAs to determine the sites of cleavage, analysis of hybrid pre-tRNA substrates containing eukaryal and archaeal sequences, described here, reveals that the eukaryal enzyme retains the ability to use the archaeal recognition signals. This result indicates that there may be a common ancestral mechanism for recognition of pre-tRNA by proteins.	CNR, Ist Biol Cellulare, I-00137 Rome, Italy; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Ist Guido Donegani SpA, EniChem, Lab Biotecnol, I-00015 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Chicago	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, Viale Marx 43, I-00137 Rome, Italy.		Di Nicola Negri, Elisa/G-2251-2014	Di Nicola, Elisa/0000-0003-3659-9708				ATTARDI DG, 1989, METHOD ENZYMOL, V181, P510; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; Negri ED, 1997, CELL, V89, P859, DOI 10.1016/S0092-8674(00)80271-8; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1988, J BIOL CHEM, V263, P1751; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6	10	50	55	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					284	286		10.1126/science.280.5361.284	http://dx.doi.org/10.1126/science.280.5361.284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535657				2022-12-28	WOS:000073082400050
J	Li, H; Trotta, CR; Abelson, J				Li, H; Trotta, CR; Abelson, J			Crystal structure and evolution of a transfer RNA splicing enzyme	SCIENCE			English	Article							PROTEIN MODELS; RECOGNITION; GENES; CONFORMATION; BACTERIA; INTRONS	The splicing of transfer RNA precursors is similar in Eucarya and Archaea. In both kingdoms an endonuclease recognizes the splice sites and releases the intron, but the mechanism of splice site recognition is different in each kingdom. The crystal structure of the endonuclease from the archaeon Methanococcus jannaschii was determined to a resolution of 2.3 angstroms. The structure indicates that the cleavage reaction is similar to that of ribonuclease A and the arrangement of the active sites is conserved between the archaeal and eucaryal enzymes. These results suggest an evolutionary pathway for splice site recognition.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Abelson, J (corresponding author), CALTECH, Div Biol, Mail Code 147-75, Pasadena, CA 91125 USA.	abelson@cco.caltech.edu		Li, Hong/0000-0003-2046-9861	NIGMS NIH HHS [F32 GM188930-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BRUNGER AT, 1996, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; DANIELS CJ, COMMUNICATION; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FABBRI S, 1998, IN PRESS SCIENCE; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KJERNS J, 1989, CAN J MICROBIOL, V35, P210; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KRAUT J, 1962, P NATL ACAD SCI USA, V48, P1417, DOI 10.1073/pnas.48.8.1417; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESLIE AGW, 1996, CCP4 ESF EACMB NEWSL, V32, P2; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LykkeAndersen J, 1997, EMBO J, V16, P6290, DOI 10.1093/emboj/16.20.6290; Minor W., 1993, XDISPLAYF PROGRAM; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PALMER JR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P315, DOI 10.1016/0167-4781(92)90168-Y; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; TROTTA CR, UNPUB; WALSH CT, 1979, ENZYMATIC REACTION M; Westaway Shawn K., 1995, P79	38	116	124	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					279	284		10.1126/science.280.5361.279	http://dx.doi.org/10.1126/science.280.5361.279			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535656				2022-12-28	WOS:000073082400049
J	Ploegh, HL				Ploegh, HL			Viral strategies of immune evasion	SCIENCE			English	Article							INHIBITS ANTIGEN PRESENTATION; CLASS-I MOLECULES; BINDING-SITE; VIRUS; PROTEIN; TAP; CELLS; ENDOCYTOSIS; EXPRESSION; TRANSPORT	The vertebrate body is an ideal breeding ground for viruses and provides the conditions that promote their growth, survival, and transmission. The immune system evolved and deals with this challenge. Mutually assured destruction is not a viable evolutionary strategy; thus, the study of host-virus interactions provides not only a glimpse of life at immunity's edge, but it has also illuminated essential functions of the immune system, in particular, the area of major histocompatibility complex-restricted antigen presentation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	ploegh@hms.harvard.edu						Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; COLLINS KL, IN PRESS NATURE; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DAVISPOYNTER NJ, IN PRESS SEMIN VIROL; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Farrell HE, 1997, NATURE, V386, P510, DOI 10.1038/386510a0; Gilbert MJ, 1996, NATURE, V383, P720, DOI 10.1038/383720a0; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Hengel H, 1997, CURR OPIN IMMUNOL, V9, P470, DOI 10.1016/S0952-7915(97)80097-0; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Karre K, 1997, NATURE, V386, P446, DOI 10.1038/386446a0; Karre K, 1997, IMMUNOL REV, V155, P5, DOI 10.1111/j.1600-065X.1997.tb00935.x; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kleijnen MF, 1997, EMBO J, V16, P685, DOI 10.1093/emboj/16.4.685; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Koppelman B, 1997, IMMUNITY, V7, P861, DOI 10.1016/S1074-7613(00)80404-5; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; McFadden G, 1996, TRANSPL P, V28, P2085; Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; PAABO S, 1989, ADV CANCER RES, V52, P151; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SEDMAK DD, 1994, AM J PATHOL, V144, P683; Shisler JL, 1998, SCIENCE, V279, P102, DOI 10.1126/science.279.5347.102; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; STROCKBINE LD, IN PRESS J VIROL; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; Zeidler R, 1997, BLOOD, V90, P2390	54	640	657	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					248	253		10.1126/science.280.5361.248	http://dx.doi.org/10.1126/science.280.5361.248			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535648				2022-12-28	WOS:000073082400041
J	Welch, GN; Loscalzo, J				Welch, GN; Loscalzo, J			Homocysteine and atherothrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; ELEVATED PLASMA HOMOCYST(E)INE; PREMATURE VASCULAR-DISEASE; ARTERIAL OCCLUSIVE DISEASE; BETA-SYNTHASE DEFICIENCY; SERUM TOTAL HOMOCYSTEINE; INDEPENDENT RISK FACTOR; CORONARY HEART-DISEASE; CONTAINING AMINO-ACIDS		Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Loscalzo, J (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W-507, Boston, MA 02118 USA.		Loscalzo, Joseph/ABD-8980-2021		NHLBI NIH HHS [HL53919, HL55993, HL58976] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058976, P50HL055993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ANDERSSON A, 1995, CLIN CHEM, V41, P361; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Arruda VR, 1997, THROMB HAEMOSTASIS, V77, P818; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BLOM HJ, 1995, EUR J CLIN INVEST, V25, P149, DOI 10.1111/j.1365-2362.1995.tb01541.x; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CAREY MC, 1968, AM J MED, V45, P7, DOI 10.1016/0002-9343(68)90003-X; CELERMAJER DS, 1993, J AM COLL CARDIOL, V22, P854, DOI 10.1016/0735-1097(93)90203-D; CHAUVEAU P, 1993, KIDNEY INT S, V41, pS72; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; DAngelo A, 1997, BLOOD, V90, P1; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; Deloughery TG, 1996, CIRCULATION, V94, P3074, DOI 10.1161/01.CIR.94.12.3074; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; Erbe RW, 1986, FOLATES PTERINS, P413; FINKELSTEIN JD, 1988, J BIOL CHEM, V263, P11750; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; Gallagher PM, 1996, CIRCULATION, V94, P2154, DOI 10.1161/01.CIR.94.9.2154; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; Heinecke JW, 1988, OXYRADICALS MOL BIOL, P443; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; JAMES TN, 1990, J AM COLL CARDIOL, V15, P763, DOI 10.1016/0735-1097(90)90272-Q; KANG SS, 1988, AM J HUM GENET, V43, P414; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1990, CORONARY ARTERY DIS, V2, P4; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCCULLY KS, 1971, NATURE, V231, P391, DOI 10.1038/231391a0; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; MCCULLY KS, 1994, ANN CLIN LAB SCI, V24, P27; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; MCCULLY KS, 1994, ANN CLIN LAB SCI, V24, P134; MISRA HP, 1974, J BIOL CHEM, V249, P2151; MOREL DW, 1983, J LIPID RES, V24, P1070; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1972, BIOCHEM BIOPH RES CO, V46, P905; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; RATNOFF OD, 1968, SCIENCE, V162, P1007, DOI 10.1126/science.162.3857.1007-a; REFSUM H, 1991, CANCER RES, V51, P828; Ridker PM, 1997, CIRCULATION, V95, P1777; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROWLEY DA, 1982, FEBS LETT, V138, P33, DOI 10.1016/0014-5793(82)80388-8; SALTZMAN E, 1994, CLIN RES, V42, pA172; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Ubbink JB, 1996, J CLIN INVEST, V98, P177, DOI 10.1172/JCI118763; UELAND PM, 1995, CLIN CHEM, V41, P340; UELAND PM, 1989, J LAB CLIN MED, V114, P473; UELAND PM, 1993, CLIN CHEM, V39, P1764; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; vanBockxmeer FM, 1997, CIRCULATION, V95, P21, DOI 10.1161/01.CIR.95.1.21; VANDENBERG M, 1995, EUR J CLIN INVEST, V25, P176; VELURY S, 1988, J CHROMATOGR-BIOMED, V424, P141, DOI 10.1016/S0378-4347(00)81085-3; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; VERMAAK WJH, 1990, AM J CLIN NUTR, V51, P1058, DOI 10.1093/ajcn/51.6.1058; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; Welch GN, 1997, ANN NY ACAD SCI, V811, P48, DOI 10.1111/j.1749-6632.1997.tb51988.x; Welch GN, 1998, P ASSOC AM PHYSICIAN, V110, P22; WILCKEN DEL, 1979, EUR J CLIN INVEST, V9, P301, DOI 10.1111/j.1365-2362.1979.tb00888.x	102	1675	1792	1	47	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1042	1050		10.1056/NEJM199804093381507	http://dx.doi.org/10.1056/NEJM199804093381507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535670				2022-12-28	WOS:000072969500007
J	Weiss, RS				Weiss, RS			Coping with loss - Separation and other problems that threaten relationships	BRITISH MEDICAL JOURNAL			English	Article									Univ Massachusetts, Inst Gerontol, Boston, MA 02125 USA	University of Massachusetts System; University of Massachusetts Boston	Weiss, RS (corresponding author), Univ Massachusetts, Inst Gerontol, Boston, MA 02125 USA.							Parkes CM, 1998, BRIT MED J, V316, P856, DOI 10.1136/bmj.316.7134.856; Weiss, 1975, MARITAL SEPARATION; Weiss R. S, 1973, LONELINESS EXPERIENC; WEISS RS, 1979, GOINT IT ALONE FAMIL	4	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1011	1013		10.1136/bmj.316.7136.1011	http://dx.doi.org/10.1136/bmj.316.7136.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550968	Green Published			2022-12-28	WOS:000072856100037
J	Teo, KK				Teo, KK			Recent advances - Cardiology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; THERAPY; MORTALITY; STENT; DEFIBRILLATOR; PRAVASTATIN		Univ Alberta, Dept Med, Div Cardiol, EPICORE Ctr, Edmonton, AB T6G 2B7, Canada	University of Alberta	Teo, KK (corresponding author), Univ Alberta, Dept Med, Div Cardiol, EPICORE Ctr, Edmonton, AB T6G 2B7, Canada.	kkt@tachy.uah.ualberta.ca						ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Campeau L, 1997, NEW ENGL J MED, V336, P153; COWLEY AJ, 1994, BRIT HEART J, V72, P226; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GOY JJ, 1995, CATHETER CARDIO DIAG, V34, P128, DOI 10.1002/ccd.1810340410; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HAMM CW, 1995, AM HEART J, V129, P423, DOI 10.1016/0002-8703(95)90262-7; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; Moliterno, 1995, J Thromb Thrombolysis, V2, P165; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; *ORG ASS STRAT ISC, IN PRESS CIRCULATION; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PEDERSEN TR, 1994, LANCET, V344, P1383; Perry G, 1997, NEW ENGL J MED, V336, P525; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; Simoons ML, 1997, LANCET, V349, P1429; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; TOPOL E, 1994, CIRCULATION, V90, P1631; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1996, NEW ENGL J MED, V335, P775; TSUYUKI RT, 1995, CAN J CARDIOL SE, V11, pE101; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Wever EFD, 1996, CIRCULATION, V93, P489, DOI 10.1161/01.CIR.93.3.489; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZJISTRA F, 1993, NEW ENGL J MED, V328, P680	41	4	4	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	1998	316	7135					911	915		10.1136/bmj.316.7135.911	http://dx.doi.org/10.1136/bmj.316.7135.911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552843	Green Published			2022-12-28	WOS:000072713300032
J	Vostanis, P; Grattan, E; Cumella, S				Vostanis, P; Grattan, E; Cumella, S			Mental health problems of homeless children and families: Longitudinal study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To establish the mental health needs of homeless children and families before and after rehousing. Design: Cross sectional, longitudinal study. Setting: City of Birmingham. Subjects: 58 rehoused families with 103 children aged 2-16 years and 21 comparison families of low socioeconomic status in stable housing, with 54 children. Main outcome measures: Children's mental health problems and level of communication; mothers' mental health problems and social support one year after rehousing. Results: Mental health problems remained significantly higher in rehoused mothers and their children than in the comparison group (mothers 26% v 5%, P = 0.04; children 39% v 11%, P = 0.0003). Homeless mothers continued to have significantly less social support at follow up. Mothers with a history of abuse and poor social integration were more likely to have children with persistent mental health problems. Conclusions: Homeless families have a high level of complex needs that cannot be met by conventional health services and arrangements. Local strategies for rapid rehousing into permanent accommodation, effective social support and health care for parents and children, and protection from violence and intimidation should be developed and implemented.	Univ Birmingham, Parkview Clin, Dept Child & Adolescent Psychiat, Birmingham B13 8QE, W Midlands, England; Queen Elizabeth Psychiat Hosp, Dept Psychiat, Birmingham B15 2QZ, W Midlands, England	University of Birmingham; University of Birmingham	Vostanis, P (corresponding author), Univ Birmingham, Parkview Clin, Dept Child & Adolescent Psychiat, Birmingham B13 8QE, W Midlands, England.		Cumella, Stuart/H-8633-2019					Achenbach T. M., 1992, MANUAL CHILD BEHAV C; Amery J, 1995, PUBLIC HEALTH, V109, P421, DOI 10.1016/S0033-3506(95)80046-8; [Anonymous], 1991, MANUAL CHILD BEHAV C; BHUGRA TS, 1996, HOMELESSNESS MENTAL; BROOKS L, 1995, HOMELESSNESS HLTH RI; CONNELLY J, 1994, HOMELESSNESS ILL HLT; CONWAY J, 1988, PRESCRIPTION POOR HL; FINKELSTEIN JA, 1993, AM J DIS CHILD, V147, P520, DOI 10.1001/archpedi.1993.02160290026011; Goldberg D, 1978, MANUAL GEN HLTH QUES; Goldberg DP., 1992, COMMON MENTAL DISORD; HAMMOND L, 1995, ASS CHILD PSYCHOL PS, V17, P132; HEATH L, 1995, BRIT MED J, V309, P1675; HENDERSON S, 1980, NEUROSIS SOCIAL ENV; HENDERSON S, 1981, INTERVIEW SCHEDULE S; LEFF J, 1993, BMJ-BRIT MED J, V306, P669, DOI 10.1136/bmj.306.6879.669; *OFF POP CENS SURV, 1980, CLASS OCC 1989; Power S., 1995, NO PLACE LEARN HOMEL; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; STEWART G, 1992, BRIT J SOC WORK, V22, P271; THOMAS A, 1989, LIVING TEMPORARY ACC; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725; Vostanis P, 1996, EUR J PSYCHIAT, V10, P108; Vostanis P, 1997, J AM ACAD CHILD PSY, V36, P881, DOI 10.1097/00004583-199707000-00009	23	57	57	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					899	902		10.1136/bmj.316.7135.899	http://dx.doi.org/10.1136/bmj.316.7135.899			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD691	9552837	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072713300027
J	Cheng, CH; Kussie, P; Pavletich, N; Shuman, S				Cheng, CH; Kussie, P; Pavletich, N; Shuman, S			Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases	CELL			English	Article							ACTIVE-SITE; ESCHERICHIA-COLI; FLP RECOMBINASE; STRAND CLEAVAGE; DNA CLEAVAGE; DUPLEX DNA; PROTEIN; MUTANTS; BINDING; RESOLUTION	Vaccinia DNA topoisomerase breaks and rejoins DNA strands through a DNA-(3'-phosphotyrosyl)-enzyme intermediate. A C-terminal catalytic domain, Topo(81-314), suffices for transesterification chemistry. The domain contains a constellation of five amino acids, conserved in all eukaryotic type IB topoisomerases, that catalyzes attack of the tyrosine nucleophile on the scissile phosphate. The structure of the catalytic domain, consisting of ten alpha helices and a three-strand beta sheet, resembles the catalytic domains of site-specific recombinases that act via a topoisomerase IB-like mechanism. The topoisomerase catalytic pentad is conserved in the tertiary structures of the recombinases despite scant sequence similarity overall. This implies that the catalytic domains of type IB topoisomerases and recombinases derive from a common ancestral strand transferase.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Sloan Kettering Inst, Cellular Biochem Program, New York, NY 10021 USA; Sloan Kettering Inst, Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1986, J BIOL CHEM, V261, P391; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Caron P R, 1994, Adv Pharmacol, V29B, P271; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; ENG W, 1989, J BIOL CHEM, V262, P13373; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEE J, 1993, J BIOL CHEM, V268, P17564; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Shuman S, 1997, EMBO J, V16, P6584, DOI 10.1093/emboj/16.21.6584; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SHUMAN S, 1997, P NATL ACAD SCI USA, V16, P6584; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LK, 1997, BIOCHEMISTRY-US, V36, P3909, DOI 10.1021/bi962754p; Wang LK, 1997, BIOCHEMISTRY-US, V36, P7944, DOI 10.1021/bi970498q; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Yang W, 1997, STRUCTURE, V5, P1401, DOI 10.1016/S0969-2126(97)00290-6	55	206	227	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					841	850		10.1016/S0092-8674(00)81411-7	http://dx.doi.org/10.1016/S0092-8674(00)81411-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529259	Bronze			2022-12-28	WOS:000072661200016
J	Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ				Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ			Postmenopausal hormone use and risk for colorectal cancer and adenoma	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; estrogen replacement therapy; adenoma; colonoscopy; sigmoidoscopy	LARGE-BOWEL-CANCER; EXOGENOUS FEMALE HORMONES; COLON-CANCER; REPRODUCTIVE FACTORS; ESTROGEN-RECEPTOR; PROGESTERONE RECEPTORS; REPLACEMENT THERAPY; PROSPECTIVE COHORT; UNITED-STATES; CELL-LINES	Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [Cl, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with greater than or equal to 5 years of use. 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (greater than or equal to 1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Grodstein, F (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BURCH JC, 1975, ESTROGENS POST MENOP, P208; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CHUTE CG, 1991, EPIDEMIOLOGY, V2, P395, DOI 10.1097/00001648-199109000-00019; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CONCOLINO G, 1986, CANCER DETECT PREV, V9, P477; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS FG, 1989, INT J CANCER, V43, P587, DOI 10.1002/ijc.2910430409; DEVERDIER MG, 1992, CANCER CAUSE CONTROL, V3, P355, DOI 10.1007/BF00146889; FURNER SE, 1989, CANCER RES, V49, P4936; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HENDRICKSE CW, 1993, BRIT J SURG, V80, P636, DOI 10.1002/bjs.1800800531; HOSMER DW, 1989, APPL LOGISTIC REGRES; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; JACOBSON JS, 1995, CANCER CAUSE CONTROL, V6, P513, DOI 10.1007/BF00054159; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; LOINTIER P, 1992, ANTICANCER RES, V12, P1327; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; MOROTOMI M, 1990, CANCER RES, V50, P3595; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; Peipins LA, 1997, CANCER EPIDEM BIOMAR, V6, P671; PETERS RK, 1990, BRIT J CANCER, V61, P741, DOI 10.1038/bjc.1990.166; Potter JD, 1996, CANCER EPIDEM BIOMAR, V5, P779; POTTER JD, 1995, JNCI-J NATL CANCER I, V87, P1039, DOI 10.1093/jnci/87.14.1039; POTTER JD, 1983, J NATL CANCER I, V71, P703; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RISCH HA, 1995, CANCER EPIDEM BIOMAR, V4, P21; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SICA V, 1984, CANCER RES, V44, P4670; SINGH S, 1994, ANTICANCER RES, V14, P1037; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; Troisi R, 1997, CANCER CAUSE CONTROL, V8, P130, DOI 10.1023/A:1018455810238; WEISS NS, 1981, J NATL CANCER I, V67, P57; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; WUWILLIAMS AH, 1991, CANCER RES, V51, P2307; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197	43	230	236	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					705	+		10.7326/0003-4819-128-9-199805010-00001	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556463				2022-12-28	WOS:000073363800001
J	Heller, MA; Eisenberg, RS				Heller, MA; Eisenberg, RS			Can patents deter innovation? The anticommons in biomedical research	SCIENCE			English	Review								The "tragedy of the commons" metaphor helps explain why people overuse shared resources. However, the recent proliferation of intellectual property rights in biomedical research suggests a different tragedy, an "anticommons" in which people underuse scarce resources because too many owners can block each other. Privatization of biomedical research must be more carefully deployed to sustain both upstream research and downstream product development. Otherwise, more intellectual property rights may lead paradoxically to fewer useful products for improving human health.	Univ Michigan, Sch Law, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Heller, MA (corresponding author), Univ Michigan, Sch Law, Ann Arbor, MI 48109 USA.		Eisenberg, Robert/P-6070-2019					Baird Douglas G, 1994, GAME THEORY LAW, P21; BITTLINGMAYER G, 1988, J LAW ECON, V31, P227, DOI 10.1086/467155; COASE RH, 1960, J LAW ECON, V3, P1, DOI 10.1086/466560; COASE RH, 1988, FIRM MARKET LAW, P174; Demsetz H, 1967, AM ECON REV, V57, P347; Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; Eisenberg RS, 1996, VA LAW REV, V82, P1663, DOI 10.2307/1073686; Ellickson R., 1991, ORDER WITHOUT LAW; FUNDENBERG D, 1986, ECONOMETRICA, V54, P533; GOULD J, 1997, IDEA, V37, P449; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Heller MA, 1998, HARVARD LAW REV, V111, P621, DOI 10.2307/1342203; Hohfeld Wesley Newcomb, 1923, FUNDAMENTAL LEGAL CO; Kenney Martin, 1986, BIOTECHNOLOGY U IND; LEHMAN DR, 1988, AM PSYCHOL, V43, P431, DOI 10.1037/0003-066X.43.6.431; LEVIN RC, 1987, BROOKINGS PAP ECO AC, P783; Libecap G., 1989, CONTRACTING PROPERTY; Merges Robert P., 1995, AIPLA Q J, V23, P1; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; Merges RP, 1996, CALIF LAW REV, V84, P1293, DOI 10.2307/3480996; Merton R.K., 1979, SOCIOLOGY SCI; MICHELMAN F, 1982, NOMOS, V24, P3; *NAT HUM GEN RES I, 1996, 95005 NHGRI RFA; *NAT RES CONC, 1997, INT PROP RIGHTS RES; Ostrom E., 1990, GOVERNING COMMONS EV; ROSE C, 1986, U CHICAGO LAW REV, V53, P711, DOI 10.2307/1599583; Ross L, 1982, JUDGMENT UNCERTAINTY, P129, DOI [DOI 10.1017/CBO9780511809477, DOI 10.1017/CBO9780511809477.010]; TVERSKY A, 1992, J RISK UNCERTAINTY, V5, P297, DOI 10.1007/BF00122574; *US PAT TARD OFF, 1996, BNA PAT TRADEMARK CO, V52, P732; 1988, BIOTECHNOLOGY NEWSWA, V8, P7	30	1508	1545	9	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					698	701		10.1126/science.280.5364.698	http://dx.doi.org/10.1126/science.280.5364.698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZL268	9563938	Green Submitted			2022-12-28	WOS:000073415600036
J	Keen, J				Keen, J			Rethinking NHS networking	BRITISH MEDICAL JOURNAL			English	Article							CARE		Brunel Univ, Dept Govt, Uxbridge UB8 3PH, Middx, England	Brunel University	Keen, J (corresponding author), Kings Fund, London W1M 0AN, England.							ANDERSON R, 1995, BRIT MED J, V311, P5, DOI 10.1136/bmj.311.6996.5; ANTONELLI C, 1992, EC INFORMATION NETWO, P1; *AUD COMM, 1995, YOUR INF; Besanko D., 1996, EC STRATEGY; *COMM PUBL ACC, 1996, HOSP INF SUP SYST IN; *COMM PUBL ACC, 1993, WESS REG HLTH AUTH R; *DEP HLTH, 1997, REP REV PAT INF; *DEP HLTH, 1997, NEW NHS MOD MOD DEP; *DEP HLTH, 1996, NAT HLTH SERV SERV A; Ferguson B, 1996, HEALTH ECON, V5, P25, DOI 10.1002/(SICI)1099-1050(199601)5:1<25::AID-HEC181>3.0.CO;2-F; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Lock C, 1996, BRIT MED J, V312, P1407; *NAT AUD OFF, 1996, DEP HLTH HOSP INF SU; *NHS EX, 1995, PAT NOT PAP; *NHS EX, 1996, SEEING WOOD SPAR TRE; *NHS MAN EX INF MA, 1993, INV APPR BEN REAL IM, V2; NHS Management Executive, 1992, INF MAN TECHN STRAT; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; *US C, 1995, OTAITC624; WYATT JC, 1995, BRIT MED J, V311, P175, DOI 10.1136/bmj.311.6998.175	20	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1291	1293		10.1136/bmj.316.7140.1291	http://dx.doi.org/10.1136/bmj.316.7140.1291			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554901	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000073335900025
J	Thiadens, HA; de Bock, GH; Deker, FW; Huysman, JAN; van Houwelingen, JC; Springer, MP; Postma, DS				Thiadens, HA; de Bock, GH; Deker, FW; Huysman, JAN; van Houwelingen, JC; Springer, MP; Postma, DS			Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; BRONCHIAL HYPERRESPONSIVENESS; OFFICIAL STATEMENT; RESPONSIVENESS; BRONCHODILATOR; ASSOCIATION; COMMUNITY; SYMPTOMS; ADULTS	Objective: To determine the prevalence of asthma and chronic obstructive pulmonary disease in patients not known to have these disorders, who present in general practice with persistent cough, and to ascertain criteria to help general practitioners in diagnosis. Design: Descriptive study. Setting: Primary healthcare centre in the Netherlands. Subjects: 192 patients aged 18-75 years, not known to have asthma or chronic obstructive pulmonary disease, attending their general practitioner with cough persisting for at least 2 weeks. Methods: A diagnosis of asthma or chronic obstructive pulmonary was based on the recurrence of airway symptoms in the past year accompanied by spirometric measurements (including bronchodilator testing) and methacholine provocation tests. A scoring formula to estimate the probability of asthma or chronic obstructive pulmonary disease, based on history and physical examination, was generated by means of logistic regression. Results: 74 patients (39%) were classified as having asthma, 14 (7%) as hating chronic obstructive pulmonary disease. The best formula for predicting asthma or chronic obstructive pulmonary disease used scores for three symptoms: (reported) wheeze, (reported) dyspnoea, and allergen induced symptoms, together with prolonged expiration, pack years of smoking, and female sex variables were scored 1 when present and 0 when absent except for allergen induced symptoms (1.5) and number of pack years of smoking (n/25). With a cut off value of 3 on the scoring formula 76% of the patients could be classified correctly. Conclusions: About half of patients with persistent cough who present to a general practitioner have asthma or chronic obstructive pulmonary disease. With a simple formula based on three symptoms and prolonged expiration, pack years of smoking, and female sex most patients may be identified correctly in general practice.	Leiden Univ, Med Ctr, Dept Gen Practice, NL-2301 CB Leiden, Netherlands; Leiden Univ, Med Ctr, Med Decis Making Unit, NL-2301 CB Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2301 CB Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Groningen Hosp, Dept Lung Dis, NL-9700 RB Groningen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Thiadens, HA (corresponding author), Leiden Univ, Med Ctr, Dept Gen Practice, POB 2088, NL-2301 CB Leiden, Netherlands.		de Bock, Geertruida Hendrika/F-6529-2014; van houwelingen, hans c/C-1872-2008; Dekker, Friedo/B-6452-2011	de Bock, Geertruida Hendrika/0000-0003-3104-4471; van houwelingen, hans c/0000-0002-0494-4637; Dekker, Friedo/0000-0002-2433-2494	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOEZEN HM, 1995, THORAX, V50, P121, DOI 10.1136/thx.50.2.121; BOTTEMA BJA, 1993, THESIS U AMSTERDAM A, P64; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; CERVERI I, 1993, EUR RESPIR REV, V14, P424; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; HALLETT JS, 1985, ANN ALLERGY, V55, P568; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; RUTTEN GEHM, 1988, HUISARTS WETENSCHAP, V31, P293; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TRIGG CJ, 1990, THORAX, V45, P866, DOI 10.1136/thx.45.11.866; VANDELENDE R, 1991, SCAND J RESPIR DIS, V4, P612; WILLIAMSON HA, 1987, J FAM PRACTICE, V24, P35; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	19	46	48	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1998	316	7140					1286	1290		10.1136/bmj.316.7140.1286	http://dx.doi.org/10.1136/bmj.316.7140.1286			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554899	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000073335900023
J	Madhavan, V; Chen, W; Jamneala, T; Crommie, MF; Wingreen, NS				Madhavan, V; Chen, W; Jamneala, T; Crommie, MF; Wingreen, NS			Tunneling into a single magnetic atom: Spectroscopic evidence of the Kondo resonance	SCIENCE			English	Article							ELECTRONIC-STRUCTURE; ANDERSON MODEL; SCATTERING; METALS; IMPURITIES; MICROSCOPE; SURFACES; SIZE; 3D	The Kondo effect arises from the quantum mechanical interplay between the electrons of a host metal and a magnetic impurity and is predicted to result in local charge and spin variations around the magnetic impurity. A cryogenic scanning tunneling microscope was used to spatially resolve the electronic properties of individual magnetic atoms displaying the Kondo effect. Spectroscopic measurements performed on individual cobalt atoms on the surface of gold show an energetically narrow feature that is identified as the Kondo resonance-the predicted response of a Kondo impurity. Unexpected structure in the Kondo resonance is shown to arise from quantum mechanical interference between the d orbital and conduction electron channels for an electron tunneling into a magnetic atom in a metallic host.	Boston Univ, Dept Phys, Boston, MA 02215 USA; NEC Res Inst, Princeton, NJ 08540 USA	Boston University; NEC Corporation	Madhavan, V (corresponding author), Boston Univ, Dept Phys, 590 Commonwealth Ave, Boston, MA 02215 USA.							ALLEN JW, 1992, SYNCHROTRON RAD RES, V1, P253, DOI DOI 10.1007/978-1-4615-3280-4_6; ANDERSON PW, 1961, PHYS REV, V124, P41, DOI 10.1103/PhysRev.124.41; AVOURIS P, 1994, J VAC SCI TECHNOL B, V12, P1447, DOI 10.1116/1.587314; BLACHLY MA, 1995, PHYS REV B, V51, P12537, DOI 10.1103/PhysRevB.51.12537; BOYCE JB, 1974, PHYS REV LETT, V32, P61, DOI 10.1103/PhysRevLett.32.61; CHANDRASEKHAR V, 1994, PHYS REV LETT, V72, P2053, DOI 10.1103/PhysRevLett.72.2053; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; DAYBELL MD, 1968, REV MOD PHYS, V40, P380, DOI 10.1103/RevModPhys.40.380; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; GREGORY S, 1992, PHYS REV LETT, V68, P2070, DOI 10.1103/PhysRevLett.68.2070; GRUNER G, 1974, REP PROG PHYS, V37, P1497, DOI 10.1088/0034-4885/37/12/001; Hewson A C, 1993, KONDO PROBLEM HEAVY; HOUGHTON A, 1987, PHYS REV B, V35, P5123, DOI 10.1103/PhysRevB.35.5123; KEVAN SD, 1987, PHYS REV B, V36, P5809, DOI 10.1103/PhysRevB.36.5809; KONDO J, 1964, PROG THEOR PHYS, V32, P37, DOI 10.1143/PTP.32.37; LANG ND, 1987, PHYS REV LETT, V58, P45, DOI 10.1103/PhysRevLett.58.45; LANG ND, 1986, PHYS REV B, V34, P5947, DOI 10.1103/PhysRevB.34.5947; Li J. P. H., UNPUB; MAMY R, 1993, J PHYS-CONDENS MAT, V5, P6537, DOI 10.1088/0953-8984/5/36/008; MEIR Y, 1992, PHYS REV LETT, V68, P2512, DOI 10.1103/PhysRevLett.68.2512; PODLOUCKY R, 1980, PHYS REV B, V22, P5777, DOI 10.1103/PhysRevB.22.5777; RALPH DC, 1994, PHYS REV LETT, V72, P3401, DOI 10.1103/PhysRevLett.72.3401; REEHAL HS, 1980, J PHYS F MET PHYS, V10, P1631, DOI 10.1088/0305-4608/10/7/030; RIEGEL D, 1990, PHYSICA B, V163, P678, DOI 10.1016/0921-4526(90)90306-F; STEINER P, 1980, Z PHYS B CON MAT, V38, P191, DOI 10.1007/BF01315657; WEI W, 1989, PHYS REV B, V39, P4568, DOI 10.1103/PhysRevB.39.4568; Wolf E.L., 1985, PRINCIPLES ELECT TUN; WOLL C, 1989, PHYS REV B, V39, P7988, DOI 10.1103/PhysRevB.39.7988; Yazdani A, 1997, SCIENCE, V275, P1767, DOI 10.1126/science.275.5307.1767	30	820	830	3	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					567	569		10.1126/science.280.5363.567	http://dx.doi.org/10.1126/science.280.5363.567			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554843				2022-12-28	WOS:000073242100040
J	Simon, JB				Simon, JB			Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; COST-EFFECTIVENESS; MORTALITY; PROGRAM; CHANCE		Queens Univ, Kingston, ON K7L 5G2, Canada	Queens University - Canada	Simon, JB (corresponding author), Hotwl Dieu Hosp, Div Gastroenterol, 166 Brock St, Kingston, ON K7L 5G2, Canada.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; MORRIS JB, 1991, AM J SURG, V161, P101, DOI 10.1016/0002-9610(91)90368-N; Simon J B, 1998, Gastroenterologist, V6, P66; SIMON JB, 1990, JAMA-J AM MED ASSOC, V264, P84, DOI 10.1001/jama.264.1.84; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; Wagner JL, 1996, PREVENTION EARLY DET, P321; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WINCHESTER DP, 1980, CANCER, V45, P2955, DOI 10.1002/1097-0142(19800615)45:12<2955::AID-CNCR2820451211>3.0.CO;2-T; WINDELER J, 1987, INT J COLORECTAL DIS, V2, P223, DOI 10.1007/BF01649510; Wolf AMD, 1996, ARCH INTERN MED, V156, P1069, DOI 10.1001/archinte.156.10.1069	16	28	28	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1151	1152						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545367				2022-12-28	WOS:000073070100012
J	Vita, AJ; Terry, RB; Hubert, HB; Fries, JF				Vita, AJ; Terry, RB; Hubert, HB; Fries, JF			Aging, health risks, and cumulative disability	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; ELDERLY POPULATION; COLLEGE ALUMNI; OLDER PERSONS; LONGER LIFE; FOLLOW-UP; MEN; COMPRESSION; MORBIDITY	Background Persons with lower health risks tend to live longer than those with higher health risks, but there has been concern that greater longevity may bring with it greater disability. We performed a longitudinal study to determine whether persons with lower potentially modifiable health risks have more or less cumulative disability. Methods We studied 1741 university alumni who were surveyed first in 1962 (average age, 43 years) and then annually starting in 1986, Strata of high, moderate, and low risk were defined on the basis of smoking, body-mass index, and exercise patterns. Cumulative disability was determined with a health-assessment questionnaire and scored on a scale of 0 to 3. Cumulative disability from 1986 to 1994 (average age in 1994, 75 years) or death was the measure of lifetime disability. Results Persons with high health risks in 1962 or 1986 had twice the cumulative disability of those with low health risks (disability index, 1.02 vs. 0.49; P < 0.001). The results were consistent among survivors, subjects who died, men, and women and for both the last year and the last two years of observation. The onset of disability was postponed by more than five years in the low-risk group as compared with the high-risk group. The disability index for the low-risk subjects who died was half that for the high-risk subjects in the last one or two years of observation. Conclusions Smoking, body-mass index, and exercise patterns in midlife and late adulthood are predictors of subsequent disability. Not only do persons with better health habits survive longer, but in such persons, disability is postponed and compressed into fewer years at the end of life. (C) 1998, Massachusetts Medical Society.	Stanford Univ, Sch Med, Dept Med, Stanford, CA USA	Stanford University	Fries, JF (corresponding author), 1000 Welch Rd,Suite 203, Palo Alto, CA 94304 USA.		Fries, James F/F-6271-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043584] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43584] Funding Source: Medline; NICHD NIH HHS [R01 HD35641-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BROWN JH, 1984, AM J PUBLIC HEALTH, V74, P159, DOI 10.2105/AJPH.74.2.159; CRIMMINS EM, 1990, J INSURANCE MED, V22, P89; *DEP HLTH HUM SERV, 1990, DHHS PUBL PHS; *DEP HLTH HUM SERV, 1996, DHHS PUBL PHS; DUFFY ME, 1990, GERONTOLOGIST, V30, P503, DOI 10.1093/geront/30.4.503; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1994, ANN INTERN MED, V121, P502, DOI 10.7326/0003-4819-121-7-199410010-00005; FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRIES JF, 1982, J RHEUMATOL, V9, P789; Fries JF, 1981, VITALITY AGING; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; HJERMANN I, 1981, LANCET, V2, P1303; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HUBERT HB, 1993, J RHEUMATOL, V20, P480; Hubert Helen B., 1994, Annals of Epidemiology, V4, P285; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEIGH JP, 1994, INT J AGING HUM DEV, V39, P233, DOI 10.2190/XQXR-UTGP-WA8X-9FQJ; Lewis CE, 1997, AM J PUBLIC HEALTH, V87, P635, DOI 10.2105/AJPH.87.4.635; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; MYERS GC, 1984, GERONTOLOGIST, V24, P346, DOI 10.1093/geront/24.4.346; Nusselder WJ, 1996, GERONTOLOGIST, V36, P773, DOI 10.1093/geront/36.6.773; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; OLSHANSKY SJ, 1986, MILBANK Q, V64, P355, DOI 10.2307/3350025; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Ramey D., 1996, QUALITY LIFE PHARMAC, V2nd ed, P227; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; ROGERS A, 1990, GERONTOLOGIST, V30, P640, DOI 10.1093/geront/30.5.640; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; *SAS I, 1989, SAS STAT US GUID VER; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; STEWART AL, 1993, GERONTOLOGIST, V33, P782, DOI 10.1093/geront/33.6.782; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; WAIDMANN T, 1995, MILBANK Q, V73, P253, DOI 10.2307/3350259; WARNER KE, 1992, AM J PUBLIC HEALTH, V82, P126, DOI 10.2105/AJPH.82.1.126; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106	43	435	440	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1035	1041		10.1056/NEJM199804093381506	http://dx.doi.org/10.1056/NEJM199804093381506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG134	9535669				2022-12-28	WOS:000072969500006
J	Bignall, J				Bignall, J			Continuing medical education: shibboleth or necessity?	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Bignall, J (corresponding author), Lancet, London WC1B 3SL, England.							Grant J., 1988, EFFECTIVENESS CONTIN	1	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1004	1004		10.1016/S0140-6736(05)78994-7	http://dx.doi.org/10.1016/S0140-6736(05)78994-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546504				2022-12-28	WOS:000072927200008
J	Nathanson, V				Nathanson, V			Cambodia - after the killing fields	BRITISH MEDICAL JOURNAL			English	Article									BMA, Profess Resources & Res Grp, London WC1H 9JP, England		Nathanson, V (corresponding author), BMA, Profess Resources & Res Grp, London WC1H 9JP, England.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1082	1086						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552916				2022-12-28	WOS:000072987400037
J	Lebron, JA; Bennett, MJ; Vaughn, DE; Chirino, AJ; Snow, PM; Mintier, GA; Feder, JN; Bjorkman, PJ				Lebron, JA; Bennett, MJ; Vaughn, DE; Chirino, AJ; Snow, PM; Mintier, GA; Feder, JN; Bjorkman, PJ			Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor	CELL			English	Article							NEONATAL FC RECEPTOR; CLASS-I MOLECULES; HEREDITARY HEMOCHROMATOSIS; VIRAL PEPTIDES; BINDING; ASSOCIATION; RESOLUTION; PROGRAM; HLA-A2	HFE is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. HFE binds to transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating HFE in iron metabolism. The 2.6 Angstrom crystal structure of HFE reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that soluble TfR and HFE bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:HFE stoichiometry (2:1) differs from TfR: transferrin stoichiometry (2:2), implying a different mode of binding for HFE and transferrin to TfR, consistent with our demonstration that HFE, transferrin, and TfR form a ternary complex.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Caltech Prot Express Ctr, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Progenitor Inc, Menlo Park, CA 94025 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; California Institute of Technology	Lebron, JA (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							BACON BR, 1996, HEPATOLOGY TXB LIVER; Bebbington CRH, 1987, DNA CLONING; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Beutler E, 1997, AM J HUM GENET, V61, P762; BORHANI DW, 1991, J MOL BIOL, V218, P685, DOI 10.1016/0022-2836(91)90255-5; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chapman TL, 1998, J VIROL, V72, P460, DOI 10.1128/JVI.72.1.460-466.1998; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cuthbert JA, 1997, J INVEST MED, V45, P518; ENNS CA, 1981, J BIOL CHEM, V256, P9820; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fersht A., 1985, ENZYME STRUCTURE MEC; Hashimoto K, 1997, BIOCHEM BIOPH RES CO, V230, P35, DOI 10.1006/bbrc.1996.5889; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Malmqvist Magnus, 1994, Methods (Orlando), V6, P95, DOI 10.1006/meth.1994.1012; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; Vaughn DE, 1997, BIOCHEMISTRY-US, V36, P9374, DOI 10.1021/bi970841r; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	50	506	520	3	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					111	123		10.1016/S0092-8674(00)81151-4	http://dx.doi.org/10.1016/S0092-8674(00)81151-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546397	Bronze			2022-12-28	WOS:000072910800015
J	DiGuiseppi, C; Li, L; Roberts, I				DiGuiseppi, C; Li, L; Roberts, I			Influence of travel patterns on mortality from injury among teenagers in England and Wales, 1985-95: trend analysis	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Med, Inst Child Hlth, Dept Epidemiol,Child Hlth Monitoring Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	DiGuiseppi, C (corresponding author), UCL, Sch Med, Inst Child Hlth, Dept Epidemiol,Child Hlth Monitoring Unit, London WC1N 1EH, England.		DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817				*DEP TRANSP, 1992, TRANSP STAT REP NAT; Department of Health, 1992, HLTH NAT STRAT HLTH; DiGuiseppi C, 1997, BRIT MED J, V314, P710, DOI 10.1136/bmj.314.7082.710; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; WOODROFFE C, 1993, CHILDREN TEENAGERS H	5	8	9	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					904	905		10.1136/bmj.316.7135.904	http://dx.doi.org/10.1136/bmj.316.7135.904			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552840	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072713300030
J	Behrens, J; Jerchow, BA; Wurtele, M; Grimm, J; Asbrand, C; Wirtz, R; Kuhl, M; Wedlich, D; Birchmeier, W				Behrens, J; Jerchow, BA; Wurtele, M; Grimm, J; Asbrand, C; Wirtz, R; Kuhl, M; Wedlich, D; Birchmeier, W			Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3 beta	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; E-CADHERIN; XENOPUS; ASSOCIATION; EXPRESSION; MIGRATION; MESODERM; COMPLEX	Control of stability of beta-catenin is central in the wnt signaling pathway. Here, the protein conductin was found to form a complex with both beta-catenin and the tumor suppressor gene product adenomatous polyposis coli (APC), Conductin induced beta-catenin degradation, whereas mutants of conductin that were deficient in complex formation stabilized beta-catenin. Fragments of APC that contained a conductin-binding domain also blocked beta-catenin degradation. Thus, conductin is a component of the multiprotein complex that directs beta-catenin to degradation and is located downstream of APC. In Xenopus embryos, conductin interfered with wnt-induced axis formation.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Ulm, D-89081 Ulm, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ulm University	Birchmeier, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.	wbirch@mdc-berlin.de	Würtele, Martin/D-2686-2012	Jerchow, Boris-Alexander/0000-0002-7031-8730				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1994, J CELL SCI, V107, P3655; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLADT D, 1996, NATURE, V376, P768; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 1996, MECH DEVELOP, V54, P71, DOI 10.1016/0925-4773(95)00462-9; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	35	1072	1103	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					596	599		10.1126/science.280.5363.596	http://dx.doi.org/10.1126/science.280.5363.596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554852				2022-12-28	WOS:000073242100049
J	Nelms, BE; Maser, RS; MacKay, JF; Lagally, MG; Petrini, JHJ				Nelms, BE; Maser, RS; MacKay, JF; Lagally, MG; Petrini, JHJ			In situ visualization of DNA double-strand break repair in human fibroblasts	SCIENCE			English	Article							CULTURED MAMMALIAN-CELLS; ULTRASOFT X-RAYS; ESCHERICHIA-COLI; RAD51 GENE; RECOMBINATION; DAMAGE; PROTEIN; INACTIVATION; RADIATIONS; EXPRESSION	A method was developed to examine DNA repair within the intact cell. Ultrasoft x-rays were used to induce DNA double-strand breaks (DSBs) in defined subnuclear volumes of human fibroblasts and DNA repair was visualized at those sites. The DSBs remained in a fixed position during the initial stages of DNA repair, and the DSB repair protein hMre11 migrated to the sites of damage within 30 minutes. In contrast, hRad51, a human RecA homolog, did not localize at sites of DNA damage, a finding consistent with the distinct roles of these proteins in DNA repair.	Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Phys, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Mat Sci & Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Petrini, JHJ (corresponding author), Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA.		Maser, Richard/B-2970-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, T32GM007133] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM08349, 5T32GM07133] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADIE C, 1995, CANCER RES, V55, P1232; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Botchway SW, 1997, RADIAT RES, V148, P317, DOI 10.2307/3579516; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; CORNFORTH MN, 1983, SCIENCE, V222, P1141, DOI 10.1126/science.6648528; COX R, 1977, INT J RADIAT BIOL, V31, P561, DOI 10.1080/09553007714550661; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; GOODHEAD DT, 1993, INT J RADIAT BIOL, V63, P543, DOI 10.1080/09553009314450721; GOODHEAD DT, 1979, INT J RADIAT BIOL, V36, P101, DOI 10.1080/09553007914550861; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Jackson SP, 1996, CANCER SURV, V28, P261; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kanaar Roland, 1997, Genes and Function, V1, P165; KODYM R, 1995, INT J RADIAT BIOL, V68, P133, DOI 10.1080/09553009514551031; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; MACKAY JF, IN PRESS MED PHYS; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; NELMS BE, IN PRESS RAD RES; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVALDINE B, 1993, RADIAT RES, V133, P370, DOI 10.2307/3578224; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Strouboulis J, 1996, J CELL SCI, V109, P1991; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VIRSIKPEUCKERT RP, 1983, RAD INDUCED CHROMOSO, V4, P51; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Yamamoto A, 1996, MOL GEN GENET, V251, P1	42	411	419	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					590	592		10.1126/science.280.5363.590	http://dx.doi.org/10.1126/science.280.5363.590			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554850				2022-12-28	WOS:000073242100047
J	Nureki, O; Vassylyev, DG; Tateno, M; Shimada, A; Nakama, T; Fukai, S; Konno, M; Hendrickson, TL; Schimmel, P; Yokoyama, S				Nureki, O; Vassylyev, DG; Tateno, M; Shimada, A; Nakama, T; Fukai, S; Konno, M; Hendrickson, TL; Schimmel, P; Yokoyama, S			Enzyme structure with two catalytic sites for double-sieve selection of substrate	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASES; PROTEIN-SYNTHESIS; VALINE; ISOLEUCINE; DISCRIMINATION; RECOGNITION; MECHANISMS; RESIDUES; ERRORS	High-fidelity transfers of genetic information in the central dogma can be achieved by a reaction called editing. The crystal structure of an enzyme with editing activity in translation is presented here at 2.5 angstroms resolution. The enzyme, isoleucyl-transfer RNA synthetase, activates not only the cognate substrate L-isoleucine but also the minimally distinct L-valine in the first, aminoacylation step. Then, in a second, "editing" step, the synthetase itself rapidly hydrolyzes only the valylated products. For this two-step substrate selection, a "double-sieve" mechanism has already been proposed. The present crystal structures of the synthetase in complexes with L-isoleucine and L-valine demonstrate that the first sieve is on the aminoacylation domain containing the Rossmann fold, whereas the second, editing sieve exists on a globular beta-barrel domain that protrudes from the aminoacylation domain.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 113, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan; Matsushita Elect Ind Co Ltd, Int Inst Adv Res, Cent Res Labs, Kyoto 61902, Japan; Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 112, Japan; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	University of Tokyo; RIKEN; Panasonic; Ochanomizu University; Scripps Research Institute	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	yokoyama@y-sun.biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Vassylyev, Dmitry/A-9005-2008; Fukai, Shuya/X-4838-2018	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fukai, Shuya/0000-0002-1241-1443; Shimada, Atsushi/0000-0002-4108-770X	NIGMS NIH HHS [GM15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FARRASH MA, 1994, J VIROL, V68, P233; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; FUKAI S, UNPUB; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NUREKI O, UNPUB; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1957, FESTSCHRIFT ARTHUR S, P597; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT EG, UNPUB; SNEDDON SF, 1992, BIOCHEMISTRY-US, V31, P2842, DOI 10.1021/bi00125a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TAKANO K, 1995, J MOL BIOL, V254, P62, DOI 10.1006/jmbi.1995.0599; Zhang ZY, 1996, CANCER RES, V56, P3926	34	310	324	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					578	582		10.1126/science.280.5363.578	http://dx.doi.org/10.1126/science.280.5363.578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554847				2022-12-28	WOS:000073242100044
J	Perneger, TV				Perneger, TV			What's wrong with Bonferroni adjustments	BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE		Univ Geneva, Inst Social & Prevent Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Perneger, TV (corresponding author), Univ Geneva, Inst Social & Prevent Med, CH-1211 Geneva 4, Switzerland.							Berkson J, 1942, J AM STAT ASSOC, V37, P325, DOI 10.2307/2279000; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; GOODMAN SN, 1988, AM J PUBLIC HEALTH, V78, P1568, DOI 10.2105/AJPH.78.12.1568; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P364; JONES DR, 1982, INT J EPIDEMIOL, V11, P275; Neyman J, 1928, BIOMETRIKA, V20A, P175, DOI 10.2307/2331945; OAKES M, 1990, STAT INFERENCE; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; ROYALL R, 1997, STAT INFERENCE LIKEL; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584	12	4227	4242	5	219	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1236	1238		10.1136/bmj.316.7139.1236	http://dx.doi.org/10.1136/bmj.316.7139.1236			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553006	Green Published			2022-12-28	WOS:000073224100034
J	Burns, JO				Burns, JO			Stormy weather in galaxy clusters	SCIENCE			English	Review							X-RAY-CLUSTERS; RADIO-SOURCES; ABELL CLUSTERS; COOLING FLOWS; DYNAMICAL EVOLUTION; RICH CLUSTERS; COMA CLUSTER; CD CLUSTERS; SUBSTRUCTURE; MORPHOLOGIES	Recent x-ray, optical, and radio observations coupled with particle and gas dynamics numerical simulations reveal an unexpectedly complex environment within clusters of galaxies, driven by ongoing accretion of matter from large-scale supercluster filaments. Mergers between clusters and continuous infall of dark matter and baryons from the cluster periphery produce long-lived "stormy weather" within the gaseous cluster atmosphere-shocks, turbulence, and winds of more than 1000 kilometers per second. This weather may be responsible for shaping a rich variety of extended radio sources, which in turn act as "barometers" and "anemometers" of cluster weather.	Univ Missouri, Res Off, Columbia, MO 65211 USA; Univ Missouri, Dept Phys & Astron, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Burns, JO (corresponding author), Univ Missouri, Res Off, 205 Jesse Hall, Columbia, MO 65211 USA.	burns@research.missouri.edu						ABELL GO, 1989, ASTROPHYS J SUPPL S, V70, P1, DOI 10.1086/191333; Allen SW, 1996, MON NOT R ASTRON SOC, V279, P615, DOI 10.1093/mnras/279.2.615; Bahcall NA, 1997, ASTROPHYS J, V485, pL53, DOI 10.1086/310814; Balland C, 1997, ASTROPHYS J, V487, P33, DOI 10.1086/304612; BEERS TC, 1990, ASTRON J, V100, P32, DOI 10.1086/115487; BEGELMAN MC, 1979, NATURE, V279, P770, DOI 10.1038/279770a0; BIRD C, 1996, ASTRON J, V109, P920; BIRD CM, 1994, ASTRON J, V107, P1637, DOI 10.1086/116973; BLITON M, IN PRESS MON NOT R A; BUOTE DA, 1995, ASTROPHYS J, V452, P522, DOI 10.1086/176326; Buote DA, 1996, ASTROPHYS J, V458, P27, DOI 10.1086/176790; BURNS JO, 1994, ASTROPHYS J, V423, P94, DOI 10.1086/173792; BURNS JO, 1995, ASTROPHYS J, V446, P583, DOI 10.1086/175817; BURNS JO, 1991, SCIENCE, V253, P522, DOI 10.1126/science.253.5019.522; BURNS JO, 1994, ASTROPHYS J LETT, V427, P687; BUTCHER H, 1984, ASTROPHYS J, V285, P426, DOI 10.1086/162519; CEN RY, 1993, ASTROPHYS J, V417, P404, DOI 10.1086/173321; COUCH WJ, 1994, ASTROPHYS J, V430, P121, DOI 10.1086/174387; DAVIS DS, 1993, ASTRON J, V105, P409, DOI 10.1086/116439; DEYOUNG DS, 1980, ASTROPHYS J, V241, P81, DOI 10.1086/158320; DRESSLER A, 1994, ASTROPHYS J, V430, P107, DOI 10.1086/174386; EDGE AC, 1992, MON NOT R ASTRON SOC, V258, P177, DOI 10.1093/mnras/258.1.177; EILEK JA, 1990, ASTROPHYSICAL JETS, P428; EVRARD A, 1994, ASTROPHYS J, V437, P564; EVRARD AE, 1990, ASTROPHYS J, V363, P349, DOI 10.1086/169350; Evrard AE, 1997, MON NOT R ASTRON SOC, V292, P289, DOI 10.1093/mnras/292.2.289; EVRARD AE, 1993, ASTROPHYS J, V419, pL9, DOI 10.1086/187124; FABIAN AC, 1991, MON NOT R ASTRON SOC, V252, pP17, DOI 10.1093/mnras/252.1.17P; Gomez PL, 1997, ASTRON J, V114, P1711, DOI 10.1086/118600; Gomez PL, 1997, ASTROPHYS J, V474, P580, DOI 10.1086/303473; HANISCH RJ, 1980, ASTRON J, V85, P1565, DOI 10.1086/112834; HENRY JP, 1995, ASTROPHYS J, V443, pL9, DOI 10.1086/187823; Henry JP, 1997, ASTROPHYS J, V489, pL1, DOI 10.1086/310949; HILL JM, 1993, ASTRON J, V106, P831, DOI 10.1086/116688; JONES C, 1992, NATO ADV SCI I C-MAT, V366, P49; JONES TW, 1979, ASTROPHYS J, V234, P818, DOI 10.1086/157561; KIM KT, 1990, ASTROPHYS J, V355, P29, DOI 10.1086/168737; KOO DC, 1997, APJ, V478, P49; LAVERY RJ, 1988, ASTROPHYS J, V330, P596, DOI 10.1086/166496; LEDLOW M, 1997, 2 STROMLO S NATURE E, V116, P421; Loewenstein M, 1996, ASTROPHYS J, V466, P695, DOI 10.1086/177542; LOKEN C, 1995, ASTROPHYS J, V445, P80, DOI 10.1086/175674; LOKEN C, UNPUB; MARKEVITCH M, 1994, ASTROPHYS J, V436, pL71, DOI 10.1086/187635; MELOTT AL, 1983, PHYS REV LETT, V51, P935, DOI 10.1103/PhysRevLett.51.935; MELOTT AL, 1993, ASTROPHYS J, V410, P469, DOI 10.1086/172763; MIRALDAESCUDE J, 1995, ASTROPHYS J, V449, P18, DOI 10.1086/176027; MOHR JJ, 1993, ASTROPHYS J, V413, P492, DOI 10.1086/173019; MOHR JJ, 1995, ASTROPHYS J, V447, P8, DOI 10.1086/175852; Moore B, 1996, NATURE, V379, P613, DOI 10.1038/379613a0; NORMAN ML, 1997, P 12 KINGST M THEOR, P363; ODEA CP, 1985, ASTROPHYS J, V295, P80, DOI 10.1086/163351; OEGERLE WR, 1994, ASTRON J, V107, P857, DOI 10.1086/116899; Owen FN, 1997, ASTROPHYS J SUPPL S, V108, P41, DOI 10.1086/312954; PEEBLES PJE, 1993, PRINCIPLES PHYSICAL; PINKNEY J, 1994, ASTRON J, V108, P2031, DOI 10.1086/117216; PINKNEY J, 1993, ASTROPHYS J, V416, P36, DOI 10.1086/173213; Pinkney J, 1996, ASTROPHYS J SUPPL S, V104, P1, DOI 10.1086/192290; RAKOS KD, 1995, ASTROPHYS J, V439, P47, DOI 10.1086/175150; RICHSTONE D, 1992, ASTROPHYS J, V393, P477, DOI 10.1086/171521; Roettiger K, 1997, ASTROPHYS J SUPPL S, V109, P307, DOI 10.1086/312979; ROETTIGER K, 1995, ASTROPHYS J, V453, P634, DOI 10.1086/176426; Roettiger K, 1996, ASTROPHYS J, V473, P651, DOI 10.1086/178179; ROETTIGER K, 1993, ASTROPHYS J, V407, pL53, DOI 10.1086/186804; Roettiger K, 1998, ASTROPHYS J, V493, P62, DOI 10.1086/305102; ROETTIGER K, 1997, B AM ASTRON SOC, V29, P1302; SARAZIN CL, 1986, REV MOD PHYS, V58, P1, DOI 10.1103/RevModPhys.58.1; SCHINDLER S, 1993, ASTRON ASTROPHYS, V272, P137; SHORE SN, 1992, INTRO ASTROPHYSICAL, P107; SLEZAK E, 1994, ASTRON J, V108, P1996, DOI 10.1086/117212; TRIBBLE PC, 1993, MON NOT R ASTRON SOC, V263, P31, DOI 10.1093/mnras/263.1.31; TRUMPER J, 1993, SCIENCE, V260, P1769, DOI 10.1126/science.260.5115.1769; VOGES W, 1992, P EUROPEAN INT SPACE, P9; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WHITE SDM, 1993, MON NOT R ASTRON SOC, V261, pL18; ZHAO JH, 1989, ASTRON J, V98, P64, DOI 10.1086/115128; [No title captured]	77	57	57	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					400	404		10.1126/science.280.5362.400	http://dx.doi.org/10.1126/science.280.5362.400			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545210				2022-12-28	WOS:000073159600036
J	Fletcher, RH				Fletcher, RH			Should all people over the age of 50 have regular fecal occult-blood tests? If it works, why not do it?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; PREVENTION		Harvard Univ, Sch Med, Dep Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fletcher, RH (corresponding author), Harvard Univ, Sch Med, Dep Ambulatory Care & Prevent, 126 Brookline Ave, Boston, MA 02215 USA.							Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Church TR, 1997, JNCI-J NATL CANCER I, V89, P1440, DOI 10.1093/jnci/89.19.1440; Ederer F, 1997, J NATL CANCER I, V89, P1423, DOI 10.1093/jnci/89.19.1423; FLEISHER M, 1991, ANN INTERN MED, V114, P875, DOI 10.7326/0003-4819-114-10-875; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Wagner JL, 1996, PREVENTION EARLY DET, P321; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1995, B WORLD HEALTH ORGAN, V73, P7; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P1060; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1995, MMWR MORB MORTAL WKL, V45, P57	16	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1153	1154						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9547141				2022-12-28	WOS:000073070100013
J	Reynolds, T				Reynolds, T			Epilepsy treatment enters a new era	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					702	704		10.7326/0003-4819-128-8-199804150-00039	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537959				2022-12-28	WOS:000073052500032
J	Beecham, L				Beecham, L			Safeguards sought for winding up fundholding	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1098	1098						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552929				2022-12-28	WOS:000072987400076
J	Ruston, A; Clayton, J; Calnan, M				Ruston, A; Clayton, J; Calnan, M			Patients' action during their cardiac event: qualitative study exploring differences and modifiable factors	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION	Objectives: To explore the circumstances and factors that explain variations in response to a cardiac event and to identify potentially modifiable factors. Design: Qualitative analysis of semistructured, face to face interviews with patients admitted to two district hospitals for a cardiac event. Patients were divided into three groups according to the length of delay between onset of symptoms and calling for medical help. Subjects: 43 patients and 21 other people present at the time of the cardiac event. Patients were divided into three groups according to the length of time between onset of symptoms and seeking medical help: non-delayers (<4 h; n = 21), delayers (4-12 h; n = 12), and extended delayers (>12 h; n = 10). Main outcome measures: Decision making process, strategies for dealing with symptoms, and perception of risk and of heart attacks before the event according to delay in seeking help. Results: The illness and help seeking behaviour of informants had several components, including warning, interpretation, preliminary action, re-evaluation, and final action stages. The length of each stage was variable and depended on the extent to which informants mobilised and integrated resources into a strategy to bring their symptoms under control. There were obvious differences in informants' knowledge of the symptoms that they associated with a heart attack before the event. Non-delayers described a wider range of symptoms before their heart attack and twice as many (13) considered themselves to be potentially at risk of a heart attack compared with the other two groups. For most informants the heart attack differed considerably from their concept of a heart attack. Conclusion: The most critical factor influencing the time between onset of symptoms and calling for professional medical help is that patients and others recognise their symptoms as cardiac in origin. This study suggests that various points of intervention in the decision making process could assist symptom recognition and therefore faster access to effective treatment.	Univ Kent, Ctr Hlth Serv Studies, Canterbury CT2 7NF, Kent, England	University of Kent	Ruston, A (corresponding author), Univ Kent, Ctr Hlth Serv Studies, George Allen Wing, Canterbury CT2 7NF, Kent, England.	a.ruston@ukc.ac.uk						*BRIGHT HEART ATT, 1995, HEART ATT ACT LEAFL; *BRIT HEART FDN, 1996, INF CARD; *E KENT HLTH AUTH, 1993, HOM TREATM GUID; HACKETT TP, 1969, AM J CARDIOL, V24, P651, DOI 10.1016/0002-9149(69)90452-4; HERIOT AG, 1993, J ROY SOC MED, V86, P642; Julian DG, 1996, EUR HEART J, V17, P43; MAYCUT P, 1994, BEGINNING QUALITATIV; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; WEILGOSZ AT, 1991, CIRCULATION, V84, P2193; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767	10	111	111	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1060	1064						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552909				2022-12-28	WOS:000072987400027
J	Zatonski, WA; McMichael, AJ; Powles, JW				Zatonski, WA; McMichael, AJ; Powles, JW			Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIET; ACID	Objective: To investigate the reasons for the decline in deaths attributed to ischaemic heart disease in Poland since 1991 after two decades of rising rates. Design: Recent changes in mortality were measured as percentage deviations in 1994 from rates predicted by extrapolation of sex and age specific death rates for 1980-91 for diseases of the circulatory system and selected other categories, Available data on national and household food availability, alcohol consumption, cigarette smoking, socioeconomic indices, and medical services over time were reviewed. Main outcome measures: Age specific and age standardised rates of death attributed to ischaemic heart disease and related causes. Results: The change in trend in mortality attributed to diseases of the circulatory system was similar in men and women and most marked (> 20%) in early middle age, For ages 45 to 64 the decrease was greatest for deaths attributed to ischaemic heart disease and atherosclerosis (around 25%) and less for stroke (< 10%), For most of the potentially explanatory variables considered, there were no corresponding changes in trend. However, between 1986-90 and 1994 there was a marked switch from animal fats (estimated availability down 23%) to vegetable fats (up 48%) and increased imports of fruit. Conclusion: Reporting biases are unlikely to have exaggerated the true fall in ischaemic heart disease; neither is it likely to be mainly due to changes in smoking, drinking, stress, or medical care, Changes in type of dietary fat and increased supplies of fresh fruit and vegetables seem to be the best candidates.	Maria Sklodowska Curie Mem Canc Ctr, Dept Epidemiol & Canc Prevent, PL-02781 Warsaw, Poland; Inst Oncol, PL-02781 Warsaw, Poland; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Inst Publ Hlth, Cambridge CB2 2SR, England	Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge	Zatonski, WA (corresponding author), Maria Sklodowska Curie Mem Canc Ctr, Dept Epidemiol & Canc Prevent, PL-02781 Warsaw, Poland.	zatonskiw@coi.waw.pl		Powles, John/0000-0002-0766-7989				Bobak M, 1996, BRIT MED J, V312, P421; BRUTHANS J, 1997, CAN J CARDIOL SB, V13; BURR ML, 1989, LANCET, V2, P757; *CENTR STAT OFF, 1995, ROCZN STAT DEM; *CENTR STAT OFF, 1995, ROCZN STAT; *CENTR STAT OFF, 1970, ROCZN STAT; CHALLARAJ G, 1996, TRENDS HLTH STATUS S, V2, P44; CHARNOCK JS, 1994, PROG LIPID RES, V33, P355, DOI 10.1016/0163-7827(94)90023-X; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP STAT INF AN, 1995, HLTH CAR NUMB; DESPAIGNET ET, 1991, AUSTR I HLTH MORTALI, V1, P94; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; HEINEMANN L, 1994, ACTA CARDIOL, V44, P338; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; KOZAK LJ, 1988, COMP INT VITAL HLTH, V5; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; McLennan P, 1996, EUR J PHARMACOL, V300, P83, DOI 10.1016/0014-2999(95)00861-6; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; OKOLSKI M, 1994, STUD DEMOGR, V17, P3; OLES P, 1983, WORLD SMOKING HLTH, V8, P38; Pajak A, 1996, Przegl Lek, V53, P707; Powles JW, 1996, LANCET, V348, P898, DOI 10.1016/S0140-6736(05)64777-0; SCHWARTZ S, 1994, AM J PUBLIC HEALTH, V84, P819, DOI 10.2105/AJPH.84.5.819; Sekula W, 1996, FOOD CONSUMPTION POL; SEKULA W, 1970, BUDZETY GOSPONDARSTW; SIEROSLAWSKI J, 1995, ALKOHOLIZM NARKOMANI, V3, P57; STEWART AW, 1994, INT J EPIDEMIOL, V23, P505; STROM A, 1948, ACTA MED SCAND, V214, P22; STROM A, LANCET, V1, P126; Thiel Christine, 1996, Reviews on Environmental Health, V11, P35; THOM TJ, 1992, NIH PUBL; Waterhouse J., 1976, CANCER INCIDENCE 5 C, V3, P456; WATSON P, 1996, E W LIFE EXP GAP EUR, P152; *WHO, 1997, HLTH DATA BAS COMP P; *WHO, 1960, WORLD HLTH STAT ANN; *WHO, 1988, WORLD HLTH STAT ANN, pR17; *WORLD BANK, 1996, PLAN MARK WORLD DEV, P173; Zatonski W, 1995, Public Health Rev, V23, P139; ZATONSKI W, 1996, EVOLUTION HLTH POLAN, P27	40	146	149	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1047	1051						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552904				2022-12-28	WOS:000072987400022
J	Raftery, J				Raftery, J			Economic notes - Economic evaluation: a introduction	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE		Univ Birmingham, Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Raftery, J (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England.							*COMM AUSTR, 1992, GUID PHARM BEN ADV C; CULYER AJ, 1991, PROVIDING HLTH CARE; Drummond M., 1994, EC ANAL ALONGSIDE CO; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Gold MR, 1996, COST EFFECTIVENESS H; HUTTON J, 1994, HEALTH ECON, V3, P1, DOI 10.1002/hec.4730030103; Sheldon TA, 1996, HEALTH ECON, V5, P1; Tengs TO, 1996, HEALTH ECON, V5, P171, DOI 10.1002/(SICI)1099-1050(199605)5:3<171::AID-HEC210>3.0.CO;2-5	8	10	11	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1013	1014		10.1136/bmj.316.7136.1013	http://dx.doi.org/10.1136/bmj.316.7136.1013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF034	9550969	Green Published			2022-12-28	WOS:000072856100038
J	An, WG; Kanekal, M; Simon, MC; Maltepe, E; Blagosklonny, MV; Neckers, LM				An, WG; Kanekal, M; Simon, MC; Maltepe, E; Blagosklonny, MV; Neckers, LM			Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha	NATURE			English	Article							DNA-BINDING ACTIVITY; GROWTH-FACTOR GENE; FACTOR-I; TRANSCRIPTION FACTOR; ERYTHROPOIETIN GENE; SIGNAL-TRANSDUCTION; ACTIVATION; EXPRESSION; RECEPTOR; PROTEIN	Although hypoxia (lack of oxygen in body tissues) is perhaps the most physiological inducer of the wild-type p53 gene(1), the mechanism of this induction is unknown. Cells may detect low oxygen levels through a haem-containing sensor protein(2), The hypoxic state can be mimicked by using cobalt chloride and the iron chelator desferrioxamine(2-5): like hypoxia, cobalt chloride and desferrioxamine activate hypoxia-inducible factor 1 alpha (HIF-1 alpha) (ref. 6), which stimulates the transcription of several genes that are associated with hypoxia(6-9). Here we show that these treatments induce accumulation of wild-type p53 through HIF-1 alpha-dependent stabilization of p53 protein. Induction of p53 does not occur in either a mutant hepatoma cell line that is unable to induce HIF-1 alpha (ref. 10) or embryonic stem cells derived from mice lacking HIF-1 beta (ref. 11). HIF-1 alpha is found in p53 immunoprecipitates from II MCF7 cells that express wild-type p53 and are either hypoxic or have been exposed to desferrioxamine. Similarly, anti-haemagglutinin immunoprecipitates from lysates of normoxic PC3M cells that had been co-transfected with haemagglutinin-tagged HIF-1 alpha and wild-type p53 also contain p53. Transfection of normoxic MCF7 cells with HIF-1 alpha. stimulates a co-transfected p53-dependent reporter plasmid and increases the amount of endogenous p53. Our results suggest that hypoxic induction of transcriptionally active wild-type p53 is achieved as a result of the stabilization of p53 by its association with HIF-1 alpha.	NCI, Med Branch, NIH, Rockville, MD 20850 USA; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Dept Pathol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Neckers, LM (corresponding author), NCI, Med Branch, NIH, Key W Facil,9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.	len@helix.nih.gov	Simon, Celeste/AAG-3941-2021					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gradin K, 1996, MOL CELL BIOL, V16, P5221; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maki CG, 1996, CANCER RES, V56, P2649; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	23	727	762	3	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					405	408		10.1038/32925	http://dx.doi.org/10.1038/32925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537326				2022-12-28	WOS:000072713600056
J	Peppercorn, MA				Peppercorn, MA			A 66-year-old woman with ulcerative colitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; 5-AMINOSALICYLIC ACID; DOUBLE-BLIND; 6-MERCAPTOPURINE; TERM; SULPHASALAZINE; MANAGEMENT; THERAPY; TRIAL		Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Peppercorn, MA (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ASLAN A, 1992, AM J GASTROENTEROL, V87, P432; Bayless TM, 1996, GASTROENTEROLOGY, V111, P573, DOI 10.1053/gast.1996.v111.pm8780559; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; DHaens G, 1997, AM J GASTROENTEROL, V92, P1275; DICK AP, 1964, GUT, V5, P437, DOI 10.1136/gut.5.5.437; GARLAND CF, 1981, GASTROENTEROLOGY, V81, P1115; George J, 1996, AM J GASTROENTEROL, V91, P1711; Hawkey CJ, 1997, GASTROENTEROLOGY, V112, P718, DOI 10.1053/gast.1997.v112.pm9041232; LANGHOLZ E, 1992, GASTROENTEROLOGY, V103, P1444, DOI 10.1016/0016-5085(92)91163-X; LANGHOLZ E, 1994, GASTROENTEROLOGY, V107, P3, DOI 10.1016/0016-5085(94)90054-X; LENNARDJONES JE, 1995, EUR J CANCER, V31A, P1178, DOI 10.1016/0959-8049(95)00132-3; MARSHALL JK, 1995, ALIMENT PHARM THERAP, V9, P293; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; Peppercorn MA, 1996, AM J GASTROENTEROL, V91, P1689; PEPPERCORN MA, 1994, GASTROENTEROLOGY, V106, P751; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202; RACHMILEWITZ D, 1989, BMJ-BRIT MED J, V298, P82, DOI 10.1136/bmj.298.6666.82; RAO SSC, 1989, GUT, V30, P675, DOI 10.1136/gut.30.5.675; Sandborn WJ, 1997, ANN INTERN MED, V126, P364, DOI 10.7326/0003-4819-126-5-199703010-00004; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SOFDI M, 1997, AM J GASTROENTEROL, V92, P1867; Steinhart AH, 1996, ALIMENT PHARM THER, V10, P729, DOI 10.1046/j.1365-2036.1996.d01-509.x; SUTHERLAND CR, 1994, INFLAMM BOWEL DIS, P279; SUTHERLAND LR, 1964, GUT, V5, P437; TRUELOVE SC, 1958, BRIT MED J, V2, P1072, DOI 10.1136/bmj.2.5104.1072; TURNBULL RB, 1971, AM J SURG, V122, P325, DOI 10.1016/0002-9610(71)90252-2; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; VERNIA P, 1995, ALIMENT PHARM THERAP, V9, P306; WEISS EG, 1995, GASTROENTEROL CLIN N, V24, P559; WEXNER SD, 1990, AM J SURG, V159, P178, DOI 10.1016/S0002-9610(05)80625-7	32	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					949	953		10.1001/jama.279.12.949	http://dx.doi.org/10.1001/jama.279.12.949			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544770				2022-12-28	WOS:000072563600036
J	Juvonen, J; Juvonen, T; Laurila, A; Kuusisto, J; Alarakkola, E; Sarkioja, T; Bodian, CA; Kairaluoma, MI; Saikku, P				Juvonen, J; Juvonen, T; Laurila, A; Kuusisto, J; Alarakkola, E; Sarkioja, T; Bodian, CA; Kairaluoma, MI; Saikku, P			Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection?	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERIES; DISEASE; TWAR; HEART	Background: The cause of age-related degenerative (tricuspid) aortic valve calcification is largely unknown, but one typical characteristic is an active inflammatory process. The presence of Chlamydia pneumoniae in aortic valve stenosis was recently shown. Objective: To test the hypothesis that if persistent C. pneumoniae infection plays an active role in the development of aortic stenosis, the organism can be detected in the healthy aortic valves of young persons. Design: A cadaver study. Setting: Oulu University Hospital, Oulu, Finland. Subjects: 46 consecutive cadavers undergoing autopsy. Measurements: Macroscopic and histologic pathology of aortic valves was determined. The presence of C, pneumoniae was determined by immunohistochemistry. Results: 34 of 46 valves were macroscopically normal. Early lesions of aortic valve disease were found in 12 valves (no lesions in valves from persons 20 to 40 years of age [n = 15], 4 lesions in valves from persons 41 to 60 years of age [n = 16], and 8 lesions in valves from persons older than 60 years of age [n = 15]; P = 0.004). Fifteen of 34 normal valves (44%) and 10 of 12 valves with early lesions (83%) had positive results on staining for C. pneumoniae (P = 0.02). In persons older than 60 years of age, the chance of an early lesion was higher if the valve tested positive for C. pneumoniae (7 of 8 valves with C. pneumoniae infection compared with 1 of 7 valves without C. pneumoniae infection; P = 0.01). Conclusions: Chlamydia pneumoniae is frequently present in aortic valves and is associated with early lesions of aortic valve stenosis in elderly persons.	Oulu Univ Hosp, Dept Surg, Natl Publ Hlth Inst, FIN-90220 Oulu, Finland; Univ Oulu, Dept Forens Med, FIN-90220 Oulu, Finland; Kuopio Univ Hosp, Dept Internal Med, FIN-70211 Kuopio, Finland; Univ Kuopio, FIN-70211 Kuopio, Finland; Mt Sinai Sch Med, Dept Biomath, New York, NY 10029 USA	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Icahn School of Medicine at Mount Sinai	Juvonen, T (corresponding author), Oulu Univ Hosp, Dept Surg, Natl Publ Hlth Inst, FIN-90220 Oulu, Finland.							DARE AJ, 1993, HUM PATHOL, V24, P1330, DOI 10.1016/0046-8177(93)90267-K; Davies MJ, 1996, HEART, V75, P174, DOI 10.1136/hrt.75.2.174; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; HAMMERSCHLAG MR, 1992, CLIN INFECT DIS, V14, P178, DOI 10.1093/clinids/14.1.178; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; Juvonen J, 1997, J AM COLL CARDIOL, V29, P1054, DOI 10.1016/S0735-1097(97)00003-X; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; LEINONEN M, 1990, MICROB PATHOGENESIS, V9, P67, DOI 10.1016/0882-4010(90)90042-O; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; ODEH M, 1992, EUR J CLIN MICROBIOL, V11, P885, DOI 10.1007/BF01962368; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAIKKU P, 1985, J INFECT DIS, V151, P832, DOI 10.1093/infdis/151.5.832; WALLER BF, 1994, CLIN CARDIOL, V17, P150, DOI 10.1002/clc.4960170308; WARD C, 1974, LANCET, V2, P734; Ward ME, 1995, APMIS, V103, P769, DOI 10.1111/j.1699-0463.1995.tb01436.x	20	48	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					741	744		10.7326/0003-4819-128-9-199805010-00007	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556468				2022-12-28	WOS:000073363800006
J	McCarthy, EP; Burns, RB; Coughlin, SS; Freund, KM; Rice, J; Marwill, SL; Ash, A; Shwartz, M; Moskowitz, MA				McCarthy, EP; Burns, RB; Coughlin, SS; Freund, KM; Rice, J; Marwill, SL; Ash, A; Shwartz, M; Moskowitz, MA			Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		mammography; breast neoplasms; neoplasm staging; racial stocks	SOCIOECONOMIC-STATUS; HEALTH-SERVICES; RACE; AGE; SURVIVAL; INSURANCE; COVERAGE; DISEASE; EXTENT; CARE	Background: Older black women are less likely to undergo mammography and are more often given a diagnosis of advanced-stage breast cancer than older white women. Objective: To investigate the extent to which previous mammography explains observed differences in cancer stage at diagnosis between older black and white women with breast cancer. Design: Retrospective cohort study using the Linked Medicare-Tumor Registry Database. Setting: Population-based data from three geographic areas of the United States included in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (Connecticut; metropolitan Atlanta, Georgia; and Seattle-Puget Sound, Washington). Participants: Black and white women 67 years of age and older in whom breast cancer was diagnosed between 1987 and 1989. Measurements: Medicare claims were used to classify women according to mammography use in the 2 years before diagnosis as nonusers (no previous mammography), regular users (greater than or equal to 2 mammographies done at least 10 months apart), or peri-diagnosis users (mammography done only within 3 months before diagnosis). Information on mammography use was linked with SEER data to determine cancer stage at diagnosis. Stage was classified as early (in situ or local) or late (regional or distant). Results: Black women were more likely to not undergo mammography (odds ratio [OR], 3.00 [95% Cl, 2.41 to 3.75]) and to be given a diagnosis of late-stage disease (OR, 2.49 [CI, 1.59 to 3.92]) than white women. When women were stratified by previous mammography use, the black-white difference in cancer stage occurred only among nonusers (adjusted OR, 2.54 [CI, 1.37 to 4.71]). Among regular users, cancer was diagnosed in black and white women at similar stages (adjusted OR, 1.34 [CI, 0.40 to 4.51]). In logistic modeling, previous mammography alone explained about 30% of the excess late-stage disease in black women. In a separate model, previous mammography explained 12% of the excess late-stage disease among black women after adjustment for sociodemographic and comorbidity information. Conclusion: Differences in breast cancer stage at diagnosis between older black and white women are related to previous mammography use. Increased regular use of mammography may result in a shift toward earlier-stage disease at diagnosis and narrow the observed differences in stage at diagnosis between older black and white women.	Boston Med Ctr, Evans Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA; Boston Univ, Sch Management, Boston, MA 02215 USA	Boston Medical Center; Tulane University; Boston University	McCarthy, EP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, 330 Brookline Ave,Libby 326, Boston, MA 02215 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Freund, Karen/0000-0002-9049-5574	PHS HHS [30-P-90665/6] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; *BUR DAT MAN STRAT, 1997, US DEP HLTH HUM SERV; BURACK RC, 1989, AM J PUBLIC HEALTH, V79, P721, DOI 10.2105/AJPH.79.6.721; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; Burns RB, 1996, J AM GERIATR SOC, V44, P922, DOI 10.1111/j.1532-5415.1996.tb01861.x; CAPLAN LS, 1992, J GERONTOL, V47, P101; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; JONES BA, 1995, CANCER, V75, P2103, DOI 10.1002/1097-0142(19950415)75:8<2103::AID-CNCR2820750813>3.0.CO;2-2; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCWHORTER WP, 1989, CANCER, V63, P982, DOI 10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I; OMalley MS, 1997, AM J PUBLIC HEALTH, V87, P782, DOI 10.2105/AJPH.87.5.782; POTOSKY AL, 1993, MED CARE, V31, P732; Preston JA, 1997, J AM GERIATR SOC, V45, P1310, DOI 10.1111/j.1532-5415.1997.tb02929.x; *SAS I, 1992, SAS STAT US GUID VER, V2; *SAS I, 1992, SAS STAT US GUID VER, V1; SATARIANO WA, 1986, AM J PUBLIC HEALTH, V76, P779, DOI 10.2105/AJPH.76.7.779; *SEER PROGR, 1994, NIH PUBL; SONDIK EJ, 1994, CANCER, V74, P995, DOI 10.1002/1097-0142(19940801)74:3+<995::AID-CNCR2820741504>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; SWANSON GM, 1990, CANCER, V66, P1267; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; 1995, MMWR MORB MORTAL WKL, V45, P57; 1995, MMWR MORB MORTAL WKL, V44, P777	35	148	148	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					729	+		10.7326/0003-4819-128-9-199805010-00005	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZK790	9556466				2022-12-28	WOS:000073363800004
J	Grossniklaus, U; Vielle-Calzada, JP; Hoeppner, MA; Gagliano, WB				Grossniklaus, U; Vielle-Calzada, JP; Hoeppner, MA; Gagliano, WB			Maternal control of embryogenesis by medea, a Polycomb group gene in Arabidopsis	SCIENCE			English	Article							DROSOPHILA; EXPRESSION; ENDOSPERM; TRITHORAX; TRANSFORMATION; REGULATOR; EVOLUTION; MUTATION; ENHANCER; THALIANA	The gametophytic maternal effect mutant medea (mea) shows aberrant growth regulation during embryogenesis in Arabidopsis thaliana. Embryos derived from mea eggs grow excessively and die during seed desiccation. Embryo lethality is independent of the paternal contribution and gene dosage. The mea phenotype is consistent with the parental conflict theory for the evolution of parent-of-origin-specific effects. MEA encodes a SET domain protein similar to Enhancer of zeste, a member of the Polycomb group. In animals, Polycomb group proteins ensure the stable inheritance of expression patterns through cell division and regulate the control of cell proliferation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Grossniklaus, U (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	grossnik@cshl.org	Vielle-Calzada, Jean-Philippe/AAG-4036-2019; Grossniklaus, Ueli/A-2736-2012; Grossniklaus, Ueli/E-9995-2016	Grossniklaus, Ueli/0000-0002-0522-8974; Vielle-Calzada, Jean-Philippe/0000-0002-3017-2490				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; BERLETH T, 1993, DEVELOPMENT, V118, P575; BOUHARMONT J, 1972, J GENET CYTOL, V14, P257; CAPOWSKI EE, 1991, GENETICS, V129, P1061; Carrington EA, 1996, DEVELOPMENT, V122, P4073; CASTLE LA, 1993, MOL GEN GENET, V241, P504, DOI 10.1007/BF00279892; Chaudhury AM, 1997, P NATL ACAD SCI USA, V94, P4223, DOI 10.1073/pnas.94.8.4223; Colombo L, 1997, PLANT CELL, V9, P703, DOI 10.1105/tpc.9.5.703; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; HAIG D, 1991, CELL, V64, P1045; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HOLDERMAN R, COMMUNICATION; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KERMICLE J, 1990, DEVELOPMENT S, V1, P9; LIN BY, 1982, GENETICS, V100, P475; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MALUSZYNSKA J, 1993, ANN BOT-LONDON, V71, P479, DOI 10.1006/anbo.1993.1063; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; McDowell JM, 1996, GENETICS, V142, P587; Ohad N, 1996, P NATL ACAD SCI USA, V93, P5319, DOI 10.1073/pnas.93.11.5319; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PHILLIPS MD, 1990, GENETICS, V125, P91; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Ray S, 1996, DEV BIOL, V180, P365, DOI 10.1006/dbio.1996.0309; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; ROBBELEN G, 1966, ARABID INF SERV, V3, P16; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; TKACHUK DC, 1992, CELL, V71, P869; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; VANDERVEEN JH, 1973, ARABID INF SERV, V10, P11; VIELLECALZADA JP, UNPUB; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YU BD, 1995, NATURE, V378, P595	43	663	714	5	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					446	450		10.1126/science.280.5362.446	http://dx.doi.org/10.1126/science.280.5362.446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545225				2022-12-28	WOS:000073159600051
J	Lazarou, J; Pomeranz, BH; Corey, PN				Lazarou, J; Pomeranz, BH; Corey, PN			Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SURVEILLANCE-PROGRAM; PSYCHIATRIC UNIT; ADMISSIONS; EVENTS; QUALITY; PREVENTABILITY; METAANALYSIS; ILLNESS; CARE	Objective.-To estimate the incidence of serious and fatal adverse drug reactions (ADR) in hospital patients. Data Sources.-Four electronic databases were searched from 1966 to 1996. Study Selection.-Of 153, we selected 39 prospective studies from US hospitals. Data Extraction.-Data extracted independently by 2 investigators were analyzed by a random-effects model, To obtain the overall incidence of ADRs in hospitalized patients, we combined the incidence of ADRs occurring while in the hospital plus the incidence of ADRs causing admission to hospital. We excluded errors in drug administration, noncompliance, overdose, drug abuse, therapeutic failures, and possible ADRs. Serious ADRs were defined as those that required hospitalization, were permanently disabling, or resulted in death. Data Synthesis.-The overall incidence of serious ADRs was 6.7% (95% confidence interval [CI], 5.2%-8.2%) and of fatal ADRs was 0.32% (95% CI, 0.23%-0.41%) of hospitalized patients. We estimated that in 1994 overall 2 216 000 (1721 000-2 711 000) hospitalized patients had serious ADRs and 106 000 (76 000-137 000) had fatal ADRs, making these reactions between the fourth and sixth leading cause of death. Conclusions.-The incidence of serious and fatal ADRs in US hospitals was found to be extremely high, While our results must be viewed with circumspection because of heterogeneity among studies and small biases in the samples, these data nevertheless suggest that ADRs represent an important clinical issue.	Univ Toronto, Dept Physiol, Toronto, ON M5S 3G5, Canada; Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5S 3G5, Canada	University of Toronto; University of Toronto; University of Toronto	Pomeranz, BH (corresponding author), Univ Toronto, Dept Physiol, 25 Harbord St, Toronto, ON M5S 3G5, Canada.							*AM HOSP ASS, 1994, HOSP STAT 1993 1994; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BENNETT BS, 1977, AM J HOSP PHARM, V34, P931, DOI 10.1093/ajhp/34.9.931; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BIGBY J, 1987, AM J MED, V83, P1031, DOI 10.1016/0002-9343(87)90938-7; BORDA IT, 1968, JAMA-J AM MED ASSOC, V205, P99; Bowman Lee, 1994, Canadian Journal of Hospital Pharmacy, V47, P209; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CARBONIN P, 1991, J AM GERIATR SOC, V39, P1093, DOI 10.1111/j.1532-5415.1991.tb02875.x; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; CLUFF LE, 1964, JAMA-J AM MED ASSOC, V188, P976; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; DARCY PF, 1994, ADVERSE DRUG REACT T, V13, P65; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOMECQ C, 1980, INT J CLIN PHARM TH, V18, P362; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; FRISK PA, 1977, AM J HOSP PHARM, V34, P738, DOI 10.1093/ajhp/34.7.738; GARDNER P, 1970, CLIN PHARMACOL THER, V11, P802; Gray JB, 1996, NY TIMES, pA11; HURWITZ N, 1969, BRIT MED J, V1, P536, DOI 10.1136/bmj.1.5643.536; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; KARCH FE, 1976, CLIN PHARMACOL THER, V19, P489; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; MAY FE, 1977, J AM PHARM ASSOC, V17, P560, DOI 10.1016/S0003-0465(16)34453-6; MCKENNEY JM, 1976, AM J HOSP PHARM, V33, P792, DOI 10.1093/ajhp/33.8.792; MCKENZIE MW, 1976, J PEDIATR-US, V89, P487, DOI 10.1016/S0022-3476(76)80560-4; MCKENZIE MW, 1973, AM J HOSP PHARM, V30, P898, DOI 10.1093/ajhp/30.10.898; MILLER RR, 1974, ARCH INTERN MED, V134, P219, DOI 10.1001/archinte.134.2.219; MILLER RR, 1973, AM J HOSP PHARM, V30, P584, DOI 10.1093/ajhp/30.7.584; MITCHELL AA, 1988, PEDIATRICS, V82, P24; MITCHELL AA, 1979, AM J EPIDEMIOL, V110, P196, DOI 10.1093/oxfordjournals.aje.a112804; MORGAN KO, 1996, HLTH CARE STATE RANK; *NAT CTR HLTH STAT, 1994, US DEP HHS PUBL; Nelson KM, 1996, PHARMACOTHERAPY, V16, P701; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; OHara DA, 1997, MED J AUSTRALIA, V166, P460, DOI 10.5694/j.1326-5377.1997.tb123216.x; Rawlins MD, 1991, TXB ADVERSE DRUG REA; REICHEL W, 1965, J AM GERIATR SOC, V13, P973, DOI 10.1111/j.1532-5415.1965.tb02784.x; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; SALEM RB, 1984, DRUG INTEL CLIN PHAR, V18, P74, DOI 10.1177/106002808401800117; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; Sidel V W, 1967, Hospitals, V41, P80; SMIDT NA, 1972, NEW ZEAL MED J, V76, P397; SMIDT NA, 1973, NEW ZEAL MED J, V78, P39; SMITH JW, 1966, ANN INTERN MED, V65, P629, DOI 10.7326/0003-4819-65-4-629; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART RB, 1980, AM J PSYCHIAT, V137, P1093; WANG RIH, 1971, J CLIN PHARMACOL N D, V11, P14, DOI 10.1177/009127007101100102; World Health Organization, 1966, WHO TECHN REP SER, V425; ZILLERUELO I, 1987, INT J CLIN PHARM TH, V25, P328	59	3200	3399	6	149	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1200	1205		10.1001/jama.279.15.1200	http://dx.doi.org/10.1001/jama.279.15.1200			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555760				2022-12-28	WOS:000072969400034
J	Kerridge, I; Lowe, M; Henry, D				Kerridge, I; Lowe, M; Henry, D			Personal paper - Ethics and evidence based medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOTHERMIA EXPERIMENTS; TRIALS; WILL		Univ Newcastle, Fac Med & Hlth Sci, Clin Unit Eth & Hlth Law, Callaghan, NSW 2308, Australia	University of Newcastle	Kerridge, I (corresponding author), John Hunter Hosp, Locked Bag 1,Newcastle Mail Reg Ctr, Newcastle, NSW 2310, Australia.		Kerridge, Ian H/A-8355-2011; Henry, David/AAU-4650-2020; Henry, David/L-3895-2017	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242; Kerridge, Ian/0000-0001-7445-4660				ANGELL M, 1990, NEW ENGL J MED, V322, P1462, DOI 10.1056/NEJM199005173222011; [Anonymous], 1990, LANCET, V336, P65; BASTIAN H, 1994, POWER SHARING KNOWLE; BERGER RL, 1990, NEW ENGL J MED, V322, P1435, DOI 10.1056/NEJM199005173222006; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; Dowie J, 1996, J Health Serv Res Policy, V1, P104; DOWNEY M, 1997, SYDNEY MORNING  0510, P1; Eddy DM, 1996, JAMA-J AM MED ASSOC, V275, P650, DOI 10.1001/jama.275.8.650; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; Henry D, 1992, Pharmacoeconomics, V1, P54, DOI 10.2165/00019053-199201010-00010; HLAKTY MA, 1990, J AM COLL CARDIOL, V15, P1; HOPE T, 1995, J MED ETHICS, V21, P259, DOI 10.1136/jme.21.5.259; Maynard A, 1997, LANCET, V349, P126, DOI 10.1016/S0140-6736(96)05153-7; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; OLIVER SR, 1995, BRIT MED J, V310, P1318, DOI 10.1136/bmj.310.6990.1318; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1249; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SAMEI E, 1995, HEALTH PHYS, V69, P885, DOI 10.1097/00004032-199512000-00001; SHIMM DS, 1993, DRUGS, V46, P579, DOI 10.2165/00003495-199346040-00001; Smith R, 1997, BRIT MED J, V314, P1059, DOI 10.1136/bmj.314.7087.1059; Urbach P., 1993, SCI REASONING BAYESI, V2; *US PREV SERV TASK, 1995, GUID CLIN PREV SERV, P862; WALSH JT, 1995, BRIT HEART J, V73, P470; Williams Bernard, 1972, MORALITY; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	29	88	93	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	1998	316	7138					1151	1153		10.1136/bmj.316.7138.1151	http://dx.doi.org/10.1136/bmj.316.7138.1151			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552959	Green Published, Green Submitted			2022-12-28	WOS:000073067500038
J	Podmore, ID; Griffiths, HR; Herbert, KE; Mistry, N; Mistry, P; Lunec, J				Podmore, ID; Griffiths, HR; Herbert, KE; Mistry, N; Mistry, P; Lunec, J			Vitamin C exhibits pro-oxidant properties	NATURE			English	Letter							CHROMATOGRAPHY MASS-SPECTROMETRY; OXIDATIVE DNA-DAMAGE; BASE DAMAGE; 7,8-DIHYDRO-8-OXOADENINE; MUTAGENESIS; REPAIR; CELLS		Univ Leicester, CMHT, Div Chem Pathol, Leicester LE1 9HN, Leics, England	University of Leicester	Podmore, ID (corresponding author), Univ Leicester, CMHT, Div Chem Pathol, Leicester LE1 9HN, Leics, England.		Griffiths, Helen R./E-3453-2013	Griffiths, Helen R./0000-0002-2666-2147; Herbert, Karl/0000-0002-6760-7929				ARUOMA OI, 1991, CHEM BRIT, V27, P149; DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P3; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; HAMBERG M, 1995, ANAL BIOCHEM, V229, P336, DOI 10.1006/abio.1995.1422; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; Liu PK, 1996, J NEUROSCI, V16, P6795; LUNEC J, 1992, J INT FED CLIN CHEM, V4, P58; *MIN AGR FISH FOOD, 1995, ANT PROGR; Olinski R, 1996, CANCER LETT, V106, P207, DOI 10.1016/0304-3835(96)04320-0; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P1039, DOI 10.1021/tx00050a007; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023	12	637	668	1	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					559	559		10.1038/33308	http://dx.doi.org/10.1038/33308			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560150				2022-12-28	WOS:000072987200038
J	Anand, SS; Wells, PS; Hunt, D; Brill-Edwards, P; Cook, D; Ginsberg, JS				Anand, SS; Wells, PS; Hunt, D; Brill-Edwards, P; Cook, D; Ginsberg, JS			Does this patient have deep vein thrombosis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSPECTED VENOUS THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; TIME COMPRESSION ULTRASONOGRAPHY; B-MODE ULTRASONOGRAPHY; SYMPTOMATIC OUTPATIENTS; DIAGNOSTIC MANAGEMENT; CLINICAL EXAMINATION; PULMONARY-EMBOLISM; D-DIMER; VENOGRAPHY	Objective.-To review the validity of the clinical assessment and diagnostic tests in patients with suspected deep vein thrombosis (DVT). Methods.-A comprehensive review of the literature was conducted by searching MEDLINE from 1966 to April 1997. Results.-Individual symptoms and signs alone do nor reliably predict which patients have DVT, Overall, the diagnostic properties of the clinical examination are poor; the sensitivity of the clinical examination ranges from 60% to 96%, and the specificity ranges from 20% to 72%, However, using specific combinations of risk factors, symptoms, and physical signs for DVT, clinicians can reliably stratify patients with suspected DVT into low, moderate, or high pretest probability categories of actually suffering from DVT, This stratification process in combination with noninvasive testing, such as compression ultrasonography, simplifies the management strategies for patients with suspected DVT. Conclusions.-Use of a clinical prediction guide that includes specific factors from both the history and physical examination in combination with noninvasive tests simplifies management strategies for patients with suspected DVT.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; Ottawa Civic Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada	McMaster University; McMaster University; University of Ottawa; Ottawa Hospital Research Institute	Anand, SS (corresponding author), Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	anands@ths.momaster.ca	ginsberg, jeffrey s/ABC-1065-2020					ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; BARNES RW, 1975, JAMA-J AM MED ASSOC, V234, P605, DOI 10.1001/jama.234.6.605; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BROWSE N, 1969, BRIT MED J, V684, P676; COGO A, 1994, ARCH INTERN MED, V154, P164, DOI 10.1001/archinte.154.2.164; COGO A, 1994, ANGIOLOGY, V45, P377, DOI 10.1177/000331979404500507; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; COGO A, 1995, THROMB HAEMOSTASIS, V73, P1098; COGO A, 1993, THROMB HAEMOSTASIS, V70, P404; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; GINSBERG JS, 1994, ARCH INTERN MED, V154, P1930, DOI 10.1001/archinte.154.17.1930; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; GUNINTINI C, 1995, CHEST, V107, pS3; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, ARCH INTERN MED, V152, P1901, DOI 10.1001/archinte.152.9.1901; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB114, DOI 10.1016/S0735-1097(86)80013-4; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1984, CLIN CHEST MED, V5, P439; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; LANDEFELD CS, 1990, AM J MED, V88, P388; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; MOLLOY W, 1982, IRISH MED J, V75, P119; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P229; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SALE S, 1994, THROMB HEMOST, V71, P270; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; SIMPSON FG, 1980, LANCET, V1, P331; VINE HS, 1981, AM J ROENTGENOL, V136, P167, DOI 10.2214/ajr.136.1.167; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS P, 1997, LANCET, V356, P1795; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297	51	133	136	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1094	1099		10.1001/jama.279.14.1094	http://dx.doi.org/10.1001/jama.279.14.1094			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546569				2022-12-28	WOS:000072875300034
J	Owsley, C; Ball, K; McGwin, G; Sloane, ME; Roenker, DL; White, MF; Overley, ET				Owsley, C; Ball, K; McGwin, G; Sloane, ME; Roenker, DL; White, MF; Overley, ET			Visual processing impairment and risk of motor vehicle crash among older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY DRIVERS; ACCIDENTS; FIELD; SENSITIVITY; ATTENTION; AGE	Context.-Motor vehicle crash risk in older drivers has been associated with visual acuity loss, but only weakly so, suggesting other factors contribute. The useful field of view is a measure that reflects decline in visual sensory function, slowed visual processing speed, and impaired visual attention skills. Objective.-To identify whether measures of visual processing ability, including the useful field of view test, are associated with crash involvement by older drivers. Design.-Prospective cohort study with 3 years of follow-up, 1990-1993. Setting.-Ophthalmology clinic assessment of community-based sample. Patients.-A total of 294 drivers aged 55 to 87 years at enrollment. Main Outcome Measure.-Motor vehicle crash occurrence. Results.-Older drivers with a 40% or greater impairment in the useful field of view were 2.2 times (95% confidence interval, 1.2-4.1) more likely to incur a crash during 3 years of follow-up, after adjusting for age, sex, race, chronic medical conditions, mental status, and days driven per week, This association was primarily mediated by difficulty in dividing attention under brief target durations. Conclusion.-Reduction in the useful field of view increases crash risk in older drivers, Given the relatively high prevalence of visual processing impairment among the elderly, visual dysfunction and eye disease deserve further examination as causes of motor vehicle crashes and injury.	Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Psychol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Epidemiol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Physiol Opt, Birmingham, AL USA; Western Kentucky Univ, Dept Psychol, Bowling Green, KY 42101 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Western Kentucky University	Owsley, C (corresponding author), Univ Alabama Birmingham, Sch Med, Eye Fdn Hosp, Dept Ophthalmol,Clin Res Unit, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.	owsley@eyes.uab.edu		Ball, Karlene/0000-0003-1811-9870	NATIONAL INSTITUTE ON AGING [P50AG011684, R01AG005739, R01AG004212, R37AG005739] Funding Source: NIH RePORTER; NIA NIH HHS [AG04212, AG05739, AG11684] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison P. D., 1995, SURVIVAL ANAL USING; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K., 1990, DEV ATTENTION RES TH, V69, P489, DOI DOI 10.1016/S0166-4115(08)60472-0; BALL K, IN PRESS ACCID ANAL; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BRENTON RS, 1986, OPHTHALMOLOGICA, V193, P56, DOI 10.1159/000309679; Collett D, 1994, MODELLING SURVIVAL D; COOPER PJ, 1993, J SAFETY RES, V24, P9, DOI 10.1016/0022-4375(93)90047-Q; DECINA LE, 1993, ACCIDENT ANAL PREV, V25, P267, DOI 10.1016/0001-4575(93)90021-N; DRACHMAN DA, 1988, ANN NEUROL, V24, P787, DOI 10.1002/ana.410240614; EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013; Evans L., 1991, TRAFFIC SAFETY DRIVE; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; FLAHERTY JH, 1995, CLIN GERIATR MED, V3, P44; FOLEY DJ, 1995, J AM GERIATR SOC, V43, P776, DOI 10.1111/j.1532-5415.1995.tb07049.x; Haapanen N, 1997, AM J EPIDEMIOL, V145, P762, DOI 10.1093/aje/145.8.762; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Janke M., 1994, TRANSPORT RES REC, V1438, P77; Johansson K, 1996, J AM GERIATR SOC, V44, P1198, DOI 10.1111/j.1532-5415.1996.tb01369.x; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; KAHNEMAN D, 1973, J APPL PSYCHOL, V58, P113, DOI 10.1037/h0035426; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; KELTNER JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1697, DOI 10.1001/archopht.1992.01080240037023; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; KOEPSEL TD, 1994, J AM GERIATR SOC, V42, P695, DOI 10.1111/j.1532-5415.1994.tb06526.x; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; MAROTTOLI RA, 1994, ANN INTERN MED, V121, P842, DOI 10.7326/0003-4819-121-11-199412010-00003; MARTINEZ R, 1995, JAMA-J AM MED ASSOC, V274, P1060, DOI 10.1001/jama.274.13.1060; MCKNIGHT AJ, 1982, HS806336 DOT; Murakami E, 1997, COMP COMPUTER ASSIST; *NAT HIGHW TRAFF S, 1989, C RES DEV NEED IMPR; OWSLEY C, 1995, VISION RES, V35, P579, DOI 10.1016/0042-6989(94)00166-J; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; OWSLEY C, IN PRESS OPHTHALMIC; PELLI DG, 1988, CLIN VISION SCI, V2, P187; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; ROENKER DL, 1997, INVEST OPHTHALMOL  S, V38, P871; Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557; SANDERS A F, 1970, Ergonomics, V13, P101, DOI 10.1080/00140137008931124; SIMONS K, 1981, ARCH OPHTHALMOL-CHIC, V99, P446; Transportation Research Board, 1988, TRANSP AG SOC, V1; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0	44	569	574	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1083	1088		10.1001/jama.279.14.1083	http://dx.doi.org/10.1001/jama.279.14.1083			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546567	Bronze			2022-12-28	WOS:000072875300032
J	Montgomery, SM; Morris, DL; Thompson, NP; Subhani, J; Pounder, RE; Wakefield, AJ				Montgomery, SM; Morris, DL; Thompson, NP; Subhani, J; Pounder, RE; Wakefield, AJ			Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Montgomery, SM (corresponding author), Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England.		Montgomery, Scott/AAN-2546-2020	Montgomery, Scott/0000-0001-6328-5494				EKINSMYTH C, 1993, INTEGRATED APPROACH; EVANS JG, 1965, GUT, V6, P311, DOI 10.1136/gut.6.4.311; KEIGHLEY A, 1976, SCAND J GASTROENTERO, V2, P293; MAYBERRY J, 1979, GUT, V20, P602, DOI 10.1136/gut.20.7.602; Montgomery SM, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61183-X	5	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1058	1059						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552907				2022-12-28	WOS:000072987400025
J	DeRosier, DJ				DeRosier, DJ			The turn of the screw: The bacterial flagellar motor	CELL			English	Review							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; REGULATED UNDEREXPRESSION; FLIM; PROTEIN; SWITCH; COMPONENTS; MUTATIONS		Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02254 USA	Brandeis University	DeRosier, DJ (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02254 USA.							Berry RM, 1997, P NATL ACAD SCI USA, V94, P14433, DOI 10.1073/pnas.94.26.14433; BERRY RM, 1995, BIOPHYS J, V69, P280, DOI 10.1016/S0006-3495(95)79900-3; CAPLAN SR, 1993, INT REV CYTOL, V147, P97, DOI 10.1016/S0074-7696(08)60767-6; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Garza AG, 1996, J MOL BIOL, V258, P270, DOI 10.1006/jmbi.1996.0249; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; Lloyd SA, 1997, J MOL BIOL, V266, P733, DOI 10.1006/jmbi.1996.0836; Lloyd SA, 1996, J BACTERIOL, V178, P223, DOI 10.1128/jb.178.1.223-231.1996; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Marykwas DL, 1996, J BACTERIOL, V178, P1289, DOI 10.1128/jb.178.5.1289-1294.1996; TANG H, 1995, J BACTERIOL, V177, P3496, DOI 10.1128/jb.177.12.3496-3503.1995; TANG H, 1995, J BACTERIOL, V177, P3485, DOI 10.1128/jb.177.12.3485-3495.1995; Togashi F, 1997, J BACTERIOL, V179, P2994, DOI 10.1128/jb.179.9.2994-3003.1997; Toker AS, 1996, J BACTERIOL, V178, P7069, DOI 10.1128/jb.178.24.7069-7079.1996; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; Zhao RB, 1996, J BACTERIOL, V178, P258, DOI 10.1128/jb.178.1.258-265.1996; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452; Zhou JD, 1997, J MOL BIOL, V273, P428, DOI 10.1006/jmbi.1997.1316	18	121	124	3	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					17	20		10.1016/S0092-8674(00)81141-1	http://dx.doi.org/10.1016/S0092-8674(00)81141-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546387	Bronze			2022-12-28	WOS:000072910800005
J	Kinosita, K; Yasuda, R; Noji, H; Ishiwata, S; Yoshida, M				Kinosita, K; Yasuda, R; Noji, H; Ishiwata, S; Yoshida, M			F-1-ATPase: A rotary motor made of a single molecule	CELL			English	Review									Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, CREST, Nogawa, Kawasaki 2160001, Japan; Waseda Univ, Sch Sci & Engn, Dept Phys, Tokyo 1698555, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama 2268503, Kanagawa, Japan	Keio University; Japan Science & Technology Agency (JST); Teikyo University; Waseda University; Tokyo Institute of Technology	Kinosita, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; NISHIZAKA T, 1993, NATURE, V361, P269, DOI 10.1038/361269a0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1996, J BIOENERG BIOMEMBR, V28, P451, DOI 10.1007/BF02113988; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291	18	140	149	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					21	24		10.1016/S0092-8674(00)81142-3	http://dx.doi.org/10.1016/S0092-8674(00)81142-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546388	Bronze			2022-12-28	WOS:000072910800006
J	Lohman, TM; Thorn, K; Vale, RD				Lohman, TM; Thorn, K; Vale, RD			Staying on track: Common features of DNA helicases and microtubule motors	CELL			English	Review							COLI REP HELICASE; SINGLE-STRANDED-DNA; ATP HYDROLYSIS; KINESIN; TRANSLOCATION; SUBUNITS; BINDING		Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63122 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmacol, San Francisco, CA 94143 USA	Washington University (WUSTL); Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lohman, TM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63122 USA.			Thorn, Kurt/0000-0001-9310-288X	NIGMS NIH HHS [R01 GM045948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMBERG L, 1998, IN PRESS J CELL BIOL; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Wong I, 1996, P NATL ACAD SCI USA, V93, P10051, DOI 10.1073/pnas.93.19.10051; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	20	60	63	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					9	12		10.1016/S0092-8674(00)81139-3	http://dx.doi.org/10.1016/S0092-8674(00)81139-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546385	Bronze			2022-12-28	WOS:000072910800003
J	Greenhalgh, T; Helman, C; Chowdhury, AM				Greenhalgh, T; Helman, C; Chowdhury, AM			Health beliefs and folk models of diabetes in British Bangladeshis: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							OJIBWAY	Objective: To explore the experience of diabetes in British Bangladeshis, since successful management of diabetes requires attention not just to observable behaviour but to the underlying attitudes and belief systems which drive that behaviour. Design: Qualitative study of subjects' experience of diabetes using narratives, semi-structured interviews, focus groups, and pile sorting exercises. A new qualitative method, the structured vignette, was developed for validating researchers' understanding of primary level culture. Subjects: 40 British Bangladeshi patients with diabetes, and 10 non-Bangladeshi controls, recruited from primary care. Result: Several constructs were detected in relation to body image, cause and nature of diabetes, food classification, and knowledge of complications. In some areas, the similarities between Bangladeshi and non-Bangladeshi subjects were as striking as their differences. There was little evidence of a fatalistic or deterministic attitude to prognosis, and most informants seemed highly motivated to alter their diet and comply with treatment Structural and material barriers to behaviour change were at least as important as "cultural" ones. Conclusion: Bangladeshi culture is neither seamless nor static, but some widely held beliefs and behaviours have been identified. Some of these have a potentially beneficial effect on health and should be used as the starting point for culturally sensitive diabetes education.	UCL, Royal Free Hosp,Sch Med,Whittington Hosp, Joint Dept Primary Care & Populat, Qualitat Res Unit, London N19 5NF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Greenhalgh, T (corresponding author), UCL, Royal Free Hosp,Sch Med,Whittington Hosp, Joint Dept Primary Care & Populat, Qualitat Res Unit, London N19 5NF, England.	p.greenhalgh@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIRHIHENBUWA CO, 1992, AIDS EDUC PREV, V4, P267; AIRHIHENBUWA CO, 1995, HLTH CULTURE W PARAD, P25; ANDERSON JM, 1995, SOC SCI MED, V41, P181, DOI 10.1016/0277-9536(94)00324-M; Becker M H, 1986, Public Health Rev, V14, P15; BRADLEY C, 1994, DIABETIC MED, V11, P510, DOI 10.1111/j.1464-5491.1994.tb00316.x; Calman KC, 1997, BRIT MED J, V314, P1187, DOI 10.1136/bmj.314.7088.1187a; CHOWDHURY AM, 1986, THESIS U EXETER EXET; Clandinin DJ., 1994, HDB QUALITATIVE RES, P413; Crawford Robert, 1984, ISSUES POLITICAL EC, P60; Daniel M, 1995, DIABET SPECTRUM, V8, P80; Garro L C, 1995, Soc Sci Med, V40, P37, DOI 10.1016/0277-9536(94)00125-D; Gittelsohn J, 1996, HEALTH EDUC QUART, V23, P365, DOI 10.1177/109019819602300307; Grams GD, 1996, CAN MED ASSOC J, V155, P1563; Greenhalgh PM, 1997, DIABETIC MED, V14, P10; HALL ET, 1977, BEYOND CULTURE; HAYES BE, 1994, QUALITY PROGR    FEB, P41; HELMAN C, 1994, CULTURE HLTH ILLNESS, P21; HELMAN CG, 1991, PRIMARY CARE RES TRA, P105; Helman CG, 1994, CULTURE HLTH ILLNESS; Hiller, 1996, RES CULTURAL DIFFERE, P220; *HLTH ED AUTH, 1994, HLTH LIF SURV BLACK; KITZINGER J, 1994, SOCIOLOGY HLTH ILLNE, V16, P104; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; LAMBERT H, 1996, MISUNDERSTANDING SCI, P65, DOI DOI 10.1017/CBO9780511563737.004; PIERCE M, 1997, THESIS U LONDON LOND; [No title captured]	26	196	197	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					978	983		10.1136/bmj.316.7136.978	http://dx.doi.org/10.1136/bmj.316.7136.978			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550958	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072856100022
J	Seedat, YK				Seedat, YK			Isidor ("Okkie") Gordon - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		GORDON IO, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					941	941		10.1136/bmj.316.7135.941	http://dx.doi.org/10.1136/bmj.316.7135.941			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552864	Green Published			2022-12-28	WOS:000072713300074
J	Steel, KP				Steel, KP			Progress in progressive hearing loss	SCIENCE			English	Article							HAIR-CELLS; TRANSDUCTION		MRC, Inst Hearing Res, Nottingham NG7 2RD, England		Steel, KP (corresponding author), MRC, Inst Hearing Res, Nottingham NG7 2RD, England.							DAVIS AC, 1989, INT J EPIDEMIOL, V18, P911, DOI 10.1093/ije/18.4.911; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676; Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695; Gorlin RJ, 1995, HEREDITARY HEARING L; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; Johnson KR, 1997, HEARING RES, V114, P83, DOI 10.1016/S0378-5955(97)00155-X; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; Ryan AF, 1997, SEMIN CELL DEV BIOL, V8, P249, DOI 10.1006/scdb.1997.0146; RYAN AF, 1998, ASS RES OTOLARYNGOL, V697; STEEL KP, 1994, TRENDS GENET, V10, P428, DOI 10.1016/0168-9525(94)90113-9; Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950; VanCamp G, 1997, AM J HUM GENET, V60, P758; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445	18	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1870	1871		10.1126/science.279.5358.1870	http://dx.doi.org/10.1126/science.279.5358.1870			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537904				2022-12-28	WOS:000072613300027
J	Ebenbichler, GR; Resch, KL; Nicolakis, P; Wiesinger, GF; Uhl, F; Ghanem, AH; Fialka, V				Ebenbichler, GR; Resch, KL; Nicolakis, P; Wiesinger, GF; Uhl, F; Ghanem, AH; Fialka, V			Ultrasound treatment for treating the carpal tunnel syndrome: randomised "sham" controlled trial	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC ULTRASOUND; STEROID INJECTION	Objective: To assess the efficacy of ultrasound treatment for mild to moderate idiopathic carpal tunnel syndrome. Design: Randomised, double blind, "sham" controlled trial with assessments at baseline, after 2 weeks' and 7 weeks' treatment and at a follow up assessment 6 months later (8 months after baseline evaluation), Setting Outpatient clinic of a university department of physical medicine and rehabilitation in Vienna. Subjects: 45 patients with mild to moderate bilateral carpal tunnel syndrome as verified by electroneurography. Intervention: 20 sessions of ultrasound (active) treatment (1 MHz, 1.0 W/cm(2), pulsed mode 1:4, 15 minutes per session) applied to the area over the carpal tunnel of one wrist, and indistinguishable sham ultrasound treatment applied to the other. The first 10 treatments were performed daily (5 sessions/week); 10 further treatments were twice weekly for 5 weeks. Main outcome measures: Score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity). Results: Improvement was significantly more pronounced in actively treated than in sham treated mists for both subjective symptoms (P < 0.001, paired t test) and electroneurographic variables (motor distal latency P < 0.001, paired t test; sensory antidromic nerve conduction velocity P < 0.001, paired t test). Effects were sustained at 6 months' follow up. Conclusion: Results suggest there are satisfying short to medium term effects due to ultrasound treatment in patients with mild to moderate idiopathic carpal tunnel syndrome. Findings need to be confirmed, and ultrasound treatment will have to be compared with standard conservative and invasive treatment options.	Univ Vienna, Dept Phys Med & Rehabil, A-1090 Vienna, Austria; Univ Exeter, Dept Complementary Med, Exeter, Devon, England; Univ Vienna, Dept Neurol, A-1090 Vienna, Austria	University of Vienna; University of Exeter; University of Vienna	Ebenbichler, GR (corresponding author), Univ Vienna, Dept Phys Med & Rehabil, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.							BARNETT SB, 1994, ULTRASOUND MED BIOL, V20, P205, DOI 10.1016/0301-5629(94)90060-4; BAYSAL AI, 1993, ACTA NEUROL SCAND, V88, P213; BINDER A, 1985, BRIT MED J, V290, P512, DOI 10.1136/bmj.290.6467.512; BURKE DT, 1994, ARCH PHYS MED REHAB, V75, P1241, DOI 10.1016/0003-9993(94)90012-4; BURTON RI, 1975, CURR PROBL SURG S7, V12, P17; BYL NN, 1992, ARCH PHYS MED REHAB, V73, P656; COTTON P, 1991, JAMA-J AM MED ASSOC, V265, P1921; CURRIER DP, 1978, ARCH PHYS MED REHAB, V59, P181; DAWSON DM, 1993, NEW ENGL J MED, V329, P2013, DOI 10.1056/NEJM199312303292707; DYSON M, 1987, PHYSIOTHERAPY, V73, P116; EDEL H, 1970, Archiv fuer Physikalische Therapie, V22, P255; ELHAG M, 1985, BRIT J ORAL MAX SURG, V23, P17, DOI 10.1016/0266-4356(85)90074-9; GELBERMAN RH, 1980, J BONE JOINT SURG AM, V62, P1181, DOI 10.2106/00004623-198062070-00020; GELBERMAN RH, 1981, J BONE JOINT SURG AM, V63, P380, DOI 10.2106/00004623-198163030-00009; GIANNINI F, 1991, ARCH PHYS MED REHAB, V72, P738; GIRLANDA P, 1993, J NEUROL, V240, P187, DOI 10.1007/BF00857526; HONG CZ, 1988, ARCH PHYS MED REHAB, V69, P410; KRAMER JF, 1989, AM J PHYS MED, V64, P1; Ludin HP, 1993, PRAKTISCHE ELEKTROMY; MAYR H, 1994, OSTERR Z PHYS MED, V4, P95; MCCONNELL JR, 1990, CLIN ORTHOP RELAT R, P181; OMALLEY MJ, 1992, J HAND SURG-AM, V17A, P638, DOI 10.1016/0363-5023(92)90307-B; STEVENS JC, 1987, MUSCLE NERVE, V10, P99, DOI 10.1002/mus.880100202; 1985, LANCET, V1, P854	24	148	150	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					731	735		10.1136/bmj.316.7133.731	http://dx.doi.org/10.1136/bmj.316.7133.731			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529407	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072463700029
J	Zhou, WZ; Thomas, JM; Shephard, DS; Johnson, BFG; Ozkaya, D; Maschmeyer, T; Bell, RG; Ge, QF				Zhou, WZ; Thomas, JM; Shephard, DS; Johnson, BFG; Ozkaya, D; Maschmeyer, T; Bell, RG; Ge, QF			Ordering of ruthenium cluster carbonyls in mesoporous silica	SCIENCE			English	Article							CATALYSTS; CHEMISTRY; PARTICLES; METALS	The anionic ruthenium cluster carbonylates [Ru6C(CO)(16)](2-) or [H2Ru10(CO)(25)](2-) interspersed with bis(triphenylphosphino)iminium counterions (PPN+) are incorporated from solution into the pores of MCM-41 mesoporous silica (3 nanometers in diameter), where they form tightly packed arrays. These arrays were shown by high-resolution transmission electron microscopy, Fourier transform optical diffraction, and computer simulations to be well ordered both along and perpendicular to the axis of the cylindrical pores. In their denuded state produced by gentle thermolysis, the cluster carbonylates yield nanoparticles of ruthenium that are less well ordered than their assimilated precursors but show good activity as hydrogenation catalysts for hexene and cyclooctene. In both their as-prepared and denuded states, these encapsulated clusters are likely to exhibit interesting electronic and other properties.	Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England; UCL Royal Inst Great Britain, Davy Faraday Res Lab, London W1X 4BS, England; Univ Cambridge, Dept Mat Sci, Cambridge CB2 3QZ, England	University of Cambridge; University of London; University College London; University of Cambridge	Zhou, WZ (corresponding author), Univ Cambridge, Chem Lab, Lensfield Rd, Cambridge CB2 1EW, England.	wz100@cus.cam.ac.uk	Zhou, Wuzong/AAA-8268-2019; Ge, Qingfeng/A-8498-2009; Bell, Robert G/C-4007-2008; Maschmeyer, Thomas/H-5993-2015; Way, James Douglas/A-9408-2010; Zhou, Wuzong/GPS-4743-2022	Ge, Qingfeng/0000-0001-6026-6693; Maschmeyer, Thomas/0000-0001-8494-9907; Way, James Douglas/0000-0001-9612-8508; Zhou, Wuzong/0000-0001-9752-7076				Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Andres RP, 1996, SCIENCE, V273, P1690, DOI 10.1126/science.273.5282.1690; BAHL OP, 1967, SURF SCI, V8, P473, DOI 10.1016/0039-6028(67)90056-8; Bailey PJ, 1996, J CHEM SOC DALTON, P3515, DOI 10.1039/dt9960003515; BECK JS, 1992, J AM CHEM SOC, V114, P10835; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; CHE M, 1989, ADV CATAL, V36, P55, DOI 10.1016/S0360-0564(08)60017-6; FALTHOUSE TR, 1996, ADV CATALYSTS NANOST, P91; Faraday M., 1857, PHILOS T ROY SOC LON, V147, P145, DOI [10.1098/rstl.1857.001, DOI 10.1098/RSTL.1857.0011]; Francis GM, 1996, J CHEM SOC DALTON, P665, DOI 10.1039/dt9960000665; GEORGIADES G, 1987, ANGEW CHEM INT EDIT, V26, P1042, DOI 10.1002/anie.198710421; HENGLEIN A, 1993, ISRAEL J CHEM, V33, P77; HILL JR, 1994, J PHYS CHEM-US, V98, P1238, DOI 10.1021/j100055a032; JEFFERSON DA, 1979, NATURE, V281, P51, DOI 10.1038/281051a0; JEFFERSON DA, 1986, NATURE, V323, P428, DOI 10.1038/323428a0; JOHNSON BFG, 1980, J ORGANOMET CHEM, V191, pC3, DOI 10.1016/S0022-328X(00)81077-3; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; KURODA H, 1989, INT REV PHYS CHEM, V8, P207, DOI 10.1080/01442358909353229; Maschmeyer T, 1997, ANGEW CHEM INT EDIT, V36, P1639, DOI 10.1002/anie.199716391; MASCHMEYER T, 1995, NATURE, V378, P159, DOI 10.1038/378159a0; MILLWARD GR, 1974, P CARB GRAPH C SOC C, P492; RAIMONDI ME, 1997, J CHEM SOC CHEM COMM, P1843; Schmid G, 1997, CURR OPIN SOLID ST M, V2, P204, DOI 10.1016/S1359-0286(97)80067-8; Shephard DS, 1997, ANGEW CHEM INT EDIT, V36, P2242, DOI 10.1002/anie.199722421; SHEPHARD DS, 1993, J CHEM SOC FARADAY T, V89, P3437; SIMON A, 1988, ANGEW CHEM INT EDIT, V27, P159, DOI 10.1002/anie.198801591; Sinfelt J. H., 1983, BIMETALLIC CATALYSTS; SINFELT JH, 1988, INT REV PHYS CHEM, V7, P281, DOI 10.1080/01442358809353215; Sloan J, 1997, J MATER CHEM, V7, P1089, DOI 10.1039/a700035i; THOMAS JM, 1988, PURE APPL CHEM, V60, P1517, DOI 10.1351/pac198860101517; THOMAS JM, 1972, P ROY SOC LOND A MAT, V331, P417, DOI 10.1098/rspa.1972.0188; Thomas JM, 1996, FARADAY DISCUSS, V105, P1, DOI 10.1039/fd9960500001; Thomas JM, 1997, CHEM-EUR J, V3, P1557, DOI 10.1002/chem.19970031004; VALOKITIN Y, 1997, NATURE, V384, P621; VESSAL B, 1993, J NON-CRYST SOLIDS, V159, P184, DOI 10.1016/0022-3093(93)91295-E; Whetten RL, 1996, ADV MATER, V8, P428, DOI 10.1002/adma.19960080513; Yamamoto T, 1996, J AM CHEM SOC, V118, P5810, DOI 10.1021/ja953065o	37	230	243	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					705	708		10.1126/science.280.5364.705	http://dx.doi.org/10.1126/science.280.5364.705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563939				2022-12-28	WOS:000073415600037
J	van Turennout, M; Hagoort, P; Brown, CM				van Turennout, M; Hagoort, P; Brown, CM			Brain activity during speaking: From syntax to phonology in 40 milliseconds	SCIENCE			English	Article							PARTIAL INFORMATION; LEXICAL ACCESS; POTENTIALS	In normal conversation, speakers translate thoughts into words at high speed. To enable this speed, the retrieval of distinct types of linguistic knowledge has to be orchestrated with millisecond precision. The nature of this orchestration is still largely unknown. This report presents dynamic measures of the real-time activation of two basic types of linguistic knowledge, syntax and phonology. Electrophysiological data demonstrate that during noun-phrase production speakers retrieve the syntactic gender of a noun before its abstract phonological properties. This two-step process operates at high speed: the data show that phonological information is already available 40 milliseconds after syntactic properties have been retrieved.	Max Planck Inst Psycholinguist, NL-6525 XD Nijmegen, Netherlands	Max Planck Society	van Turennout, M (corresponding author), NIMH, Lab Brain & Cognit, Bldg 10,Room 4C104,10 Ctr Dr,MSC 1366, Bethesda, MD 20892 USA.		Hagoort, Peter/B-7417-2012					Butterworth B., 1989, LEXICAL REPRESENTATI, P108; COLES MGH, 1989, PSYCHOPHYSIOLOGY, V26, P251, DOI 10.1111/j.1469-8986.1989.tb01916.x; COLES MGH, 1995, OX PSYCH S, P86; DEJONG R, 1988, J EXP PSYCHOL HUMAN, V14, P682, DOI 10.1037/0096-1523.14.4.682; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; GARRETT M, 1992, COGNITION, V42, P143, DOI 10.1016/0010-0277(92)90042-G; KUTAS M, 1980, BRAIN RES, V202, P95, DOI 10.1016/S0006-8993(80)80037-0; LEVELT WJM, 1991, PSYCHOL REV, V98, P122, DOI 10.1037/0033-295X.98.1.122; LEVELT WJM, 1989, SPEAKING INTENTION A; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; Miozzo M, 1997, J COGNITIVE NEUROSCI, V9, P160, DOI 10.1162/jocn.1997.9.1.160; OSMAN A, 1992, J EXP PSYCHOL HUMAN, V18, P217, DOI 10.1037/0096-1523.18.1.217; SMID HGOM, 1992, J EXP PSYCHOL HUMAN, V18, P1101, DOI 10.1037/0096-1523.18.4.1101	13	177	179	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					572	574		10.1126/science.280.5363.572	http://dx.doi.org/10.1126/science.280.5363.572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZJ684	9554845	Green Submitted			2022-12-28	WOS:000073242100042
J	Elmore, G; Barton, MB; Moceri, VM; Polk, S; Arena, PJ; Fletcher, SW				Elmore, G; Barton, MB; Moceri, VM; Polk, S; Arena, PJ; Fletcher, SW			Ten-year risk of false positive screening mammograms and clinical breast examinations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	National Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med			PREDICTIVE VALUE; CANCER; AUDIT; ANXIETY	Background The cumulative risk of a false positive result of a breast-cancer screening test is unknown. Methods We performed a 10-year retrospective cohort study of breast-cancer screening and diagnostic evaluations among 2400 women who were 40 to 69 years old at study entry. Mammograms or clinical breast examinations that were interpreted as indeterminate, aroused a suspicion of cancer, or prompted recommendations for additional workup in women in whom breast cancer was not diagnosed within the next year were considered to be false positive tests. Results A total of 9762 screening mammograms and 10,905 screening clinical breast examinations were performed, for a median of 4 mammograms and 5 clinical breast examinations per woman over the 10-year period. Of the women who were screened, 23.8 percent had at least one false positive mammogram, 13.4 percent had at least one false positive breast examination, and 31.7 percent had at least one false positive result for either test. The estimated cumulative risk of a false positive result was 49.1 percent (95 percent confidence interval, 40.3 to 64.1 percent) after 10 mammograms and 22.3 percent (95 percent confidence interval, 19.2 to 27.5 percent) after 10 clinical breast examinations. The false positive tests led to 870 outpatient appointments, 539 diagnostic mammograms, 186 ultrasound examinations, 188 biopsies, and 1 hospitalization. We estimate that among women who do not have breast cancer, 18.6 percent (95 percent confidence interval, 9.8 to 41.2 percent) will undergo a biopsy after 10 mammograms, and 6.2 percent (95 percent confidence interval, 3.7 to 11.2 percent) after 10 clinical breast examinations. For every $100 spent for screening, an additional $33 was spent to evaluate the false positive results. Conclusions Over 10 years, one third of the women screened had abnormal test results requiring additional evaluation, even though no breast cancer was present. Techniques are needed to decrease false positive results while maintaining high sensitivity. Physicians should educate women about the risk of a false positive result of a screening test for breast cancer. (C) 1998, Massachusetts Medical Society.	Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA 98195 USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Dept Diagnost Radiol, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard Pilgrim Health Care; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Elmore, G (corresponding author), Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, 1959 NE Pacific,Rm BB527E,Box 356429, Seattle, WA 98195 USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; Bassett LW, 1994, AHCPR PUBLICATION; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BULL AR, 1991, BRIT J RADIOL, V64, P510, DOI 10.1259/0007-1285-64-762-510; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; ELLMAN R, 1989, BRIT J CANCER, V60, P781, DOI 10.1038/bjc.1989.359; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; GRAM IT, 1992, AM J PUBLIC HEALTH, V82, P249, DOI 10.2105/AJPH.82.2.249; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KIRSCHNER CG, 1994, PHYSICIANS CURRENT P; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; LERMAN C, 1991, J CLIN ONCOL, V9, P1275, DOI 10.1200/JCO.1991.9.7.1275; Lidbrink E, 1996, BRIT MED J, V312, P273; LINVER MN, 1995, AM J ROENTGENOL, V165, P19, DOI 10.2214/ajr.165.1.7785586; Paskett ED, 1995, J WOMENS HEALTH, V4, P73; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; *SAS I, 1996, SAS VERS 6 11; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SUTTON S, 1995, J EPIDEMIOL COMMUN H, V49, P413, DOI 10.1136/jech.49.4.413; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; 1995, MMWR MORB MORTAL WKL, V45, P57; 1996, FED REG, V61, P59490	27	761	777	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1089	1096		10.1056/NEJM199804163381601	http://dx.doi.org/10.1056/NEJM199804163381601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545356	Bronze			2022-12-28	WOS:000073070100001
J	Ouriel, K; Veith, FJ; Sasahara, AA				Ouriel, K; Veith, FJ; Sasahara, AA		Thrombolysis Peripheral Arterial Surg TOPAS In	A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOLYTIC THERAPY; PERIPHERAL ARTERIAL; ISCHEMIA; MANAGEMENT	Background Recent controlled trials suggest that thrombolytic therapy may be an effective initial treatment for acute arterial occlusion of the legs. A major potential benefit of initial thrombolytic therapy is that limb ischemia can be managed with less invasive interventions. Methods In this randomized, multicenter trial conducted at 113 North American and European sites, we compared vascular surgery (e.g., thrombectomy or bypass surgery) with thrombolysis by catheter-directed intraarterial recombinant urokinase; all patients (272 per group) had had acute arterial obstruction of the legs for 14 days or less. Infusions were limited to a period of 48 hours (mean [+/-SE], 24.4+/-0.86), after which lesions were corrected by surgery or angioplasty if needed. The primary end point was the amputation-free survival rate at six months. Results Final angiograms, which were available for 246 patients treated with urokinase, revealed recanalization in 196 (79.7 percent) and complete dissolution of thrombus in 167 (67.9 percent). Both treatment groups had similar significant improvements in mean ankle-brachial blood-pressure index. Amputation-free survival rates in the urokinase group were 71.8 percent at six months and 65.0 percent at one year, as compared with respective rates of 74.8 percent and 69.9 percent in the surgery group; the 95 percent confidence intervals for the differences were -10.5 to 4.5 percentage points at six months (P = 0.43) and -12.9 to 3.1 percentage points at one year (P = 0.23), At six months the surgery group had undergone 551 open operative procedures (excluding amputations), as compared with 315 in the thrombolysis group. Major hemorrhage occurred in 32 patients in the urokinase group (12.5 percent) as compared with 14 patients in the surgery group (5.5 percent) (P = 0.005). There were four episodes of intracranial hemorrhage in the urokinase group (1.6 percent), one of which was fatal. By contrast, there were no episodes of intracranial hemorrhage in the surgery group. Conclusions Despite its association with a higher frequency of hemorrhagic complications, intraarterial infusion of urokinase reduced the need for open surgical procedures, with no significantly increased risk of amputation or death. (C) 1998, Massachusetts Medical Society.	Univ Rochester, Sch Med & Dent, Dept Surg, Rochester, NY 14642 USA; Albert Einstein Sch Med, Dept Surg, Bronx, NY USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Rochester; Yeshiva University; Harvard University; Harvard Medical School	Ouriel, K (corresponding author), Univ Rochester, Sch Med & Dent, Dept Surg, 601 Elmwood Ave, Rochester, NY 14642 USA.							DORTER CT, 1974, RADIOLOGY, V111, P31; EARNSHAW JJ, 1991, BRIT J SURG, V78, P261, DOI 10.1002/bjs.1800780304; GRAOR RA, 1994, ANN SURG, V220, P251; GRAOR RA, 1985, J VASC SURG, V2, P406, DOI 10.1067/mva.1985.avs0020406; HESS H, 1982, NEW ENGL J MED, V307, P1627, DOI 10.1056/NEJM198212233072606; HILL SL, 1994, AM SURGEON, V60, P907; JIVEGARD L, 1988, J CARDIOVASC SURG, V29, P32; MARDER VJ, 1990, AM J HOSP PHARM, V47, pS15, DOI 10.1093/ajhp/47.9_Suppl_2.S15; MCNAMARA TO, 1985, AM J ROENTGENOL, V144, P769, DOI 10.2214/ajr.144.4.769; OURIEL K, 1994, J VASC SURG, V19, P1021, DOI 10.1016/S0741-5214(94)70214-4; Ouriel K, 1996, J VASC SURG, V23, P64, DOI 10.1016/S0741-5214(05)80036-9; RICOTTA J, 1991, CIRCULATION, V83, P120; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; SICARD GA, 1985, J VASC SURG, V2, P65, DOI 10.1067/mva.1985.avs0020065; YEAGER RA, 1992, J VASC SURG, V15, P385, DOI 10.1016/0741-5214(92)90260-F	15	475	504	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1105	1111		10.1056/NEJM199804163381603	http://dx.doi.org/10.1056/NEJM199804163381603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545358				2022-12-28	WOS:000073070100003
J	Papile, LA; Tyson, JE; Stoll, BJ; Wright, LL; Donovan, EF; Bauer, CR; Krause-Steinrauf, H; Verter, J; Korones, SB; Lemons, JA; Fanaroff, AA; Stevenson, DK				Papile, LA; Tyson, JE; Stoll, BJ; Wright, LL; Donovan, EF; Bauer, CR; Krause-Steinrauf, H; Verter, J; Korones, SB; Lemons, JA; Fanaroff, AA; Stevenson, DK			A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LUNG-DISEASE; EARLY POSTNATAL DEXAMETHASONE; RESPIRATORY-DISTRESS SYNDROME; BIRTH-WEIGHT INFANTS; BRONCHOPULMONARY DYSPLASIA; FOLLOW-UP; PRETERM INFANTS; CLINICAL-TRIALS; THERAPY	Background Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. Methods We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator-dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory-index scores (mean airway pressure x the fraction of inspired oxygen) of greater than or equal to 2.4 at two weeks of age. One hundred eighty-two infants received dexamethasone for two weeks followed by placebo for two weeks, and 189 infants received placebo for two weeks followed by either dexamethasone (those with a respiratory-index score of greater than or equal to 2.4 on treatment day 14) or additional placebo for two weeks. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose was then tapered. Results The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks' postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P<0.001) in both groups. Conclusions Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age. (C) 1998, Massachusetts Medical Society.	Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Albuquerque, NM 87131 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Emory Univ, Atlanta, GA 30322 USA; NICHHD, Bethesda, MD 20892 USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Univ Miami, Miami, FL 33152 USA; George Washington Univ, Ctr Biostat, Rockville, MD USA; Univ Tennessee, Memphis, TN USA; Indiana Univ, Indianapolis, IN 46204 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Stanford Univ, Stanford, CA 94305 USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; Yale Univ, New Haven, CT USA; Wayne State Univ, Detroit, MI USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University System of Ohio; University of Cincinnati; University of Miami; George Washington University; University of Tennessee System; University of Tennessee Health Science Center; Indiana University System; Indiana University-Purdue University Indianapolis; Case Western Reserve University; Stanford University; Brown University; Women & Infants Hospital Rhode Island; Yale University; Wayne State University	Papile, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pediat, UNMH ACC 3 W, Albuquerque, NM 87131 USA.				NICHD NIH HHS [U10 HD21373, U10 HD27851, U10 HD27881] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021373, U10HD027851] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD027881] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASSADI FK, 1996, INTENSIVE CARE FETUS, P1050; AVERY GB, 1985, PEDIATRICS, V75, P106; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; COTTERRELL M, 1972, J NEUROCHEM, V19, P2151, DOI 10.1111/j.1471-4159.1972.tb05124.x; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; DURAND M, 1995, PEDIATRICS, V95, P584; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FURMAN L, 1995, J PEDIATR-US, V126, P434, DOI 10.1016/S0022-3476(95)70464-7; GLADSTONE IM, 1989, PEDIATRICS, V84, P1072; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; JONES R, 1991, PEDIATRICS, V88, P421; JONES R, 1995, PEDIATRICS, V96, P897; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAZZI NJ, 1990, PEDIATRICS, V86, P722; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MAMMEL MC, 1987, DEV PHARMACOL THERAP, V10, P1; Marinelli KA, 1997, J PEDIATR-US, V130, P594, DOI 10.1016/S0022-3476(97)70244-0; NG PC, 1990, ARCH DIS CHILD-FETAL, V65, P54, DOI 10.1136/adc.65.1_Spec_No.54; OSHEA TM, 1993, AM J DIS CHILD, V147, P658, DOI 10.1001/archpedi.1993.02160300064024; OSHEA TM, 1997, PEDIATR RES, V41, pA207; PAPILE LA, 1994, PEDIATR RES, V35, pA246; Rastogi A, 1996, PEDIATRICS, V98, P204; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; Shinwell ES, 1996, ARCH DIS CHILD-FETAL, V74, pF33, DOI 10.1136/fn.74.1.F33; Stoll BJ, 1996, J PEDIATR-US, V129, P63, DOI 10.1016/S0022-3476(96)70191-9; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEICHSEL ME, 1977, ANN NEUROL, V2, P364, DOI 10.1002/ana.410020503; Yeh T. F., 1997, Pediatric Research, V41, p188A; YEH TF, 1990, J PEDIATR-US, V117, P273, DOI 10.1016/S0022-3476(05)80547-5; YEH TF, 1995, PEDIATR RES, V37, pA247	30	121	124	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1112	1118		10.1056/NEJM199804163381604	http://dx.doi.org/10.1056/NEJM199804163381604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545359	Bronze			2022-12-28	WOS:000073070100004
J	Rugg, MD; Mark, RE; Walla, P; Schloerscheidt, AM; Birch, CS; Allan, K				Rugg, MD; Mark, RE; Walla, P; Schloerscheidt, AM; Birch, CS; Allan, K			Dissociation of the neural correlates of implicit and explicit memory	NATURE			English	Article							RECOGNITION MEMORY; CONSCIOUS RECOLLECTION; RETRIEVAL; POTENTIALS; JUDGMENTS	One presentation of a word to a subject is enough to change the way in which the word is processed subsequently, even when there is no conscious (explicit) memory of the original presentation. This phenomenon is known as implicit memory(1-3). The neural correlates of implicit memory have been studied previously(4-11), but they have never been compared with the correlates of explicit memory while holding task conditions constant or while using a procedure that ensured that the neural correlates were not 'contaminated' by explicit memory. Here we use scalp-recorded event-related brain potentials to identify neural activity associated with implicit and explicit memory during the performance of a recognition memory task, Relative to new words, recently studied words produced activity in three neuroanatomically and functionally dissociable neural populations. One of these populations was activated whether or not the word was consciously recognized, and its activity therefore represents a neural correlate of implicit memory. Thus, when task and memory contamination effects are eliminated, the neural correlates of explicit and implicit memory differ qualitatively.	Univ St Andrews, Sch Psychol, Wellcome Brain Res Grp, St Andrews KY16 9JU, Fife, Scotland; Univ Vienna, Dept Neurol, A-1180 Vienna, Austria	University of St Andrews; University of Vienna	Rugg, MD (corresponding author), Univ St Andrews, Sch Psychol, Wellcome Brain Res Grp, St Andrews KY16 9JU, Fife, Scotland.		Allan, Kevin/C-4951-2008; Walla, Peter/B-4225-2008; Walla, Peter/G-8167-2013	Mark, Ruth/0000-0003-2765-7646; Walla, Peter/0000-0002-0207-7699	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allan K, 1998, ACTA PSYCHOL, V98, P231, DOI 10.1016/S0001-6918(97)00044-9; Allan K, 1997, NEUROPSYCHOLOGIA, V35, P387, DOI 10.1016/S0028-3932(96)00094-2; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Buckner RL, 1998, NEURON, V20, P285, DOI 10.1016/S0896-6273(00)80456-0; Gardiner JM, 1996, CAN J EXP PSYCHOL, V50, P114, DOI 10.1037/1196-1961.50.1.114; Gardiner John M., 1993, P163; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; HINTZMAN DL, 1994, J MEM LANG, V33, P1, DOI 10.1006/jmla.1994.1001; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; MANDLER G, 1980, PSYCHOL REV, V87, P252, DOI 10.1037/0033-295X.87.3.252; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; MOSCOVITCH M, 1993, HDB NEUROPSYCHOLOGY, V8, P133; Ostergaard Arne L., 1993, P327; PALLER KA, 1992, J COGNITIVE NEUROSCI, V4, P375, DOI 10.1162/jocn.1992.4.4.375; PALLER KA, IN PRESS CONSCIOUS C; PALLERT KA, IN PRESS NEUROPSYCHO; PERRIN F, 1987, ELECTROEN CLIN NEURO, V66, P75, DOI 10.1016/0013-4694(87)90141-6; Roediger H. L., 1993, HANDB NEUR, P63; Rugg M.D., 1995, OX PSYCH S, P133; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SMITH ME, 1993, J COGNITIVE NEUROSCI, V5, P1, DOI 10.1162/jocn.1993.5.1.1; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; YONELINAS AP, 1994, J EXP PSYCHOL LEARN, V20, P1341, DOI 10.1037/0278-7393.20.6.1341	27	571	595	2	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					595	598		10.1038/33396	http://dx.doi.org/10.1038/33396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZG300	9560154				2022-12-28	WOS:000072987200057
J	Burtscher, M; Likar, R; Nachbauer, W; Philadelphy, M				Burtscher, M; Likar, R; Nachbauer, W; Philadelphy, M			Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MOUNTAIN-SICKNESS		Univ Innsbruck, Dept Sport Sci, Med Sect, A-6020 Innsbruck, Austria; Gen Hosp, Dept Anaesthesia, A-9020 Klagenfurt, Austria; Austrian Alpine Club, Hlth Sect, Innsbruck, Austria	University of Innsbruck	Burtscher, M (corresponding author), Univ Innsbruck, Dept Sport Sci, Med Sect, A-6020 Innsbruck, Austria.	Martin.Burtscher@uibk.ac.at	Burtscher, Martin/M-7015-2019	Burtscher, Martin/0000-0002-5232-3632				HACKETT PH, 1976, LANCET, V2, P1149; MAGGIORINI M, 1990, BRIT MED J, V301, P853, DOI 10.1136/bmj.301.6756.853; RICHALET JP, 1991, RESP PHYSIOL, V85, P205, DOI 10.1016/0034-5687(91)90062-N; RICHALET JP, 1992, INT J SPORTS MED, V13, pS22, DOI 10.1055/s-2007-1024582; SHEPHERD JT, 1987, CIRCULATION, V76, P37	5	67	68	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1057	1058						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552906				2022-12-28	WOS:000072987400024
J	Goldman, YE				Goldman, YE			Wag the tail: Structural dynamics of actomyosin	CELL			English	Review							MYOSIN MOTOR DOMAIN; SKELETAL-MUSCLE; RESOLUTION; MOVEMENT; COMPLEX; REGION; CHAIN		Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Goldman, YE (corresponding author), Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.							Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Barsotti RJ, 1996, NAT STRUCT BIOL, V3, P737, DOI 10.1038/nsb0996-737; Berger CL, 1996, BIOPHYS J, V71, P3330, DOI 10.1016/S0006-3495(96)79526-7; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; Corrie JET, 1998, BIOCONJUGATE CHEM, V9, P160, DOI 10.1021/bc970174e; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; HOPKINS KC, 1998, IN PRESS BIOPHYS J; Irving M, 1997, NEWS PHYSIOL SCI, V12, P249; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; LINARI M, 1998, IN PRESS BIOPHYS J; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Sweeney HL, 1996, ANNU REV PHYSIOL, V58, P751, DOI 10.1146/annurev.ph.58.030196.003535; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	20	82	84	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					1	4		10.1016/S0092-8674(00)81137-X	http://dx.doi.org/10.1016/S0092-8674(00)81137-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546383	hybrid			2022-12-28	WOS:000072910800001
J	Devitt, A; Moffatt, OD; Raykundalia, C; Capra, JD; Simmons, DL; Gregory, CD				Devitt, A; Moffatt, OD; Raykundalia, C; Capra, JD; Simmons, DL; Gregory, CD			Human CD14 mediates recognition and phagocytosis of apoptotic cells	NATURE			English	Article							MACROPHAGE RECOGNITION; VITRONECTIN RECEPTOR; BINDING-PROTEIN; HUMAN-MONOCYTES; ANTIGEN; STIMULATION; ENDOTOXIN; ANTIBODY; POLYMERS; DEATH	Cells undergoing programmed cell death (apoptosis) are cleared rapidly in vivo by phagocytes without inducing inflammation(1), Here we show that the glycosylphosphatidylinositol-linked plasma-membrane glycoprotein CD14 (refs 2, 3) on the surface of human macrophages is important for the recognition and clearance of apoptotic cells, CD14 can also act as a receptor that binds bacterial lipopolysaccharide (LPS), triggering inflammatory responses(4), Overstimulation of CD14 by LPS can cause the often fatal toxic-shock syndrome(5,6). Here we show that apoptotic cells interact with CD14, triggering phagocytosis of the apoptotic cells, This interaction depends on a region of CD14 that is identical to, or at least closely associated with, a region known to bind LPS, However, apoptotic cells, unlike LPS, do not provoke the release of pro-inflammatory cytokines from macrophages, These results indicate that clearance of apoptotic cells is mediated by a receptor whose interactions with 'non-self' components (LPS) and 'self' components (apoptotic cells) produce distinct macrophage responses.	Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	University of Birmingham; University of Nottingham; University of Nottingham; Oklahoma Medical Research Foundation; GlaxoSmithKline	Gregory, CD (corresponding author), Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England.		Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132; Devitt, Andrew/0000-0002-4651-6761				Cavaillon JM, 1996, J ENDOTOXIN RES, V3, P471, DOI 10.1177/096805199600300605; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DUVALL E, 1985, IMMUNOLOGY, V56, P351; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P380; FLORA PK, 1994, EUR J IMMUNOL, V24, P2625, DOI 10.1002/eji.1830241109; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HARIOT A, 1996, IMMUNITY, V4, P407; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; NEWMAN SL, 1995, J IMMUNOL, V154, P753; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SIMMONS DL, 1989, BLOOD, V73, P284; SOELL M, 1995, J IMMUNOL, V154, P851; UGOLINI V, 1980, P NATL ACAD SCI-BIOL, V77, P6764, DOI 10.1073/pnas.77.11.6764; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	30	547	561	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					505	509		10.1038/33169	http://dx.doi.org/10.1038/33169			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548256				2022-12-28	WOS:000072875200061
J	Campbell, EG; Louis, KS; Blumenthal, D				Campbell, EG; Louis, KS; Blumenthal, D			Looking a gift horse in the mouth - Corporate gifts supporting life sciences research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUSTRY	Context.-Throughout the last decade a number of studies have been conducted to examine academic-industry research relationships. However, to our knowledge, no studies to date have empirically examined academic scientists' experience with research-related gifts from companies. Objective.-To examine the frequency, importance, and potential implications of research-related gifts from companies to academic life scientists. Design.-A mailed survey conducted in 1994 and 1995 of 3394 faculty who conduct life science research at the 50 universities that received the most research funding from the National Institutes of Health in 1993. Setting.-Research-intensive universities. Participants.-A total of 2167 of the 3394 faculty responded to the survey (response rate, 64%). Main Outcome Measures.-The percentage of faculty who received a research-related gift from a company in the last 3 years, the perceived importance of gifts to respondents' research, and what, if anything, the recipient thought the donor(s) expected in return for the gift. Results.-Forty-three percent of respondents received a research-related gift in the last 3 years independent of a grant or contract. The most frequently received gifts were biomaterials (24%), discretionary funds (15%), research equipment and trips to meetings (11% each), support for students (9%), and other research-related gifts (3%). Of those who received a gift, 66% reported the gift was important to their research, More than half of the recipients reported that donors expected the following in return for the gift: acknowledgment in publications (63%), that the gift not be passed on to a third party (60%), and that the gift be used only for the agreed-on purposes (59%). A total of 32% of recipients reported that the donor wanted prepublication review of any articles or reports stemming from the use of the gift, 30% indicated the company expected testing of their products, and 19% indicated that a donor expected ownership of all patentable results from the research in which a gift was used. However, what recipients thought donors expected differed by the type of gift received. Conclusions.-Research-related gifts are a common and important form of research support for academic life scientists. However, recipients frequently think that donors place restrictions and expect returns that may be problematic for recipients as well as institutions.	Massachusetts Gen Hosp, Hlth Policy Res & Dev Unit, Div Gen Internal Med, Boston, MA 02114 USA; Partners Healthcare Syst Inc, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Univ Minnesota, Coll Educ & Human Dev, Minneapolis, MN USA	Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Campbell, EG (corresponding author), Med Practices Evaluat Ctr, Hlth Policy Res & Dev Unit, 50 Staniford St,9th Floor, Boston, MA 02114 USA.			Seashore, Karen/0000-0003-1070-0273	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000724, R01HG000724] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00724-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHRENS E, 1992, CRISIS CLIN RES OVER, P51; Blumenthal D, 1996, NEW ENGL J MED, V335, P1734, DOI 10.1056/NEJM199612053352305; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; BOWIE NE, 1994, U BUSINESS PARTNERSH; CALDART CC, 1983, SCI TECHNOL, V8, P24; COHEN W, 1994, U IND RES RELATIONSH; *NAT SCI FDN, 1983, U IND RES REL SEL ST; *PET GUID, 1994, PET GUID GRAD PROGR; Rosenberg SA, 1996, NEW ENGL J MED, V334, P392, DOI 10.1056/NEJM199602083340610; WAUGAMAN PG, 1992, BIOMEDICAL RES COLLA, P93; WEINBERG RA, 1993, RESPONSIBLE SCI ENSU, V2, P66	12	87	89	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					995	999		10.1001/jama.279.13.995	http://dx.doi.org/10.1001/jama.279.13.995			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533497	Bronze			2022-12-28	WOS:000072669700026
J	Boyle, JS; Brady, JL; Lew, AM				Boyle, JS; Brady, JL; Lew, AM			Enhanced response to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction	NATURE			English	Article							PROTEIN; MICE; IMMUNIZATION; CTLA4IG; INVIVO	Viral infection and vaccination with DNA both induce similar immune responses to encoded antigens that are produced by the host(1,2). The availability of antigens in lymphoid organs is important in generating an immune response to viral challenge(3). Antigen availability may also be important in the response to DNA vaccines, because immune responses are stronger when antigen is secreted from DNA-transfected cells(4,5). We directed antigen to lymphoid organs by vaccination,vith DNA encoding antigen-ligand fusion proteins, The two ligands examined bind to receptors that are present on high endothelial venule cells of lymph nodes or on antigen-presenting cells. Here we show that both the humoral and the cellular immune responses to a model DNA vaccine were enhanced using either antigen-targeting strategy. Moreover, directing antigen to antigen-presenting cells speeded up, and altered the form of, the immune response, Directing antigen to sites of immune-response induction may represent a generic means of tailoring a potent and effective immune response to a DNA vaccine.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Melbourne, Vic 3050, Australia	QIMR Berghofer Medical Research Institute; Walter & Eliza Hall Institute	Lew, AM (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia.	lew@wehi.edu.au	Lew, Andrew M/C-7248-2013	Lew, Andrew M/0000-0002-2198-8164				AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Boyle JS, 1997, P NATL ACAD SCI USA, V94, P14626, DOI 10.1073/pnas.94.26.14626; Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897; Catalina MD, 1996, J EXP MED, V184, P2341, DOI 10.1084/jem.184.6.2341; Inchauspe G, 1997, DNA CELL BIOL, V16, P185, DOI 10.1089/dna.1997.16.185; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Lew AM, 1996, TRANSPLANTATION, V62, P83, DOI 10.1097/00007890-199607150-00017; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; MOR G, 1995, J IMMUNOL, V155, P2039; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8	19	215	255	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					408	411		10.1038/32932	http://dx.doi.org/10.1038/32932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537327				2022-12-28	WOS:000072713600057
J	Malone, KE; Daling, JR; Thompson, JD; O'Brien, CA; Francisco, LV; Ostrander, EA				Malone, KE; Daling, JR; Thompson, JD; O'Brien, CA; Francisco, LV; Ostrander, EA			BRCA1 mutations and breast cancer in the general population - Analyses in women before age 35 years and in women before age 45 years with first-degree family history	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-ONSET BREAST; OVARIAN-CANCER; YOUNG-WOMEN; JEWISH WOMEN; SURVIVAL; LINKAGE; ORIGINS; RISK	Context.-Studies of high-risk families with multiple early-onset cases of breast cancer have been useful for assessing the type and spectrum of germline mutations on the BRCA1 gene, but do not provide guidance to women with modest family history profiles. Thus, studies of women from the general population are needed to determine the BRCA1 mutation frequency in women perceived to be at high risk, and to develop profiles of those most likely to be carriers. Objective.-To characterize frequency and spectrum of germline BRCA1 mutations in 2 categories of women identified via population-based studies hypothesized to be at increased risk of carrying such mutations: those diagnosed as having breast cancer before age 35 years and those diagnosed before age 35 years who have first-degree breast cancer family history, Design.-Study subjects were drawn from 2 population-based case-control studies of breast cancer in young women on the basis of their family history or their age of diagnosis. Cases were younger than 35 years or were younger than 45 years with first-degree family history at the time of breast cancer diagnosis and were ascertained via a population-based cancer registry, and controls (women without breast cancer) were identified via random-digit dialing. Setting.-Three counties in western Washington State, Main Outcome Measure.-BRCA1 germline mutations in study subjects identified in DNA from peripheral blood lymphocytes by single-strand conformation polymorphism analysis using primer pairs that span the BRCA1 coding region and intron-exon boundaries. Results.-Of 193 women diagnosed as having breast cancer before age 35 years, none of whom were selected on the basis of family history status, 12 (6.2%, 95% confidence interval [CI], 3.2%-10.6%) had germline BRCA1 mutations. in 208 women diagnosed before age 45 years who had first-degree breast cancer family history, 15 (7.2%, 95% CI, 4.1%-11.6%) had germline mutations in BRCA1. In both groups, there were variations in mutation frequency noted by age and by family history. Mutation frequency decreased with increasing age of diagnosis. Higher proportions of mutations were seen in cases with at least 1 relative diagnosed as having breast cancer before age 45 years, in cases with greater numbers of affected relatives, and those with ovarian cancer family history. Mutation frequency did not vary by bilateral breast cancer family history. No frameshift or nonsense mutations were observed in 71 control women with a first-degree family history, although missense changes of unknown significance were seen in cases and controls. Conclusions.-Women with BRCA1 germline mutations lacked a common family history profile. Also, a large proportion of the women with a first-degree breast cancer family history and women diagnosed as having breast cancer before age 35 years did not carry germline BRCA1 mutations. Hence, while early-onset disease and a strong breast cancer family history may be useful guidelines for checking BRCA1 status, these findings on women drawn from the general population suggest that it may be difficult to develop BRCA1 mutation screening criteria among women with modest family history profiles.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Malone, KE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,POB 19024,MP-381, Seattle, WA 98109 USA.			Ostrander, Elaine/0000-0001-6075-9738	NCI NIH HHS [N01-CP-95671, R01-CA-41416, R01-CA-63705] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095671] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063705, R01CA041416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DB, 1996, AM J HUM GENET, V58, P1166; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; COUCH FJ, 1995, J NCI MONOGR, V17, P9; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1547; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Hakansson S, 1997, AM J HUM GENET, V60, P1068; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; Mathew CG, 1996, NEW ENGL J MED, V334, P1198; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Serova O, 1996, AM J HUM GENET, V58, P42; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Szabo CI, 1997, AM J HUM GENET, V60, P1013; TONIN P, 1995, AM J HUM GENET, V57, P189; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; Whittemore AS, 1997, AM J HUM GENET, V60, P496	37	182	188	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					922	929		10.1001/jama.279.12.922	http://dx.doi.org/10.1001/jama.279.12.922			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544766				2022-12-28	WOS:000072563600032
J	Mackay, IS; Durham, SR				Mackay, IS; Durham, SR			ABC of allergies - Perennial rhinitis	BRITISH MEDICAL JOURNAL			English	Article									Royal Brompton Hosp, London SW3 6LY, England; Charing Cross Hosp, London, England	Royal Brompton Hospital; Imperial College London	Mackay, IS (corresponding author), Royal Brompton Hosp, London SW3 6LY, England.							DURHAM SR, 1995, RESP MED, V2, P1006; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; LUND V, 1994, ALLERGY S19, V49; SIBBALD B, 1991, THORAX, V46, P859	4	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					917	920		10.1136/bmj.316.7135.917	http://dx.doi.org/10.1136/bmj.316.7135.917			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552846	Green Published			2022-12-28	WOS:000072713300035
J	Tweed, MJ; Roland, JM				Tweed, MJ; Roland, JM			Lesson of the week - Haemochromatosis as an endocrine cause of subfertility	BRITISH MEDICAL JOURNAL			English	Article							JUVENILE IDIOPATHIC HEMOCHROMATOSIS; HYPOGONADOTROPIC HYPOGONADISM; GENETIC HEMOCHROMATOSIS; IRON DEPLETION; TESTOSTERONE; RECOVERY		Peterborough Dist Gen Hosp, Peterborough PE3 6DA, England		Roland, JM (corresponding author), Peterborough Dist Gen Hosp, Peterborough PE3 6DA, England.							Bennett JC, 1996, CECIL TXB MED; BESSER GM, 1994, CLIN ENDOCRINOLOGY; Beutler E, 1997, LANCET, V349, P296, DOI 10.1016/S0140-6736(97)22005-2; Bhansali A, 1992, J Assoc Physicians India, V40, P757; CAZZOLA M, 1983, HUM GENET, V65, P149, DOI 10.1007/BF00286653; CUNDY T, 1993, CLIN ENDOCRINOL, V38, P617, DOI 10.1111/j.1365-2265.1993.tb02143.x; DAMJANOV I, 1993, PATHOLOGY INFERTILIT; DURANTEAU L, 1993, ACTA ENDOCRINOL-COP, V128, P351, DOI 10.1530/acta.0.1280351; FARINA G, 1995, HAEMATOLOGICA, V80, P335; FUJISAWA I, 1988, RADIOLOGY, V168, P213, DOI 10.1148/radiology.168.1.3380960; GAMA R, 1995, POSTGRAD MED J, V71, P297, DOI 10.1136/pgmj.71.835.297; GLUCKMAN E, 1996, NEW ENGL J MED, V24, P1837; KLEY HK, 1992, CLIN INVESTIGATOR, V70, P566; Nachtigall LB, 1997, NEW ENGL J MED, V336, P410, DOI 10.1056/NEJM199702063360604; NIEDERAU C, 1994, BAILLIERE CLIN HAEM, V7, P881, DOI 10.1016/S0950-3536(05)80129-5; OERTER KE, 1993, J CLIN ENDOCR METAB, V76, P357, DOI 10.1210/jc.76.2.357; PIPERNO A, 1992, J ENDOCRINOL INVEST, V15, P423, DOI 10.1007/BF03348765; Schaal KP., 1996, OXFORD TXB MED, V1, P680; SIEMONS LJ, 1987, J CLIN ENDOCR METAB, V65, P585, DOI 10.1210/jcem-65-3-585; SIMINOSKI K, 1990, J ENDOCRINOL INVEST, V13, P849, DOI 10.1007/BF03349640; VOGT HJ, 1987, ANDROLOGIA, V19, P532; [No title captured]	22	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					915	916		10.1136/bmj.316.7135.915	http://dx.doi.org/10.1136/bmj.316.7135.915			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552844	Green Published			2022-12-28	WOS:000072713300033
J	Melzer, D				Melzer, D			Personal paper - New drug treatment for Alzheimer's disease: lessons for healthcare policy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM-CARE		Univ Cambridge, Inst Publ Hlth, Dept Community Med, Cambridge CB2 2SR, England	University of Cambridge	Melzer, D (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Community Med, Cambridge CB2 2SR, England.	dm214@medschl.cam.ac.uk		Melzer, David/0000-0002-0170-3838				AbelSmith B, 1996, OECD HEAL POL STUD, P17; Bartlett HP, 1996, SOC SCI MED, V43, P731, DOI 10.1016/0277-9536(96)00117-7; EATON L, 1997, HLTH SERV J, V107, P6; *EIS CORP, 1996, ARICEPT DONEPEZIL LE; FERRIMAN A, 1997, INDEPENDENT     0328, P13; FLETCHER D, 1997, DAILY TELEGRAPH 0405, P9; Gray S, 1997, BRIT MED J, V314, P1555, DOI 10.1136/bmj.314.7093.1555; IMPALLOMINI M, 1994, LANCET, V334, P1230; Kelly CA, 1997, BRIT MED J, V314, P693, DOI 10.1136/bmj.314.7082.693; LAURANCE J, 1997, TIMES           0328, P6; Leber P., 1990, GUIDELINES CLIN EVAL; MURPHY E, 1992, INT J GERIATR PSYCH, V7, P851, DOI 10.1002/gps.930071202; Rittenhouse B., 1996, USES MODELS EC EVALU; ROGERS SL, 1996, NEUROLOGY, V46, pA217; RUBINSTEIN L, 1996, EPIDEMIOLOGY OLD AGE, P106; SCHNEIDER LS, 1996, ALZHEIMER INSIGHTS, V2, P17; TOYNBEE P, 1997, INDEPENDENT     0212, P13; Tugwell P, 1995, INT J TECHNOL ASSESS, V11, P650, DOI 10.1017/S0266462300009089; Wagner N, 1997, BRIT MED J, V314, P1555; Wise J, 1997, BRIT MED J, V314, P1145	20	77	80	2	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					762	764		10.1136/bmj.316.7133.762	http://dx.doi.org/10.1136/bmj.316.7133.762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529416	Green Published			2022-12-28	WOS:000072463700041
J	Nava, S; Ambrosino, N; Clini, E; Prato, M; Orlando, G; Vitacca, M; Brigada, P; Fracchia, C; Rubini, F				Nava, S; Ambrosino, N; Clini, E; Prato, M; Orlando, G; Vitacca, M; Brigada, P; Fracchia, C; Rubini, F			Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lung diseases, obstructive; respiration, artificial; ventilator weaning; respiratory insufficiency	POSITIVE-PRESSURE VENTILATION; ACUTE EXACERBATIONS; FACE MASK; NOSOCOMIAL PNEUMONIA; NASAL VENTILATION; PREDICTION; RISK; COMPLICATIONS; SURVIVAL; SUPPORT	Background: In patients with acute exacerbations of chronic obstructive pulmonary disease, mechanical ventilation is often needed. The rate of weaning failure is high in these patients, and prolonged mechanical ventilation increases intubation-associated complications. Objective: To determine whether noninvasive ventilation improves the outcome of weaning from invasive mechanical ventilation. Design: Multicenter, randomized trial. Setting: Three respiratory intensive care units. Patients: Intubated patients with chronic obstructive pulmonary disease and acute hypercapnic respiratory failure. Intervention: A T-piece weaning trial was attempted 48 hours after intubation. If this failed, two methods of weaning were compared: 1) extubation and application of: noninvasive pressure support ventilation by face mask and 2) invasive pressure support ventilation by an endotracheal tube. Measurements: Arterial blood gases, duration of mechanical ventilation, time in the intensive care unit, occurrence of nosocomial pneumonia, and survival at 60 days. Results: At admission, all patients had severe hypercapnic respiratory failure (mean pH, 7.18 +/- 0.06; mean PaCo2, 94.2 +/- 24.2 mm Hg), sensory impairment, and similar clinical characteristics. At 60 days, 22 of 25 patients (88%) who were ventilated noninvasively were successfully weaned compared with 17 of 25 patients (68%) who were ventilated invasively. The mean duration of mechanical ventilation was 16.6 +/- 11.8 days for the invasive ventilation group and 10.2 +/- 6.8 days for the noninvasive ventilation group (P = 0.021). Among patients who received noninvasive ventilation, the probability of survival and weaning during ventilation was higher (P = 0.002) and time in the intensive care unit was shorter (15.1 +/- 5.4 days compared with 24.0 +/- 13.7 days for patients who received invasive ventilation; P = 0.005). Survival rates at 60 days differed (92% for patients who received noninvasive ventilation and 72% for patients who received invasive ventilation; P = 0.009). None of the patients weaned noninvasively developed nosocomial pneumonia, whereas 7 patients weaned invasively did. Conclusions: Noninvasive pressure support ventilation during weaning reduces weaning time, shortens the time in the intensive care unit, decreases the incidence of nosocomial pneumonia, and improves 60-day survival rates.	Ctr Med Riabilitaz Montescano, Div Pneumol, I-27040 Montescano, PV, Italy; Ctr Med Riabilitaz Gussago, Div Pneumol, I-25064 Gussago, Italy; Osped S Giacomo, Serv Anestesia & Rianmaz, I-15060 Novi Ligure, Italy; Fdn S Maugeri, Ist Ricovero & Cura Carattere Sci, Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS	Nava, S (corresponding author), Ctr Med Riabilitaz Montescano, Div Pneumol, I-27040 Montescano, PV, Italy.		VITACCA, MICHELE/AAB-8883-2020; Clini, Enrico/ABE-6642-2020; Ambrosino, Nicolino/AAC-2005-2020; Clini, Enrico/A-4496-2017	VITACCA, MICHELE/0000-0002-9389-7915; Clini, Enrico/0000-0002-1515-5094; Ambrosino, Nicolino/0000-0002-5331-1393; Clini, Enrico/0000-0002-1515-5094				BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; CONTI G, 1992, CRIT CARE MED, V20, P366, DOI 10.1097/00003246-199203000-00013; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; GOLDSTONE J, 1991, THORAX, V46, P56, DOI 10.1136/thx.46.1.56; GOODENBERGER DM, 1992, CHEST, V102, P1277, DOI 10.1378/chest.102.4.1277; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LEMAIRE F, 1993, INTENS CARE MED S, V19, pS6973; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; NAVA S, 1994, EUR RESPIR J, V7, P1645, DOI 10.1183/09031936.94.07091645; Nava S, 1997, CHEST, V111, P1631, DOI 10.1378/chest.111.6.1631; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RESTRICK LJ, 1993, RESP MED, V87, P199, DOI 10.1016/0954-6111(93)90092-E; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Seneff MG, 1996, CHEST, V110, P469, DOI 10.1378/chest.110.2.469; SPORN PHS, 1988, CLIN CHEST MED, V9, P113; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; UDWADIA ZF, 1992, THORAX, V47, P715, DOI 10.1136/thx.47.9.715; VITACCA M, 1993, INTENS CARE MED, V19, P450, DOI 10.1007/BF01711086	30	420	473	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					721	+		10.7326/0003-4819-128-9-199805010-00004	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556465				2022-12-28	WOS:000073363800003
J	Wright, J; Williams, R; Wilkinson, JR				Wright, J; Williams, R; Wilkinson, JR			Health needs assessment - Development and importance of health needs assessment	BRITISH MEDICAL JOURNAL			English	Article							CARE		Bradford Royal Infirm, Bradford Hosp NHS Trust, Bradford BD9 6RJ, W Yorkshire, England; Nuffield Inst Hlth, Leeds LS2 9PL, W Yorkshire, England; N Yorkshire Hlth Author, York YO1 1PE, N Yorkshire, England	Bradford Royal Infirmary; University of Leeds	Wright, J (corresponding author), Bradford Royal Infirm, Bradford Hosp NHS Trust, Bradford BD9 6RJ, W Yorkshire, England.		Wright, John/H-1624-2012	Wright, John/0000-0001-9572-7293				ANDERSON TF, 1990, CHALLENGE MED PRACTI; [Anonymous], 1994, KEY ISSUES HLTH EC; BLACK D, 1994, DOCTOR LOOKS HLTH EC; Bradshaw J, 1972, PROBLEMS PROGR MED C, P71; CORDEN A, 1992, M NEEDS; CULYER AH, 1976, NEED NATL HLTH SERV; *DEP HLTH, 1989, WORK PAT; Department of Health, 1992, HLTH NAT STRAT HLTH; Department of Health and Social Security, 1976, SHAR RES HLTH ENGL R; DONALDSON C, 1991, BRIT MED J, V303, P1529, DOI 10.1136/bmj.303.6816.1529; FELDSTEIN MS, 1964, BRIT MED J, V2, P562; FORD HL, 1998, IN PRESS J NEUROL NE; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; GILLAM SJ, 1992, BRIT J GEN PRACT, V42, P404; GILLAM SJ, 1996, NEEDS ASSESSMENT GEN; Harrison A, 1997, BRIT MED J, V314, P139, DOI 10.1136/bmj.314.7074.139; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; JORDAN J, 1997, BR J GEN PRACT, V48, P695; Jordan J, 1996, HLTH NEEDS ASSESSMEN; KIRKUP B, 1990, J PUBLIC HEALTH MED, V12, P45, DOI 10.1093/oxfordjournals.pubmed.a042505; *LOND HLTH EC CONS, 1996, LOC HLTH VOC COMM RE; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; *NAT HLTH SERV EX, 1994, EL9454 NHSE; *NAT WORK GROUP VA, 1995, VAR HLTH WHAT CAN DE; National Health Service Management Executive, 1991, ASS HLTH CAR NEEDS; *NHS EX, 1997, NEW NHS; *ORG EC COOP DEV, 1990, SOC POL STUD, V7; *SECR STAT SCOTL, 1997, DES CAR; SHANKS J, 1995, BRIT MED J, V310, P480, DOI 10.1136/bmj.310.6978.480; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561; Stevens A, 1991, Health Trends, V23, P20; Stevens A., 1994, HLTH CARE NEEDS ASSE; WILKIN D, 1992, HOSP REFERRALS; WOMERSLEY J, 1987, J EPIDEMIOL COMMUN H, V41, P190, DOI 10.1136/jech.41.3.190	34	188	191	1	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1310	1313		10.1136/bmj.316.7140.1310	http://dx.doi.org/10.1136/bmj.316.7140.1310			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554906	Green Published			2022-12-28	WOS:000073335900031
J	[Anonymous]				[Anonymous]			BMA's counselling service takes over 6000 calls	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	1998	316	7139					1250	1250						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553025				2022-12-28	WOS:000073224100066
J	Xie, JY; McCobb, DP				Xie, JY; McCobb, DP			Control of alternative splicing of potassium channels by stress hormones	SCIENCE			English	Article							PITUITARY-ADRENOCORTICAL AXIS; ADRENAL CHROMAFFIN CELLS; EXPRESSION; GENE; IDENTIFICATION; DEXAMETHASONE; CLONING	Many molecular mechanisms for neural adaptation to stress remain unknown. Expression of alternative splice variants of Slo, a gene encoding calcium-and voltage-activated potassium channels, was measured in rat adrenal chromaffin tissue from normal and hypophysectomized animals. Hypophysectomy triggered an abrupt decrease in the proportion of Slo transcripts containing a "STREX" exon. The decrease was prevented by adrenocorticotropic hormone injections. In Xenopus oocytes, STREX variants produced channels with functional properties associated with enhanced repetitive firing Thus, the hormonal stress axis is likely to control the excitable properties of epinephrine-secreting cells by regulating alternative splicing of Slo messenger RNA.	Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA	Cornell University	McCobb, DP (corresponding author), Cornell Univ, Neurobiol & Behav Sect, Seeley G Mudd Hall, Ithaca, NY 14853 USA.	dpm9@cornell.edu	Xie, Jiuyong/D-2899-2013	Xie, Jiuyong/0000-0003-2909-1033				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; ATTARDI B, 1993, RECEPTOR CHANNEL, V1, P287; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CECCATELLI S, 1989, ACTA PHYSIOL SCAND, V137, P559, DOI 10.1111/j.1748-1716.1989.tb08800.x; Coupland RE., 1965, NATURAL HIST CHROMAF; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; EBERT SN, 1994, J BIOL CHEM, V269, P20885; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; Kraus JE, 1996, MOL BRAIN RES, V41, P97, DOI 10.1016/0169-328X(96)00072-1; LAKE RC, 1985, CATECHOLAMINES PSYCH; Levitan ES, 1996, NEUROPHARMACOLOGY, V35, P1001, DOI 10.1016/0028-3908(96)00095-0; Lingle C J, 1996, Ion Channels, V4, P261; McCobb D. P., 1997, Society for Neuroscience Abstracts, V23, P1477; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; Nussdorfer GG, 1996, PHARMACOL REV, V48, P495; ROSS ME, 1990, J NEUROSCI, V10, P520; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; SOLARO CR, 1995, J NEUROSCI, V15, P6110; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P275, DOI 10.1016/0169-328X(88)90050-2; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; TAKIMOTO K, 1994, CIRC RES, V75, P1; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VISKUPIC E, 1994, J NEUROCHEM, V63, P808; WONG DL, 1992, FASEB J, V6, P3310, DOI 10.1096/fasebj.6.14.1426768; WONG DL, 1985, BRAIN RES, V330, P209, DOI 10.1016/0006-8993(85)90679-1; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301; Xie J., 1997, Society for Neuroscience Abstracts, V23, P309; XIE J, 1996, SOC NEUR ABSTR, V22, P402	29	247	250	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					443	446		10.1126/science.280.5362.443	http://dx.doi.org/10.1126/science.280.5362.443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545224				2022-12-28	WOS:000073159600050
J	Berwick, DM				Berwick, DM			Developing and testing changes in delivery of care	ANNALS OF INTERNAL MEDICINE			English	Article							SURGERY	Improving the daily practice of medicine requires making changes in processes of care. In many circumstances, the most powerful way to make such changes is to conduct small, local tests-Plan-Do-Study-Act (PDSA) cycles-in which one learns from taking action. Learning in these cycles has much in common with learning from prudent clinical work, in which therapies are initiated under close observation and adjustments are made as data and experience accumulate. For many system improvements, PDSA cycles are more appropriate and informative than either formal studies with experimental designs (such as randomized trials) or the mere implementation of changes without reflection or evaluative measurement. Physicians can encourage systemic improvement by endorsing and participating in prudent, local tests of change in their own offices and in the health care organizations in which they work. To do this, they must understand the scientific value and integrity of such small-scale tests.	Inst Healthcare Improvement, Boston, MA 02215 USA	Institute for Healthcare Improvement	Berwick, DM (corresponding author), Inst Healthcare Improvement, 135 Francis St, Boston, MA 02215 USA.							[Anonymous], 1996, DARTMOUTH ATLAS HLTH; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; COCHRANE AL, 1972, EFFECTIVENESS EFFICI, P2; DARMAN R, 1996, NY TIMES MAGAZI 1201, P6; Kolb D.A, 1984, EXPERIENTIAL LEARNIN; Langley Gj., 1996, IMPROVEMENT GUIDE PR; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Nolan TW, 1998, ANN INTERN MED, V128, P293, DOI 10.7326/0003-4819-128-4-199802150-00009; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; PALMER RH, 1976, ASSURING QUALITY MED, P14; SANDMIRE HF, 1994, AM J OBSTET GYNECOL, V170, P1790; Schon Donald A., 1988, ED REFLECTIVE PRACTI; Senge PM, 2006, 5 DISCIPLINE ART PRA; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Wheeler DJ, 1986, UNDERSTANDING STAT P	16	301	304	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					651	656		10.7326/0003-4819-128-8-199804150-00009	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537939				2022-12-28	WOS:000073052500006
J	Lahteenmaki, P; Haukkamaa, M; Puolakka, J; Riikonen, U; Sainio, S; Suvisaari, J; Nilsson, CG				Lahteenmaki, P; Haukkamaa, M; Puolakka, J; Riikonen, U; Sainio, S; Suvisaari, J; Nilsson, CG			Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MENORRHAGIA; DEVICE; IUD; ENDOMETRIUM; ABLATION; TRIAL	Objectives: To assess whether the levonorgestrel intrauterine system could provide a conservative alternative to hysterectomy in the treatment of excessive uterine bleeding. Design: Open randomised multicentre study with two parallel groups: a levonorgestrel intrauterine system group and a control group. Setting Gynaecology departments of three hospitals in Finland, Subjects: Fifty six women aged 33-49 years scheduled to undergo hysterectomy for treatment of excessive uterine bleeding. Interventions: Women were randomised either to continue with their current medical treatment or to have a levonorgestrel intrauterine system inserted. Main outcome measure: Proportion of women cancelling their decision to undergo hysterectomy. Results: At 6 months, 64.3% (95% confidence interval 44.1 to 81.4%) of the women in the levonorgestrel intrauterine system group and 14.3% (4.0 to 32.7%) in the control group had cancelled their decision to undergo hysterectomy (P < 0.001). Conclusions: The use of the levonorgestrel intrauterine system is a good conservative alternative to hysterectomy in the treatment of menorrhagia and should be considered before hysterectomy or other invasive treatments.	Univ Helsinki, Steroid Res Lab, Inst Biomed, FIN-00014 Helsinki, Finland; City Matern Hosp, Helsinki 00610, Finland; Middle Finland Cent Hosp, Dept Obstet & Gynaecol, Jyvaskyla, Finland; Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, Helsinki 00290, Finland	University of Helsinki; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital	Lahteenmaki, P (corresponding author), Leiras Oy, Pansiontie 47,POB 415, FIN-20101 Turku, Finland.	laehteenmaeki@leiras.fi						ANDERSSON JK, 1990, BRIT J OBSTET GYNAEC, V97, P690, DOI 10.1111/j.1471-0528.1990.tb16240.x; ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0; COULTER A, 1995, INT J TECHNOL ASSESS, V11, P456, DOI 10.1017/S0266462300008679; COULTER A, 1994, FAM PRACT, V11, P394, DOI 10.1093/fampra/11.4.394; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; Lilford RJ, 1997, BRIT MED J, V314, P160, DOI 10.1136/bmj.314.7075.160; LUUKKAINEN T, 1990, ANN MED, V22, P85, DOI 10.3109/07853899009147248; MAGOS AL, 1989, BRIT MED J, V298, P1209, DOI 10.1136/bmj.298.6682.1209; MILSOM I, 1991, AM J OBSTET GYNECOL, V164, P879, DOI 10.1016/S0002-9378(11)90533-X; NILSSON CG, 1977, CONTRACEPTION, V15, P379, DOI 10.1016/0010-7824(77)90001-4; NILSSON CG, 1976, CONTRACEPTION, V13, P503; PASKOWITZ RA, 1995, J REPROD MED, V40, P333; *ROYAL COLL GEN PR, 1986, SER MB5, V1; SHAW RW, 1994, BRIT J OBSTET GYNAEC, V101, P15, DOI 10.1111/j.1471-0528.1994.tb13690.x; SILVERBERG SG, 1986, INT J GYNECOL PATHOL, V5, P235, DOI 10.1097/00004347-198609000-00005; SINGER A, 1994, OBSTET GYNECOL, V83, P732; Suvisaari J, 1996, CONTRACEPTION, V54, P201, DOI 10.1016/S0010-7824(96)00189-8; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x	18	179	181	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	1998	316	7138					1122	1126		10.1136/bmj.316.7138.1122	http://dx.doi.org/10.1136/bmj.316.7138.1122			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552948	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000073067500020
J	Bonn, D; Kellay, H; Prochnow, M; Ben-Djemiaa, K; Meunier, J				Bonn, D; Kellay, H; Prochnow, M; Ben-Djemiaa, K; Meunier, J			Delayed fracture of an inhomogeneous soft solid	SCIENCE			English	Article							BREAKING	The spontaneous fracture of polymer gels was studied. Contrary to crystalline solids, where fracture usually happens instantaneously at a well-defined breaking strength, the fracture of a polymer gel can occur with a delay. When a constant force was applied, the cracks nucleated and started to propagate after a delay that can be as long as 15 minutes, depending on the force. This phenomenon can be understood by calculating the activation energy for crack nucleation in arbitrary dimension and accounting for the inhomogeneity of the gel network in terms of its fractal dimension.	Ecole Normale Super, Phys Stat Lab, F-75231 Paris 05, France; Univ Bordeaux 1, Ctr Phys Mol Opt & Hertzienne, F-44305 Talence, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bonn, D (corresponding author), Ecole Normale Super, Phys Stat Lab, 24 Rue Lhomond, F-75231 Paris 05, France.	bonn@physique.ens.fr	Kellay, Hamid/N-6652-2014; Bonn, Daniel/F-9928-2011	Kellay, Hamid/0000-0002-3438-3236; 				Avnir D, 1998, SCIENCE, V279, P39, DOI 10.1126/science.279.5347.39; BOT A, 1996, GUMS STABILISERS FOO, V8, P117; Freund LB, 1990, DYNAMIC FRACTURE MEC, DOI [10.1017/oretCBO9780511546761-en, DOI 10.1017/ORETCBO9780511546761-EN]; Griffith A.A., 1921, PHILOS T R SOC LOND, V221, P163, DOI [10.1098/rsta.1921.0006, DOI 10.1098/RSTA.1921.0006]; KANNINEN MF, 1985, ADV FRACTURE MECH; Lawn P.R, 1993, CAMBRIDGE SOLID STAT, Vsecond; Manno M, 1997, PHYS REV LETT, V79, P4286, DOI 10.1103/PhysRevLett.79.4286; Marder M, 1996, PHYS REV E, V54, P3442, DOI 10.1103/PhysRevE.54.3442; PAUCHARD L, 1993, PHYS REV LETT, V70, P3565, DOI 10.1103/PhysRevLett.70.3565; POMEAU Y, 1992, CR ACAD SCI II, V314, P553; WEITZ DA, 1985, PHYS REV LETT, V54, P1416, DOI 10.1103/PhysRevLett.54.1416; ZARZYCKI J, 1988, J NON-CRYST SOLIDS, V100, P359, DOI 10.1016/0022-3093(88)90046-4	12	149	152	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					265	267		10.1126/science.280.5361.265	http://dx.doi.org/10.1126/science.280.5361.265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535651				2022-12-28	WOS:000073082400044
J	Liley, M; Gourdon, D; Stamou, D; Meseth, U; Fischer, TM; Lautz, C; Stahlberg, H; Vogel, H; Burnham, NA; Duschl, C				Liley, M; Gourdon, D; Stamou, D; Meseth, U; Fischer, TM; Lautz, C; Stahlberg, H; Vogel, H; Burnham, NA; Duschl, C			Friction anisotropy and asymmetry of a compliant monolayer induced by a small molecular tilt	SCIENCE			English	Article							FORCE MICROSCOPY; FILMS; MICA; GOLD	Lateral force microscopy in the wearless regime was used to study the friction behavior of a lipid monolayer on mica. In the monolayer, condensed domains with long-range orientational order of the lipid molecules were present. The domains revealed unexpectedly strong friction anisotropies and non-negligible friction asymmetries, The angular dependency of these effects correlated well with the tilt direction of the alkyl chains of the monolayer, as determined by electron diffraction and Brewster angle microscopy, The molecular tilt causing these frictional effects was less than 15 degrees, demonstrating that even small molecular tilts can make a major contribution to friction.	Swiss Fed Inst Technol, Dept Chem, CH-1015 Lausanne, Switzerland; Swiss Fed Inst Technol, Dept Phys, CH-1015 Lausanne, Switzerland; Univ Leipzig, Dept Phys, D-04103 Leipzig, Germany; Univ Lausanne, Dept Biol, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Leipzig University; University of Lausanne	Duschl, C (corresponding author), Swiss Fed Inst Technol, Dept Chem, CH-1015 Lausanne, Switzerland.	duschl@igcsun3.epfl.ch	Stamou, Dimitrios/D-5042-2016; fischer, thomas/K-6273-2013; Stahlberg, Henning/H-1868-2011; Duschl, Claus/G-6106-2016; Burnham, Nancy A/A-5210-2013	Stamou, Dimitrios/0000-0001-8456-8995; fischer, thomas/0000-0002-8852-6570; Stahlberg, Henning/0000-0002-1185-4592; 				Bowden F. P., 1954, FRICTION LUBRICATI 1; Chandrasekhar S., 1992, LIQ CRYST, DOI 10.1017/CBO9780511622496; Dowson D, 1979, HIST TRIBOLOGY; FISCHER A, 1985, NATURE, V313, P299, DOI 10.1038/313299a0; GIACOVAZZO C, 1992, FUNDAMENTALS CRYSTAL, P83; Gourdon D, 1997, TRIBOL LETT, V3, P317, DOI 10.1023/A:1019118213740; HIRANO M, 1991, PHYS REV LETT, V67, P2642, DOI 10.1103/PhysRevLett.67.2642; HONIG D, 1991, J PHYS CHEM-US, V95, P4590, DOI 10.1021/j100165a003; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; Lautz C, 1997, J CHEM PHYS, V106, P7448, DOI 10.1063/1.473704; OVERNEY RM, 1994, PHYS REV LETT, V72, P3546, DOI 10.1103/PhysRevLett.72.3546; OVERNEY RM, 1994, LANGMUIR, V10, P1281, DOI 10.1021/la00016a049; SANTESSON L, 1995, J PHYS CHEM-US, V99, P1038, DOI 10.1021/j100003a029; Schwarz UD, 1996, NATO ADV SCI I E-APP, V311, P369; Ulman A., 1991, INTRO ULTRATHIN ORGA; YOSHIZAWA H, 1993, J PHYS CHEM-US, V97, P4128, DOI 10.1021/j100118a033	16	136	137	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					273	275		10.1126/science.280.5361.273	http://dx.doi.org/10.1126/science.280.5361.273			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535654				2022-12-28	WOS:000073082400047
J	Manian, FA				Manian, FA			Should we accept mediocrity?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1067	1069		10.1056/NEJM199804093381513	http://dx.doi.org/10.1056/NEJM199804093381513			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535676				2022-12-28	WOS:000072969500013
J	Zambrowicz, BP; Friedrich, GA; Buxton, EC; Lilleberg, SL; Person, C; Sands, AT				Zambrowicz, BP; Friedrich, GA; Buxton, EC; Lilleberg, SL; Person, C; Sands, AT			Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells	NATURE			English	Article							GENOME PROJECT; PROMOTER TRAPS; MICE; VECTORS	The dramatic increase in sequence information in the form of expressed sequence tags (ESTs)(1) and genomic sequence has created a 'gene function gap', with the identification of new genes far outpacing the rate at which their function can be identified. The ability to create mutations in embryonic stem (ES) cells on a large scale by tagged random mutagenesis provides a powerful approach for determining gene function in a mammalian system; this approach is well established in lower organisms(2,3). Here we describe a high-throughput mutagenesis method based on gene trapping that allows the automated identification of sequence tags from the mutated genes, This method traps and mutates genes regardless of their expression status in ES cells, To facilitate the study of gene function on a large scale, we are using these techniques to create a library of ES cells called Omnibank, from which sequence-tagged mutations in 2,000 genes are described.	Lexicon Genet, The Woodlands, TX 77381 USA	Lexicon Pharmaceuticals	Zambrowicz, BP (corresponding author), Lexicon Genet, 4000 Res Forest Dr, The Woodlands, TX 77381 USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DEWEERS M, 1993, EUR J IMMUNOL, V23, P319; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GOSSLER A, 1993, GENE TARGETING PRACT, P181; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Oeltjen JC, 1997, GENOME RES, V7, P315, DOI 10.1101/gr.7.4.315; PLASTERK RHA, 1992, BIOESSAYS, V14, P629, DOI 10.1002/bies.950140911; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; ZAMBROWICZ P, 1997, P NATL ACAD SCI USA, V94, P3789; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	20	394	425	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					608	611		10.1038/33423	http://dx.doi.org/10.1038/33423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560157				2022-12-28	WOS:000072987200061
J	Drife, JO				Drife, JO			Pray silence	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1099	1099						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552930				2022-12-28	WOS:000072987400077
J	Walsh, T; Grimes, D; Frezieres, R; Nelson, A; Bernstein, L; Coulson, A; Bernstein, G				Walsh, T; Grimes, D; Frezieres, R; Nelson, A; Bernstein, L; Coulson, A; Bernstein, G		IUD Study Grp	Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices	LANCET			English	Article							PELVIC INFLAMMATORY DISEASE	Background The value of antibiotic prophylaxis before insertion of an intrauterine device (IUD) remains uncertain, We undertook a triple-masked, randomised, placebo-controlled trial to find out whether such prophylaxis reduces the rate of IUD removal within 90 days. Methods 11 clinic sites in southern California enrolled women who requested IUD insertion and were at low risk of sexually transmitted infection according to self-reported medical history. We randomly assigned 1985 participants either 500 mg azithromycin or placebo capsules of identical appearance taken about 1 h before insertion of a Copper T 380A IUD. 118 women did not have an IUD inserted. We followed up 1833 of the remaining 1867 (98%) participants for at least 90 days after insertion. Findings The rate of IUD removal for any reason other than partial expulsion was 3.8% (35/918) in the antibiotic group and 3.4% (31/915) in the placebo group (relative risk 1.1 [95% CI 0.7-1.8]). The two treatment groups sought medical attention with equal frequency (mean 38 visits per 100 women). During the 90 days after IUD insertion, only one woman from each assignment group had salpingitis, as defined by established criteria. Interpretation Prophylaxis with azithromycin did not affect the likelihood that a woman would retain her IUD at 90 days or the frequency of postinsertion medical attention. In appropriately screened women, the risk of upper-genital-tract infection is negligible after IUD insertion, with or without the administration of prophylactic antibiotics.	Calif Family Hlth Council, Div Res, Los Angeles, CA USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Harbor UCLA Med Ctr, Dept Obstet & Gynecol, Torrance, CA 90509 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of Southern California; University of California System; University of California Los Angeles	Grimes, D (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	dgrimes@fhi.org			NICHD NIH HHS [N01-HD-1-3112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD013112] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*AM MED ASS, 1995, AMA DRUG EV ANN 1995, P1507; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; HAGER WD, 1983, OBSTET GYNECOL, V61, P113; KOOIKER CH, 1990, WESTERN J MED, V153, P279; LADIPO O A, 1991, Advances in Contraception, V7, P43, DOI 10.1007/BF01850718; LEE NC, 1983, OBSTET GYNECOL, V62, P1; MISHELL DR, 1966, AM J OBSTET GYNECOL, V96, P119, DOI 10.1016/S0002-9378(16)34650-6; RIVERA R, 1994, P 4 INT C IUDS, P171; Sawaya GF, 1996, OBSTET GYNECOL, V87, P884; SAXENA BN, 1989, CONTRACEPTION, V39, P37; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; SIVIN I, 1990, CONTRACEPTION, V42, P361, DOI 10.1016/0010-7824(90)90046-X; TIETZE C, 1970, STUD FAMILY PLANN, P1; *US PHARM CONV INC, 1997, DRUG INF HLTH CAR PR, P487; WALSH TL, 1994, CONTRACEPTION, V50, P319, DOI 10.1016/0010-7824(94)90019-1; *WHO, 1987, TECHN REP SER, V753	17	64	64	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1005	1008		10.1016/S0140-6736(97)09086-7	http://dx.doi.org/10.1016/S0140-6736(97)09086-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546505				2022-12-28	WOS:000072927200009
J	Hannaford, PC; Owen-Smith, V				Hannaford, PC; Owen-Smith, V			Using epidemiological data to guide clinical practice: Review of studies on cardiovascular disease and use of combined oral contraceptives	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NONFATAL MYOCARDIAL-INFARCTION; FATAL SUBARACHNOID HEMORRHAGE; VENOUS THROMBOEMBOLISM; YOUNG-WOMEN; RISK-FACTORS; SMOKING; MIGRAINE; STROKE	Objective: To explore the usefulnesss of epidemiological data to guide clinical practice by seeking an answer to the question "What is the risk of cardiovascular disease among users of currently available, low dose, combined oral contraceptives who are aged less than 35, ears, do not smoke, and do not have a medical condition known to increase the risk of vascular disease?" Design: Review of all relevant published studies identified from the library of references held by Royal College of General Practitioners' Manchester Research Unit, checking of reference lists of identified studies, and Medline search. Main outcome measures: Identification of methodologically sound studies able to address the specific clinical question. Results: Our literature search identified 74 papers about the relation between current use of combined oral contraceptives and cardiovascular disease: 23 papers reporting risk of venous thromboembolism 22 on ischaemic stroke, 13 on haemorrhagic stroke or subarachnoid haemorrhage, 13 on all stroke, and 33 on myocardial infarction. Only five papers provided information that directly addressed our clinical question: all related to the risk of venous thromboembolism. Fourteen of the discarded papers probably had the potential to answer our clinical question. Conclusions: Much of the epidemiological data about the risk of cardiovascular disease in users of combined oral contraceptives is not useful to clinicians. Some of the discarded data could be made more useful to clinicians by reanalysis. This situation is unlikely to be unique to use of contraceptives.	Royal Coll Gen Practitioners, Manchester Res Unit, Pkwy House, Manchester M22 4DB, Lancs, England		Hannaford, PC (corresponding author), Foresterhill Hlth Ctr, RCGP Ctr Primary Care Res & Epidemiol, Aberdeen AB25 2AY, Scotland.	p.hannaford@abdn.ac.uk	Hannaford, Philip C/B-7867-2012					ADAM SA, 1981, BRIT J OBSTET GYNAEC, V88, P838, DOI 10.1111/j.1471-0528.1981.tb01311.x; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; Carolei A, 1996, LANCET, V347, P1503, DOI 10.1016/S0140-6736(96)90669-8; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DAVANZO B, 1994, J EPIDEMIOL COMMUN H, V48, P324, DOI 10.1136/jech.48.3.324; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; Hannaford PC, 1996, CONTRACEPTION, V54, P125, DOI 10.1016/S0010-7824(96)00167-9; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; INMAN WHW, 1979, BRIT MED J, V2, P1468, DOI 10.1136/bmj.2.6203.1468; JENSEN G, 1991, EUR HEART J, V12, P298, DOI 10.1093/oxfordjournals.eurheartj.a059894; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1403, DOI 10.1001/jama.239.14.1403; KRUEGER DE, 1980, AM J EPIDEMIOL, V111, P655, DOI 10.1093/oxfordjournals.aje.a112944; Last J., 1988, DICT EPIDEMIOLOGY; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; OLECKNO WA, 1988, PUBLIC HEALTH, V102, P45, DOI 10.1016/S0033-3506(88)80009-X; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; ROSENBERG L, 1980, AM J EPIDEMIOL, V111, P59, DOI 10.1093/oxfordjournals.aje.a112874; SALONEN JT, 1982, ACTA MED SCAND, V212, P141; SHAPIRO S, 1979, LANCET, V1, P743; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; THOROGOOD M, 1981, BRIT MED J, V283, P762, DOI 10.1136/bmj.283.6294.762; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526	35	36	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	1998	316	7136					984	987		10.1136/bmj.316.7136.984	http://dx.doi.org/10.1136/bmj.316.7136.984			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550959	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072856100023
J	Hood, CA; Hope, T; Dove, P				Hood, CA; Hope, T; Dove, P			Videos, photographs, and patient consent	BRITISH MEDICAL JOURNAL			English	Article									Ethox, Div Publ Hlth & Primary Care, Inst Hlth Care Sci, Oxford OX3 7LF, England; John Radcliffe Hosp, Oxford Med Illustrat, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Hood, CA (corresponding author), Ethox, Div Publ Hlth & Primary Care, Inst Hlth Care Sci, Oxford OX3 7LF, England.							Beauchamp T., 1994, PRINCIPLES BIOMEDICA, P120; *BMA ETH SCI INF D, 1993, MED ETH TOD ITS PRAC; Clever LH, 1997, JAMA-J AM MED ASSOC, V278, P628, DOI 10.1001/jama.278.8.628; DAVIDOFF F, 1995, BRIT MED J, V311, P1272; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P682, DOI 10.1001/jama.278.8.682; *GEN MED COUNC, 1996, DUT DOCT; *GEN MED COUNC, 1997, MAK US VIS AUD REC P; GILLON R, 1986, PHILOS MD ETHICS; *I MED ILL, 1996, COD PROF COND MED IL; MUIR H, 1996, DAILY TELEGRAPH 0315, P1; SMITH R, 1995, BRIT MED J, V311, P1240, DOI 10.1136/bmj.311.7015.1240; Smith R, 1996, BRIT MED J, V313, P16, DOI 10.1136/bmj.313.7048.16; Snider DE, 1997, JAMA-J AM MED ASSOC, V278, P624, DOI 10.1001/jama.278.8.624	13	43	44	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1009	1011		10.1136/bmj.316.7136.1009	http://dx.doi.org/10.1136/bmj.316.7136.1009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550967	Green Published			2022-12-28	WOS:000072856100036
J	Beecham, L				Beecham, L			Scotland needs different models of health care	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					943	943						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552865				2022-12-28	WOS:000072713300082
J	Kind, P; Dolan, P; Gudex, C; Williams, A				Kind, P; Dolan, P; Gudex, C; Williams, A			Variations in population health status: results from a United Kingdom national questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; EUROQOL; SF-36; VALIDITY; INDEX	Objective: To measure the health of a representative sample of the population of the United Kingdom by using the EuroQoL EQ-5D questionnaire. Design: Stratified random sample representative of the general population aged 18 and over and living in the community. Setting: United Kingdom. Subjects: 3395 people resident in the United Kingdom. Main outcome measures: Average values for mobility, self care, usual activities, pain or discomfort, and anxiety or depression. Results: One in three respondents reported problems with pain or discomfort There were differences in the perception of health according to the respondent's age, social class, education, housing tenure, economic position, and smoking behaviour. Conclusions: The EQ-5D questionnaire is a practical way; of measuring the health of a population and of detecting differences in subgroups of the population.	Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of York - UK	Kind, P (corresponding author), Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England.	pk1@york.ac.uk		Gudex, Claire/0000-0003-3881-9890; kind, paul/0000-0003-2377-1652				BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; Black D, 1980, INEQUALITIES HLTH RE; BRAZIER J, 1993, QUAL LIFE RES, V2, P169, DOI 10.1007/BF00435221; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; *DEP HLTH, 1976, PREV HLTH EV BUS REA; Dolan P., 1995, SOCIAL TARIFF EUROQO; ERENS B, 1994, HLTH RELATED QUALITY; EssinkBot ML, 1997, MED CARE, V35, P522, DOI 10.1097/00005650-199705000-00008; HOLLINGWORTH W, 1995, QUAL LIFE RES, V4, P325, DOI 10.1007/BF01593885; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; HURST NP, 1994, BRIT J RHEUMATOL, V33, P655; Kish L, 1965, SURVEY SAMPLING; MARTIN J, 1988, 1 OPCS; PATRICK DL, 1973, HEALTH SERV RES, V11, P516; Prescott-Clarke P., 1998, HLTH SURVEY ENGLAND; RAHKONEN O, 1995, SOC SCI MED, V41, P163, DOI 10.1016/0277-9536(94)00320-S; ROSSER RM, 1972, INT J EPIDEMIOL, V1, P361, DOI 10.1093/ije/1.4.361; Sculpher MJ, 1996, BRIT J OBSTET GYNAEC, V103, P142, DOI 10.1111/j.1471-0528.1996.tb09666.x; SINTONEN H, 1981, SOC SCI MED-MED ECON, V15, P55, DOI 10.1016/0160-7995(81)90019-8; THOMAS M, 1994, OPCS SERIES GHS, V23; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; VANAGT HME, 1994, SOC SCI MED, V39, P1537, DOI 10.1016/0277-9536(94)90005-1; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WILLIIAMS AH, 1995, 136 CTR HLTH EC	26	810	828	0	47	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					736	741		10.1136/bmj.316.7133.736	http://dx.doi.org/10.1136/bmj.316.7133.736			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB358	9529408	Bronze, Green Published			2022-12-28	WOS:000072463700030
J	Kinmonth, AL; Reinhard, J; Bobrow, M; Pauker, S				Kinmonth, AL; Reinhard, J; Bobrow, M; Pauker, S			The new genetics: Implications for clinical services in Britain and the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CYSTIC-FIBROSIS; PRIMARY-CARE; GENERAL-PRACTITIONERS; COST-EFFECTIVENESS; REGISTER; COMMUNITY; DISEASES; RISK		Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England; SUNY Buffalo, Buffalo, NY 14260 USA; Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Cambridge CB2 2QQ, England; Harvard Pilgrim Hlth Care, Dept Genet, Boston, MA 02116 USA	University of Cambridge; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Harvard Pilgrim Health Care	Kinmonth, AL (corresponding author), Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.	alk25@medschl.cam.ac.uk						Bachman R P, 1996, HMO Pract, V10, P54; BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Boulton M, 1996, BRIT J GEN PRACT, V46, P299; BROCK DJH, 1995, J INHERIT METAB DIS, V18, P525, DOI 10.1007/BF00710064; BULOW S, 1993, INT J COLORECTAL DIS, V8, P34, DOI 10.1007/BF00341274; BURN J, 1991, J MED GENET, V28, P289, DOI 10.1136/jmg.28.5.289; CLARKE A, 1995, BRIT MED J, V311, P1463, DOI 10.1136/bmj.311.7018.1463; COHEN MM, 1994, AM J HUM GENET, V55, pR1; CUCKLE HS, 1995, BRIT MED J, V311, P1460, DOI 10.1136/bmj.311.7018.1460; DAVIES F, 1991, Q J MED, V79, P477; DAVISON C, 1994, SOCIOL HEALTH ILL, V16, P340, DOI 10.1111/1467-9566.ep11348762; Davison C., 1996, TROUBLED HELIX SOCIA, P317; *DEP HLTH, 1995, 2 DOH NHS RES DEV DI; *DEP HLTH, 1995, 1 DOH NHS RES DEV DI; Doherty RA, 1996, PRENATAL DIAG, V16, P397, DOI 10.1002/(SICI)1097-0223(199605)16:5<397::AID-PD864>3.0.CO;2-I; FADEN RR, 1994, AM J MED GENET, V50, P1, DOI 10.1002/ajmg.1320500102; Geller G, 1993, Arch Fam Med, V2, P1119, DOI 10.1001/archfami.2.11.1119; Harper PS, 1995, LANCET, V346, P1645, DOI 10.1016/S0140-6736(95)92835-9; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; LERMAN C, 1997, JNCI-J NATL CANCER I, V89, P48; Loader S, 1996, AM J HUM GENET, V59, P234; MACKAV J, 1997, STRATEGY MANAGEMENT; Marteau TM, 1998, BMJ-BRIT MED J, V316, P693, DOI 10.1136/bmj.316.7132.693; PARSONS E, 1992, SOCIOL HEALTH ILL, V14, P437, DOI 10.1111/1467-9566.ep10493083; Payne Y, 1997, CLIN GENET, V51, P153; READ AP, 1986, J MED GENET, V23, P581, DOI 10.1136/jmg.23.6.581; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P167; Teague K E, 1996, J Cancer Educ, V11, P196; *U CENTR LANC DEP, ROYAL MANCH CHILDR H; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1996, CM3990	33	61	61	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					767	770		10.1136/bmj.316.7133.767	http://dx.doi.org/10.1136/bmj.316.7133.767			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529418	Green Published			2022-12-28	WOS:000072463700043
J	Naas, AAO; Davidson, NC; Thompson, C; Cummings, F; Ogston, SA; Jung, RT; Newton, RW; Struthers, AD				Naas, AAO; Davidson, NC; Thompson, C; Cummings, F; Ogston, SA; Jung, RT; Newton, RW; Struthers, AD			QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Ctr Diabet, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Struthers, AD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.			Cummings, Fraser/0000-0002-9659-3247; Struthers, Allan/0000-0002-2926-2528				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; Darbar D, 1996, BRIT MED J, V312, P874; DINEEN S, 1995, DIABETES S1, V44, pA124; Fu GS, 1997, EUR HEART J, V18, P281; SAWICKI PT, 1996, DIABETES S2, V45, pA128	5	114	117	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					745	746		10.1136/bmj.316.7133.745	http://dx.doi.org/10.1136/bmj.316.7133.745			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529410	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072463700032
J	Flexner, C				Flexner, C			HIV-protease inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PROTEASE; IN-VIVO; RITONAVIR; GAG; RESISTANCE; VARIANTS; METABOLISM; GENERATION; INFECTION		Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Flexner, C (corresponding author), Johns Hopkins Univ Hosp, Osler 524,600 N Wolfe St, Baltimore, MD 21287 USA.							BILELLO JA, 1995, J INFECT DIS, V171, P546, DOI 10.1093/infdis/171.3.546; Brau N, 1997, LANCET, V349, P924, DOI 10.1016/S0140-6736(05)62700-6; BRYANT M, 1995, ANTIMICROB AGENTS CH, V39, P2229, DOI 10.1128/AAC.39.10.2229; CAMERON DW, 1996, 11 INT C AIDS VANC B, V1, P24; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CAVET W, 1996, 4 C RETR OPP INF WAS, P207; Chiba M, 1996, DRUG METAB DISPOS, V24, P307; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COHEN C, 1996, 36 INT C ANT AG CHEM, P8; COLLIER AC, 1997, INF DIS SOC AM 35 AN, P75; CONDRA J, 1996, 11 INT C AIDS VANC S, P19; CONDRA J, 1995, 4 INT WORKSH HIV DRU, P82; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; COX SR, 1997, 4 C RETR OPP INF WAS, P133; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; *DEP HHS PAN CLIN, 1997, GUID US ANT AG HIV I; DONG BJ, 1998, 5 C RETR OPP INF CHI, P157; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; EMINI EA, 1996, 11 INT C AIDS VANC J, V1, P18; Erickson J, 1996, NAT STRUCT BIOL, V3, P103; ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fitzsimmons ME, 1997, DRUG METAB DISPOS, V25, P256; FLEXNER C, 1988, VIROLOGY, V166, P339, DOI 10.1016/0042-6822(88)90504-1; FLEXNER C, 1996, INFECT MED SF, V13, P16; FLEXNER C, 1995, ANTIVIR RES, V26, pA282; Flexner Charles, 1997, P479; GATHE J, 1996, 11 INT C AIDS VANC J, V1, P25; GILQUIN J, 1997, 4 C RETR OPP INF WAS, P129; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAVLIR DV, 1998, 5 C RETR OPP INF CHI, P225; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HENRY K, 1997, 37 INT C ANT AG CHEM, P282; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; Hsu A, 1997, ANTIMICROB AGENTS CH, V41, P898, DOI 10.1128/AAC.41.5.898; JACOBSON MA, 1997, 4 C RETR OPP INF WAS, P129; KAGEYAMA S, 1994, ANTIMICROB AGENTS CH, V38, P1107, DOI 10.1128/AAC.38.5.1107; KAHN J, 1998, 5 C RETR OPP INF CHI, P208; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KERULY JC, 1998, 5 C RETR OPP INF CHI, P157; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Kopp JB, 1997, ANN INTERN MED, V127, P119, DOI 10.7326/0003-4819-127-2-199707150-00004; KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008; Kumar GN, 1997, J PHARMACOL EXP THER, V281, P1506; Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423; Lazdins JK, 1997, J INFECT DIS, V175, P1063, DOI 10.1086/520352; LEDERMAN M, 1997, 4 C RETR OPP INF WAS, P208; LEGRICE SFJ, 1988, EMBO J, V7, P2547, DOI 10.1002/j.1460-2075.1988.tb03103.x; MANN M, 1998, 5 C RETR OPP INF, P157; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MARKOWITZ M, 1996, 11 INT C AIDS VANC J, P28; McCrea J., 1997, Clinical Pharmacology and Therapeutics, V61, P152; MCCREA J, 1997, 4 C RETR OPP INF WAS, P177; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Moore RD, 1996, PHARMACOECONOMICS, V10, P109, DOI 10.2165/00019053-199610020-00002; MOYLE GL, 1996, 11 INT C AIDS VANC J, V1, P18; MOYLE GLJ, 1997, INF DIS SOC AM 35 AN, P115; MURPHY R, 1997, 4 C RETR OPP INF WAS, P133; NABULSI AA, 1996, 11 INT C AIDS VANC J, V2, P31; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; OVERTON HA, 1990, VIROLOGY, V179, P508, DOI 10.1016/0042-6822(90)90326-M; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Piscitelli SC, 1996, CLIN INFECT DIS, V23, P685, DOI 10.1093/clinids/23.4.685; RAFFI F, 1998, 5 C RETR OPP INF CHI, P225; ROBERTS AD, 1997, INF DIS SOC AM 35 AN, P114; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; *ROCH LAB, 1997, FORT SAQ SOFT GEL CA; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SAAG M, 1997, INF DIS SOC AM 35 AN, P112; SALGO MP, 1996, 11 INT C AIDS VANC B, V1, P24; SAMPSON M, 1997, 37 INT C ANT AG CHEM, P262; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; SCHAPIRO JM, 1996, 11 INT C AIDS VANC J, V1, P25; SCHINAZI RF, 1996, INT ANTIVIRAL NEWS, V4, P95; SCHOOLEY RT, 1996, 36 INT C ANT AG CHEM, P8; SONG JK, 1997, SCIENCE, V278, P1291; STEIGBIGEL RT, 3 C RETR OPP INF WAS, V80, P96; Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006; Sun Eugene, 1996, P18; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; [No title captured]; 1996, MMWR MORB MORTAL WKL, V45, P921	95	678	701	3	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1281	1292		10.1056/NEJM199804303381808	http://dx.doi.org/10.1056/NEJM199804303381808			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562584				2022-12-28	WOS:000073335800008
J	Ruokolainen, J; Makinen, R; Torkkeli, M; Makela, T; Serimaa, R; ten Brinke, G; Ikkala, O				Ruokolainen, J; Makinen, R; Torkkeli, M; Makela, T; Serimaa, R; ten Brinke, G; Ikkala, O			Switching supramolecular polymeric materials with multiple length scales	SCIENCE			English	Article							BLOCK; THERMODYNAMICS; COPOLYMERS	It was demonstrated that polymeric supramolecular nanostructures with several length scales allow straightforward tailoring of hierarchical order-disorder and order-order transitions and the concurrent switching of functional properties. Poly(4-vinyl pyridine) (P4VP) was stoichiometrically protonated with methane sulfonic acid (MSA) to form P4VP(MSA)(1.0), which was then hydrogen-bonded to pentadecylphenol. Microphase separation, re-entrant closed-loop macrophase separation, and high-temperature macrophase separation were observed. When MSA and pentadecylphenol were complexed to the P4VP block of a microphase-separated diblock copolymer poly[styrene-block(4-vinyl pyridine)], self-organized structures-in-structures were obtained whose hierarchical phase transitions can be controlled systematically. This microstructural control on two different length scales (in the present case, at 48 and 350 angstroms) was then used to introduce temperature-dependent transitions in electrical conductivity.	Univ Groningen, Dept Polymer Sci, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands; Helsinki Univ Technol, Dept Engn Phys & Math, FIN-020215 Espoo, Finland; Univ Helsinki, Dept Phys, FIN-00014 Helsinki, Finland; Tech Res Ctr Finland, VTT Microelect, FIN-02044 Espoo, Finland	University of Groningen; University of Groningen; Aalto University; University of Helsinki; VTT Technical Research Center Finland	ten Brinke, G (corresponding author), Univ Groningen, Dept Polymer Sci, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	G.ten.Brinke@chem.rug.nl; Olli.Ikkala@hut.fi	Ikkala, Olli T./K-7447-2012; Ruokolainen, Janne T/F-6369-2010; Torkkeli, Mika/O-4362-2014; Mäkelä, Tapio/E-9749-2017	Ikkala, Olli T./0000-0002-0470-1889; Torkkeli, Mika/0000-0001-8039-4000; Mäkelä, Tapio/0000-0002-8765-3738; Ruokolainen, Janne Tapio/0000-0003-2214-0621				Antonietti M, 1997, TRENDS POLYM SCI, V5, P262; Arstila H, 1998, J CHEM PHYS, V108, P1031, DOI 10.1063/1.475496; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; CAO Y, 1992, SYNTHETIC MET, V48, P91, DOI 10.1016/0379-6779(92)90053-L; DANIEL MF, 1988, SOLID STATE IONICS, V28, P637, DOI 10.1016/S0167-2738(88)80116-4; de Genes P. G., 1979, SCALING CONCEPTS POL; Faraggi EZ, 1997, SYNTHETIC MET, V85, P1247, DOI 10.1016/S0379-6779(97)80224-X; Fischer H, 1996, ACTA POLYM, V47, P413, DOI 10.1002/actp.1996.010471001; Ikkala OT, 1997, SYNTHETIC MET, V84, P55, DOI 10.1016/S0379-6779(97)80663-7; LEIBLER L, 1980, MACROMOLECULES, V13, P1602, DOI 10.1021/ma60078a047; Mao G, 1997, ACTA POLYM, V48, P405, DOI 10.1002/actp.1997.010481001; Mao GP, 1997, MACROMOLECULES, V30, P2556, DOI 10.1021/ma9617835; Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225; Ober CK, 1997, ADV MATER, V9, P17, DOI 10.1002/adma.19970090104; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Ruokolainen J, 1997, MACROMOLECULES, V30, P2002, DOI 10.1021/ma961609g; Ruokolainen J, 1996, PHYS REV E, V54, P6646, DOI 10.1103/PhysRevE.54.6646; Ruokolainen J, 1996, MACROMOLECULES, V29, P6621, DOI 10.1021/ma951800a; SANCHEZ IC, 1991, MACROMOLECULES, V24, P908, DOI 10.1021/ma00004a016; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; tenBrinke G, 1997, TRENDS POLYM SCI, V5, P213; WALKER JS, 1987, SCI AM, V256, P98, DOI 10.1038/scientificamerican0587-98; Wang YZ, 1997, SYNTHETIC MET, V85, P1179, DOI 10.1016/S0379-6779(97)80201-9; WEGNER G, 1986, MAKROMOL CHEM-M SYMP, V1, P151, DOI 10.1002/masy.19860010113; YAMADA M, 1995, MACROMOLECULES, V28, P50, DOI 10.1021/ma00105a006	25	616	625	6	216	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					557	560		10.1126/science.280.5363.557	http://dx.doi.org/10.1126/science.280.5363.557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554840	Green Submitted			2022-12-28	WOS:000073242100037
J	Lamas, GA; Orav, J; Stambler, BS; Ellenbogen, KA; Sgarbossa, EB; Huang, SKS; Marinchak, RA; Estes, NAM; Mitchell, GF; Lieberman, EH; Mangione, CM; Goldman, L				Lamas, GA; Orav, J; Stambler, BS; Ellenbogen, KA; Sgarbossa, EB; Huang, SKS; Marinchak, RA; Estes, NAM; Mitchell, GF; Lieberman, EH; Mangione, CM; Goldman, L		Pacemaker Selection Elderly Investigators	Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PACEMAKER SYNDROME; LONG-TERM; OF-LIFE; SELECTION; DEVICES; DDD; ASSOCIATION; GUIDELINES; CROSSOVER; BLIND	Background Standard clinical practice permits the use of either single-chamber ventricular pacemakers or dual-chamber pacemakers for most patients who require cardiac pacing. Ventricular pacemakers are less expensive, but dual-chamber pacemakers are believed to be more physiologic. However, it is not known whether either type of pacemaker results in superior clinical outcomes. Methods The Pacemaker Selection in the Elderly study was a 30-month, single-blind, randomized, controlled comparison of ventricular pacing and dual-chamber pacing in 407 patients 65 years of age or older in 29 centers. Patients received a dual-chamber pacemaker that had been randomly programmed to either ventricular pacing or dual-chamber pacing. The primary end point was health-related quality of life as measured by the 36-item Medical Outcomes Study Short-Form General Health Survey. Results The average age of the patients was 76 years (range, 65 to 96), and 60 percent were men. Quality of life improved significantly after pacemaker implantation (P<0.001), but there were no differences between the two pacing modes in either the quality of life or prespecified clinical outcomes (including cardiovascular events or death). However, 53 patients assigned to ventricular pacing (26 percent) were crossed over to dual-chamber pacing because of symptoms related to the pacemaker syndrome. Patients with sinus-node dysfunction, but not those with atrioventricular block, had moderately better quality of life and cardiovascular functional status with dual-chamber pacing than with ventricular pacing. Trends of borderline statistical significance in clinical end points favoring dual-chamber pacing were observed in patients with sinus-node dysfunction, but not in those with atrioventricular block. Conclusions The implantation of a permanent pacemaker improves health-related quality of life. The quality-of-life benefits associated with dual-chamber pacing as compared with ventricular pacing are observed principally in the subgroup of patients with sinus-node dysfunction. (C) 1998, Massachusetts Medical Society.	Mt Sinai Med Ctr, Div Cardiol, Miami Beach, FL 33140 USA; Univ Miami, Sch Med, Miami Beach, FL USA; Brigham & Womens Hosp, Clin Epidemiol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; McGuire Dept Vet Affairs Med Ctr, Richmond, VA USA; Med Coll Virginia Hosp, Richmond, VA USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Natl Taiwan Univ, Coll Med, Taipei 10018, Taiwan; Lankenau Hosp, Wynnewood, PA USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Virginia Beach Gen Hosp, Virginia Beach, VA USA; Baylor Med Ctr, Dallas, TX USA; Lahey Clin Fdn, Burlington, MA 01805 USA	Mount Sinai Medical Center; University of Miami; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; Cleveland Clinic Foundation; National Taiwan University; Lankenau Medical Center; Tufts Medical Center; Tufts University; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Lahey Hospital & Medical Center	Lamas, GA (corresponding author), Mt Sinai Med Ctr, Div Cardiol, 4300 Alton Rd, Miami Beach, FL 33140 USA.		Stambler, Bruce/ABC-1982-2021; Ellenbogen, Kenneth/AAJ-3992-2021					Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; BERNSTEIN AD, 1992, AM J CARDIOL, V69, P331, DOI 10.1016/0002-9149(92)90229-R; BERNSTEIN AD, 1987, PACE, V10, P794, DOI 10.1111/j.1540-8159.1987.tb06035.x; BONOW RO, 1988, J AM COLL CARDIOL, V11, P50, DOI 10.1016/0735-1097(88)90166-0; BRINKER JA, 1995, PACE, V18, P953, DOI 10.1111/j.1540-8159.1995.tb04733.x; COX DR, 1972, J R STAT SOC B, V34, P187; Deharo JC, 1996, PACE, V19, P1320, DOI 10.1111/j.1540-8159.1996.tb04210.x; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DREIFUS LS, 1991, CIRCULATION, V84, P455, DOI 10.1161/01.CIR.84.1.455; Ellenbogen KA, 1997, AM J CARDIOL, V79, P1226, DOI 10.1016/S0002-9149(97)00085-4; ELLENBOGEN KA, 1990, AM J CARDIOL, V65, P53, DOI 10.1016/0002-9149(90)90025-V; FURMAN S, 1994, PACE, V17, P1, DOI 10.1111/j.1540-8159.1994.tb01342.x; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HELDMAN D, 1990, PACE, V13, P1742, DOI 10.1111/j.1540-8159.1990.tb06883.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; JUTZY RV, 1990, PACE, V13, P1838, DOI 10.1111/j.1540-8159.1990.tb06900.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMAS GA, 1995, CIRCULATION, V91, P1063, DOI 10.1161/01.CIR.91.4.1063; LAMAS GA, 1992, CIRCULATION, V86, P449; LAMAS GA, 1988, PACE, V11, P1098, DOI 10.1111/j.1540-8159.1988.tb03957.x; LAMAS GA, 1993, PACING CLIN ELECTROP, V15, P1109; LINDEEDELSTAM C, 1992, PACE, V15, P1467, DOI 10.1111/j.1540-8159.1992.tb02920.x; LINDEEDELSTAM C, 1992, PACE, V15, P425, DOI 10.1111/j.1540-8159.1992.tb05138.x; MILLER TR, 1986, AM J CARDIOL, V58, P531, DOI 10.1016/0002-9149(86)90028-7; PEHRSSON SK, 1983, ACTA MED SCAND, V214, P311; REDIKER DE, 1988, AM J CARDIOL, V61, P323, DOI 10.1016/0002-9149(88)90938-1; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SAMET P, 1966, AM J CARDIOL, V18, P522, DOI 10.1016/0002-9149(66)90004-X; SULKE N, 1992, BRIT HEART J, V67, P57; Ware J. E., 1993, SF36 HLTH SURVEY MAN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	31	436	453	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1097	1104		10.1056/NEJM199804163381602	http://dx.doi.org/10.1056/NEJM199804163381602			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545357	Green Published			2022-12-28	WOS:000073070100002
J	Stollberger, C; Chnupa, P; Kronik, G; Brainin, M; Finsterer, J; Schneider, B; Slany, J				Stollberger, C; Chnupa, P; Kronik, G; Brainin, M; Finsterer, J; Schneider, B; Slany, J		ELAT Study Grp	Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Article						echocardiography, transesophageal; atrial fibrillation; embolism and thrombosis; cerebrovascular disorders; atrial function, left	SPONTANEOUS ECHO CONTRAST; MITRAL-VALVE DISEASE; APPENDAGE THROMBUS; ANATOMIC CORRELATIONS; CLINICAL-APPLICATIONS; THROMBOEMBOLIC RISK; STROKE	Background: Transesophageal echocardiography visualizes the left atrium and its appendage, thrombi, and spontaneous echocardiographic contrast. Objective: To assess the association of transesophageal echocardiographic characteristics with stroke or embolism in atrial fibrillation. Design: Multicenter observational follow-up study. Setting: Hospitals in Austria and Slovakia. Patients: 409 outpatients with nonrheumatic atrial fibrillation and without recent stroke. Intervention: Patients with thrombi received anticoagulation, and patients without thrombi received aspirin. Measurements: Primary events were stroke or embolism. Secondary events were death not caused by stroke or embolism and need for anticoagulation. Results: In the left atrium or left atrial appendage, 10 patients (2.5%) had thrombi and 47 (12%) had spontaneous echocardiographic contrast. The appendage had a mean (+/- SD) length of 44 +/- 10 mm, a mean width of 23 +/- 6 mm, and a mean area of 5.8 +/- 2.5 cm(2). Follow-up ranged from 1 to 74 months (mean, 58 months). Fifty patients had stroke or embolism, 53 died of a cause other than stroke or embolism, and 38 required anticoagulation. On univariate analysis, thrombi (risk ratio, 3.9 [95% CI, 1.4 to 10.1]; P = 0.009), length of the left atrial appendage (risk ratio, 1.6 [CI, 1.05 to 2.5]; P = 0.03), and width of the left atrial appendage (risk ratio, 2.4 [CI, 1.2 to 4.8]; P = 0.01) were associated with stroke or embolism. Multivariate analysis identified hypertension (risk ratio, 3.6 [CI, 1.8 to 8.4]; P = 0.001), previous stroke (risk ratio, 3.7 [CI, 1.5 to 7.5]; P = 0.002), and age (risk ratio, 1.1 [CI, 1.0 to 1.1]; P < 0.001) as risk factors for stroke or embolism and provided evidence of an association between thrombi and stroke or embolism (risk ratio, 2.4 [CI, 0.9 to 6.9]; P = 0.09). Conclusions: In outpatients with atrial fibrillation and without recent stroke, thrombi of the left atrium or left atrial appendage and length and width of the left atrial appendage were associated with stroke or embolism in univariate analysis. In a multivariate analysis, age, hypertension, and previous stroke were risk factors for stroke or embolism, and thrombi of the left atrium or left atrial appendage were possible risk factors. In these patients, history may be more useful than transesophageal echocardiography for the assessment of embolic risk.	Ustav Kardiovaskularnych Chorob, SK-81105 Bratislava, Slovakia; Krankenhaus Krems, A-3500 Krems, Austria; Neurol Krankenhaus, A-3400 Maria Gugging, Austria; Neurol Krankenhaus Rosenhugel, Inst Med Stat, A-1130 Vienna, Austria; Krankenanstalt Rudolfstiftung Wien, Vienna, Austria	Rudolfstiftung Hospital	Stollberger, C (corresponding author), Steingasse 31-18, A-1030 Vienna, Austria.		Finsterer, J/AAE-5733-2020					ABERG H, 1969, ACTA MED SCAND, V185, P373; ARCHER SL, 1995, AM HEART J, V130, P287, DOI 10.1016/0002-8703(95)90442-5; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; BEPPU S, 1985, J AM COLL CARDIOL, V6, P744, DOI 10.1016/S0735-1097(85)80476-9; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; BRAININ M, 1992, NEUROEPIDEMIOLOGY, V11, P190, DOI 10.1159/000110931; CHAN SK, 1995, AM J CARDIOL, V76, P528, DOI 10.1016/S0002-9149(99)80147-7; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; ERNST G, 1995, ANAT REC, V242, P553, DOI 10.1002/ar.1092420411; FATKIN D, 1994, J AM COLL CARDIOL, V23, P961, DOI 10.1016/0735-1097(94)90644-0; KRONIK G, 1995, BRIT HEART J, V74, P80; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEUNG DYC, 1994, J AM COLL CARDIOL, V24, P755, DOI 10.1016/0735-1097(94)90025-6; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MUGGE A, 1990, American Journal of Cardiac Imaging, V4, P173; MUGGE A, 1994, J AM COLL CARDIOL, V23, P599; Orsinelli DA, 1996, AM HEART J, V131, P622, DOI 10.1016/S0002-8703(96)90553-0; POLLICK C, 1991, CIRCULATION, V84, P223, DOI 10.1161/01.CIR.84.1.223; Pozzoli M, 1991, J Am Soc Echocardiogr, V4, P435; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHERMAN DG, 1986, ARCH NEUROL-CHICAGO, V43, P68, DOI 10.1001/archneur.1986.00520010062024; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; STOLLBERGER C, 1995, CARDIOLOGY, V86, P457, DOI 10.1159/000176923	28	145	151	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					630	+		10.7326/0003-4819-128-8-199804150-00004	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537936				2022-12-28	WOS:000073052500003
J	Maison, P; Balkau, B; Simon, D; Chanson, P; Rosselin, G; Eschwege, E				Maison, P; Balkau, B; Simon, D; Chanson, P; Rosselin, G; Eschwege, E			Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study	BRITISH MEDICAL JOURNAL			English	Article									Fac Med Paris Sud, INSERM, U21, F-94807 Villejuif, France; Hop St Antoine, INSERM, U55, F-75571 Paris, France; Hop Bicetre, Serv Endocrinol, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Maison, P (corresponding author), Fac Med Paris Sud, INSERM, U21, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Chanson, Philippe/F-8511-2013	Chanson, Philippe/0000-0001-5096-5722				BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555	5	61	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1132	1133		10.1136/bmj.316.7138.1132	http://dx.doi.org/10.1136/bmj.316.7138.1132			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552951	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000073067500024
J	Rosenberg, L; Rao, S; Palmer, JR; Strom, BL; Stolley, PD; Zauber, AG; Warshauer, ME; Shapiro, S				Rosenberg, L; Rao, S; Palmer, JR; Strom, BL; Stolley, PD; Zauber, AG; Warshauer, ME; Shapiro, S			Calcium channel blockers and the risk of cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-CELL CARCINOMA; DEPENDENT TISSUES; KIDNEY CANCER; APOPTOSIS; DEATH; DIURETICS; DISEASE; HYPERTENSION; INCREASE; OBESITY	Context.-Recent epidemiologic studies have raised the concern that calcium channel blocker use may increase the risk of cancer overall and of several specific cancers. Objective.-To assess whether calcium channel blocker use increases the risk of cancer overall and of specific cancers, Design,-Case-control drug surveillance study based on data collected from 1983 to 1996. Setting.-Hospitals in Baltimore, Md, New York, NY, and Philadelphia, Pa. Patients.-A total of 9513 patients aged 40 to 69 years with incident cancer of various sites and 6492 controls aged 40 to 69 years admitted for nonmalignant conditions. Main Outcome Measures.-Incident cancer overall and 23 specific cancers, Results.-Calcium channel blocker use was unrelated to the risk of cancer overall (relative risk [RR], 1.1; 95% confidence interval [CI], 0.9-1.3). Use was not significantly associated with increased risks of individual cancers, including those previously implicated, except cancer of the kidney (RR, 1.8; 95% CI, 1.1-2.7). Recent use, use for 5 or more years, and use of individual calcium channel blocker drugs were also not associated with cancer incidence, Use of beta-blockers and angiotensin-converting enzyme inhibitors was generally unrelated to cancer overall or individual cancers, but both were associated with kidney cancer (RR, 1.8; 95% CI, 1.3-2.5; and RR, 1.9, 95% CI, 1.2-3.0, respectively). Conclusions.-The present study suggests that the use of calcium channel blockers is unrelated to an increase in the overall risk of cancer or of individual cancers, except kidney cancer, which has been associated with hypertension or drugs to treat hypertension in previous studies.	Boston Univ, Sch Med, Sch Publ Hlth, Sloan Epidemiol Unit, Brookline, MA 02146 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Publ Hlth, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA	Boston University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University System of Maryland; University of Maryland Baltimore; Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center	Rosenberg, L (corresponding author), Boston Univ, Sch Med, Sch Publ Hlth, Sloan Epidemiol Unit, 1371 Beacon St, Brookline, MA 02146 USA.			Rosenberg, Lynn/0000-0003-2760-2987; Palmer, Julie/0000-0002-6534-335X	NATIONAL CANCER INSTITUTE [R01CA045762] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45762] Funding Source: Medline; FDA HHS [FD-U-000082] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		ASAL NR, 1988, CANCER DETECT PREV, V13, P263; Balakumaran A, 1996, TOXICOL APPL PHARM, V139, P122, DOI 10.1006/taap.1996.0150; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; Daling JR, 1996, AM J HYPERTENS, V9, P713; FINKLE WD, 1993, CANC CAUSES CONTROL, V4, P55; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; Heath CW, 1997, AM J EPIDEMIOL, V145, P607, DOI 10.1093/oxfordjournals.aje.a009157; HIATT RA, 1994, CANCER CAUSE CONTROL, V5, P319, DOI 10.1007/BF01804982; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KREIGER N, 1993, CANCER CAUSE CONTROL, V4, P101, DOI 10.1007/BF00053150; LINDBLAD P, 1993, INT J CANCER, V55, P5, DOI 10.1002/ijc.2910550103; MCCREDIE M, 1992, CANCER CAUSE CONTROL, V3, P323, DOI 10.1007/BF00146885; MCLAUGHLIN JK, 1984, JNCI-J NATL CANCER I, V72, P275; MCLAUGHLIN JK, 1995, INT J CANCER, V63, P216, DOI 10.1002/ijc.2910630212; MELLEMGAARD A, 1992, CANCER CAUSE CONTROL, V3, P309, DOI 10.1007/BF00146883; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Prineas RJ, 1997, EPIDEMIOLOGY, V8, P31, DOI 10.1097/00001648-199701000-00005; RAY SD, 1993, FASEB J, V7, P453, DOI 10.1096/fasebj.7.5.8462787; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEN S, 1992, BIOL REV, V67, P287, DOI 10.1111/j.1469-185X.1992.tb00727.x; Shapiro S., 1994, PHARMACOEPIDEM DR S, P301; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; YU MC, 1986, JNCI-J NATL CANCER I, V77, P351	31	126	126	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1000	1004		10.1001/jama.279.13.1000	http://dx.doi.org/10.1001/jama.279.13.1000			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533498	Bronze			2022-12-28	WOS:000072669700027
J	Watts, TLP				Watts, TLP			Fortnightly review - Periodontitis for medical practitioners	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DEPENDENT DIABETES-MELLITUS; DOUBLE-BLIND TRIAL; SURGICAL-TREATMENT; DISEASE; ATTACHMENT		United Med & Dent Sch Guys & St Thomas Hosp, Dept Periodontol & Prevent Dent, London SE1 9RT, England	University of London; King's College London	Watts, TLP (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Periodontol & Prevent Dent, London SE1 9RT, England.	t.watts@umds.ac.uk						ALLEN DL, 1965, J PERIODONTOL, V36, P121, DOI 10.1902/jop.1965.36.2.121; BASS C C, 1954, J La State Med Soc, V106, P100; BERGSTROM J, 1994, J PERIODONTOL, V65, P545, DOI 10.1902/jop.1994.65.5s.545; CORBET EF, 1993, J CLIN PERIODONTOL, V20, P402, DOI 10.1111/j.1600-051X.1993.tb00380.x; EMRICH LJ, 1991, J PERIODONTOL, V62, P123, DOI 10.1902/jop.1991.62.2.123; GOLUB LM, 1985, J PERIODONTAL RES, V20, P12, DOI 10.1111/j.1600-0765.1985.tb00405.x; Heijl L, 1997, J CLIN PERIODONTOL, V24, P705, DOI 10.1111/j.1600-051X.1997.tb00253.x; KNOWLES JW, 1979, J PERIODONTOL, V50, P225, DOI 10.1902/jop.1979.50.5.225; LANG NP, 1973, J PERIODONTOL, V44, P396, DOI 10.1902/jop.1973.44.7.396; LINDHE J, 1984, J CLIN PERIODONTOL, V11, P448, DOI 10.1111/j.1600-051X.1984.tb01344.x; Listgarten M A, 1972, Oral Sci Rev, V1, P3; LOE H, 1986, J CLIN PERIODONTOL, V13, P431, DOI 10.1111/j.1600-051X.1986.tb01487.x; Loe H, 1970, DENT PLAQUE, P247; LOESCHE W J, 1976, Oral Sciences Reviews, V9, P65; MOORE WEC, 1985, INFECT IMMUN, V48, P507, DOI 10.1128/IAI.48.2.507-519.1985; NOVAK MJ, 1983, J PERIODONTOL, V54, P112, DOI 10.1902/jop.1983.54.2.112; NYMAN S, 1982, J CLIN PERIODONTOL, V9, P290, DOI 10.1111/j.1600-051X.1982.tb02095.x; PAGE RC, 1983, J PERIODONTOL, V54, P197, DOI 10.1902/jop.1983.54.4.197; PAGE RC, 1983, J PERIODONTOL, V54, P257, DOI 10.1902/jop.1983.54.5.257; Palmer RM, 1996, J CLIN PERIODONTOL, V23, P670, DOI 10.1111/j.1600-051X.1996.tb00592.x; POLSON AM, 1978, J CLIN PERIODONTOL, V5, P13, DOI 10.1111/j.1600-051X.1978.tb01902.x; RUSSELL A. L., 1963, JOUR DENT RES, V42, P233; SAFKANSEPPALA B, 1992, J CLIN PERIODONTOL, V19, P24, DOI 10.1111/j.1600-051X.1992.tb01144.x; SEYMOUR GJ, 1993, J PERIODONTAL RES, V28, P478, DOI 10.1111/j.1600-0765.1993.tb02108.x; SOCRANSKY SS, 1979, J CLIN PERIODONTOL, V6, P16, DOI 10.1111/j.1600-051X.1979.tb02114.x; SOCRANSKY SS, 1984, J CLIN PERIODONTOL, V11, P21, DOI 10.1111/j.1600-051X.1984.tb01305.x; WATTS T, 1986, J CLIN PERIODONTOL, V13, P939, DOI 10.1111/j.1600-051X.1986.tb01431.x; Watts T L, 1995, Oral Dis, V1, P254; WESTFELT E, 1983, J CLIN PERIODONTOL, V10, P22, DOI 10.1111/j.1600-051X.1983.tb01264.x	29	7	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	1998	316	7136					993	996		10.1136/bmj.316.7136.993	http://dx.doi.org/10.1136/bmj.316.7136.993			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550962	Green Published			2022-12-28	WOS:000072856100027
J	Goldring, O				Goldring, O			Therapeutics: a glimpse of the future	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					420	420		10.1038/32957	http://dx.doi.org/10.1038/32957			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537332				2022-12-28	WOS:000072713600063
J	Lederle, FA				Lederle, FA			Heparin prophylaxis for medical patients?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM PROPHYLAXIS; FATAL PULMONARY-EMBOLISM; LOW-DOSE HEPARIN; RANDOMIZED TRIALS; STANDARD HEPARIN; PREVENTION; INPATIENTS; ENOXAPARIN		Vet Affairs Med Ctr, Dept Med 3 0, Minneapolis, MN 55417 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Lederle, FA (corresponding author), Vet Affairs Med Ctr, Dept Med 3 0, 1 Vet Dr, Minneapolis, MN 55417 USA.							ANDERSON FA, 1991, ANN INTERN MED, V115, P591, DOI 10.7326/0003-4819-591; Bergmann JF, 1996, LANCET, V348, P205, DOI 10.1016/S0140-6736(05)66160-0; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; CAULIN C, 1989, FRAXIPARINE, P149; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Collins R, 1996, BMJ-BRIT MED J, V313, P652; DAHAN R, 1986, HAEMOSTASIS, V16, P159; FERNANDEZ BB, 1995, CHEST, V107, P296, DOI 10.1378/chest.107.1.296; FLORDAL PA, 1995, THROMB RES, V80, P491, DOI 10.1016/0049-3848(95)00204-9; Gardlund B, 1996, LANCET, V347, P1357; Graves E.J., 1995, VITAL HLTH STAT, V13, P1; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; KEANE MG, 1994, CHEST, V106, P13, DOI 10.1378/chest.106.1.13; Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605; Lechler E, 1996, HAEMOSTASIS, V26, P49; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; Nicolaides AN, 1997, INT ANGIOL, V16, P3; NURMOHAMED MT, 1995, AM J SURG, V169, P567, DOI 10.1016/S0002-9610(99)80222-0; Sandercock P, 1997, LANCET, V349, P1569; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17	23	33	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					768	770		10.7326/0003-4819-128-9-199805010-00011	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556472				2022-12-28	WOS:000073363800010
J	D'Amico, G; Politi, F; D'Antoni, A; Giannuoli, G; Pasta, L; Vizziani, G; Traina, M; Morabito, A; Pagliaro, L				D'Amico, G; Politi, F; D'Antoni, A; Giannuoli, G; Pasta, L; Vizziani, G; Traina, M; Morabito, A; Pagliaro, L			Second study shows that octreotide may prevent early rebleeding in cirrhosis	BRITISH MEDICAL JOURNAL			English	Letter							SCLEROTHERAPY		Osped V Cervello, Div Med, I-90146 Palermo, Italy		D'Amico, G (corresponding author), Osped V Cervello, Div Med, I-90146 Palermo, Italy.		traina, mario/A-1309-2012	politi, flavia/0000-0002-6162-8972				BESSON I, 1995, NEW ENGL J MED, V333, P555, DOI 10.1056/NEJM199508313330904; Jenkins SA, 1997, BRIT MED J, V315, P1338, DOI 10.1136/bmj.315.7119.1338; PRIMIGNANI M, 1995, HEPATOLOGY, V21, P1322, DOI 10.1016/0270-9139(95)90054-3	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1320	1320		10.1136/bmj.316.7140.1320	http://dx.doi.org/10.1136/bmj.316.7140.1320			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554914	Green Published			2022-12-28	WOS:000073335900045
J	Artlett, CM; Smith, JB; Jimenez, SA				Artlett, CM; Smith, JB; Jimenez, SA			Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; CHRONIC GRAFT; AUTOIMMUNE-DISEASE; SCLERODERMA; EPIDEMIOLOGY; BLOOD; CHIMERISM	Background Systemic sclerosis is a disease of unknown origin which often occurs in women after their childbearing years. It has many clinical and histopathological similarities to chronic graft-versus-host disease. Recent studies indicate that fetal stem cells can survive in the maternal circulation for many years post partum. This finding suggests that fetal cells persisting in the maternal circulation or tissues could be involved in the pathogenesis of systemic sclerosis by initiating a graft-versus-host reaction. Methods We used the polymerase chain reaction (PCR) to identify Y-chromosome sequences in DNA extracted from peripheral-blood cells and skin lesions from women with systemic sclerosis of recent onset. To confirm the PCR findings, we used fluorescence in situ hybridization of peripheral-blood cells and cells within chronic inflammatory-cell infiltrates in biopsy specimens of affected skin. Results Y-chromosome sequences were found in DNA from peripheral-blood cells in 32 of 69 women with systemic sclerosis (46 percent), as compared with 1 of 25 normal women (4 percent, P<0.001), and in T lymphocytes from 3 women with systemic sclerosis who had male offspring. Furthermore, Y-chromosome sequences were identified in skin-biopsy specimens from 11 of 19 women with systemic sclerosis (58 percent); 9 of the 11 were known to have carried male fetuses. Nucleated cells containing Y chromosomes were detected by fluorescence in situ hybridization in paraffin-embedded sections of skin lesions from all seven women we tested whose skin-biopsy specimens contained Y-chromosome sequences. Conclusions Fetal antimaternal graft-versus-host reactions may be involved in the pathogenesis of systemic sclerosis in some women. (C)1998, Massachusetts Medical Society.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Philadelphia, PA 19107 USA	Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Rm 509,Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.			Jimenez, Sergio/0000-0001-5213-1203	NIADDK NIH HHS [AM19616] Funding Source: Medline; PHS HHS [CRMC-92-15] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019616] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; APPLETON AL, 1994, BONE MARROW TRANSPL, V14, P157; Artlett CM, 1997, IMMUNOGENETICS, V47, P17, DOI 10.1007/s002510050321; BASSUKAS ID, 1992, MED HYPOTHESES, V38, P334, DOI 10.1016/0306-9877(92)90028-B; Bell SA, 1996, BRIT J DERMATOL, V134, P848; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BLACK CM, 1989, RHEUM DIS CLIN N AM, V15, P193; BOS GMJ, 1989, TRANSPLANT P, V21, P3262; BRUBAKER DB, 1993, P SOC EXP BIOL MED, V202, P122; CHOSIDOW O, 1992, J AM ACAD DERMATOL, V26, P49, DOI 10.1016/0190-9622(92)70005-Z; CLEMENTS PJ, 1985, CURRENT TOPICS RHEUM, P376; FAGUNDUS DM, 1994, CLIN DERMATOL, V12, P407, DOI 10.1016/0738-081X(94)90293-3; FLEISCHMAJER R, 1977, ARTHRITIS RHEUM, V20, P975, DOI 10.1002/art.1780200410; GILL TJ, 1977, TRANSPLANT P, V9, P1423; GRAHAMBROWN RAC, 1983, CLIN EXP DERMATOL, V8, P531, DOI 10.1111/j.1365-2230.1983.tb01820.x; HERZOG P, 1980, J RHEUMATOL, V7, P56; JANINMERCIER A, 1984, AM J PATHOL, V115, P296; JIMENEZ SA, 1983, SEMIN ARTHRITIS RHEU, V13, P104, DOI 10.1016/0049-0172(83)90029-X; JUJI T, 1989, NEW ENGL J MED, V321, P56; KAHALEH MB, 1989, ANN INTERN MED, V110, P446, DOI 10.7326/0003-4819-110-6-446; LAMPERT IA, 1981, LANCET, V2, P1352; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; MEDSGER TA, 1994, CLIN DERMATOL, V12, P207, DOI 10.1016/S0738-081X(94)90323-9; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; OREILLY RJ, 1973, TRANSPLANTATION, V15, P505; PATRI S, 1994, PCR METH APPL, V3, P361; Postlethwaite Arnold E., 1993, Current Opinion in Rheumatology, V5, P766; SCHRODER J, 1975, J MED GENET, V12, P230, DOI 10.1136/jmg.12.3.230; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P441, DOI 10.1136/ard.47.6.441; SILMAN AJ, 1996, EPIDEMIOLOGY DEMOGRA, P23; Steele CD, 1996, CLIN OBSTET GYNECOL, V39, P801, DOI 10.1097/00003081-199612000-00009; STEEN VD, 1990, RHEUM DIS CLIN N AM, V16, P1; VALENTA LJ, 1987, ARCH DERMATOL, V123, P1438, DOI 10.1001/archderm.123.11.1438	36	364	371	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1186	1191		10.1056/NEJM199804233381704	http://dx.doi.org/10.1056/NEJM199804233381704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554859	Green Published			2022-12-28	WOS:000073208400004
J	Pinos, T; Xiol, X				Pinos, T; Xiol, X			The Gaudi-colon connection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Atenc Primaria II Cerdanyola, Barcelona 08291, Spain; Bellvitge Hosp, Barcelona 08907, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Pinos, T (corresponding author), Ctr Atenc Primaria II Cerdanyola, Barcelona 08291, Spain.			Xiol, Xavier/0000-0002-4461-4704					0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1192	1192		10.1056/NEJM199804233381705	http://dx.doi.org/10.1056/NEJM199804233381705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554860	Green Published			2022-12-28	WOS:000073208400005
J	Cheng, KS; Dai, ZG; Wei, DM; Lu, T				Cheng, KS; Dai, ZG; Wei, DM; Lu, T			Is GRO J1744-28 a strange star?	SCIENCE			English	Article							GAMMA-RAY BURSTS; NEUTRON-STARS; QUARK STARS; FIREBALLS; ORIGIN; MATTER; MODELS	The unusual hard x-ray burster GRO J1744-28 recently discovered by the Compton Gamma-Ray Observatory can be modeled as a strange star with a dipolar magnetic field of less than or equal to 10(11) gauss. According to this model, when the accreted mass of the star exceeds some critical mass, its crust breaks, resulting in the conversion of the accreted matter into strange matter and a release of energy. Subsequently, a fireball forms and expands relativistically outward. The expanding fireball interacts with the surrounding interstellar medium, causing its kinetic energy to be radiated in shock waves and producing a burst of x-ray radiation. The burst energy, duration, interval, and spectrum derived from such a model are consistent with the observations of GRO J1744-28.	Univ Hong Kong, Dept Phys, Hong Kong, Peoples R China; Nanjing Univ, Dept Astron, Nanjing 210093, Peoples R China; Acad Sinica, Purple Mt Observ, Nanjing 210008, Peoples R China; Chinese Ctr Adv Sci & Technol, World Lab, Beijing 100080, Peoples R China	University of Hong Kong; Nanjing University; Chinese Academy of Sciences; Nanjing Institute of Astronomical Optics & Technology, NAOC, CAS; Purple Mountain Observatory, CAS; China Center of Advanced Science & Technology (CCAST)	Cheng, KS (corresponding author), Univ Hong Kong, Dept Phys, Hong Kong, Peoples R China.		Cheng, Kwong Sang/D-3073-2009					ALCOCK C, 1986, ASTROPHYS J, V310, P261, DOI 10.1086/164679; BAYM G, 1971, ANN PHYS-NEW YORK, V66, P816, DOI 10.1016/0003-4916(71)90084-4; BAYM G, 1991, NATO ADV SCI I C-MAT, V344, P21; BAYM G, 1985, PHYS LETT B, V160, P181, DOI 10.1016/0370-2693(85)91489-3; BLANDFORD R, 1987, PHYS REP, V154, P1, DOI 10.1016/0370-1573(87)90134-7; BODMER AR, 1971, PHYS REV D, V4, P1601, DOI 10.1103/PhysRevD.4.1601; CALDWELL RR, 1991, PHYS LETT B, V264, P143, DOI 10.1016/0370-2693(91)90718-6; CANNIZZO JK, 1906, ASTROPHYS J, V466, pL31; Cheng KS, 1997, ASTROPHYS J, V476, pL39, DOI 10.1086/310486; Cheng KS, 1998, PHYS REV LETT, V80, P18, DOI 10.1103/PhysRevLett.80.18; Cheng KS, 1996, PHYS REV LETT, V77, P1210, DOI 10.1103/PhysRevLett.77.1210; Cheng KS, 1996, MON NOT R ASTRON SOC, V283, pL133, DOI 10.1093/mnras/283.4.L133; CHENG KS, IN PRESS INT J MOD D; Daumerie P, 1996, NATURE, V382, P141, DOI 10.1038/382141a0; FARHI E, 1984, PHYS REV D, V30, P2379, DOI 10.1103/PhysRevD.30.2379; Finger MH, 1996, NATURE, V381, P291, DOI 10.1038/381291a0; FISHMAN GJ, 1995, 6272 IAU; GHOSH P, 1979, ASTROPHYS J, V234, P296, DOI 10.1086/157498; Giles AB, 1996, ASTROPHYS J, V469, pL25, DOI 10.1086/310262; Glendenning N. K., 1991, Nuclear Physics B, Proceedings Supplements, V24B, P110, DOI 10.1016/0920-5632(91)90307-Z; GLENDENNING NK, 1992, ASTROPHYS J, V400, P647, DOI 10.1086/172026; GLENDENNING NK, 1992, PHYS REV D, V46, P1274, DOI 10.1103/PhysRevD.46.1274; HAENSEL P, 1986, ASTRON ASTROPHYS, V160, P121; HEISELBERG H, 1993, PHYS REV LETT, V70, P1355, DOI 10.1103/PhysRevLett.70.1355; JAHODA K, 1997, S ACT XRAY SKY ROM; KLUZNIAK W, 1994, ASTRON ASTROPHYS, V286, pL17; Kouveliotou C, 1996, NATURE, V379, P799, DOI 10.1038/379799a0; Lewin WHG, 1996, ASTROPHYS J, V462, pL39, DOI 10.1088/1538-4357/462/1/L39; MESZAROS P, 1993, ASTROPHYS J, V405, P278, DOI 10.1086/172360; MESZAROS P, 1992, ASTROPHYS J, V397, P570, DOI 10.1086/171813; Meszaros P., 1992, HIGH ENERGY RAD MAGN; PANDHARIPANDE VR, 1994, P 2 INT C PHYS ASTR, P56; PINES D, 1985, NATURE, V316, P27, DOI 10.1038/316027a0; PRAKASH M, 1995, PHYS REV D, V52, P661, DOI 10.1103/PhysRevD.52.661; SHEMI A, 1990, ASTROPHYS J, V365, pL55, DOI 10.1086/185887; SPITZER L, 1962, PHYSICS FULLY IONIZE, P42; Stark MJ, 1996, ASTROPHYS J, V470, pL109, DOI 10.1086/310311; Strickman MS, 1996, ASTROPHYS J, V464, pL131, DOI 10.1086/310112; STRNER SJ, 1996, ASTROPHYS J, V465, pL31; Waxman E, 1997, ASTROPHYS J, V489, pL33, DOI 10.1086/310960; Waxman E, 1997, ASTROPHYS J, V491, pL19, DOI 10.1086/311057; Waxman E, 1997, ASTROPHYS J, V485, pL5, DOI 10.1086/310809; WITTEN E, 1984, PHYS REV D, V30, P272, DOI 10.1103/PhysRevD.30.272	43	74	76	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					407	409		10.1126/science.280.5362.407	http://dx.doi.org/10.1126/science.280.5362.407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545212				2022-12-28	WOS:000073159600038
J	Levy, NT; Olson, LJ; Weyand, C; Brack, A; Tazelaar, HD; Edwards, WD; Hammill, SC				Levy, NT; Olson, LJ; Weyand, C; Brack, A; Tazelaar, HD; Edwards, WD; Hammill, SC			Histologic and cytokine response to immunosuppression in giant-cell myocarditis	ANNALS OF INTERNAL MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE MYOCARDITIS		Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Olson, LJ (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021					Cooper LT, 1997, NEW ENGL J MED, V336, P1860, DOI 10.1056/NEJM199706263362603; COOPER LT, 1995, J HEART LUNG TRANSPL, V14, P394; HANAWA H, 1994, CLIN EXP IMMUNOL, V96, P470; Litovsky SH, 1996, MODERN PATHOL, V9, P1126; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; REN H, 1993, MODERN PATHOL, V6, P402; SAEKI M, 1994, TOHOKU J EXP MED, V172, P195, DOI 10.1620/tjem.172.195; TESLUK H, 1956, AM J CLIN PATHOL, V26, P1326; THEAKER JM, 1988, HUM PATHOL, V19, P974, DOI 10.1016/S0046-8177(88)80015-7; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105; ZHANG SS, 1993, J AM COLL CARDIOL, V21, P1254, DOI 10.1016/0735-1097(93)90254-X	11	13	13	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					648	650		10.7326/0003-4819-128-8-199804150-00007	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537938				2022-12-28	WOS:000073052500005
J	Green, R; Switzer, C; Noller, HF				Green, R; Switzer, C; Noller, HF			Ribosome-catalyzed peptide-bond formation with an a-site substrate covalently linked to 23S ribosomal RNA	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOMES; DIRECTED CROSS-LINKING; TRANSFERASE CENTER; DOMAIN-V; P-SITES; 16S RNA; IDENTIFICATION; POSITIONS; COMPLEXES; REGION	In the ribosome, the aminoacyl-transfer RNA (tRNA) analog 4-thio-dT-p-C-p-puromycin crosslinks photochemically with G2553 of 23S ribosomal RNA (rRNA). This covalently linked substrate reacts with a peptidyl-tRNA analog to form a peptide bond in a peptidyl transferase-catalyzed reaction. This result places the conserved 2555 loop of 23S rRNA at the peptidyl transferase A site and suggests that peptide bond formation can occur uncoupled from movement of the A-site tRNA. Crosslink formation depends on occupancy of the P site by a tRNA carrying an intact CCA acceptor end, indicating that peptidyl-tRNA, directly or indirectly, helps to create the peptidyl transferase A site.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA	University of California System; University of California Santa Cruz; University of California System; University of California Riverside	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.	harry@nuvolari.ucsc.edu						ATKINSON T, 1985, OLIGONUCLEOTIDE SYNT, P35; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; ECKERMANN DJ, 1978, EUR J BIOCHEM, V82, P225, DOI 10.1111/j.1432-1033.1978.tb12015.x; GOLDBERG IH, 1967, BIOCHEMISTRY-US, V6, P383, DOI 10.1021/bi00854a003; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Green R, 1996, RNA, V2, P1011; Green R.A., UNPUB; HALL CC, 1988, BIOCHEMISTRY-US, V27, P3983, DOI 10.1021/bi00411a014; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HISHIZAWA T, 1971, ARCH BIOCHEM BIOPHYS, V147, P624, DOI 10.1016/0003-9861(71)90421-8; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MITCHELL P, 1993, NUCLEIC ACIDS RES, V15, P8783; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; PESTKA S, 1969, COLD SPRING HARB SYM, V34, P395, DOI 10.1101/SQB.1969.034.01.046; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P12565, DOI 10.1021/bi00165a004; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHWARTZ I, 1978, BIOCHEMISTRY-US, V17, P2524, DOI 10.1021/bi00606a011; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; ULBRICH B, 1978, ARCH BIOCHEM BIOPHYS, V190, P149, DOI 10.1016/0003-9861(78)90262-X; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	33	79	81	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					286	289		10.1126/science.280.5361.286	http://dx.doi.org/10.1126/science.280.5361.286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535658				2022-12-28	WOS:000073082400051
J	Bushdid, PB; Brantley, DM; Yull, FE; Blaeuer, GL; Hoffman, LH; Niswander, L; Kerr, LD				Bushdid, PB; Brantley, DM; Yull, FE; Blaeuer, GL; Hoffman, LH; Niswander, L; Kerr, LD			Inhibition of NF-kappa B activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis	NATURE			English	Article							CHICK LIMB; SONIC-HEDGEHOG; VERTEBRATE LIMB; FEEDBACK LOOP; GROWTH; TRANSCRIPTION; DROSOPHILA; EXPRESSION; PROMOTER; INITIATION	In Drosophila, the Dorsal protein establishes the embryonic dorso-ventral axis during development(1), Here we show that the vertebrate homologue of Dorsal, nuclear factor-kappa B (NF-kappa B), is vital for the formation of the proximo-distal organizer of the developing limb bud, the apical ectodermal ridge (AER). Transcription of the NF-kappa B proto-oncogene c-rel is regulated, in part, during morphogenesis of the limb bud by AER-derived signals such as fibroblast growth factors. Interruption of NF-kappa B activity using viral-mediated delivery of an inhibitor results in a highly dysmorphic AER, reduction in overall limb size, loss of distal elements and reversal in the direction of limb outgrowth. Furthermore, inhibition of NF-kappa B activity in limb mesenchyme leads to a reduction in expression of Sonic hedgehog and Twist but derepresses expression of the bone morphogenetic protein-4 gene. These results are the first evidence that vertebrate NF-kappa B proteins act to transmit growth factor signals between the ectoderm and the underlying mesenchyme during embryonic limb formation.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Memorial Sloan Kettering Cancer Center	Kerr, LD (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; ROS MA, 1993, PROG CLIN BIOL RES, V383, P79; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; TRANCKNER EB, 1995, EMBO J, V14, P2876; Vogel A, 1996, DEVELOPMENT, V122, P1737; WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925-4773(95)00453-X; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725	29	148	151	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					615	618		10.1038/33435	http://dx.doi.org/10.1038/33435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560159				2022-12-28	WOS:000072987200063
J	Sheikhzadeh, A; Gehl, HB				Sheikhzadeh, A; Gehl, HB			Thromboatheromatous aortic coarctation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Lubeck, D-23538 Lubeck, Germany	University of Lubeck	Sheikhzadeh, A (corresponding author), Univ Lubeck, D-23538 Lubeck, Germany.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1034	1034		10.1056/NEJM199804093381505	http://dx.doi.org/10.1056/NEJM199804093381505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535668				2022-12-28	WOS:000072969500005
J	Goldman, LS; Genel, M; Bezman, RJ; Slanetz, PJ				Goldman, LS; Genel, M; Bezman, RJ; Slanetz, PJ		Amer Med Assoc	Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; STIMULANT TREATMENT; PSYCHIATRIC-DISORDERS; MULTIMODAL TREATMENT; CONDUCT PROBLEMS; PRIMARY CARE; RISK-FACTORS; METHYLPHENIDATE; PREVALENCE; ADHD	Objective.-To deal with public and professional concern regarding possible overprescription of attention-deficit/hyperactivity disorder (ADHD) medications, particularly methylphenidate, by reviewing issues related to the diagnosis, optimal treatment, and actual care of ADHD patients and of evidence of patient misuse of ADHD medications. Data Sources.-Literature review using a National Library of Medicine database search far 1975 through March 1997 on the terms attention deficit disorder with hyperactivity methylphenidate, stimulants, and stimulant abuse and dependence, Relevant documents from the Drug Enforcement Administration were also reviewed. Study Selection.-All English-language studies dealing with children of elementary school through high school age were included. Data Extraction.-All searched articles were selected and were made available to coauthors for review, Additional articles known to coauthors were added to the initial list, and a consensus was developed among the coauthors regarding the articles most pertinent to the issues requested in the resolution calling for this report, Relevant information from these articles was included in the report. Data Synthesis.-Diagnostic criteria for ADHD are based on extensive empirical research and, if applied appropriately, lead to the diagnosis of a syndrome with high interrater reliability, good face validity, and high predictability of course and medication responsiveness, The criteria of what constitutes ADHD in children have broadened, and there is a growing appreciation of the persistence of ADHD into adolescence and adulthood, As a result, more children (especially girls), adolescents, and adults are being diagnosed and treated with stimulant medication, and children are being treated for longer periods of time, Epidemiologic studies using standardized diagnostic criteria suggest that 3% to 6% of the school-aged population (elementary through high school) may suffer from ADHD, although the percentage of US youth being treated for ADHD is al most at the lower end of this prevalence range, Pharmacotherapy, particularly use of stimulants, has been extensively studied and generally provides significant short-term symptomatic and academic improvement, There is little evidence that stimulant abuse or diversion is currently a major problem, particularly among those with ADHD, although recent trends suggest that this could increase with the expanding production and use of stimulants. Conclusions.-Although some children are being diagnosed as having ADHD with insufficient evaluation and in some cases stimulant medication is prescribed when treatment alternatives exist, there is little evidence of widespread overdiagnosis or misdiagnosis of ADHD or of widespread overprescription of methylphenidate by physicians.	Amer Med Assoc, Council Sci Affairs, Chicago, IL 60610 USA	American Medical Association	Goldman, LS (corresponding author), Amer Med Assoc, Council Sci Affairs, 515 N State St, Chicago, IL 60610 USA.		Fahimifar, Sepideh/M-5303-2019	Williams, Michael/0000-0002-7284-8014; Slanetz, Priscilla/0000-0003-1248-5116				AHMANN PA, 1993, PEDIATRICS, V91, P1101; *AM AC CHILD AD PS, 1997, ACAD CHILD ADOLESC S, V36, pS85; *AM MED ASS, 1996, POL COMP, P92; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P78; ANDERSON JC, 1987, ARCH GEN PSYCHIAT, V44, P69; Arnold LE, 1997, ARCH GEN PSYCHIAT, V54, P865; Barkley R. A., 1998, ATTENTION DEFICIT HY, V2nd; BAUMGAERTEL A, 1995, J AM ACAD CHILD PSY, V34, P629, DOI 10.1097/00004583-199505000-00015; BERRY CA, 1985, PEDIATRICS, V76, P801; Biederman J, 1997, J AM ACAD CHILD PSY, V36, P21, DOI 10.1097/00004583-199701000-00013; Biederman J, 1996, J AM ACAD CHILD PSY, V35, P343, DOI 10.1097/00004583-199603000-00016; BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564; Biederman J, 1996, J AM ACAD CHILD PSY, V35, P997, DOI 10.1097/00004583-199608000-00010; BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120; Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; Brown FR, 1996, CONT PEDIAT, V13, P25; CANTWELL DP, 1985, ARCH GEN PSYCHIAT, V42, P1026; Cantwell DP, 1996, J AM ACAD CHILD PSY, V35, P978, DOI 10.1097/00004583-199608000-00008; Cantwell DP, 1996, J CHILD PSYCHOL PSYC, V37, P3, DOI 10.1111/j.1469-7610.1996.tb01377.x; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; CLEMENTS SD, 1962, ARCH GEN PSYCHIAT, V6, P185; COHEN M, 1988, J ABNORM CHILD PSYCH, V16, P187, DOI 10.1007/BF00913594; Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018; COSTELLO EJ, 1988, ARCH GEN PSYCHIAT, V45, P1107; Diller LD, 1996, HASTINGS CENT REP, V26, P12, DOI 10.2307/3528571; *DRUG ENF ADM, 1995, RESP PET TRANSF METH; ELIA J, 1993, DRUGS, V46, P863, DOI 10.2165/00003495-199346050-00006; ESSER G, 1990, J CHILD PSYCHOL PSYC, V31, P243, DOI 10.1111/j.1469-7610.1990.tb01565.x; FULTON AI, 1988, AM FAM PHYSICIAN, V38, P143; GILGER JW, 1992, J AM ACAD CHILD PSY, V31, P343, DOI 10.1097/00004583-199203000-00024; GILLIS JJ, 1992, J ABNORM CHILD PSYCH, V20, P303, DOI 10.1007/BF00916694; GOODMAN R, 1989, J CHILD PSYCHOL PSYC, V30, P691, DOI 10.1111/j.1469-7610.1989.tb00782.x; GOYER PF, 1979, J AM ACAD CHILD PSY, V18, P170, DOI 10.1016/S0002-7138(09)60486-6; GREENHILL LL, 1973, ARCH GEN PSYCHIAT, V28, P636; Greenhill LL, 1995, CHILD ADOL PSYCH CL, V4, P123; HECHTMAN L, 1984, J AM ACAD CHILD PSY, V23, P261, DOI 10.1016/S0002-7138(09)60501-X; HECHTMAN L, 1985, PSYCHOPHARMACOL BULL, V21, P178; HECHTMAN L, 1993, CAN J PSYCHIAT, V38, P458, DOI 10.1177/070674379303800614; Hill JC, 1996, AM J PSYCHIAT, V153, P1143; HINSHAW SP, 1987, PSYCHOL BULL, V101, P443, DOI 10.1037/0033-2909.101.3.443; HUNT RD, 1995, J AM ACAD CHILD PSY, V34, P50, DOI 10.1097/00004583-199501000-00013; HUNT RD, 1987, PSYCHOPHARMACOL BULL, V23, P111; JAFFE SL, 1991, J AM ACAD CHILD PSY, V30, P773, DOI 10.1097/00004583-199109000-00012; KLEIN RG, 1988, ARCH GEN PSYCHIAT, V45, P1127; KLEIN RG, 1988, ARCH GEN PSYCHIAT, V45, P1131; KOLATA G, 1996, NY TIMES        0515, P13; LAHEY BB, 1987, J AM ACAD CHILD PSY, V26, P718, DOI 10.1097/00004583-198709000-00017; LINDGREN S, 1990, 8 ANN M SOC BEH PED; LOU HC, 1989, ARCH NEUROL-CHICAGO, V46, P48, DOI 10.1001/archneur.1989.00520370050018; MANNUZZA S, 1993, ARCH GEN PSYCHIAT, V50, P565; Masand PS, 1996, PSYCHIAT CLIN N AM, V19, P515, DOI 10.1016/S0193-953X(05)70304-X; MUNOZMILLAN RJ, 1989, HOSP COMMUNITY PSYCH, V40, P699; NEWCORN JH, 1989, J AM ACAD CHILD PSY, V28, P734; *NIH, 1982, DEF DIETS CHILDH HYP; PELHAM WE, 1992, J AM ACAD CHILD PSY, V31, P210, DOI 10.1097/00004583-199203000-00006; PELOQUIN LJ, 1986, J ABNORM PSYCHOL, V95, P88, DOI 10.1037/0021-843X.95.1.88; PERMAN ES, 1970, NEW ENGL J MED, V283, P760, DOI 10.1056/NEJM197010012831410; Perrin J, 1996, PEDIATRICS, V98, P301; RAPOPORT JL, 1978, SCIENCE, V199, P560, DOI 10.1126/science.341313; RICHTERS JE, 1995, J AM ACAD CHILD PSY, V34, P987, DOI 10.1097/00004583-199508000-00008; SAFER DJ, 1992, JAMA-J AM MED ASSOC, V268, P1004, DOI 10.1001/jama.268.8.1004; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; Safer DJ, 1996, PEDIATRICS, V98, P1084; SATEL SL, 1989, J CLIN PSYCHIAT, V50, P241; SATTERFIELD JH, 1987, J AM ACAD CHILD PSY, V26, P56, DOI 10.1097/00004583-198701000-00012; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; Shaywitz B A, 1997, Adv Pediatr, V44, P331; SHAYWITZ BA, 1995, J CHILD NEUROL, V10, pS50, DOI 10.1177/08830738950100S111; SILVER LB, 1992, ATTENTION DEFICIT HY; SLEATOR EK, 1981, PEDIATRICS, V67, P13; Spencer T, 1996, J AM ACAD CHILD PSY, V35, P409, DOI 10.1097/00004583-199604000-00008; Spencer TJ, 1996, J AM ACAD CHILD PSY, V35, P1460, DOI 10.1097/00004583-199611000-00014; SWANSON JM, 1995, NEW ENGL J MED, V333, P944, DOI 10.1056/NEJM199510053331419; SWANSON JM, 1993, EXCEPT CHILDREN, V60, P154, DOI 10.1177/001440299306000209; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; Taylor E, 1996, J AM ACAD CHILD PSY, V35, P1213, DOI 10.1097/00004583-199609000-00019; WALDROP RD, 1994, CLIN PEDIATR, V33, P83, DOI 10.1177/000992289403300204; Wallis Claudia, 1994, TIME            0718, P42; WILENS TE, 1992, PSYCHIAT CLIN N AM, V15, P191; Wilens TE, 1996, CURR AFFECT ILLNESS, V15, P5; Wolraich ML, 1996, J AM ACAD CHILD PSY, V35, P319, DOI 10.1097/00004583-199603000-00013; WOLRAICH ML, 1990, PEDIATRICS, V86, P95; ZAMETKIN A, 1985, ARCH GEN PSYCHIAT, V42, P962	86	736	760	2	218	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1100	1107		10.1001/jama.279.14.1100	http://dx.doi.org/10.1001/jama.279.14.1100			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546570				2022-12-28	WOS:000072875300035
J	Stansby, G				Stansby, G			Vein quality in vascular surgery	LANCET			English	Editorial Material							SAPHENOUS-VEIN; GRAFT; FAILURE; DISEASE		Imperial Coll Sch Med, Div Surg Anaesthet & Intens Care, London W2 1NY, England	Imperial College London	Stansby, G (corresponding author), Imperial Coll Sch Med, Div Surg Anaesthet & Intens Care, London W2 1NY, England.			Stansby, Gerard/0000-0001-5539-3049				ADCOCK OT, 1984, SURGERY, V96, P886; DAVIES MG, 1995, EUR J VASC ENDOVASC, V9, P7, DOI 10.1016/S1078-5884(05)80218-7; Giannoukas AD, 1997, EUR J VASC ENDOVASC, V14, P37, DOI 10.1016/S1078-5884(97)80223-7; HARRIS PL, 1993, BRIT J SURG, V80, P173, DOI 10.1002/bjs.1800800213; Hedin U, 1997, EUR J VASC ENDOVASC, V13, P101, DOI 10.1016/S1078-5884(97)80004-4; MOODY AP, 1992, EUR J VASCULAR SURG, V6, P509, DOI 10.1016/S0950-821X(05)80625-5; PANETTA TF, 1992, J VASC SURG, V15, P102, DOI 10.1016/0741-5214(92)70018-G; SALES CM, 1993, J VASC SURG, V18, P198, DOI 10.1016/0741-5214(93)90599-H; THIENE G, 1980, THORAX, V35, P519, DOI 10.1136/thx.35.7.519; Wilson YG, 1998, ANN ROY COLL SURG, V80, P3	10	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1001	1002		10.1016/S0140-6736(05)78990-X	http://dx.doi.org/10.1016/S0140-6736(05)78990-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546500				2022-12-28	WOS:000072927200004
J	Rosa, L; Rosa, E; Sarner, L; Barrett, S				Rosa, L; Rosa, E; Sarner, L; Barrett, S			A close look at therapeutic touch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								Context.-Therapeutic Touch (TT) is a widely used nursing practice rooted in mysticism but alleged to have a scientific basis. Practitioners of TT claim to treat many medical conditions by using their hands to manipulate a "human energy field" perceptible above the patient's skin. Objective.-To investigate whether TT practitioners can actually perceive a "human energy field." Design.-Twenty-one practitioners with TT experience for from 1 to 27 years were tested under blinded conditions to determine whether they could correctly identify which of their hands was closest to the investigator's hand. Placement of the investigator's hand was determined by flipping a coin. Fourteen practitioners were tested 10 times each, and 7 practitioners were tested 20 times each. Main Outcome Measure.-Practitioners of TT were asked to state whether the investigator's unseen hand hovered above their right hand or their left hand. To show the validity of TT theory, the practitioners should have been able to locate the investigator's hand 100% of the time. A score of 50% would be expected through chance alone. Results.-Practitioners of TT identified the correct hand in only 123 (44%) of 280 trials, which is close to what would be expected for random chance. There was no significant correlation between the practitioner's score and length of experience (r=0.23). The statistical power of this experiment was sufficient to conclude that if TT practitioners could reliably detect a human energy field, the study would have demonstrated this. Conclusions.-Twenty-one experienced TT practitioners were unable to detect the investigator's "energy field." Their failure to substantiate TT's most fundamental claim is unrefuted evidence that the claims of TT are groundless and that further professional use is unjustified.	Natl Therapeut Touch Study Grp, Loveland, CO 80537 USA; Natl Council Against Hlth Fraud Inc, Questionable Nurse Practices Task Force, Loveland, CO USA; Quackwatch Inc, Allentown, PA USA		Sarner, L (corresponding author), Natl Therapeut Touch Study Grp, 711 W 9th St, Loveland, CO 80537 USA.	nttsg@ezlink.com; sbinfo@quackwatch.com						BANDMAN EL, 1995, CRITICAL THINKING NU; BARRETT EAM, 1990, VISIONS ROGERS SCI B, P15; Bogulawski M, 1980, Top Clin Nurs, V2, P27; Boguslawski M, 1979, J Contin Educ Nurs, V10, P9; BOWERS DP, 1992, THESIS SAN JOSE STAT; BRIERTON TD, 1992, LABOR LAW J, V43, P411; BROWN CC, 1977, J ALTER ST CONSCIOUS, V3, P169; BROWN PR, 1981, THESIS U NEVADA RENO; BRUNJES CAF, 1983, TOP CLIN NURS, V5, P72; BULLOUGH VL, 1993, SKEPTICAL INQUIRER, V17, P169; BUSH AM, 1992, PSYCHOL REP, V70, P891, DOI 10.2466/PR0.70.3.891-896; BUTGEREIT B, 1994, BIRMINGHAM NEWS 1117, pA1; CABICO LL, 1992, THESIS DYOUVILLE COL; CALVERT R, 1994, MASSAGE MAGAZINES, V47, P56; CARPENITO LJ, 1995, NURISNG DIAGNOSIS AP, P355; CHIAPPONE J, 1989, LIGHT TOUCH EASY GUI, P14; Claman HN, 1994, REPORT CHANCELLORS C; CLARK AJ, 1992, 3 ANN W AL C CLIN NU; CLARK PE, 1984, NURS RES, V33, P37; *COL STAT BOARD NU, 1992, SUBC INV AW CONT ED; COWENS C, 1996, GIFT HEALING YOU CAN; DOLLAR CE, 1993, THESIS U MISSISSIPPI; EDGE H, 1979, 22 ANN CONV PAR ASS; EMERY CE, 1994, PROVIDENCE SUN  1127, pA1; FEDORUK RB, 1984, THESIS U MARYLAND BA; FIELY D, 1995, COLUMBUS DISPAT 0820, pB1; Fish S, 1993, J Christ Nurs, V10, P6; France N E, 1993, J Holist Nurs, V11, P319, DOI 10.1177/089801019301100402; Gagne D, 1994, Arch Psychiatr Nurs, V8, P184, DOI 10.1016/0883-9417(94)90052-3; GLAZER S, 1995, WASHINGTON POST 1219, P19; GUERRERO MA, 1985, THESIS U TEXAS GALVE; Haddad A, 1994, RN, V57, P21; HADDAD A, 1994, RN, V57, P24; HALE EH, 1986, THESIS TEXAS WOMENS; HAMILTONWYATT GK, 1988, THESIS MICHIGAN STAT; HEIDT P, 1981, NURS RES, V30, P32, DOI 10.1097/00006199-198101000-00014; Heidt P R, 1990, Image J Nurs Sch, V22, P180; HINZE ML, 1988, THESIS U TEXAS AUSTI; Hogg P, 1985, THESIS CALIFORNIA SC; Hover D, 1992, Beginnings, V12, P3; HUGHES PP, 1994, THESIS U NEW MEXICO; JACKSON MEM, 1981, THERPAEUTIC TOUCH BO, P72; JARBOUX D, 1994, BOULDER SUNDARY 0102, pE3; JOEL LA, 1995, AM J NURS, V95, P7; Karagulla S., 1989, CHAKRAS HUMAN ENERGY; KAUFFOLD MP, 1995, CHICAGO TRIBUNE 1119, P1; Keegan L, 1996, RN, V59, P59; Keegan L, 1989, J Post Anesth Nurs, V4, P17; KELLER E, 1986, NURS RES, V35, P101; KNASTER M, 1989, E W, V19, P54; KNASTER M, 1989, E W, V19, P59; KNASTER M, 1989, E W, V19, P79; Kramer N A, 1990, Pediatr Nurs, V16, P483; Krieger D, 1975, J N Y State Nurses Assoc, V6, P6; Krieger D, 1990, Imprint, V37, P86; Krieger D, 1975, Am J Nurs, V75, P784; KRIEGER D, 1979, AM J NURS, V79, P660, DOI 10.2307/3462338; KRIEGER D, 1975, J HOLISTIC HLTH, V1, P23; KRIEGER D, 1990, IMPRINT, V37, P86; KRIEGER D, 1997, THERAPEUTIC TOUCH IN, P162; KRIEGER D, 1972, HUMAN DIMENSIONS AUT, P12; Krieger D., 1987, LIVING THERAPEUTIC T; KRIEGER D, 1976, INT J PSYCHOENERGY S, V1, P121; KRIEGER D, 1987, LIVING THERAPEUTIC T, P157; KRIEGER D, 1973, P 9 ANA NURS RES C N, P39; Krieger D. K., 1993, ACCEPTING YOUR POWER; Leduc E, 1987, Neonatal Netw, V5, P46; Ledwith S P, 1995, RN, V58, P51; LEVINE ME, 1979, AM J NURS, V79, P1379, DOI 10.1097/00000446-197908000-00011; LIKONBERGER HJ, 1985, INTERPRETIVE STUDY N; LIONBERGER HJ, 1986, NURSING RES METHODOL, P169; MACKEY RB, 1995, AM J NURS, V95, P27; MACRAE J, 1979, AM J NURS, V79, P664; MAXWELL J, 1996, CHRISTIANITY TODAY, V40, P96; MEEHAN MTC, 1990, NATL LEAGUE NURISNG, P67; MEEHAN MTC, 1992, NURSING INTERVETIONS, P201; MEEHAN MTC, 1990, VISIONS ROGERS SCI B, P197; MEEHAN MTC, 1985, EFFECT THERAPEUTIC T; Meehan T C, 1993, Nurs Sci Q, V6, P69, DOI 10.1177/089431849300600206; MEEHAN TC, 1995, RES NURS HEALTH, V18, P471, DOI 10.1002/nur.4770180512; MEEHAN TC, 1995, AM J NURS, V95, P17; Mersmann C.A., 1993, THESIS NEW YORK U NE; MESENGER TC, 1994, J GERONTOL NURS, V20, P17; MISRA MM, 1993, THESIS CALIFORNIA ST; MOCCIA P, 1986, NEW APPROACHES THEOR, P15; MOCCIA P, 1994, TIME, V144, P18; Mulloney S S, 1996, J Cardiovasc Nurs, V10, P27; NODINE JL, 1987, THESIS U ARIZONA TUC; OLSON T, 1995, N&HC PERSPECT COMMUN, V16, P97; PARKES BS, 1985, THESIS U TEXAS AUSTI; PETERS PJ, 1992, THESIS WALDEN U MINN; POLK SH, 1995, THESIS ARIZONA STATE; POST NW, 1990, THESIS SAN JOSE STAT; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P550; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P47; QUINN J, 1982, INVESTIGATION EFFECT; Quinn J F, 1992, Holist Nurs Pract, V6, P26; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Quinn J F, 1989, Nurs Sci Q, V2, P79, DOI 10.1177/089431848900200207; Quinn J F, 1992, Holist Nurs Pract, V7, P32; QUINN JF, 1993, ADV NURS SCI, V15, P13, DOI 10.1097/00012272-199306000-00003; QUINN JF, 1979, AM J NURS, V79, P662; QUINN JF, 1994, THERAPEUTIC TOUCH HE; Randolph G, 1979, Top Clin Nurs, V1, P31; RANDOLPH GL, 1984, NURS RES, V33, P33; RAUCHEISEN ML, 1984, RN MAG, V47, P49; Rogers M.E., 1970, INTRO THEORETICAL BA; ROSA LA, 1906, SUREY THERAPEUTIC TO; ROSA LA, 1993, ROCKY MOUNTAIN SKEPT, V10, P10; SAMAREL N, 1992, J ADV NURS, V17, P651, DOI 10.1111/j.1365-2648.1992.tb01960.x; Sandroff R, 1980, RN, V43, P24; SANDROFF R, 1980, RN, V43, P82; SATIR F, 1994, OLYMPIAN        0719; SCHLOTFELDT RM, 1973, P 9 ANA NURS RES C N, P59; Schmidt C M, 1995, RN, V58, P54; SCHMIDT CM, 1995, RN, V58, P52; SCHMIDT CM, 1995, RN, V58, P54; SCHWEITZER SF, 1980, THESIS U NEVADA RENO; SHUZMAN E, 1993, THESIS NEW YORK U NE; SIES MM, 1993, THESIS MICHIGAN STAT; Simington J A, 1993, Clin Nurs Res, V2, P438, DOI 10.1177/105477389300200406; Snyder M, 1995, J Gerontol Nurs, V21, P34; SNYDER M, 1995, J GERONTOL NURS, V21, P54; SODERGREN KA, 1993, THESIS U MINNESOTA M; STRANEVA JAE, 1992, THESIS INDIANA U BLO; Swackhamer A H, 1995, RN, V58, P49; THARNSTROM CAL, 1993, THESIS SAN JOSE STAT; Thayer M B, 1990, Pediatr Nurs, V16, P70; THOMASBECKETT JG, 1991, THESIS MICHIGAN STAT; TURNER JG, 1996, EFFECT THERAPEUTIC T; TURNER JG, 1994, TRISERVICE NURSING R; WALIKE BC, 1975, AM J NURS, V75, P1278; WALIKE BC, 1975, AM J NURS, V75, P1275; WALKE BC, 1975, AM J NURS, V75, P1292; Wirth DP, 1993, COMPLEMENTARY THERAP, V1, P127; Wirth DP, 1990, SUBTLE ENERGIES, V1, P1; WOODS DL, 1993, THESIS SEATTLE U WAS; 1989, U COLORADO SCH N MAY, P1	138	135	137	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1005	1010		10.1001/jama.279.13.1005	http://dx.doi.org/10.1001/jama.279.13.1005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533499	Bronze, Green Published			2022-12-28	WOS:000072669700028
J	Chaulk, CP; Kazandjian, VA				Chaulk, CP; Kazandjian, VA		Public Hlth Tuberculosis Guidelines Panel	Directly observed therapy for treatment completion of pulmonary tuberculosis - Consensus statement of the public health tuberculosis guidelines panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1998 Centers-for-Disease-Control-and-Prevention National TB Controllers Workshop	JAN 29, 1998	ATLANTA, GA	Ctr Dis Control & Prevent			SHORT-COURSE CHEMOTHERAPY; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; NEW-YORK-CITY; UNITED-STATES; TREATMENT PROGRAM; DRUG-RESISTANCE; COMMUNITY; EPIDEMIOLOGY; REGIMEN; TRANSMISSION	Objective.-To evaluate evidence on the relative effectiveness of directly observed therapy in achieving treatment completion for pulmonary tuberculosis. Participants.-A panel of 11 practitioners representing the public health, behavioral, and clinical management of tuberculosis was convened by the Council on Linkages Between Academia and Public Health Practice in 1995 to develop public health guidelines for tuberculosis treatment completion. Evidence.-English-language articles identified through MEDLINE (1966 to August 1, 1996) with original data on directly observed therapy, supervised therapy, compliance, treatment completion, case management, and treatment adherence for tuberculosis. Consensus Process.-Each eligible article underwent structured review by at least 2 panel members for study design, sample size, evaluation methods, and treatment completion as the primary outcome. The full panel was convened twice, with intercurrent small group meetings, conference calls, and summary workshop to review findings. Recommendations made through this process were drafted by the panel chair and circulated twice for additional panel comments. Conclusions.-Treatment completion rates for pulmonary tuberculosis are most likely to exceed 90%, as recommended by the Centers for Disease Control and Prevention, when treatment is based on a patient-centered approach using directly observed therapy with multiple enablers and enhancers. Other less intensive interventions, including nonsupervised strategies and modified approaches to directly observed therapy, are unlikely to achieve this recommended treatment completion goal. Directly observed therapy also appears to be cost-effective compared with self-administered therapy, although data on cost-effectiveness are limited.	Annie E Casey Fdn, Baltimore, MD 21202 USA; Johns Hopkins Sch Hyg & Publ Hlth, Baltimore, MD USA; Johns Hopkins Sch Med, Baltimore, MD USA; Ctr Performance Sci Inc, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Chaulk, CP (corresponding author), Annie E Casey Fdn, 701 St Paul St, Baltimore, MD 21202 USA.	patch@aecf.org						ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; *ADV GROUP COUNC L, 1995, PRACT GUID PUBL HLTH; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], COMPLIANCE HLTH CARE; ARMSTRONG RH, 1984, CENT AFR J MED, V30, P144; ARNEIL AS, 1973, CAN J PUBLIC HEALTH, V64, P497; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOCH AB, 1996, J RESP CRIT CARE MED, V153, pA333; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; *BRIT MED RES COUN, 1984, TUBERCULE, V65, P5; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Burman WJ, 1997, CHEST, V112, P63, DOI 10.1378/chest.112.1.63; Caminero JA, 1996, THORAX, V51, P1130, DOI 10.1136/thx.51.11.1130; *CDC, 1990, MMWR-MORBID MORTAL W, V39, P8; *CDC, 1990, MMWR-MORBID MORTAL W, V39, P369; *CDCP, 1993, TUB PROGR MAN US 198; Centers for Disease Control and Prevention, 1994, IMPR PAT ADH TUB TRE; CHAN SL, 1994, TUBERCLE LUNG DIS, V75, P245, DOI 10.1016/0962-8479(94)90128-7; Chaulk C P, 1994, Health Care Financ Rev, V15, P7; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; CLEVELAND JL, 1995, INFECT CONT HOSP EP, V16, P7; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; COOK DJ, 1992, CHEST, V102, pS305; COWIE RL, 1990, S AFR MED J, V77, P390; DUTT AK, 1984, AM J MED, V77, P233, DOI 10.1016/0002-9343(84)90697-1; ElSadr W, 1996, AM J PUBLIC HEALTH, V86, P1146, DOI 10.2105/AJPH.86.8_Pt_1.1146; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; JIN BW, 1993, TUBERCLE LUNG DIS, V74, P267, DOI 10.1016/0962-8479(93)90053-Z; KAN GQ, 1985, TUBERCLE, V66, P1, DOI 10.1016/0041-3879(85)90047-9; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; Liu K, 1992, Health Care Financ Rev, V13, P105; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MANALO F, 1990, AM REV RESPIR DIS, V142, P1301, DOI 10.1164/ajrccm/142.6_Pt_1.1301; MENZIES R, 1993, TUBERCLE LUNG DIS, V74, P32, DOI 10.1016/0962-8479(93)90066-7; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; Moore RD, 1996, AM J RESP CRIT CARE, V154, P1013, DOI 10.1164/ajrccm.154.4.8887600; ORMEROD LP, 1991, RESP MED, V85, P291, DOI 10.1016/S0954-6111(06)80099-5; PABLOSMENDEZ A, 1990, NEW YORK STATE J MED, V90, P351; POZSIK C, 1981, MMWR-MORBID MORTAL W, V42, P74; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; Rosenbaum S., 1997, NEGOTIATING NEW HLTH; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P361, DOI 10.2105/AJPH.75.4.361; Samuel G E, 1976, Indian J Public Health, V20, P21; Sbarbaro J A, 1994, Semin Respir Infect, V9, P120; SBARBARO JA, 1981, AM REV RESPIR DIS, V123, P147; SBARBARO JA, 1979, CHEST, V76, P750, DOI 10.1378/chest.76.6.750; SBARBARO JA, 1985, AM J MED, V79, P34, DOI 10.1016/0002-9343(85)90085-3; SCHLUGER N, 1995, AM J RESP CRIT CARE, V151, P1486, DOI 10.1164/ajrccm.151.5.7735604; Seetha M A, 1982, Indian J Public Health, V26, P234; SELIK RM, 1993, JAMA-J AM MED ASSOC, V269, P2991, DOI 10.1001/jama.269.23.2991; SLOAN JP, 1981, T ROY SOC TROP MED H, V75, P717, DOI 10.1016/0035-9203(81)90161-9; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1984, AM REV RESPIR DIS, V129, P573; Sorensen AA, 1991, PUBLIC HLTH FACULTY; SUKRAKANCHANATRIKHAM P, 1992, TUBERCLE LUNG DIS, V73, P384, DOI 10.1016/0962-8479(92)90045-L; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; U. S. Department of Health and Human Services Public Health Service Office of Disease Prevention and Health Promotion., 1994, CLIN HDB PREV SERV P; VALEZA FS, 1990, LANCET, V335, P473, DOI 10.1016/0140-6736(90)90705-A; VANDERWERF TS, 1990, TUBERCLE, V71, P247, DOI 10.1016/0041-3879(90)90036-8; WERHANE MJ, 1989, CHEST, V96, P815, DOI 10.1378/chest.96.4.815; WESTAWAY MS, 1991, TUBERCLE, V72, P140, DOI 10.1016/0041-3879(91)90041-P; *WHO, 1997, REP TUB EP 1997; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; WOLDE K, 1992, ETHIOPIAN MED J, V30, P63; 1994, MMWR MORB MORTAL WKL, V43, P361	73	187	192	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					943	948		10.1001/jama.279.12.943	http://dx.doi.org/10.1001/jama.279.12.943			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZC304	9544769				2022-12-28	WOS:000072563600035
J	Kee, F; McDonald, P; Kirwan, JR; Patterson, CC; Love, AHG				Kee, F; McDonald, P; Kirwan, JR; Patterson, CC; Love, AHG			Urgency and priority for cardiac surgery: a clinical judgment analysis	BRITISH MEDICAL JOURNAL			English	Article							ARTERY BYPASS-SURGERY; CHRONIC STABLE ANGINA; CORONARY REVASCULARIZATION		Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland; No Hlth & Social Serv Board, Dept Publ Hlth Med, Belfast BT42 1QB, Antrim, North Ireland; Univ Bristol, Dept Rheumatol, Bristol BS8 1QE, Avon, England; Queens Univ Belfast, Dept Med, Belfast BT7 1NN, Antrim, North Ireland	Queens University Belfast; University of Bristol; Queens University Belfast	Kee, F (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.	frank.kee@nhssb.n-i.nhs.uk		Kirwan, John/0000-0002-6617-3217				BREHMER B, 1988, HUMAN JUDGEMENT SOCI; *CLIN STAND ADV GR, 1993, COR ART BYP GRAFT CO; DARLINGTON RB, 1968, PSYCHOL BULL, V69, P161, DOI 10.1037/h0025471; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; Hadorn DC, 1997, BRIT MED J, V314, P135, DOI 10.1136/bmj.314.7074.135; Hughes D, 1996, SOCIOL HEALTH ILL, V18, P172, DOI 10.1111/1467-9566.ep10934703; JULIAN DG, 1994, BRIT HEART J, V72, P9; Kee F, 1997, QJM-MON J ASSOC PHYS, V90, P669, DOI 10.1093/qjmed/90.11.669; KEE F, 1995, QJM-MON J ASSOC PHYS, V88, P15; KEE F, 1995, BRIT HEART J, V73, P129; KIMBALL BP, 1994, CAN J CARDIOL, V10, P815; KLEIN LW, 1994, CATHETER CARDIO DIAG, V32, P330, DOI 10.1002/ccd.1810320408; LI TCM, 1984, MED DECIS MAKING, V4, P165, DOI 10.1177/0272989X8400400205; NAYLOR CD, 1990, AM J PUBLIC HEALTH, V80, P1246, DOI 10.2105/AJPH.80.10.1246; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NAYLOR CD, 1992, CHEST, V101, P715, DOI 10.1378/chest.101.3.715; NWASOKWA ON, 1991, ANN INTERN MED, V114, P1035, DOI 10.7326/0003-4819-114-12-1035; PRASAD US, 1991, EUR J CARDIO-THORAC, V5, P65; ROVER S, 1995, BRIT MED J, V310, P975; UNDERWOOD MJ, 1993, BMJ-BRIT MED J, V306, P1047, DOI 10.1136/bmj.306.6884.1047; WEST R, 1992, J EPIDEMIOL COMMUN H, V46, P321, DOI 10.1136/jech.46.4.321; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; ZOLESE G, 1993, BRIT MED J, V306, P1408, DOI 10.1136/bmj.306.6889.1408-b	23	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					925	929		10.1136/bmj.316.7135.925	http://dx.doi.org/10.1136/bmj.316.7135.925			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552849	Green Published			2022-12-28	WOS:000072713300042
J	Danesh, J; Appleby, P; Peto, R				Danesh, J; Appleby, P; Peto, R			How often does surgery for peptic ulceration eradicate Helicobacter pylori? Systematic review of 36 studies	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford OX2 6HE, England; Radcliffe Infirm, Imperial Canc Res Fund, Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England.	john.danesh@balliol.ox.ac.uk						FINEBERG HV, 1981, LANCET, V1, P1305; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; OCONNOR HJ, 1986, LANCET, V2, P1178	4	40	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					746	747		10.1136/bmj.316.7133.746	http://dx.doi.org/10.1136/bmj.316.7133.746			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529411	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000072463700033
J	Yule, B				Yule, B			A memorable patient - Old remedy effective	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1240	1240		10.1136/bmj.316.7139.1240	http://dx.doi.org/10.1136/bmj.316.7139.1240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553008	Green Published			2022-12-28	WOS:000073224100036
J	Balaban, N; Goldkorn, T; Nhan, RT; Dang, LB; Scott, S; Ridgley, RM; Rasooly, A; Wright, SC; Larrick, JW; Rasooly, R; Carlson, JR				Balaban, N; Goldkorn, T; Nhan, RT; Dang, LB; Scott, S; Ridgley, RM; Rasooly, A; Wright, SC; Larrick, JW; Rasooly, R; Carlson, JR			Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus	SCIENCE			English	Article							REGULATORY RNA MOLECULE; PSEUDOMONAS-AERUGINOSA; RESISTANCE	Staphylococcus aureus causes pathologies ranging from minor skin infections to life-threatening diseases. Pathogenic effects are largely due to production of bacterial toxin, which is regulated by an RNA molecule, RNAIII. The S. aureus protein called RAP (RNAIII activating protein) activates RNAIII, and a peptide called RIP (RNAIII inhibiting peptide), produced by a nonpathogenic bacteria, inhibits RNAIII. Mice vaccinated with RAP or treated with purified or synthetic RIP were protected from S. aureus pathology. Thus, these two molecules may provide useful approaches for the prevention and treatment of diseases caused by S. aureus.	Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA; Univ Calif Davis, Davis Med Ctr, Dept Internal Med, Davis, CA 95616 USA; Univ Maryland, Dept Microbiol, College Pk, MD 20742 USA; Palo Alto Inst Mol Med, Mt View, CA 94043 USA	University of California System; University of California Davis; University of California System; University of California Davis; University System of Maryland; University of Maryland College Park	Balaban, N (corresponding author), Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA.	nbalaban@ucdavis.edu	Rasooly, Avraham/AAH-4518-2021		NIAID NIH HHS [AI40830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI040830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BALABAN N, 1995, FEMS MICROBIOL LETT, V133, P155, DOI 10.1016/0378-1097(95)00356-A; BALABAN N, 1995, P NATL ACAD SCI USA, V92, P1619, DOI 10.1073/pnas.92.5.1619; BUNCE C, 1992, INFECT IMMUN, V60, P2636, DOI 10.1128/IAI.60.7.2636-2640.1992; GUANGYONG J, 1995, P NATL ACAD SCI USA, V92, P12055; Lee JC, 1996, TRENDS MICROBIOL, V4, P162, DOI 10.1016/0966-842X(96)10021-4; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MOERFELDT E, 1995, EMBO J, V14, P4569; NASO R, 1996, NOVEL STRATEGIES DES, P133; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; RAPPUOLI R, 1995, SIGNAL TRANSDUCTION, P1; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SILVERSTEIN SC, 1990, MICROBIOLOGY, P485; Swift Simon, 1994, Trends in Microbiology, V2, P193, DOI 10.1016/0966-842X(94)90110-Q; WEST TE, 1985, J CLIN MICROBIOL, V21, P490, DOI 10.1128/JCM.21.4.490-492.1985	18	177	210	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					438	440		10.1126/science.280.5362.438	http://dx.doi.org/10.1126/science.280.5362.438			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545222				2022-12-28	WOS:000073159600048
J	Glaser, SJ; Schulte-Herbruggen, T; Sieveking, M; Schedletzky, O; Nielsen, NC; Sorensen, OW; Griesinger, C				Glaser, SJ; Schulte-Herbruggen, T; Sieveking, M; Schedletzky, O; Nielsen, NC; Sorensen, OW; Griesinger, C			Unitary control in quantum ensembles: Maximizing signal intensity in coherent spectroscopy	SCIENCE			English	Article							PULSED-FIELD GRADIENTS; SENSITIVITY IMPROVEMENT; NUMERICAL RANGES; NMR-SPECTROSCOPY; SPIN DYNAMICS; HETERONUCLEAR; ENHANCEMENT; SYMMETRY; SYSTEMS	Experiments in coherent magnetic resonance, microwave, and optical spectroscopy control quantum-mechanical ensembles by guiding them from initial states toward target states by unitary transformation. Often, the coherences detected as signals are represented by a non-Hermitian operator. Hence, spectroscopic experiments, such as those used in nuclear magnetic resonance, correspond to unitary transformations between operators that in general are not Hermitian, A gradient-based systematic procedure for optimizing these transformations is described that finds the largest projection of a transformed initial operator onto the target operator and, thus, the maximum spectroscopic signal. This method can also be used in applied mathematics and control theory.	Univ Frankfurt, Inst Organ Chem, D-60439 Frankfurt, Germany; ETH Zentrum, Phys Chem Lab, CH-8092 Zurich, Switzerland; Univ Frankfurt, Inst Angew Math, D-60439 Frankfurt, Germany; Aarhus Univ, Dept Chem, Instrument Ctr Solid State NMR Spect, DK-8000 Aarhus C, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark	Goethe University Frankfurt; Swiss Federal Institutes of Technology Domain; ETH Zurich; Goethe University Frankfurt; Aarhus University	Griesinger, C (corresponding author), Univ Frankfurt, Inst Organ Chem, Marie Curie Str 11, D-60439 Frankfurt, Germany.	sg@org.chemie.uni-frankfurt.de; cigr@org.chemie.uni-frankfurt.de	Sørensen, Ole Winneche W/M-9759-2018; Glaser, Steffen J/B-7335-2009	Sørensen, Ole Winneche W/0000-0002-7888-7807; Glaser, Steffen J/0000-0003-4099-3177; Nielsen, Niels Chr./0000-0003-2978-4366				Blum K., 2012, P SOC BRAIN MAPP THE, Vthird edn.; Brockett R. W., 1988, Proceedings of the 27th IEEE Conference on Decision and Control (IEEE Cat. No.88CH2531-2), P799, DOI 10.1109/CDC.1988.194420; BROCKETT RW, 1993, P S PURE MATH, V54, P96; CARAVATTI P, 1983, CHEM PHYS LETT, V100, P305, DOI 10.1016/0009-2614(83)80276-0; CAVANAGH J, 1991, J MAGN RESON, V91, P429, DOI 10.1016/0022-2364(91)90209-C; Cheung W.-S., 1996, LINEAR MULTILINEAR A, V41, P245, DOI DOI 10.1080/03081089608818479; Cory DG, 1997, P NATL ACAD SCI USA, V94, P1634, DOI 10.1073/pnas.94.5.1634; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FANO U, 1957, REV MOD PHYS, V29, P74, DOI 10.1103/RevModPhys.29.74; GEMPERIE C, 1991, CHEM REV, V91, P481; Gershenfeld N, 1997, SCIENCE, V277, P1689; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Glaser S.J., 1996, ADV MAGNETIC OPTICAL, P59; GOLDBERG M, 1977, LINEAR ALGEBRA APPL, V18, P1, DOI 10.1016/0024-3795(77)90075-1; Helmke U., 1994, OPTIMIZATION DYNAMIC; Horn R A, 1991, TOPICS MATRIX ANAL; JUDSON RS, 1990, J MOL STRUCT, V223, P425, DOI 10.1016/0022-2860(90)80485-3; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; Landau L., 1927, Z PHYS, V45, P430, DOI DOI 10.1007/BF01343064; Li C.-K., 1984, LINEAR MULTILINEAR A, V16, P215, DOI [10.1080/03081088408817624, DOI 10.1080/03081088408817624]; LI CK, 1991, P AM MATH SOC, V111, P19, DOI 10.2307/2047854; LI CK, 1994, MULTILIN ALG, V37, P51; Lutkepohl H., 1996, HDB MATRICES; Messiah A., 1961, QUANTUM MECH; NIELSEN NC, 1995, MOL PHYS, V85, P1205, DOI 10.1080/00268979500101771; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; QUACK M, 1978, J CHEM PHYS, V69, P1282, DOI 10.1063/1.436667; RABITZ H, 1993, NATURE, V366, P304, DOI 10.1038/366304a0; RAMAKRISHNA V, 1995, PHYS REV A, V51, P960, DOI 10.1103/PhysRevA.51.960; SATTLER M, 1995, J MAGN RESON SER B, V108, P235, DOI 10.1006/jmrb.1995.1128; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Schweiger A., 1990, MODERN PULSED CONTIN, P43; Seierstad Atle., 1987, OPTIMAL CONTROL THEO, V20; SORENSEN OW, 1990, J MAGN RESON, V86, P435, DOI 10.1016/0022-2364(90)90278-H; SORENSEN OW, 1989, PROG NUCL MAG RES SP, V21, P503, DOI 10.1016/0079-6565(89)80006-8; STOUSTRUP J, 1995, PHYS REV LETT, V74, P2921, DOI 10.1103/PhysRevLett.74.2921; TANNOR DJ, 1992, NATO ADV SCI INST SE, V299, P347; Taubes G, 1997, SCIENCE, V275, P307, DOI 10.1126/science.275.5298.307; Von Neumann J., 1937, TOMSK U REV, V1, P286; von Neumann J, 1927, NACHRICHTEN GESELLSC, P245; WARREN WS, 1993, SCIENCE, V259, P1581, DOI 10.1126/science.259.5101.1581; Warren WS, 1997, SCIENCE, V277, P1688, DOI 10.1126/science.277.5332.1688; WEITEKAMP DP, 1982, J CHEM PHYS, V77, P2870, DOI 10.1063/1.444180; [No title captured]	44	158	161	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					421	424		10.1126/science.280.5362.421	http://dx.doi.org/10.1126/science.280.5362.421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545217				2022-12-28	WOS:000073159600043
J	Veazey, RS; DeMaria, M; Chalifoux, LV; Shvetz, DE; Pauley, DR; Knight, HL; Rosenzweig, M; Johnson, RP; Desrosiers, RC; Lackner, AA				Veazey, RS; DeMaria, M; Chalifoux, LV; Shvetz, DE; Pauley, DR; Knight, HL; Rosenzweig, M; Johnson, RP; Desrosiers, RC; Lackner, AA			Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; INTESTINAL LAMINA PROPRIA; RHESUS-MONKEYS; HIV-INFECTION; NEF GENE; LYMPHOCYTES; MACAQUES; ANTIGEN; AIDS; EXPRESSION	Human and simian immunodeficiency virus (HIV and SIV) replicate optimally in activated memory CD4(+) T cells, a cell type that is abundant in the intestine. SIV infection of rhesus monkeys resulted in profound and selective depletion of CD4(+) T cells in the intestine within days of infection, before any such changes in peripheral lymphoid tissues. The loss of CD4(+) T cells in the intestine occurred coincident with productive infection of large numbers of mononuclear cells at this site. The intestine appears to be a major target for SIV replication and the major site of CD4(+) T cell loss in early SIV infection.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA	Harvard University	Lackner, AA (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, 1 Pine Hill Dr,POB 9102, Southborough, MA 01772 USA.	alackner@warren.med.harvard.edu	Abrams, William R/A-5782-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038559, R37AI025328, R01AI025328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25328, AI38559] Funding Source: Medline; NIDDK NIH HHS [DK50550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amadori A, 1996, IMMUNOL TODAY, V17, P414, DOI 10.1016/0167-5699(96)10049-9; CERFBENSUSSAN N, 1991, GASTROENTEROL CLIN N, V20, P549; Clayton F, 1997, CLIN EXP IMMUNOL, V107, P288, DOI 10.1111/j.1365-2249.1997.236-ce1111.x; CLAYTON F, 1992, GASTROENTEROLOGY, V103, P919, DOI 10.1016/0016-5085(92)90026-U; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; HEISE C, 1993, AM J PATHOL, V142, P1759; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HORVATH CJ, 1993, J LEUKOCYTE BIOL, V53, P532, DOI 10.1002/jlb.53.5.532; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; KAWAI T, 1994, TRANSPLANT P, V26, P1845; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; Lackner A A, 1994, Curr Top Microbiol Immunol, V188, P35; Lane JH, 1996, AM J PATHOL, V149, P1097; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; MacDonald TT, 1994, GASTROINTESTINAL HEP, P1; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; Sasseville VG, 1996, AM J PATHOL, V149, P163; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SCHNEIDER T, 1994, CLIN EXP IMMUNOL, V95, P430, DOI 10.1111/j.1365-2249.1994.tb07014.x; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHRAPPEBACHER M, 1990, J ACQ IMMUN DEF SYND, V3, P238; VANNOESEL CJ, 1990, J CLIN INVEST, V86; Veazey RS, 1997, CLIN IMMUNOL IMMUNOP, V82, P230, DOI 10.1006/clin.1996.4318; VEAZEY RS, UNPUB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P647, DOI 10.1016/0016-5085(88)90235-1	35	1138	1170	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					427	431		10.1126/science.280.5362.427	http://dx.doi.org/10.1126/science.280.5362.427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545219				2022-12-28	WOS:000073159600045
J	Nelson, K; Brown, ME; Lurie, N				Nelson, K; Brown, ME; Lurie, N			Hunger in an adult patient population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; FOOD INSECURITY; MALNUTRITION	Context.-Although clinical observations suggest that some patients experience hunger and food insecurity, there are limited data on the prevalence of hunger in adult patients. Objective.-To determine the prevalence of hunger and food insecurity in adult patients at an urban county hospital. Design.-Cross-sectional survey conducted in 1997. Patients.-The primary survey included all patients aged 18 years or older who were admitted to the medicine, surgery, and neurology services during a 2-week period, and all patients who attended the hospital's general medicine clinic during 1 week. A second survey included primary care patients who received insulin from the hospital pharmacy during a 1-month period. Main Outcome Measures.-Rates of hunger and food insecurity. Results.-Of 709 eligible patients, 567 (participation rate, 80%) were interviewed in either the clinic (n=281) or hospital (n=286). An additional 170 patients who received insulin were interviewed by telephone (response rate, 75%). Of the primary sample, 68 (12%) respondents reported not having enough food, 75 (13%) reported not eating for an entire day, acid 77 (14%) reported going hungry but not eating because they could not afford food. A total of 222 (40%) had received food stamps in the previous year and of those, 113 (50%) had their food stamps reduced or eliminated. Recipients whose food stamps had been eliminated or reduced were more likely to report not having enough food (18% vs 13%, P=.006), not eating for a whole day (20% vs 16%, P=.01), going hungry but not eating (20% vs 16%, P=.08), and cutting down on the size of meals or skipping meals (33% vs 27%, P=.01). In multivariate analysis, independent predictors of hunger included an annual income of less than $10 000 (odds ratio [OR], 7.55; 95% CI, 3.01-18.92), drug use (OR, 3.56; 95% CI, 1.46-8.66), and a reduction in food stamp benefits (OR, 1.73; 95% CI, 1.01-2.96). Predictors of food insecurity included an annual income of less than $10 000 (OR, 4.12; 95% confidence interval [CI], 1.98-8.58), drug use (OR, 2.11; 95% CI, 1.66-5.08), and a reduction in food stamps (OR, 2.02; 95% CI, 1.23-3.32). In addition, 103 (61%) patients in the sample of diabetics reported hypoglycemic reactions; 32 (31%) of these were attributed to inability to afford food. Conclusion.-Hunger and food insecurity are common among patients seeking care at an urban county hospital.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Publ Hlth, Inst Hlth Serv Res, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Lurie, N (corresponding author), Univ Minnesota, Sch Med, Dept Med, 420 Delaware St SE,Box 741, Minneapolis, MN 55455 USA.							BROWN JL, 1988, ANNU REV PUBL HEALTH, V9, P503; CAMPBELL CC, 1991, J NUTR, V121, P408, DOI 10.1093/jn/121.3.408; Cohen B. E., 1990, NUTR TODAY, V25, P23, DOI DOI 10.1097/00017285-199007000-00004; EDMUND EJ, 1994, ADV DATA VITAL HLTH, V278; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HAMILTON WL, 1997, MEASURING FOOD SECUR; KENDALL A, 1995, J NUTR, V125, P2793; KINSEY JD, 1994, J NUTR, V124, pS1878, DOI 10.1093/jn/124.suppl_9.1878S; Maslow A.H., 1954, MOTIVATION PERSONALI; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; *PHYS TASK FOR HUN, 1985, HUNG AM GROW EP; PINCUS T, 1994, J CLIN EPIDEMIOL, V47, P355, DOI 10.1016/0895-4356(94)90156-2; ROSENBERG E, 1992, SOC WORK HEALTH CARE, V16, P83, DOI 10.1300/J010v16n03_08; ROUBENOFF R, 1987, ARCH INTERN MED, V147, P1462, DOI 10.1001/archinte.147.8.1462; SMITH AD, 1997, BRIT MED J, V314, P547; STEFFEE WP, 1980, JAMA-J AM MED ASSOC, V244, P2630, DOI 10.1001/jama.244.23.2630; UVIN P, 1994, NUTR REV, V52, P151, DOI 10.1111/j.1753-4887.1994.tb01411.x; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677	19	82	85	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1211	1214		10.1001/jama.279.15.1211	http://dx.doi.org/10.1001/jama.279.15.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555762	Bronze			2022-12-28	WOS:000072969400036
J	Golbe, LI				Golbe, LI			Pallidotomy for Parkinson's disease: hitting the target?	LANCET			English	Editorial Material									Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Golbe, LI (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.							Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Ondo WG, 1998, NEUROLOGY, V50, P266, DOI 10.1212/WNL.50.1.266; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Shannon KM, 1998, NEUROLOGY, V50, P434, DOI 10.1212/WNL.50.2.434	7	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					998	999		10.1016/S0140-6736(98)22014-9	http://dx.doi.org/10.1016/S0140-6736(98)22014-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546498				2022-12-28	WOS:000072927200002
J	Lambert, CM; Hurst, NP; Forbes, JF; Lochhead, A; Macleod, M; Nuki, G				Lambert, CM; Hurst, NP; Forbes, JF; Lochhead, A; Macleod, M; Nuki, G			Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; TRIAL	Objective: To test the clinical equivalence and resource consequences of day care with inpatient care for active rheumatoid arthritis. Design: Randomised controlled clinical trial with integrated cost minimisation economic evaluation. Setting: Rheumatic diseases unit at a teaching hospital between 1994 and 1996. Subjects: 118 consecutive patients with active rheumatoid arthritis randomised to receive either day care or inpatient care. Main outcome measures: Clinical assessments recorded on admission, discharge, and follow up at 12 months comprised: the health assessment questionnaire, Ritchie articular index, erythrocyte sedimentation rate, hospital anxiety and depression scale, and Steinbrocker functional class. Resource estimates were of the direct and indirect costs relating to treatment for rheumatoid arthritis. Secondary outcome measures (health utility) were ascertained by time trade off and with the quality of well being scale. Results: Both groups had improvement in scores on the health assessment questionnaire and Ritchie index and erythrocyte sedimentation rate after hospital treatment (P < 0.0001) but clinical outcome did not differ significantly between the groups either at discharge or follow up. The mean hospital cost per patient for day care, pound 798 (95% confidence interval pound 705 to pound 888), was lower than for inpatient care, pound 1253 (pound 1155 to pound 1370), but this difference was offset by higher community travel, and readmission costs. The difference in total cost per patient between day care and inpatient care was small (pound 1789 (pound 1539 to pound 2027) v pound 2021 (pound 1834 to pound 2230)). Quantile regression analysis showed a cost difference in favour of day care up to the 50th centile (pound 374; pound 639 to pound 109). Conclusions: Day care and inpatient care for patients with uncomplicated active rheumatoid arthritis have equivalent clinical outcome with a small difference in overall resource cost in favour of day care. The choice of management strategy may depend increasingly on convenience, satisfaction, or more comprehensive health measures reflecting the preferences of patients, providers, and service commissioners.	Univ Edinburgh, Western Gen Hosp, Dept Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Lambert, CM (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Med, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.		Forbes, John F/L-2558-2013	Forbes, John F/0000-0002-8255-3762				ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; ANAND KB, 1982, J ROY COLL PHYS LOND, V16, P53; ANDERSON RB, 1988, J RHEUMATOL, V15, P556; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; CAPELL HM, 1992, J ROY COLL PHYS LOND, V26, P76; Chaudhary MA, 1996, STAT MED, V15, P1447; Efron B., 1994, MONOGRAPHS STAT APPL; Gould W, 1992, STATA TECHNICAL B RE, V2, P137; HART LE, 1995, ARTHRITIS RHEUM S, V38, P382; HELEWA A, 1989, ARTHRITIS RHEUM, V32, P1505, DOI 10.1002/anr.1780321203; JOHANNESSON M, 1993, J HEALTH ECON, V12, P459, DOI 10.1016/0167-6296(93)90005-Y; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; Kwoh CK, 1996, ARTHRITIS RHEUM-US, V39, P713; LAMBERT CM, 1994, BRIT J RHEUMATOL, V33, P383; LAMBERT CM, 1995, BRIT J RHEUMATOL, V34, P774; LEE P, 1974, Q J MED, V43, P205; MOR V, 1988, J CLIN EPIDEMIOL, V41, P771, DOI 10.1016/0895-4356(88)90164-3; RITCHIE DM, 1968, Q J MED, V37, P393; ROBINSON R, 1993, BRIT MED J, V307, P726, DOI 10.1136/bmj.307.6906.726; ROSENBERG K, 1990, BAILLIERE CLIN OB GY, V4, P89, DOI 10.1016/S0950-3552(05)80214-7; *STAT, 1997, STAT STAT SOFTW REL; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; Torrance G W, 1972, Health Serv Res, V7, P118; VLIELAND TPM, 1997, BR J RHEUMATOL, V37, P82; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; ZELIN M, 1979, NEW ENGL J MED, V300, P1242; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	27	55	56	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					965	969		10.1136/bmj.316.7136.965	http://dx.doi.org/10.1136/bmj.316.7136.965			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550954	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072856100018
J	Cao, YQ; Mantyh, PW; Carlson, EJ; Gillespie, AM; Epstein, CJH; Basbaum, AI				Cao, YQ; Mantyh, PW; Carlson, EJ; Gillespie, AM; Epstein, CJH; Basbaum, AI			Primary afferent tachykinins are required to experience moderate to intense pain	NATURE			English	Article							DORSAL HORN NEURONS; SUBSTANCE-P; RECEPTOR; RAT; HYPERALGESIA; INFLAMMATION; INHIBITION; ACTIVATION; GLUTAMATE; FORMALIN	The excitatory neurotransmitter glutamate coexists,vith the peptide known as substance P in primary afferents that respond to painful stimulation(1). Because blockers of glutamate receptors reliably reduce pain behaviour(2-4), it is assumed that 'pain' messages are mediated by glutamate action on dorsal horn neurons, The contribution of substance P, however, is still unclear, We have now disrupted the mouse preprotachykinin A gene (PPT-A), which encodes substance P and a related tachykinin, neurokinin A (ref. 5). We find that although the behavioural response to mildly painful stimuli is intact in these mice, the response to moderate to intense pain is significantly reduced. Neurogenic inflammation, which results from peripheral release of substance P and neurokinin A (ref. 6), is almost absent in the mutant mice. We conclude that the release of tachykinins from primary afferent pain-sensing receptors (nociceptors) is required to produce moderate to intense pain.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, Dept Pediat, San Francisco, CA 94143 USA; Vet Adm Med Ctr, Mol Neurobiol Lab, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55417 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Basbaum, AI (corresponding author), Univ Calif San Francisco, Dept Anat, UCSF Box 0452, San Francisco, CA 94143 USA.	aib@phy.ucsf.edu						Abbadie C, 1997, J NEUROSCI, V17, P8049; AMANN R, 1995, N-S ARCH PHARMACOL, V352, P201; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; DEFELIPE C, 1997, NEUR ABSTR, V23, P2354; DUGGAN AW, 1995, NEUROSCIENCE, V65, P849, DOI 10.1016/0306-4522(94)00541-C; GYIRES K, 1984, ARCH INT PHARMACOD T, V267, P131; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HERRERO JF, 1997, NEUR ABSTR, V23, P2354; HUNTER JC, 1994, NEUROSCI LETT, V174, P217, DOI 10.1016/0304-3940(94)90025-6; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; KAKO K, 1993, BIOMED RES-TOKYO, V14, P253, DOI 10.2220/biomedres.14.253; LANEUVILLE O, 1988, LIFE SCI, V42, P1295, DOI 10.1016/0024-3205(88)90223-8; Lawson SN, 1997, J PHYSIOL-LONDON, V505, P177, DOI 10.1111/j.1469-7793.1997.00177.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MANTYH PW, 1989, J NEUROSCI, V9, P258; Marvizon JCG, 1997, J NEUROSCI, V17, P8129; MELLER ST, 1993, NEUROREPORT, V4, P879, DOI 10.1097/00001756-199307000-00010; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; RUSIN KI, 1992, J NEUROPHYSIOL, V68, P265, DOI 10.1152/jn.1992.68.1.265; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; VIGNA SR, 1994, J NEUROSCI, V14, P834; WILCOX GL, 1991, PAIN RES CL, V4, P97; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630	29	473	498	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					390	394		10.1038/32897	http://dx.doi.org/10.1038/32897			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537322				2022-12-28	WOS:000072713600052
J	McKinstry, RC; Feinberg, DA				McKinstry, RC; Feinberg, DA			A new window on brain research	SCIENCE			English	Article							SENSORY STIMULATION; MR; STROKE; MOTION		Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Neuroradiol Sect, St Louis, MO 63110 USA	Washington University (WUSTL)	McKinstry, RC (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Neuroradiol Sect, St Louis, MO 63110 USA.	mckinstry@mirlink.wustl.edu						Binder J, 1997, NEUROSURG CLIN N AM, V8, P383; BLEIER AR, 1991, MAGNET RESON MED, V21, P132, DOI 10.1002/mrm.1910210116; Chen YCI, 1997, MAGNET RESON MED, V38, P389, DOI 10.1002/mrm.1910380306; Davis TL, 1998, P NATL ACAD SCI USA, V95, P1834, DOI 10.1073/pnas.95.4.1834; EHMAN RL, 1997, RADIOLOGY P, V205, P487; ENZMANN DR, 1992, RADIOLOGY, V185, P653, DOI 10.1148/radiology.185.3.1438741; ERNST T, 1994, MAGN RESON MED, V32, P146, DOI 10.1002/mrm.1910320122; FEINBERG D, 1986, RADIOLOGY, V161, P571; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; FEINBERG DA, 1995, MAGNET RESON MED, V33, P529, DOI 10.1002/mrm.1910330411; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hennig J., 1993, MAGMA, V1, P39, DOI 10.1007/BF02660372; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; Kim SG, 1997, MAGN RESON MED, V38, P59, DOI 10.1002/mrm.1910380110; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MARGOS P, 1986, HLTH CARE INSTR, V1, P295; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Mueller WM, 1997, NEUROSURG CLIN N AM, V8, P373; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; PONCELET BP, 1992, RADIOLOGY, V185, P645, DOI 10.1148/radiology.185.3.1438740; ROBERTS DA, 1994, P NATL ACAD SCI USA, V91, P33, DOI 10.1073/pnas.91.1.33; ROSEN BR, 1991, MAGNET RESON MED, V19, P285, DOI 10.1002/mrm.1910190216; SILVERMAN SG, 1995, RADIOLOGY, V197, P175, DOI 10.1148/radiology.197.1.7568819; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; TURNER R, 1990, J MAGN RESON, V86, P445, DOI 10.1016/0022-2364(90)90023-3; VanEssen DC, 1997, J NEUROSCI, V17, P7079; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; Yang YH, 1998, MAGNET RESON MED, V39, P61, DOI 10.1002/mrm.1910390111	33	8	8	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1965	1966		10.1126/science.279.5358.1965	http://dx.doi.org/10.1126/science.279.5358.1965			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537906				2022-12-28	WOS:000072613300054
J	Sturmer, T; Glynn, RJ; Lee, IM; Manson, JE; Buring, JE; Hennekens, CH				Sturmer, T; Glynn, RJ; Lee, IM; Manson, JE; Buring, JE; Hennekens, CH			Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study	ANNALS OF INTERNAL MEDICINE			English	Article						aspirin; colorectal neoplasms; dose-response relationship, drug; placebos; outcome assessment (health care)	NONSTEROIDAL ANTIINFLAMMATORY DRUG; LARGE-BOWEL CANCER; COLON-CANCER; MYOCARDIAL-INFARCTION; CIGARETTE-SMOKING; RISK; CARCINOGENESIS; INDOMETHACIN; ADENOMA; TUMORS	Background: In contrast to most observational studies, the randomized Physicians' Health Study found no association between aspirin use and colorectal cancer after 5 years. Objective: To determine the effect of randomly assigned aspirin treatment and self-selected aspirin use on the incidence of colorectal cancer after 12 years and to identify factors influencing the self-selection of regular aspirin use. Design: Randomized clinical trial and prospective cohort study. Setting: Male physicians throughout the United States. Patients: 22 071 healthy male physicians who were 40 to 84 years of age in 1982. Intervention: 325 mg of aspirin every other day. In 1988, the aspirin arm of the randomized trial was stopped early. Participants then chose to receive either aspirin or placebo for the rest of the study. Measurements: Annual questionnaires asking about aspirin use and other variables, including occurrence of cancer. Results: Colorectal cancer was diagnosed in 341 patients during the study period. Over 12 years of follow-up, random assignment to aspirin was associated with a relative risk for colorectal cancer of 1.03 (95% CI, 0.83 to 1.28). Various gastrointestinal symptoms and diagnoses were strong predictors of less frequent aspirin use in 1988. The relative risk for colorectal cancer in persons who used aspirin frequently after 1988 was 1.07 (CI, 0.75 to 1.53). Conclusions: In the Physicians' Health Study, both randomized and observational analyses indicate that there is no association between the use of aspirin and the incidence of colorectal cancer. The low dose of aspirin used and the short treatment period may account for the null findings. However, other characteristics associated with the use of aspirin in observational studies remain a plausible alternative explanation.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, Boston, MA 02215 USA; Univ Ulm, Dept Epidemiol, D-89081 Ulm, Germany; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Ulm University; Harvard University; Harvard T.H. Chan School of Public Health	Hennekens, CH (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.		Stürmer, Til/AAB-5459-2022; Lee, I-Min/ABD-5409-2021		NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARON JA, 1994, EPIDEMIOLOGY, V5, P133; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; De Vita Jr VT, 1993, CANC PRINCIPLES PRAC; DUBACH UC, 1991, NEW ENGL J MED, V324, P155, DOI 10.1056/NEJM199101173240304; FURUTA Y, 1988, CANCER RES, V48, P3002; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1993, GASTROENTEROLOGY, V105, P130, DOI 10.1016/0016-5085(93)90018-8; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GLYNN RJ, 1994, ARCH INTERN MED, V154, P2649, DOI 10.1001/archinte.1994.00420230032005; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HENNEKENS CH, 1994, NEW ENGL J MED, V330, P1080, DOI 10.1056/NEJM199404143301510; Jacobs E. J., 1996, American Journal of Epidemiology, V143, pS61; KUDO T, 1980, GANN, V71, P260; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MARNETT LJ, 1992, CANCER RES, V52, P5575; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; NARISAWA T, 1983, CARCINOGENESIS, V4, P1225, DOI 10.1093/carcin/4.10.1225; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PAUL J, 1992, AM J GASTROENTEROL, V87, P1120; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1987, CANCER RES, V47, P5340; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; ROSENBERG L, 1991, J NATL CANCER I, V83, P1183, DOI 10.1093/jnci/83.16.1183; Rothman K, 1986, MODERN EPIDEMIOLOGY; SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; SONNENBERG A, 1993, PHARMACOLOGY, V47, P224, DOI 10.1159/000139862; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Walker AM, 1996, EPIDEMIOLOGY, V7, P335	41	237	247	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					713	+		10.7326/0003-4819-128-9-199805010-00003	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556464				2022-12-28	WOS:000073363800002
J	Negrier, S; Escudier, B; Lasset, C; Douillard, JY; Savary, J; Chevreau, C; Ravaud, A; Mercatello, A; Peny, J; Mousseau, M; Philip, T; Tursz, T				Negrier, S; Escudier, B; Lasset, C; Douillard, JY; Savary, J; Chevreau, C; Ravaud, A; Mercatello, A; Peny, J; Mousseau, M; Philip, T; Tursz, T		Grp Francais Immunotherapie	Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED KILLER-CELLS; CONTINUOUS INFUSION INTERLEUKIN-2; II CLINICAL-TRIAL; ADVANCED CANCER; ADOPTIVE IMMUNOTHERAPY; PROGNOSTIC FACTORS; SURVIVAL; THERAPY	Background Recombinant human interleukin-2 (aldesleukin) and recombinant human interferon alfa can induce notable tumor regression in a limited number of patients with metastatic renal-cell carcinoma. We conducted a multicenter, randomized trial to determine the effect of each cytokine independently and in combination, and to identify patients who are best suited for this treatment. Methods Four hundred twenty-five patients with metastatic renal-cell carcinoma were randomly assigned to receive either a continuous intravenous infusion of interleukin-2, subcutaneous injections of interferon alfa-2a, or both. The main outcome measure was the response rate; secondary outcomes were the rates of event-free and overall survival. Predictive factors for response and rapid progression were identified by multivariate analysis. Results Response rates were 6.5 percent, 7.5 percent, and 18.6 percent (P<0.01) for the groups receiving interleukin-2, interferon alfa-2a, and interleukin-2 plus interferon alfa-2a, respectively. At one year, the event-free survival rates were 15 percent, 12 percent, and 20 percent, respectively (P=0.01). There was no significant difference in overall survival among the three groups. Toxic effects of therapy were more common in patients receiving interleukin-2 than in those receiving interferon alfa-2a. Response to treatment was associated with having metastasis to a single organ and with receiving the combined treatment. The probability of rapid progression of disease was at least 70 percent for patients with at least two metastatic sites, liver metastases, and a period of less than one year between the diagnosis of the primary tumor and the appearance of metastases. Conclusions Cytokines are active in a few patients with metastatic renal-cell carcinoma. The higher response rate and longer event-free survival obtained with a combination of cytokines must be balanced against the toxicity of such treatment. (C)1998, Massachusetts Medical Society.	Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon 08, France; Ctr Leon Berard, Dept Biostat, F-69373 Lyon 08, France; Inst Gustave Roussy, Villejuif, France; Ctr Rene Gauducheau, F-44035 Nantes, France; Ctr Claudius Regaud, Toulouse, France; Inst Bergonie, Bordeaux, France; Hop Edouard Herriot, Lyon, France; Ctr Francois Baclesse, F-14021 Caen, France; Hop Michalon, Grenoble, France	UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; UNICANCER; Gustave Roussy; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Bergonie; CHU Lyon; UNICANCER; Centre Francois Baclesse; CHU Grenoble Alpes	Negrier, S (corresponding author), Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon 08, France.		Chevreau, Christine/A-5565-2015; Mousseau, Mireille/M-5942-2014	Ravaud, Alain/0000-0001-9455-6744				ATZPODIEN J, 1990, LANCET, V335, P1509, DOI 10.1016/0140-6736(90)93039-R; DEKERNION JB, 1978, J UROLOGY, V120, P148, DOI 10.1016/S0022-5347(17)57082-2; DILLMAN RO, 1991, J CLIN ONCOL, V9, P1233, DOI 10.1200/JCO.1991.9.7.1233; ELSON PJ, 1988, CANCER RES, V48, P7310; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; FOSSA SD, 1994, EUR J CANCER, V30A, P1310, DOI 10.1016/0959-8049(94)90179-1; JONES M, 1993, CANCER BIOTHERAPY, V8, P275, DOI 10.1089/cbr.1993.8.275; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; NEGRIER S, 1989, EUR J CANCER CLIN ON, V25, pS21; OLIVER RTD, 1994, EUR J CANCER, V30A, P1214, DOI 10.1016/0959-8049(94)90159-7; PALMER PA, 1992, ANN ONCOL, V3, P475, DOI 10.1093/oxfordjournals.annonc.a058239; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1630, DOI 10.1200/JCO.1990.8.10.1630; PHILIP T, 1993, BRIT J CANCER, V68, P1036, DOI 10.1038/bjc.1993.476; POCKAJ BA, 1993, J CLIN ONCOL, V11, P136, DOI 10.1200/JCO.1993.11.1.136; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; Thiesse P, 1997, J CLIN ONCOL, V15, P3507, DOI 10.1200/JCO.1997.15.12.3507; WANG JCL, 1989, J CLIN ONCOL, V7, P1885, DOI 10.1200/JCO.1989.7.12.1885; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; WIRTH MP, 1993, UROL CLIN N AM, V20, P283	23	777	797	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 30	1998	338	18					1272	1278		10.1056/NEJM199804303381805	http://dx.doi.org/10.1056/NEJM199804303381805			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK547	9562581	Bronze			2022-12-28	WOS:000073335800005
J	Mandrup-Poulsen, T				Mandrup-Poulsen, T			Diabetes	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SUSCEPTIBILITY GENES; MELLITUS; ONSET; IDDM; DECARBOXYLASE; ASSOCIATION; MORTALITY; CHILDREN; SEARCH; RISK		Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Steno Diabetes Center	Mandrup-Poulsen, T (corresponding author), Steno Diabet Ctr, DK-2820 Gentofte, Denmark.	tmpo@novo.dk		Mandrup-Poulsen, Thomas/0000-0002-3215-9273				[Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; [Anonymous], 1996, DIABETES, V45, P1289; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 1995, DIABETES AM; BLOOMGARDEN ZT, 1995, DIABETES CARE, V18, P1215, DOI 10.2337/diacare.18.8.1215; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; Dahlquist G, 1996, BRIT MED J, V313, P1174, DOI 10.1136/bmj.313.7066.1174; DAHLQUIST GG, 1995, DIABETES, V44, P408, DOI 10.2337/diabetes.44.4.408; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Diabet Control Complications Trial Res Grp, 1996, ANN INTERN MED, V124, P379, DOI 10.7326/0003-4819-124-4-199602150-00001; Gardner SG, 1997, BRIT MED J, V315, P713, DOI 10.1136/bmj.315.7110.713; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; Ghosh S, 1996, DIABETES, V45, P1, DOI 10.2337/diabetes.45.1.1; GREEN A, 1985, DIABETOLOGIA, V28, P339; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Hansen T, 1997, DIABETES, V46, P726, DOI 10.2337/diabetes.46.4.726; JAVITT JC, 1995, DIABETES AM, P601; JONER G, 1991, DIABETOLOGIA, V34, P29, DOI 10.1007/BF00404021; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; MCCARTY D, 1994, DIABETES 1994 2010 G, P1; MOLBAK AG, 1994, DIABETIC MED, V11, P650, DOI 10.1111/j.1464-5491.1994.tb00327.x; Mortensen HB, 1997, DIABETES CARE, V20, P714, DOI 10.2337/diacare.20.5.714; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; PETERSEN JS, 1994, DIABETES, V43, P1478, DOI 10.2337/diabetes.43.12.1478; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; PINKNEY JH, 1994, DIABETOLOGIA, V37, P70; PORTUESE E, 1995, NIH PUBLICATION, P221; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; Vaarala O, 1998, SCAND J IMMUNOL, V47, P131; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; YkiJarvinen H, 1996, DIABETOLOGIA, V39, P115	42	58	62	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	1998	316	7139					1221	1225		10.1136/bmj.316.7139.1221	http://dx.doi.org/10.1136/bmj.316.7139.1221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553001	Green Published			2022-12-28	WOS:000073224100028
J	Fitzgerald, RG; Parkes, CM				Fitzgerald, RG; Parkes, CM			Coping with loss - Blindness and loss of other sensory and cognitive functions	BRITISH MEDICAL JOURNAL			English	Article									Thomas Jefferson Univ, Philadelphia, PA 19107 USA; St Christophers Hospice, London SE26 6DZ, England	Jefferson University	Fitzgerald, RG (corresponding author), Thomas Jefferson Univ, Philadelphia, PA 19107 USA.							FITZGERALD RG, 1971, AM J PSYCHIAT, V127, P1533, DOI 10.1176/ajp.127.11.1533; FITZGERALD RG, 1970, ARCH GEN PSYCHIAT, V22, P370; FITZGERALD RG, 1987, PERCEPT MOTOR SKILL, V64, P363, DOI 10.2466/pms.1987.64.2.363; FITZGERALD RG, 1973, EYE EAR NOSE THROAT, V5, P99; FITZGERALD RG, 1973, EYE EAR NOSE THROAT, V5, P127; FITZGERALD RG, 1973, MED ASPECTS HUM SEX, V7, P60; JONES L, 1987, WORDS APART LOSING Y; KNAPP PH, 1948, PSYCHOSOM MED, V10, P203, DOI 10.1097/00006842-194807000-00002; OEHLERGIARRATANA J, 1980, ARCH GEN PSYCHIAT, V37, P463; SWASH M, 1991, CLIN NEUROLOGY, V1; THEUT SK, 1991, INT J AGING HUM DEV, V33, P113, DOI 10.2190/4KYG-J2E1-5KEM-LEBA; Thomas A, 1980, Br J Audiol, V14, P76, DOI 10.3109/03005368009078906	12	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1160	1163		10.1136/bmj.316.7138.1160	http://dx.doi.org/10.1136/bmj.316.7138.1160			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZH054	9552962	Green Published			2022-12-28	WOS:000073067500041
J	Roscoe, SB; Frechet, JMJ; Walzer, JF; Dias, AJ				Roscoe, SB; Frechet, JMJ; Walzer, JF; Dias, AJ			Polyolefin spheres from metallocenes supported on noninteracting polystyrene	SCIENCE			English	Article							ZIEGLER-NATTA CATALYSTS; OLEFIN POLYMERIZATION; PHASE CATALYSTS; PROPYLENE; ETHYLENE	To obviate the destructive interaction of highly reactive metallocene catalysts with classical silica-based supports while retaining the advantage of supported catalysts, a noninteracting polystyrene support was developed. Supported catalysts for the polymerization of alpha-olefins are prepared by treating lightly cross-linked, chloromethylated polystyrene beads consecutively with a secondary amine, an ammonium salt of a weakly coordinating anion, and a neutral dialkylmetallocene. Catalytic sites are distributed homogeneously throughout the support particle, and the polymerization occurs within the bead, in contrast to traditional surface-supported metallocene catalysts. The copolymerization of ethylene and 1-hexene at 40 degrees C affords discrete spherical polyolefin beads with a size (0.3 to 1.4 millimeters) that varies according to the polymerization time.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Exxon Chem Co, Baytown Polymer Ctr, Baytown, TX 77520 USA	University of California System; University of California Berkeley; Exxon Mobil Corporation	Roscoe, SB (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		FRECHET, Jean M/P-1497-2016	Frechet, Jean/0000-0001-6419-0163				Bochmann M, 1996, J CHEM SOC DALTON, P255, DOI 10.1039/dt9960000255; BRINTZINGER HH, 1995, ANGEW CHEM INT EDIT, V34, P1143, DOI 10.1002/anie.199511431; CHIEN JCW, 1991, J AM CHEM SOC, V113, P8570, DOI 10.1021/ja00022a081; COATES GW, 1995, SCIENCE, V267, P217, DOI 10.1126/science.267.5195.217; FRECHET JMJ, 1977, CHEM PROPERTIES CROS, P59; GRUBBS RH, 1977, CHEMTECH, V7, P512; GRUBBS RH, 1976, CATALYSIS ORGANIC SY, P153; HLATKY GG, 1990, Patent No. 459921; ITSUNO S, 1987, J ORG CHEM, V52, P4140, DOI 10.1021/jo00227a043; ITSUNO S, 1990, J ORG CHEM, V55, P304, DOI 10.1021/jo00288a051; Johnson LK, 1996, J AM CHEM SOC, V118, P267, DOI 10.1021/ja953247i; JOHNSON LK, 1995, J AM CHEM SOC, V117, P6414, DOI 10.1021/ja00128a054; KAMINSKY W, 1994, CATAL TODAY, V20, P257, DOI 10.1016/0920-5861(94)80005-7; MARKS TJ, 1992, ACCOUNTS CHEM RES, V25, P57, DOI 10.1021/ar00014a001; MCQUILLIN JF, 1963, J AM CHEM SOC, P5996; MOHRING PC, 1994, J ORGANOMET CHEM, V479, P1, DOI 10.1016/0022-328X(94)84087-3; MRKTCHYAN SA, 1986, POLYM SCI USSR, V28, P2343; NGUYEN ST, 1995, J ORGANOMET CHEM, V497, P195, DOI 10.1016/0022-328X(95)00122-7; NISHIDA H, 1995, MACROMOL RAPID COMM, V16, P821, DOI 10.1002/marc.1995.030161107; PEPPER KW, 1953, J CHEM SOC, P4097, DOI 10.1039/jr9530004097; SOGA K, 1995, MACROMOL RAPID COMM, V16, P905, DOI 10.1002/marc.1995.030161205; SUN L, 1994, STUD SURF SCI CATAL, V89, P81, DOI 10.1016/S0167-2991(08)63023-2; SUN L, 1994, J POLYM SCI POL CHEM, V32, P2127, DOI 10.1002/pola.1994.080321115; TROST BM, 1978, J AM CHEM SOC, V100, P7780; XIANG XD, 1995, SCIENCE, V268, P1738, DOI 10.1126/science.268.5218.1738; YANG XM, 1991, ORGANOMETALLICS, V10, P840, DOI 10.1021/om00050a008	26	139	155	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					270	273		10.1126/science.280.5361.270	http://dx.doi.org/10.1126/science.280.5361.270			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535653				2022-12-28	WOS:000073082400046
J	Lee, HW; Blasco, MA; Gottlieb, GJ; Horner, JW; Greider, CW; DePinho, RA				Lee, HW; Blasco, MA; Gottlieb, GJ; Horner, JW; Greider, CW; DePinho, RA			Essential role of mouse telomerase in highly proliferative organs	NATURE			English	Article							IMMORTAL CELLS; RNA; CHROMOSOMES; ACTIVATION; GROWTH; YEAST; DNA	We have investigated the role of the enzyme telomerase in highly proliferative organs in successive generations of mice lacking telomerase RNA. Late-generation animals exhibited defective spermatogenesis, with increased programmed cell death (apoptosis) and decreased proliferation in the testis. The proliferative capacity of haematopoietic cells In the bone marrow and spleen was also compromised. These progressively adverse effects coincided with substantial erosion of telomeres (the termini of eukaryotic chromosomes) and fusion and loss of chromosomes. These findings indicate an essential role for telomerase, and hence telomeres, in the maintenance of genomic integrity and in the long-term viability of high-renewal organ systems.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Quest Diagnost Inc, Teterboro, NJ 07608 USA	Yeshiva University; Albert Einstein College of Medicine; Cold Spring Harbor Laboratory; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Greider, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; DePinho, Ronald/0000-0002-5625-577X				Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Cannizzaro L A, 1997, Methods Mol Biol, V75, P313; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DROST JB, 1995, ENVIRON MOL MUTAGEN, V25, P48, DOI 10.1002/em.2850250609; ERSLEV AJ, 1993, HEMATOLOGY, P37; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muller H., 1938, COLLECT NET, V13, P182; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; NANDA I, 1995, CHROMOSOME RES, V3, P399, DOI 10.1007/BF00713889; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHIMA H, 1990, ENDOCRINOLOGY, V127, P3222, DOI 10.1210/endo-127-6-3222; SINGER MS, 1994, SCIENCE, V266, P403; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WATT SM, 1992, CELL PROLIFERAT, V25, P263, DOI 10.1111/j.1365-2184.1992.tb01440.x; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Wright S, 1921, GENETICS, V6, P111; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	41	1048	1100	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					569	574		10.1038/33345	http://dx.doi.org/10.1038/33345			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560153				2022-12-28	WOS:000072987200049
J	Green, J				Green, J			Commentary: Grounded theory and the constant comparative method	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITATIVE RESEARCH		Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Green, J (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.			Green, Judith/0000-0002-2315-5326				BLACK N, 1994, J EPIDEMIOL COMMUN H, V48, P425, DOI 10.1136/jech.48.5.425-a; Blaxter M., 1996, MED SOCIOLOGY NEWS, V22, P68; Boulton M, 1996, J Eval Clin Pract, V2, P171, DOI 10.1111/j.1365-2753.1996.tb00041.x; BOULTON M, 1997, EVID BASED HEALTHC, V4, P83; Chard JA, 1997, J ROY SOC MED, V90, P604, DOI 10.1177/014107689709001104; DOWELL J, 1995, SCOTTISH CONSENSUS S; Fitzpatrick R, 1994, Qual Health Care, V3, P107; Glaser B.G., 1965, AWARENESS DYING; Jeffery R, 1979, Sociol Health Illn, V1, P90, DOI 10.1111/1467-9566.ep11006793; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Seale C, 1997, EUR J PUBLIC HEALTH, V7, P379, DOI 10.1093/eurpub/7.4.379; Strauss A., 1990, BASICS QUALITATIVE R; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319	13	94	94	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1064	1065						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9558994				2022-12-28	WOS:000072987400028
J	Prescott, E; Hippe, M; Schnohr, P; Hein, HO; Vestbo, J				Prescott, E; Hippe, M; Schnohr, P; Hein, HO; Vestbo, J			Smoking and risk of myocardial infarction in women and men: longitudinal population study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; BRITISH DOCTORS; OLDER MEN; MORTALITY; ESTROGEN; HEALTH	Objective: To compare risk of myocardial infarction associated with smoking in men and women, taking into consideration differences in smoking behaviour and a number of potential confounding variables. Design: Prospective cohort study with follow up of myocardial infarction. Setting: Pooled data from three population studies conducted in Copenhagen. Subjects: 11 472 women and 13 191 men followed for a mean of 12.3 years. Main outcome measures: First admission to hospital or death caused by myocardial infarction. Results: 1251 men and 512 women had a myocardial infarction during follow up. Compared with non-smokers, female current smokers had a relative risk of myocardial infarction of 2.24 (range 1.85-2.71) and male smokers 1.43 (1.26-1.62); ratio 1.57 (1.25-1.97). Relative risk of myocardial infarction increased with tobacco consumption in both men and women and was higher in inhalers than in non-inhalers. The risks associated with smoking, measured by both current and accumulated tobacco exposure, were consistently higher in women than in men and did not depend on age. This sex difference was not affected by adjustment for arterial blood pressure, total and high density lipoprotein cholesterol concentrations, triglyceride concentrations, diabetes, body mass index, height, alcohol intake, physical activity, and level of education. Conclusion: Women may be more sensitive than men to some of the harmful effects of smoking. Interactions between components of smoke and hormonal factors that may be involved in development of ischaemic heart disease should be examined further.	Univ Copenhagen, Inst Prevent Med, Copenhagen Ctr Prespect Populat Studies, Danish Epidemiol Sci Ctr, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Copenhagen City Heart Study, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Epidemiol Res Unit, DK-1168 Copenhagen, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital	Prescott, E (corresponding author), Kommune Hosp Copenhagen, Inst Prevent Med, DK-1399 Copenhagen K, Denmark.	eva.prescott@ipm.hosp.dk	Prescott, Eva/AAJ-7441-2020; Vestbo, Jorgen/Y-2912-2019	Prescott, Eva/0000-0002-4134-0349; Vestbo, Jorgen/0000-0001-6355-6362				BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIS MA, 1994, PREV MED, V23, P369, DOI 10.1006/pmed.1994.1051; Department of Health and Human Services. Epidemiology In National Heart Lung and Blood Institute, 1994, REP TASK FORC RES EP, P19; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; FLODERUS B, 1988, INT J EPIDEMIOL, V17, P332, DOI 10.1093/ije/17.2.332; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; JANGHORBANI M, 1993, INT J EPIDEMIOL, V22, P1056, DOI 10.1093/ije/22.6.1056; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; MICHNOVICZ JJ, 1989, METABOLISM, V38, P537, DOI 10.1016/0026-0495(89)90213-8; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; Njolstad I, 1996, CIRCULATION, V93, P450; NYBOE J, 1991, AM HEART J, V122, P438, DOI 10.1016/0002-8703(91)90997-V; Peto R, 1994, MORTALITY SMOKING DE; PRESCOTT E, IN PRESS INT J EPIDE; SELTZER CC, 1989, J CLIN EPIDEMIOL, V42, P743, DOI 10.1016/0895-4356(89)90070-X; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; *STAT, 1997, STAT STAT SOFTW REL; THUN MJ, 1995, AM J PUBLIC HEALTH, V85, P1223, DOI 10.2105/AJPH.85.9.1223; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	25	379	394	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1043	1047						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552903				2022-12-28	WOS:000072987400021
J	Hyatt, BA; Yost, HJ				Hyatt, BA; Yost, HJ			The left-right coordinator: The role of Vg1 in organizing left-right axis formation	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; LEFT-RIGHT ASYMMETRY; XENOPUS EMBRYOS; MESODERM INDUCTION; TRUNCATED ACTIVIN; NODAL EXPRESSION; SITUS-INVERSUS; NOGGIN; BMP-4; SPECIFICATION	The asymmetries of internal organs are consistently oriented along the left-right axis in all vertebrates, and perturbations of left-right orientation lead to significant congenital disease. We propose a model in which a "left-right coordinator" interacts with the Spemann organizer to coordinate the evolutionarily conserved three-dimensional asymmetries in the embryo. The Vg1 cell-signaling pathway plays a central role in left-right coordinator function. Antagonists of Vg1 alter left-right development; antagonists of other members of the TGF beta family do not. Cell-lineage directed expression of Vg1 protein can fully invert the left-right axis (situs inversus), can randomize left-right asymmetries, or can "rescue" a perturbed left-right axis in conjoined twins to normal orientation (situs solitus), indicating that Vg1 can mimic left-right coordinator activity. These are the first molecular manipulations in any vertebrate by which the left-right axis can be reliably controlled.	Univ Minnesota, Grad Program Mol Cell Dev Biol & Genet, Minneapolis, MN 55455 USA; Univ Utah, Huntsman Canc Inst, Ctr Children, Dept Oncol Sci, Salt Lake City, UT 84103 USA; Univ Utah, Huntsman Canc Inst, Ctr Children, Dept Pediat, Salt Lake City, UT 84103 USA	University of Minnesota System; University of Minnesota Twin Cities; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Yost, HJ (corresponding author), Univ Minnesota, Grad Program Mol Cell Dev Biol & Genet, Minneapolis, MN 55455 USA.							Bowers PN, 1996, PROG PEDIATR CARDIOL, V6, P53, DOI 10.1016/1058-9813(96)00171-3; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen JN, 1997, DEVELOPMENT, V124, P4373; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Frisch A, 1998, DEVELOPMENT, V125, P431; FUKUI A, 1993, DEV BIOL, V159, P131, DOI 10.1006/dbio.1993.1227; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HIROSE G, 1979, DEV BIOL, V71, P191, DOI 10.1016/0012-1606(79)90163-5; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; JOHNSON AD, 1994, GENE, V147, P223, DOI 10.1016/0378-1119(94)90070-1; Jones CM, 1996, DEVELOPMENT, V122, P1545; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; NAKAMURA O, 1971, P JPN ACAD, V47, P407, DOI 10.2183/pjab1945.47.407; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; Sampath K, 1997, DEVELOPMENT, V124, P3293; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; Spemann H, 1919, ARCH ENTWICKLUNG ORG, V45, P371, DOI 10.1007/BF02554405; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Wilson PA, 1997, DEVELOPMENT, V124, P3177; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOSH HJ, 1995, CELL, V82, P689; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	49	135	138	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					37	46		10.1016/S0092-8674(00)81144-7	http://dx.doi.org/10.1016/S0092-8674(00)81144-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546390	Bronze			2022-12-28	WOS:000072910800008
J	Nichols, WC; Seligsohn, U; Zivelin, A; Terry, VH; Hertel, CE; Wheatley, MA; Moussalli, MJ; Hauri, HP; Ciavarella, N; Kaufman, RJ; Ginsburg, D				Nichols, WC; Seligsohn, U; Zivelin, A; Terry, VH; Hertel, CE; Wheatley, MA; Moussalli, MJ; Hauri, HP; Ciavarella, N; Kaufman, RJ; Ginsburg, D			Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII	CELL			English	Article							EFFICIENT THROMBIN CLEAVAGE; FACTOR-BASED VECTOR; ENDOPLASMIC-RETICULUM; C INHIBITOR; MEMBRANE-PROTEIN; PROCOAGULANT ACTIVITY; LEGUMINOUS LECTINS; RECYCLING PATHWAY; MAMMALIAN-CELLS; CIS-GOLGI	Combined deficiency of factors V and VIII is an autosomal recessive bleeding disorder resulting from alterations in an unknown gene on chromosome 18q, distinct from the factor V and factor VIII genes. ERGIC-53, a component of the ER-Golgi intermediate compartment, was mapped to a YAC and BAC contig containing the critical region for the combined factors V and VIII deficiency gene. DNA sequence analysis identified two different mutations, accounting for all affected individuals in nine families studied. Immunofluorescence and Western analysis of immortalized lymphocytes from patients homozygous for either of the two mutations demonstrate complete lack of expression of the mutated gene in these cells. These findings suggest that ERGIC-53 may function as a molecular chaperone for the transport from ER to Golgi of a specific subset of secreted proteins, including coagulation factors V and VIII.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel; Univ Basel, Biozentrum, Basel, Switzerland; Policlin Bari, Univ Hosp, Dept Blood Coagulat, I-70124 Bari, Italy; Policlin Bari, Univ Hosp, Hemophilia Ctr, I-70124 Bari, Italy	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; University of Basel; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ginsburg, D (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.			Wheatley, Matthew/0000-0002-4816-9548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039693, R37HL039693, P01HL057346] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39693, HL57346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM KAR, 1985, SCAND J HAEMATOL, V34, P401; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BONTEMPO FA, 1987, BLOOD, V69, P1721; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; CANFIELD WM, 1982, J CLIN INVEST, V70, P1260, DOI 10.1172/JCI110725; CHANDRASEKHARAP.SC, 1992, ELECTROPHORESIS PROT, P235; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GARDINER JE, 1984, THROMB RES, V36, P197, DOI 10.1016/0049-3848(84)90219-6; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GINSBURG D, 1997, EMERY RIMOINS PRINCI, P1651; GIROLAMI A, 1976, BLUT, V32, P415, DOI 10.1007/BF01013881; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KAUFMAN RJ, 1998, IN PRESS THROMB HAEM; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANN KG, 1984, J BIOL CHEM, V259, P2949; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; MAZZONE D, 1982, ACTA HAEMATOL-BASEL, V68, P337, DOI 10.1159/000207005; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NeermanArbez M, 1997, AM J HUM GENET, V61, P143, DOI 10.1086/513897; Nichols WC, 1997, J CLIN INVEST, V99, P596, DOI 10.1172/JCI119201; Nichols WC, 1996, BLOOD, V88, P4429, DOI 10.1182/blood.V88.12.4429.bloodjournal88124429; OERI J, 1954, MED PROBL PAEDIAT, V1, P575; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; OZSOYLU S, 1983, ACTA HAEMATOL-BASEL, V70, P207, DOI 10.1159/000206726; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SELIGSOHN U, 1982, NEW ENGL J MED, V307, P1191, DOI 10.1056/NEJM198211043071907; Seligsohn U, 1989, FACTOR 8 VON WILLEBR, P89; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; SUZUKI K, 1983, BLOOD, V62, P1266; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0	61	330	338	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					61	70		10.1016/S0092-8674(00)81146-0	http://dx.doi.org/10.1016/S0092-8674(00)81146-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546392	Bronze			2022-12-28	WOS:000072910800010
J	Singson, A; Mercer, KB; L'Hernault, SW				Singson, A; Mercer, KB; L'Hernault, SW			The C-elegans spe-9 gene encodes a sperm transmembrane protein that contains EGF-like repeats and is required for fertilization	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EPIDERMAL GROWTH-FACTOR; MEMBRANE-PROTEIN; DROSOPHILA; DELTA; NOTCH; SERRATE; CELL; RECEPTOR; GENOME	In the nematode worm C. elegans, individuals with mutations in the spe-g gene produce spermatozoa with wild-type morphology and motility that cannot fertilize oocytes even after contact between gametes. Therefore, disruption of spe9 function affects either gamete recognition, adhesion, signaling, and/or fusion; The spe-g gene encodes a sperm transmembrane protein with an extracellular domain that contains ten epidermal growth factor-like repeats. A common feature of proteins that include epidermal growth factor-like motifs is their involvement in extracellular functions such as adhesive and ligand-receptor interactions. Additionally, the overall structure of the predicted SPE-9 protein is similar to that of ligands for the Notch/LIN-12/GLP-1 family of transmembrane receptors. These results suggest that SPE-9 functions in the specialized cell-cell interactions required for fertilization.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University	Singson, A (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM40697] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040697, R01GM040697] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achanzar WE, 1997, J CELL SCI, V110, P1073; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRENNER S, 1974, GENETICS, V77, P71; Browning H, 1996, DEVELOPMENT, V122, P391; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DAVIS C G, 1990, New Biologist, V2, P410; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; GREENSPAN R J, 1990, New Biologist, V2, P595; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Herman RK, 1995, METHOD CELL BIOL, V48, P123; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Krause M, 1995, METHOD CELL BIOL, V48, P483; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; L'Hernault SW, 1997, C ELEGANS, P271; LHERNAULT SW, 1988, GENETICS, V120, P435; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LHernault SW, 1995, METHOD CELL BIOL, V48, P273; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PRIMAKOFF P, 1983, DEV BIOL, V98, P417, DOI 10.1016/0012-1606(83)90371-8; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Riddle DL, 1997, C ELEGANS; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEDL T, 1997, C ELEGANS, V2, P241; SHAKES DC, 1989, DEV BIOL, V134, P189, DOI 10.1016/0012-1606(89)90088-2; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; Sun X, 1996, DEVELOPMENT, V122, P2465; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; WARD S, 1979, DEV BIOL, V73, P304, DOI 10.1016/0012-1606(79)90069-1; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yanagimachi R., 1994, P189	53	101	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					71	79		10.1016/S0092-8674(00)81147-2	http://dx.doi.org/10.1016/S0092-8674(00)81147-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546393	Bronze			2022-12-28	WOS:000072910800011
J	Tacke, R; Tohyama, M; Ogawa, S; Manley, JL				Tacke, R; Tohyama, M; Ogawa, S; Manley, JL			Human Tra2 proteins are sequence-specific activators of pre-mRNA splicing	CELL			English	Article							T ALTERNATIVE EXON; RNA-BINDING PROTEINS; SR-PROTEINS; MESSENGER-RNA; PREMESSENGER RNA; SEX DETERMINATION; DROSOPHILA-MELANOGASTER; REGULATORY ELEMENTS; CONSERVED FAMILY; ENHANCER COMPLEX	The RNA-binding protein Tra2 is an important regulator of sex determination in Drosophila. Recently, two mammalian Tra2 homologs of unknown function have been described. Here, we show that human Tra2 proteins are present in HeLa cell nuclear extracts and that they bind efficiently and specifically to a previously characterized pre-mRNA splicing enhancer element. Indeed, both purified proteins bound preferentially to RNA sequences containing GAA repeats, characteristic of many enhancer elements. Neither Tra2 protein functioned in constitutive splicing in vitro, but both activated enhancer-dependent splicing in a sequence-specific manner and restored it after inhibition with competitor RNA. Our findings indicate that mammalian Tra2 proteins are sequence-specific splicing activators that likely participate in the control of cell-specific splicing patterns.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Osaka Univ, Sch Med, Dept Anat & Neurosci, Suita, Osaka 565, Japan	Columbia University; Osaka University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048259, R01GM048259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1980, GENETICS, V94, P383; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAZELRIGG T, 1994, P NATL ACAD SCI USA, V91, P10752, DOI 10.1073/pnas.91.22.10752; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Madigan SJ, 1996, MOL CELL BIOL, V16, P4222; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; Mattox W, 1996, GENETICS, V143, P303; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; PENG XB, 1995, MOL CELL BIOL, V15, P6273; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YEAKLEY JM, 1993, MOL CELL BIOL, V13, P5999, DOI 10.1128/MCB.13.10.5999; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	173	180	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					139	148		10.1016/S0092-8674(00)81153-8	http://dx.doi.org/10.1016/S0092-8674(00)81153-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546399	hybrid			2022-12-28	WOS:000072910800017
J	Randolph, AG; Cook, DJ; Gonzales, CA; Andrew, M				Randolph, AG; Cook, DJ; Gonzales, CA; Andrew, M			Benefit of heparin in peripheral venous and arterial catheters: Systematic review and meta-analysis of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							SODIUM-CHLORIDE INJECTION; NORMAL SALINE; DOUBLE-BLIND; INDUCED THROMBOCYTOPENIA; INTRAVENOUS INFUSIONS; MAINTENANCE; PATENCY; LINES; PHLEBITIS; PREVENTION	Objective: To evaluate the effect of heparin on duration of catheter patency and on prevention of complications associated with use of peripheral venous and arterial catheters, Design: Critical appraisal and meta-analysis of 26 randomised controlled trials that evaluated infusion of heparin intermittently or continuously. Thirteen trials of peripheral venous catheters and two of peripheral arterial catheters met criteria for inclusion, Main outcome measures: Data on the populations, interventions, outcomes, and methodological duality, Results: For peripheral venous catheters locked between use flushing with 10 U/ml of heparin instead of normal saline did not reduce the incidence of catheter clotting and phlebitis or improve catheter patency, When heparin was given as a continuous infusion at 1 U/ml the risk of phlebitis decreased (relative risk 0.55; 95% confidence interval 0.39 to 0.77), the duration of patency increased, and infusion failure was reduced (0.88; 0.72 to 1.07), Heparin significantly prolonged duration of patency of radial artery catheters and decreased the risk of clot formation (0.51; 0.42 to 0.61), Conclusions: Use of intermittent heparin flushes at doses of 10 U/ml in peripheral venous catheters locked between use had no benefit over normal saline flush, Infusion of low dose heparin through a peripheral arterial catheter prolonged the duration of patency but further study is needed to establish its benefit for peripheral venous catheters.	Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Harvard Univ, Sch Med, Multidisciplinary Intens Care Unit, Boston, MA 02115 USA; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Calif San Francisco, Dept Pediat, Div Pediat Crit Care, San Francisco, CA 94143 USA; McMaster Univ, Dept Paediat, Div Paediat Haematol, Hamilton, ON, Canada	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; McMaster University; University of California System; University of California San Francisco; McMaster University	Randolph, AG (corresponding author), Childrens Hosp, Dept Pediat, Farley 517,300 Longwood Ave, Boston, MA 02115 USA.			Randolph, Adrienne/0000-0002-3084-3071	AHRQ HHS [F32 HS000106] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [F32HS000106] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALPAN G, 1984, PEDIATRICS, V74, P375; *AM ASS CRIT CAR N, 1993, AM J CRIT CARE, V2, P3; American Society of Hospital Pharmacists, 1994, AM J HOSP PHARM, V51, P1572; ASHTON J, 1990, HEART LUNG, V19, P608; Barrett P J, 1990, Hosp Pharm, V25, P115; BASSAN MM, 1983, CHEST, V84, P439, DOI 10.1378/chest.84.4.439; Bolgiano C S, 1990, Crit Care Nurse, V10, P47; BRANSON PK, 1993, CHEST, V103, P882, DOI 10.1378/chest.103.3.882; BRISMAR B, 1982, ARCH SURG-CHICAGO, V117, P1196; BUTT W, 1987, CRIT CARE MED, V15, P230, DOI 10.1097/00003246-198703000-00010; CLIFTON GD, 1991, HEART LUNG, V20, P115; Danek G D, 1992, Pediatr Nurs, V18, P111; DANIELL HW, 1973, JAMA-J AM MED ASSOC, V226, P1317, DOI 10.1001/jama.226.11.1317; Donham J A, 1987, Kans Nurse, V62, P6; EPPERSON EL, 1984, CLIN PHARMACY, V3, P626; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GARRELTS JC, 1989, CLIN PHARMACY, V8, P34; GAUER PK, 1982, RESPIRATORY CARE, V27, P435; Geritz M A, 1992, West J Nurs Res, V14, P131, DOI 10.1177/019394599201400202; GOODE CJ, 1991, NURS RES, V40, P324; HAMILTON RA, 1988, CLIN PHARMACY, V7, P439; HANSON RL, 1976, SURG GYNECOL OBSTET, V142, P373; HEULITT MJ, 1993, CRIT CARE MED, V21, P825, DOI 10.1097/00003246-199306000-00008; Jowett N I, 1986, Intensive Care Nurs, V2, P16, DOI 10.1016/0266-612X(86)90070-2; KLEIBER G, 1993, PEDIAT NURS, V19, P405; Kotter R W, 1996, Neonatal Netw, V15, P43; KULKARNI M, 1994, CAN J SURG, V37, P37; MADDOX RR, 1977, AM J HOSP PHARM, V34, P29, DOI 10.1093/ajhp/34.1.29; MCMULLEN A, 1993, AM J MATERN CHILD NU, V18, P78; MESSING B, 1985, NEW ENGL J MED, V312, P1432; MEYER BA, 1995, OBSTET GYNECOL, V85, P433, DOI 10.1016/0029-7844(94)00409-7; Moclair AE, 1991, INT J PHARM PRACT, V1, P38; PETERSON FY, 1991, HEART LUNG, V20, P631; RAISBAHRAMI K, 1990, AM J PERINAT, V7, P122, DOI 10.1055/s-2007-999461; Robertson J, 1994, Contemp Nurse, V3, P174; SHINOZAKI T, 1983, JAMA-J AM MED ASSOC, V249, P223, DOI 10.1001/jama.249.2.223; Shoaf J, 1992, Appl Nurs Res, V5, P9; SKETCH MH, 1972, CHEST, V62, P684, DOI 10.1378/chest.62.6.684; SMITH I, 1990, RES NURS HEALTH, V13, P367, DOI 10.1002/nur.4770130604; SPADONE D, 1992, J VASC SURG, V15, P306, DOI 10.1016/0741-5214(92)90252-4; STRADLING JR, 1978, BRIT MED J, V2, P1195, DOI 10.1136/bmj.2.6146.1195; TANNER WA, 1980, BRIT J SURG, V67, P311, DOI 10.1002/bjs.1800670503; TAYLOR J, 1989, CLIN PEDIATR, V28, P237, DOI 10.1177/000992288902800509; TREAS LS, 1991, J OBSTET GYNECOL NEO, V21, P214; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; WRIGHT A, 1995, HEART LUNG, V24, P79, DOI 10.1016/S0147-9563(05)80099-8	46	119	129	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					969	975		10.1136/bmj.316.7136.969	http://dx.doi.org/10.1136/bmj.316.7136.969			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550955	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072856100019
J	Beecham, L				Beecham, L			Health secretary wants to work with clinicians	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					943	943						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552865				2022-12-28	WOS:000072713300083
J	Wray, GA				Wray, GA			Transcription - Promoter logic	SCIENCE			English	Article							EMBRYO		SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wray, GA (corresponding author), SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA.							Arnone MI, 1997, DEVELOPMENT, V124, P1851; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; YUH CH, 1994, MECH DEVELOP, V47, P165, DOI 10.1016/0925-4773(94)90088-4	4	15	16	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1871	1872		10.1126/science.279.5358.1871	http://dx.doi.org/10.1126/science.279.5358.1871			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537905				2022-12-28	WOS:000072613300028
J	Simmons, D; Searle, M				Simmons, D; Searle, M			Personal paper - Risk of diabetic nephropathy in potential living related kidney donors	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PIMA-INDIANS; MELLITUS; HYPERINSULINEMIA; SUSCEPTIBILITY; HYPERTENSION; PROTEINURIA; NEPHRECTOMY; RELATIVES; DISEASE		Univ Auckland, Middlemore Hosp, Auckland 6, New Zealand	University of Auckland	Simmons, D (corresponding author), Univ Auckland, Middlemore Hosp, Private Bag 93 311, Auckland 6, New Zealand.			Simmons, David/0000-0003-0560-0761				ALI Z, 1990, DIABETES CARE, V13, P527, DOI 10.2337/diacare.13.5.527; BERNSTEIN J, 1971, Pediatric Clinics of North America, V18, P395; DISNEY APS, 1994, ANZDATA REPORT 1994; Disney APS, 1993, ANZDATA REPORT 1993; FABRE J, 1982, KIDNEY INT, V21, P730, DOI 10.1038/ki.1982.90; GROSSMAN HB, 1994, BRIT J UROL, V74, P279, DOI 10.1111/j.1464-410X.1994.tb16610.x; Harris MI, 1996, DIABETIC MED, V13, pS9; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; KLEIN R, 1993, DIABETES, V42, P381, DOI 10.2337/diabetes.42.3.381; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KUNZELMAN CL, 1989, KIDNEY INT, V35, P681, DOI 10.1038/ki.1989.39; LORENZEN T, 1994, DIABETOLOGIA, V37, P321, DOI 10.1007/BF00398061; MCCANCE DR, 1995, DIABETOLOGIA, V38, P221, DOI 10.1007/s001250050274; MCCARTY D, 1994, DIABETES 1994 2010 G, P46; MENEILLY GS, 1995, DIABETIC MED, V12, P949, DOI 10.1111/j.1464-5491.1995.tb00405.x; MORALES PA, 1993, DIABETES, V42, P154, DOI 10.2337/diabetes.42.1.154; NAGI DK, 1995, DIABETOLOGIA, V38, P187, DOI 10.1007/s001250050269; NIELSON FS, 1995, AM J KIDNEY DIS, V26, P893; OSULLIVAN JB, 1984, CARBOHYD METABOL, P174; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; SAMPSON MJ, 1990, DIABETIC MED, V7, P258, DOI 10.1111/j.1464-5491.1990.tb01381.x; SCHMITZ A, 1989, AM J KIDNEY DIS, V13, P131, DOI 10.1016/S0272-6386(89)80131-3; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; Simmons D, 1996, DIABETIC MED, V13, P371, DOI 10.1002/(SICI)1096-9136(199604)13:4<371::AID-DIA38>3.0.CO;2-O; SIMMONS D, 1995, J INTERN MED, V237, P315, DOI 10.1111/j.1365-2796.1995.tb01181.x; SIMMONS D, 1993, DIABETIC MED, V10, P264, DOI 10.1111/j.1464-5491.1993.tb00055.x; STEFFES MW, 1978, DIABETES, V27, P35, DOI 10.2337/diabetes.27.1.35; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; ZIMMET PZ, 1992, DIABETOLOGIA, V35, P534, DOI 10.1007/BF00400481	30	8	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					846	848		10.1136/bmj.316.7134.846	http://dx.doi.org/10.1136/bmj.316.7134.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549459	Green Published			2022-12-28	WOS:000072584300039
J	Takenaka, K; Moriguchi, T; Nishida, E				Takenaka, K; Moriguchi, T; Nishida, E			Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest	SCIENCE			English	Article							XENOPUS-OOCYTE MATURATION; MAP KINASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; MAMMALIAN-CELLS; CASCADE; INDUCTION; METAPHASE; HOMOLOG	The mitogen-activated protein kinase (MAPK) superfamily comprises classical MAPK (also called ERK), c-Jun amino-terminal or stress-activated protein kinase (JNK or SAPK), and p38. Although MAPK is essential for meiotic processes in Xenopus oocytes and the spindle assembly checkpoint in Xenopus egg extracts, the role of members of the MAPK superfamily in M phase or the spindle assembly checkpoint during somatic cell cycles has not been elucidated. The kinase p38, but not MAPK or JNK, was activated in mammalian cultured cells when the cells were arrested in M phase by disruption of the spindle with nocodazole, Addition of activated recombinant p38 to Xenopus cell-free extracts caused arrest of the extracts in M phase, and injection of activated p38 into cleaving embryos induced mitotic arrest. Treatment of NIH 3T3 cells with a specific inhibitor of p38 suppressed activation of the checkpoint by nocodazole, Thus, p38 functions as a component of the spindle assembly checkpoint in somatic cell cycles.	Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 60601, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 60601, Japan.		Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MASUYAMA N, UNPUB; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TAKENAKA K, UNPUB; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	40	231	240	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					599	602		10.1126/science.280.5363.599	http://dx.doi.org/10.1126/science.280.5363.599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554853				2022-12-28	WOS:000073242100050
J	Bennet, G				Bennet, G			Coping with loss - The doctor's losses: ideals versus realities	BRITISH MEDICAL JOURNAL			English	Article									United Bristol Healthcare NHS Trust, Bristol, Avon, England		Bennet, G (corresponding author), 44 Wellington Pk, Bristol BS8 2UW, Avon, England.							Bennet G., 1987, WOUND DOCTOR HEALING	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1238	1240		10.1136/bmj.316.7139.1238	http://dx.doi.org/10.1136/bmj.316.7139.1238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553007	Green Published			2022-12-28	WOS:000073224100035
J	Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ				Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ			Effect of electrical cardioversion on myocardial cells in patients in intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, A-6020 Innsbruck, Austria	University of Innsbruck	Neumayr, G (corresponding author), Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.		Wiedermann, Christian J./ABG-9521-2020					DOHERTY PW, 1979, AM J CARDIOL, V43, P225, DOI 10.1016/S0002-9149(79)80008-9; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; METCALFE MJ, 1988, BRIT MED J, V296, P1364, DOI 10.1136/bmj.296.6633.1364	5	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1207	1207		10.1136/bmj.316.7139.1207	http://dx.doi.org/10.1136/bmj.316.7139.1207			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552995	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000073224100023
J	Gostin, LO; Webber, DW				Gostin, LO; Webber, DW			HIV infection and AIDS in the public health and health care systems - The role of law and litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RIGHTS COMMISSION DECISIONS; TRANSMISSION; PROJECT; COURT	The AIDS Litigation Project has reviewed nearly 600 reported cases involving individuals with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal and state courts in the United States between 1991 and 1997. Cases were identified through a federal and 50-state computer and library search. An important subset of litigation relates to HIV/AIDS in the public health and health care systems, since the law affects health care institutions and professionals, patients, and public health policy in America. This subset of HIV/AIDS litigation includes testing and reporting; privacy, the duty to warn, and the right to know; physician standards of care in prevention and treatment; and discrimination and access to health care. In broad terms, the review demonstrates a reliance on voluntary testing and protection of patient privacy through HIV-specific statutes and the common law. Negligence with potential civil and criminal liability has been alleged in cases of erroneous or missed diagnosis of HIV infection. In the first AIDS case to be considered by the Supreme Court, the Court will decide whether patients with asymptomatic HIV infection are protected under the Americans with Disabilities Act. Considerable progress has been made, both socially and legally, during the first 2 decades of the epidemic, but much still needs to be accomplished to protect privacy, prevent discrimination, and promote tolerance.	Georgetown Johns Hopkins Program Law & Publ Hlth, Washington, DC USA; Georgetown Johns Hopkins Program Law & Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Burris S, 1996, AM J PUBLIC HEALTH, V86, P1161, DOI 10.2105/AJPH.86.8_Pt_1.1161; Burris Scott, 1992, Univ Miami Law Rev, V47, P291; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDC, 1985, MMWR-MORBID MORTAL W, V34, P1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; Centers for Disease Control and Prevention, 1997, HIV PREV B MED ADV P; *EEOC, 1993, EEOC INT GUID APPL A; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GOSTIN L, 1998, AM DISABILITIES ACT; Gostin L O, 1997, Emory Law J, V46, P587; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Gostin LO, 1997, JAMA-J AM MED ASSOC, V277, P53, DOI 10.1001/jama.277.1.53; GOSTIN LO, 1990, NEW ENGL J MED, V322, P1743, DOI 10.1056/NEJM199006143222411; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; GOSTIN LO, IN PRESS DUKE J GEND; GOSTIN LO, 1990, AIDS HLTH CARE SYSTE; MILLER P, 1997, AM J PUBLIC HEALTH, V87, P1558; NORMAND J, 1995, PREVENTING HIV TRANS; *NY DEP HLTH, 1997, 972 NEW YORK DEP HLT; Parmet WE, 1997, AM J LAW MED, V23, P7; *PC, 1988, REP PRES COMM HUM IM; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; WEBBER DW, 1997, AIDS LAW	28	23	24	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1108	1113		10.1001/jama.279.14.1108	http://dx.doi.org/10.1001/jama.279.14.1108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546571				2022-12-28	WOS:000072875300036
J	Feig, DS; Naylor, CD				Feig, DS; Naylor, CD			Eating for two: are guidelines for weight gain during pregnancy too liberal?	LANCET			English	Editorial Material							3RD-TRIMESTER; DELIVERY; GROWTH; BIRTH; RISK		Univ Toronto, Dept Med, Toronto, ON, Canada; Mt Sinai Hosp, Div Endocrinol & Metab, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Naylor, CD (corresponding author), Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, N York, ON M4N 3M5, Canada.		Feig, Denice/C-4606-2015					*AM COLL OBST GYN, 1993, ACOG TECHN B, V179, P1; Barker DJP, 1996, NUTR REV, V54, pS1; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; *I MED, 1990, NUTR PREGN WEIGHT GA; JOHNSON JWC, 1992, AM J OBSTET GYNECOL, V167, P353, DOI 10.1016/S0002-9378(11)91414-8; Johnson JWC, 1996, AM J OBSTET GYNECOL, V174, P254, DOI 10.1016/S0002-9378(96)70403-9; KEPPEL KG, 1993, AM J PUBLIC HEALTH, V83, P1100, DOI 10.2105/AJPH.83.8.1100; KRAMER M, 1995, COCHRANE PREGNANCY C, P1; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRAMER MS, 1995, COCHRANE PREGNANCY C; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; *REP PAN DIET REF, 1991, DIET REF VAL FOOD EN, P30; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SCHOLL TO, 1995, OBSTET GYNECOL, V86, P423, DOI 10.1016/0029-7844(95)00190-3; SHEPARD MJ, 1986, AM J OBSTET GYNECOL, V155, P947, DOI 10.1016/0002-9378(86)90323-6; SiegaRiz AM, 1996, J NUTR, V126, P146, DOI 10.1093/jn/126.1.146; SMITH DE, 1994, JAMA-J AM MED ASSOC, V271, P1747, DOI 10.1001/jama.271.22.1747; STEIN AD, 1995, HUM BIOL, V67, P135; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665	19	52	55	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1054	1055		10.1016/S0140-6736(97)06261-2	http://dx.doi.org/10.1016/S0140-6736(97)06261-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546528				2022-12-28	WOS:000072927200045
J	Power, C; Matthews, S; Manor, O				Power, C; Matthews, S; Manor, O			Inequalities in self-rated health: explanations from different stages of life	LANCET			English	Article							SOCIAL SUPPORT; WHITEHALL-II; FOLLOW-UP; MORTALITY; POPULATION; COHORT	Background Inequalities in health are a major public-health concern. A greater understanding is needed on the relative importance of different causes. We investigated the contribution of risk factors identified at different life stages to inequalities in self-rated health. Methods We used data from 5606 men and 5799 women in the 1958 British birth cohort followed-up to age 33 years, on health behaviour, education, adolescent health, family structure and social support, work characteristics, and material circumstances. We assessed the contribution of different factors to social-class differences in self-rated health by adjustment of odds ratios (classes IV and V vs I and II). Findings Odds ratios of poor-rated health at age 33 were 3.15 for men and 2.30 for women, which decreased to 2.06 and 1.34, respectively, after adjustment for previously identified factors from birth to early adulthood. Adjustment for adult work characteristics, material circumstances, and health behaviour between ages 23 years and 33 years further decreased the odds ratios to 1.64 (men) and 1.11 (women). Most factors contributed to the reduction in odds ratios, socioemotional adjustment, class qualifications, and psychosocial job strain were especially important, Additional key factors for men were adult smoking and job insecurity, and for women, housing during childhood, adult income, and age at first child. Interpretation There was no single cause of health inequality at age 33 years. Explanations spanned from early life to young adulthood. Policy implications include reduction of social differences in material circumstances and of differences in individual skills and resources acquired in early life.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Hebrew Univ Jerusalem, Hadassah, Sch Publ Hlth & Community Med, Jerusalem, Israel	University of London; University College London; Hebrew University of Jerusalem; Hadassah University Medical Center	Power, C (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.			Matthews, Sharon/0000-0003-3105-7029				Appels A, 1996, SOC SCI MED, V42, P681, DOI 10.1016/0277-9536(95)00195-6; BARKER DJP, 1992, FETAL INFANT ORIGINS, P68; Benzeval M, 1995, TACKLING INEQUALITIE; BOBAK M, IN PRESS EPIDEMIOL; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; DAVEYSMITH G, 1990, BRIT MED J, V301, P373; FERRI E, 1993, LIFE 33 5 FOLLOW UP; FERRIE JE, 1995, BRIT MED J, V311, P1264, DOI 10.1136/bmj.311.7015.1264; GOLDBLATT P, 1990, 6 OPCS LS; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HEDGES B, 1996, HLTH SURVEY ENGLAND; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; Kuh D, 1997, LIFE COURSE APPROACH; MACINTYRE S, 1998, HUMAN BIOL SOCIAL IN; Manor O, 1997, SOC SCI MED, V45, P761, DOI 10.1016/S0277-9536(96)00412-1; Marmot M., 1995, SOC HLTH, P172; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; MATTHEWS S, IN PRESS SOC SCI MED; McDonough P, 1997, AM J PUBLIC HEALTH, V87, P1476, DOI 10.2105/AJPH.87.9.1476; Moller L, 1996, J EPIDEMIOL COMMUN H, V50, P423, DOI 10.1136/jech.50.4.423; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; Power C, 1997, AM J PUBLIC HEALTH, V87, P1499, DOI 10.2105/AJPH.87.9.1499; Power C, 1996, BRIT MED J, V313, P449; Power C., 1991, HLTH CLASS EARLY YEA; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; Townsend P, 1992, INEQUALITIES HLTH BL; TURNER RJ, 1994, J HEALTH SOC BEHAV, V35, P193, DOI 10.2307/2137276; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591	32	197	200	1	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1009	1014		10.1016/S0140-6736(97)11082-0	http://dx.doi.org/10.1016/S0140-6736(97)11082-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF730	9546506				2022-12-28	WOS:000072927200010
J	Schiff, GD; Rucker, TD				Schiff, GD; Rucker, TD			Computerized prescribing - Building the electronic infrastructure for better medication usage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHYSICIAN ORDER ENTRY; PRACTICE GUIDELINES; DECISION-SUPPORT; HEALTH-CARE; PATIENT; INFORMATION; SYSTEM; ERRORS; DRUGS; PREVENTION	Computerized prescribing in the practice of medicine is a change that is overdue. Virtually all prescriptions in the United States are still handwritten. instead, medications should be ordered on a computer interacting with 3 databases: patient drug history, scientific drug information and guideline reference, and patient-specific (weight, laboratory) data. Current problems with prescribing on which computerized prescribing could have a positive impact include (1) drug selection; (2) patient role in pharmacotherapy risk-benefit decision making; (3) screening for interactions (drug-drug, drug-laboratory, drug-disease); (4) linkages between laboratory and pharmacy; (5) dosing calculations and scheduling; (6) coordination between team members, particularly concerning patient education; (7) monitoring and documenting adverse effects; and (8) postmarketing surveillance of therapy outcomes, Computerized prescribing is an important component of clinician order entry. Development of this tool has been impeded by a number of conceptual, implementation, and policy barriers. Overcoming these constraints will require clinically and professionally guided vision and leadership.	Cook Cty Hosp, Dept Med, Collaborat Res Unit, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Chicago, IL USA	John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schiff, GD (corresponding author), Cook Cty Hosp, Dept Med, Collaborat Res Unit, 1825 W Harrison St,Room 220,Adm Bldg, Chicago, IL 60612 USA.	gdschiff@aol.com						*AG HLTH CAR POL R, 1995, AHCPR PUBL; Amatayakul M, 1997, Health Data Manag, V5, P56; Andrade Susan E., 1996, Pharmacoepidemiology and Drug Safety, V5, P113; [Anonymous], 1997, LANCET, V349, P369; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P400, DOI 10.1093/ajhp/52.4.400; Bates D W, 1994, Qual Manag Health Care, V2, P18; Bates DW, 1996, DRUG SAFETY, V15, P303, DOI 10.2165/00002018-199615050-00001; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1996, AM J HEALTH-SYST PH, V53, P747; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLOBEL B, 1997, ELECT PATIENT REC, V5, P3; Bradley CP, 1997, BRIT MED J, V314, P744, DOI 10.1136/bmj.314.7082.744; Cannon B, 1996, J Am Pharm Assoc (Wash), VNS36, P668; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Chewning B, 1996, SOC SCI MED, V42, P389, DOI 10.1016/0277-9536(95)00156-5; Chin T L, 1997, Health Data Manag, V5, P78; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Cohen MR, 1996, AM J HEALTH-SYST PH, V53, P737, DOI 10.1093/ajhp/53.7.737; *COUNC COMP, 1998, HIGHW HLTH TRANSF US; CROSS MA, 1996, HLTH DATA MANAGE, V4, P70; DAVIS P, 1996, CONTESTED GROUND PUB; DOYLE E, 1995, AM COLL PHYS OBSERVE, V15, P7; ELLINOY BJ, 1989, AM J HOSP PHARM, V46, P1549, DOI 10.1093/ajhp/46.8.1549a; Elson RB, 1997, J AM MED INFORM ASSN, V4, P266, DOI 10.1136/jamia.1997.0040266; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; Faich Gerald A., 1996, Pharmacoepidemiology and Drug Safety, V5, P393, DOI 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.3.CO;2-8; Felkey BG, 1997, AM J HEALTH-SYST PH, V54, P274, DOI 10.1093/ajhp/54.3.274; Gabrieli E R, 1991, Top Health Rec Manage, V11, P27; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GIBBS S, 1990, J ROY SOC MED, V83, P292, DOI 10.1177/014107689008300505; GLABMAN M, 1996, AM COLL PHYS OBS OCT, V16, P8; GRAY BH, 1997, HLTH AFF MILLWOOD, V16, P106; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Hampton C. E., 1997, Journal of Investigative Medicine, V45, p311A; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; HEADDEN S, 1996, US NEWS WORLD R 0826, P47; *I MED COMM IMPR M, 1991, COMP BAS PAT REC ESS; *INT SOC PHARM, 1997, DAT PRIV MED REC CON; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEGLER JD, 1990, M D COMPUT, V7, P155; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; LIPTON HL, 1995, INT J TECHNOL ASSESS, V11, P485, DOI 10.1017/S0266462300008692; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LORTIE FM, 1986, CAN MED ASSOC J, V135, P27; Lyons RF, 1996, J CLIN PHARM THER, V21, P221, DOI 10.1111/j.1365-2710.1996.tb01142.x; Marsa L., 1997, PRESCRIPTION PROFIT; MARTIN J, 1995, GRET TRANSITION USIN; Martin R, 1996, BRIT MED J, V312, P1418; MARUYAMA H, 1989, ANN INTERN MED, V110, P333; McCarthy R, 1997, Bus Health, V15, P39; MCCARTHY R, 1997, DRUG BENEFIT TRENDS, V9, P36; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; MILES P, 1995, JOINT COMM J QUAL IM, V21, P32; Miller RA, 1997, J AM MED INFORM ASSN, V4, P442, DOI 10.1136/jamia.1997.0040442; Morris LA, 1997, MED CARE, V35, P996, DOI 10.1097/00005650-199710000-00002; MUIRHEAD G, 1996, DRUG TOPICS, V140, P61; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; *NAT COUNC PAT INF, 1995, PRESCR MED COMPL REV; NIGHTINGALE SL, 1995, INT J TECHNOL ASSESS, V11, P399, DOI 10.1017/S026646230000862X; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Poikonen J, 1997, AM J HEALTH-SYST PH, V54, P281, DOI 10.1093/ajhp/54.3.281; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; RASON JT, 1990, HUMAN ERROR; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RELMAN AS, 1982, NEW ENGL J MED, V306, P669, DOI 10.1056/NEJM198203183061109; Rovelli F, 1996, LANCET, V348, P169; RUCKER TD, 1990, MED CARE, V28, P928, DOI 10.1097/00005650-199010000-00007; RUCKER TD, 1974, JAMA-J AM MED ASSOC, V230, P889; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SCHIFF GD, 1995, JOINT COMM J QUAL IM, V21, P549, DOI 10.1016/S1070-3241(16)30181-X; SCHIFF GD, 1996, EX ERR HLTH CAR DEV; SCHIFF GD, 1993, U S P OP C PAT ED RO, P13; SCHNEIDER R, 1995, AM J HEALTH-SYST PH, V52, P2184, DOI 10.1093/ajhp/52.20.2184; SCHOENENBERGER RA, 1995, JAMA-J AM MED ASSOC, V274, P1622, DOI 10.1001/jama.274.20.1622; Schriger DL, 1997, JAMA-J AM MED ASSOC, V278, P1585, DOI 10.1001/jama.278.19.1585; Schulman KA, 1996, ANN INTERN MED, V124, P906, DOI 10.7326/0003-4819-124-10-199605150-00008; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Siwicki B, 1997, Health Data Manag, V5, P54; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; *SOW UN PRIM CAR I, 1996, PROD PUBL, V24; SZOLOVITS P, 1996, ELECT PATIENT RECORD, V4, P8; Thompson CA, 1996, AM J HEALTH-SYST PH, V53, P712, DOI 10.1093/ajhp/53.7.712; TOGNONI G, 1986, LANCET, V2, P1028; Tuttle MS, 1997, J AM MED INFORM ASSN, V4, P322, DOI 10.1136/jamia.1997.0040322; United States Department of Health and Human Services, 1996, HLTH PEOPL 2000 REV HLTH PEOPL 2000 REV; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Walton RT, 1997, BRIT MED J, V315, P791; Weed LL, 1997, BRIT MED J, V315, P231, DOI 10.1136/bmj.315.7102.231; Weingarten S, 1997, JAMA-J AM MED ASSOC, V277, P1977, DOI 10.1001/jama.277.24.1977; WIJNANDS MJH, 1992, BRIT J RHEUMATOL, V31, P253, DOI 10.1093/rheumatology/31.4.253; Wolinsky H, 1997, ANN INTERN MED, V127, P953, DOI 10.7326/0003-4819-127-10-199711150-00026; WYATT J, 1995, BRIT MED J, V311, P1181, DOI 10.1136/bmj.311.7014.1181; 1996, LANCET, V347, P1127; 1995, FED REG, V60, P44182; 1994, DRUG THER B, V32, P32	108	174	180	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1024	1029		10.1001/jama.279.13.1024	http://dx.doi.org/10.1001/jama.279.13.1024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533503				2022-12-28	WOS:000072669700032
J	Benatar, D; Benatar, SR				Benatar, D; Benatar, SR			Informed consent and research	BRITISH MEDICAL JOURNAL			English	Article									Univ Cape Town, Dept Philosophy, ZA-7700 Rondebosch, South Africa; Univ Cape Town, Ctr Bioeth, ZA-7700 Rondebosch, South Africa; Univ Cape Town, Ctr Bioeth, ZA-7925 Western Cape, South Africa; Univ Cape Town, Dept Med, ZA-7925 Western Cape, South Africa	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town	Benatar, D (corresponding author), Univ Cape Town, Dept Philosophy, ZA-7700 Rondebosch, South Africa.							Bhagwanjee S, 1997, BRIT MED J, V314, P1077, DOI 10.1136/bmj.314.7087.1077a; Doyal L, 1997, BMJ-BRIT MED J, V314, P1107, DOI 10.1136/bmj.314.7087.1107	2	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1008	1008		10.1136/bmj.316.7136.1008	http://dx.doi.org/10.1136/bmj.316.7136.1008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550966	Green Published			2022-12-28	WOS:000072856100035
J	Taylor, AJN				Taylor, AJN			ABC of allergies - Asthma and allergy	BRITISH MEDICAL JOURNAL			English	Article									Royal Brompton Hosp, London SW3 6LY, England	Royal Brompton Hospital	Taylor, AJN (corresponding author), Royal Brompton Hosp, London SW3 6LY, England.							BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; COCKCROFT, 1997, CLIN ALLERGY, V7, P503	2	7	7	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					997	999		10.1136/bmj.316.7136.997	http://dx.doi.org/10.1136/bmj.316.7136.997			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550963	Green Published			2022-12-28	WOS:000072856100028
J	Guilford, P; Hopkins, J; Harraway, J; McLeod, M; McLeod, N; Harawira, P; Taite, H; Scoular, R; Miller, A; Reeve, AE				Guilford, P; Hopkins, J; Harraway, J; McLeod, M; McLeod, N; Harawira, P; Taite, H; Scoular, R; Miller, A; Reeve, AE			E-cadherin germline mutations in familial gastric cancer	NATURE			English	Article							INVASION-SUPPRESSOR GENE; LOBULAR BREAST CANCERS; CARCINOMA CELL-LINES; EXPRESSION; EXTRACTION; STOMACH	The identification of genes predisposing to familial cancer is an essential step towards understanding the molecular events underlying tumorigenesis and is critical for the clinical management of affected families. Despite a declining incidence, gastric cancer remains a major cause of cancer death worldwide(1), and about 10% of cases show familial clustering(2,3), The relative contributions of inherited susceptibility and environmental effects to familial gastric cancer are poorly understood because little is known of the genetic events that predispose to gastric cancer. Here we describe the identification of the gene responsible for early-onset, histologically poorly differentiated, high grade, diffuse gastric cancer(4) in a large kindred from New Zealand (Aotearoa), Genetic linkage analysis demonstrated significant Linkage to markers flanking the gene for the calcium-dependent cell-adhesion protein E-cadherin. Sequencing of the E-cadherin gene revealed a G-->T nucleotide substitution in the donor splice consensus sequence of exon 7, leading to a truncated gene product, Diminished E-cadherin expression is associated with aggressive, poorly differentiated carcinomas(5). Underexpression of E-cadherin is a prognostic marker of poor clinical outcome in many tumour types(6), and restored expression of E-cadherin in tumour models can suppress the invasiveness of epithelial tumour cells(7,8). The role of E-cadherin in gastric cancer susceptibility was confirmed by identifying inactivating mutations in other gastric cancer families, In one family a frameshift mutation,vas identified in exon 15, and in a second family a premature stop codon interrupted exon 13, These results describe, to our knowledge for the first time, a molecular basis for familial gastric cancer, and confirm the important role of E-cadherin mutations in cancer.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, Aotearoa, New Zealand; Kimi Hauora Hlth Clin, Mt Maunganui S, Aotearoa, New Zealand; Tauranga Publ Hosp, Tauranga, Aotearoa, New Zealand; Univ Otago, Dept Pathol, Dunedin, Aotearoa, New Zealand	University of Otago; University of Otago	Guilford, P (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, Aotearoa, New Zealand.	parry.guilford@stonebow.otago.ac.nz		Guilford, Parry/0000-0002-7256-9576				BANERJEE SK, 1995, BIOTECHNIQUES, V18, P768; BECKER KF, 1994, CANCER RES, V54, P3845; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JONES E. G., 1964, NEW ZEAL MED J, V63, P287; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAVECCHIA C, 1992, CANCER, V70, P50, DOI 10.1002/1097-0142(19920701)70:1<50::AID-CNCR2820700109>3.0.CO;2-I; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muta H, 1996, JPN J CANCER RES, V87, P843, DOI 10.1111/j.1349-7006.1996.tb02109.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZANGHIERI G, 1990, CANCER, V66, P2047, DOI 10.1002/1097-0142(19901101)66:9<2047::AID-CNCR2820660934>3.0.CO;2-G	29	1207	1269	4	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					402	405		10.1038/32918	http://dx.doi.org/10.1038/32918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537325				2022-12-28	WOS:000072713600055
J	Collins, S; Woodman, CBJ; Threlfall, A; Prior, P				Collins, S; Woodman, CBJ; Threlfall, A; Prior, P			Survival rates from interval cancer in NHS breast screening programme	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Christie Hosp NHS Trust, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Collins, S (corresponding author), Univ Manchester, Christie Hosp NHS Trust, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Day N, 1995, J Med Screen, V2, P180; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					832	833		10.1136/bmj.316.7134.832	http://dx.doi.org/10.1136/bmj.316.7134.832			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549455	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000072584300032
J	Headrick, LA; Wilcock, PM; Batalden, PB				Headrick, LA; Wilcock, PM; Batalden, PB			Continuing medical education - Interprofessional working and continuing medical education	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; PROGRAM; QUALITY		Case Western Reserve Univ, Metrohlth Med Ctr, Dept Med, Cleveland, OH 44109 USA; Bournemouth Univ, Inst Hlth & Community Studies, Bournemouth BH12 5BB, Dorset, England; Dartmouth Coll, Sch Med, Hanover, NH 03755 USA	Case Western Reserve University; MetroHealth System; Bournemouth University; Dartmouth College	Headrick, LA (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Dept Med, Room 221,2500 Metro Hlth Dr, Cleveland, OH 44109 USA.							BALDWIN DC, 1994, 921009P BUR HLTH PRO; Benner P., 1984, NOVICE EXPERT; BERNARD M, 1995, NATL AGENDA GERIATRI, P57; Brookfield S., 1986, UNDERSTANDING FACILI; CAMPIONSMITH C, 1997, INTERIM REPORT DORSE; COLES C, 1995, PATIENT EDUC COUNS, V26, P239, DOI 10.1016/0738-3991(95)00727-H; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Hackman J. R, 1990, GROUPS WORK THOSE DO; Headrick L, 1996, AM J RESP CRIT CARE, V154, pS96, DOI 10.1164/ajrccm/154.3_Pt_2.S96; Headrick LA, 1996, JOINT COMM J QUAL IM, V22, P149, DOI 10.1016/S1070-3241(16)30217-6; HILL LA, 1995, MANAGING YOUR TEAM; Katzenbach JR, 1993, WISDOM TEAMS CREATIN; Kolb D.A, 1984, EXPERIENTIAL LEARNIN; Lawrence M, 1996, QUAL HEALTH CARE, V5, P151, DOI 10.1136/qshc.5.3.151; LNAGLEY GJ, 1996, IMPROVEMENT GUIDE; NELSON GC, 1998, CLIN IMPROVEMENT ACT; *NHS EX S W REG IN, 1997, 1997 20001 INV BID M; Ovretveit J., 1997, INTERPROFESSIONAL WO; POULTON B, 1993, HLTH SOC CARE, V2, P77; POULTON BC, 1993, J ADV NURS, V18, P918, DOI 10.1046/j.1365-2648.1993.18060918.x; SCHOLTES PR, 1988, TEAM HDB; Schon D.A., 1987, ED REFLECTIVE PRACTI; *STAND COMM POSTGR, 1994, CONT PROF DEV DOCT D; *UK CTR ADV INT ED, 1996, CAIPE B, V11, P1; WEISS KB, 1997, BREAKTHROUGH SERIES; WEST M, 1997, NEWSLETTER EUROP FEB, P12	26	91	92	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					771	774		10.1136/bmj.316.7133.771	http://dx.doi.org/10.1136/bmj.316.7133.771			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB358	9529419	Green Published			2022-12-28	WOS:000072463700044
J	[Anonymous]				[Anonymous]			Britain needs 1000 more GPs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1998	316	7140					1323	1323						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554919				2022-12-28	WOS:000073335900054
J	Lamond, AI; Earnshaw, WC				Lamond, AI; Earnshaw, WC			Structure and function in the nucleus	SCIENCE			English	Review							ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA TRANSPORT; AMPHIBIAN GERMINAL VESICLE; TRACT-BINDING PROTEIN; KINESIN-LIKE PROTEIN; XENOPUS EGG EXTRACT; PML-RAR-ALPHA; COILED BODIES; INTRANUCLEAR DISTRIBUTION; CHROMOSOME TERRITORIES	Current evidence suggests that the nucleus has a distinct substructure, albeit one that is dynamic rather than a rigid framework. Viral infection, oncogene expression, and inherited human disorders can each cause profound and specific changes in nuclear organization. This review summarizes recent progress in understanding nuclear organization, highlighting in particular the dynamic aspects of nuclear structure.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Dundee; University of Edinburgh	Lamond, AI (corresponding author), Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland.	a.i.lamond@dundee.ac.uk	Earnshaw, William/AAY-7438-2020	Lamond, Angus/0000-0001-6204-6045; Earnshaw, William/0000-0002-7191-0621	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Abney JR, 1997, J CELL BIOL, V137, P1459, DOI 10.1083/jcb.137.7.1459; AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; Alliegro MC, 1998, EXP CELL RES, V239, P60, DOI 10.1006/excr.1997.3867; Allshire RC, 1997, CURR OPIN GENET DEV, V7, P264, DOI 10.1016/S0959-437X(97)80137-2; ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BAUER DW, 1994, MOL BIOL CELL, V5, P633, DOI 10.1091/mbc.5.6.633; Bauer DW, 1997, MOL BIOL CELL, V8, P73, DOI 10.1091/mbc.8.1.73; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BELL P, 1992, J CELL BIOL, V118, P1297, DOI 10.1083/jcb.118.6.1297; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; Bohmann K, 1995, J CELL SCI, P107; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Chen GQ, 1997, BLOOD, V89, P3345; Cleard F, 1997, EMBO J, V16, P5280, DOI 10.1093/emboj/16.17.5280; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; Eils R, 1996, J CELL BIOL, V135, P1427, DOI 10.1083/jcb.135.6.1427; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FREY MR, 1995, P NATL ACAD SCI USA, V92, P5915, DOI 10.1073/pnas.92.13.5915; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; Gao LI, 1997, NUCLEIC ACIDS RES, V25, P4740, DOI 10.1093/nar/25.23.4740; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GOTTA M, 1995, J CELL BIOL, V134, P139; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUIDNER HH, 1992, J IMMUNOL, V149, P4067; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heng HHQ, 1997, BIOESSAYS, V19, P75, DOI 10.1002/bies.950190112; HENIKOFF S, 1995, GENETICS, V140, P1007; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Jackson DA, 1995, INT REV CYTOL, V162A, P125; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; JIMENEZGARCIA LF, 1994, MOL BIOL CELL, V5, P955, DOI 10.1091/mbc.5.9.955; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Kramer Joseph, 1994, Trends in Cell Biology, V4, P35, DOI 10.1016/0962-8924(94)90001-9; Kurz A, 1996, J CELL BIOL, V135, P1195, DOI 10.1083/jcb.135.5.1195; LAMOND AI, 1993, MOL BIOL REP, V18, P127, DOI 10.1007/BF00986767; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LAVAU C, 1995, ONCOGENE, V11, P871; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LESER GP, 1989, EUR J CELL BIOL, V50, P376; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LOCKE J, 1988, GENETICS, V120, P181; LUBYPHELPS K, 1986, J CELL BIOL, V102, P2015, DOI 10.1083/jcb.102.6.2015; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Lyon CE, 1997, EXP CELL RES, V230, P84, DOI 10.1006/excr.1996.3380; Maden BEH, 1997, CHROMOSOMA, V105, P391, DOI 10.1007/s004120050200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; MALATESTA M, 1994, EUR J CELL BIOL, V65, P82; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; MATERA AG, 1995, J CELL BIOL, V129, P1181, DOI 10.1083/jcb.129.5.1181; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; Matunis M, 1997, MOL BIOL CELL, V8, P1367; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MEIER UT, 1992, CELL, V70, P127; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MOEN PT, 1995, MOL BIOL CELL, V6, P1773; MONNERON A, 1969, J ULTRA MOL STRUCT R, V27, P266, DOI 10.1016/S0022-5320(69)80017-1; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; OCHS RL, 1994, J CELL SCI, V107, P385; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Ramon y Cajal S., 1903, TRAD LAB INVEST BIOL, V2, P129; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; REUTER R, 1985, EXP CELL RES, V159, P63, DOI 10.1016/S0014-4827(85)80038-0; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Santama N, 1996, EUR J NEUROSCI, V8, P892, DOI 10.1111/j.1460-9568.1996.tb01576.x; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHARDIN M, 1985, HUM GENET, V71, P281, DOI 10.1007/BF00388452; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; SEELER JS, UNPUB; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; SHAW PJ, 1997, ANN REV CELL DEV BIO, V11, P93; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; SIDEBOTTOM E, 1969, J CELL SCI, V5, P351; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Smith KP, 1995, J CELL BIOCHEM, V59, P473, DOI 10.1002/jcb.240590408; SMITH KP, 1995, MOL BIOL CELL, V6, P1127; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; SPECTOR DL, 1992, MOL BIOL CELL, V3, P555, DOI 10.1091/mbc.3.5.555; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Sternsdorf T, 1997, J CELL BIOL, V138, P435, DOI 10.1083/jcb.138.2.435; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; THIRY M, 1994, CHROMOSOMA, V103, P268, DOI 10.1007/BF00352251; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TUMA RS, 1993, J CELL BIOL, V122, P767, DOI 10.1083/jcb.122.4.767; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; VISA N, 1993, EUR J CELL BIOL, V60, P308; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; WANG SZ, 1995, J CELL BIOL, V128, P761, DOI 10.1083/jcb.128.5.761; Wansink DG, 1996, J CELL BIOCHEM, V62, P10, DOI 10.1002/(SICI)1097-4644(199607)62:1<10::AID-JCB2>3.0.CO;2-4; WANSINK DG, 1994, J CELL SCI, V107, P1449; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WU CHH, 1993, P NATL ACAD SCI USA, V90, P6257, DOI 10.1073/pnas.90.13.6257; WU ZA, 1994, MOL BIOL CELL, V5, P1119, DOI 10.1091/mbc.5.10.1119; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZHANG GH, 1994, NATURE, V372, P809; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; Zink D, 1998, HUM GENET, V102, P241, DOI 10.1007/s004390050686	176	759	775	3	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					547	553		10.1126/science.280.5363.547	http://dx.doi.org/10.1126/science.280.5363.547			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554838	Green Submitted			2022-12-28	WOS:000073242100035
J	Hotopf, M; Carr, S; Mayou, R; Wadsworth, M; Wessely, S				Hotopf, M; Carr, S; Mayou, R; Wadsworth, M; Wessely, S			Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDERS; BIRTH COHORT; LIFE EVENTS; FOLLOW-UP; FAMILIES; SOMATIZATION; ADOLESCENTS; SYMPTOMS	Objective: To test the hypotheses that children with abdominal pain have anxious parents and come from families with high rates of physical illness and that they grow up to suffer from high rates of medically unexplained symptoms and psychiatric disorders. Design: Population based birth cohort study. Setting: General population. Subjects: Participants in the Medical Research Council (MRC) national survey of health and development, a population based bir th cohort study established in 1946. Main outcome measures: Abdominal pain present throughout childhood in the absence of defined organic disease, and measures of physical symptoms and psychiatric disorder at age 36 years. Results: There were high rates of complaints about physical health among the parents of children with persistent abdominal pain, and the mothers had higher neuroticism scores. Children with persistent abdominal pain were more likely to suffer from psychiatric disorders in adulthood (odds ratio 2.72 (95% confidence interval 1.65 to 4.49)) but were not especially prone to physical symptoms once psychiatric disorder was controlled for (odds ratio 1.39 (0.83 to 2.36)). Conclusions: Persistent abdominal pain is associated with poor health and emotional disorder in the parents. Children with abdominal pain do not necessarily continue to experience physical symptoms into adulthood but are at increased risk of adult psychiatric disorders.	Kings Coll London, Sch Med & Dent, Dept Psychol Med, London SE5 8AZ, England; Inst Psychiat, London SE5 8AZ, England; Royal Free Hosp, Dept Paediat, London NW3 2QG, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; UCL, Univ Coll & Middlesex Sch Med, Dept Epidemiol & Publ Hlth, MRC,Natl Survey Hlth & Dev, London WC1E 6BT, England	University of London; King's College London; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford; University of London; University College London	Hotopf, M (corresponding author), Kings Coll London, Sch Med & Dent, Dept Psychol Med, London SE5 8AZ, England.	m.hotopf@iop.bpmf.ac.uk	Wessely, Simon C/A-8713-2008; Hotopf, Matthew/E-4971-2010	Hotopf, Matthew/0000-0002-3980-4466; Wessely, Simon Charles/0000-0002-6743-9929				APLEY J, 1973, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5870.7; APLEY J, 1957, ARCH DIS CHILD, P165; CAMPO JV, 1994, J AM ACAD CHILD PSY, V33, P1223, DOI 10.1097/00004583-199411000-00003; Caspi A, 1996, ARCH GEN PSYCHIAT, V53, P1033; CHRISTENSEN MF, 1975, ARCH DIS CHILD, V50, P110, DOI 10.1136/adc.50.2.110; EYSENCK HJ, 1958, J APPL PSYCHOL, V42, P14, DOI 10.1037/h0041738; GARBER J, 1990, J AM ACAD CHILD PSY, V29, P648, DOI 10.1097/00004583-199007000-00021; GOODMAN JE, 1991, PAIN, V46, P247, DOI 10.1016/0304-3959(91)90108-A; HODGES K, 1984, J PSYCHOSOM RES, V28, P185, DOI 10.1016/0022-3999(84)90018-7; HODGES K, 1985, J PEDIATR-US, V107, P622, DOI 10.1016/S0022-3476(85)80037-8; MAGNI G, 1987, EUR J PEDIATR, V146, P72, DOI 10.1007/BF00647291; Pintner R, 1938, J EDUC PSYCHOL, V29, P93, DOI 10.1037/h0059933; ROBINSON JO, 1990, J PSYCHOSOM RES, V34, P171, DOI 10.1016/0022-3999(90)90051-5; SANDERS MR, 1994, J CONSULT CLIN PSYCH, V62, P306, DOI 10.1037/0022-006X.62.2.306; Scharff L, 1997, CLIN PSYCHOL REV, V17, P145, DOI 10.1016/S0272-7358(96)00001-3; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; WALKER LS, 1993, J ABNORM PSYCHOL, V102, P248, DOI 10.1037/0021-843X.102.2.248; WALKER LS, 1989, J PEDIATR PSYCHOL, V14, P231, DOI 10.1093/jpepsy/14.2.231; WALKER LS, 1991, J ABNORM CHILD PSYCH, V19, P379, DOI 10.1007/BF00919084; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOODBURY MM, 1993, PSYCHOSOMATICS, V34, P485, DOI 10.1016/S0033-3182(93)71822-8	22	224	224	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1196	1200		10.1136/bmj.316.7139.1196	http://dx.doi.org/10.1136/bmj.316.7139.1196			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZJ518	9552994	Green Submitted, Green Published			2022-12-28	WOS:000073224100019
J	Tang, JL; Armitage, JM; Lancaster, T; Silagy, CA; Fowler, GH; Neil, HAW				Tang, JL; Armitage, JM; Lancaster, T; Silagy, CA; Fowler, GH; Neil, HAW			Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-FAT DIET; SERUM-CHOLESTEROL; WEIGHT-REDUCTION; GENERAL-PRACTICE; CLINICAL-TRIALS; HEART-DISEASE; RISK-FACTORS; LIPOPROTEINS; METAANALYSIS; LIPIDS	Objectives: To estimate the efficacy of dietary advice to lower blood total cholesterol concentration in free-living subjects and to investigate the efficacy of different dietary recommendations. Design: Systematic overview of 19 randomised controlled trials including 28 comparisons. Subjects: Free-living subjects. Interventions: Individualised dietary advice to modify fat intake. Main outcome measure: Percentage difference in blood total cholesterol concentration between the intervention and control groups. Results: The percentage reduction in blood total cholesterol attributable to dietary advice after at least six months of intervention was 5.3% (95% confidence interval 4.7% to 5.9%). Including both short and long duration studies, the effect was 8.5% at 3 months and 5.5% at 12 months. Diets equivalent to the step 2 diet of the American Heart Association were of similar efficacy to diets that aimed to lower total fat intake or to raise the polyunsaturated to saturated fatty acid ratio. These diets were moderately more effective than the step 1 diet of the American Heart Association (6.1% v 3.0% reduction in blood total cholesterol concentration; P < 0.0001). On the basis of reported food intake, the targets for dietary change were seldom achieved. The observed reductions in blood total cholesterol concentrations in the individual trials were consistent with those predicted from dietary intake on the basis of the Keys equation. Conclusions: Individualised dietary advice for reducing cholesterol concentration is modestly effective in free-living subjects. More intensive diets achieve a greater reduction in serum cholesterol concentration. Failure to comply fully with dietary recommendations is the likely explanation for this limited efficacy.	Radcliffe Infirm, Clin Trial Serv Unit, Oxford, England; Radcliffe Infirm, Epidemiol Studies Unit, Oxford, England; Univ Oxford, Radcliffe Infirm, Div Publ Hlth & Primary Care, Oxford OX2 6HE, England; Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Flinders University South Australia	Armitage, JM (corresponding author), Radcliffe Infirm, Clin Trial Serv Unit, Harkness Bldg, Oxford, England.	Jane.armitage@ctsu.ox.ac.uk	Tang, JL/G-1759-2013; Tang, Jin-Ling/AAJ-4090-2021					ANDERSON JW, 1992, AM J CLIN NUTR, V56, P887, DOI 10.1093/ajcn/56.5.887; [Anonymous], 1995, JAMA, V273, P1429; [Anonymous], 1965, LANCET, V2, P501; BARON JA, 1990, BRIT J GEN PRACT, V40, P137; BLOEMBERG BPM, 1991, AM J EPIDEMIOL, V134, P39, DOI 10.1093/oxfordjournals.aje.a115991; BOYD NF, 1988, JNCI-J NATL CANCER I, V80, P1244, DOI 10.1093/jnci/80.15.1244; Bracken Michael B., 1992, P13; BURR ML, 1989, LANCET, V2, P757; BUZZARD IM, 1990, J AM DIET ASSOC, V90, P42; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CURZIO JL, 1989, J HYPERTENS, V7, pS254, DOI 10.1097/00004872-198900076-00123; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DELORGERIL, 1995, LANCET, V345, P738; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DEMARKWAHNEFRIED W, 1990, J AM DIET ASSOC, V90, P223; DENKE MA, 1995, ARCH INTERN MED, V155, P17, DOI 10.1001/archinte.155.1.17; DREON DM, 1990, JAMA-J AM MED ASSOC, V263, P2462, DOI 10.1001/jama.263.18.2462; DUFFIELD RGM, 1983, LANCET, V2, P639; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Gregory J., 1990, DIETARY NUTR SURVEY; HARRIS WS, 1989, J LIPID RES, V30, P785; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; INSULL W, 1990, ARCH INTERN MED, V150, P421, DOI 10.1001/archinte.150.2.421; JALKANEN L, 1991, SCAND J SOC MED, V19, P66, DOI 10.1177/140349489101900112; JOHNSTON HJ, 1995, MED J AUSTRALIA, V162, P524, DOI 10.5694/j.1326-5377.1995.tb138510.x; KEYS A, 1957, LANCET, V2, P959; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P368; KORMHOUT D, 1986, BIBL NUTR DIET, V37, P119; KUUSI T, 1985, J LIPID RES, V26, P360; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEREN P, 1968, B NEW YORK ACAD MED, V44, P1012; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; MACMAHON S, 1987, NEPHRON, V47, P8, DOI 10.1159/000184544; MARNIEMI J, 1990, INT J OBESITY, V14, P113; MARTIN MJ, 1986, LANCET, V2, P933; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; REID CM, 1994, J HYPERTENS, V12, P291; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; RIVELLESE AA, 1994, BRIT MED J, V308, P227, DOI 10.1136/bmj.308.6923.227; SARKKINEN ES, 1994, ATHEROSCLEROSIS, V105, P9, DOI 10.1016/0021-9150(94)90003-5; SCIARRONE SEG, 1992, J HYPERTENS, V10, P287, DOI 10.1097/00004872-199203000-00013; *SECR STAT HLTH, 1992, CMNDCMND; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SINGH RB, 1991, NUTRITION, V7, P210; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1968, CIRCULATION, V37, P428	56	183	188	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	1998	316	7139					1213	1219		10.1136/bmj.316.7139.1213	http://dx.doi.org/10.1136/bmj.316.7139.1213			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552999	Green Published			2022-12-28	WOS:000073224100025
J	Taylor, A				Taylor, A			Violations of the international code of marketing of breast milk substitutes: prevalence in four countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DURATION; SAMPLES	Objective: To estimate the prevalence of violations of the international code of marketing of substitutes for breast milk in one city in each of Bangladesh, Poland, South Africa, and Thailand. Design: Multistage random sampling was used to select pregnant women and mothers of infants less than or equal to 6 months old to interview at health facilities. Women were asked whether they had received free samples of substitutes for breast milk (including infant formula designed to meet the nutritional needs of infants from birth to 4 to 6 months of age, follow on formula designed to replace infant formula at the age of 4 to 6 months, and complementary foods for infants aged less than or equal to 6 months), bottles, or teats. The source of the free -sample and when it had been given to the women was also determined. 3 health workers were interviewed at each facility to assess whether the facility had received free samples, to determine how they had been used, and to determine whether gifts had been given to health workers by companies that manufactured or distributed breast milk substitutes. Compliance with the marketing code for information given to health workers was evaluated using a checklist. Setting: Health facilities in Dhaka, Bangladesh; Warsaw, Poland; Durban, South Africa; and Bangkok, Thailand. Subjects: 1468 pregnant women, 1582 mothers of infants aged less than or equal to 6 months, and 466 health workers at 165 health facilities. Main outcome measures: Number of fi-ee samples received by pregnant women, mothers, and health workers; number of gifts given to health workers; and availability of information that violated the code in health facilities. Results: 97 out of 370 (26%) mothers in Bangkok reported receiving free samples of breast milk substitutes, infant formula, bottles, or teats compared with only 1 out of 385 mothers in Dhaka. Across the four cities from 3 out of 40 (8%) to 20 out of 40 (50%) health facilities had received free samples which were not being used for research or professional evaluation; from 2 out of 123 (2%) to 21 out of 119 (18%) health workers had received gifts from companies involved in the manufacturing or distribution of breast mill; substitutes. From 6 out of 40 (15%) to 22 out of 39 (56%) health facilities information that violated the code had been provided by companies and was available to staff. Conclusion: Violations of the code were detected with a simple survey instrument in all Of the four countries studied. Governmental and non-governmental agencies should monitor the prevalence of code violations using the simple methodology developed for this study.	Unicef United Kingdom Comm, Interagcy Grp Breastfeeding Monitoring, London WC2A 3NB, England		Taylor, A (corresponding author), Unicef United Kingdom Comm, Interagcy Grp Breastfeeding Monitoring, London WC2A 3NB, England.							*BAB MILK ACT, 1994, BREAK RUL; BERGEVIN Y, 1983, LANCET, V1, P1148; Collett D., 1991, MODELLING BINARY DAT; DUNGY CI, 1992, PEDIATRICS, V90, P233; Evans C J, 1986, J Obstet Gynecol Neonatal Nurs, V15, P401, DOI 10.1111/j.1552-6909.1986.tb01414.x; FEINSTEIN JM, 1986, PEDIATRICS, V78, P210; FRANK DA, 1987, PEDIATRICS, V80, P845; INCH S, 1988, EFFECTIVE CARE PREGN; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; SOKOL E, 1997, CODE HANDBOOK; World Health Organization, 1981, INT COD MARK BREASTM; World Health Organization, 1993, INF YOUNG CHILD NUTR; 1995, INFANT FORMULA FOLOW	13	56	56	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	1998	316	7138					1117	1122		10.1136/bmj.316.7138.1117	http://dx.doi.org/10.1136/bmj.316.7138.1117			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552947	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000073067500019
J	Hall, C				Hall, C			The teaching case	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1053	1053		10.1001/jama.279.14.1053	http://dx.doi.org/10.1001/jama.279.14.1053			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546549				2022-12-28	WOS:000072875300001
J	Acheson, DWK				Acheson, DWK			Nomenclature of enterotoxins	LANCET			English	Editorial Material							ESCHERICHIA-COLI		New England Med Ctr, Div Infect Dis, Boston, MA 02111 USA	Tufts Medical Center	Acheson, DWK (corresponding author), New England Med Ctr, Div Infect Dis, 750 Washington St, Boston, MA 02111 USA.							Calderwood SB, 1996, ASM NEWS, V62, P118; Karmali MA, 1996, ASM NEWS, V62, P167; KONOWALCHUCK J, 1997, INFECT IMMUN, V18, P775; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; OBRIEN AD, 1982, J INFECT DIS, V146, P763, DOI 10.1093/infdis/146.6.763; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203	6	5	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1003	1003		10.1016/S0140-6736(05)78992-3	http://dx.doi.org/10.1016/S0140-6736(05)78992-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546502				2022-12-28	WOS:000072927200006
J	Block, SM				Block, SM			Kinesin: What gives?	CELL			English	Review							MOTORS		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Block, SM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOCK SM, 1995, BIOPHYS J, V68, pS230; BLOOM G, PROTEIN PROFILE, V1109, P9506; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Gelles J, 1998, CELL, V93, P13, DOI 10.1016/S0092-8674(00)81140-X; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HANCOCK WO, 1998, IN PRESS J CELL BIOL; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; ROMBERG L, 1998, IN PRESS J CELL BIOL; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; YOUNG EC, 1998, IN PRESS BIOCHEMISTR	28	89	91	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					5	8		10.1016/S0092-8674(00)81138-1	http://dx.doi.org/10.1016/S0092-8674(00)81138-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546384	Bronze			2022-12-28	WOS:000072910800002
J	Murthy, VN; Stevens, CF				Murthy, VN; Stevens, CF			Synaptic vesicles retain their identity through the endocytic cycle	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; HIPPOCAMPAL SYNAPSES; NERVE-TERMINALS; DYNAMIN; POOL; TRANSMITTER; MEMBRANE; RINGS	After fusion of synaptic vesicles with presynaptic membrane and secretion of the contents of the vesicles into the synaptic cleft (a process known as exocytosis), the vesicular membrane is retrieved by endocytosis (internalization) for re-use(1,2). Several issues regarding endocytosis at central synapses are unresolved, including the location of membrane retrieval (relative to the active zone, where exocytosis occurs), the time course of various endocytic steps, and the recycling path taken by newly endocytosed membranes. The classical model of synaptic-vesicle recycling, proposed by analogy to other cellular endocytic pathways, involves retrieval of the membrane, fusion of the membrane with endosome-like compartments and, finally, budding of new synaptic vesicles from endosomes(1), although the endosomal station may not be obligatory(3). Here we test the classical model by using the fluorescent membrane dye FM1-43 (refs 4-6) with quantitative fluorescence microscopy. We find that the amount of dye per vesicle taken up by endocytosis equals the amount of dye a vesicle releases on exocytosis; therefore, we conclude that the internalized vesicles do not, as the classical picture suggests, communicate with intermediate endosome-like compartments during the recycling process.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute	Stevens, CF (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cfs@salk.edu		Murthy, Venkatesh/0000-0003-2443-4252				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; Schikorski T, 1997, J NEUROSCI, V17, P5858; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237	17	207	212	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					497	501		10.1038/33152	http://dx.doi.org/10.1038/33152			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548254				2022-12-28	WOS:000072875200059
J	Parkins, KJ; Poets, CF; O'Brien, LM; Stebbens, VA; Southall, DP				Parkins, KJ; Poets, CF; O'Brien, LM; Stebbens, VA; Southall, DP			Effect of exposure to 15% oxygen on breathing patterns and oxygen saturation in infants: interventional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE-THREATENING EVENTS; FULL-TERM INFANTS; 1ST 6 MONTHS; SLEEP; SIDS; HYPOXEMIA; ALTITUDE; SIBLINGS; TIBET; BORN	Objective: To assess the response of healthy infants to airway hypoxia (15% oxygen in nitrogen). Design: Interventional study. Settings: Infants' homes and paediatric ward. Subjects: 34 healthy infants (20 boys) born at term; mean age at study 3.1 months. 13 of the infants had siblings whose deaths had been ascribed to the sudden infant death syndrome. Intervention: Respiratory variables were measured in room air (pre-challenge), while infants were exposed to 15% oxygen (challenge), and after infants were returned to room air (post-challenge). Main outcome measures: Baseline oxygen saturation as measured by pulse oximetry, frequency of isolated and periodic apnoea, and frequency of desaturation (oxygen saturation less than or equal to 80% for greater than or equal to 4 s), Exposure to 15% oxygen was terminated if oxygen saturation fell to less than or equal to 80% for greater than or equal to 1 min. Results: Mean duration of exposure to 15% oxygen was 6.3 (SD 2.9) hours. Baseline oxygen saturation fell from a median of 97.6% (range 94.0% to 100%) in room air to 92.8% (84.7% to 100%) in 15% oxygen. There was no correlation between baseline oxygen saturation in room air and the extent of the fall in baseline oxygen saturation on exposure to 15% oxygen. During exposure to 15% oxygen there was a reduction in the proportion of time spent in regular breathing pattern and a 3.5-fold increasein the proportion of time spent in periodic apnoea (P < 0.001). There was an increase in the frequency of desaturation from 0 episodes per hour (range 0 to 0.2) to 0.4 episodes per hour (0 to 35) (P < 0.001). In 4 infants exposure to hypoxic conditions was ended early because of prolonged and severe falls in oxygen saturation. Conclusions: A proportion of infants had episodes of prolonged (less than or equal to 80% for greater than or equal to 1 min) or recurrent shorter (less than or equal to 80% for greater than or equal to 4 s) desaturation, or both, when exposed to airway hypoxia. The quality and quantity of this response was unpredictable. These findings may explain why some infants with airway hypoxia caused by respiratory infection develop more severe hypoxaemia than others. Exposure to airway hypoxia similar to that experienced during air travel or on holiday at high altitude may be harmful to some infants.	N Staffordshire Hosp, Acad Dept Paediat, Stoke On Trent ST4 6QG, Staffs, England; Sch Med, Dept Paediat, D-30623 Hannover, Germany	Keele University; University Hospital of North Staffordshire NHS Trust	Southall, DP (corresponding author), N Staffordshire Hosp, Acad Dept Paediat, Stoke On Trent ST4 6QG, Staffs, England.	cai.uk@compuserve.com						ANAS N, 1982, J PEDIATR-US, V101, P65, DOI 10.1016/S0022-3476(82)80184-4; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; GETTS AG, 1982, DEV MED CHILD NEUROL, V24, P61; HEATH D, 1989, THORAX, V44, P981, DOI 10.1136/thx.44.12.981; HEWERTSON J, 1994, PEDIATRICS, V94, P148; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOPPENBROUWERS T, 1989, SLEEP, V12, P265; HULTGREN HN, 1968, ANNU REV MED, V19, P119, DOI 10.1146/annurev.me.19.020168.001003; LOZANO JM, 1992, ARCH DIS CHILD, V67, P299, DOI 10.1136/adc.67.3.299; NIERMEYER S, 1995, NEW ENGL J MED, V333, P1248, DOI 10.1056/NEJM199511093331903; POETS CF, 1991, J DEV PHYSIOL, V15, P341; POETS CF, 1992, ACTA PAEDIATR, V81, P536, DOI 10.1111/j.1651-2227.1992.tb12290.x; RICHARDS JM, 1984, PEDIATRICS, V74, P763; RIGATTO H, 1972, PEDIATRICS, V50, P219; SAMUELS MP, 1994, J PEDIATR-US, V125, P441, DOI 10.1016/S0022-3476(05)83292-5; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SCHAFER T, 1993, J APPL PHYSIOL, V74, P88, DOI 10.1152/jappl.1993.74.1.88; STEBBENS VA, 1991, ARCH DIS CHILD, V66, P569, DOI 10.1136/adc.66.5.569; Tappin DM, 1996, ARCH DIS CHILD, V74, P427, DOI 10.1136/adc.74.5.427; Weil JV, 1978, SLEEP APNEA SYNDROME, P119; Zinman R, 1985, Pediatr Pulmonol, V1, P325, DOI 10.1002/ppul.1950010610	21	60	61	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	1998	316	7135					887	891		10.1136/bmj.316.7135.887	http://dx.doi.org/10.1136/bmj.316.7135.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552835	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000072713300022
J	Weijer, C				Weijer, C			Commentary: Self interest is not the sole legitimate basis for making decisions	BRITISH MEDICAL JOURNAL			English	Editorial Material									Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Weijer, C (corresponding author), Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.			Weijer, Charles/0000-0002-5510-1074				ANNAS GJ, 1990, HASTINGS CENT REP, V20, P27, DOI 10.2307/3562763; Houghton AN, 1996, SURG CLIN N AM, V76, P1343, DOI 10.1016/S0039-6109(05)70519-3; KJEMS E, 1993, ACTA ONCOL, V32, P371, DOI 10.3109/02841869309093613; Mahowald MB, 1993, WOMEN CHILDREN HLTH, P131; SIEGLER M, 1992, CAMBRIDGE Q HLTH CAR, V1, P320	5	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					850	850						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549462				2022-12-28	WOS:000072584300042
J	Hassler, DR; Shimizu, N				Hassler, DR; Shimizu, N			Osmium isotopic evidence for ancient subcontinental lithospheric mantle beneath the Kerguelen Islands, southern Indian Ocean	SCIENCE			English	Article							RE-OS; CONTINENTAL FRAGMENT; ABYSSAL PERIDOTITES; SM-ND; BASALTS; SYSTEMATICS; RIDGE; PLUME; GEOCHEMISTRY; ARCHIPELAGO	Upper mantle xenoliths found in ocean island basalts are an important window through which the oceanic mantle lithosphere may be viewed directly. Osmium isotopic data on peridotite xenoliths from the Kerguelen Islands, an archipelago that is located on the northern Kerguelen Plateau in the southern Indian Ocean, demonstrate that pieces of mantle of diverse provenance are present beneath the Islands. In particular, peridotites with unradiogenic osmium and ancient rhenium-depletion ages (to 1.36 x 10(9) years old) may be pieces of the Gondwanaland subcontinental lithosphere that were incorporated into the Indian Ocean lithosphere as a result of the rifting process.	MIT, Woods Hole Oceanog Inst, Joint Program Oceanog, Dept Geol & Geophys, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Hassler, DR (corresponding author), MIT, Woods Hole Oceanog Inst, Joint Program Oceanog, Dept Geol & Geophys, Woods Hole, MA 02543 USA.							ALIBERT C, 1991, P OCEAN DRILLING PRO, V0119; CARLSON RW, 1994, EARTH PLANET SC LETT, V126, P457, DOI 10.1016/0012-821X(94)90124-4; DAVIES HL, 1989, CONTRIB MINERAL PETR, V103, P457, DOI 10.1007/BF01041753; DOSSO L, 1988, EARTH PLANET SC LETT, V88, P47, DOI 10.1016/0012-821X(88)90045-3; DOSSO L, 1979, EARTH PLANET SC LETT, V43, P46, DOI 10.1016/0012-821X(79)90154-7; Duncan R.A., 1991, PROC OCEAN DRILL SCI, V121, P507; DUNCAN RA, 1978, J VOLCANOL GEOTH RES, V4, P283, DOI 10.1016/0377-0273(78)90018-5; Frey FA, 1996, EARTH PLANET SC LETT, V144, P163, DOI 10.1016/0012-821X(96)00150-1; GAUTIER I, 1990, EARTH PLANET SC LETT, V100, P59, DOI 10.1016/0012-821X(90)90176-X; Giret A., 1983, Antarctic Earth Science. Fourth International Symposium, P646; Hart S.R., 1996, GEOPHYS MONOGR SER, V95, P123; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; HASSLER DR, 1994, EOS, V75, P710; HASSLER DR, UNPUB; Hauri EH, 1996, NATURE, V382, P415, DOI 10.1038/382415a0; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; HAURI EH, 1992, THESIS MIT; HAWKESWORTH CJ, 1986, NATURE, V322, P356, DOI 10.1038/322356a0; HORAN MF, 1992, SCIENCE, V255, P1118, DOI 10.1126/science.255.5048.1118; MAHONEY J, 1992, J GEOPHYS RES, V97, P19; MAHONEY JJ, 1995, CHEM GEOL, V120, P315, DOI 10.1016/0009-2541(94)00144-W; MAHONEY JJ, 1989, J GEOPHYS RES-SOLID, V94, P4033, DOI 10.1029/JB094iB04p04033; Mahoney JJ, 1996, GEOLOGY, V24, P615, DOI 10.1130/0091-7613(1996)024<0615:BELFAN>2.3.CO;2; MARTIN CE, 1991, GEOCHIM COSMOCHIM AC, V55, P1421, DOI 10.1016/0016-7037(91)90318-Y; Mattielli N, 1996, LITHOS, V37, P261, DOI 10.1016/0024-4937(95)00040-2; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; Meisel T, 1996, GEOCHIM COSMOCHIM AC, V60, P2583, DOI 10.1016/0016-7037(96)00107-X; MICHARD A, 1986, EARTH PLANET SC LETT, V78, P104, DOI 10.1016/0012-821X(86)90176-7; MORGAN JW, 1986, J GEOPHYS RES, V91, P12; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; NICOLAYSEN K, 1996, EOS T AM GEOPHYS UN, V77, P824; NOUGIER J, 1972, INT UNION GEOLOGIC B, V1, P803; OPERTO S, 1995, GEOLOGY, V23, P137, DOI 10.1130/0091-7613(1995)023<0137:KPAVPM>2.3.CO;2; PEARSON DG, 1995, GEOCHIM COSMOCHIM AC, V59, P959, DOI 10.1016/00167-0379(50)00143-; PRINGLE MS, 1997, EOS, V78, P728; RAVIZZA G, 1993, EARTH PLANET SC LETT, V118, P335, DOI 10.1016/0012-821X(93)90177-B; RECQ M, 1990, TECTONOPHYSICS, V182, P227, DOI 10.1016/0040-1951(90)90165-5; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; REISBERG L, 1995, NATURE, V376, P159, DOI 10.1038/376159a0; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; Royer J.-Y., 1989, J GEOPHYS RES, V94, P13; SHIREY SB, 1987, NATURE, V325, P217, DOI 10.1038/325217a0; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X; STOREY BC, 1995, NATURE, V377, P301, DOI 10.1038/377301a0; STOREY M, 1989, NATURE, V338, P574, DOI 10.1038/338574a0; STOREY M, 1996, EOS, V77, pW123; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8; WATKINS ND, 1974, GEOL SOC AM BULL, V85, P201, DOI 10.1130/0016-7606(1974)85<201:KCFOOI>2.0.CO;2; WEIS D, 1993, EARTH PLANET SC LETT, V118, P101, DOI 10.1016/0012-821X(93)90162-3; WEIS D, 1996, J GEOPHYS RES, V101, P13; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; WHITE RS, 1987, NATURE, V327, P191, DOI 10.1038/327191a0; WHITECHURCH H, 1992, P OC DRILL PROGR SCI, V0120; Widom E, 1996, EARTH PLANET SC LETT, V142, P451, DOI 10.1016/0012-821X(96)00111-2; YANG HJ, IN PRESS J PETROL	55	70	73	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					418	421		10.1126/science.280.5362.418	http://dx.doi.org/10.1126/science.280.5362.418			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545216				2022-12-28	WOS:000073159600042
J	Kanegae, Y; Tavares, AT; Belmonte, JCI; Verma, IM				Kanegae, Y; Tavares, AT; Belmonte, JCI; Verma, IM			Role of Rel/NF-kappa B transcription factors during the outgrowth of the vertebrate limb	NATURE			English	Article							APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; FEEDBACK LOOP; CHICK; INITIATION; GROWTH; BUD; EXPRESSION; DROSOPHILA; INDUCTION	The development of the vertebrate limb serves as an amenable system for studying signaling pathways that lead to tissue patterning and proliferation(1). Limbs originate as a consequence of a differential growth of cells from the lateral plate mesoderm at specific axial levels(2). At the tip of the limb primordia the progress zone, a proliferating group of mesenchymal cells, induces the overlying ectoderm to differentiate into a specialized structure termed the apical ectodermal ridge. Subsequent limb outgrowth requires reciprocal signalling between the ridge and the progress zone(3-6). The Rel/NF-kappa B family of transcription factors is induced in response to several signals that lead to cell growth, differentiation, inflammatory responses, apoptosis and neoplastic transformation(7), In unstimulated cells, NF-kappa B is associated in the cytoplasm with an inhibitory protein, I-kappa B. In response to an external signal, I-kappa B is phosphorylated, ubiquitinated and degraded, releasing NF-kappa B to enter the nucleus and activate transcription(7). Here we show that Rel/NF-kappa B genes are expressed in the progress zone of the developing chick limb bud. When the activity of Rel/NF-kappa B proteins is blocked by infection with viral vectors that produce transdominant-negative I-kappa B alpha proteins, limb outgrowth is arrested, Our results indicate that Rel/NF-kappa B transcription factors play a role in vertebrate limb development.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Tavares, Ana Teresa/I-3086-2013	Tavares, Ana Teresa/0000-0002-3495-5513				BELMONTE JCI, 1993, CELL, V74, P645; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; ElGhouzzi V, 1997, NAT GENET, V15, P42; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Ogura T, 1996, DEVELOPMENT, V122, P537; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SHEN RQ, 1994, CELL MOL BIOL RES, V40, P297; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogel A, 1996, DEVELOPMENT, V122, P1737	30	182	187	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					611	614		10.1038/33429	http://dx.doi.org/10.1038/33429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560158				2022-12-28	WOS:000072987200062
J	Carvalho, JS; Moscoso, G; Ville, Y				Carvalho, JS; Moscoso, G; Ville, Y			First-trimester transabdominal fetal echocardiography	LANCET			English	Article							NUCHAL TRANSLUCENCY THICKNESS; CONGENITAL HEART-DISEASE; MATERNAL AGE; HIGH-RISK; DIAGNOSIS; GESTATION; PREGNANCIES; FETUSES; DEFECTS	Background Fetal echocardiography is usually done during the second trimester of pregnancy, but waiting until that time can lead to anxiety for the parents if the fetus is at high risk of having cardiac abnormalities. We report the feasibility of transabdominal first-trimester fetal echocardiography for early reassurance of normality or a prenatal diagnosis of a cardiac malformation. Methods We did first-trimester fetal echocardiography and colour-flow mapping with a 5 MHz curvilinear transducer at 13 weeks' gestation (range 12-13+6 days) in 15 fetuses at risk of cardiac defects. The fetus was judged to be normal if the investigation showed normal visceral situs, four-chamber view, and two normally related great arteries of similar size. We did second-trimester scans and neonatal follow-up for the women who continued with their pregnancies; necropsy was done in two cases of pregnancy termination. Findings Ten fetuses had normal hearts at the time of the first scan, which was confirmed during second-trimester assessment, In one fetus, the four-chamber view was asymmetrical and a moderate-sized apical muscular ventricular septal defect (VSD) was diagnosed after birth. In another two fetuses we diagnosed small muscular VSD on the second-trimester scans. A complex cardiac malformation was correctly diagnosed in one fetus at 12 weeks of gestation. Thus, in 11 fetuses, the imaging was of sufficient quality to reassure the family or to diagnose an abnormality. In the other four fetuses, the investigation was judged to be incomplete, but no definite cardiac abnormality was identified. Interpretation Transabdominal fetal echocardiography in the first trimester of pregnancy is feasible. In most patients the resolution of images is sufficient to allow assessment of basic cardiac anatomy, when normal, or detection of complex malformations, when present.	Royal Brompton Hosp NHS Trust, London SW3 6NP, England; St Georges Hosp NHS Trust, Fetal Med Unit, London, England	Royal Brompton Hospital; St Georges University London	Carvalho, JS (corresponding author), Royal Brompton Hosp NHS Trust, London SW3 6NP, England.	carvalho@eas-jsc.demon.co.uk	Carvalho, Julene/E-8842-2015	Carvalho, Julene/0000-0002-5698-5828				ACHIRON R, 1994, J ULTRAS MED, V13, P783; Allan LD, 1997, HEART, V77, P68, DOI 10.1136/hrt.77.1.68; ALLAN LD, 1994, J AM COLL CARDIOL, V23, P1452, DOI 10.1016/0735-1097(94)90391-3; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; Bjorkhem G, 1997, J Matern Fetal Med, V6, P87; BRONSHTEIN M, 1993, OBSTET GYNECOL, V82, P225; Buskens E, 1996, OBSTET GYNECOL, V87, P423, DOI 10.1016/0029-7844(95)00439-4; DAMELIO R, 1991, PRENATAL DIAG, V11, P69, DOI 10.1002/pd.1970110202; DOLKART LA, 1991, AM J OBSTET GYNECOL, V165, P688, DOI 10.1016/0002-9378(91)90310-N; DONNAI P, 1981, BRIT MED J, V282, P621, DOI 10.1136/bmj.282.6264.621; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; GITTENBERGERDEG.AC, 1996, ULTRASOUND FETAL HEA, P1; Hyett J, 1996, ULTRASOUND OBST GYN, V7, P245, DOI 10.1046/j.1469-0705.1996.07040245.x; Hyett JA, 1997, ULTRASOUND OBST GYN, V10, P242, DOI 10.1046/j.1469-0705.1997.10040242.x; HYETT JA, 1995, AM J MED GENET, V58, P374, DOI 10.1002/ajmg.1320580415; OTT WJ, 1995, AM J OBSTET GYNECOL, V172, P1741, DOI 10.1016/0002-9378(95)91406-4; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P15, DOI 10.1046/j.1469-0705.1995.05010015.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x	20	83	86	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1023	1027		10.1016/S0140-6736(97)08406-7	http://dx.doi.org/10.1016/S0140-6736(97)08406-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546509				2022-12-28	WOS:000072927200013
J	Whittle, IR; Pringle, AM; Taylor, R				Whittle, IR; Pringle, AM; Taylor, R			Effects of resective surgery for left-sided intracranial tumours on language function: a prospective study	LANCET			English	Article							DOMINANT HEMISPHERE; LOCALIZATION; GLIOMAS; APHASIA; TUMORS; AGE	Background Although language disorders occur in about 50% of patients with a left hemispheric tumour and are a significant cause of morbidity, the effects of resective neurosurgery and their relation to tumour pathology are unclear. We report the immediate effects of resective surgery on language functions in a heterogeneous group of patients with left-sided intracranial tumours. Methods 40 patients were studied. The Western Aphasia Battery (WAB) and Boston Naming Test (BNT) were administered preoperatively and before discharge following resective neurosurgery. Dexamethasone dose at time of testing was recorded, as was time taken to complete the tests, and tumour neuropathology. Findings 15 patients with normal aphasia quotients and language quotients before resective surgery all had normal quotients postoperatively. 25 who were dysphasic tie, aphasia quotient <93.8) preoperatively showed significant postoperative improvements in both their mean aphasia quotient (from 81.8 to 89.1, p=0.004) and their mean language quotient (from 73.4 to 85.4, p=0.001), though 13 remained dysphasic. Two of the 25 dysphasic patients had their WAB scores lowered by tumour resection. The findings and postoperative changes in BNT scores were almost identical to the pattern of those in WAB scores. At second assessment, dexamethasone therapy was significantly (p<0.01) lower than preoperative dose (reduction from mean 10.3 mg/day to 0.7 mg/day in the dysphasic group). Patients with glioblastoma were more likely to have lower aphasia quotients, language quotients, and BNT scores than patients with anaplastic glioma, metastasis, or meningioma, Although the glioblastoma group had the greatest improvements in WAB operative scores, 57% remained dysphasic after resective surgery. Two additional patients declined postoperative assessment. Interpretation Resective surgery for left-sided intracranial tumours significantly improves language function in dysphasic patients, and is unlikely to impair language functions in non-dysphasic patients. Dysphasia and its response to resective surgery are related to the tumour neuropathology.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Whittle, IR (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	irw@skull.dcn.ac.ed.uk	whittle, ian/AAX-7309-2021					BRIGGS G G, 1975, Cortex, V11, P230; BURGER PC, 1988, J NEUROSURG, V68, P698, DOI 10.3171/jns.1988.68.5.0698; CABANTOG AM, 1994, CAN J NEUROL SCI, V21, P213, DOI 10.1017/S0317167100041184; CIRIC I, 1987, NEUROSURGERY, V21, P21, DOI 10.1227/00006123-198707000-00005; COHADON F, 1990, ADV TECHNICAL STANDA, V17, P190; Dorward NL, 1997, BRIT J NEUROSURG, V11, P101, DOI 10.1080/02688699746429; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; Goodglass H., 1983, BOSTON NAMING TEST; HAGLUND MM, 1994, NEUROSURGERY, V34, P567, DOI 10.1227/00006123-199404000-00001; HERMANN BP, 1994, NEUROSURGERY, V35, P52, DOI 10.1227/00006123-199407000-00008; Kertesz A., 2007, WAB R W APHASIA BATT; KETESZ A, 1979, APHASIA ASS DISORDER; LATIF AZB, 1998, IN PRESS J NEUROL NE; LATIF AZB, 1998, IN PRESS BR J NEUROS; MICELI G, 1981, ACTA NEUROL SCAND, V64, P370; OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316; RECHT LD, 1989, NEUROLOGY, V39, P48, DOI 10.1212/WNL.39.1.48; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; Russell D, 1989, PATHOLOGY TUMOURS NE; SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22; Skirboll SS, 1996, NEUROSURGERY, V38, P678, DOI 10.1227/00006123-199604000-00008; TANDON P, 1993, ACT NEUR S, V56, P67; THOMSON AM, 1997, J NEUROSURG, V89, P923; VECHT CJ, 1990, J NEUROL NEUROSUR PS, V53, P466, DOI 10.1136/jnnp.53.6.466; WEISSMAN DE, 1987, J NEURO-ONCOL, V5, P125, DOI 10.1007/BF02571300; WHITTLE IR, 1991, AUST NZ J SURG, V61, P919, DOI 10.1111/j.1445-2197.1991.tb00010.x; WHITTLE IR, 1992, NEUROSURG QUART, V2, P174	27	31	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1014	1018		10.1016/S0140-6736(97)08295-0	http://dx.doi.org/10.1016/S0140-6736(97)08295-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546507				2022-12-28	WOS:000072927200011
J	Nightingale, SL				Nightingale, SL			New national campaign to help stop tobacco sales to children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-28	WOS:000072669700005
J	Dunea, G				Dunea, G			Mistakes	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cook Cty Hosp, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County	Dunea, G (corresponding author), Cook Cty Hosp, Chicago, IL 60612 USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1026	1026		10.1136/bmj.316.7136.1026	http://dx.doi.org/10.1136/bmj.316.7136.1026			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9552884	Green Published			2022-12-28	WOS:000072856100079
J	Gulmezoglu, AM; Duley, L				Gulmezoglu, AM; Duley, L			Use of anticonvulsants in eclampsia and pre-eclampsia: survey of obstetricians in the United Kingdom and Republic of Ireland	BRITISH MEDICAL JOURNAL			English	Article									Radcliffe Infirm, Natl Perinatal Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Gulmezoglu, AM (corresponding author), United Kingdom Cochrane Ctr, NHS Res & Dev Programme, Summertown Pavil, Oxford OX2 7LG, England.	mgulmezoglu@cochrane.co.uk	Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178				CHAMBERLAIN GVP, 1978, BRIT MED J, V276, P626; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1997, COCHRANE LIB COCHRAN; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					975	976		10.1136/bmj.316.7136.975	http://dx.doi.org/10.1136/bmj.316.7136.975			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550956	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000072856100020
J	Schierhout, G; Roberts, I				Schierhout, G; Roberts, I			Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN	Objective: To determine the effect on mortality of resuscitation with colloid solutions compared with resuscitation with crystalloids. Design: Systematic review of randomised controlled trials of resuscitation with colloids compared with crystalloids for volume replacement of critically ill patients; analysis stratified according to patient type and quality of allocation concealment Subjects: 37 randomised controlled trials were eligible, of which 26 unconfounded trials compared colloids with crystalloids (n = 1622). (The 10 trials that compared colloid in hypertonic crystalloid with isotonic crystalloid (n = 1422) and one trial that compared colloid in isotonic crystalloid with hypertonic crystalloid (n = 38) are described in the longer version on our website www.bmj.com). Main outcome measures: Mortality from all causes at end of follow up for each trial. Results: Resuscitation with colloids was associated with an increased absolute risk of mortality of 4% (95% confidence interval 0% to 8%), or four extra deaths for every 100 patients resuscitated. The summary effect measure shifted towards increased mortality with colloids when only trials with adequate concealment of allocation were included. There was no evidence for differences in effect among patients with different types of injury that required fluid resuscitation. Conclusions: This systematic review does not support the continued use of colloids for volume replacement in critically ill patients.	UCL, Sch Med, Inst Child Hlth,Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	Schierhout, G (corresponding author), UCL, Sch Med, Inst Child Hlth,Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England.			Schierhout, Gill/0000-0002-6399-7624				Armstrong RF, 1994, CRITICAL CARE ALGORI; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BISONNI RS, 1991, J FAM PRACTICE, V32, P387; EGGER M, IN PRESS BMJ; Fakhry S. M., 1995, Journal of Burn Care and Rehabilitation, V16, P86; MCGRATH K, 1991, MED J AUSTRALIA, V154, P657, DOI 10.5694/j.1326-5377.1991.tb121251.x; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; SCHNEIDER M, IN PRESS J EVAL CLIN; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; VELANOVICH V, 1989, SURGERY, V105, P65; VERMEULEN LC, 1995, ARCH INTERN MED, V155, P373, DOI 10.1001/archinte.155.4.373; YIM JM, 1995, ARCH INTERN MED, V155, P2450, DOI 10.1001/archinte.155.22.2450	12	361	390	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	1998	316	7136					961	964		10.1136/bmj.316.7136.961	http://dx.doi.org/10.1136/bmj.316.7136.961			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550953	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000072856100017
J	Baldeweg, SE				Baldeweg, SE			A shaggy dog story - Caffeine and canine	BRITISH MEDICAL JOURNAL			English	Article														Baldeweg, Stephanie E/0000-0002-8381-1612					0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					916	916		10.1136/bmj.316.7135.916	http://dx.doi.org/10.1136/bmj.316.7135.916			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552845	Green Published			2022-12-28	WOS:000072713300034
J	Farrell, L				Farrell, L			What rough beast?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1324	1324		10.1136/bmj.316.7140.1324	http://dx.doi.org/10.1136/bmj.316.7140.1324			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554920	Green Published			2022-12-28	WOS:000073335900057
J	Kubori, T; Matsushima, Y; Nakamura, D; Uralil, J; Lara-Tejero, M; Sukhan, A; Galan, JE; Aizawa, S				Kubori, T; Matsushima, Y; Nakamura, D; Uralil, J; Lara-Tejero, M; Sukhan, A; Galan, JE; Aizawa, S			Supramolecular structure of the Salmonella typhimurium type III protein secretion system	SCIENCE			English	Article							FUNCTIONAL CONSERVATION; INVASION GENES; HOST-CELLS; BASAL BODY; IDENTIFICATION; COMPLEX; FAMILY	The type III secretion system of Salmonella typhimurium directs the translocation of proteins into host cells. Evolutionarily related to the flagellar assembly machinery, this system is also present in other pathogenic bacteria, but its organization is unknown. Electron microscopy revealed supramolecular structures spanning the inner and outer membranes of flagellated and nonflagellated strains; such structures were not detected in strains carrying null mutations in components of the type III apparatus. Isolated structures were found to contain at least three proteins of this secretion system. Thus, the type III apparatus of S. typhimurium, and presumably other bacteria, exists as a supramolecular structure in the bacterial envelope.	Teikyo Univ, Dept Biosci, Utsunomiya, Tochigi 320, Japan; SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Teikyo University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Galan, JE (corresponding author), Teikyo Univ, Dept Biosci, 1-1 Toyosatodai, Utsunomiya, Tochigi 320, Japan.		Kubori, Tomoko/AAH-3609-2019	Kubori, Tomoko/0000-0003-1098-6021; Aizawa, Shin-Ichi/0000-0002-9068-0825				AIZAWA S, 1985, J BACTERIOL, V161, P836, DOI 10.1128/JB.161.3.836-849.1985; Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Collazo CM, 1996, INFECT IMMUN, V64, P3524, DOI 10.1128/IAI.64.9.3524-3531.1996; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1996, ANNU REV CELL DEV BI, V12, P219; GINOCCHIO CC, 1995, INFECT IMMUN, V63, P729, DOI 10.1128/IAI.63.2.729-732.1995; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Koster M, 1997, MOL MICROBIOL, V26, P789, DOI 10.1046/j.1365-2958.1997.6141981.x; KUBORI T, 1992, J MOL BIOL, V226, P433, DOI 10.1016/0022-2836(92)90958-M; KUBORI T, UNPUB; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; PEGUES DA, 1995, MOL MICROBIOL, V17, P169, DOI 10.1111/j.1365-2958.1995.mmi_17010169.x; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; UENO T, 1994, J MOL BIOL, V236, P546, DOI 10.1006/jmbi.1994.1164; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986	24	685	715	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					602	605		10.1126/science.280.5363.602	http://dx.doi.org/10.1126/science.280.5363.602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554854				2022-12-28	WOS:000073242100051
J	Bodenheimer, T; Sullivan, K				Bodenheimer, T; Sullivan, K			How large employers are shaping the health care marketplace - Part 2	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							QUALITY		Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA USA; Minnesota Citizens Organized Acting Together, St Paul, MN USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), 1580 Valencia St,Suite 201, San Francisco, CA 94110 USA.							Agretelis J, 1997, JAMA-J AM MED ASSOC, V278, P1733; Anders G., 1996, HLTH WEALTH HMOS BRE; Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; Bailit MH, 1997, HEALTH AFFAIR, V16, P85, DOI 10.1377/hlthaff.16.6.85; Bodenheimer T, 1997, INT J HEALTH SERV, V27, P409, DOI 10.2190/YAGR-4KXN-J50E-B62H; *BUS HLTH, 1997, STAT HLTH CAR AM 199; Coleman D L, 1997, Bus Health, V15, P38; Cooper PF, 1997, HEALTH AFFAIR, V16, P142, DOI 10.1377/hlthaff.16.6.142; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; FREUDENHEIM M, 1996, NY TIMES        0519, pA1; Fronstin P, 1996, INQUIRY-J HEALTH CAR, V33, P317; FRONSTIN P, 1997, SOURCES HLTH INSURAN; FUCHS VR, 1994, HEALTH AFFAIR, V13, P102, DOI 10.1377/hlthaff.13.1.102; *GEN ACC OFF, 1994, 94219 GAOHEHS; HERZLINGER R, 1997, MARKET DRIVEN HLTH C; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Jewett JJ, 1996, HEALTH CARE FINANC R, V18, P75; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Kuttner R, 1997, NEW ENGL J MED, V336, P386, DOI 10.1056/NEJM199701303360522; Meyer H, 1996, HOSP HEALTH NETWORK, V70, P34; MILLER K, 1997, CALIFORNIA MED   SEP, P40; POOLE W, 1997, CALIFORNIA MED   JUN, P18; Reese S, 1997, Bus Health, V15, P32; Robinson M L, 1996, Bus Health, V14, P46; Smith BM, 1997, NEW ENGL J MED, V337, P1000, DOI 10.1056/NEJM199710023371410; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027	27	30	30	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1084	1087		10.1056/NEJM199804093381525	http://dx.doi.org/10.1056/NEJM199804093381525			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG134	9535677				2022-12-28	WOS:000072969500030
J	Hall, RA; Premont, RT; Chow, CW; Blitzer, JT; Pitcher, JA; Claing, A; Stoffel, RH; Barak, LS; Shenolikar, S; Weinman, EJ; Grinstein, S; Lefkowitz, RJ				Hall, RA; Premont, RT; Chow, CW; Blitzer, JT; Pitcher, JA; Claing, A; Stoffel, RH; Barak, LS; Shenolikar, S; Weinman, EJ; Grinstein, S; Lefkowitz, RJ			The beta(2)-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange	NATURE			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE; PROXIMAL TUBULE; CAMP; SEQUESTRATION; REABSORPTION; ACTIVATION; INHIBITION; COFACTOR	Stimulation of beta(2)-adrenergic receptors on the cell surface by adrenaline or noradrenaline leads to alterations in the metabolism, excitability, differentiation and growth of many cell types. These effects have traditionally been thought to be mediated exclusively by receptor activation of intracellular G proteins(1). However, certain physiological effects of beta(2)-adrenergic receptor stimulation, notably the regulation of cellular pH by modulation of Na+/H+ exchanger (NHE) function, do not seem to be entirely dependent on G-protein activation(2-7). We report here a direct agonist-promoted association of the beta(2)-adrenergic receptor with the Na+/H+ exchanger regulatory factor (NHERF), a protein that regulates the activity of the Na+/H+ exchanger type 3 (NHE3)(8). NHERF binds to the beta(2)-adrenergic receptor by means of a PDZ-domain-mediated interaction with the last few residues of the carboxy-terminal cytoplasmic domain of the receptor. Mutation of the final residue of the beta(2)-adrenergic receptor from leucine to alanine abolishes the receptor's interaction with NHERF and also markedly alters beta(2)-adrenergic receptor regulation of NHE3 in cells without altering receptor-mediated activation of adenylyl cyclase. Our findings indicate that agonist-defendent beta(2)-adrenergic receptor binding of NHERF plays a role in beta(2)-adrenergic receptor-mediated regulation of Na+/H+ exchange.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Hosp Sick Children, Res Inst, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; W Virginia Univ, Dept Med, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; Dept Vet Affairs Med Ctr, Med Serv, Clarksburg, WV 26301 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Duke University; West Virginia University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020; Chow, Chung-Wai/AAP-5533-2020	Chow, Chung-Wai/0000-0001-9344-8522; Premont, Richard/0000-0002-8053-5026; Hall, Randy/0000-0002-8318-8728				AGUS ZS, 1971, J CLIN INVEST, V50, P617, DOI 10.1172/JCI106532; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BELLOREUSS E, 1980, AM J PHYSIOL, V238, pF347, DOI 10.1152/ajprenal.1980.238.5.F347; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOLSON GM, 1985, AM J PHYSIOL, V249, pF409, DOI 10.1152/ajprenal.1985.249.3.F409; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; GANZ MB, 1990, J BIOL CHEM, V265, P8989; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1982, J MEMBRANE BIOL, V69, P107, DOI 10.1007/BF01872270; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	30	482	490	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					626	630		10.1038/33458	http://dx.doi.org/10.1038/33458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560162				2022-12-28	WOS:000072987200066
J	Malinow, MR; Duell, PB; Hess, DL; Anderson, PH; Kruger, WD; Phillipson, BE; Gluckman, RA; Block, PC; Upson, BM				Malinow, MR; Duell, PB; Hess, DL; Anderson, PH; Kruger, WD; Phillipson, BE; Gluckman, RA; Block, PC; Upson, BM			Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; RISK FACTOR; METHYLENETETRAHYDROFOLATE REDUCTASE; VASCULAR-DISEASE; COMMON MUTATION; ARTERY DISEASE; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; HYPERHOMOCYST(E)INEMIA; ATHEROSCLEROSIS	Background The Food and Drug Administration (FDA) has recommended that cereal-grain products be fortified with folic acid to prevent congenital neural-tube defects. Since folic acid supplementation reduces levels of plasma homocyst(e)ine, or plasma total homocysteine, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid fortification might reduce plasma homocyst(e)ine levels. Methods To test this hypothesis, we assessed the effects of breakfast cereals fortified with three levels of folic acid, and also containing the recommended dietary allowances of vitamins B-6 and B-12, in a randomized, double-blind, placebo-controlled, crossover trial in 75 men and women with coronary artery disease. Results Plasma folic acid increased and plasma homocyst(e)ine decreased proportionately with the folic acid content of the breakfast cereal. Cereal providing 127 mu g of folic acid daily, approximating the increased daily intake that may result from the FDA's enrichment policy, increased plasma folic acid by 30.8 percent (P = 0.045) but decreased plasma homocyst(e)ine by only 3.7 percent (P = 0.24). However, cereals providing 499 and 665 mu g of folic acid daily increased plasma folic acid by 64.8 percent (P < 0.001) and 105.7 percent (P = 0.001), respectively, and decreased plasma homocyst(e)ine by 11.0 percent (P < 0.001) and 14.0 percent (P = 0.001), respectively. Conclusions Cereal fortified with folic acid has the potential to increase plasma folic acid levels and reduce plasma homocyst(e)ine levels. Further clinical trials are required to determine whether folic acid fortification may prevent vascular disease. Until then, our results suggest that folic acid fortification at levels higher than that recommended by the FDA may be warranted. (C) 1998, Massachusetts Medical Society.	Oregon Reg Primate Res Ctr, Div Pathobiol & Immunol, Beaverton, OR 97006 USA; Oregon Reg Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Providence St Vincent Med Ctr, Portland, OR USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Fox Chase Cancer Center	Malinow, MR (corresponding author), Oregon Reg Primate Res Ctr, Div Pathobiol & Immunol, 505 NW 185th Ave, Beaverton, OR 97006 USA.		Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albertson A. M., 1997, Topics in Clinical Nutrition, V12, P58; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; Bostom AG, 1996, KIDNEY INT, V49, P147, DOI 10.1038/ki.1996.19; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; CUNNIFF P, 1996, OFFICIAL METHODS ANA, V1; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Duell PB, 1997, CURR OPIN LIPIDOL, V8, P28, DOI 10.1097/00041433-199702000-00007; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; HIBBARD ED, 1965, LANCET, V1, P1254; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; KANG SS, 1988, METABOLISM, V37, P611, DOI 10.1016/0026-0495(88)90076-5; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; MALINOW MR, 1990, CORONARY ARTERY DIS, V1, P215, DOI 10.1097/00019501-199003000-00010; MALINOW MR, 1994, CLIN CHEM, V40, P857; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; Rajkovic A, 1997, OBSTET GYNECOL, V90, P168, DOI 10.1016/S0029-7844(97)00223-8; Rozen R, 1996, CLIN INVEST MED, V19, P171; Shimakawa T, 1997, ANN EPIDEMIOL, V7, P285, DOI 10.1016/S1047-2797(97)00004-5; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; Tucker KL, 1996, JAMA-J AM MED ASSOC, V276, P1879, DOI 10.1001/jama.276.23.1879; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; WAGNER WE, 1993, CURR CONCEPTS NUTR, V8, P1; WALD N, 1991, LANCET, V338, P131; WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820; 1989, RECOMMENDED DIETARY; 1993, FED REG, V58, P53254; 1993, FED REG, V58, P53305	39	315	329	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1009	1015		10.1056/NEJM199804093381501	http://dx.doi.org/10.1056/NEJM199804093381501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535664				2022-12-28	WOS:000072969500001
J	van der Horst, CMAM; Koster, PHL; de Borgie, CAJM; Bossuyt, PMM; van Gemert, MJC				van der Horst, CMAM; Koster, PHL; de Borgie, CAJM; Bossuyt, PMM; van Gemert, MJC			Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed dye-laser	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-EXPERIENCE; CHILDREN; THERAPY	Background Port-wine stains can be treated with a flash-lamp-pumped pulsed-dye laser, but it is uncertain whether this treatment is more effective if administered early in life, when the skin is thinner and the lesion is smaller, Methods We prospectively studied 100 patients with a previously untreated part-wine stain of the head or neck. They were treated with the flash-lamp-pumped pulsed-dye laser and divided into four age groups (0 to 5, 6 to 12, 12 to 17, and 18 to 31 years), The outcome measure was lightening of the port-wine stain (reduction in the difference in color between the skin with the stain and contralateral healthy skin) as measured with a colorimeter after an average of five treatments (range, three to seven) of the entire lesion. Results Of the 100 patients, 11 could not be included in the analysis because they had received fewer than three or more than seven treatments, had an erroneous base-line color measurement, or were lost to follow-up, The sizes, locations, and colors of the port-wine stains were similar among the groups. When all 89 patients were analyzed together, the average reduction in the difference in color between the skin with the port-wine stain and contralateral healthy skin was 40 percent, The differences between age groups in the average reduction in color differences were not significant (P = 0.26). By the end of the study, only 7 of 89 patients had completed laser therapy, and in no case was clearance complete. Treatment was discontinued in all seven because the last three treatments did not lead to further lightening. Conclusions We found no evidence that treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser in early childhood is more effective than treatment at a later age. (C) 1998, Massachusetts Medical Society.	Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Laser, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van der Horst, CMAM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; van der Horst, chantal/0000-0002-4937-3786				ACHAUER BM, 1990, ANN PLAS SURG, V25, P344, DOI 10.1097/00000637-199011000-00002; ALSTER TS, 1994, ANN PLAS SURG, V32, P478, DOI 10.1097/00000637-199405000-00007; Altman D.G., 1991, PRACTICAL STAT MED R; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ASHINOFF R, 1991, J AM ACAD DERMATOL, V24, P467, DOI 10.1016/0190-9622(91)70075-D; DIXON JA, 1984, PLAST RECONSTR SURG, V73, P771, DOI 10.1097/00006534-198405000-00009; Fiskerstrand EJ, 1996, BRIT J DERMATOL, V134, P1039, DOI 10.1046/j.1365-2133.1996.d01-898.x; GARDEN JM, 1989, NEW ENGL J MED, V321, P901; GARDEN JM, 1988, ARCH DERMATOL, V124, P889, DOI 10.1001/archderm.124.6.889; GOLDMAN MP, 1993, J PEDIATR-US, V122, P71, DOI 10.1016/S0022-3476(05)83489-4; GOLDMAN MP, 1994, CUTANEOUS LASER SURG, P19; HELLER A, 1985, AM J DIS CHILD, V139, P257, DOI 10.1001/archpedi.1985.02140050051021; JACOBS AH, 1976, PEDIATRICS, V58, P218; KAUVAR ANB, 1995, DERMATOL SURG, V21, P515, DOI 10.1111/j.1524-4725.1995.tb00256.x; LANIGAN SW, 1989, BRIT J DERMATOL, V121, P209, DOI 10.1111/j.1365-2133.1989.tb01800.x; MORELLI JG, 1995, ARCH PEDIAT ADOL MED, V149, P1142, DOI 10.1001/archpedi.1995.02170230096014; MORELLI JG, 1992, MANAGEMENT TREATMENT; NOE JM, 1980, PLAST RECONSTR SURG, V65, P130, DOI 10.1097/00006534-198002000-00002; ONIZUKA K, 1995, BRIT J PLAST SURG, V48, P271, DOI 10.1016/0007-1226(95)90064-0; REYES BA, 1990, J AM ACAD DERMATOL, V23, P1142, DOI 10.1016/0190-9622(90)70348-L; SCHEEPERS JH, 1994, BRIT J PLAST SURG, V47, P112, DOI 10.1016/0007-1226(94)90169-4; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; vanderHorst CMAM, 1997, BRIT J PLAST SURG, V50, P463, DOI 10.1016/S0007-1226(97)90335-0; vanGemert MJC, 1997, PHYS MED BIOL, V42, P41, DOI 10.1088/0031-9155/42/1/002; WESTERHOF W, 1986, PHOTODERMATOLOGY, V3, P310; Wyszecki G., 1982, COLOR SCI CONCEPTS M, V2nd, P130	26	121	121	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1028	1033		10.1056/NEJM199804093381504	http://dx.doi.org/10.1056/NEJM199804093381504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535667	Bronze			2022-12-28	WOS:000072969500004
J	Ioannidis, JPA; Cappelleri, JC; Lau, J				Ioannidis, JPA; Cappelleri, JC; Lau, J			Issues in comparisons between meta-analyses and large trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIALS; ACUTE MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; PUBLICATION BIAS; METAANALYSIS; MANAGEMENT; RATES; RISK	Context.-The extent of concordance between meta-analyses and large trials on the same topic has been investigated with different protocols. Inconsistent conclusions created confusion regarding the validity of these major tools of clinical evidence. Objective.-To evaluate protocols comparing meta-analyses and large trials in order to understand if and why they disagree on the concordance of these 2 clinical research methods, Design.-Systematic comparison of protocol designs, study selection, definitions of agreement, analysis methods, and reported discrepancies between large trials and meta-analyses. Results.-More discrepancies were claimed when large trials were selected from influential journals (which may prefer trials disagreeing with prior evidence) than from already performed meta-analyses (which may target homogeneous trials) and when both primary and secondary (rather than only primary) end points were considered. Depending on how agreement was defined, kappa coefficients varied from 0.22 (low agreement) to 0.72 (excellent agreement), The correlation of treatment effects between large trials and meta-analyses varied from -0.12 to 0.76, but was more similar (0.50-0.76) when only primary end points were considered, When both the magnitude and uncertainty of treatment effects were considered, large trials disagreed with meta-analyses 10% to 23% of the time, Discrepancies were attributed to different disease risks, variable protocols, quality, and publication bias. Conclusions.-Comparisons of large trials with meta-analyses may reach different conclusions depending on how trials and meta-analyses are selected and how end points and agreement are defined. Scrutiny of these 2 major research methods can enhance our appreciation of both for guiding medical practice.	NIAID, Therapeut Res Program, Div Aids, NIH, Bethesda, MD 20852 USA; Pfizer Inc, Pfizer Cent Res, Dept Clin Res, Groton, CT 06340 USA; Tufts Univ, New England Med Ctr, Sch Med, Div Clin Care Res, Boston, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pfizer; Tufts Medical Center; Tufts University	Ioannidis, JPA (corresponding author), NIAID, Therapeut Res Program, Div Aids, NIH, Solar Bldg,Room 2C31,6003 Execut Blvd, Bethesda, MD 20852 USA.	ji24m@nih.gov	Ioannidis, John P. A./G-9836-2011					[Anonymous], 1997, LANCET, V350, P675; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Bailar JC, 1998, NEW ENGL J MED, V338, P62; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Berlin JA, 1994, ONLINE J CURR CLIN T, P134; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; Cappelleri JC, 1997, JAMA-J AM MED ASSOC, V277, P377; Chalmers TC, 1996, STAT MED, V15, P1263, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1263::AID-SIM305>3.3.CO;2-B; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; *CYT SOFTW CORP, 1995, STATX VERS 3 STAT SO; DEEKS JJ, 1997, CONTROL CLIN TRIALS, V18, pS84; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ENKIN MW, 1996, PREGNANCY CHILDHOOD; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Horwitz R I, 1987, Am J Med, V82, P498, DOI 10.1016/0002-9343(87)90450-5; Horwitz RI, 1996, J CLIN EPIDEMIOL, V49, P395, DOI 10.1016/0895-4356(95)00058-5; Ioannidis JPA, 1996, LANCET, V348, P756, DOI 10.1016/S0140-6736(05)65647-4; Ioannidis JPA, 1997, CONTROL CLIN TRIALS, V18, P431, DOI 10.1016/S0197-2456(97)00097-4; Ioannidis JPA, 1998, NEW ENGL J MED, V338, P59; Ioannidis JPA, 1997, J CLIN EPIDEMIOL, V50, P1089, DOI 10.1016/S0895-4356(97)00149-2; Ioannidis JPA, 1997, J ACQ IMMUN DEF SYND, V16, P22, DOI 10.1097/00042560-199709010-00004; Ioannidis JPA, 1996, AM J EPIDEMIOL, V144, P1074, DOI 10.1093/oxfordjournals.aje.a008881; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P319, DOI 10.1001/jama.279.4.319; LAKATOS E, 1986, CONTROL CLIN TRIALS, V7, P189, DOI 10.1016/0197-2456(86)90047-4; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LeLorier J, 1998, NEW ENGL J MED, V338, P61; McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; Naylor CD, 1997, BMJ-BRIT MED J, V315, P617, DOI 10.1136/bmj.315.7109.617; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; ROTHMAN KJ, 1978, NEW ENGL J MED, V299, P1362; SCHMID CH, IN PRESS STAT MED; Sharp SJ, 1996, BRIT MED J, V313, P735; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; WOODS KL, 1995, LANCET, V346, P611, DOI 10.1016/S0140-6736(95)91440-4; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	48	191	193	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1089	1093		10.1001/jama.279.14.1089	http://dx.doi.org/10.1001/jama.279.14.1089			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546568				2022-12-28	WOS:000072875300033
J	Kendall, J; Reeves, B; Clancy, M				Kendall, J; Reeves, B; Clancy, M			Point of care testing: randomised controlled trial of clinical outcome	BRITISH MEDICAL JOURNAL			English	Article							OF-CARE; EMERGENCY; ANALYZER	Objectives: To describe the proportion of patients attending an accident and emergency department for whom blood analysis at the point of care brought about a change in management; to measure the extent to which point of care testing resulted in differences in clinical outcome for these patients when compared with patients whose samples were tested by the hospital laboratory. Design: Open, single centre, randomised controlled trial, Blood samples were randomly allocated to point of care testing or testing by the hospital's central laboratory. Setting: The accident and emergency department of the Bristol Royal Infirmary, a large teaching hospital which cares fur an inner city population. Subjects: Representative sample of patients who attended the department between April 1996 and April 1997 and who required blood, tests, Data collection was structured in 8 hour blocks so that all hours of the day and all days of the week were equally represented. Main outcome measures: The proportion of patients for whom point of care testing brought about a change in treatment in which timing was considered to be critical to clinical outcome. Mortality, the length of stay in hospital, admission rate, the amount of time spent waiting for results of blood tests, the amount of time taken to decide on management plans, and the amount of time patients spent in the department were compared between patients whose samples were tested at the point of care and those whose samples were sent to the laboratory. Results: Samples were obtained from 1728 patients. Changes in management in which timing was considered to be critical occurred in 59 out of 859 (6.9%, 95% confidence interval 5.3% to 8.8%) patients in the point of care arm of the trial, Decisions were made 74 minutes earlier (68 min to 80 min, P < 0.0001) when point of care testing was used for haematological tests as compared to central laboratory testing, 86 minutes earlier (80 min to 92 min, P < 0.0001) for biochemical tests, and 21 minutes earlier (-3 min to 44 min, P = 0.09) for analyses of arterial blood gases, There were no differences between the groups in the amount of time spent in the department, length of stay in hospital, admission rates, or mortality. Conclusion: Point of care testing reduced the time taken to make decisions on patient management that were dependent on the results of blood tests, It also brought about Easter changes in treatment for which timing nas considered to be critical in about 7% of patients, These changes did not affect clinical outcome or the amount of time patients spent in the department.	Univ Bristol, Bristol Royal Infirm, Dept Accid & Emergency Med, Bristol BS2 8HW, Avon, England; Univ Bristol, Dept Social Med, Res & Dev Support Unit, Bristol BS8 2PR, Avon, England	Bristol Royal Infirmary; University of Bristol; University of Bristol	Kendall, J (corresponding author), Frenchay Hosp NHS Trust, Bristol BS16 1LE, Avon, England.							BINGHAM D, IN PRESS ANN CLIN BI; BROWN H, 1997, BRIT MED J, V314, P1785; Clancy MJ, 1996, J ACCID EMERG MED, V13, P149; FLEISHER M, 1993, CLIN BIOCHEM, V26, P6, DOI 10.1016/0009-9120(93)90004-P; FLEISHER M, 1995, AM J CLIN PATHOL, V104, pS18; FRANKEL HL, 1994, J TRAUMA, V37, P728, DOI 10.1097/00005373-199411000-00006; *I STAT CORP, 1996, I STAT MAN; JACOBS E, 1993, CLIN CHEM, V39, P1069; JATLOW P, 1993, AM J CLIN PATHOL, V100, P591, DOI 10.1093/ajcp/100.6.591; KENDALL JM, IN PRESS J HLTH SERV; Parvin CA, 1996, CLIN CHEM, V42, P711; SANDS VM, 1995, ACAD EMERG MED, V2, P172, DOI 10.1111/j.1553-2712.1995.tb03190.x; SANTRACH PJ, 1995, MAYO CLIN PROC, V70, P493, DOI 10.4065/70.5.493; SAXENA S, 1993, AM J CLIN PATHOL, V100, P606, DOI 10.1093/ajcp/100.6.606; TSAI WW, 1994, CLIN THER, V16, P898; WOO J, 1993, AM J CLIN PATHOL, V100, P599, DOI 10.1093/ajcp/100.6.599; ZALOGA GP, 1989, CRIT CARE MED, V17, P920, DOI 10.1097/00003246-198909000-00017	17	136	142	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1052	1057						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552905				2022-12-28	WOS:000072987400023
J	Pagan-Westphal, SM; Tabin, CJ				Pagan-Westphal, SM; Tabin, CJ			The transfer of left-right positional information during chick embryogenesis	CELL			English	Article							LEFT-RIGHT ASYMMETRY; SONIC HEDGEHOG; NODAL EXPRESSION; INDUCTION; GENE; RECEPTOR; MICE; CONSERVATION; PATHWAY; EMBRYO	The earliest known left-right asymmetric genes are expressed at Hensen's node during chick gastrulation. Gene expression following reorientation of the node shows asymmetry is instructed by adjacent tissue, hence left-right information originates outside the node. Subsequently, the node signals back to the lateral tissue, initiating a cascade leading to left-sided expression of nodal in the lateral plate mesoderm. Loss of nodal expression in the presence of blocking antibodies confirms that Sonic hedgehog is the key signal conveying left-right information from the node; however, manipulation of explant cultures suggests that the induction of nodal requires secondary signals produced in the paraxial mesoderm. These experiments establish the time of action of these signals to and from Hensen's node in establishing left-right asymmetry.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							ABERCROMBIE M, 1950, PHILOS T R SOC B, V234, P317, DOI 10.1098/rstb.1950.0004; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; EKKER SC, 1995, DEVELOPMENT, V121, P2337; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HYATT BA, 1998, CELL, V93; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KING T, 1997, CURR BIOL, V7, pF212; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LEVIN M, 1996, THESIS HARVARD U CAM; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEVELOPMENT, V122, P1225; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Pannett C.A., 1924, LANCET, V206, P381; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Sampath K, 1997, DEVELOPMENT, V124, P3293; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1	31	152	156	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					25	35		10.1016/S0092-8674(00)81143-5	http://dx.doi.org/10.1016/S0092-8674(00)81143-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546389	Bronze			2022-12-28	WOS:000072910800007
J	Schacter, DL				Schacter, DL			Memory and awareness	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; IMPLICIT MEMORY; HIPPOCAMPUS; ACTIVATION; HUMANS		Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Schacter, DL (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.			Schacter, Daniel/0000-0002-2460-6061	NATIONAL INSTITUTE ON AGING [R37AG008441, R01AG008441] Funding Source: NIH RePORTER; NIA NIH HHS [AG08441] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Blaxton TA, 1996, J NEUROSCI, V16, P4032; BOWERS JS, 1990, J EXP PSYCHOL LEARN, V16, P404, DOI 10.1037/0278-7393.16.3.404; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; CURRAN T, 1997, HDB IMPLICIT LEARNIN, P365; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; McKone E, 1997, MEM COGNITION, V25, P352, DOI 10.3758/BF03211291; MERIKLE PM, 1991, J EXP PSYCHOL LEARN, V17, P224, DOI 10.1037/0278-7393.17.2.224; Rugg MD, 1997, NEUROREPORT, V8, P1283, DOI 10.1097/00001756-199703240-00045; Schacter DL, 1998, NEURON, V20, P185, DOI 10.1016/S0896-6273(00)80448-1; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SHANKS DR, 1994, BEHAV BRAIN SCI, V17, P367, DOI 10.1017/S0140525X00035032; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769	16	45	46	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					59	60		10.1126/science.280.5360.59	http://dx.doi.org/10.1126/science.280.5360.59			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZF314	9556454				2022-12-28	WOS:000072885100033
J	Doyal, L				Doyal, L			Informed consent - a response to recent correspondence	BRITISH MEDICAL JOURNAL			English	Article									St Bartholomews, London E1 2AD, England; Royal London Hosp, Sch Med & Dent, London E1 2AD, England	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Doyal, L (corresponding author), St Bartholomews, London E1 2AD, England.							Baum M, 1997, BRIT MED J, V314, P1482; Bhagwanjee S, 1997, BRIT MED J, V314, P1077, DOI 10.1136/bmj.314.7087.1077a; Doyal L, 1997, BMJ-BRIT MED J, V314, P1107, DOI 10.1136/bmj.314.7087.1107; Little P, 1997, BRIT MED J, V314, P1478; Pfeffer N, 1997, BRIT MED J, V315, P247, DOI 10.1136/bmj.315.7102.247; Soutter P, 1997, BRIT MED J, V314, P1477; Tobias JS, 1997, BRIT MED J, V314, P1111, DOI 10.1136/bmj.314.7087.1111; 1997, BMJ, V314, P1477; 1997, BMJ, V315, P247	9	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1000	1001		10.1136/bmj.316.7136.1000	http://dx.doi.org/10.1136/bmj.316.7136.1000			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550964	Green Published			2022-12-28	WOS:000072856100029
J	Lindley, RI				Lindley, RI			Thrombolytic treatment for acute ischaemic stroke: consent can be ethical	BRITISH MEDICAL JOURNAL			English	Article							RECRUITMENT; TRIALS		Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Lindley, RI (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.		Lindley, Richard/B-8148-2013	Lindley, Richard/0000-0002-0104-5679				BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; Doyal L, 1997, BMJ-BRIT MED J, V314, P1107, DOI 10.1136/bmj.314.7087.1107; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *ROYAL COLL PHYS L, 1990, REP ROYAL COLL PHYS; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; THORNTON H, 1993, LANCET, V341, P795, DOI 10.1016/0140-6736(93)90568-2; TOYNBEE P, 1997, BMJ NEWS REV     MAR, P34; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	12	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1005	1007		10.1136/bmj.316.7136.1005	http://dx.doi.org/10.1136/bmj.316.7136.1005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550965	Green Published			2022-12-28	WOS:000072856100034
J	Beecham, L				Beecham, L			BMA spouse membership widened	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					943	943						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552865				2022-12-28	WOS:000072713300081
J	Johnston, SRD; Broadley, K; Henson, G; Fisher, C; Henk, M; Gore, ME				Johnston, SRD; Broadley, K; Henson, G; Fisher, C; Henk, M; Gore, ME			A difficult case - Management of metastatic melanoma during pregnancy	BRITISH MEDICAL JOURNAL			English	Article									Royal Marsden Hosp, Melanoma Unit, London SW3 6JJ, England; Royal Marsden Hosp, Palliat Care Unit, London SW3 6JJ, England; Royal Marsden Hosp, Dept Pathol, London SW3 6JJ, England; Whittington Hosp, Dept Obstet & Gynaecol, London N19 5NF, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; University College London	Johnston, SRD (corresponding author), Royal Marsden Hosp, Melanoma Unit, London SW3 6JJ, England.							REINTGEN DS, 1985, CANCER, V55, P1340, DOI 10.1002/1097-0142(19850315)55:6<1340::AID-CNCR2820550630>3.0.CO;2-T	1	10	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					848	849		10.1136/bmj.316.7134.848	http://dx.doi.org/10.1136/bmj.316.7134.848			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549460	Green Published			2022-12-28	WOS:000072584300040
J	Vallance, P				Vallance, P			Separate R & D budget is needed for monitoring effects of new drugs	BRITISH MEDICAL JOURNAL			English	Letter									UCL, Dept Med, Ctr Clin Pharmacol, Cruciform Project, London W1P 9LN, England	University of London; University College London	Vallance, P (corresponding author), UCL, Dept Med, Ctr Clin Pharmacol, Cruciform Project, London W1P 9LN, England.	patrick.vallance@ucl.ac.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					939	939		10.1136/bmj.316.7135.939b	http://dx.doi.org/10.1136/bmj.316.7135.939b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552860				2022-12-28	WOS:000072713300065
J	Bullimore, D				Bullimore, D			Publication of pictures of patient on BMJ's website was mistake	BRITISH MEDICAL JOURNAL			English	Letter									Barnsley Dist Gen Hosp Trust, Barnsley S75 2EP, England		Bullimore, D (corresponding author), Barnsley Dist Gen Hosp Trust, Barnsley S75 2EP, England.							Abbasi K, 1998, BRIT MED J, V316, P170	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1022	1022		10.1136/bmj.316.7136.1022a	http://dx.doi.org/10.1136/bmj.316.7136.1022a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550988	Green Published			2022-12-28	WOS:000072856100061
J	McCormack, P; Levine, M; Rangno, RE				McCormack, P; Levine, M; Rangno, RE			Patients offered treatment for CHD need full information to make decision	BRITISH MEDICAL JOURNAL			English	Letter									Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	McCormack, P (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V5Z 1M9, Canada.			McCormack, James/0000-0002-7801-5515				FREEMANTLE M, 1997, BRIT MED J, V315, P826; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; McCormack JP, 1997, CAN MED ASSOC J, V157, P422; Muldoon MF, 1997, BRIT MED J, V315, P1554, DOI 10.1136/bmj.315.7122.1554; 1997, BMJ, V315, P1615	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1021	1022		10.1136/bmj.316.7136.1021a	http://dx.doi.org/10.1136/bmj.316.7136.1021a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550986				2022-12-28	WOS:000072856100059
J	Moss, N				Moss, N			Resource allocation to health authorities - Expenditure on private health care must be taken into account	BRITISH MEDICAL JOURNAL			English	Letter									Bro Taf Hlth Author, Cardiff CF1 3NW, S Glam, Wales		Moss, N (corresponding author), Bro Taf Hlth Author, Cardiff CF1 3NW, S Glam, Wales.		Diderichsen, Finn/P-4654-2019	Diderichsen, Finn/0000-0002-9998-4972				CARSTAIRS V, 1989, COMMUNITY MED, V11, P364; Diderichsen F, 1997, BRIT MED J, V315, P875, DOI 10.1136/bmj.315.7112.875; Mays N, 1997, BRIT MED J, V315, P652, DOI 10.1136/bmj.315.7109.652; TIMMINS N, 1997, FINANCIAL TIMES 0912; *WELSH OFF NHS DIR, 1990, IMPL WHIT PAP OPT WE	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					939	940		10.1136/bmj.316.7135.939c	http://dx.doi.org/10.1136/bmj.316.7135.939c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552861	Green Published			2022-12-28	WOS:000072713300066
J	Davis, B; Johnson, S				Davis, B; Johnson, S			Rationing health care - Patients need to be prioritised	BRITISH MEDICAL JOURNAL			English	Letter									W Wales Gen Hosp, Carmarthen & Dist NHS Trust, Carmarthen SA31 2AF, Dyfed, Wales		Davis, B (corresponding author), W Wales Gen Hosp, Carmarthen & Dist NHS Trust, Carmarthen SA31 2AF, Dyfed, Wales.							Weale A, 1998, BRIT MED J, V316, P410, DOI 10.1136/bmj.316.7129.410	1	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1092	1093						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552924				2022-12-28	WOS:000072987400050
J	Toh, KW; Fawcett, WJ				Toh, KW; Fawcett, WJ			Intravascular volume optimisation during repair of proximal femoral fracture - Intravascular volume was depleted perioperatively in control group	BRITISH MEDICAL JOURNAL			English	Letter									Royal Surrey Cty Hosp Trust, Surrey GU2 5XX, England	Royal Surrey County Hospital	Toh, KW (corresponding author), Royal Surrey Cty Hosp Trust, Surrey GU2 5XX, England.							Sinclair S, 1997, BMJ-BRIT MED J, V315, P909; WILLETT KM, 1990, BRIT MED J, V301, P229, DOI 10.1136/bmj.301.6745.229	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1089	1089						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552919				2022-12-28	WOS:000072987400040
J	Dash, CH				Dash, CH			Blood products produced from plasma from donors in UK are still being made	BRITISH MEDICAL JOURNAL			English	Letter									BPL, Elstree WD6 3BX, Herts, England		Dash, CH (corresponding author), BPL, Elstree WD6 3BX, Herts, England.							Barbara J, 1998, BRIT MED J, V316, P717, DOI 10.1136/bmj.316.7133.717; Warden J, 1998, BRIT MED J, V316, P726	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1017	1017		10.1136/bmj.316.7136.1017a	http://dx.doi.org/10.1136/bmj.316.7136.1017a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9552879				2022-12-28	WOS:000072856100047
J	Venn-Treloar, J				Venn-Treloar, J			Nuchal translucency - screening without consent	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					1027	1027						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	11645042				2022-12-28	WOS:000072856100081
J	Hughes, CG				Hughes, CG			BMA cannot bring proceedings arising out of incidents in other countries	BRITISH MEDICAL JOURNAL			English	Letter									BMA, Legal Serv, London WC1H 9JP, England		Hughes, CG (corresponding author), BMA, Legal Serv, London WC1H 9JP, England.							Khan HK, 1998, BRIT MED J, V316, P390, DOI 10.1136/bmj.316.7128.390	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					940	940		10.1136/bmj.316.7135.940a	http://dx.doi.org/10.1136/bmj.316.7135.940a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552863				2022-12-28	WOS:000072713300068
J	Hardy, K				Hardy, K			Use of lasers can cause visual impairment	BRITISH MEDICAL JOURNAL			English	Letter									Whiston Hosp, Dept Med, Prescot L35 5DR, Merseyside, England	Whiston Hospital	Hardy, K (corresponding author), Whiston Hosp, Dept Med, York House, Prescot L35 5DR, Merseyside, England.							HARDY KJ, 1991, LANCET, V338, P1338, DOI 10.1016/0140-6736(91)92643-G; HARWERTH RS, 1971, SCIENCE, V174, P520, DOI 10.1126/science.174.4008.520; Marshall J, 1997, BRIT MED J, V315, P1392, DOI 10.1136/bmj.315.7120.1392	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					939	939		10.1136/bmj.316.7135.939a	http://dx.doi.org/10.1136/bmj.316.7135.939a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552859				2022-12-28	WOS:000072713300064
